PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, FL; Hersh, BM; Conradt, B; Zhou, Z; Riemer, D; Gruenbaum, Y; Horvitz, HR				Chen, FL; Hersh, BM; Conradt, B; Zhou, Z; Riemer, D; Gruenbaum, Y; Horvitz, HR			Translocation of C. elegans CED-4 to nuclear membranes during programmed cell death	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BCL-X-L; SUBCELLULAR-LOCALIZATION; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; REGULATORS CED-9; OUTER-MEMBRANE; PROTEIN; APOPTOSIS; ENCODES	The Caenorhabditis elegans Bcl-2-like protein CED-9 prevents programmed cell death by antagonizing the Apaf-1-like cell-death activator CED-4. Endogenous CED-9 and CED-4 proteins localized to mitochondria in wild-type embryos, in which most cells survive. By contrast, in embryos in which cells had been induced to die, CED-4 assumed a perinuclear localization. CED-4 translocation induced by the cell-death activator EGL-1 was blocked by a gain-of-function mutation in ced-9 but was not dependent on ced-3 function, suggesting that CED-4 translocation precedes caspase activation and the execution phase of programmed cell death. Thus, a change in the subcellular Localization of CED-4 may drive programmed cell death.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; Max Planck Inst Biophys Chem, Dept Biochem, D-37016 Gottingen, Germany; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Max Planck Society; Hebrew University of Jerusalem	Chen, FL (corresponding author), MIT, Whitehead Inst Biomed Res, Dept Biol, WI-525, Cambridge, MA 02139 USA.		Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308; Hersh, Bradley/0000-0003-2098-4417				AKAO Y, 1994, CANCER RES, V54, P2468; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Guenther C, 1996, DEVELOPMENT, V122, P3509; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; RIEMER D, 1993, EUR J CELL BIOL, V62, P214; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	188	200	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1485	1489		10.1126/science.287.5457.1485	http://dx.doi.org/10.1126/science.287.5457.1485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688797	Green Submitted			2022-12-24	WOS:000085531600051
J	Priola, SA; Raines, A; Caughey, WS				Priola, SA; Raines, A; Caughey, WS			Porphyrin and phthalocyanine antiscrapie compounds	SCIENCE			English	Article							RESISTANT PRION PROTEIN; HAMSTER SCRAPIE; AMPHOTERICIN-B; VARIANT CJD; CONGO RED; PRP; INHIBITION; AGENT; PATHOGENESIS; EXPRESSION	The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases for which no effective treatments are available. The Likelihood that a bovine form of TSE has crossed species barriers and infected humans underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetrapyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit the in vitro formation of PrP-res, a protease-resistant protein critical for TSE pathogenesis. We now report that treatment of TSE-infected animals with three such compounds increased survival time from 50 to 300%. The significant inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these compounds as anti-TSE drugs.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA.				NIA NIH HHS [AG04342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONNETT R, 1995, CHEM SOC REV, V24, P19, DOI 10.1039/cs9952400019; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Caughey WS, 1998, P NATL ACAD SCI USA, V95, P12117, DOI 10.1073/pnas.95.21.12117; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DEMAIMAY R, 1994, J GEN VIROL, V75, P2499, DOI 10.1099/0022-1317-75-9-2499; Dolphin D., 1978, PORPHYRINS; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; FRASER H, 1978, J COMP PATHOL, V88, P563, DOI 10.1016/0021-9975(78)90010-5; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Paquette, 1992, PHOTODYNAMIC THERAPY, P145; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; PRIOLA SA, UNPUB; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Sassa S, 1996, CURR MED CHEM, V3, P273; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1999, LANCET, V353, P979, DOI 10.1016/S0140-6736(99)01160-5	26	264	281	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1503	1506		10.1126/science.287.5457.1503	http://dx.doi.org/10.1126/science.287.5457.1503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688802				2022-12-24	WOS:000085531600056
J	Martinez, JS; Zhang, GP; Holt, PD; Jung, HT; Carrano, CJ; Haygood, MG; Butler, A				Martinez, JS; Zhang, GP; Holt, PD; Jung, HT; Carrano, CJ; Haygood, MG; Butler, A			Self-assembling amphiphilic siderophores from marine bacteria	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; MYCOBACTERIUM-TUBERCULOSIS; AMINO-ACIDS; IRON; ORGANIZATION; ACQUISITION; EXOCHELINS; ECOSYSTEMS; WATERS	Most aerobic bacteria secrete siderophores to facilitate iron acquisition. Two families of siderophores were isolated from strains belonging to two different genera of marine bacteria. The aquachelins, from Halomonas aquamarina strain DS40M3, and the marinobactins, from Marinobacter sp. strains DS40M6 and DS40M8, each contain a unique peptidic head group that coordinates iron(III) and an appendage of one of a series of fatty acid moieties. These siderophores have low critical micelle concentrations (CMCs). In the absence of iron, the marinobactins are present as micelles at concentrations exceeding their CMC; upon addition of iron(III), the micelles undergo a spontaneous phase change to form vesicles. These observations suggest that unique iron acquisition mechanisms may have evolved in marine bacteria.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; SW Texas State Univ, Dept Chem, San Marcos, TX 78666 USA; Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Texas State University System; Texas State University San Marcos; University of California System; University of California San Diego; Scripps Institution of Oceanography	Butler, A (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.		Butler, Alison/D-5094-2015; Jung, Hee-Tae/C-1574-2011	Butler, Alison/0000-0002-3525-7864; 	NIGMS NIH HHS [GM38130] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038130, R29GM038130, R55GM038130] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; Butler A, 1998, SCIENCE, V281, P207, DOI 10.1126/science.281.5374.207; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; DEMANGE P, 1988, J CHROMATOGR, V438, P291, DOI 10.1016/S0021-9673(00)90260-7; Fendler JH, 1994, COLLOIDAL DOMAIN PHY, DOI [10.1002/adma.19960080318, DOI 10.1002/ADMA.19960080318]; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; GOYNE ER, 1974, LIMNOL OCEANOGR, V19, P840; Granger J, 1999, LIMNOL OCEANOGR, V44, P541, DOI 10.4319/lo.1999.44.3.0541; HAYGOOD MG, 1993, LIMNOL OCEANOGR, V38, P1091, DOI 10.4319/lo.1993.38.5.1091; Hutchins DA, 1999, NATURE, V400, P858, DOI 10.1038/23680; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; Lee KC, 1999, LANGMUIR, V15, P5500, DOI 10.1021/la9900775; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; OKUJO N, 1994, BIOMETALS, V7, P109; Pakulski JD, 1996, NATURE, V383, P133, DOI 10.1038/383133b0; REID RT, 1993, NATURE, V366, P455, DOI 10.1038/366455a0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAAGER PM, 1989, GEOCHIM COSMOCHIM AC, V53, P2259, DOI 10.1016/0016-7037(89)90348-7; Stackebrandt E, 1990, NUCL ACID TECHNIQUES, P115; SWOFFORD DL, 1999, PAUP PHYLOGENETIC AN; Tortell PD, 1999, FEMS MICROBIOL ECOL, V29, P1; Tortell PD, 1996, NATURE, V383, P330, DOI 10.1038/383330a0; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; Wilhelm SW, 1996, LIMNOL OCEANOGR, V41, P89, DOI 10.4319/lo.1996.41.1.0089; WILHELM SW, 1994, LIMNOL OCEANOGR, V39, P1974; Wu JF, 1996, GEOCHIM COSMOCHIM AC, V60, P2729, DOI 10.1016/0016-7037(96)00135-4	34	249	260	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1245	1247		10.1126/science.287.5456.1245	http://dx.doi.org/10.1126/science.287.5456.1245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678827				2022-12-24	WOS:000085444700044
J	Vijan, S; Hofer, TP; Hayward, RA				Vijan, S; Hofer, TP; Hayward, RA			Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HISPANIC WHITES; MEXICAN-AMERICANS; COMPLICATIONS; NIDDM; MORTALITY; CARE; OPHTHALMOSCOPY; PHOTOGRAPHY; POPULATION; MODEL	Context Annual eye screening for patients with diabetes mellitus is frequently proposed as a measure of quality of care. However, the benefit of annual vs less frequent screening intervals has not been well evaluated, especially for low-risk patients. Objective To examine the marginal cost-effectiveness of various screening intervals for eye disease in patients with type 2 diabetes, stratified by age and level of glycemic control. Design Markov cost-effectiveness model. Setting and Participants Hypothetical patients based on the US population of diabetic patients older than 40 years from the Third National Health and Nutrition Examination Survey. Main Outcome Measures Patient time spent blind, quality-adjusted life-years (QALYs), and costs of annual vs less frequent screening compared by age and level of hemoglobin A(1c). Results Retinal screening in patients with type 2 diabetes is an effective intervention; however, the risk reduction varies dramatically by age and level of glycemic control. On average, a high-risk patient who is aged 45 years and has a hemoglobin A(1c) level of 11% gains 21 days of sight when screened annually as opposed to every third year, while a low-risk patient who is aged 65 years and has a hemoglobin A(1c) level of 7% gains an average of 3 days of sight. The marginal cost-effectiveness of screening annually vs every other year also varies; patients in the high-risk group cost an additional $40 530 per QALY gained, while those in the low-risk group cost an additional $211 570 per QALY gained. In the US population, retinal screening annually vs every other year for patients with type 2 diabetes costs $107 510 per QALY gained, while screening every other year vs every third year costs $49 760 per QALY gained. Conclusions Annual retinal screening for all patients with type 2 diabetes without previously detected retinopathy may not be warranted on the basis of cost-effectiveness, and tailoring recommendations to individual circumstances may be preferable. Organizations evaluating quality of care should consider costs and benefits carefully before setting universal standards.	Vet Affairs Hlth Serv Res & Dev, Qual Enhancement Res Initiat, Ann Arbor, MI 48113 USA; Univ Michigan, Michigan Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vijan, S (corresponding author), Vet Affairs Hlth Serv Res & Dev, Qual Enhancement Res Initiat, POB 130170, Ann Arbor, MI 48113 USA.	svijan@umich.edu	Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1995, DIAB AM; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; DASBACH EJ, 1992, MED DECIS MAKING, V12, P4; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761; FREDERICK FL, 1993, JAMA-J AM MED ASSOC, V269, P1290; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; Harris EL, 1999, DIABETES CARE, V22, P779, DOI 10.2337/diacare.22.5.779; HARRIS EL, 1993, DIABETES CARE, V16, P748, DOI 10.2337/diacare.16.5.748; Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; KLEIN R, 1986, AM J EPIDEMIOL, V124, P104, DOI 10.1093/oxfordjournals.aje.a114353; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MANNING WG, 1996, COST EFFECTIVENESS H; MARTIN TL, 1995, DIABETES CARE, V18, P1124, DOI 10.2337/diacare.18.8.1124; MAYFIELD JA, 1994, DIABETES CARE, V17, P918, DOI 10.2337/diacare.17.8.918; Medhi J, 1994, STOCHASTIC PROCESSES; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; MULLAHY J, 1995, STAT ISSUES COST EFF, P149; *NAT COMM QUAL ASS, 1997, HLTH EMPL DAT INF SE, P2; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; Nathan DM, 1996, ANN INTERN MED, V124, P86, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00002; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; Tudor SM, 1998, DIABETES CARE, V21, P53, DOI 10.2337/diacare.21.1.53; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; WYLIEROSETT J, 1995, J DIABETES COMPLICAT, V9, P49, DOI 10.1016/1056-8727(94)00005-9; 1996, FED REG, V61; 1994, VITAL HLTH STAT 1, V32, P1	57	180	185	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2000	283	7					889	896		10.1001/jama.283.7.889	http://dx.doi.org/10.1001/jama.283.7.889			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281WT	10685713				2022-12-24	WOS:000085185000027
J	Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM				Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM			Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration	SCIENCE			English	Article							3-KINASE; KINASE; PHOSPHORYLATION; INHIBITION; WORTMANNIN; PEPTIDE; SYSTEM; PI3K	Phosphoinositide 3-kinases (PI3Ks) regulate fundamental cellular responses such as proliferation, apoptosis, cell motility, and adhesion. Viable gene-targeted mice Lacking the p110 catalytic subunit of PI3K gamma were generated. We show that PI3K gamma controls thymocyte survival and activation of mature T cells but has no role in the development or function of B cells. PI3K gamma-deficient neutrophils exhibited severe defects in migration and respiratory burst in response to heterotrimeric CTP-binding protein (G protein)-coupled receptor (GPCR) agonists and chemotactic agents. PI3K gamma Links GPCR stimulation to the formation of phosphatidylinositol 3,4,5-triphosphate and the activation of protein kinase B, ribosomal protein S6 kinase, and extracellular signal-regulated kinases 1 and 2. Thus, PI3K gamma regulates thymocyte development, T cell activation, neutrophil migration, and the oxidative burst.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Amgen, Dept Pathol, Thousand Oaks, CA 91320 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Jones, Russell/AAC-2861-2022; Penninger, Josef M/I-6860-2013; Suzuki, Akira/GYD-6697-2022; Jones, Russell Graham/ABD-5261-2021	Penninger, Josef M/0000-0002-8194-3777; Suzuki, Akira/0000-0002-5950-8808; Jones, Russell Graham/0000-0003-2250-4675; Stanford, William/0000-0002-5813-8016; Ohashi, Pamela S./0000-0003-2915-9317; Sasaki, Takehiko/0000-0003-1837-3748				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; COURNOYER D, 1993, ANNU REV IMMUNOL, V11, P297; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Mariathasan S, 1999, SEMIN IMMUNOL, V11, P263, DOI 10.1006/smim.1999.0182; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	23	891	988	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1040	1046		10.1126/science.287.5455.1040	http://dx.doi.org/10.1126/science.287.5455.1040			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669416				2022-12-24	WOS:000085245400048
J	Bachiller, D; Klingensmith, J; Kemp, C; Belo, JA; Anderson, RM; May, SR; McMahon, JA; McMahon, AP; Harland, RM; Rossant, J; De Robertis, EM				Bachiller, D; Klingensmith, J; Kemp, C; Belo, JA; Anderson, RM; May, SR; McMahon, JA; McMahon, AP; Harland, RM; Rossant, J; De Robertis, EM			The organizer factors Chordin and Noggin are required for mouse forebrain development	NATURE			English	Article							ANTERIOR PRIMITIVE ENDODERM; SPEMANN ORGANIZER; VISCERAL ENDODERM; SECRETED FACTOR; SONIC HEDGEHOG; NEURAL PLATE; GENE; ZEBRAFISH; CERBERUS; SUGGESTS	In mice, there is evidence suggesting that the development of head and trunk structures is organized by distinctly separated cell populations(1,2). The head organizer is located in the anterior visceral endoderm (AVE) and the trunk organizer in the node and anterior primitive streak. In amphibians, Spemann's organizer, which is homologous to the node, partially overlaps with anterior endoderm cells expressing homologues of the AVE markers cerberus, Hex and Hesx1 (refs 3-6). For mice, this raises the question of whether the AVE and node are independent of each other, as suggested by their anatomical separation, or functionally interdependent as is the case in amphibians(3-5). Chordin and Noggin are secreted bone morphogenetic protein (BMP) antagonists(7,8) expressed in the mouse node, but not in the AVE. Here we show that mice double-homozygous mutants that are for chordin and noggin display severe defects in the development of the prosencephalon, The results show that BMP antagonists in the node and its derivatives are required for head development.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Duke University; Harvard University; University of California System; University of California Berkeley; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.		McMahon, Andrew P/ABE-7520-2020; Belo, José A. A/F-4444-2012	Belo, José A. A/0000-0001-7384-0949; Bachiller, Daniel/0000-0002-5016-317X				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Arkell R, 1997, DEVELOPMENT, V124, P1; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; Dufort D, 1998, DEVELOPMENT, V125, P3015; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GOLDEN JA, 1999, P NATL ACAD SCI USA, V54, P623; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oliver G, 1995, DEVELOPMENT, V121, P4045; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Rhinn M, 1998, DEVELOPMENT, V125, P845; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Solloway MJ, 1999, DEVELOPMENT, V126, P1753; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zorn AM, 1999, DEV BIOL, V209, P282, DOI 10.1006/dbio.1999.9257	30	397	423	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					658	661		10.1038/35001072	http://dx.doi.org/10.1038/35001072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688202				2022-12-24	WOS:000085288200054
J	Song, WQ; Raden, D; Mandon, EC; Gilmore, R				Song, WQ; Raden, D; Mandon, EC; Gilmore, R			Role of Sec61 alpha in the regulated transfer of the ribosome-nascent chain complex from the signal recognition particle to the translocation channel	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; GTP HYDROLYSIS; BETA-SUBUNIT; ER MEMBRANE; SEQUENCE RECOGNITION; SECRETORY PROTEIN; ALPHA-SUBUNIT; RECEPTOR; BINDING	Targeting of ribosome-nascent chain complexes to the translocon in the endoplasmic reticulum is mediated by the concerted action of the signal recognition particle (SRP) and the SRP receptor (SR). Ribosome-stripped microsomes were digested with proteases to sever cytoplasmic domains of SR alpha, SR beta, TRAM, and the Sec61 complex. We characterized protein translocation intermediates that accumulate when Sec61 alpha or SRP is inactivated by proteolysis. In the absence of a functional Sec61 complex, dissociation of SRP54 from the signal sequence is blocked. Experiments using SR proteoliposomes confirmed the assembly of a membrane-bound posttargeting intermediate. These results strongly suggest that the Sec61 complex regulates the GTP hydrolysis cycle of the SRP-SR complex at the stage of signal sequence dissociation from SRP54.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Gilmore, R (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA.	reid.gilmore@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; Knight BC, 1998, BIOCHEM J, V331, P161, DOI 10.1042/bj3310161; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	38	113	115	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					333	343		10.1016/S0092-8674(00)80669-8	http://dx.doi.org/10.1016/S0092-8674(00)80669-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676815	Bronze			2022-12-24	WOS:000085204400007
J	Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC				Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC			Synaptic assembly of the brain in the absence of neurotransmitter secretion	SCIENCE			English	Article							ACETYLCHOLINE-RELEASE; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; VESICLE EXOCYTOSIS; EMBRYONIC NEURON; AXON GUIDANCE; SYNAPSIN-I; RAT-BRAIN; PROTEIN; SYNTAXIN	Brain function requires precisely orchestrated connectivity between neurons. Establishment of these connections is believed to require signals secreted from outgrowing axons, followed by synapse formation between selected neurons. Deletion of a single protein, Munc18-1, in mice Leads to a complete Loss of neurotransmitter secretion from synaptic vesicles throughout development. However, this does not prevent normal brain assembly, including formation of Layered structures, fiber pathways, and morphologically defined synapses. After assembly is completed, neurons undergo apoptosis, leading to widespread neurodegeneration. Thus, synaptic connectivity does not depend on neurotransmitter secretion, but its maintenance does. Neurotransmitter secretion probably functions to validate already established synaptic connections.	Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Physiol, Leiden, Netherlands; Vrije Univ Amsterdam, Inst Neurosci, Dept Neurophysiol, Amsterdam, Netherlands; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Vrije Univ Amsterdam, Dept Cell Biol & Immunol, Amsterdam, Netherlands; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Utrecht University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam; Utrecht University	Verhage, M (corresponding author), Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands.		Heeroma, Joost/C-1749-2008; Heeroma, Joost/AAF-4310-2022; van den Berg, Timo K/AAC-2479-2022; Heeroma, Joost/AFI-8727-2022	Hammer, Robert E./0000-0001-5487-7551; Missler, Markus/0000-0001-8008-984X; verhage, matthijs/0000-0002-6085-7503				[Anonymous], 1990, SYNAPTIC ORG BRAIN; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Calakos N, 1996, PHYSIOL REV, V76, P1; CATSICAS S, 1994, TRENDS NEUROSCI, V17, P368, DOI 10.1016/0166-2236(94)90045-0; Coco S, 1998, J NEUROCHEM, V71, P1987; Daly C, 1997, J NEUROSCI, V17, P2365; de Vries J., UNPUB; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Hallonet M, 1998, DEVELOPMENT, V125, P2599; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; Igarashi M, 1997, J NEUROSCI, V17, P1460; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; MAIA AS, UNPUB; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Milner LD, 1999, J NEUROSCI, V19, P3007; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PLOMP JJ, 1994, J PHYSIOL-LONDON, V478, P125, DOI 10.1113/jphysiol.1994.sp020236; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Williamson LC, 1998, J NEUROSCI RES, V52, P569, DOI 10.1002/(SICI)1097-4547(19980601)52:5<569::AID-JNR9>3.0.CO;2-A; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069	42	947	976	0	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					864	869		10.1126/science.287.5454.864	http://dx.doi.org/10.1126/science.287.5454.864			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657302				2022-12-24	WOS:000085136400049
J	Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J				Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J			Physiology - A function for guttural pouches in the horse	NATURE			English	Article							BLOOD-FLOW; EXERCISE; HEAT		Univ Saskatchewan, Dept Vet Internal Med, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Vet Anaesthesia Radiol & Surg, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Agr Engn, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Baptiste, KE (corresponding author), Danish Vet Lab, Bulowsvej 27, Copenhagen, Denmark.	keb@svs.dk						BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; BRANDT JF, 1863, B ACAD IMPERIAL SCI, V5, P508; Day M, 1999, NEW SCI, V161, P7; Ghoshal N, 1981, VENOUS DRAINAGE DOME; HINCHCLIFFE R, 1969, J ZOOL, V157, P277; HODGSON DR, 1993, J APPL PHYSIOL, V74, P1161, DOI 10.1152/jappl.1993.74.3.1161; McConaghy F F, 1996, Equine Vet J Suppl, P42; McConaghy FF, 1995, J APPL PHYSIOL, V79, P1849, DOI 10.1152/jappl.1995.79.6.1849; ORR JA, 1983, AM J PHYSIOL, V244, pH142, DOI 10.1152/ajpheart.1983.244.1.H142; PARKS CM, 1983, AM J VET RES, V44, P1861	10	36	37	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					382	383		10.1038/35000284	http://dx.doi.org/10.1038/35000284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667779				2022-12-24	WOS:000085121100035
J	Reacher, MH; Shah, A; Livermore, DM; Wale, MCJ; Graham, C; Johnson, AP; Heine, H; Monnickendam, MA; Barker, KF; James, D; George, RC				Reacher, MH; Shah, A; Livermore, DM; Wale, MCJ; Graham, C; Johnson, AP; Heine, H; Monnickendam, MA; Barker, KF; James, D; George, RC			Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIMICROBIAL RESISTANCE; BLOOD	Objectives Determination of causes, trends, and antibiotic resistance in reports of bacterial pathogens isolated from blood in England and Wales from 1990 to 1998. Design Description of bacterial isolates from blood, judged to be clinically significant by microbiology staff, reported to the Communicable Disease Surveillance Centre. Setting Microbiology laboratories in England and Wales. Subjects Patients yielding clinically significant isolates from blood. Main outcome measures Frequency and Poisson regression analyses for trend of reported causes of bacteraemia and proportions of antibiotic resistant isolates. Results There was an upward trend in total numbers of reports of bacteraemia. The five most cited organisms accounted for over 60% of reports each year. There was a substantial increase in the proportion of reports of Staphylococcus aureus resistant to methicillin, Streptococcus pneumoniae resistance to penicillin and erythromycin, and Enterococcus faecalis and Enterococcus faecium resistance to vancomycin. No increase was seen in resistance of Escherichia coli to gentamicin. Conclusions Reports from laboratories provide Valuable information on trends and antibiotic resistance in bacteraemia and show a worrying increase in resistance to important antibiotics.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; PHLS Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England; PHLS Cent Publ Hlth Lab, Resp & Systemat Infect Lab, London NW9 5HT, England; Queens Med Ctr, PHLS Antimicrobial Susceptibil Surveillance Unit, Nottingham NG7 2UH, England; PHLS Stat Unit, London NW9 5EQ, England; PHLS Headquarters, London NW9 5DF, England; SmithKline Beecham Pharmaceut, Int Med Dept, Brentford TW8 9BD, Middx, England	Public Health England; University of Nottingham; GlaxoSmithKline	Reacher, MH (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England.	mreacher@phls.nhs.uk	Reacher, Mark/Y-6979-2018; Johnson, Alan P/F-4420-2014	Reacher, Mark/0000-0001-6871-7903; 				*ASS MED MICR, 1998, AMM DIR MED MICR SER, P139; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; Cockerill FR, 1997, CLIN INFECT DIS, V24, P403, DOI 10.1093/clinids/24.3.403; Grant A D, 1993, Commun Dis Rep CDR Rev, V3, pR75; Hargreaves RM, 1996, BRIT MED J, V312, P160; Henry R., 1996, PHLS Microbiology Digest, V13, P26; *HOSP INF WORK GRO, 1995, HOSP INF CONTR GUID; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; Johnson AP, 1998, J HOSP INFECT, V40, P17, DOI 10.1016/S0195-6701(98)90020-2; Johnson AP, 1999, J ANTIMICROB CHEMOTH, V43, P160, DOI 10.1093/jac/43.1.160; Laurichesse H, 1998, Commun Dis Public Health, V1, P22; Livermore DM, 1998, BRIT MED J, V317, P614, DOI 10.1136/bmj.317.7159.614; LIVERMORE DM, INPRESS J ANTIMICROB; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; Speller DCE, 1997, LANCET, V350, P323, DOI 10.1016/S0140-6736(97)12148-1; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609; Young L. S., 1995, PRINCIPLES PRACTICE, P690; 1999, COMMUN DIS REP CDR W, V9, P185; [No title captured]; [No title captured]; 1996, COMMUN DIS REPORT CD, V6, P83; 1997, COMMUN DIS REPORT CD, V7, P13	24	235	245	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2000	320	7229					213	216		10.1136/bmj.320.7229.213	http://dx.doi.org/10.1136/bmj.320.7229.213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10642227	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000085029600022
J	Barth, JH				Barth, JH			Should men still go bald gracefully?	LANCET			English	Editorial Material							ANDROGENETIC ALOPECIA; RECEPTOR; WOMEN		Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Barth, JH (corresponding author), Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England.		Barth, Julian H/F-6028-2010					GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Orme S, 1999, BRIT J DERMATOL, V141, P521; Price VH, 1999, J AM ACAD DERMATOL, V41, P717, DOI 10.1016/S0190-9622(99)70006-X; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Roberts JL, 1999, J AM ACAD DERMATOL, V41, P555, DOI 10.1016/S0190-9622(99)70296-3; RUSHTON DH, 1992, CLIN ENDOCRINOL, V36, P421; RUSHTON DH, 1991, CLIN EXP DERMATOL, V16, P188, DOI 10.1111/j.1365-2230.1991.tb00343.x; Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779	10	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					161	162		10.1016/S0140-6736(99)00412-2	http://dx.doi.org/10.1016/S0140-6736(99)00412-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675111				2022-12-24	WOS:000084879700005
J	Britton-Davidian, J; Catalan, J; Ramalhinho, MD; Ganem, G; Auffray, JC; Capela, R; Biscoito, M; Searle, JB; Mathias, MD				Britton-Davidian, J; Catalan, J; Ramalhinho, MD; Ganem, G; Auffray, JC; Capela, R; Biscoito, M; Searle, JB; Mathias, MD			Environmental genetics - Rapid chromosomal evolution in island mice	NATURE			English	Article							MUS-MUSCULUS-DOMESTICUS		Univ Montpellier 2, ISEM, Lab Genet & Environm, CNRS,UMR 5554, F-34095 Montpellier 5, France; Museo Nacl Hist Nat, Ctr Biol Ambiental, P-1200 Lisbon, Portugal; Univ Madeira, Dept Biol, P-9000 Funchal, Madeira, Portugal; CITMA, P-9000 Funchal, Madeira, Portugal; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Lisbon, Fac Ciencias, Dept Zool & Anthropol, P-1700 Lisbon, Portugal	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Universidade da Madeira; University of York - UK; Universidade de Lisboa	Britton-Davidian, J (corresponding author), Univ Montpellier 2, ISEM, Lab Genet & Environm, CNRS,UMR 5554, F-34095 Montpellier 5, France.		da Luz Mathias, Maria/V-9931-2018; Ganem, Guila/AAC-1872-2022; Auffray, Jean-Christophe/AAW-1052-2020; Biscoito, Manuel/AAC-4390-2021; Auffray, jean-christophe/HCI-4881-2022; AUFFRAY, Jean-Christophe/H-1907-2011; Auffray, Jean-Christophe/AAH-6131-2019	da Luz Mathias, Maria/0000-0003-3876-958X; Ganem, Guila/0000-0002-5244-4979; Auffray, Jean-Christophe/0000-0002-5184-0507; Biscoito, Manuel/0000-0002-9347-0823; 				BAKER RJ, 1986, P NATL ACAD SCI USA, V83, P8245, DOI 10.1073/pnas.83.21.8245; GARAGNA S, 1997, NATURE, V390, P242; Grant P.R., 1998, EVOLUTION ISLANDS; Hauffe HC, 1998, GENETICS, V150, P1143; HAUFFE HC, 1993, EVOLUTION, V47, P1374, DOI 10.1111/j.1558-5646.1993.tb02161.x; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; MATHIAS MD, 1992, BIOL J LINN SOC, V46, P13, DOI 10.1111/j.1095-8312.1992.tb00846.x; NACHMAN MW, 1995, TRENDS ECOL EVOL, V10, P397, DOI 10.1016/S0169-5347(00)89155-7; Provine W.B., 1989, P43	9	130	135	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					158	158		10.1038/35003116	http://dx.doi.org/10.1038/35003116			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646592				2022-12-24	WOS:000084835300043
J	Jenni, OG				Jenni, OG			On the other of the tracks	LANCET			English	Editorial Material									Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Jenni, OG (corresponding author), Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland.		Jenni, Oskar/AAG-4391-2019	Jenni, Oskar/0000-0002-4561-6277					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					139	140		10.1016/S0140-6736(99)11156-5	http://dx.doi.org/10.1016/S0140-6736(99)11156-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675183				2022-12-24	WOS:000085557200040
J	Murray, TJ				Murray, TJ			Personal time: The patient's experience	ANNALS OF INTERNAL MEDICINE			English	Article								When a life-threatening or chronic disease is diagnosed, patients may find that their sense of time, the passage of days, and their view of the future are altered. Most of the time, people live in a sense of linear time, or kronos. When illness strikes, they may begin to spend more time in kairos, a sense of soul-satisfying time, such as the feeling one gets when walking on the seashore with a grandchild, working in the garden, or talking with friends over good food and wine. This article comments on two patients, one who explores kairos through a diary that documents her positive attitude toward coping with multiple sclerosis, and one, a young artist with Hodgkin disease, who explores his condition through 96 paintings of his experience of the disease. Rather than "the devouring tyrant of linear time," life can be seen in a circular fashion, the eternal braid of Hofstadter. Patients begin to see life more in terms of cycles of daily events, routines, and the change of seasons. Illness brings one "close to the bone" of the soul's needs, with a reappraisal of the journey of life as a continuous line, to life spread out on a landscape that includes the past and the future.	Dalhousie Univ, Sch Med, Halifax, NS B3H 4H7, Canada	Dalhousie University	Murray, TJ (corresponding author), Dalhousie Univ, Sch Med, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.	jock.murray@dal.ca						AMIS M, 1998, TIMES ARROW; [Anonymous], ECCLESIASTES, V3; BOLEN JS, 1996, CLOSE BONE, P86; CAPPELLA B, 1977, PERCEPT MOTOR SKILL, V44, P787, DOI 10.2466/pms.1977.44.3.787; Dossey L., 1982, SPACE TIME MED; EDDINGTON AS, 1957, MATH THEORY RELATIVI, P23; Hofstadter D.R, 1979, GODEL ESCHER BACH ET; JANTSCH E, 1980, SELF ORG UNIVERSE SC, P97; McLuhan M., 1964, UNDERSTANDING MEDIA; Pope R, 1991, ILLNESS HEALING IMAG; Priestley J.B., 1978, MAN TIME; Shallis M., 1983, TIME INVESTIGATION S; SZAMOSI G, 1986, ORIGIN TIME MEDIEVAL, P33	13	14	14	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					58	62		10.7326/0003-4819-132-1-200001040-00010	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627253				2022-12-24	WOS:000084518600009
J	Voss, LD; Mulligan, J				Voss, LD; Mulligan, J			Bullying in school: are short pupils at risk? Questionnaire study in a cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp, Univ Child Hlth, Southampton SO21 16YD, Hants, England		Voss, LD (corresponding author), Southampton Gen Hosp, Univ Child Hlth, Southampton SO21 16YD, Hants, England.	linda.voss@phnt.swest.nhs.uk						Leff S, 1999, BRIT MED J, V318, P1076, DOI 10.1136/bmj.318.7190.1076; Olweus D., 1993, AGGRESSIVE BEHAV CUR; Salmon G, 1998, BRIT MED J, V317, P924; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; WHITNEY I, 1993, EDUC RES, V35, P3, DOI 10.1080/0013188930350101	5	82	82	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2000	320	7235					612	613		10.1136/bmj.320.7235.612	http://dx.doi.org/10.1136/bmj.320.7235.612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	291NH	10698879	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000085742600025
J	Distel, DL; Baco, AR; Chuang, E; Morrill, W; Cavanaugh, C; Smith, CR				Distel, DL; Baco, AR; Chuang, E; Morrill, W; Cavanaugh, C; Smith, CR			Marine ecology - Do mussels take wooden steps to deep-sea vents?	NATURE			English	Article							WHALE FALL; ENVIRONMENTS; BIVALVIA; COMMUNITY; MYTILIDAE; OCEAN		Univ Maine, Dept Biochem Microbiol & Mol Biol, Orono, ME 04469 USA; Univ Hawaii, Dept Oceanog, Honolulu, HI 96822 USA; Harvard Univ, Biol Labs, Cambridge, MA 02138 USA	University of Maine System; University of Maine Orono; University of Hawaii System; Harvard University	Distel, DL (corresponding author), Univ Maine, Dept Biochem Microbiol & Mol Biol, Orono, ME 04469 USA.		Distel, Daniel/A-8047-2017	Distel, Daniel/0000-0002-3860-194X				BENNETT BA, 1994, MAR ECOL PROG SER, V108, P205, DOI 10.3354/meps108205; CAMPBELL KA, 1995, GEOLOGY, V23, P321, DOI 10.1130/0091-7613(1995)023<0321:BACBIP>2.3.CO;2; DANDO PR, 1992, NATURE, V356, P667, DOI 10.1038/356667a0; DEAN HK, 1993, MALACOLOGIA, V35, P21; DELL R K, 1987, National Museum of New Zealand Records, V3, P17; Deming JW, 1997, MICROSC RES TECHNIQ, V37, P162, DOI 10.1002/(SICI)1097-0029(19970415)37:2<162::AID-JEMT4>3.0.CO;2-Q; DISTEL DL, IN PRESS MOL PHYLOGE; Feldman RA, 1998, BIOL BULL, V194, P116, DOI 10.2307/1543041; GRASSLE JF, 1987, DEEP-SEA RES, V34, P1911, DOI 10.1016/0198-0149(87)90091-4; Gustafson RG, 1998, MALACOLOGIA, V40, P63; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; KENK VC, 1985, MALACOLOGIA, V26, P253; LESCHINE SB, 1995, ANNU REV MICROBIOL, V49, P399, DOI 10.1146/annurev.mi.49.100195.002151; REID RGB, 1980, CAN J ZOOL, V58, P386, DOI 10.1139/z80-050; SMITH CR, 1989, NATURE, V341, P27, DOI 10.1038/341027a0; SWOFFORD DL, 1997, PAUP 4 0; WOLFF T, 1979, SARSIA, V64, P117, DOI 10.1080/00364827.1979.10411373	17	231	244	2	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					725	726		10.1038/35001667	http://dx.doi.org/10.1038/35001667			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693793				2022-12-24	WOS:000085423100040
J	Imai, S; Armstrong, CM; Kaeberlein, M; Guarente, L				Imai, S; Armstrong, CM; Kaeberlein, M; Guarente, L			Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ADP-RIBOSYLATION; RIBOSOMAL DNA; YEAST; INVIVO; HETEROCHROMATIN; RECOMBINATION; ACETYLATION; RESTRICTION; REPRESSION	Yeast Sir2 is a heterochromatin component that silences transcription at silent mating loci(1), telomeres(2) and the ribosomal DNA(3,4), and that also suppresses recombination in the rDNA(5) and extends replicative life span(6). Mutational studies indicate that lysine 16 in the amino-terminal tail of histone H4 and lysines 9, 14 and 18 in H3 are critically important in silencing, whereas lysines 5, 8 and 12 of H4 have more redundant functions(7-9). Lysines 9 and 14 of histone H3 and lysines 5, 8 and 16 of H4 are acetylated in active chromatin and hypoacetylated in silenced chromatin, and overexpression of Sir2 promotes global deacetylation of histones(9,10), indicating that Sir2. may be a histone deacetylase. Deacetylation of lysine 16 of H4 is necessary for binding the silencing protein, Sir3 (ref. 8). Here we show that yeast and mouse Sir2 proteins are nicotinamide adenine dinucleotide (NAD)dependent histone deacetylases, which deacetylate lysines 9 and 14 of H3 and specifically lysine 16 of H4. Our analysis of two SIR2 mutations supports the idea that this deacetylase activity accounts for silencing, recombination suppression and extension of life span in vivo. These findings provide a molecular framework of NAD-dependent histone deacetylation that connects metabolism, genomic silencing and ageing in yeast and, perhaps, in higher eukaryotes.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							ADAMIETZ P, 1984, J BIOL CHEM, V259, P6841; BANASIK M, 1994, MOL CELL BIOCHEM, V138, P185, DOI 10.1007/BF00928461; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KREIMEYER A, 1984, J BIOL CHEM, V259, P890; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; PERO RW, 1985, MUTAT RES, V142, P69, DOI 10.1016/S0165-7992(85)80016-6; RINE J, 1987, GENETICS, V116, P9; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; SINCLAIR DA, 1997, CELL, V91, P1; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	30	2640	2775	13	252	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					795	800		10.1038/35001622	http://dx.doi.org/10.1038/35001622			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693811				2022-12-24	WOS:000085423100058
J	Mesecar, AD; Koshland, DE				Mesecar, AD; Koshland, DE			Structural biology - A new model for protein stereospecificity	NATURE			English	Article									Univ Illinois, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Adv Mat, Berkeley, CA 94720 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Mesecar, AD (corresponding author), Univ Illinois, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol, 900 S Ashland Ave MC 870, Chicago, IL 60607 USA.			Mesecar, Andrew/0000-0002-1241-2577				Dixon M., 1979, ENZYMES, Vthird; Easson LH, 1933, BIOCHEM J, V27, P1257, DOI 10.1042/bj0271257; Lehninger A L, 1982, PRINCIPLES BIOCH; Lewis DL, 1999, NATURE, V401, P898, DOI 10.1038/44801; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; OGSTON AG, 1948, NATURE, V162, P963, DOI 10.1038/162963b0; SEGEL IH, 1972, ENZYME KINETICS; Stryer L., 1988, BIOCHEMISTRY-US; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409	9	106	107	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					614	615		10.1038/35001144	http://dx.doi.org/10.1038/35001144			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688187				2022-12-24	WOS:000085288200039
J	Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H				Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H			Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity	SCIENCE			English	Article							HERPES STROMAL KERATITIS; DENDRITIC CELLS; IN-VITRO; SECRETED PHOSPHOPROTEIN; BACTERIAL-INFECTION; GRANULOMA-FORMATION; GENETIC-RESISTANCE; AUTOIMMUNE-DISEASE; ESCHERICHIA-COLI; UP-REGULATION	Cell-mediated (type-1) immunity is necessary for immune protection against most intracellular pathogens and, when excessive, can mediate organ-specific autoimmune destruction. Mice deficient in Eta-1 (also called osteopontin) gene expression have severely impaired type-1 immunity to viral infection [herpes simplex virus-type 1 (KOS strain)] and bacterial infection (Listeria monocytogenes) and do not develop sarcoid-type granulomas. Interleukin-12 (IL-12) and interferon-gamma production is diminished, and IL-10 production is increased. A phosphorylation-dependent interaction between the amino-terminal portion of Eta-1 and its integrin receptor stimulated IL-12 expression, whereas a phosphorylation-independent interaction with CD44 inhibited IL-10 expression. These findings identify Eta-1 as a key cytokine that sets the stage for efficient type-1 immune responses through differential regulation of macrophage IL-12 and IL-10 cytokine expression.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp,Dept Orthoped Surg, Lab Skeletal Disorders & Rehabil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rutgers State Univ, Fac Arts & Sci, Div Life Sci, Piscataway, NJ 08854 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rutgers State University New Brunswick	Cantor, H (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	Harvey_Cantor@DFCl.harvard.edu	Eckhardt, Erik/G-1567-2010	Panoutsakopoulou, Vily/0000-0002-1569-1508	NCI NIH HHS [CA76176] Funding Source: Medline; NIAID NIH HHS [AI12184, AI37833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012184, P01AI037833, R37AI012184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V194, P274, DOI 10.1006/bbrc.1993.1815; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CONSTANT SL, 1999, ANNU REV IMMUNOL, V15, P297; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; Daheshia M, 1997, J IMMUNOL, V159, P1945; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; JERRELLS TR, 1981, INFECT IMMUN, V31, P1014, DOI 10.1128/IAI.31.3.1014-1022.1981; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; NEMIR M, 1989, J BIOL CHEM, V264, P18202; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Oxenius A, 1999, J IMMUNOL, V162, P965; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; Ria F, 1998, EUR J IMMUNOL, V28, P2003, DOI 10.1002/(SICI)1521-4141(199806)28:06<2003::AID-IMMU2003>3.0.CO;2-S; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; Sharma MD, 1998, J IMMUNOL, V161, P5357; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SORENSEN ES, 1994, BIOCHEM BIOPH RES CO, V198, P200, DOI 10.1006/bbrc.1994.1028; Stordeur P, 1998, Int Rev Immunol, V16, P501, DOI 10.3109/08830189809043006; STORDEUR P, 1995, MOL IMMUNOL, V32, P233, DOI 10.1016/0161-5890(94)00158-W; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; TRIPP CS, 1994, J IMMUNOL, V152, P1883; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; TRIPP CS, 1995, J IMMUNOL, V155, P3427; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; VANDENBOGERT C, 1986, VIRCHOWS ARCH B, V51, P39; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yin ZH, 1997, ARTHRITIS RHEUM, V40, P1788, DOI 10.1002/art.1780401010; Yu XQ, 1998, P ASSOC AM PHYSICIAN, V110, P50; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	52	921	984	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					860	864		10.1126/science.287.5454.860	http://dx.doi.org/10.1126/science.287.5454.860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657301				2022-12-24	WOS:000085136400048
J	Urano, F; Wang, XZ; Bertolotti, A; Zhang, YH; Chung, P; Harding, HP; Ron, D				Urano, F; Wang, XZ; Bertolotti, A; Zhang, YH; Chung, P; Harding, HP; Ron, D			Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1	SCIENCE			English	Article							NF-KAPPA-B; C-JUN; ENDOPLASMIC-RETICULUM; TERMINAL KINASE; TNF RECEPTOR-1; PATHWAY; TRAF2; NUCLEUS; PHOSPHORYLATION; REQUIRES	Malfolded proteins in the endoplasmic reticulum (ER) induce cellular stress and activate c-Jun amino-terminal kinases (JNKs or SAPKs), Mammalian homologs of yeast IRE1, which activate chaperone genes in response to ER stress, also activated INK, and IRE1 alpha(-/-) fibroblasts were impaired in JNK activation by ER stress. The cytoplasmic part of IRE1 bound TRAF2, an adaptor protein that couples plasma membrane receptors to JNK activation. Dominant-negative TRAF2 inhibited activation of JNK by IRE1. Activation of JNK by endogenous signals initiated in the ER proceeds by a pathway similar to that initiated by cell surface receptors in response to extracellular signals.	NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, Dept Med, New York, NY 10016 USA	New York University; New York University	Ron, D (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA.	ron@saturn.med.nyu.edu	Urano, Fumihiko/AAF-4492-2020; Longo, Kenneth A/A-5631-2010	Harding, Heather P/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047119, R01DK047119, R29DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MORI K, 1993, CELL, V74, P743; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; YAN MH, 1994, NATURE, V372, P798; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	33	2061	2131	10	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					664	666		10.1126/science.287.5453.664	http://dx.doi.org/10.1126/science.287.5453.664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650002				2022-12-24	WOS:000084989400051
J	Koskelainen, A; Ala-Laurila, P; Fyhrquist, N; Donner, K				Koskelainen, A; Ala-Laurila, P; Fyhrquist, N; Donner, K			Measurement of thermal contribution to photoreceptor sensitivity	NATURE			English	Article							FROG RETINA; NOISE; CONE; PIGMENTS; VISION	Activation of a visual pigment molecule to initiate phototransduction requires a minimum energy, E-a, that need not be wholly derived from a photon, but may be supplemented by heat(1), Theory(2,3) predicts that absorbance at very long wavelengths declines with the fraction of molecules that have a sufficient complement of thermal energy, and that E-a is inversely related to the wavelength of maximum absorbance (lambda(max)) of the pigment, Consistent with the first of these predictions, warming increases relative visual sensitivity to long wavelengths(4-8). Here we measure this effect in amphibian photoreceptors with different pigments to estimate E-a (refs 2, 5-7) and test experimentally the predictions of an inverse relation between E-a and lambda(max). For rods and 'red' cones in the adult frog retina, we find no significant difference in E-a between the two pigments involved, although their lambda(max) values are very different. We also determined E-a for the rhodopsin in toad retinal rods--spectrally similar to frog rhodopsin hut differing in amino-acid sequence-and found that it was significantly higher. In addition, we estimated E-a for two pigments whose lambda(max) difference was due only to a chromophore difference (A1 and A2 pigment, in adult and larval bag cones), Here E-a for A2 was lower than for Al. Our results refute the idea of a necessary relation between lambda(max) and E-a but show that the A1 --> A2 chromophore substitution decreases E-a.	Aalto Univ, Biomed Engn Lab, FIN-02015 Espoo, Finland; Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland	Aalto University; University of Helsinki	Koskelainen, A (corresponding author), Aalto Univ, Biomed Engn Lab, POB 2200, FIN-02015 Espoo, Finland.	ari.koskelainen@hut.fi	Ala-Laurila, Petri/AAE-1203-2019	Ala-Laurila, Petri/0000-0002-6139-6825; Fyhrquist, Nanna Theresia/0000-0002-5408-0005				BARLOW HB, 1956, J OPT SOC AM, V46, P634, DOI 10.1364/JOSA.46.000634; BARLOW HB, 1957, NATURE, V179, P255, DOI 10.1038/179255b0; BARLOW RB, 1993, NATURE, V366, P64, DOI 10.1038/366064a0; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BOWMAKER JK, 1994, VISION RES, V34, P591, DOI 10.1016/0042-6989(94)90015-9; Bridges CDB, 1972, HDB SENSORY PHYSIOLO, P417, DOI DOI 10.1007/978-3-642-65066-6_11; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; Dartnall H. J. A., 1965, Vision Research, V5, P81, DOI 10.1016/0042-6989(65)90057-X; DENTON EJ, 1954, J PHYSIOL-LONDON, V125, P181, DOI 10.1113/jphysiol.1954.sp005149; DONNER K, 1990, J PHYSIOL-LONDON, V428, P673, DOI 10.1113/jphysiol.1990.sp018234; Donner K, 1998, VISION RES, V38, P19, DOI 10.1016/S0042-6989(97)00144-2; DONNER K, 1992, VISION RES, V32, P853, DOI 10.1016/0042-6989(92)90028-H; FIRSOV ML, 1990, SENSORY SYSTEMS, V4, P25; Fyhrquist N, 1998, EXP EYE RES, V66, P295, DOI 10.1006/exer.1997.0430; Goldsmith T.H., 1989, P1; GOVARDOVSKII VI, IN PRESS VIS NEUROSC; KOSKELAINEN A, 1994, ACTA PHYSIOL SCAND, V152, P115, DOI 10.1111/j.1748-1716.1994.tb09790.x; KUNLIN J, 1948, CR HEBD ACAD SCI, V226, P357, DOI 10.1007/BF00369741; LAMB TD, 1977, J PHYSIOL-LONDON, V272, P435, DOI 10.1113/jphysiol.1977.sp012053; LAMB TD, 1984, J PHYSIOL-LONDON, V346, P557, DOI 10.1113/jphysiol.1984.sp015041; LEWIS PR, 1955, J PHYSIOL-LONDON, V130, P45, DOI 10.1113/jphysiol.1955.sp005391; LUTHGOE JN, 1988, SENSORY BIOL AQUATIC, P57; Lythgoe RJ, 1938, J PHYSIOL-LONDON, V93, P24, DOI 10.1113/jphysiol.1938.sp003622; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Reuter T., 1969, Acta Zoologica Fennica, V122, P1; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SREBRO R, 1966, J PHYSIOL-LONDON, V187, P417, DOI 10.1113/jphysiol.1966.sp008099; STGEORGE RCC, 1952, J GEN PHYSIOL, V35, P495, DOI 10.1085/jgp.35.3.495; Stiles W. S., 1948, T OPTICAL CONVENTION, P97; WILLIAMS TP, 1968, VISION RES, V8, P359, DOI 10.1016/0042-6989(68)90105-3	30	31	33	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					220	223		10.1038/35003242	http://dx.doi.org/10.1038/35003242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646610				2022-12-24	WOS:000084835300061
J	Lipper, GM; Arndt, KA; Dover, JS				Lipper, GM; Arndt, KA; Dover, JS			Recent therapeutic advances in dermatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; BURN CENTER; TOPICAL TACROLIMUS; IMIQUIMOD; INHIBITION; INTERFERON		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Dover, JS (corresponding author), Harvard Univ, Med Fac Phys, Cosmet Surg & Laser Ctr, Beth Israel Deaconess Med Ctr, 25 Boylston St,Suite 104, Chestnut Hill, MA 02167 USA.							Chaidemenos GC, 1997, INT J DERMATOL, V36, P218, DOI 10.1046/j.1365-4362.1997.00192.x; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; Edwards L, 1998, ARCH DERMATOL, V134, P25, DOI 10.1001/archderm.134.1.25; Egan CA, 1999, J AM ACAD DERMATOL, V40, P458, DOI 10.1016/S0190-9622(99)70497-4; HALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001; HENG MCY, 1991, J AM ACAD DERMATOL, V25, P778, DOI 10.1016/S0190-9622(08)80969-3; KELEMEN JJ, 1995, J AM COLL SURGEONS, V180, P273; McGee T, 1998, PLAST RECONSTR SURG, V102, P1018, DOI 10.1097/00006534-199809040-00014; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Reich K, 1998, BRIT J DERMATOL, V139, P755; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; Rzany B, 1996, BRIT J DERMATOL, V135, P6; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SIDKY YA, 1992, CANCER RES, V52, P3528; STANLEY MA, 1999, PAPILLOMAVIRUS REP, V10, P23; Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309; Tyring SK, 1998, J INFECT DIS, V178, P551, DOI 10.1086/517472; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; WEEKS CE, 1994, J INTERFERON RES, V14, P81, DOI 10.1089/jir.1994.14.81; Wolkenstein P, 1998, LANCET, V352, P1586, DOI 10.1016/S0140-6736(98)02197-7; Zonneveld IM, 1998, ARCH DERMATOL, V134, P1101, DOI 10.1001/archderm.134.9.1101	23	14	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					175	177		10.1001/jama.283.2.175	http://dx.doi.org/10.1001/jama.283.2.175			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634322				2022-12-24	WOS:000084661400002
J	Hong, K; Nishiyama, M; Henley, J; Tessier-Lavigne, M; Poo, MM				Hong, K; Nishiyama, M; Henley, J; Tessier-Lavigne, M; Poo, MM			Calcium signalling in the guidance of nerve growth by netrin-1	NATURE			English	Article							CONES; CELLS; INHIBITION; MODULATION; RECEPTOR; NEURONS; CA-2+	Pathfinding by growing axons in the developing nervous system is guided by diffusible or bound factors that attract or repel the axonal growth cone(1,2). The cytoplasmic signalling mechanisms that trigger the responses of the growth cone to guidance factors are mostly unknown(3). Previous studies have shown that the level and temporal patterns of cytoplasmic Ca2+ can regulate the rate of growth-cone extension in vitro(4-8) and in vivo(9). Here we report that Ca2+ also mediates the turning behaviour of the growth cones of cultured Xenopus neurons that are induced by an extracellular gradient of netrin-1, an established diffusible guidance factor in vivo(1,10). The netrin-1-induced turning response depends on Ca2+ influx through plasma membrane Ca2+ channels, as well as Ca2+-induced Ca2+ release from cytoplasmic stores(11). Reduction of Ca2+ signals by blocking either of these two Ca2+ sources converted the netrin-1-induced response from attraction to repulsion. Activation of Ca2+-induced Ca2+ release from internal stores with a gradient of ryanodine in the absence of netrin-1 was Sufficient to trigger either attractive or repulsive responses, depending on the ryanodine concentration used. These results support the model that cytoplasmic Ca2+ signals mediate growth-cone guidance by netrin-1, and different patterns of Ca2+ elevation trigger attractive and repulsive turning responses.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Henley, John/D-7171-2011	Henley, John/0000-0003-1846-5941				ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Leis HJ, 1996, BRIT J PHARMACOL, V117, P540, DOI 10.1111/j.1476-5381.1996.tb15224.x; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; LOHOF AM, 1992, J NEUROSCI, V12, P1253; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MARCHETTI C, 1995, J NEUROPHYSIOL, V73, P1169, DOI 10.1152/jn.1995.73.3.1169; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zucchi R, 1997, PHARMACOL REV, V49, P1	30	299	307	1	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					93	98		10.1038/47507	http://dx.doi.org/10.1038/47507			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638760				2022-12-24	WOS:000084687400050
J	Zheng, JQ				Zheng, JQ			Turning of nerve growth cones induced by localized increases in intracellular calcium ions	NATURE			English	Article							SPINAL NEURONS; GUIDANCE; RESPONSES	Guidance of developing axons involves turning of the motile tip, the growth cone, in response to a variety of extracellular cues(1,2) Little is known about the intracellular mechanism by which the directional signal is transduced, Ca2+ is a key second messenger in growth cone extension(3,4) and has been implicated in growth-cone turning(5,6). Here I report that a direct, spatially restricted elevation of intracellular Ca2+ concentration ([Ca2+](i)) on one side of the growth cone by focal laser-induced photolysis (FLIP) of caged Ca2+ consistently induced turning of the growth cone to the side with elevated [Ca2+](i) (attraction). Furthermore, when the resting [Ca2+](i) at the growth cone was decreased by the removal of extracellular Ca2+, the same focal elevation of [Ca2+](i) by FLIP induced repulsion. These results provide direct evidence that a localized Ca2+ signal in the growth cone can provide the intracellular directional cue for extension and is sufficient to initiate both attraction and repulsion. By integrating local and global Ca2+ signals, a growth cone could thus generate different turning responses under different environmental conditions during guidance.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Zheng, JQ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 675 Hoes Lane, Piscataway, NJ 08854 USA.							AHMED Z, 1988, CELL CALCIUM, V9, P57, DOI 10.1016/0143-4160(88)90025-5; BASHAW GJ, 1999, NEURON, V97, P917; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CONNOR JA, 1984, CELL MOL NEUROBIOL, V4, P53, DOI 10.1007/BF00710942; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; HONG K, 1999, NEURON, V97, P427; Ishihara A, 1997, BIOTECHNIQUES, V23, P268, DOI 10.2144/97232st01; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; KATER SB, 1991, J NEUROSCI, V11, P891; LANKFORD KL, 1991, CELL MOTIL CYTOSKEL, V20, P7, DOI 10.1002/cm.970200103; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Ming GL, 1997, J NEUROSCI, V17, P7860; SNOW DM, 1994, DEV BIOL, V166, P87, DOI 10.1006/dbio.1994.1298; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; TABTI N, 1990, CULTURING NERVE CELL, P137; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TSIEN RY, 1988, TRENDS NEUROSCI, V11, P419, DOI 10.1016/0166-2236(88)90192-0; Wang Q, 1998, J NEUROSCI, V18, P4973; Zheng B, 1996, J CLIN IMMUNOL, V16, P1, DOI 10.1007/BF01540967; Zheng JQ, 1996, PERSPECT DEV NEUROBI, V4, P205; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	28	227	233	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					89	93		10.1038/47501	http://dx.doi.org/10.1038/47501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638759				2022-12-24	WOS:000084687400049
J	Henderson, SW				Henderson, SW			The unnatural nature of pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Illinois, Coll Med, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Henderson, SW (corresponding author), Univ Illinois, Coll Med, Chicago, IL 60680 USA.							BATES MS, 1993, PAIN, V52, P101, DOI 10.1016/0304-3959(93)90120-E; DANTE, DIVINE COMEDY, V1; France CR, 1999, PAIN, V81, P77, DOI 10.1016/S0304-3959(98)00272-3; HOOPER E, 1999, RIVER JOURNEY SOURCE, P151; MERSKEY H, 1980, PAIN, V9, P3, DOI 10.1016/0304-3959(80)90024-X; MILTON J, PARADISE LOST; Scarry Elaine, 1985, BODY PAIN MAKING UNM, P4; Shakespeare William, HAMLET; Sheiner EK, 1999, PAIN, V81, P299, DOI 10.1016/S0304-3959(99)00019-6	9	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					117	117		10.1001/jama.283.1.117	http://dx.doi.org/10.1001/jama.283.1.117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632294	hybrid			2022-12-24	WOS:000084514400039
J	Cates, W; Dallabetta, G				Cates, W; Dallabetta, G			The staying power of sexually transmitted diseases	LANCET			English	Article									Family Hlth Int, HIV AIDS Prevent & Care Dept, Tech Support, Res Triangle Pk, NC 27709 USA		Cates, W (corresponding author), Family Hlth Int, HIV AIDS Prevent & Care Dept, Tech Support, POB 13950, Res Triangle Pk, NC 27709 USA.								0	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC	1999	354			S			62	62						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267DT	10691477				2022-12-24	WOS:000084342100063
J	Collett, T				Collett, T			Behavior - Measuring beelines to food	SCIENCE			English	Editorial Material									Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Collett, T (corresponding author), Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Biol Bldg, Brighton BN1 9QG, E Sussex, England.							BRANINGER HD, 1957, Z VERGL PHYSIOL, V40, P264; Esch HE, 1996, J EXP BIOL, V199, P155; RONACHER B, IN PRESS J EXP BIOL; Srinivasan MV, 1996, J EXP BIOL, V199, P237; Srinivasan MV, 2000, SCIENCE, V287, P851, DOI 10.1126/science.287.5454.851; von Frisch K., 1967, DANCE LANGUAGE ORIEN	6	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					817	818		10.1126/science.287.5454.817	http://dx.doi.org/10.1126/science.287.5454.817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10691558				2022-12-24	WOS:000085136400034
J	An, WF; Bowlby, MR; Betty, M; Cao, J; Ling, HP; Mendoza, G; Hinson, JW; Mattsson, KI; Strassle, BW; Trimmer, JS; Rhodes, KJ				An, WF; Bowlby, MR; Betty, M; Cao, J; Ling, HP; Mendoza, G; Hinson, JW; Mattsson, KI; Strassle, BW; Trimmer, JS; Rhodes, KJ			Modulation of A-type potassium channels by a family of calcium sensors	NATURE			English	Article							K+ CHANNEL; SUBTHRESHOLD POTENTIALS; PYRAMIDAL NEURONS; BINDING PROTEIN; MAMMALIAN BRAIN; ASSOCIATION; DENDRITES; SUBUNITS; SYSTEM	In the brain and heart, rapidly inactivating (A-type) voltage-gated potassium (Kv) currents operate at subthreshold membrane potentials to control the excitability of neurons and cardiac myocytes(1,2). Although pore-forming alpha-subunits of the Kv4, or Shal-related, channel family form A-type currents in heterologous cells(3), these differ significantly from native A-type currents. Here we describe three Kv channel-interacting proteins (KChIPs) that bind to the cytoplasmic amino termini of Kv4 alpha-subunits. We find that expression of KChIP and Kv4 together reconstitutes several features of native A-type currents by modulating the density, inactivation kinetics and rate of recovery from inactivation of Kv4 channels in heterologous cells. All three KChIPs co-localize and co-immunoprecipitate with brain Kv4 alpha-subunits, and are thus integral components of native Kv4 channel complexes. The KChIPs have four EF-hand-like domains and bind calcium ions. As the activity and density of neuronal A-type currents tightly control responses to excitatory synaptic inputs, these KChIPs may regulate A-type currents, and hence neuronal excitability, in response to changes in intracellular calcium.	Wyeth Ayerst Res, Div Neurosci, Princeton, NJ 08543 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Pfizer; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rhodes, KJ (corresponding author), Wyeth Ayerst Res, Div Neurosci, Princeton, NJ 08543 USA.							BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BOWLBY MR, 1995, J NEUROPHYSIOL, V73, P2221, DOI 10.1152/jn.1995.73.6.2221; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hoffman DA, 1998, J NEUROSCI, V18, P3521; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Linse Sara, 1995, V30, P89; NEF P, 1996, GUIDEBOOK CALCIUM BI, P94; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Song WJ, 1998, J NEUROSCI, V18, P3124; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	22	783	811	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					553	556		10.1038/35000592	http://dx.doi.org/10.1038/35000592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676964				2022-12-24	WOS:000085227300052
J	GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM				GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM			Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein	NATURE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; FAMILY ENCODING RETICULONS; GROWTH CONE COLLAPSE; NEURITE GROWTH; GENOMIC ORGANIZATION; GENE; EXPRESSION	Adult mammalian axon regeneration is generally successful in the peripheral nervous system (PNS) but is dismally poor in the central nervous system (CNS), However, many classes of CNS axons can extend for long distances in peripheral nerve grafts(1). A comparison of myelin from the CNS and the PNS has revealed that CNS white matter is selectively inhibitory for axonal outgrowth(2). Several components of CNS white matter, NI35, NI250(Nogo) and MAG, that have inhibitory activity for axon extension have been described(3-7) The IN-1 antibody, which recognizes NI35 and NI250(Nogo), allows moderate degrees of axonal regeneration and functional recovery after spinal cord injury(8,9). Here we identify Nogo as a member of the Reticulon family, Reticulon 4-A. Nogo is expressed by oligodendrocytes but not by Schwann cells, and associates primarily with the endoplasmic reticulum. A 66-residue lumenal/extracellular domain inhibits axonal extension and collapses dorsal root ganglion growth cones. In contrast to Nogo, Reticulon 1 and 3 ape not expressed by oligodendrocytes, and the 66-residue lumenal/extracellular domains from Reticulon 1, 2 and 3 do not inhibit axonal regeneration. These data provide a molecular basis to assess the contribution of Nogo to the failure of axonal regeneration in the adult CNS.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA	Yale University; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Bandtlow CE, 1997, EUR J NEUROSCI, V9, P2743, DOI 10.1111/j.1460-9568.1997.tb01703.x; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jin Z, 1997, J NEUROSCI, V17, P6256; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; MORRIS NJ, 1991, BIOCHIM BIOPHYS ACTA, V1450, P68; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 2000, CONT NEUROS, P131	25	931	1052	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					439	444		10.1038/35000226	http://dx.doi.org/10.1038/35000226			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667797				2022-12-24	WOS:000085121100053
J	Elowitz, MB; Leibler, S				Elowitz, MB; Leibler, S			A synthetic oscillatory network of transcriptional regulators	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; TAGGING SYSTEM; DEGRADATION; ELEMENTS	Networks of interacting biomolecules carry out many essential functions in living cells(1), but the 'design principles' underlying the functioning of such intracellular networks remain poorly understood, despite intensive efforts including quantitative analysis of relatively simple systems(2). Here we present a complementary approach to this problem: the design and construction of a synthetic network to implement a particular function. We used three transcriptional repressor systems that are not part of any natural biological clock(3-5) to build an oscillating network, termed the repressilator, in Escherichia coli. The network periodically induces the synthesis of green fluorescent protein as a readout of its state in individual cells. The resulting oscillations, with typical periods of hours, are slower than the cell-division cycle, so the state of the oscillator has to be transmitted from generation to generation. This artificial clock displays noisy behaviour, possibly because of stochastic fluctuations of its components. Such 'rational network design' may lead both to the engineering of new cellular behaviours and to an improved understanding of naturally occurring networks.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University	Elowitz, MB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; dAri R., 1990, BIOL FEEDBACK; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Elowitz MB., 1999, THESIS PRINCETON U P; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glascock CB, 1998, GENE, V223, P221, DOI 10.1016/S0378-1119(98)00240-6; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KUSHNER SR, 1996, ESCHERICHIA COLI SAL; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Winfree AT, 1990, GEOMETRY BIOL TIME	20	3026	3205	34	714	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					335	338		10.1038/35002125	http://dx.doi.org/10.1038/35002125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659856				2022-12-24	WOS:000084899700059
J	Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH				Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH			Annual fluxes or carbon from deforestation and regrowth in the Brazilian Amazon	NATURE			English	Article							PASTURE SOILS; LAND-USE; FOREST; BIOMASS; BUDGET	The distribution of sources and sinks of carbon among the world's ecosystems is uncertain. Some analyses show northern midlatitude lands to be a large sink, whereas the tropics are a net source(1); other analyses show the tropics to be nearly neutral. whereas northern mid-latitudes are a small sink(2,3). Here we show that the annual flux of carbon from deforestation and abandonment of agricultural lands in the Brazilian Amazon was a source of about 0.2 g C yr(-1) over the period 1989-1998 (1 Pg is 10(15) g). This estimate is based on annual rates of deforestation and spatially detailed estimates of deforestation, regrowing forests and biomass. Logging may add another 5-10% to this estimate(4), and fires may double the magnitude of the source in years following a drought(4), The annual source of carbon from land-use change and fire approximately offsets the sink calculated for natural ecosystems in the region(5,6). Thus this large area of tropical forest is nearly balanced with respect to carbon, but has an interannual variability of +/- 0.2 PgC yr(-1).	Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Michigan State Univ, Dept Geog, E Lansing, MI 48824 USA; Inst Nacl Pesquisas Espaciais, BR-12201970 Sao Jose Dos Campos, SP, Brazil	Woods Hole Research Center; Michigan State University; Instituto Nacional de Pesquisas Espaciais (INPE)	Houghton, RA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.			skole, david/0000-0002-8575-3540				Alves DS, 1996, INT J REMOTE SENS, V17, P835, DOI 10.1080/01431169608949049; *BRAZ MIN MIN EN D, 1973, LEV REC NAT, V1; BROWN S, 1992, INTERCIENCIA, V17, P8; BROWN S, 1990, J TROP ECOL, V6, P1, DOI 10.1017/S0266467400003989; BROWN S, 1989, FOREST SCI, V35, P881; Cairns MA, 1997, OECOLOGIA, V111, P1, DOI 10.1007/s004420050201; Carrera-Rotllan J, 1998, MECH AGEING DEV, V103, P13, DOI 10.1016/S0047-6374(98)00007-4; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; Cochrane MA, 1999, SCIENCE, V284, P1832, DOI 10.1126/science.284.5421.1832; DAVIDSON EA, 1995, NATURE, V376, P472, DOI 10.1038/376472a0; Delaney M, 1998, BIOTROPICA, V30, P2, DOI 10.1111/j.1744-7429.1998.tb00364.x; Fearnside P., 1986, HUMAN CARRYING CAPAC; Fearnside Philip M., 1998, Forest Ecology and Management, V108, P147, DOI 10.1016/S0378-1127(98)00222-9; Fearnside PM, 1997, CLIMATIC CHANGE, V35, P321, DOI 10.1023/A:1005336724350; FEARNSIDE PM, 1992, INTERCIENCIA, V17, P19; FEARNSIDE PM, 1993, J GEOPHYS RES-ATMOS, V98, P16733, DOI 10.1029/93JD01140; FISHER MJ, 1994, NATURE, V371, P236, DOI 10.1038/371236a0; HALL CAS, 1991, CAN J FOREST RES, V21, P118, DOI 10.1139/x91-016; HOUGHTON R A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P122; Houghton RA, 1999, TELLUS B, V51, P298, DOI 10.1034/j.1600-0889.1999.00013.x; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; MORAN EF, 1994, BIOSCIENCE, V44, P329, DOI 10.2307/1312383; Neill C, 1996, OECOLOGIA, V107, P113, DOI 10.1007/BF00582241; NEPSTAD DC, 1991, AMBIO, V20, P248; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Prentice IC, 1998, NATURE, V396, P619, DOI 10.1038/25224; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; SCHROEDER PE, 1995, FOREST ECOL MANAG, V75, P87, DOI 10.1016/0378-1127(95)03533-G; SKOLE DL, 1994, BIOSCIENCE, V44, P314, DOI 10.2307/1312381; Tian HQ, 1998, NATURE, V396, P664, DOI 10.1038/25328	30	502	610	6	173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					301	304		10.1038/35002062	http://dx.doi.org/10.1038/35002062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659847				2022-12-24	WOS:000084899700050
J	Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT				Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT			The joining of ribosomal subunits in eukaryotes requires eIF5B	NATURE			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; RABBIT RETICULOCYTES; FACTOR-5; PURIFICATION; COMPLEX; BINDING; CODON	Initiation of eukaryotic protein synthesis begins with the ribosome separated into its 40S and 60S subunits(1). The 40S subunit first binds eukaryotic initiation factor (eIF) 3 and an eIF2-GTP-initiator transfer RNA ternary complex. The resulting complex requires eIF1, eIF1A, eIF4A, eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon(2). eIF5 stimulates hydrolysis of eIF2-bound GTP and eIF2 is released from the 48S complex formed at the initiation codon before it is joined by a 60S subunit to form an active 80S ribosome(3-8). Here we show that hydrolysis of eIF2-bound GTP induced by eIF5 in 48S complexes is necessary but not sufficient for the subunits to join. A second factor termed eIF5B (relative molecular mass 175,000) is essential for this process. It is a homologue of the prokaryotic initiation factor IF2 (refs 6, 7) and, like it(8-12), mediates joining of subunits and has a ribosome-dependent GTPase activity that is essential for its function.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Lomonosov Moscow State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pestova, TV (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Lomakin, Ivan/0000-0001-6528-5068	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010, ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004, Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GODEFROYCOLBURN T, 1975, J MOL BIOL, V94, P461, DOI 10.1016/0022-2836(75)90215-6; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; KOLAKOFSKY D, 1968, P NATL ACAD SCI USA, V61, P1066, DOI 10.1073/pnas.61.3.1066; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LOCKWOOD AH, 1972, P NATL ACAD SCI USA, V69, P3602, DOI 10.1073/pnas.69.12.3602; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8	17	295	299	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					332	335		10.1038/35002118	http://dx.doi.org/10.1038/35002118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659855				2022-12-24	WOS:000084899700058
J	Lee, TH; Cleeman, JI; Grundy, SM; Gillett, C; Pasternak, RC; Seidman, J; Sennett, C				Lee, TH; Cleeman, JI; Grundy, SM; Gillett, C; Pasternak, RC; Seidman, J; Sennett, C			Clinical coals and performance measures for cholesterol management in secondary prevention of coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM-CHOLESTEROL; LOWERING THERAPY; EVENTS; RISK; PRAVASTATIN; REDUCTION; PROGRAM; TRIAL; DEATH	Guidelines from the National Cholesterol Education Program (NCEP) recommend reduction of low-density lipoprotein cholesterol (LDL-C) to 100 mg/dL (2.59 mmol/l)or less in patients with established coronary heart disease (CHD), However, the National Committee for Quality Assurance (NCQA) is implementing a new performance measure as part of the Health Plan Employer and Data Information Set (HEDIS) that appears to endorse a different target. The new HEDIS measure will require managed care organizations seeking NCQA accreditation to measure and report the percentage of patients who have had major CHD events who achieve LDL-C levels less than 130 mg/dL (3.36 mmol/L) between 60 and 365 days after discharge. These different LDL-C thresholds emphasize the difference between a clinical goal for the management of individual patients (less than or equal to 100 mg/dL) and a performance measure used to evaluate the care of a population of patients (<130 mg/dL), This article discusses the rationale for each threshold and explains the use of 2 different thresholds for these 2 purposes. Both the NCQA and NCEP expect that the new HEDIS measure will encourage managed care organizations to develop systems that improve secondary prevention of CHD.	Partners Community HealthCare Inc, Boston, MA 02199 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NHLBI, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Grp Hlth Cooperat Puget Sound, Clin Planning & Improvement, Seattle, WA 98121 USA; Natl Comm Qual Assurance, Washington, DC USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Group Health Cooperative	Lee, TH (corresponding author), Partners Community HealthCare Inc, Prudential Tower,Suite 1150,800 Boylston St, Boston, MA 02199 USA.	thlee@partners.org						BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Campeau L, 1997, NEW ENGL J MED, V336, P153; Grundy SM, 1998, CIRCULATION, V97, P1436; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SMITH SC, 1995, CIRCULATION, V92, P2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	16	36	37	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					94	98		10.1001/jama.283.1.94	http://dx.doi.org/10.1001/jama.283.1.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632286				2022-12-24	WOS:000084514400031
J	Johnson, AP; Livermore, DM				Johnson, AP; Livermore, DM			Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal	LANCET			English	Editorial Material							STAPHYLOCOCCUS-AUREUS; VANCOMYCIN; BACTERIA		Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England	Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England.		Johnson, Alan P/F-4420-2014					Leclercq R, 1998, LANCET, V352, P591, DOI 10.1016/S0140-6736(05)79570-2; Low DE, 1997, J ANTIMICROB CHEMOTH, V39, P53, DOI 10.1093/jac/39.suppl_1.53; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P25, DOI 10.1093/jac/44.suppl_1.25; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P251, DOI 10.1093/jac/44.2.251; NADLER H, 1999, CLIN MICROBIOL NEWSL, V13, P103; Nichols RL, 1999, J ANTIMICROB CHEMOTH, V44, P19, DOI 10.1093/jac/44.suppl_1.19; Nichols RL, 1999, J ANTIMICROB CHEMOTH, V44, P263, DOI 10.1093/jac/44.2.263; Ploy MC, 1998, LANCET, V351, P1212, DOI 10.1016/S0140-6736(05)79166-2; Rubinstein E, 1999, J ANTIMICROB CHEMOTH, V44, P37, DOI 10.1093/jac/44.suppl_1.37; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; Thal LA, 1999, J ANTIMICROB CHEMOTH, V43, P171, DOI 10.1093/jac/43.2.171; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	12	28	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2012	2013		10.1016/S0140-6736(99)00344-X	http://dx.doi.org/10.1016/S0140-6736(99)00344-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636359				2022-12-24	WOS:000084183300002
J	Houry, WA; Frishman, D; Eckerskorn, C; Lottspeich, F; Hartl, FU				Houry, WA; Frishman, D; Eckerskorn, C; Lottspeich, F; Hartl, FU			Identification of in vivo substrates of the chaperonin GroEL	NATURE			English	Article							COLI RNA-POLYMERASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; POLYPEPTIDE BINDING; ATP HYDROLYSIS; GENE-PRODUCTS; IN-VIVO; SEQUENCE; DOMAIN	The chaperonin GroEL has an essential role in mediating protein folding in the cytosol of Escherichia coli. Here we show that GroEL interacts strongly with a well-defined set of approximately 300 newly translated polypeptides, including essential components of the transcription/translation machinery and metabolic enzymes. About one third of these proteins are structurally unstable and repeatedly return to GroEL for conformational maintenance. GroEL substrates consist preferentially of two or more domains with ap-folds, which contain a-helices and buried P-sheets with extensive hydrophobic surfaces. These proteins are expected to fold slowly and be prone to aggregation. The hydrophobic binding regions of GroEL may be well adapted to interact with the non-native states of ap-domain proteins.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biochem, GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequences, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Prot Analyt, D-82152 Martinsried, Germany; Toplab GmbH, Proteom Div, D-82152 Martinsried, Germany	Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Frishman, Dmitrij/AAT-7815-2020; Hartl, F. Ulrich/Y-8206-2019					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; EISENBERG D, 1986, J CELL BIOCHEM, V31, P11, DOI 10.1002/jcb.240310103; Ellis RJ, 1997, CURR BIOL, V7, pR531, DOI 10.1016/S0960-9822(06)00273-9; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Frishman D, 1997, TRENDS GENET, V13, P415, DOI 10.1016/S0168-9525(97)01224-9; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Huynen M, 1998, J MOL BIOL, V280, P323, DOI 10.1006/jmbi.1998.1884; Karp PD, 1998, NUCLEIC ACIDS RES, V26, P50, DOI 10.1093/nar/26.1.50; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Meyer S. L., 1975, DATA ANAL SCI ENG; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orengo CA, 1999, NUCLEIC ACIDS RES, V27, P275, DOI 10.1093/nar/27.1.275; PEDERSEN S, 1984, EMBO J, V3, P2895, DOI 10.1002/j.1460-2075.1984.tb02227.x; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Smith KE, 1998, J BIOL CHEM, V273, P28677, DOI 10.1074/jbc.273.44.28677; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; WADA M, 1987, J BACTERIOL, V169, P1102, DOI 10.1128/jb.169.3.1102-1106.1987; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Xu D, 1998, FOLD DES, V3, P11, DOI 10.1016/S1359-0278(98)00004-2; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	48	416	443	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					147	154		10.1038/45977	http://dx.doi.org/10.1038/45977			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647006				2022-12-24	WOS:000083716400039
J	Reiner, DJ; Newton, EM; Tian, H; Thomas, JH				Reiner, DJ; Newton, EM; Tian, H; Thomas, JH			Diverse behavioural defects caused by mutations in Caenorhabditis elegans unc-43 CaM kinase II	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; C-ELEGANS; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; NERVOUS-SYSTEM; MUTANT MICE; CALMODULIN; DROSOPHILA; MICROSCOPY; FREQUENCY	Calcium/calmodulin-dependent serine/threonine kinase type II (CaMKII) is one of the most abundant proteins in the mammalian brain, where it is thought to regulate synaptic plasticity and other processes(1-3). Activation of the multisubunit kinase(4) by calcium is effectively cooperative and can persist long after transient calcium rises(1,5,6). Despite extensive biochemical characterization of CaMKII and identification of numerous in vitro kinase targets(1), little is known about its function in vivo. Here we report that unc-43 encodes the only Caenorhabditis elegans CaMKII. A gain-of-function unc-43 mutation reduces locomotory activity, alters excitation of three muscle types and lengthens the period of the motor output of a behavioural clock. Null unc-43 mutations cause phenotypes generally opposite to those of the gain-of-function mutation. Mutations in the unc-103 potassium channel gene suppress a gain-of-function phenotype of unc-43 in one tissue without affecting other tissues; thus, UNC-103 may be a tissue-specific target of CaMKII in vivo.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Thomas, JH (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.	jht@genetics.washington.edu		Reiner, David/0000-0002-0344-7161	NIGMS NIH HHS [R01 GM085309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BROCKE L, 1995, J NEUROSCI, V15, P6797; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; GUTAROY B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Johnstone DB, 1997, NEURON, V19, P151, DOI 10.1016/S0896-6273(00)80355-4; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; LIU DWC, 1994, J NEUROSCI, V14, P1953; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; Miller DM, 1995, METHOD CELL BIOL, V48, P365; PARK EC, 1986, GENETICS, V113, P821; REINER DJ, 1986, GENETICS, V113, P821; Rongo C, 1999, NATURE, V402, P195, DOI 10.1038/46065; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; THOMAS JH, 1990, GENETICS, V124, P855; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	31	103	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	1999	402	6758					199	203		10.1038/46072	http://dx.doi.org/10.1038/46072			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647014				2022-12-24	WOS:000083716400055
J	Nuorti, JP; Butler, JC; Farley, MM; Harrison, LH; McGeer, A; Kolczak, MS; Breiman, RF				Nuorti, JP; Butler, JC; Farley, MM; Harrison, LH; McGeer, A; Kolczak, MS; Breiman, RF		Active Bacterial Core Surveillance	Cigarette smoking and invasive pneumococcal disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBIOTIC-RESISTANT PNEUMOCOCCI; LOS-ANGELES-COUNTY; RISK-FACTORS; STREPTOCOCCUS-PNEUMONIAE; MENINGOCOCCAL DISEASE; NASOPHARYNGEAL COLONIZATION; POLYSACCHARIDE VACCINE; RESPIRATORY-TRACT; EPITHELIAL-CELLS	Background: Approximately half of otherwise healthy adults with invasive pneumococcal disease are cigarette smokers. We conducted a population-based case-control study to assess the importance of cigarette smoking and other factors as risk factors for pneumococcal infections. Methods: We identified immunocompetent patients who were 18 to 64 years old and who had invasive pneumococcal disease (as defined by the isolation of Streptococcus pneumoniae from a normally sterile site) by active surveillance of laboratories in metropolitan Atlanta, Baltimore, and Toronto. Telephone interviews were conducted with 228 patients and 301 control subjects who were reached by random-digit dialing. Results: Fifty-eight percent of the patients and 24 percent of the control subjects were current smokers. Invasive pneumococcal disease was associated with cigarette smoking (odds ratio, 4.1; 95 percent confidence interval, 2.4 to 7.3) and with passive smoking among nonsmokers (odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.1) after adjustment by logistic-regression analysis for age, study site, and independent risk factors such as male sex, black race, chronic illness, low level of education, and living with young children who were in day care. There were dose-response relations for the current number of cigarettes smoked per day, pack-years of smoking, and time since quitting. The adjusted population attributable risk was 51 percent for cigarette smoking, 17 percent for passive smoking, and 14 percent for chronic illness. Conclusions: Cigarette smoking is the strongest independent risk factor for invasive pneumococcal disease among immunocompetent, nonelderly adults. Because of the high prevalence of smoking and the large population attributable risk, programs to reduce both smoking and exposure to environmental tobacco smoke have the potential to reduce the incidence of pneumococcal disease. (N Engl J Med 2000;342:681-9.) (C)2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Butler, JC (corresponding author), Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.	jcb3@cdc.gov	McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137				*ACP TASK FORC AD, 1994, INF DIS SOC AM GUID, P107; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; *BEH RISK FACT SUR, 1997, MMWR SURVEILL SUMM, V46, P1; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BURMAN LA, 1985, REV INFECT DIS, V7, P133; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611; Dagan R, 1996, J INFECT DIS, V174, P1352, DOI 10.1093/infdis/174.6.1352; DYE JA, 1994, THORAX, V49, P825, DOI 10.1136/thx.49.8.825; ESCOBEDO LG, 1995, J NATL CANCER I, V87, P1552, DOI 10.1093/jnci/87.20.1552; FAINSTEIN V, 1979, INFECT IMMUN, V26, P178, DOI 10.1128/IAI.26.1.178-182.1979; FINKLEA JF, 1969, AM J EPIDEMIOL, V90, P390, DOI 10.1093/oxfordjournals.aje.a121084; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; GREEN GM, 1967, NEW ENGL J MED, V276, P421, DOI 10.1056/NEJM196702232760801; GWINN ML, 1990, J CLIN EPIDEMIOL, V43, P559, DOI 10.1016/0895-4356(90)90160-Q; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; HOLT PG, 1987, THORAX, V42, P241, DOI 10.1136/thx.42.4.241; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; JANOFF EN, 1993, J INFECT DIS, V167, P49, DOI 10.1093/infdis/167.1.49; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P320; Levine OS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e28; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; Margolis PA, 1997, PEDIATR PULM, V23, P417, DOI 10.1002/(SICI)1099-0496(199706)23:6<417::AID-PPUL4>3.0.CO;2-F; MILI F, 1991, CLIN IMMUNOL IMMUNOP, V59, P187, DOI 10.1016/0090-1229(91)90017-5; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Nuorti JP, 2000, ANN INTERN MED, V132, P182, DOI 10.7326/0003-4819-132-3-200002010-00003; ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885; OLSON SH, 1992, AM J EPIDEMIOL, V135, P210, DOI 10.1093/oxfordjournals.aje.a116273; Pastor P, 1998, CLIN INFECT DIS, V26, P590, DOI 10.1086/514589; *PHS, 1991, DHHS PUBL; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RAMAN AS, 1983, CHEST, V83, P23, DOI 10.1378/chest.83.1.23; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Sankilampi U, 1997, INT J EPIDEMIOL, V26, P420, DOI 10.1093/ije/26.2.420; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P181; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685; STUART JM, 1988, COMMUNITY MED, V10, P139; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; TAKALA AK, 1995, JAMA-J AM MED ASSOC, V273, P859, DOI 10.1001/jama.273.11.859; Tappero JW, 1996, NEW ENGL J MED, V335, P833, DOI 10.1056/NEJM199609193351201; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Zhu BP, 1997, AM J PUBLIC HEALTH, V87, P168; Zhu BP, 1996, AM J PUBLIC HEALTH, V86, P1582, DOI 10.2105/AJPH.86.11.1582; 1993, MMWR MORB MORTAL WKL, V42, P645; 1997, MMWR MORB MORTAL WKL, V46, P1217	58	558	578	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2000	342	10					681	689		10.1056/NEJM200003093421002	http://dx.doi.org/10.1056/NEJM200003093421002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ZW	10706897				2022-12-24	WOS:000085708800002
J	Coulehan, J				Coulehan, J			Attention must be paid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					976	976		10.1001/jama.283.8.976	http://dx.doi.org/10.1001/jama.283.8.976			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697044				2022-12-24	WOS:000085308600001
J	Li, LM; Lindquist, S				Li, LM; Lindquist, S			Creating a protein-based element of inheritance	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PRION-LIKE FACTOR; SUP35 GENE; GLUCOCORTICOID RECEPTOR; PSI; PROPAGATION; DETERMINANT; TRANSLATION; TERMINATION; URE3	Proteins capable of self-perpetuating changes in conformation and function (known as prions) can serve as genetic elements. To test whether novel prions could be created by recombinant methods, a yeast prion determinant was fused to the rat glucocorticoid receptor. The fusion protein existed in different heritable functional states, switched between states at a Low spontaneous rate, and could be induced to switch by experimental manipulations. The complete change in phenotype achieved by transferring a prion determinant from one protein to another confirms the protein-only nature of prion inheritance and establishes a mechanism for engineering heritable changes in phenotype that should be broadly applicable.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave MC 1028, Chicago, IL 60637 USA.							CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1996, GENETICS, V144, P1375; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Liu J., UNPUB; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; PATINO M, UNPUB; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	23	146	151	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					661	664		10.1126/science.287.5453.661	http://dx.doi.org/10.1126/science.287.5453.661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650001				2022-12-24	WOS:000084989400050
J	Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL				Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL			Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study	LANCET			English	Article							PULMONARY TUBERCULOSIS; IMMUNODEFICIENCY; HIV	Background Previous studies concerning the relative infectiousness of HIV-1-positive individuals with pulmonary tuberculosis have produced conflicting results, Thus, we assessed the effect of HIV-1 on the infectiousness of Mycobacterium tuberculosis in a prospective study. Methods We organised in Santo Domingo, Dominican Republic, a cohort study of household contacts of HIV-1-positive and HIV-1-negative individuals with newly diagnosed pulmonary tuberculosis. Household contacts were assessed at their houses at baseline and followed up for 14 months for evidence of M tuberculosis infection and tuberculosis with a multi-step tuberculin skin test, anergy skin test, physical examinations, chest radiographs, and sputum smears. Findings Tuberculin induration of 5 mm or greater was seen in 153 (61%) of 252 household contacts of HIV-1-positive index cases and in 418 (76%) of 551 household contacts of HIV-1-negative index cases (odds ratio 0.49 [95% CI 0.35-0.67], p=0.00001). In multivariate logistic-regression analysis after allowance for between-household variation in tuberculin response, HIV-1 infection of the index case remained inversely associated with the tuberculin response of the household contacts (0.52 [0.29-0.93], p=0.02). When the analysis was restricted to household contacts aged between 2 years and 15 years the adjusted association remained significant (0.37 [0.14-0.98], p=0.04). Among household contacts who had a negative tuberculin skin test at baseline, conversion to tuberculin skin test positivity was less frequent among household contacts of HIV-1-posilive index cases (cut-off greater than or equal to 5 mm: 32/131 [24%] vs 71/204 [35%], p=0.05; cut-off greater than or equal to 10 mm: 23/153 [15%] vs 55/245 [22%0], p=0.07). Interpretation These data suggest that HIV-1-positive individuals with tuberculosis are less likely than HIV-1-negative individuals with tuberculosis to transmit M tuberculosis to their close contacts. No changes in the current policy regarding tuberculosis contact tracing are needed in the presence of HIV-1.	Natl Ctr Res Maternal & Child Hlth, Santo Domingo, Dominican Rep; Antituberculosis Dispensary, Santo Domingo, Dominican Rep; Padre Billini Hosp, Santo Domingo, Dominican Rep; Francisco Moscoso Puello Hosp, Santo Domingo, Dominican Rep; Univ Calif Berkeley, Sch Publ Hlth, Div Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Espinal, RA (corresponding author), WHO Communicable Dis Surveillance & Response, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	espinalm@who.ch		Perez-Then, Eddy/0000-0001-7724-0668	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		*AM THOR SOC, 1981, AM REV RESPIR DIS, V124, P356; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Cayla J, 1993, 9 INT C AIDS BERL GE; ELLIOTT AM, 1993, AIDS, V7, P981, DOI 10.1097/00002030-199307000-00012; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GAUTHEN GM, 1996, AM J EPIDEMIOL, V144, P69; GUWATUDDE D, 1998, 12 INT C AIDS GEN SW, P138; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; KALENDE P, 1988, MED TROP, V48, P19; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109; MANFRIN V, 1993, 9 INT C AIDS BERL GE; NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; Toman K, 1979, TUBERCULOSIS CASE FI, P65; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO, 1991, WHO WORK GROUP M GEN	21	73	74	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2000	355	9200					275	280		10.1016/S0140-6736(99)04402-5	http://dx.doi.org/10.1016/S0140-6736(99)04402-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675075				2022-12-24	WOS:000085045600011
J	Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG				Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG			Antenatal corticosteroids: is more better?	LANCET			English	Editorial Material							BRAIN; GROWTH; GLUCOCORTICOIDS; DEXAMETHASONE; BETAMETHASONE; SINGLE		Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Anat, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Cell Biol, Kingston, ON K7L 2V7, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Duke Univ, Dept Anaesthesia, Durham, NC 27706 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; University of Toronto; University of Toronto; Duke University	Smith, GN (corresponding author), Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada.		Kingdom, John/A-3247-2013; Smith, Graeme Neil/ABB-6863-2021; Matthews, Stephen/R-5147-2019; Matthews, Stephen G/N-7555-2018; Kingdom, John/AAF-2145-2020	Smith, Graeme Neil/0000-0002-3128-4523; Matthews, Stephen/0000-0002-9654-9940; Matthews, Stephen G/0000-0002-9654-9940; Penning, Donald/0000-0001-7010-2430				Banks BA, 1999, AM J OBSTET GYNECOL, V181, P709, DOI 10.1016/S0002-9378(99)70517-X; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; CROWLEY P, 1999, COCHRANE LIB; Dean F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Huang WL, 1999, OBSTET GYNECOL, V94, P213, DOI 10.1016/S0029-7844(99)00265-3; Ikegami M, 1997, AM J RESP CRIT CARE, V156, P178, DOI 10.1164/ajrccm.156.1.9612036; Jobe AH, 1998, AM J OBSTET GYNECOL, V178, P880, DOI 10.1016/S0002-9378(98)70518-6; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; LIGGINS GC, 1969, J ENDOCRINOL, V45, P515, DOI 10.1677/joe.0.0450515; MACARTHUR BA, 1982, PEDIATRICS, V70, P99; Matthews SG, 1998, DEV BRAIN RES, V107, P123, DOI 10.1016/S0165-3806(98)00008-X; Pratt L, 1999, AM J OBSTET GYNECOL, V180, P995, DOI 10.1016/S0002-9378(99)70672-1; Quinlivan JA, 1999, PRENAT NEONAT MED, V4, P47; Stewart JD, 1998, AM J OBSTET GYNECOL, V179, P1241, DOI 10.1016/S0002-9378(98)70140-1; UNO H, 1990, DEV BRAIN RES, V53, P157, DOI 10.1016/0165-3806(90)90002-G; UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/hbeh.1994.1030	19	38	39	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					251	252		10.1016/S0140-6736(99)00448-1	http://dx.doi.org/10.1016/S0140-6736(99)00448-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675070				2022-12-24	WOS:000085045600006
J	Majeed, A; Lehmann, P; Kirby, L; Knight, R; Coleman, M				Majeed, A; Lehmann, P; Kirby, L; Knight, R; Coleman, M			Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records	BRITISH MEDICAL JOURNAL			English	Article							PRION DISEASE; VARIANT; WALES	Objective To investigate the extent to which deaths from Creutzfeldt-Jakob,disease were misclassified during 1979-96. Design Structured review of clinical records based on predetermined criteria to determine whether death could have been due to sporadic or variant Creutzfeldt-Jakob disease. Setting 100 health authorities and 275 NHS trusts in England. Subjects 1485 people who died aged 15-44 years from selected neurological disorders in England during 1979-96. Main outcome measure Cause of death. Results The clinical records of 705 (48%) subjects were successfully traced. Tracing of clinical records was highest in subjects who died during 1990-6. There was sufficient information in the records of 640 (91%) of the 705 subjects to exclude Creutzfeldt-Jakob disease as a cause of death. In 61 (9%) subjects, there was insufficient information to reach any conclusion about the validity of the cause of death recorded on the death certificate. The clinical records of four subjects were examined further by the National Creutzfeldt-Jakob Disease Surveillance Unit; none was thought to have died from Creutzfeldt-Jakob disease. Conclusions No new cases of sporadic or variant Creutzfeldt-Jakob disease were detected in a sample of deaths most likely to have included misclassified cases. This suggests that the surveillance system is unlikely to have missed a significant number of cases among people aged 15-44 years. Hence, any rapid increase in the number of cases of variant Creutzfeldt-Jakob disease in this age group is likely to be real not artefactual.	Off Natl Stat, London SW1V 2QQ, England; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine	Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.		Greiver, Michelle/N-8764-2015; Coleman, Michel/AAA-9543-2020	Greiver, Michelle/0000-0001-8957-0285; Coleman, Michel/0000-0001-8940-3807; Majeed, Azeem/0000-0002-2357-9858				AYLIN P, 1996, POPUL TRENDS, V85, P34; Baker HF, 1996, BRAIN RES BULL, V40, P237, DOI 10.1016/0361-9230(96)00162-1; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 1996, LANCET, V347, P916, DOI 10.1016/S0140-6736(96)91407-5; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Kirby L., 1998, POPULATION TRENDS, V92, P23; Majeed A, 1998, BRIT MED J, V317, P320, DOI 10.1136/bmj.317.7154.320; SOUTHWOOD R, 1989, REPORT WORKING PARTY; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Will RG, 1999, LANCET, V353, P979, DOI 10.1016/S0140-6736(99)01160-5	12	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					145	147		10.1136/bmj.320.7228.145	http://dx.doi.org/10.1136/bmj.320.7228.145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634732	Green Published, Green Submitted			2022-12-24	WOS:000084860300022
J	Ahmed, S; Hodgkin, J				Ahmed, S; Hodgkin, J			MRT-2 checkpoint protein is required for germline immortality and telomere replication in C-elegans	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; ATAXIA-TELANGIECTASIA; YEAST TELOMERE; FISSION YEAST; MAINTENANCE; HOMOLOG; LENGTH	The germ line is an immortal cell lineage that is passed indefinitely from one generation to the next. To identify the genes that are required for germline immortality, we isolated Caenorhabditis elegans mutants with mortal germ lines-worms that can reproduce for several healthy generations but eventually become sterile. One of these mortal germline (mrt) mutants, mrt-2, exhibits progressive telomere shortening and accumulates end-to-end chromosome fusions in later generations, indicating that the MRT-2 protein is required for telomere replication. In addition, the germ line of mrt-2 is hypersensitive to X-rays and to transposon activity. Therefore, mrt-2 has defects in responding both to damaged DNA and to normal double-strand breaks present at telomeres. mrt-2 encodes a homologue of a checkpoint gene that is required to sense DMA damage in yeast. These results indicate that telomeres may be identified as a type of DNA damage and then repaired by the telomere-replication enzyme telomerase.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Ahmed, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; di Fagagna FD, 1999, NAT GENET, V23, P76; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANG GW, 1995, J CELL BIOL, V130, P243, DOI 10.1083/jcb.130.2.243; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HENDERSON E, 1995, TELOMERES, P35; HERMAN RK, 1982, GENETICS, V102, P379; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1979, GENETICS, V91, P67; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Matsuura A, 1999, GENETICS, V152, P1501; McClintock B, 1941, GENETICS, V26, P234; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PLASTERK RHA, 1997, TRANSPORSONS C ELEGA, V2, P97; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sprung CN, 1997, MUTAT RES-FUND MOL M, V379, P177, DOI 10.1016/S0027-5107(97)00119-X; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; Sulston J, 1988, NEMATODE CAENORHABDI, P587; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WEINERT TA, 1993, GENETICS, V134, P63; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7	50	211	215	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					159	164		10.1038/35003120	http://dx.doi.org/10.1038/35003120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646593				2022-12-24	WOS:000084835300044
J	Jones, TF; Craig, AS; Hoy, D; Gunter, EW; Ashley, DL; Barr, DB; Brock, JW; Schaffner, W				Jones, TF; Craig, AS; Hoy, D; Gunter, EW; Ashley, DL; Barr, DB; Brock, JW; Schaffner, W			Mass psychogenic illness attributed to toxic exposure at a high school	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 18-21, 1999	PHILADELPHIA, PENNSYLVANIA	Infect Dis Soc Amer			EPIDEMIC HYSTERIA; ELEMENTARY-SCHOOL	Background: Mass psychogenic illness may be difficult to differentiate from illness caused by bioterrorism, rapidly spreading infection, or toxic substances. We investigated symptoms attributed to exposure to toxic gas at a high school in Tennessee. Methods: In November 1998, a teacher noticed a "gasoline-like'' smell in her classroom, and soon thereafter she had a headache, nausea, shortness of breath, and dizziness. The school was evacuated, and 80 students and 19 staff members went to the emergency room at the local hospital; 38 persons were hospitalized overnight. Five days later, after the school had reopened, another 71 persons went to the emergency room. An extensive investigation was performed by several government agencies. Results: We were unable to find a medical or environmental explanation for the reported illnesses. The persons who reported symptoms on the first day came from 36 classrooms scattered throughout the school. The most frequent symptoms (in this group and the group of people who reported symptoms five days later) were headache, dizziness, nausea, and drowsiness. Blood and urine specimens showed no evidence of carbon monoxide, volatile organic compounds, pesticides, polychlorinated biphenyls, paraquat, or mercury. There was no evidence of toxic compounds in the environment. A questionnaire administered a month later showed that the reported symptoms were significantly associated with female sex, seeing another ill person, knowing that a classmate was ill, and reporting an unusual odor at the school. Conclusions: This illness, attributed to toxic exposure, had features of mass psychogenic illness - notably, widespread subjective symptoms thought to be associated with environmental exposure to a toxic substance in the absence of objective evidence of an environmental cause. (N Engl J Med 2000;342:96-100.) (C) 2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Environm Hlth Labs, Natl Ctr Environm Hlth, Atlanta, GA USA; Tennessee Dept Hlth, CEDS, Nashville, TN 37247 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Tennessee Dept Hlth, Cookeville, TN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Tennessee Department Health; Vanderbilt University; Tennessee Department Health	Jones, TF (corresponding author), Tennessee Dept Hlth, CEDS, 4th Fl,Cordell Hull Bldg,425 5th Ave N, Nashville, TN 37247 USA.		Barr, Dana B/E-6369-2011; Barr, Dana B/E-2276-2013					ALEXANDER RW, 1986, J OCCUP ENVIRON MED, V28, P42, DOI 10.1097/00043764-198601000-00011; ARAKI S, 1986, ARCH ENVIRON HEALTH, V41, P159, DOI 10.1080/00039896.1986.9935771; Boss LP, 1997, EPIDEMIOL REV, V19, P233, DOI 10.1093/oxfordjournals.epirev.a017955; CARTTER ML, 1989, AM J DIS CHILD, V143, P269, DOI 10.1001/archpedi.1989.02150150019001; *CTR ENV RES INF, 1999, COMP METH DET TOX OR; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; Dean A.G., 1994, EPI INFO VERSION 6 W; DICKER RC, 1996, FIELD EPIDEMIOLOGY, P92; HEFEZ A, 1985, AM J PSYCHIAT, V142, P833; LANDRIGAN PJ, 1983, LANCET, V2, P1474; Nitzkin J L, 1976, J Fla Med Assoc, V63, P357; *OFF SOL WAST EM R, 1986, SW846 EPA OFF SOL WA; PHILEN RM, 1989, LANCET, V2, P1372; ROBINSON P, 1984, ARCH INTERN MED, V144, P1959, DOI 10.1001/archinte.144.10.1959; SANDY, 1991, MED DETECTIVES, P317; SELDEN BS, 1989, ANN EMERG MED, V18, P892, DOI 10.1016/S0196-0644(89)80221-5; Small G W, 1994, Arch Fam Med, V3, P711, DOI 10.1001/archfami.3.8.711; WASON S, 1983, LANCET, V2, P731	18	94	100	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2000	342	2					96	100		10.1056/NEJM200001133420206	http://dx.doi.org/10.1056/NEJM200001133420206			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273TQ	10631279				2022-12-24	WOS:000084723900006
J	Schroeder, BC; Waldegger, S; Fehr, S; Bleich, M; Warth, R; Greger, R; Jentsch, TJ				Schroeder, BC; Waldegger, S; Fehr, S; Bleich, M; Warth, R; Greger, R; Jentsch, TJ			A constitutively open potassium channel formed by KCNQ1 and KCNE3	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; LONG QT SYNDROME; K+ CONDUCTANCE; CL SECRETION; RABBIT COLON; MUTATIONS; KVLQT1; GENE; CELLS; EPITHELIA	Mutations in all four known KCNQ potassium channel or-subunit genes lead to human diseases(1-6). KCNQ1 (KvLQT1)(1) interacts with the beta-subunit KCNE1 (IsK, minK)(7) to form the slow, depolarization-activated potassium current I-Ks(8,9) that is affected in some forms of cardiac arrhythmia. Here we show that the novel beta-subunit KCNE3 markedly changes KCNQ1 properties to yield currents that are nearly instantaneous and depend linearly on voltage, It also suppresses the currents of KCNQ4 and HERG potassium channels. In the intestine, KCNQ1 and KCNE3 messenger RNAs colocalized in crypt cells. This localization and the pharmacology, voltage-dependence and stimulation by cyclic AMP of KCNQ1/KCNE3 currents indicate that these proteins may assemble to form the potassium channel that is important for cyclic AMP-stimulated intestinal chloride secretion and that is involved in secretory diarrhoea and cystic fibrosis.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Warth, Richard/N-7119-2014; Bleich, Markus/A-2812-2010	Warth, Richard/0000-0001-6084-0659; Bleich, Markus/0000-0002-1745-2295; Jentsch, Thomas/0000-0002-3509-2553				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Diener M, 1996, BRIT J PHARMACOL, V118, P1477, DOI 10.1111/j.1476-5381.1996.tb15563.x; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; LOHRMANN E, 1995, PFLUG ARCH EUR J PHY, V429, P517, DOI 10.1007/BF00704157; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; Mall M, 1998, AM J PHYSIOL-GASTR L, V275, pG1274, DOI 10.1152/ajpgi.1998.275.6.G1274; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; OFFNER FF, 1987, HEARING RES, V29, P117, DOI 10.1016/0378-5955(87)90160-2; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Suessbrich H, 1996, FEBS LETT, V396, P271, DOI 10.1016/0014-5793(96)01113-1; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Warth R, 1996, PFLUG ARCH EUR J PHY, V432, P81, DOI 10.1007/s004240050108; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	30	361	379	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					196	199		10.1038/35003200	http://dx.doi.org/10.1038/35003200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646604				2022-12-24	WOS:000084835300055
J	Strahl, BD; Allis, CD				Strahl, BD; Allis, CD			The language of covalent histone modifications	NATURE			English	Article							MITOTIC CHROMOSOME CONDENSATION; CHROMATIN STRUCTURE; LYSINE RESIDUES; ACETYLATION; H3; PHOSPHORYLATION; NUCLEOSOME; H4; HETEROCHROMATIN; TRANSCRIPTION	Histone proteins and the nucleosomes they form with DNA are the fundamental building blocks of eukaryotic chromatin. A diverse array of post-translational modifications that often occur on tail domains of these proteins has been well documented. Although the function of these highly conserved modifications has remained elusive, converging biochemical and genetic evidence suggests functions in several chromatin-based processes. We propose that distinct histone modifications, on one or more tails, act sequentially or in combination to form a 'histone code' that is, read by other proteins to bring about distinct downstream events.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Allis, CD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	allis@virginia.edu	Strahl, Brian/C-7601-2012	Strahl, Brian/0000-0002-4947-6259				ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ANNUNZIATO AT, 1993, NUCLEUS, P31; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CLARK D, 1993, COLD SPRING HARB SYM, V58, P1; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DeRubertis F, 1996, NATURE, V384, P589; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Jin Y, 1999, MOL CELL, V4, P129, DOI 10.1016/S1097-2765(00)80195-1; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; Luduena RF, 1998, INT REV CYTOL, V178, P207; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roberts SM, 1997, GENETICS, V147, P451; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sternglanz R, 1999, P NATL ACAD SCI USA, V96, P8807, DOI 10.1073/pnas.96.16.8807; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TORDERA V, 1993, EXPERIENTIA, V49, P780, DOI 10.1007/BF01923548; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; VANHOLDE KE, 1988, CHROMATIN, P111; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	69	6124	6417	10	791	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					41	45		10.1038/47412	http://dx.doi.org/10.1038/47412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638745				2022-12-24	WOS:000084687400035
J	Kelly, M; Bedell, R				Kelly, M; Bedell, R			Assessment of international medical evacuations in Macedonia	LANCET			English	Editorial Material									Med Sans Frontieres, NL-100 EA Amsterdam, Netherlands	Doctors Without Borders	Kelly, M (corresponding author), Med Sans Frontieres, Max Euwepl 40,POB 10014, NL-100 EA Amsterdam, Netherlands.		Bedell, Richard/AAC-2595-2020	Bedell, Richard/0000-0002-5687-8053					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2076	2077		10.1016/S0140-6736(05)76814-8	http://dx.doi.org/10.1016/S0140-6736(05)76814-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636389				2022-12-24	WOS:000084183300049
J	Gilbertson, L; Langhorne, P; Walker, A; Allen, A; Murray, GD				Gilbertson, L; Langhorne, P; Walker, A; Allen, A; Murray, GD			Domiciliary occupational therapy for patients with stroke discharged from hospital: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION	Objective To establish if a brief programme of domiciliary occupational therapy could improve the recovery of patients with stroke discharged from hospital. Design Single blind randomised controlled trial. Setting Two hospital sites within a UK teaching hospital. Subjects 138 patients with stroke with a definite plan for discharge home from hospital. Intervention Six week domiciliary occupational therapy or routine follow up. Main outcome measures Nottingham extended activities of daily living score and "global outcome" (deterioration according to the Barthel activities of daily living index, or death). Results By eight weeks the mean Nottingham extended activities of daily living score in the intervention group was 4.8 points (95% confidence interval -0.5 to 10.0, P = 0.08) greater than that of the control group. Overall, 16 (24%) intervention patients had a poor global outcome compared with 30 (42%) control patients (odds ratio 0.43, 0.21 to 0.89, P = 0.02). These patterns persisted at six months but were not statistically significant Patients in the intervention group were more likely to report satisfaction with a range of aspects of services. Conclusion The functional outcome and satisfaction of patients with stroke can be improved by a brief occupational therapy programme carried out in the patient's home immediately after discharge. Major benefits may not, however, be sustained.	Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Glasgow Royal Infirm, Dept Occupat Therapy, Glasgow G4 0SF, Lanark, Scotland; Greater Glasgow Hlth Board, Glasgow G3 8YU, Lanark, Scotland; Univ Edinburgh, Dept Community Hlth Sci, Med Stat Unit, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Glasgow; University of Glasgow; University of Edinburgh	Langhorne, P (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.			Murray, Gordon/0000-0001-9866-4734				Corr S, 1995, CLIN REHABIL, V9, P291; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; GILBERTSON L, 1998, THESIS U GLASGOW; Gladman J, 1996, BRIT MED J, V312, P1623, DOI 10.1136/bmj.312.7047.1623; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Rodgers H, 1997, CLIN REHABIL, V11, P280, DOI 10.1177/026921559701100403; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; Wade DT., 1992, MEASUREMENT NEUROLOG; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	11	88	90	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	2000	320	7235					603	606		10.1136/bmj.320.7235.603	http://dx.doi.org/10.1136/bmj.320.7235.603			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291NH	10698876	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-24	WOS:000085742600022
J	Cluzel, P; Surette, M; Leibler, S				Cluzel, P; Surette, M; Leibler, S			An ultrasensitive bacterial motor revealed by monitoring signaling proteins in single cells	SCIENCE			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; FLAGELLAR ROTATION; ESCHERICHIA-COLI; CHEMOTAXIS; SWITCH; PHOSPHORYLATION; DIAGNOSTICS; ADAPTATION; MOLECULES; DIRECTION	Understanding biology at the single-cell Level requires simultaneous measurements of biochemical parameters and behavioral characteristics in individual cells. Here, the output of individual flagellar motors in Escherichia coli was measured as a function of the intracellular concentration of the chemotactic signaling protein. The concentration of this molecule, fused to green fluorescent protein, was monitored with fluorescence correlation spectroscopy. Motors from different bacteria exhibited an identical steep input-output relation, suggesting that they actively contribute to signal amplification in chemotaxis. This experimental approach can be extended to quantitative in vivo studies of other biochemical networks.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Princeton University; Princeton University; University of Calgary	Cluzel, P (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	phcluzel@phoenix.princeton.edu						Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; Blat Y, 1998, J MOL BIOL, V284, P1191, DOI 10.1006/jmbi.1998.2224; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; CLUZEL P, UNPUB; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; ISHIHARA A, 1983, J BACTERIOL, V155, P228, DOI 10.1128/JB.155.1.228-237.1983; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; MACNAB RM, 1995, 2 COMPONENT SIGNAL T, P181; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; RIGLER R, 1992, FLUORESCENCE SPECTRO, P13; Scharf BE, 1998, J BACTERIOL, V180, P5123, DOI 10.1128/JB.180.19.5123-5128.1998; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Zhao RB, 1996, J BACTERIOL, V178, P258, DOI 10.1128/jb.178.1.258-265.1996	31	459	464	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2000	287	5458					1652	1655		10.1126/science.287.5458.1652	http://dx.doi.org/10.1126/science.287.5458.1652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698740				2022-12-24	WOS:000085628200038
J	Winkler, KE; Swenson, KI; Kornbluth, S; Means, AR				Winkler, KE; Swenson, KI; Kornbluth, S; Means, AR			Requirement of the prolyl isomerase Pin1 for the replication checkpoint	SCIENCE			English	Article							CELL-CYCLE; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; EGG EXTRACTS; MITOSIS; XENOPUS; COMPLETION; MATURATION; SEQUENCE; PROTEIN	The peptidyl-prolyl isomerase Pin1 has been implicated in regulating cell cycle progression. Pin1 was found to be required for the DNA replication checkpoint in Xenopus laevis, Egg extracts depleted of Pin1 inappropriately transited from the G(2) to the M phase of the cell cycle in the presence of the DNA replication inhibitor aphidicolin. This defect in replication checkpoint function was reversed after the addition of recombinant wild-type Pin1, but not an isomerase-inactive mutant, to the depleted extract. Premature mitotic entry in the absence of Pin1 was accompanied by hyperphosphorylation of Cdc25, activation of Cdc2/cyclin B, and generation of epitopes recognized by the mitotic phosphoprotein antibody, MPM-2. Therefore, Pin1 appears to be required for the checkpoint delaying the onset of mitosis in response to incomplete replication.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NATIONAL CANCER INSTITUTE [R01CA082845] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert A, 1999, J CELL SCI, V112, P2493; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; SCHLEGEL R, 1987, P NATL ACAD SCI USA, V84, P9025, DOI 10.1073/pnas.84.24.9025; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; WILCOX C, UNPUB; WINKLER K, UNPUB; WU XT, COMMUNICATION; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	33	148	153	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1644	1647		10.1126/science.287.5458.1644	http://dx.doi.org/10.1126/science.287.5458.1644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698738				2022-12-24	WOS:000085628200036
J	Christensen, SK; Dagenais, N; Chory, J; Weigel, D				Christensen, SK; Dagenais, N; Chory, J; Weigel, D			Regulation of auxin response by the protein kinase PINOID	CELL			English	Article							ARABIDOPSIS GENE MONOPTEROS; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; AUX/IAA PROTEINS; POLAR TRANSPORT; THALIANA; MUTANTS; EXPRESSION; ENCODES; EMBRYO	Arabidopsis plants carrying mutations in the PINOID (PID) gene have a pleiotropic shoot phenotype that mimics that of plants grown on auxin transport inhibitors or of plants mutant for the auxin efflux carrier PINFORMED (PIN), with defects in the formation of cotyledons, flowers, and floral organs. We have cloned PID and find that it is transiently expressed in the embryo and in initiating floral anlagen, demonstrating a specific role for PID in promoting primordium development. Constitutive expression of PID causes a phenotype in both shoots and roots that is similar to that of auxin-insensitive plants, implying that PID, which encodes a serine-threonine protein kinase, negatively regulates auxin signaling.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963				Aloni Roni, 1995, P531; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; BERLETH T, 1993, DEVELOPMENT, V118, P575; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Davies Peter J., 1995, P1; Ephritikhine G, 1999, PLANT J, V18, P303, DOI 10.1046/j.1365-313X.1999.00454.x; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; Fischer C, 1996, PLANT J, V9, P659, DOI 10.1046/j.1365-313X.1996.9050659.x; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Garbers C, 1996, EMBO J, V15, P2115, DOI 10.1002/j.1460-2075.1996.tb00565.x; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; Hadfi K, 1998, DEVELOPMENT, V125, P879; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; JURGENS G, 1993, COLOUR ATLAS DEV EMB, P7; Kaufman Peter B., 1995, P547; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lee I, 1997, CURR BIOL, V7, P95, DOI 10.1016/S0960-9822(06)00053-4; Lehman A, 1996, CELL, V85, P183, DOI 10.1016/S0092-8674(00)81095-8; Leyser HMO, 1996, PLANT J, V10, P403, DOI 10.1046/j.1365-313x.1996.10030403.x; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Long JA, 1998, DEVELOPMENT, V125, P3027; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Mattsson J, 1999, DEVELOPMENT, V126, P2979; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nilsson O, 1998, PLANT J, V15, P799, DOI 10.1046/j.1365-313X.1998.00260.x; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Reed RC, 1998, PLANT PHYSIOL, V118, P1369, DOI 10.1104/pp.118.4.1369; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; SCIAVONE FM, 1987, CELL DIFFER, V21, P53; SESSIONS RA, 1995, DEVELOPMENT, V121, P1519; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Tian Q, 1999, DEVELOPMENT, V126, P711; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x; Ulmasov T, 1999, PLANT J, V19, P309, DOI 10.1046/j.1365-313X.1999.00538.x; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 2000, IN PRESS PLANT PHYSL	63	353	382	4	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 18	2000	100	4					469	478		10.1016/S0092-8674(00)80682-0	http://dx.doi.org/10.1016/S0092-8674(00)80682-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693763	Bronze			2022-12-24	WOS:000085446900009
J	Kobayashi, N; Fujiwara, T; Westerman, KA; Inoue, Y; Sakaguchi, M; Noguchi, H; Miyazaki, M; Cai, J; Tanaka, N; Fox, IJ; Leboulch, P				Kobayashi, N; Fujiwara, T; Westerman, KA; Inoue, Y; Sakaguchi, M; Noguchi, H; Miyazaki, M; Cai, J; Tanaka, N; Fox, IJ; Leboulch, P			Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes	SCIENCE			English	Article							MAMMALIAN-CELLS; TRANSPLANTATION; ACTIVATION	Because of a critical shortage in suitable organs, many patients with terminal liver disease die each year before liver transplantation can be performed. Transplantation of isolated hepatocytes has been proposed for the temporary metabolic support of patients awaiting liver transplantation or spontaneous reversion of their liver disease. A major limitation of this form of therapy is the present inability to isolate an adequate number of transplantable hepatocytes. A highly differentiated cell line, NKNT-3, was generated by retroviral transfer in normal primary adult human hepatocytes of an immortalizing gene that can be subsequently and completely excised by Cre/Lox site-specific recombination. When transplanted into the spleen of rats under transient immunosuppression, reversibly immortalized NKNT-3 cells provided life-saving metabolic support during acute liver failure induced by 90% hepatectomy.	Okayama Univ, Dept Surg 1, Okayama 7008558, Japan; Okayama Univ, Dept Cell Biol, Okayama 7008558, Japan; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; Univ Nebraska, Dept Surg, Omaha, NE 68198 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA	Okayama University; Okayama University; Massachusetts Institute of Technology (MIT); University of Nebraska System; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kobayashi, N (corresponding author), Okayama Univ, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Sakaguchi, Masakiyo/B-2280-2011; Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482; Noguchi, Hirofumi/0000-0002-0880-6805	NHLBI NIH HHS [HL55435] Funding Source: Medline; NIDDK NIH HHS [DK48794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048794] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkadopoulos N, 1998, HEPATOLOGY, V28, P1365, DOI 10.1002/hep.510280527; Chowdhury JR, 1998, PEDIATRICS, V102, P647, DOI 10.1542/peds.102.3.647; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Gartner HV, 1996, NEW ENGL J MED, V335, P1494, DOI 10.1056/NEJM199611143352004; GEBHARDT R, 1989, HISTOCHEMISTRY, V92, P337, DOI 10.1007/BF00500550; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Nakamura J, 1997, TRANSPLANTATION, V63, P1541, DOI 10.1097/00007890-199706150-00001; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Pawliuk R, 1999, NAT MED, V5, P768, DOI 10.1038/10488; Schumacher IK, 1996, HEPATOLOGY, V24, P337; Strom SC, 1997, TRANSPLANTATION, V63, P559, DOI 10.1097/00007890-199702270-00014; Strom SC, 1999, SEMIN LIVER DIS, V19, P39, DOI 10.1055/s-2007-1007096; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971	15	244	301	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1258	1262		10.1126/science.287.5456.1258	http://dx.doi.org/10.1126/science.287.5456.1258			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678831				2022-12-24	WOS:000085444700048
J	Mao, YX; Nickitenko, A; Duan, XQ; Lloyd, TE; Wu, MN; Bellen, H; Quiocho, FA				Mao, YX; Nickitenko, A; Duan, XQ; Lloyd, TE; Wu, MN; Bellen, H; Quiocho, FA			Crystal structure of the VHS and FYVE tandem domains of Hrs, a protein involved in membrane trafficking and signal transduction	CELL			English	Article							ZINC-FINGER DOMAIN; ADAPTER MOLECULE; CELL-GROWTH; MOLSCRIPT; BINDING; PROGRAM; MOTIF; STAM; EEA1	We have determined the 2 Angstrom X-ray structure of the 219-residue N-terminal VHS and MIE tandem domain unit of Drosophila Hrs. The unit assumes a pyramidal structure in which the much larger YHS domain (residues 1-153) forms a rectangular base and the FYVE domain occupies the apical end. The VHS domain is comprised of an unusual "superhelix" of eight alpha helices, and the MIE domain is mainly built of loops, two double-stranded antiparallel sheets, and a helix stabilized by two tetrahedrally coordinated zinc atoms. The two-domain structure forms an exact 2-fold-related homodimer through antiparallel association of mainly FYVE domains. Dimerization creates two identical pockets designed for binding ligands with multiple negative charges such as citrate or phosphatidylinositol 3-phosphate.	Baylor Coll Med, Struct & Computat Biol & Mol Biophys Grad Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Quiocho, FA (corresponding author), Baylor Coll Med, Struct & Computat Biol & Mol Biophys Grad Program, Houston, TX 77030 USA.			Lloyd, Thomas/0000-0003-4756-3700; Bellen, Hugo/0000-0001-5992-5989; Mao, Yuxin/0000-0002-5064-1397				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Carbone R, 1997, CANCER RES, V57, P5498; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; [No title captured]	39	137	138	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 18	2000	100	4					447	456		10.1016/S0092-8674(00)80680-7	http://dx.doi.org/10.1016/S0092-8674(00)80680-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693761	Bronze			2022-12-24	WOS:000085446900007
J	Donovan, A; Brownlie, A; Zhou, Y; Shepard, J; Pratt, SJ; Moynihan, J; Paw, BH; Drejer, A; Barut, B; Zapata, A; Law, TC; Brugnara, C; Kingsley, PD; Palis, J; Fleming, MD; Andrews, NC; Zon, LI				Donovan, A; Brownlie, A; Zhou, Y; Shepard, J; Pratt, SJ; Moynihan, J; Paw, BH; Drejer, A; Barut, B; Zapata, A; Law, TC; Brugnara, C; Kingsley, PD; Palis, J; Fleming, MD; Andrews, NC; Zon, LI			Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter	NATURE			English	Article							DANIO-RERIO; GENE; HEMATOPOIESIS; TRANSPORTER; MUTATION; DEFECTS; ANEMIA; MAP	Defects in iron absorption and utilization lead to iron deficiency and overload disorders. Adult mammals absorb iron through the duodenum, whereas embryos obtain iron through placental transport. Iron uptake from the intestinal lumen through the apical surface of polarized duodenal enterocytes is mediated by the divalent metal transporter, DMT1 (refs 1-3). A second transporter has been postulated to export iron across the basolateral surface to the circulation. Here we have used positional cloning to identify the gene responsible for the hypochromic anaemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a multiple-transmembrane domain protein, expressed in the yolk sac, that is a candidate for the elusive iron exporter. Zebrafish ferroportin1 is required for the transport of iron from maternally derived yolk stores to the circulation and functions as an iron exporter when expressed in Xenopus oocytes. Human Ferroportin1 is found at the basal surface of placental syncytiotrophoblasts, suggesting that it also transports iron from mother to embryo. Mammalian Ferroportin1 is expressed at the basolateral surface of duodenal enterocytes and could export cellular iron into the circulation. We propose that Ferroportin1 function may be perturbed in mammalian disorders of iron deficiency or overload.	Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA; Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Complutense University of Madrid; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; University of Rochester; University of Rochester	Zon, LI (corresponding author), Childrens Hosp, Dept Med, Div Hematol Oncol, 300 Longwood Ave, Boston, MA 02115 USA.	zon@rascal.med.harvard.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Fleming, Mark/0000-0003-0948-4024; Cutts, Alison/0000-0002-4986-573X; Zapata, Agustin G/0000-0003-0576-2672; Palis, James/0000-0001-7324-1049; Andrews, Nancy/0000-0003-0243-4462; Paw, Barry/0000-0002-0492-1419				ALADHAMI MA, 1977, DEV GROWTH DIFFER, V19, P171; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BANNERMAN RM, 1976, FED PROC, V35, P2281; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; CRAIK JCA, 1986, COMP BIOCHEM PHYS A, V83, P515, DOI 10.1016/0300-9629(86)90138-6; DUMONT JN, 1978, J EXP ZOOL, V204, P193, DOI 10.1002/jez.1402040208; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Haffter P, 1996, DEVELOPMENT, V123, P1; JOHNSON SL, 1995, GENETICS, V139, P1727; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINGSTON PJ, 1978, BRIT J HAEMATOL, V40, P265, DOI 10.1111/j.1365-2141.1978.tb03663.x; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; PALIS J, 1995, MOL REPROD DEV, V42, P19, DOI 10.1002/mrd.1080420104; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Ransom DG, 1999, METHOD CELL BIOL, V60, P195; Ransom DG, 1996, DEVELOPMENT, V123, P311; Richards MP, 1997, POULTRY SCI, V76, P152, DOI 10.1093/ps/76.1.152; RIEB J-P, 1973, Annales d'Embryologie et de Morphogenese, V6, P43; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Westerfield M, 1993, ZEBRAFISH BOOK; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	29	1242	1321	6	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					776	781		10.1038/35001596	http://dx.doi.org/10.1038/35001596			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693807				2022-12-24	WOS:000085423100054
J	Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M				Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M		TTI Study Grp	Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; TRANSMISSION; DONORS; RISK; SURGEON; HIV	Objectives To follow up recipients of 20 000 units of blood to identify any transmissions of infections through blood transfusion. Design Follow up study of recipients of transfusion. Setting 22 hospitals in north London. Participant Adult patients who had recently been transfused. Main outcome measures Patients had further blood samples taken at 9 months that were tested for markers of hepatitis B and C and HIV and human T cell leukaemia/lymphoma virus type I or II (HTLV) infections. Recent infections were distinguished from pre-existing infections by comparison with blood samples taken before transfusion. Results 9220 patients were recruited, and 5579 recipients of 21 923 units of blood were followed up. No transfusion transmitted infections were identified. The incidence of transfusion transmitted infections was 0 in 21 043 units (95% confidence interval for risk 0 to 1 in 5706 recipients) for hepatitis B; 0 in 21 800 units (0 to 1 in 5911 recipients) for hepatitis C; 0 in 21 923 units (0 to 1 in 5944 recipients) for HIV; and 0 in 21 902 units (0 to 1 in 5939 recipients) for human T cell leukaemia/lymphoma virus. Three patients acquired hepatitis B during or after hospital admission but not through transfusion; 176 (3%) had pre-existing hepatitis B infection. Sixteen (0.29%) patients had hepatitis C, and five (0.09%) had human T cell leukaemia/lymphoma virus. Conclusions The current risk of transfusion transmitted infections in the United Kingdom is very small, though hospital acquired infections may arise from sources other than transfusion. A considerable proportion of patients have pre-existing infections.	Natl Blood Serv, N London Ctr, London NW9 5BG, England		Hewitt, P (corresponding author), Natl Blood Serv, N London Ctr, London & S East Zone, London NW9 5BG, England.							ALLAIN JP, 1995, TRANSFUSION MED, V5, P259, DOI 10.1111/j.1365-3148.1995.tb00211.x; ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALTER HJ, 1992, HEPATOLOGY, V15, P350, DOI 10.1002/hep.1840150228; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; BLAJCHMAN MA, 1995, LANCET, V345, P21, DOI 10.1016/S0140-6736(95)91153-7; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CONTRERAS M, 1993, CURRENT MED LIT RSM, V4, P67; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FLANAGAN P, 1995, VOX SANG, V68, P220, DOI 10.1111/j.1423-0410.1995.tb02576.x; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; MOSELY JW, 1995, TRANSFUSION, V35, P5; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996; 1995, NIH CONSENSUS STATEM, V13, P1	19	63	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					403	406		10.1136/bmj.320.7232.403	http://dx.doi.org/10.1136/bmj.320.7232.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669443	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000085377400020
J	Drummond, SPA; Brown, GG; Gillin, JC; Stricker, JL; Wong, EC; Buxton, RB				Drummond, SPA; Brown, GG; Gillin, JC; Stricker, JL; Wong, EC; Buxton, RB			Altered brain response to verbal learning following sleep deprivation	NATURE			English	Article							PERFORMANCE; MEMORY; TOMOGRAPHY; LANGUAGE; HUMANS; FMRI	The effects of sleep deprivation on the neural substrates of cognition are poorly understood. Here we used functional magnetic resonance imaging to measure the effects of 35 hours of sleep deprivation on cerebral activation during verbal learning in normal young volunteers. On the basis of a previous hypothesis', we predicted that the prefrontal cortex (PFC) would be less responsive to cognitive demands following sleep deprivation. Contrary to our expectations, however, the PFC was more responsive after one night of sleep deprivation than after normal sleep. Increased subjective sleepiness in sleep-deprived subjects correlated significantly with activation of the PFC. The temporal lobe was activated after normal sleep but not after sleep deprivation; in contrast, the parietal lobes were not activated after normal sleep but were activated after sleep deprivation. Although sleep deprivation significantly impaired free recall compared with the rested state, better free recall in sleep-deprived subjects was associated with greater parietal lobe activation, These findings show that there are dynamic, compensatory changes in cerebral activation during verbal learning after sleep deprivation and implicate the PFC and parietal lobes in this compensation.	Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; Univ Calif San Diego, San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA; Vet Adm San Diego Healthcare Syst, Psychiat Serv 116A, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; University of California System; University of California San Diego	Gillin, JC (corresponding author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jgillin@ucsd.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Drummond, Sean/0000-0002-9815-626X				BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Brown GG, 1999, J INT NEUROPSYCH SOC, V5, P308, DOI 10.1017/S1355617799544020; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dinges DF., 1991, SLEEP SLEEPINESS PER, P97; Drummond SPA, 1999, NEUROREPORT, V10, P3745, DOI 10.1097/00001756-199912160-00004; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; Harrison Y, 1997, SLEEP, V20, P871, DOI 10.1093/sleep/20.10.871; Harrison Y, 1998, J SLEEP RES, V7, P95, DOI 10.1046/j.1365-2869.1998.00104.x; Hockey GRJ, 1997, BIOL PSYCHOL, V45, P73; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; HORNE JA, 1988, SLEEP, V11, P528, DOI 10.1093/sleep/11.6.528; HORNE JA, 1993, BRIT J PSYCHIAT, V162, P413, DOI 10.1192/bjp.162.3.413; LUBIN A, 1976, PSYCHOPHYSIOLOGY, V13, P334, DOI 10.1111/j.1469-8986.1976.tb03086.x; PIETAU C, 1998, J SLEEP RES, V7, P208; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; POLZELLA DJ, 1975, J EXP PSYCHOL-HUM L, V104, P194; Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265; Portas CM, 1998, J NEUROSCI, V18, P8979; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Talairach J., 1988, COPLANAR STEREOTAXIC; THOMAS ML, 1993, J CEREBR BLOOD FLOW, V13, pS531; Werth E, 1996, NEUROREPORT, V8, P123, DOI 10.1097/00001756-199612200-00025; WILLIAMS HL, 1966, PERCEPT MOTOR SKILL, V23, P1287, DOI 10.2466/pms.1966.23.3f.1287; WOLFE N, 1995, ARCH NEUROL-CHICAGO, V52, P257, DOI 10.1001/archneur.1995.00540270049018; WONG EC, 1992, P SOC MAGN RESON MED, V1, P105; WU JC, 1991, SLEEP, V14, P155	30	378	390	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					655	657		10.1038/35001068	http://dx.doi.org/10.1038/35001068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	283RD	10688201				2022-12-24	WOS:000085288200053
J	Williams, AG; Rayson, MP; Jubb, M; World, M; Woods, DR; Hayward, M; Martin, J; Humphries, SE; Montgomery, HE				Williams, AG; Rayson, MP; Jubb, M; World, M; Woods, DR; Hayward, M; Martin, J; Humphries, SE; Montgomery, HE			Physiology - The ACE gene and muscle performance	NATURE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MUSCULAR EFFICIENCY; HUMAN HEART; POLYMORPHISM		Optimal Preformance, Farnham GU9 7EB, Surrey, England; Rayne Inst, RFUCLMS, Ctr Cardiovasc Genet, British Heart Fdn, London WC1E 6JJ, England	University of London; King's College London; University College London	Williams, AG (corresponding author), Optimal Preformance, 93-94 West St, Farnham GU9 7EB, Surrey, England.		Montgomery, Hugh/L-1229-2019; Humphries, Stephen E/C-5075-2008; Williams, Alun G/B-6817-2008; Montgomery, Hugh/C-2592-2008	Williams, Alun G/0000-0002-8052-8184; Jubb, Michael/0000-0001-5639-473X; Montgomery, Hugh/0000-0001-8797-5019				BALL SG, 1993, LANCET, V342, P821; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; CONLEY DL, 1980, MED SCI SPORT EXER, V12, P357, DOI 10.1249/00005768-198012050-00010; COYLE EF, 1992, MED SCI SPORT EXER, V24, P782; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; DRAGOVIC T, 1996, DIABETES S1, V45, P34; GAESSER GA, 1975, J APPL PHYSIOL, V38, P1132, DOI 10.1152/jappl.1975.38.6.1132; Kemp GJ, 1996, HEART, V76, P35, DOI 10.1136/hrt.76.1.35; KULKARNI RN, 1992, ANN HUM BIOL, V19, P421, DOI 10.1080/03014469200002272; McArdle W., 2014, EXERCISE PHYSL ENERG, P253; Montgomery H, 1999, LANCET, V353, P541, DOI 10.1016/S0140-6736(98)07131-1; Montgomery HE, 1997, CIRCULATION, V96, P741; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Morris SD, 1997, J AM COLL CARDIOL, V29, P1599, DOI 10.1016/S0735-1097(97)00087-9; Spurr GB, 1998, EUR J CLIN NUTR, V52, P17, DOI 10.1038/sj.ejcn.1600504; Zhao G, 1999, CORONARY ARTERY DIS, V10, P315, DOI 10.1097/00019501-199907000-00007	16	209	226	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					614	614		10.1038/35001141	http://dx.doi.org/10.1038/35001141			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688186	Green Accepted			2022-12-24	WOS:000085288200038
J	Bruce, MC; Donnelly, CA; Alpers, MP; Galinski, MR; Barnwell, JW; Walliker, D; Day, KP				Bruce, MC; Donnelly, CA; Alpers, MP; Galinski, MR; Barnwell, JW; Walliker, D; Day, KP			Cross-species interactions between malaria parasites in humans	SCIENCE			English	Article							PAPUA-NEW-GUINEA; PLASMODIUM-FALCIPARUM; DENSITY-DEPENDENCE; IMMUNITY; VIVAX; RESISTANCE; DYNAMICS; CHILDREN; MADANG; TESTS	The dynamics of multiple Plasmodium infections in asymptomatic children Living under intense malaria transmission pressure provide evidence for a density-dependent regulation that transcends species as well as genotype. This regulation, in combination with species- and genotype-specific immune responses, results in nonindependent, sequential episodes of infection with each species.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England; Papua New Guinea Inst Med Res, Madang, Papua N Guinea; Emory Univ, Sch Med, Emory Vaccine Ctr Yerkes, Dept Med,Div Infect Dis, Atlanta, GA 30329 USA; Ctr Dis Control & Prevent, Biol & Diagnost Branch, Div Parasit Dis, Atlanta, GA 30341 USA; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JN, Midlothian, Scotland	University of Oxford; PNG Institute Of Medical Research; Emory University; Centers for Disease Control & Prevention - USA; University of Edinburgh	Bruce, MC (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.		Day, Karen/F-3697-2015	Day, Karen/0000-0002-6115-6135; Donnelly, Christl/0000-0002-0195-2463	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI137545, U01AI037545, R22AI024710, R01AI024710] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37545, AI24710] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1; BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P578, DOI 10.1016/0035-9203(91)90349-4; Boyd M. F., 1937, American Journal of Tropical Medicine, V17, P855; BOYD MARK F., 1938, AMER JOUR TROP MED, V18, P521; BROWN KN, 1990, IMMUNOL LETT, V25, P97, DOI 10.1016/0165-2478(90)90098-B; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; BRUCE M, IN PRESS PARASITOLOG; Bruce MC, 1999, AM J TROP MED HYG, V61, P518, DOI 10.4269/ajtmh.1999.61.518; BULMER MG, 1975, BIOMETRICS, V31, P901, DOI 10.2307/2529815; BURKOT TR, 1987, B WORLD HEALTH ORGAN, V65, P375; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; Ciuca M., 1934, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V27, P619, DOI 10.1016/S0035-9203(34)90111-5; COHEN JE, 1973, Q REV BIOL, V48, P467, DOI 10.1086/407705; COX MJ, 1994, T ROY SOC TROP MED H, V88, P191, DOI 10.1016/0035-9203(94)90292-5; Farnert A, 1997, AM J TROP MED HYG, V56, P538, DOI 10.4269/ajtmh.1997.56.538; FOX DR, 1995, OECOLOGIA, V103, P435, DOI 10.1007/BF00328681; Galinski MR, 1999, MOL BIOCHEM PARASIT, V101, P131, DOI 10.1016/S0166-6851(99)00063-8; GUNEWARDENA DM, 1994, MEM I O CRUZ, V89, P61; JEFFERY GM, 1966, B WORLD HEALTH ORGAN, V35, P873; Karunaweera ND, 1998, AM J TROP MED HYG, V58, P204, DOI 10.4269/ajtmh.1998.58.204; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; KYES S, 1993, EXP PARASITOL, V77, P473, DOI 10.1006/expr.1993.1108; Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2; MOLINEAUX L, 1980, AM J TROP MED HYG, V29, P725, DOI 10.4269/ajtmh.1980.29.725; NTOUMI F, 1995, AM J TROP MED HYG, V52, P81, DOI 10.4269/ajtmh.1995.52.81; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; RITCHIE TL, 1988, PARASITOLOGY, V96, P607; Staalsoe T, 1998, PARASITOL TODAY, V14, P177, DOI 10.1016/S0169-4758(98)01228-9; TALIAFERRO WH, 1939, MELARIOLOGY; WOLDA H, 1993, OECOLOGIA, V95, P581, DOI 10.1007/BF00317444	31	180	183	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					845	848		10.1126/science.287.5454.845	http://dx.doi.org/10.1126/science.287.5454.845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657296				2022-12-24	WOS:000085136400043
J	Cane, DE				Cane, DE			Biosynthetic pathways - Biosynthesis meets bioinformatics	SCIENCE			English	Editorial Material							CLAVULANIC ACID; 1-DEOXY-D-XYLULOSE 5-PHOSPHATE; PRECURSOR; PYRIDOXOL; THIAMIN; ENZYME		Brown Univ, Dept Chem, Providence, RI 02912 USA	Brown University	Cane, DE (corresponding author), Brown Univ, Dept Chem, Box H, Providence, RI 02912 USA.	David_Cane@brown.edu						Baggaley KH, 1997, NAT PROD REP, V14, P309, DOI 10.1039/np9971400309; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; ELSON SW, 1978, J ANTIBIOT, V31, P586, DOI 10.7164/antibiotics.31.586; Jensen SE, 1999, ANTON LEEUW INT J G, V75, P125, DOI 10.1023/A:1001755724055; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Perez-Redondo R, 1999, J BACTERIOL, V181, P6922; Pitlik J, 1997, CHEM COMMUN, P225, DOI 10.1039/a607078g; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857	14	15	17	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					818	819		10.1126/science.287.5454.818	http://dx.doi.org/10.1126/science.287.5454.818			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10691559				2022-12-24	WOS:000085136400035
J	Benton, MJ; Wills, MA; Hitchin, R				Benton, MJ; Wills, MA; Hitchin, R			Quality of the fossil record through time	NATURE			English	Article							TAXONOMIC DIVERSITY; MOLECULAR EVIDENCE; MASS EXTINCTIONS; METAZOAN PHYLA	Does the fossil record present a true picture of the history of life(1-3), or should it be viewed with caution(4-6)? Raup(5) argued that plots of the diversification of life(2) were an illustration of bias: the older the rocks, the less we know. The debate was partially resolved by the observation(7) that different data sets gave similar patterns of rising diversity through time. Here we show that new assessment methods, in which the order of fossils in the rocks (stratigraphy) is compared with the order inherent in evolutionary trees (phylogeny), provide a more convincing analytical tool: stratigraphy and phylogeny offer independent data on history. Assessments of congruence between stratigraphy and phylogeny for a sample of 1,000 published phylogenies show no evidence of diminution of quality backwards in time. Ancient rocks clearly preserve less information, on average, than more recent rocks. However, if scaled to the stratigraphic level of the stage and the taxonomic level of the family, the past 540 million years of the fossil record provide uniformly good documentation of the life of the past.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Oxford, Museum Hist Nat, Oxford OX1 3PW, England	University of Bristol; University of Oxford	Benton, MJ (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.		Wills, Matthew Albion/AAE-1790-2019; Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824; Wills, Matthew/0000-0002-7344-7749				Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Benton Michael J., 1996, Historical Biology, V12, P111; BENTON MJ, 1994, GEOLOGY, V22, P111, DOI 10.1130/0091-7613(1994)022<0111:TTQOTF>2.3.CO;2; Benton MJ, 1999, SYST BIOL, V48, P581, DOI 10.1080/106351599260157; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 1993, FOSSIL RECORD, V2; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Forey P. L, 1992, CLADISTICS PRACTICAL; HARLAND WB, 1993, GEOLOGIC TIME SCALE; Hennig W, 1999, PHYLOGENETIC SYSTEMA; Hillis DM, 1996, MOL SYSTEMATICS; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Norell Mark A., 1992, P89; PATTERSON C, 1981, ANNU REV ECOL SYST, V12, P195, DOI 10.1146/annurev.es.12.110181.001211; Paul CRC, 1998, ADEQUACY OF THE FOSSIL RECORD, P1; RAUP DM, 1972, SCIENCE, V177, P1065, DOI 10.1126/science.177.4054.1065; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; Siddall ME, 1996, SYST BIOL, V45, P111, DOI 10.2307/2413516; Simpson G.G., 1944, TEMPO MODE EVOLUTION, DOI DOI 10.1073/pnas.1821292116; Smith A.B., 1994, SYSTEMATICS FOSSIL R; Valentine J. W., 1969, Palaeontology, V12, P684; Wagner PJ, 1998, ADEQUACY OF THE FOSSIL RECORD, P165; Wills MA, 1999, SYST BIOL, V48, P559, DOI 10.1080/106351599260148; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568	30	153	162	0	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					534	537		10.1038/35000558	http://dx.doi.org/10.1038/35000558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676959				2022-12-24	WOS:000085227300047
J	Bergquist, DC; Williams, FM; Fisher, CR				Bergquist, DC; Williams, FM; Fisher, CR			Longevity record for deep-sea invertebrate - The growth rate of a marine tubeworm is tailored to different environments.	NATURE			English	Article							COMMUNITIES; ECOLOGY; VENTS		Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bergquist, DC (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.		Fisher, Charles/H-7912-2012					ANDERSON RK, 1983, SCIENCE, V222, P619, DOI 10.1126/science.222.4624.619; FISHER CR, 1997, PSZNI MAR ECOL, V18, P83; GRASSLE JF, 1986, ADV MAR BIOL, V23, P301; HECKER B, 1985, BIOL SOC WASH B, V6, P465; KENNICUTT MC, 1988, DEEP-SEA RES, V35, P1639, DOI 10.1016/0198-0149(88)90107-0; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; PAULL CK, 1984, SCIENCE, V226, P965, DOI 10.1126/science.226.4677.965; Sarrazin J, 1997, MAR ECOL PROG SER, V153, P5, DOI 10.3354/meps153005; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; Urcuyo IA, 1998, CAH BIOL MAR, V39, P267	10	80	85	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					499	500		10.1038/35000647	http://dx.doi.org/10.1038/35000647			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676948				2022-12-24	WOS:000085227300034
J	Yangco, BG; Von Bargen, JC; Moorman, AC; Holmberg, SD				Yangco, BG; Von Bargen, JC; Moorman, AC; Holmberg, SD		HIV Outpatient Study Investigators	Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article								Background: HIV-infected patients with sustained immunologic improvement from antiretroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP). Objective: To compare PCP incidence in HIV-infected patients who had sustained CD4(+) lymphocyte counts greater than 200 cells/mm(3) and who either discontinued or continued PCP prophylaxis. Design: Nonrandomized prospective cohort study. Setting::10 HIV clinics in eight U.S, cities. Patients: 146 patients had follow-up visits for a mean of 18.2 months after discontinuation of PCP prophylaxis, and 345 patients who continued PCP prophylaxis had follow-up visits for a mean of 14.0 months. Measurements: Incidence of PCP. Results: Patients who discontinued PCP prophylaxis had higher maximum and minimum CD4(+) cell counts and lower vira I loads than patients who continued PCP prophylaxis. Pneumocystis carinii pneumonia did not develop in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued PCP prophylaxis, 2.3/100 person-yea rs). Conclusions: Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infected ambulatory patients.	Infect Dis Res Inst, Tampa, FL USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Yangco, BG (corresponding author), 4728 N Habana Ave,Suite 303, Tampa, FL 33614 USA.			Moorman, Anne/0000-0003-2411-2798	PHS HHS [U64/CCU5096889] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; GARCIAVAZQUEZ E, 1998, 38 INT C ANT AG CHEM; LOPEZ JC, 1999, 6 C RETR OPP INF 31; MARADONA JA, 1998, 38 INT C ANT AG CHEM; Moorman AC, 1998, J ACQ IMMUN DEF SYND, V19, P182, DOI 10.1097/00042560-199810010-00013; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; RAVAUX I, 1998, 38 INT C ANT AG CHEM; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Von Bargen J, 1998, JAMA-J AM MED ASSOC, V280, P29, DOI 10.1001/jama.280.1.29; 1999, MMWR MORB MORTAL WKL, V48, P4	11	37	38	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					201	205		10.7326/0003-4819-132-3-200002010-00005	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276XE	10651600				2022-12-24	WOS:000084903000004
J	Chadwick, D				Chadwick, D			Seizures and epilepsy after traumatic brain injury	LANCET			English	Editorial Material							POPULATION				Chadwick, D (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England.							Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; GODDARD GV, 1969, EXP NEUROL, V25, P294; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593	10	23	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					334	336		10.1016/S0140-6736(99)00452-3	http://dx.doi.org/10.1016/S0140-6736(99)00452-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665550				2022-12-24	WOS:000085122100006
J	Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G				Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G			Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion	NATURE			English	Article							NUCLEUS-ACCUMBENS; OPIOID WITHDRAWAL; CLONIDINE; RATS; LESIONS; MEDULLA; LOCUS; RETROGRADE; MORPHINE; NALOXONE	Cessation of drug use in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidance of withdrawal or associated stimuli is a major factor contributing to opiate abuse(1,2). Increased noradrenaline in the brain has long been implicated in opiate withdrawal(3), but it has not been clear which noradrenergic systems are invoked. Here we show that microinjection of beta-noradrenergic-receptor antagonists, or of an alpha 2-receptor agonist, into the bed nucleus of the stria terminalis (BNST) in rats markedly attenuates opiate-withdrawal-induced conditioned place aversion, Immunohistochemical studies revealed that numerous BNST-projecting cells in the A1 and A2 noradrenergic cell groups of the caudal medulla were activated during withdrawal Lesion of these ascending medullary projections also greatly reduced opiate-withdrawal-induced place aversion. whereas lesion of locus coeruleus noradrenergic projections had no effect on opiate-withdrawal behaviour. We conclude that noradrenergic inputs to the BNST from the caudal medulla are critically involved in the aversiveness of opiate withdrawal.	Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Philadelphia, PA 19104 USA	University of Pennsylvania	Aston-Jones, G (corresponding author), Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Univ & Woodland Ave, Philadelphia, PA 19104 USA.							Akaoka H., 1992, Society for Neuroscience Abstracts, V18, P374; Alheid George F., 1995, P495; ASTONJONES G, 1993, NEUROBIOLOGY OPIATES, P175; Bechara A, 1998, PHARMACOL BIOCHEM BE, V59, P1, DOI 10.1016/S0091-3057(97)00047-6; Blessing WW, 1997, LOWER BRAINSTEM BODI; BRITTON KT, 1984, LIFE SCI, V34, P133, DOI 10.1016/0024-3205(84)90583-6; Brownstein MJ, 1984, HDB CHEM NEUROANAT 1, P23; Caille S, 1999, J PHARMACOL EXP THER, V290, P881; Chen S, 1996, NEUROSCIENCE, V71, P443, DOI 10.1016/0306-4522(95)00437-8; CHIENG B, 1995, NEUROSCI LETT, V186, P37, DOI 10.1016/0304-3940(95)11276-3; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; DROLET G, 1992, J NEUROSCI, V12, P3162, DOI 10.1523/JNEUROSCI.12-08-03162.1992; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; GOLD MS, 1978, LANCET, V2, P599; GROSZ HJ, 1972, LANCET, V2, P564; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; HARRIS GC, 1993, NEUROPSYCHOPHARMACOL, V9, P303, DOI 10.1038/npp.1993.66; HIGGINS GA, 1994, PHARMACOL BIOCHEM BE, V48, P1, DOI 10.1016/0091-3057(94)90489-8; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; McKittrick C. R., 1999, Society for Neuroscience Abstracts, V25, P948; Nader K, 1996, BEHAV NEUROSCI, V110, P389, DOI 10.1037/0735-7044.110.2.389; O'Brien C P, 1988, NIDA Res Monogr, V84, P44; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; ROEHRICH H, 1987, AM J PSYCHIAT, V144, P1099; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; TERENZI MG, 1995, BRAIN RES, V672, P289, DOI 10.1016/0006-8993(94)01453-O	30	360	365	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					430	434		10.1038/35000212	http://dx.doi.org/10.1038/35000212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667795				2022-12-24	WOS:000085121100051
J	Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB				Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB			Impact of respiratory virus infections on persons with chronic underlying conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNCYTIAL VIRUS; AIR-POLLUTION; DISEASE HOSPITALIZATIONS; INFLUENZA EPIDEMICS; VIRAL-INFECTIONS; ASTHMA; CHILDREN; ADULTS; ILLNESS; VACCINE	Context While hospitalization rates have declined overall, hospitalizations for acute lower respiratory tract infections have increased steadily since 1980. Development of new approaches for prevention of acute respiratory tract conditions requires studies of the etiologies of infections and quantification of the risk of hospitalization for vulnerable patients. Objective To determine the frequency of specific virus infections associated with acute respiratory tract conditions leading to hospitalization of chronically ill patients. Design Analysis of viral etiology of patients hospitalized with acute respiratory tract conditions between July 1991 and June 1995. Setting Four large clinics and related hospitals serving diverse populations representative of Harris County, Texas. Patients A total of 1029 patients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations of asthma or chronic obstructive pulmonary disease, and/or congestive heart failure. Main Outcome Measure Virus infection, defined by culture, antigen detection, and significant rise in serum antibodies, by underlying condition; hospitalization rates by low- vs middle-income status. Results Ninety-three percent of patients older than 5 years had a chronic underlying condition; a chronic pulmonary condition was most common. Patients with chronic pulmonary disease from low-income populations were hospitalized at a rate of 398.6 per 10 000, almost 8 times higher than the rate for patients from middle-income groups (52.2 per 10 000; P<.001). Of the 403 patients (44.4% of adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respiratory tract virus infections were detected in 181 (44.9%). influenza, parainfluenza, and respiratory syncytial virus (RSV) infections accounted for 75% of all virus infections. Conclusions Our study suggests that respiratory virus infections commonly trigger serious acute respiratory conditions that result in hospitalization of patients with chronic underlying conditions, highlighting the need for development of effective vaccines for these viruses, especially for parainfluenza and RSV.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Glezen, WP (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	wglezen@bcm.tmc.edu	Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015103] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15103] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON M, 1994, J ASTHMA, V31, P367, DOI 10.3109/02770909409061316; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BUSSE WW, 1993, ASTHMA, P345; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FRANK AL, 1979, J CLIN MICROBIOL, V10, P32, DOI 10.1128/JCM.10.1.32-36.1979; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HALFON N, 1993, PEDIATRICS, V91, P56; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pamuk E., 1998, SOCIOECONOMIC STATUS; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; PHILIT F, 1992, REV MAL RESPIR, V9, P191; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WOOD PR, 1993, PEDIATRICS, V91, P62	42	386	402	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					499	505		10.1001/jama.283.4.499	http://dx.doi.org/10.1001/jama.283.4.499			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659876	Bronze			2022-12-24	WOS:000084879800029
J	Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R				Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R			Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; WOMEN	Context Whether menopausal hormone replacement therapy using a combined estrogen-progestin regimen increases risk of breast cancer beyond that associated with estrogen alone is unknown. Objective To determine whether increases in risk associated with the estrogen-progestin regimen are greater than those associated with estrogen alone. Design Cohort study of follow-up data for 1980-1995 from the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine screening centers throughout the United States. Participants A total of 46 355 postmenopausal women (mean age at start of followup, 58 years). Main Outcome Measure Incident breast cancers by recency, duration, and type of hormone use. Results During follow-up, 2082 cases of breast cancer were identified. Increases in risk with estrogen only and estrogen-progestin only were restricted to use within the previous 4 years (relative risk [RR], 1.2 [95% confidence interval {CI}, 1.0-1.4] and 1.4 [95% CI, 1.1-1.8], respectively); the relative risk increased by 0.01 (95% CI, 0.002-0.03) with each year of estrogen-only use and by 0.08 (95% CI, 0.02-0.16) with each year of estrogen-progestin-only use among recent users, after adjustment for mammographic screening, age at menopause, body mass index (BMI), education, and age. The P value associated with the test of homogeneity of these estimates was .02. Among women with a BMI of 24.4 kg/m(2) or less, increases in RR with each year of estrogen-only use and estrogen-progestin-only use among recent users were 0.03 (95% CI, 0.01-0.06) and 0.12 (95% CI, 0.02-0.25), respectively. These associations were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease. Risk in heavier women did not increase with use of estrogen only or estrogen-progestin only. Conclusion Our data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Social & Sci Syst Inc, Bethesda, MD USA; Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Social & Scientific Systems; University of Massachusetts System; University of Massachusetts Amherst	Schairer, C (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS Room 7080,MSC 7234, Rockville, MD 20852 USA.		Brinton, Louise A/G-7486-2015	Brinton, Louise A/0000-0003-3853-8562	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010113] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1987, STAT METHODS CANC RE; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Greendale GA, 1997, AM J EPIDEMIOL, V146, P763; Hargreaves DF, 1998, BRIT J CANCER, V78, P945, DOI 10.1038/bjc.1998.606; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; PRESTON DL, 1996, EPICURE SOFTWARE REL; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264	15	786	821	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					485	491		10.1001/jama.283.4.485	http://dx.doi.org/10.1001/jama.283.4.485			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659874	Bronze			2022-12-24	WOS:000084879800027
J	Haslberger, AG				Haslberger, AG			Genetic technologies - Monitoring and labeling for genetically modified products	SCIENCE			English	Article									Fed Chancellory, Sci Sect Biotechnol, A-1030 Vienna, Austria		Haslberger, AG (corresponding author), Fed Chancellory, Sci Sect Biotechnol, Radetzkystr 2, A-1030 Vienna, Austria.	hasi1@via.at	Haslberger, Alexander G/B-9120-2013	Haslberger, Alexander/0000-0001-9699-537X				Butler D, 1999, NATURE, V398, P651, DOI [10.1038/19348, 10.1038/19381]; *EUR COMM SCI COMM, 1999, OP SCP BT RES MON; Ewen SWB, 1999, LANCET, V354, P684, DOI 10.1016/S0140-6736(05)77668-6; *HOUS COMM ENV AUD, 1999, GMOS ENV COORD GOV P; KILMAN S, WALL STREET J; Lehrman S, 1999, NATURE, V401, P107, DOI 10.1038/43536; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Miller HI, 1999, SCIENCE, V284, P1471, DOI 10.1126/science.284.5419.1471; Mitchell P, 1999, LANCET, V353, P1769, DOI 10.1016/S0140-6736(99)90090-9; MITSCH FJ, 1999, DTSCH BANC A BR 0712; Reichhardt T, 1999, NATURE, V400, P298, DOI 10.1038/22371; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; *UK HOUS COMM SCI, 1999, SCI ADV SYST GEN MOD; 1999, AGRAFOOD BIOTEC 1110, P15; 1999, AGRAFOOD BIOTEC 0914, P11	15	26	28	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					431	432		10.1126/science.287.5452.431	http://dx.doi.org/10.1126/science.287.5452.431			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671171				2022-12-24	WOS:000084929900026
J	Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB				Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB			Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors	NATURE			English	Article							GABA(A) RECEPTORS; BETA-SUBUNITS; PHOSPHORYLATION; SUBTYPES; CURRENTS; D1; SCHIZOPHRENIA; MODULATION; DIVERSITY; SYNAPSES	GABAA (gamma-aminobutyric-acid A) and dopamine D1 and D5 receptors represent two structurally and functionally divergent families of neurotransmitter receptors, The former comprises a class of multi-subunit ligand-gated channels mediating fast interneuronal synaptic transmission, whereas the latter belongs to the seven-transmembrane-domain single-polypeptide receptor superfamily that exerts its biological effects, including the modulation of GABA(A) receptor function, through the activation of second-messenger signalling cascades by G proteins, Here we show that GABA(A)-ligand-gated channels complex selectively with D5 receptors through the direct binding of the D5 carboxy-terminal domain with the second intracellular loop of the GABA(A) gamma 2(short) receptor subunit, This physical association enables mutually inhibitory functional interactions between these receptor systems, The data highlight a previously unknown signal transduction mechanism whereby subtype-selective G-protein-coupled receptors dynamically regulate synaptic strength independently of classically defined second-messenger systems, and provide a heuristic framework in which to view these receptor systems in the maintenance of psychomotor disease states.	Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Oral Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Mol Neurobiol Sect, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Wang, YT (corresponding author), Hosp Sick Children, Program Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015					Barnard EA, 1998, PHARMACOL REV, V50, P291; Benes FM, 1997, J PSYCHIATR RES, V31, P257, DOI 10.1016/S0022-3956(96)00044-1; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Brunig I, 1999, P NATL ACAD SCI USA, V96, P2456, DOI 10.1073/pnas.96.5.2456; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GoldmanRakic PS, 1997, SCHIZOPHRENIA BULL, V23, P437, DOI 10.1093/schbul/23.3.437; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Huntsman MM, 1998, P NATL ACAD SCI USA, V95, P15066, DOI 10.1073/pnas.95.25.15066; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keverne EB, 1999, BRAIN RES BULL, V48, P467, DOI 10.1016/S0361-9230(99)00025-8; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MARSHALL FH, 1999, TRENDS PHARMACOL SCI, V10, P369; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MCDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MONIYAMA T, 1996, J NEUROSCI, V16, P7502; Moore H, 1999, BIOL PSYCHIAT, V46, P40, DOI 10.1016/S0006-3223(99)00078-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NIZNIK HB, IN PRESS HDB EXPT PH; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; NUSSER Z, 1995, EUR J NEUROSCI, V7, P60; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; Poisbeau P, 1999, J NEUROSCI, V19, P674; Radnikow G, 1998, J NEUROSCI, V18, P2009; Sibley DR, 1999, ANNU REV PHARMACOL, V39, P313, DOI 10.1146/annurev.pharmtox.39.1.313; Sidhu A, 1998, MOL NEUROBIOL, V16, P125, DOI 10.1007/BF02740640; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1991, CELL S, V72, P653; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wan Q, 1997, J NEUROSCI, V17, P5062; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yan Z, 1997, NEURON, V19, P1115, DOI 10.1016/S0896-6273(00)80402-X; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877	49	366	380	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					274	280		10.1038/35002014	http://dx.doi.org/10.1038/35002014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659839				2022-12-24	WOS:000084899700042
J	Port, S; Demer, L; Jennrich, R; Walter, D; Garfinkel, A				Port, S; Demer, L; Jennrich, R; Walter, D; Garfinkel, A			Systolic blood pressure and mortality	LANCET			English	Article								Background The current systolic blood-pressure threshold for hypertension treatment is 140 mm Hg for all adults. WHO and the International Society of Hypertension have proposed that normal pressure be lower than 130 mm Hg, with an optimum pressure of less than 120 mm Hg. These recommendations are based largely on the assumption that cardiovascular and overall mortality depend in a strictly increasing manner on systolic blood pressure. The Framingham study was instrumental in establishing this viewpoint. We reassessed data from that study to find out whether the relation is strictly increasing or whether there is a threshold in this relation. Methods We used logistic splines to model the relation of risk of cardiovascular and all-cause death with systolic blood pressure, using age-specific and sex-specific rates. We tested for the independence of the slope parameters from age and sex, and the reduced model with common slopes was used to produce a model different from the conventional linear logistic model. Findings Against the predictions of the linear logistic model, neither all-cause nor cardiovascular deaths depended on systolic blood pressure in a strictly increasing manner. The linear logistic model was rejected by the Framingham data. Instead, risk was independent of systolic blood pressure for all pressures lower than a threshold at the 70th percentile for a person of a given age and sex. Risk sharply increased with pressure higher than the 80th percentile. Since systolic blood pressure steadily increases with age, the threshold increases with age, but more rapidly in women than in men. Interpretation The Framingham data contradict the concept that lower pressures imply lower risk and the idea that 140 mm Hg is a useful cut-off value for hypertension for all adults. There is an age-dependent and sex-dependent threshold for hypertension. A substantial proportion of the population who would currently be thought to be at increased risk are, therefore, at no increased risk.	Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Med Cardiol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90025 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Port, S (corresponding author), Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90025 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052319] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52319] Funding Source: Medline; PHS HHS [P01 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1980, 7 COUNTRIES MULTIVAR; Black HR, 1997, ARCH INTERN MED, V157, P2413; Borghi C, 1998, J CARDIOVASC PHARM, V32, pS24, DOI 10.1097/00005344-199800004-00005; Chalmers J, 1999, J HYPERTENS, V17, P151; *COOP RES, 1991, JAMA-J AM MED ASSOC, V275, P1557; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; *NAT CTR HLTH STAT, 1964, BLOOD PRESS AD AG SE; O'Brien E, 1999, LANCET, V353, P1541, DOI 10.1016/S0140-6736(99)00157-9; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; *USHEW, 1968, 74599 USHEW NIH	11	160	162	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					175	180		10.1016/S0140-6736(99)07051-8	http://dx.doi.org/10.1016/S0140-6736(99)07051-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675116				2022-12-24	WOS:000084879700010
J	Maddox, J				Maddox, J			Positioning the goalposts - The best environmental policy depends on how you frame the question.	NATURE			English	Editorial Material																			0	6	6	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					139	139		10.1038/35003065	http://dx.doi.org/10.1038/35003065			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646578	Bronze			2022-12-24	WOS:000084835300028
J	van Ginneken, VJT; van den Thillart, GEEJM				van Ginneken, VJT; van den Thillart, GEEJM			Physiology - Eel fat stores are enough to reach the Sargasso	NATURE			English	Article							SEA		Inst Ecol & Evolutionary Sci Integrat Zool, Van Der Klaauw Lab, NL-2300 RA Leiden, Netherlands		van Ginneken, VJT (corresponding author), Inst Ecol & Evolutionary Sci Integrat Zool, Van Der Klaauw Lab, POB 9511, NL-2300 RA Leiden, Netherlands.							BOETIUS I, 1980, Dana, V1, P1; Castonguay Martin, 1994, Fisheries Oceanography, V3, P197, DOI 10.1111/j.1365-2419.1994.tb00097.x; ELLIOTT JM, 1975, OECOLOGIA, V19, P195, DOI 10.1007/BF00345305; FRICKE H, 1995, NATURWISSENSCHAFTEN, V82, P32, DOI 10.1007/s001140050136; MILLER MJ, 1994, J MAR RES, V52, P743, DOI 10.1357/0022240943076948; Schmidt J, 1923, NATURE, V111, P51, DOI 10.1038/111051a0; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; Svedang H, 1997, J FISH BIOL, V50, P475, DOI 10.1111/j.1095-8649.1997.tb01943.x; Tesch F.-W., 1977, EEL BIOL MANAGEMENT; VANDIJK PLM, 1993, J FISH BIOL, V42, P661, DOI 10.1006/jfbi.1993.1075; Wootton RJ, 1979, S ZOOL SOC LOND, P133	11	97	108	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					156	157		10.1038/35003110	http://dx.doi.org/10.1038/35003110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646590				2022-12-24	WOS:000084835300041
J	Mulryan, K; Gitterman, DP; Lewis, CJ; Vial, C; Leckie, BJ; Cobb, AL; Brown, JE; Conley, EC; Buell, G; Pritchard, CA; Evans, RJ				Mulryan, K; Gitterman, DP; Lewis, CJ; Vial, C; Leckie, BJ; Cobb, AL; Brown, JE; Conley, EC; Buell, G; Pritchard, CA; Evans, RJ			Reduced vas deferens contraction and male infertility in mice lacking P2X(1) receptors	NATURE			English	Article							GATED ION CHANNELS; ALPHA,BETA-METHYLENE ATP; PURINE NUCLEOTIDES; GUINEA-PIG; RAT; MOUSE	P2X(1) receptors for ATP are ligand-gated cation channels, present on many excitable cells including vas deferens smooth muscle cells(1-5). A substantial component of the contractile response of the vas deferens to sympathetic nerve stimulation, which propels sperm into the ejaculate. is mediated through P2X receptors'. Here we show that male fertility is reduced by similar to 90% in mice with a targeted deletion of the P2X(1) receptor gene. Male mice copulate normally-reduced fertility results from a reduction of sperm in the ejaculate and not from sperm dysfunction. Female mice and heterozygote mice are unaffected. In P2X(1)-receptor-deficient mice, contraction of the vas deferens to sympathetic nerve stimulation is reduced by up to 60% and responses to P2X receptor agonists are abolished. These results show that P2X(1) receptors are essential for normal male reproductive function and suggest that the development of selective P2X(1) receptor antagonists may provide an effective non-hormonal male contraceptive pill. Also, agents that potentiate the actions of ATP at P2X(1) receptors may be useful in the treatment of male infertility.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Med, Transgen Unit, Biomed Serv, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Pathol, Leicester LE1 9HN, Leics, England; Univ Leicester, Ctr Mechanisms Human Tox, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Glaxo Wellcome Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; GlaxoSmithKline	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg, Leicester LE1 9HN, Leics, England.			Pritchard, Catrin/0000-0003-1859-4487				ALLCORN RJ, 1986, BRIT J PHARMACOL, V89, P647, DOI 10.1111/j.1476-5381.1986.tb11169.x; ANDERSON RA, 1983, J REPROD FERTIL, V68, P1, DOI 10.1530/jrf.0.0680001; BRADING AF, 1990, BRIT J PHARMACOL, V99, P493, DOI 10.1111/j.1476-5381.1990.tb12956.x; BURNSTOCK G, 1961, J PHYSIOL-LONDON, V155, P115, DOI 10.1113/jphysiol.1961.sp006617; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Collo G, 1996, J NEUROSCI, V16, P2495; Costa SL, 1997, BIOL REPROD, V56, P985, DOI 10.1095/biolreprod56.4.985; Evans RJ, 1996, SEMIN NEUROSCI, V8, P217, DOI 10.1006/smns.1996.0028; HEDLUND H, 1985, J AUTON PHARMACOL, V5, P261, DOI 10.1111/j.1474-8673.1985.tb00127.x; HOFFMAN BB, 1996, PHARMACOL BASIS THER, V9, P199; Hogan B., 1986, MANIPULATING MOUSE E; Jacobson KA, 1998, J MED CHEM, V41, P2201, DOI 10.1021/jm980183o; KENAKIN T, 1997, PHARM ANAL DRUG RECE, V3, P63; KHAKH BS, 1995, BRIT J PHARMACOL, V115, P177, DOI 10.1111/j.1476-5381.1995.tb16336.x; LEWIS C, 1998, BRIT J PHARMACOL, P1463; Ralevic V, 1998, PHARMACOL REV, V50, P413; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V342, P198, DOI 10.1007/BF00166965; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Yang LY, 1998, PHYSIOL BEHAV, V63, P675, DOI 10.1016/S0031-9384(97)00523-4	21	310	312	4	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					86	89		10.1038/47495	http://dx.doi.org/10.1038/47495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638758				2022-12-24	WOS:000084687400048
J	Plugge, B; Gazzarrini, S; Nelson, M; Cerana, R; Van Etten, JL; Derst, C; DiFrancesco, D; Moroni, A; Thiel, G				Plugge, B; Gazzarrini, S; Nelson, M; Cerana, R; Van Etten, JL; Derst, C; DiFrancesco, D; Moroni, A; Thiel, G			A potassium channel protein encoded by chlorella virus PBCV-1	SCIENCE			English	Article							XENOPUS OOCYTES; K+ CHANNELS; SEQUENCE	The Large chlorella virus PBCV-1, which contains double-stranded DNA (dsDNA), encodes a 94-codon open reading frame (ORF) that contains a motif resembling the signature sequence of the pore domain of potassium channel proteins. Phylogenetic analyses of the encoded protein, Kcv, indicate a previously unidentified type of potassium channel. The messenger RNA encoded by the ORF Leads to functional expression of a potassium-selective conductance in Xenopus laevis oocytes. The channel blockers amantadine and barium, but not cesium, inhibit this conductance, in addition to virus plaque formation. Thus, PBCV-1 encodes the first known viral protein that functions as a potassium-selective channel and is essential in the virus Life cycle.	Univ Gottingen, Albrecht von Haller Inst Pflanzenwissensch, D-37073 Gottingen, Germany; Univ Milan, I-20133 Milan, Italy; Megabase Res Prod, Lincoln, NE 68604 USA; Univ Milano Bicocca, DISAT, I-20126 Milan, Italy; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Marburg, Inst Physiol, D-35033 Marburg, Germany	University of Gottingen; University of Milan; University of Milano-Bicocca; University of Nebraska System; University of Nebraska Lincoln; Philipps University Marburg	Thiel, G (corresponding author), Univ Gottingen, Albrecht von Haller Inst Pflanzenwissensch, D-37073 Gottingen, Germany.		moroni, anna/H-2097-2014; DiFrancesco, Dario/G-8408-2017; Ebert, Barbara/E-5709-2012	moroni, anna/0000-0002-1860-406X; DiFrancesco, Dario/0000-0002-7322-1790; Thiel, Gerhard/0000-0002-2335-1351; Ebert, Barbara/0000-0003-3328-6693; gazzarrini, sabrina/0000-0003-3062-7536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32441, GM41333] Funding Source: Medline; Telethon [971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Bauer CK, 1996, PFLUG ARCH EUR J PHY, V432, P812, DOI 10.1007/s004240050203; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Derst C, 1998, J EXP BIOL, V201, P2791; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; KUSANO K, 1982, J PHYSIOL-LONDON, V328, P143, DOI 10.1113/jphysiol.1982.sp014257; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; Landstein D, 1995, VIROLOGY, V214, P413, DOI 10.1006/viro.1995.0051; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Owen JM, 1999, EXP PHYSIOL, V84, P471, DOI 10.1017/S0958067099018060; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; VANETTEN JL, 1983, VIROLOGY, V126, P117, DOI 10.1016/0042-6822(83)90466-X; VANETTEN JL, UNPUB; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7	26	143	154	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1641	1644		10.1126/science.287.5458.1641	http://dx.doi.org/10.1126/science.287.5458.1641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698737	Green Published			2022-12-24	WOS:000085628200035
J	Lee, SH; Wolf, PL; Escudero, R; Deutsch, R; Jamieson, SW; Thistlethwaite, PA				Lee, SH; Wolf, PL; Escudero, R; Deutsch, R; Jamieson, SW; Thistlethwaite, PA			Early expression of angiogenesis factors in acute myocardial ischemia and infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; PHENOL-CHLOROFORM EXTRACTION; FACTOR MESSENGER-RNA; SINGLE-STEP METHOD; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; DNA-BINDING	Background: When the myocardium is deprived of blood, a process of ischemia, infarction, and myocardial remodeling is initiated. Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating early cellular responses to hypoxia. We investigated the temporal and spatial patterns of expression of the alpha subunit of HIF-1 (HIF-1 alpha) and VEGF in specimens of human heart tissue to elucidate the early molecular responses to myocardial hypoxia. Methods: Ventricular-biopsy specimens from 37 patients undergoing coronary bypass surgery were collected. The specimens were examined by microscopy for evidence of ischemia, evolving infarction, or a normal histologic appearance. The specimens were also analyzed with the reverse-transcriptase polymerase chain reaction for HIF-1 alpha and VEGF messenger RNA (mRNA) expression and by immunohistochemical analysis for the location of the HIF-1 alpha and VEGF proteins. Results: HIF-1 alpha mRNA was detected in myocardial specimens with pathological evidence of acute ischemia (onset, <48 hours before surgery) or early infarction (onset, <24 hours before surgery). In contrast, VEGF transcripts were seen in specimens with evidence of acute ischemia or evolving infarction (onset, 24 to 120 hours before surgery). Patients with normal ventricles or evidence of infarction in the distant past had no detectable levels of either VEGF mRNA or HIF-1 alpha mRNA. HIF-1 alpha immunoreactivity was detected in the nuclei of myocytes and endothelial cells, whereas VEGF immunoreactivity was found in the cytoplasm of endothelial cells lining capillaries and arterioles. Conclusions: An increase in the level of HIF-1 alpha is an early response to myocardial ischemia or infarction. This response defines, at a molecular level, one of the first adaptations of human myocardium to a deprivation of blood. HIF-1 alpha is a useful temporal marker of acutely jeopardized myocardium. (N Engl J Med 2000;342:626-33.) (C)2000, Massachusetts Medical Society.	Univ Calif San Diego, Div Cardiothorac Surg 8892, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Gen Clin Res Ctr, San Diego, CA 92103 USA; Vet Affairs Med Ctr, Dept Pathol, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Thistlethwaite, PA (corresponding author), Univ Calif San Diego, Div Cardiothorac Surg 8892, 200 W Arbor Dr, San Diego, CA 92103 USA.	pthistlethwaite@ucsd.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 0827] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTRAN RS, 1999, ROBBINS PATHOLOGIC B, P554; Deindl E, 1998, MOL CELL BIOCHEM, V186, P43, DOI 10.1023/A:1006853432678; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hashimoto Etsuo, 1994, American Journal of Physiology, V267, pH1948; Hearse DJ, 1998, MOL CELL BIOCHEM, V186, P177, DOI 10.1023/A:1006808507605; Heusch G, 1998, MOL CELL BIOCHEM, V186, P185, DOI 10.1023/A:1006816725351; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; SABIA PJ, 1992, NEW ENGL J MED, V327, P1825, DOI 10.1056/NEJM199212243272601; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; [No title captured]	36	569	635	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2000	342	9					626	633		10.1056/NEJM200003023420904	http://dx.doi.org/10.1056/NEJM200003023420904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288QV	10699162				2022-12-24	WOS:000085575500004
J	Birk, OS; Casiano, DE; Wassif, CA; Cogliati, T; Zhao, LP; Zhao, YG; Grinberg, A; Huang, SP; Kreidberg, JA; Parker, KL; Porter, FD; Westphal, H				Birk, OS; Casiano, DE; Wassif, CA; Cogliati, T; Zhao, LP; Zhao, YG; Grinberg, A; Huang, SP; Kreidberg, JA; Parker, KL; Porter, FD; Westphal, H			The LIM homeobox gene Lhx9 is essential for mouse gonad formation	NATURE			English	Article							SEXUAL-DIFFERENTIATION; EXPRESSION	During mammalian embryonic development, the ovaries and testes develop from somatic cells of the urogenital ridges as indifferent gonads, harbouring primordial germ cells that have migrated there. After sex determination of the gonads, the testes produce testosterone and anti-Mullerian hormone which mediate male sexual differentiation, and the female developmental pathway ensues in their absence(1-3). Here we show that transcripts of the LIM homeobox gene Lhx9 are present in urogenital ridges of mice at embryonic day 9.5; later they localize to the interstitial region as morphological differentiation occurs. In mice lacking Lhx9 function, germ cells migrate normally, but somatic cells of the genital ridge fail to proliferate and a discrete gonad fails to form. In the absence of testosterone and anti-Mullerian hormone, genetically male mice are phenotypically female. The expression of steroidogenic factor 1 (Sf1), a nuclear receptor essential for gonadogenesis2, is reduced to minimal levels in the Lhx9-deficient genital ridge, indicating that Lhx9 may lie upstream of Sf1 in a developmental cascade. Unlike mice lacking other genes that mediate early stages of gonadogenesis(4-6), Lhx9 mutants do not exhibit additional major developmental defects. Thus, LHX9 mutations may underlie certain forms of isolated gonadal agenesis in humans.	NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; NICHHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Med Branch, NIH, Bethesda, MD 20889 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Boston Children's Hospital	Westphal, H (corresponding author), NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA.			Birk, Ohad/0000-0003-1430-1296; Wassif, Christopher/0000-0002-2524-1420	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000139, ZIAHD000071] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000071, Z01HD000139] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Bertuzzi S, 1999, MECH DEVELOP, V81, P193, DOI 10.1016/S0925-4773(98)00233-0; Capel B, 1998, ANNU REV PHYSIOL, V60, P497, DOI 10.1146/annurev.physiol.60.1.497; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; Gilbert S., 1997, DEV BIOL; Goodfellow PN, 1999, CELL MOL LIFE SCI, V55, P857, DOI 10.1007/PL00013201; Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KAUFMAN MH, 1999, ANATOMICAL BASIS MOU, P117; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUNIEDA T, 1992, BIOL REPROD, V46, P692, DOI 10.1095/biolreprod46.4.692; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Parker KL, 1999, ANNU REV PHYSIOL, V61, P417, DOI 10.1146/annurev.physiol.61.1.417; Porter FD, 1997, DEVELOPMENT, V124, P2935; Retaux S, 1999, J NEUROSCI, V19, P783; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Warne GL, 1998, ENDOCRIN METAB CLIN, V27, P945, DOI 10.1016/S0889-8529(05)70049-9; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822; Zhao YU, 1999, SCIENCE, V284, P1155, DOI 10.1126/science.284.5417.1155	23	255	264	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					909	913		10.1038/35002622	http://dx.doi.org/10.1038/35002622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706291				2022-12-24	WOS:000085559200062
J	Kew, MC				Kew, MC			Serum aminotransferase concentration as evidence of hepatocellular damage	LANCET			English	Editorial Material							ASPARTATE-AMINOTRANSFERASE; LIVER		Univ Witwatersrand, Sch Med, Dept Med, ZA-2193 Johannesburg, South Africa	University of Witwatersrand	Kew, MC (corresponding author), Univ Witwatersrand, Sch Med, Dept Med, ZA-2193 Johannesburg, South Africa.							BATZAKIS KG, 1979, INTREPRETIVE ENZYMOL; COHEN GA, 1976, ANN INTERN MED, V84, P275, DOI 10.7326/0003-4819-84-3-275; COHEN JA, 1979, DIGEST DIS SCI, V24, P835, DOI 10.1007/BF01324898; DAVIS GL, 1982, MAYO CLIN PROC, V57, P303; ELLIS G, 1978, AM J CLIN PATHOL, V70, P248; NALPAS B, 1984, HEPATOLOGY, V4, P893, DOI 10.1002/hep.1840040517; PATWARDHAN RV, 1987, ARCH INTERN MED, V147, P1249, DOI 10.1001/archinte.147.7.1249; REJ R, 1978, CLIN CHEM, V24, P1971; SCHMIDT E, 1979, ADV CLIN ENZYMOL, V1, P239; Whitehead MW, 1999, GUT, V45, P129, DOI 10.1136/gut.45.1.129	10	180	202	3	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					591	592		10.1016/S0140-6736(99)00219-6	http://dx.doi.org/10.1016/S0140-6736(99)00219-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696975				2022-12-24	WOS:000085615400005
J	Kroman, N; Jensen, MB; Wohlfahrt, J; Mouridsen, HT; Andersen, PK; Melbye, M				Kroman, N; Jensen, MB; Wohlfahrt, J; Mouridsen, HT; Andersen, PK; Melbye, M			Factors influencing the effect of age on prognosis in breast cancer: population based study	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL CONSENSUS PANEL; YOUNG-WOMEN; CARCINOMA; SURVIVAL; RISK; CHEMOTHERAPY; RADIOTHERAPY; RECURRENCE; HIGHLIGHTS; CHILDBIRTH	Objective To investigate whether young age at diagnosis is a negative prognostic factor in primary breast cancer and how stage of disease at diagnosis and treatment influences such an association. Design Retrospective cohort study based on a population based database of patients with breast cancer containing detailed information on tumour characteristics, treatment regimens, and survival. Setting Denmark. Subjects 10 356 women with primary breast cancer who were less than 50 years old at diagnosis. Main outcome measures Relative risk of dying within the first 10 years after. diagnosis according to age at diagnosis after adjustment for known prognostic factors and expected mortality. Results Overall, young women with low risk disease who did not receive adjuvant treatment had a significantly increased risk of dying; risk increased with decreasing age at diagnosis (adjusted relative risk: 45-49 years (reference): 1: 40-44 years: 1.12 (95% confidence interval 0.89 to 1.40): 35-39 years: 1.40 (1.10 to 1.78); < 35 years: 2.18 (1.64 to 2.89). However, no similar trend was seen in patients who received adjuvant cytotoxic treatment. The increased risk in younger women who did not receive adjuvant treatment compared with those who did remained when women were grouped according to presence of node negative disease and by tumour size. Conclusion The negative prognostic effect of young age is almost exclusively seen in women diagnosed with low risk disease who did not receive adjuvant cytotoxic treatment. These results suggest that young women with breast cancer on the basis of age alone, should be regarded as high risk patients and be given adjuvant cytotoxic treatment.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Rigshosp, Danish Breast Canc Cooperat Grp, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen; University of Copenhagen	Melbye, M (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.			melbye, mads/0000-0001-8264-6785				ABE O, 1992, LANCET, V339, P71; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; ANDERSON BO, 1995, ANN SURG ONCOL, V2, P407, DOI 10.1007/BF02306373; BONNIER P, 1995, INT J CANCER, V62, P138, DOI 10.1002/ijc.2910620205; BOYAGES J, 1990, RADIOTHER ONCOL, V19, P29, DOI 10.1016/0167-8140(90)90163-Q; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; FOWBLE BL, 1994, INT J RADIAT ONCOL, V30, P23, DOI 10.1016/0360-3016(94)90515-0; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; GOLDHIRSCH A, 1995, J NATL CANCER I, V87, P1441, DOI 10.1093/jnci/87.19.1441; Henderson IC, 1997, LANCET, V349, P1488, DOI 10.1016/S0140-6736(97)22021-0; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; Kroman N, 1998, BRIT J CANCER, V78, P1529, DOI 10.1038/bjc.1998.718; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; MAX MH, 1984, AM SURGEON, V50, P23; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; *MIN INT, 1994, STAT YB 1994; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Petrek J A, 1994, J Natl Cancer Inst Monogr, P113; REMVIKOS Y, 1995, BREAST CANCER RES TR, V34, P25, DOI 10.1007/BF00666488; SCHMIDT RT, 1991, AM J SURG, V162, P197, DOI 10.1016/0002-9610(91)90068-O; Storm H H, 1991, IARC Sci Publ, P220; VERONESI U, 1990, ANN SURG, V211, P250; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Winchester DP, 1996, CANCER-AM CANCER SOC, V78, P1838, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y	33	258	268	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					474	478		10.1136/bmj.320.7233.474	http://dx.doi.org/10.1136/bmj.320.7233.474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678859	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000085562200021
J	Lyons, RA; Wareham, K; Hutchings, HA; Major, E; Ferguson, B				Lyons, RA; Wareham, K; Hutchings, HA; Major, E; Ferguson, B			Population requirement for adult critical-care beds: a prospective quantitative and qualitative study	LANCET			English	Article								Background The provision of adult critical-care facilities is not based on a rational or scientific assessment of need. We aimed to define the numbers of adult critical-care beds required for a population of 500 000. Methods In five hospitals in Wales, UK, we classified patients who might be suitable for critical care in intensive-care or high-dependency units. On every 12th day for 1 calendar year, we counted the numbers of such patients admitted in a defined geographical population. A panel of ten intensivists made consensus decisions about whether individual patients were in the appropriate unit. The data were used to predict the numbers of beds and units required for the population. Findings 4058 patients were suitable for critical care, of whom 3028 lived in the study area. 56.4% were in general wards, 22.3% in high-dependency units, and 21.3% in intensive-care units. The mean risk of death was 22.0% and the in-hospital death rate 17.3%. According to the masked consensus, 41.3% of patients required high-dependency beds and 21.5% intensive-care beds. Mean risk of death increased from general wards (14.7%) to high-dependency units (19.2%) to intensive care (37.0%). Based on the consensus decisions, the average daily requirement of intensive-care beds was 21 and of high-dependency beds 43; to meet needs 95% of times required 30 and 55 beds, respectively, in a single critical-care unit. Interpretation We estimated, scientifically, numbers of adult critical-care beds required to meet population needs. Studies are necessary periodically to track changes in admissions requiring critical care.	Univ Wales Coll Med, Dept Epidemiol & Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Morriston Hosp, Sch Postgrad Studies Med & Hlth Care, Clin Res Unit, Swansea, W Glam, Wales; Prince Wales Hosp, Bridgend, Wales	Cardiff University; Morriston Hospital; Swansea University	Lyons, RA (corresponding author), Univ Wales Coll Med, Dept Epidemiol & Publ Hlth, Swansea SA1 1LT, W Glam, Wales.		Hutchings, Hayley A/C-9944-2013; Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X; Hutchings, Hayley Anne/0000-0003-4155-1741				Audit Commission, 1999, CRIT SUCC PLAC EFF E; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; METCALF A, 1993, STUDY PROVISION INTE; *NAT HLTH SERV WAL, 1999, CLIN IND NHS 1995 19; Townsend PP., 1988, HLTH DEPRIVATION INE; *WORK GROUP GUID A, 1996, DISCH INT CAR HIGH D	7	61	61	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					595	598		10.1016/S0140-6736(00)01265-4	http://dx.doi.org/10.1016/S0140-6736(00)01265-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696978				2022-12-24	WOS:000085615400009
J	Beech, PL; Nheu, T; Schultz, T; Herbert, S; Lithgow, T; Gilson, PR; McFadden, GI				Beech, PL; Nheu, T; Schultz, T; Herbert, S; Lithgow, T; Gilson, PR; McFadden, GI			Mitochondrial FtsZ in a chromophyte alga	SCIENCE			English	Article							BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI; PROTEIN FTSZ; HOMOLOG; DYNAMICS; FISSION; TUBULIN; FUSION; RING	A homolog of the bacterial cell division gene ftsZ was isolated from the alga Mallomonas splendens. The nuclear-encoded protein (MsFtsZ-mt) was closely related to FtsZs of the alpha-proteobacteria, possessed a mitochondrial targeting signal, and localized in a pattern consistent with a role in mitochondrial division. Although FtsZs are known to act in the division of chloroplasts, MsFtsZ-mt appears to be a mitochondrial FtsZ and may represent a mitochondrial division protein.	Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Melbourne, Vic 3125, Australia; Univ Melbourne, Plant Cell Biol Res Ctr, Melbourne, Vic 3010, Australia; Univ Melbourne, Sch Bot, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Deakin University; University of Melbourne; University of Melbourne; University of Melbourne	Beech, PL (corresponding author), Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, 221 Burwood Highway, Melbourne, Vic 3125, Australia.		Beech, Peter/C-3709-2014; Lithgow, Trevor/H-5925-2017	Beech, Peter/0000-0003-1669-6623; Schultz, Thomas/0000-0001-9694-9920; Lithgow, Trevor/0000-0002-0102-7884				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BEECH PL, 1990, J PHYCOL, V26, P90, DOI 10.1111/j.0022-3646.1990.00090.x; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; GAFFAL KP, 1987, ENDOCYTOBIOSIS CELL, V4, P41; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Margolin W, 1998, TRENDS MICROBIOL, V6, P233, DOI 10.1016/S0966-842X(98)01280-3; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Osteryoung KW, 1998, PLANT CELL, V10, P1991, DOI 10.1105/tpc.10.12.1991; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Palmer JD, 1997, SCIENCE, V275, P790, DOI 10.1126/science.275.5301.790; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Strepp R, 1998, P NATL ACAD SCI USA, V95, P4368, DOI 10.1073/pnas.95.8.4368; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	26	136	147	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1276	1279		10.1126/science.287.5456.1276	http://dx.doi.org/10.1126/science.287.5456.1276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678836				2022-12-24	WOS:000085444700053
J	Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W				Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W			Pharmacologic paralysis and withdrawal of mechanical ventilation at the end of life.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; CRITICALLY ILL PATIENTS; CLINICAL MANAGEMENT; DYING PATIENTS; STRATEGY; CARE		Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Truog, RD (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.		Burns, Jeffrey P/AAW-8474-2021					Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BURNS JP, IN PRESS CRIT CARE M; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Field MJ, 1997, APPROACHING DEATH IM; Hatherill M, 1998, BMJ-BRIT MED J, V317, P80, DOI 10.1136/bmj.317.7150.80a; Hoyt J W, 1994, New Horiz, V2, P48; HUNTER JM, 1995, NEW ENGL J MED, V332, P1691, DOI 10.1056/NEJM199506223322507; KIRKLAND L, 1994, J CLIN ETHIC, V5, P38; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LOPER KA, 1989, PAIN, V37, P315, DOI 10.1016/0304-3959(89)90196-6; MEISEL A, 1995, RIGHT DIE; RIDDICK CA, 1994, J CLIN ETHIC, V5, P41; Rushton C H, 1995, Am J Crit Care, V4, P112; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SOTTILE FD, 1995, CHEST, V108, P887, DOI 10.1378/chest.108.3.887-a; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	24	55	56	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					508	511		10.1056/NEJM200002173420712	http://dx.doi.org/10.1056/NEJM200002173420712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675435				2022-12-24	WOS:000085319100012
J	Greer, JM; Puetz, J; Thomas, KR; Capecchi, MR				Greer, JM; Puetz, J; Thomas, KR; Capecchi, MR			Maintenance of functional equivalence during paralogous Hox gene evolution	NATURE			English	Article							STEM-CELLS; TARGETED DISRUPTION; MICE; TRANSFORMATIONS; VERTEBRAE; HINDBRAIN; REVEAL; RESCUE; THYMUS	Biological diversity is driven mainly by gene duplication followed by mutation and selection. This divergence in either regulatory or protein-coding sequences can result in quite different biological functions for even closely related genes. This concept is exemplified by the mammalian Hox gene complex, a group of 39 genes which are located on 4 linkage groups, dispersed on 4 chromosomes(1-4). The evolution of this complex bee;an with amplification in cis of a primordial Hox gene to produce 13 members, followed by duplications in tuans of much of the entire unit. As a consequence, Hox genes that occupy the same relative position along the 5' to 3' chromosomal coordinate (trans-paralogous genes) share more similarity in sequence and expression pattern than do adjacent Hox genes on the same chromosome. Studies in mice indicate that although individual family members may have unique biological roles, they also share overlapping functions with their paralogues(5-12). Here we show that the proteins encoded by the paralogous genes, Hoxa3 and Hoxd3, can carry out identical biological functions, and that the different roles attributed to these genes are the result of quantitative modulations in gene expression.	Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA.	mario.capecchi@genetics.utah.edu						Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Gavalas A, 1998, DEVELOPMENT, V125, P1123; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; HORAN GSB, 1995, GENE DEV, V9, P1667, DOI 10.1101/gad.9.13.1667; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, P63; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; LONAI P, 1987, DNA-J MOLEC CELL BIO, V6, P409, DOI 10.1089/dna.1987.6.409; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Manley NR, 1997, DEV BIOL, V192, P274, DOI 10.1006/dbio.1997.8765; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ROSSEL M, IN PRESS DEVELOPMENT, V126; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; Studer M, 1998, DEVELOPMENT, V125, P1025; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; Zakany J, 1996, DEV BIOL, V176, P325, DOI 10.1006/dbio.1996.0137	30	208	211	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					661	665		10.1038/35001077	http://dx.doi.org/10.1038/35001077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688203				2022-12-24	WOS:000085288200055
J	Henney, JE				Henney, JE			First drug device to treat actinic keratoses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-24	WOS:000084956500006
J	Naumburg, E; Bellocco, R; Cnattingius, S; Hall, P; Ekbom, A				Naumburg, E; Bellocco, R; Cnattingius, S; Hall, P; Ekbom, A			Prenatal ultrasound examinations and risk of childhood leukaemia: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY		Uppsala Univ, Paediat Sect, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden; Dept Med Epidemiol, S-17177 Stockholm, Sweden	Uppsala University	Naumburg, E (corresponding author), Uppsala Univ, Paediat Sect, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden.	Estelle.Namburg@pediatrik.uu.se	Bellocco, Rino/E-7674-2018; Naumburg, Estelle/B-8539-2018	Naumburg, Estelle/0000-0001-6090-494X				CARTWRIGHT RA, 1984, LANCET, V2, P999; DINNO MA, 1989, PHYS MED BIOL, V34, P1543, DOI 10.1088/0031-9155/34/11/003; *EUR COMM ULTR RAD, 1996, EUR J ULTRASOUND, V4, P69; Kieler H, 1998, OBSTET GYNECOL, V91, P750, DOI 10.1016/S0029-7844(98)00062-3; WILSON LMK, 1984, LANCET, V2, P997	5	15	18	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2000	320	7230					282	283		10.1136/bmj.320.7230.282	http://dx.doi.org/10.1136/bmj.320.7230.282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650024	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000085132700020
J	Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM				Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM			The DExH protein NPH-II is a processive and directional motor for unwinding RNA	NATURE			English	Article							MESSENGER-RNA; HELICASE; SPECIFICITY; MECHANISMS; ENZYME	All aspects of cellular RNA metabolism and processing involve DExH/D proteins, which are a family of enzymes that unwind or manipulate RNA in an ATP-dependent fashion(1). DExH/D proteins are also essential for the replication of many viruses, and therefore provide targets for the development of therapeutics(2). All DExH/D proteins characterized to date hydrolyse nucleoside triphosphates and, in most cases, this activity is stimulated by the addition of RNA or DNA(1). Several members of the family unwind RNA duplexes in an NTP-dependent fashion in vitro(1,3); therefore it has been proposed that DExH/D proteins couple NTP hydrolysis to RNA conformational chang-e in complex macromolecular assemblies(4). Despite the central role of DExH/D proteins, their mechanism of RNA helicase activity remains unknown. Here we show that the DExH protein NPH-II unwinds RNA duplexes in a processive, unidirectional fashion with a step size of roughly one-half helix turn. We show that there is a quantitative connection between ATP utilization and helicase processivity, thereby providing direct evidence that DExH/D proteins can function as molecular motors on RNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Pyle, AM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.			Jankowsky, Eckhard/0000-0001-7677-7412				Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Jankowsky E, 1996, BIOCHEMISTRY-US, V35, P15313, DOI 10.1021/bi961397f; Jeltsch A, 1998, BIOCHEMISTRY-US, V37, P2160, DOI 10.1021/bi9719206; Kadare G, 1997, J VIROL, V71, P2583; Kelemen BR, 1999, BIOCHEMISTRY-US, V38, P5302, DOI 10.1021/bi990325w; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Pyle AM, 2000, METHOD ENZYMOL, V317, P140; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHNAPP BJ, 1995, NATURE, V373, P655, DOI 10.1038/373655a0; Shimamoto N, 1999, J BIOL CHEM, V274, P15293, DOI 10.1074/jbc.274.22.15293; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; STALEY JP, 1998, CELL, V90, P1041; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Xiang Q, 1998, BIOCHEMISTRY-US, V37, P3839, DOI 10.1021/bi972661n; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	22	189	195	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					447	451		10.1038/35000239	http://dx.doi.org/10.1038/35000239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667799				2022-12-24	WOS:000085121100055
J	Mead, DG; Ramberg, FB; Besselsen, DG; Mare, CJ				Mead, DG; Ramberg, FB; Besselsen, DG; Mare, CJ			Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice	SCIENCE			English	Article							NEW-JERSEY; SIMULIUM-VITTATUM; DIPTERA; DISEASE; PSYCHODIDAE; WILDLIFE; HAMSTERS; HOSTS; RNA	Vesicular stomatitis is an economically important arboviral disease of Livestock, Viremia is absent in infected mammalian hosts, and the mechanism by which insects become infected with the causative agents, vesicular stomatitis viruses, remains unknown. Because infected and noninfected insects potentially feed on the same host in nature, infected and noninfected black flies were allowed to feed on the same host. Viremia was not detected in the host after infection by a black fly bite, but because noninfected black flies acquired the virus while co-feeding on the same host with infected black flies, it is concluded that a viremic host is not necessary for an insect to be infected with the virus. Thus co-feeding is a mechanism of infection for an insect-transmitted virus.	Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA	University of Arizona	Mead, DG (corresponding author), Univ Arizona, Dept Vet Sci & Microbiol, 1117 E Lowell, Tucson, AZ 85721 USA.	dmead@u.arizona.edu	Mead, Daniel/F-7501-2013					AGUIRRE AA, 1992, J WILDLIFE DIS, V28, P435, DOI 10.7589/0090-3558-28.3.435; ANDERSON J. R., 1961, ANN ENT SOC AMER, V54, P716, DOI 10.1093/aesa/54.5.716; ANDERSON JOHN R., 1963, MOSQUITO NEWS, V23, P126; Barrera JD, 1996, VIROLOGY, V219, P453, DOI 10.1006/viro.1996.0271; BERNARDO MJ, 1986, ANN ENTOMOL SOC AM, V79, P610, DOI 10.1093/aesa/79.4.610; CAVE DR, 1984, J VIROL, V50, P86, DOI 10.1128/JVI.50.1.86-91.1984; COMER JA, 1995, J MED ENTOMOL, V32, P738, DOI 10.1093/jmedent/32.5.738; COTTON WE, 1926, JAVMA, V70, P168; CUPP EW, 1992, J MED ENTOMOL, V29, P137, DOI 10.1093/jmedent/29.2.137; Cupp EW, 1997, J MED ENTOMOL, V34, P87, DOI 10.1093/jmedent/34.2.87; DAVIES DOUGLAS M., 1956, CANADIAN JOUR ZOOL, V34, P615, DOI 10.1139/z56-064; FRANCY DB, 1988, J MED ENTOMOL, V25, P343, DOI 10.1093/jmedent/25.5.343; FULTZ PN, 1982, J GEN VIROL, V63, P493, DOI 10.1099/0022-1317-63-2-493; FULTZ PN, 1985, VIRUS RES, V3, P129, DOI 10.1016/0168-1702(85)90003-6; GREEN SL, 1993, VET CLIN N AM-EQUINE, V9, P349, DOI 10.1016/S0749-0739(17)30401-7; Jenney E. W., 1972, Proceedings of the United States Animal Health Association, V76, P183; Jimenez AE, 1996, J WILDLIFE DIS, V32, P274, DOI 10.7589/0090-3558-32.2.274; JONES LD, 1987, SCIENCE, V237, P775, DOI 10.1126/science.3616608; KARSTAD L, 1957, AM J VET RES, V18, P162; Knowlton GF, 1935, J ECON ENTOMOL, V28, P824, DOI 10.1093/jee/28.5.824; Labuda M, 1997, VIROLOGY, V235, P138, DOI 10.1006/viro.1997.8622; MARE CJ, 1973, INFECT IMMUN, V8, P118; MARE CJ, 1991, P US ANIM HLTH ASS, V19, P179; MULLER MJ, 1987, J MED ENTOMOL, V24, P206, DOI 10.1093/jmedent/24.2.206; MURPHY FA, 1975, EXP MOL PATHOL, V23, P426, DOI 10.1016/0014-4800(75)90035-0; MURPHY FA, 1994, VIRUS TAXONOMY CLASS; PATTERSON WC, 1955, P US LIVESTOCK SANIT, V59, P368; PETERSON B. V., 1959, CANADIAN ENT, V91, P147; REDELMAN D, 1989, VET IMMUNOL IMMUNOP, V20, P345, DOI 10.1016/0165-2427(89)90080-9; RYCKMAN RE, 1961, J PARASITOL, V47, P405, DOI 10.2307/3275364; Stallknecht DE, 1999, AM J VET RES, V60, P43; TESH RB, 1970, AM J EPIDEMIOL, V91, P216, DOI 10.1093/oxfordjournals.aje.a121130; THORNE ET, 1983, P US ANIMAL HLTH ASS, V87, P638; THURMOND MC, 1987, J AM VET MED ASSOC, V191, P965; TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5; WEBB PA, 1987, J WILDLIFE DIS, V23, P192, DOI 10.7589/0090-3558-23.2.192; *WHO, 1967, TECH REP SER, V369, P9; *WHO, 1985, TECH REP SER, V719, P36; Wikel SK, 1999, BIOSCIENCE, V49, P311, DOI 10.2307/1313614; YOUNG DG, 1984, MOSQ NEWS, V44, P263; Yuill T. M., 1981, CRC handbook series in zoonoses. Section B: viral zoonoses. Volume I, P125	41	98	103	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					485	487		10.1126/science.287.5452.485	http://dx.doi.org/10.1126/science.287.5452.485			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642550				2022-12-24	WOS:000084929900048
J	Gillick, MR				Gillick, MR			Sounding board - Rethinking the role of tube feeding in patients with advanced dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; NURSING-HOME RESIDENTS; LIFE-SUSTAINING TREATMENTS; TERMINALLY ILL PATIENTS; CARDIOPULMONARY-RESUSCITATION; ARTIFICIAL NUTRITION; SUPREME-COURT; CARE; PREFERENCES; DECISIONS		Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA		Gillick, MR (corresponding author), Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Callahan CM, 1999, J AM GERIATR SOC, V47, P1105, DOI 10.1111/j.1532-5415.1999.tb05235.x; Callahan Daniel, 1993, TROUBLED DREAM LIFE; COSTA PT, 1996, AHCPR PUBLICATION; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Fainsinger RL, 1997, SUPPORT CARE CANCER, V5, P205, DOI 10.1007/s005200050061; FEINBERG MJ, 1992, RADIOLOGY, V183, P811, DOI 10.1148/radiology.183.3.1584939; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FINUCANE TE, 1997, LANCET, V349, P364; Fischer GS, 1997, ARCH INTERN MED, V157, P801, DOI 10.1001/archinte.157.7.801; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; HODGES MO, 1994, CLIN GERIATR MED, V10, P475, DOI 10.1016/S0749-0690(18)30334-3; Kane RS, 1997, J AM GERIATR SOC, V45, P154, DOI 10.1111/j.1532-5415.1997.tb04500.x; KAW M, 1994, DIGEST DIS SCI, V39, P738, DOI 10.1007/BF02087416; LO B, 1984, NEW ENGL J MED, V311, P402, DOI 10.1056/NEJM198408093110611; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; LYNN J, 1986, BY NO EXTRORDINARY M, P47; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 1999, CAN MED ASSOC J, V160, P1705; Mitchell SL, 1998, J GERONTOL A-BIOL, V53, pM207, DOI 10.1093/gerona/53A.3.M207; Morris J, 1997, MEASUREMENT ELDERLY, P130; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT C CATH BISH, 1995, ETH REL DIR CATH HLT; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; OBrien LA, 1997, J GEN INTERN MED, V12, P364, DOI 10.1046/j.1525-1497.1997.00061.x; OUSLANDER JG, 1993, J AM GERIATR SOC, V41, P70, DOI 10.1111/j.1532-5415.1993.tb05951.x; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; Petersen TI, 1997, EUR J SURG, V163, P351; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; Post SG, 1995, MORAL CHALLENGE ALZH; Rabeneck L, 1997, LANCET, V349, P496, DOI 10.1016/S0140-6736(96)07369-2; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; Rosin AJ, 1998, J MED ETHICS, V24, P44, DOI 10.1136/jme.24.1.44; Sachs GA, 1998, J AM GERIATR SOC, V46, P782, DOI 10.1111/j.1532-5415.1998.tb03818.x; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHOSTAK RZ, 1994, J MED ETHICS, V20, P93, DOI 10.1136/jme.20.2.93; SHAILESH LTC, 1992, AM J SURG, V164, P114, DOI 10.1016/S0002-9610(05)80367-8; Sheiman SL, 1996, J AM GERIATR SOC, V44, P1268, DOI 10.1111/j.1532-5415.1996.tb01384.x; SIEGLER M, 1985, ARCH INTERN MED, V145, P129, DOI 10.1001/archinte.145.1.129; SLOMKA J, 1995, ARCH INTERN MED, V155, P1258, DOI 10.1001/archinte.155.12.1258; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STEINBROOK R, 1988, NEW ENGL J MED, V318, P286, DOI 10.1056/NEJM198802043180505; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; Sullivan-Marx EM, 1999, J AM GERIATR SOC, V47, P342, DOI 10.1111/j.1532-5415.1999.tb02999.x; TAYLOR CA, 1992, MAYO CLIN PROC, V67, P1042, DOI 10.1016/S0025-6196(12)61118-5; Thomasma D., 1992, DEMENTIA AGING ETHIC, P101; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846	50	335	343	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2000	342	3					206	210		10.1056/NEJM200001203420312	http://dx.doi.org/10.1056/NEJM200001203420312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	275ZT	10639550				2022-12-24	WOS:000084851700012
J	Chan, AWS; Dominko, T; Luetjens, CM; Neuber, E; Martinovich, C; Hewitson, L; Simerly, CR; Schatten, GP				Chan, AWS; Dominko, T; Luetjens, CM; Neuber, E; Martinovich, C; Hewitson, L; Simerly, CR; Schatten, GP			Clonal propagation of primate offspring by embryo splitting	SCIENCE			English	Article							CELLS; FETAL; MOUSE; ADULT	Primates that are identical in both nuclear and cytoplasmic components have not been produced by current cloning strategies, yet such identicals represent the ideal model for investigations of human diseases. Here, genetically identical nonhuman embryos were produced as twin and larger sets by separation and reaggregation of blastomeres of cleavage-stage embryos. A total of 368 multiples were created by the splitting of 107 rhesus embryos with four pregnancies established after 13 embryo transfers (31% versus 53% in vitro fertilization controls). The birth of Tetra, a healthy female cloned from a quarter of an embryo, proves that this approach can result in live offspring.	Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Schatten, GP (corresponding author), Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA.	schatten@ohsu.edu	simerly, Calvin/AAC-9564-2021; Schatten, Gerald/B-3253-2009	Schatten, Gerald/0000-0001-5206-7782				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; COHEN J, 1992, HUM REPROD, V7, P685, DOI 10.1093/oxfordjournals.humrep.a137720; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Gardner RL, 1997, DEVELOPMENT, V124, P289; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Hewitson L, 1998, HUM REPROD, V13, P3449, DOI 10.1093/humrep/13.12.3449; Hewitson L, 1999, NAT MED, V5, P431, DOI 10.1038/7430; Heyman Y, 1998, REPROD NUTR DEV, V38, P595, DOI 10.1051/rnd:19980602; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; KOLBERG R, 1993, SCIENCE, V262, P652, DOI 10.1126/science.8235583; Leese HJ, 1998, HUM REPROD, V13, P184, DOI 10.1093/humrep/13.suppl_4.184; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; PAPAIOANNOU VE, 1989, DEVELOPMENT, V106, P817; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; SEIKE N, 1990, JPN J VET RES, V38, P1; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; TARANTAL AF, 1988, AM J PRIMATOL, V15, P309, DOI 10.1002/ajp.1350150405; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wells DN, 1998, REPROD FERT DEVELOP, V10, P369, DOI 10.1071/R98109; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wolf DP, 1999, BIOL REPROD, V60, P199, DOI 10.1095/biolreprod60.2.199; Wu GJ, 1996, BIOL REPROD, V55, P260, DOI 10.1095/biolreprod55.2.260	28	92	101	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					317	319		10.1126/science.287.5451.317	http://dx.doi.org/10.1126/science.287.5451.317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634789				2022-12-24	WOS:000084769600044
J	Scholin, CA; Gulland, F; Doucette, GJ; Benson, S; Busman, M; Chavez, FP; Cordaro, J; DeLong, R; De Vogelaere, A; Harvey, J; Haulena, M; Lefebvre, K; Lipscomb, T; Loscutoff, S; Lowenstine, LJ; Marin, R; Miller, PE; McLellan, WA; Moeller, PDR; Powell, CL; Rowles, T; Silvagni, P; Silver, M; Spraker, T; Trainer, V; Van Dolah, FM				Scholin, CA; Gulland, F; Doucette, GJ; Benson, S; Busman, M; Chavez, FP; Cordaro, J; DeLong, R; De Vogelaere, A; Harvey, J; Haulena, M; Lefebvre, K; Lipscomb, T; Loscutoff, S; Lowenstine, LJ; Marin, R; Miller, PE; McLellan, WA; Moeller, PDR; Powell, CL; Rowles, T; Silvagni, P; Silver, M; Spraker, T; Trainer, V; Van Dolah, FM			Mortality of sea lions along the central California coast linked to a toxic diatom bloom	NATURE			English	Article							DOMOIC ACID; HIPPOCAMPAL DAMAGE; PROBES; MICE	Over 400 California sea lions (Zalophus californianus) died and many others displayed signs of neurological dysfunction along the central California coast during May and June 1998. A bloom of Pseudo-nitzschia australis (diatom) was observed in the Monterey Bay region during the same period. This bloom was associated with production of domoic acid (DA), a neurotoxin(1) that was also detected in planktivorous fish, including the northern anchovy (Engraulis mordax), and in sea lion body fluids. These and other concurrent observations demonstrate the trophic transfer of DA resulting in marine mammal mortality. In contrast to fish, blue mussels (Mytilus edulus) collected during the DA outbreak contained no DA or only trace amounts. Such findings reveal that monitoring of mussel toxicity alone does not necessarily provide adequate warning of DA entering the food web at levels sufficient to harm marine wildlife and perhaps humans.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Marin Headlands, Marine Mammal Ctr, Sausalito, CA 94965 USA; Natl Ocean Serv, Marine Biotoxins Program, NOAA, Charleston, SC 29412 USA; Moss Landing Marine Labs, Moss Landing, CA 95039 USA; Natl Marine Fisheries Serv, Long Beach, CA 90802 USA; Natl Marine Mammal Lab, Seattle, WA 98115 USA; Monterey Bay Natl Marine Sanctuary, Monterey, CA 93940 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA; Armed Forces Inst Pathol, Washington, DC 20306 USA; Calif Dept Hlth Serv, Food & Drug Branch, Sacramento, CA 94234 USA; Univ Calif Davis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Univ N Carolina, Wilmington, NC 28403 USA; Natl Marine Fisheries Serv, Silver Spring, MD 20910 USA; Colorado State Univ, Coll Vet Med, Ft Collins, CO 80523 USA; Natl Marine Fisheries Serv, NOAA, ECD, Seattle, WA 98112 USA	Monterey Bay Aquarium Research Institute; National Oceanic Atmospheric Admin (NOAA) - USA; National Ocean Service, NOAA; Moss Landing Marine Laboratories; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California Santa Cruz; United States Department of Defense; California Department of Health Care Services; University of California System; University of California Davis; University of North Carolina; University of North Carolina Wilmington; National Oceanic Atmospheric Admin (NOAA) - USA; Colorado State University; National Oceanic Atmospheric Admin (NOAA) - USA	Scholin, CA (corresponding author), Monterey Bay Aquarium Res Inst, 770 Sandholdt Rd, Moss Landing, CA 95039 USA.	scholin@mbari.org	Trainer, Vera/AAE-9306-2022; Doucette, Gregory/M-3283-2013; Busman, Mark/AAH-3042-2022; Busman, Mark/AFM-0629-2022	Busman, Mark/0000-0001-9750-064X				ANDERSON DM, 1993, 9302 WOODS HOL OC I; ANTONELIS GA, 1984, FISH B-NOAA, V82, P67; Bates S. S., 1998, PHYSL ECOLOGY HARMFU, P405; Bates S.S., 1998, PHYSL ECOLOGY HARMFU, P267; Beltran AS, 1997, TOXICON, V35, P447, DOI 10.1016/S0041-0101(96)00140-7; BOESCH DF, 1997, NOAA COASTAL OCEAN P, V10; Bossart GD, 1998, TOXICOL PATHOL, V26, P276, DOI 10.1177/019262339802600214; CHAVEZ FP, 1991, J GEOPHYS RES-OCEANS, V96, P14833, DOI 10.1029/91JC01163; DAKSHINAMURTI K, 1993, J NEUROSCI, V13, P4486; GERACI JR, 1989, CAN J FISH AQUAT SCI, V46, P1895, DOI 10.1139/f89-238; Gulland F, 1999, NMFSOPR8 NOAA; Harwood J, 1998, NATURE, V393, P17, DOI 10.1038/29877; Hatfield Christine L., 1994, Natural Toxins, V2, P206, DOI 10.1002/nt.2620020409; Luna LG, 1968, MANUAL HISTOLOGIC ST; McClain CR, 1998, SEA TECHNOL, V39, P10; Miller PE, 1998, J PHYCOL, V34, P371, DOI 10.1046/j.1529-8817.1998.340371.x; Ochoa JI, 1998, J SHELLFISH RES, V17, P1671; PARSONS TR, 1984, BIOL OCEANOGRAPHIC P, P39; QUILLIAM MA, 1995, J AOAC INT, V78, P543; Sakamoto CM, 1990, 902 MBARI; Scholin C, 1997, LIMNOL OCEANOGR, V42, P1265, DOI 10.4319/lo.1997.42.5_part_2.1265; SCHOLIN CA, IN PRESS J PHYCOL; STRAIN SM, 1991, NEUROSCIENCE, V44, P343, DOI 10.1016/0306-4522(91)90059-W; SUTHERLAND RJ, 1990, NEUROSCI LETT, V120, P221, DOI 10.1016/0304-3940(90)90043-9; VanDolah FM, 1997, ANAL BIOCHEM, V245, P102, DOI 10.1006/abio.1996.9889; WORK TM, 1993, J ZOO WILDLIFE MED, V24, P54; WRIGHT JLC, 1995, MANUAL HARMFUL MARIN, P113	27	587	612	3	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					80	84		10.1038/47481	http://dx.doi.org/10.1038/47481			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638756				2022-12-24	WOS:000084687400046
J	Spanagel, R				Spanagel, R			Is there a pharmacological basis for therapy with rapid opioid detoxification?	LANCET			English	Editorial Material							RECEPTOR BLOCKADE; ADDICTED PATIENTS; ANESTHESIA		Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany	Max Planck Society	Spanagel, R (corresponding author), Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany.							Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Kienbaum P, 1998, ANESTHESIOLOGY, V88, P1154, DOI 10.1097/00000542-199805000-00004; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Maldonado R, 1996, NEUROBIOLOGICAL MECH; Miotto K, 1997, DRUG ALCOHOL DEPEN, V45, P131, DOI 10.1016/S0376-8716(97)01348-3; MORRIS BJ, 1988, J PHARMACOL EXP THER, V247, P729; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Roizen MF, 1998, ANESTHESIOLOGY, V88, P1142, DOI 10.1097/00000542-199805000-00002; Seoane A, 1997, BRIT J PSYCHIAT, V171, P340, DOI 10.1192/bjp.171.4.340; Spanagel R, 1998, DRUG ALCOHOL DEPEN, V52, P251, DOI 10.1016/S0376-8716(98)00106-9; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2	13	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2017	2018		10.1016/S0140-6736(99)90248-9	http://dx.doi.org/10.1016/S0140-6736(99)90248-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636363				2022-12-24	WOS:000084183300006
J	Sandin, RH; Enlund, G; Samuelsson, P; Lennmarken, C				Sandin, RH; Enlund, G; Samuelsson, P; Lennmarken, C			Awareness during anaesthesia: a prospective case study	LANCET			English	Article							GENERAL-ANESTHESIA; RECALL; PROPOFOL	Background Patients who are given general anaesthesia are not guaranteed to remain unconscious during surgery. Knowledge about the effectiveness of current protective measures is scarce, as is our understanding of patients' responses to this complication. We did a prospective case study to assess conscious awareness during anaesthesia. Methods 11 785 patients who had undergone general anaesthesia were interviewed for awareness on three occasions: before they left the post-anaesthesia care unit, and 1-3 days and 7-14 days after the operation. Findings We identified 18 cases of awareness and one case of inadvertent muscle blockade that had occurred before unconsciousness. Incidence of awareness was 0.18% in cases in which neuromuscular blocking drugs were used, and 0.10% in the absence of such drugs. 17 cases of awareness were identified at the final interview, but no more than 11 would have been detected if an interview had been done only when the patients left the post-anaesthesia care unit. Four non-paralysed patients recalled intraoperative events, but none had anxiety during wakefulness or had delayed neurotic symptoms. This finding contrasts with anaesthesia with muscle relaxants, during which 11 of 14 patients had pain, anxiety, or delayed neurotic symptoms, After repeated discussion and information, the delayed neurotic symptoms resolved within 3 weeks in all patients. Analysis of individual cases suggests that a reduced incidence of recall of intraoperative events would not be achieved by monitoring of end-tidal anaesthetic gas concentration or by more frequent use of benzodiazepines. Interpretation The inability to prevent awareness by conventional measures may advocate monitoring of cerebral activity by neurophysiological techniques. However, the sensitivity of such techniques is not known, and in the light of our findings, at least 861 patients would need to be monitored to avoid one patient from suffering due to awareness during relaxant anaesthesia.	Lanssjukhuset, Dept Anaesthesia & Intens Care, S-39185 Kalmar, Sweden; Vrinnevisjukhuset, Dept Anaesthesia & Intens Care, Norrkoping, Sweden		Sandin, RH (corresponding author), Lanssjukhuset, Dept Anaesthesia & Intens Care, S-39185 Kalmar, Sweden.	rolfs@ltkalmar.se	garcia, waynice np/K-3914-2015					BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Klafta JM, 1996, ANESTH ANALG, V83, P1314, DOI 10.1097/00000539-199612000-00031; LIU WHD, 1991, ANAESTHESIA, V46, P435, DOI 10.1111/j.1365-2044.1991.tb11677.x; Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383; Nordstrom O, 1996, BRIT J ANAESTH, V76, P699, DOI 10.1093/bja/76.5.699; Nordstrom O, 1997, ACTA ANAESTH SCAND, V41, P978, DOI 10.1111/j.1399-6576.1997.tb04823.x; Pomfrett CJD, 1999, BRIT J ANAESTH, V82, P659, DOI 10.1093/bja/82.5.659; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Ranta SOV, 1998, ANESTH ANALG, V86, P1084, DOI 10.1097/00000539-199805000-00035	9	417	449	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	2000	355	9205					707	711		10.1016/S0140-6736(99)11010-9	http://dx.doi.org/10.1016/S0140-6736(99)11010-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703802				2022-12-24	WOS:000085615600012
J	Meng, XJ; Lindahl, M; Hyvonen, ME; Parvinen, M; de Rooij, DG; Hess, MW; Raatikainen-Ahokas, A; Sainio, K; Rauvala, H; Lakso, M; Pichel, JG; Westphal, H; Saarma, M; Sariola, H				Meng, XJ; Lindahl, M; Hyvonen, ME; Parvinen, M; de Rooij, DG; Hess, MW; Raatikainen-Ahokas, A; Sainio, K; Rauvala, H; Lakso, M; Pichel, JG; Westphal, H; Saarma, M; Sariola, H			Regulation of cell fate decision of undifferentiated spermatogonia by GDNF	SCIENCE			English	Article							ENTERIC NERVOUS-SYSTEM; ACID RECEPTOR-ALPHA; MICE LACKING GDNF; NEUROTROPHIC FACTOR; IN-VIVO; MOTOR-NEURONS; EXPRESSION; TESTIS; SPERMATOGENESIS; MOUSE	The molecular control of self-renewal and differentiation of stem cells has remained enigmatic. Transgenic Loss-of-function and overexpression models now show that the dosage of glial cell Line-derived neurotrophic factor (GDNF), produced by Sertoli cells, regulates cell fate decisions of undifferentiated spermatogonial cells that include the stem cells for spermatogenesis. Gene-targeted mice with one GDNF-null allele show depletion of stem cell reserves, whereas mice overexpressing GDNF show accumulation of undifferentiated spermatogonia. They are unable to respond properly to differentiation signals and undergo apoptosis upon retinoic acid treatment. Nonmetastatic testicular tumors are regularly formed in older GDNF-overexpressing mice. Thus, GDNF contributes to paracrine regulation of spermatogonial self-renewal and differentiation.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Res Program Dev Biol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Res Program Mol Neurobiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Transgen Unit, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Turku, Dept Anat, FIN-20520 Turku, Finland; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Hosp Merida, Unidad Invest, Badajoz 06800, Spain; NICHHD, Bethesda, MD 20892 USA	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Turku; Utrecht University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Sariola, H (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Res Program Dev Biol, POB 56,Viikinkaari 9, FIN-00014 Helsinki, Finland.		de Rooij, D.G./AAW-1195-2021; Lindahl, Maria/AHE-1252-2022; Hess, Michael/AAE-1985-2019; Pichel, Jose G/AAF-2255-2019	Hess, Michael/0000-0002-5154-3553; Pichel, Jose G/0000-0001-8580-0952; Rauvala, Heikki/0000-0001-7809-9811; de Rooij, Dirk/0000-0003-3932-4419; Lindahl, Maria/0000-0002-5674-8830				Akmal KM, 1998, ENDOCRINOLOGY, V139, P1239, DOI 10.1210/en.139.3.1239; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; CLERMONT Y, 1963, AM J ANAT, V112, P35, DOI 10.1002/aja.1001120103; de Rooij DG, 1999, BIOL REPROD, V61, P842, DOI 10.1095/biolreprod61.3.842; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Furuchi T, 1996, DEVELOPMENT, V122, P1703; Golden JP, 1999, EXP NEUROL, V158, P504, DOI 10.1006/exnr.1999.7127; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; Hu J, 1999, ENDOCRINOLOGY, V140, P3416, DOI 10.1210/en.140.8.3416; HUCKINS C, 1971, ANAT REC, V169, P533, DOI 10.1002/ar.1091690306; Kokaia Z, 1999, EUR J NEUROSCI, V11, P1202, DOI 10.1046/j.1460-9568.1999.00513.x; KOSHIMIZU U, 1995, MOL REPROD DEV, V40, P221, DOI 10.1002/mrd.1080400211; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Meistrich ML, 1993, CELL MOL BIOL TESTIS, P266; MENG XK, UNPUB; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Nguyen QT, 1998, SCIENCE, V279, P1725, DOI 10.1126/science.279.5357.1725; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Parvinen M, 1997, HISTOCHEM CELL BIOL, V108, P77, DOI 10.1007/s004180050148; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; PESCOVITZ OH, 1994, TRENDS ENDOCRIN MET, V5, P126, DOI 10.1016/1043-2760(94)90094-9; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Saarma M, 1999, MICROSC RES TECHNIQ, V45, P292, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8; Sainio K, 1997, DEVELOPMENT, V124, P4077; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Widenfalk J, 1997, J NEUROSCI, V17, P8506; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1756; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	39	981	1082	3	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1489	1493		10.1126/science.287.5457.1489	http://dx.doi.org/10.1126/science.287.5457.1489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688798				2022-12-24	WOS:000085531600052
J	Young, FE				Young, FE			A time for restraint	SCIENCE			English	Editorial Material								The debate on the use of human embryos for research will be one of the more important issues of the 21st century. Unlike recombinant DNA technology, embryonic stem cell research most probably will result in the destruction of living embryos. Many people consider this research immoral, illegal, and unnecessary. Therefore, it is imperative to proceed cautiously. Federal funding of research using human embryos or pluripotent cells derived from them would be inappropriate until further resolution of the ethical issues has been achieved.	Fourth Presbyterian Church, Reformed Theol Seminary, Bethesda, MD 20816 USA		Young, FE (corresponding author), Fourth Presbyterian Church, Reformed Theol Seminary, 5500 River Rd, Bethesda, MD 20816 USA.							CAMPBELL CS, 1997, CLONING HUMAN BEINGS, V2, pD3; Chan AWS, 2000, SCIENCE, V287, P317, DOI 10.1126/science.287.5451.317; FORSYTHE CD, 1998, VALPARAISO U LAW REV, V32, P491; Frisen J, 1998, CELL MOL LIFE SCI, V54, P935, DOI 10.1007/s000180050224; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kuhn HG, 1999, BIOESSAYS, V21, P625, DOI 10.1002/(SICI)1521-1878(199908)21:8<625::AID-BIES1>3.0.CO;2-6; Lanza RP, 1999, SCIENCE, V283, P1849; Luquin MR, 1999, NEURON, V22, P743, DOI 10.1016/S0896-6273(00)80733-3; *NBAC, 1999, EX SUMM ETH ISS HUM; ROBERTSON JA, 1978, SOUTHERN CALIF LAW R, V51, P1203; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; 1986, FED REG, V51, P23302	12	37	46	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	2000	287	5457					1424	1424		10.1126/science.287.5457.1424	http://dx.doi.org/10.1126/science.287.5457.1424			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688779				2022-12-24	WOS:000085531600033
J	Naeem, S; Hahn, DR; Schuurman, G				Naeem, S; Hahn, DR; Schuurman, G			Producer-decomposer co-dependency influences biodiversity effects	NATURE			English	Article							ECOSYSTEM PROCESSES; PLANT; DIVERSITY; NITROGEN; PRODUCTIVITY; BIOMASS; CARBON	Producers, such as plants and algae, acquire nutrients from inorganic sources that are supplied primarily by decomposers whereas decomposers, mostly fungi and bacteria, acquire carbon from organic sources that are supplied primarily by producers. This producer-decomposer co-dependency is important in governing ecosystem processes(1-4), which implies that the impacts of declining biodiversity on ecosystem functioning(5-7) should be strongly infuenced by this process. Here we show, by simultaneously manipulating producer (green algal) and decomposer (heterotrophic bacterial) diversity in freshwater microcosms, that algal biomass production varies considerably among microcosms (0.0-0.67 mg ml(-1)), but that neither algal nor bacterial diversity by itself can explain this variation. Instead, production is a joint function of both algal and bacterial diversity. Furthermore, the range in algal production in microscosms in which bacterial diversity was manipulated was nearly double (1.82 times) that of microcosms in which bacterial diversity was not manipulated. Measures of organic carbon use by bacteria in these microcosms indicate that carbon usage is the mechanism responsible for these results. Because both producer(8) and microbial diversity(9) respond to disturbance and habitat modification, the main causes of biodiversity loss(8), these results suggest that ecosystem response to changing biodiversity is likely to be more complex than other studies(5-7) have shown.	Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Naeem, S (corresponding author), Univ Washington, Dept Zool, 24 Kincaid Hall,Boc 351800, Seattle, WA 98195 USA.							Allsopp D., 1995, MICROBIAL DIVERSITY; BERMAN T, 1974, MAR BIOL, V28, P305, DOI 10.1007/BF00388498; Berman-Frank I, 1999, BIOSCIENCE, V49, P29, DOI 10.2307/1313491; BOCHNER BR, 1989, NATURE, V339, P157, DOI 10.1038/339157a0; Borneman J, 1997, APPL ENVIRON MICROB, V63, P2647, DOI 10.1128/AEM.63.7.2647-2653.1997; del Giorgio PA, 1998, ANNU REV ECOL SYST, V29, P503, DOI 10.1146/annurev.ecolsys.29.1.503; Elser JJ, 1996, BIOSCIENCE, V46, P674, DOI 10.2307/1312897; Griffiths BS, 1997, MICROBIAL COMMUNITIES, P1; HARTE J, 1993, AM NAT, V141, P839; HOBBIE SE, 1992, TRENDS ECOL EVOL, V7, P336, DOI 10.1016/0169-5347(92)90126-V; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; JONES AK, 1982, MICROBIAL INTERACTIO, P189; Kaye JP, 1997, TRENDS ECOL EVOL, V12, P139, DOI 10.1016/S0169-5347(97)01001-X; Lawton JH, 1998, NATURE, V391, P72, DOI 10.1038/34166; Mulder CPH, 1999, ECOL LETT, V2, P237; Naeem S, 1998, ECOLOGY, V79, P2603, DOI 10.1890/0012-9658(1998)079[2603:CSRAAB]2.0.CO;2; Naeem S, 1996, OIKOS, V76, P259, DOI 10.2307/3546198; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; PORTER KG, 1980, LIMNOL OCEANOGR, V25, P943, DOI 10.4319/lo.1980.25.5.0943; PRITCHARD PH, 1995, MICROBIAL DIVERSITY AND ECOSYSTEM FUNCTION, P161; Schlesinger WH, 1997, BIOGEOCHEMISTRY; Smalla K, 1998, APPL ENVIRON MICROB, V64, P1220; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Wall DH, 1999, BIOSCIENCE, V49, P109, DOI 10.2307/1313536; Wetzel R. G., 1991, LIMNOLOGICAL ANAL; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; WOOD A M, 1990, Marine Microbial Food Webs, V4, P103; ZAK DR, 1990, BIOGEOCHEMISTRY, V11, P111, DOI 10.1007/BF00002062; ZAK DR, 1991, OECOLOGIA, V88, P189, DOI 10.1007/BF00320810	30	165	179	5	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					762	764		10.1038/35001568	http://dx.doi.org/10.1038/35001568			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693803				2022-12-24	WOS:000085423100050
J	Mi, J; Law, C; Zhang, KL; Osmond, C; Stein, C; Barker, D				Mi, J; Law, C; Zhang, KL; Osmond, C; Stein, C; Barker, D			Effects of infant birthweight and maternal body mass index in pregnancy on components of the insulin resistance syndrome in China	ANNALS OF INTERNAL MEDICINE			English	Article						body mass index; pregnancy; birth weight; insulin resistance	DEPENDENT DIABETES-MELLITUS; BLOOD-PRESSURE; GLUCOSE-TOLERANCE; BIRTH-WEIGHT; NUTRITIONAL-STATUS; SERUM-CHOLESTEROL; HEART-DISEASE; FETAL; POPULATION; GROWTH	Background: Reduced birthweight is associated with increased risk for the insulin resistance syndrome. Part of this risk is hypothesized to originate from undernutrition in utero. The prevalence of the insulin resistance syndrome increases in countries that undergo the transition from chronic malnutrition to adequate nutrition, when postnatal nutrition improves more rapidly than prenatal nutrition. Objective: To determine whether the components of the insulin resistance syndrome are associated with reduced fetal growth and maternal undernutrition. Design: A nonconcurrent, prospective study of men and women whose mothers' heights and weights were recorded during pregnancy. Setting: Beijing, China. Participants: 627 men and women (mean age, 45 years) whose mothers' obstetric records were preserved. Measurements: Adult offspring's blood pressure, plasma glucose levels, insulin levels, and lipid concentrations during an oral glucose tolerance test. The main explanatory measurements were mothers' body mass index during pregnancy and offspring's birthweight and adult size. Results: After adjustment for sex and current body mass index, low birthweight was associated with elevated plasma glucose levels, insulin levels, triglyceride concentrations, and blood pressure. For every l-kg increase in birthweight, systolic blood pressure decreased by 2.9 mm Hg (95% CI, 0.3 to 5.4 mm Hg) and the 2-hour plasma glucose level decreased by 5.1%(CI, 0.7% to 9.3%). Low maternal body mass index in early and late pregnancy was associated with elevated levels of plasma glucose, insulin, and triglycerides in adult offspring but was not associated with elevated blood pressure. Conclusions: Risk for the insulin resistance syndrome may be partially established through low maternal body mass before pregnancy and consequent fetal undernutrition. This risk is independent of that associated with adult obesity. In developing countries such as China, improved nutrition in girls and young women may offer long-term benefits to offspring.	Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Peking Union Med Coll, Beijing, Peoples R China	University of Southampton; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Mi, J (corresponding author), Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.		Law, Catherine/A-1353-2009	Osmond, Clive/0000-0002-9054-4655; Law, Catherine/0000-0002-1777-9386				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALPHA B, 1992, EUR J CLIN CHEM CLIN, V30, P27; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Barker DJP, 1998, MOTHERS BABIES HLTH; Clark PM, 1998, OBSTET GYNECOL, V91, P103, DOI 10.1016/S0029-7844(97)00581-4; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; Gregory J., 1990, DIETARY NUTR SURVEY; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; James WPT, 1997, NUTR REV, V55, pS31, DOI 10.1111/j.1753-4887.1997.tb06097.x; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Laor A, 1997, BRIT MED J, V315, P449, DOI 10.1136/bmj.315.7106.449; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LEE C C, 1948, Chin Med J, V66, P153; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NI T. G., 1949, Chinese Medical Journal, V87, P677; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Ramachandran A, 1997, DIABETOLOGIA, V40, P232, DOI 10.1007/s001250050668; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; Taylor SJC, 1998, BRIT MED J, V317, P680, DOI 10.1136/bmj.317.7159.680; UTTLEY K. H., 1940, CHINESE MED JOUR, V58, P582; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; Zimmet PZ, 1997, J DIABETES COMPLICAT, V11, P60, DOI 10.1016/S1056-8727(96)00090-6	36	210	234	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					253	+		10.7326/0003-4819-132-4-200002150-00002	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681279				2022-12-24	WOS:000085372900001
J	Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ				Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ			Roles of PLC-beta 2 and -beta 3 and PI3K gamma in chemoattractant-mediated signal transduction	SCIENCE			English	Article							PROTEIN-KINASE-C; NADPH OXIDASE; 3-KINASE	The roles of phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC) in chemoattractant-elicited responses were studied in mice lacking these key enzymes. PI3K gamma was required for chemoattractant-induced production of phosphatidylinositol 3,4,5-trisphosphate [Ptdlns (3,4,5)P-3] and has an important role in chemoattractant-induced superoxide production and chemotaxis in mouse neutrophils and in production of T cell-independent antigen-specific antibodies composed of the immunoglobulin lambda Light chain (Tl-Ig lambda(L). The study of the mice Lacking PLC-beta 2 and -beta 3 revealed that the PLC pathways have an important role in chemoattractant-mediated production of superoxide and regulation of protein kinases, but not chemotaxis. The PLC pathways also appear to inhibit the chemotactic activity induced by certain chemoattractants and to suppress TI-Ig lambda(L) production.	Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Rochester; University of Connecticut	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Z.B., UNPUB; PARK JW, 1992, J BIOL CHEM, V267, P19901; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385	23	703	754	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1046	1049		10.1126/science.287.5455.1046	http://dx.doi.org/10.1126/science.287.5455.1046			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669417				2022-12-24	WOS:000085245400049
J	Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L				Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L			Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRENATAL-DIAGNOSIS; DISORDERS	Objective National audit of informed choice in antenatal screening for thalassaemia. Design Audit from the UK Confidential Enquiry into Counselling for Genetic Disorders. Setting Thalassaemia module of the UK Confidential Enquiry into Counselling for Genetic Disorders. Subjects 138 of 156 couples who had had a pregnancy affected by a major beta thalassaemia from 1990 to 1994. Main outcome measures How and when genetic risk was identified for each couple, and whether and when prenatal diagnosis was offered. Results Risk was detected by screening before or during the first pregnancy in 49% (68/138) of couples and by diagnosis of an affected child in 28% (38/138) of couples. Prenatal diagnosis was offered in 69% (274/400) of pregnancies, ranging from 94% (122/130) fur British Cypriots to 54% (80/149) for British Pakistanis and from 90% in the south east of England to 39% in the West Midlands. Uptake of prenatal diagnosis was 80% (216/274), ranging from 98% (117/120) among British Cypriots in either the first or second trimester to 73% (35/48) among British Pakistanis in the first trimester and 39% (11/28) in the second trimester. A demonstrable service failure occurred in 28% (110/400) of pregnancies, including 110 of 126 where prenatal diagnosis was not offered and 48 of 93 that ended with an affected liveborn infant. Conclusion Although antenatal screening and counselling fur haemoglobin disorders are standard practices in the United Kingdom, they are delivered inadequately and inequitably. An explicit national policy is needed, aiming to make prenatal diagnosis in the first trimester available to all couples and including ongoing national audit.	UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; UCL Royal Free & UCL Med Sch, Ctr Hlth Informat & Mutiprofess Educ, Whittington Hosp, London N19 5NF, England; UCL Royal Free & UCL Med Sch, Dept Obstet & Gynaecol, London WC1E 6HX, England; Kings Coll Hosp London, Sch Med, Dept Haematol Med, London SE5 9RS, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of London; University College London; University of Manchester; University of London; University College London; University of London; University College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Oxford	Modell, B (corresponding author), UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England.	b.modell@ucl.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIONWU EN, 1996, RES CULTURAL DIFFERE; Bain BJ, 1998, BRIT J HAEMATOL, V101, P783, DOI 10.1046/j.1365-2141.1998.00809.x; HARRIS R, 1991, BRIT MED J, V303, P1412, DOI 10.1136/bmj.303.6815.1412; Harris R, 1999, BRIT J OBSTET GYNAEC, V106, P658, DOI 10.1111/j.1471-0528.1999.tb08364.x; Hickman M, 1999, BRIT J HAEMATOL, V104, P860, DOI 10.1046/j.1365-2141.1999.01275.x; *HLTH ED AUTH, 1998, SICKL CELL THAL ACH; Jones D, 1998, BRIT MED J, V316, P1476, DOI 10.1136/bmj.316.7143.1476; Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL B, 1993, HLTH SERVICES RES; MODELL B, 1980, BRIT MED J, V2, P737; MODELL B, 2000, IN PRESS LANCET; MODELL B, 1985, LANCET, V2, P1383; Modell M, 1998, BMJ-BRIT MED J, V317, P788, DOI 10.1136/bmj.317.7161.788; *NAT CONF ENQ COUN, 1998, HOM BET THAL GREAT B; Neuenschwander H, 1997, BRIT MED J, V315, P784; *NUFF COUNC BIOETH, GEN SCREEN ETH ISS; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; PETROV RV, 1995, BIOSCIENCE REP, V15, P1, DOI 10.1007/BF01200210; *STAND MED ADV COM, 1994, SICKL CELL THAL OTH	19	82	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					337	341		10.1136/bmj.320.7231.337	http://dx.doi.org/10.1136/bmj.320.7231.337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657326	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000085211400021
J	Perez, GI; Trbovich, AM; Gosden, RG; Tilly, JL				Perez, GI; Trbovich, AM; Gosden, RG; Tilly, JL			Reproductive biology - Mitochondria and the death of oocytes	NATURE			English	Article							APOPTOSIS; OVARY		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Univ Leeds, Leeds Gen Infirm, Ctr Reprod Growth & Dev, Leeds LS2 9NS, W Yorkshire, England	Harvard University; Harvard Medical School; Massachusetts General Hospital; Leeds General Infirmary; University of Leeds	Perez, GI (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, VBK137E-GYN, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022					BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BEAUMONT HM, 1962, PROC R SOC SER B-BIO, V155, P557, DOI 10.1098/rspb.1962.0019; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; FORABOSCO A, 1991, ANAT RECORD, V231, P201, DOI 10.1002/ar.1092310208; Krakauer DC, 1999, NATURE, V400, P125, DOI 10.1038/22026; LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PIKO L, 1976, DEV BIOL, V49, P1, DOI 10.1016/0012-1606(76)90253-0; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TILLY JL, 1999, MOL BIOL REPROD MED, P79	14	126	140	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					500	501		10.1038/35000651	http://dx.doi.org/10.1038/35000651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676949				2022-12-24	WOS:000085227300035
J	Sacher, RA; Schreiber, GB; Kleinman, SH				Sacher, RA; Schreiber, GB; Kleinman, SH			Prevention of transfusion-transmitted hepatitis	LANCET			English	Editorial Material							POSTTRANSFUSION HEPATITIS; VIRUS-INFECTION; RISK		Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; WESTAT, Rockville, MD USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Georgetown University; Georgetown University; Georgetown University; Westat; University of British Columbia	Sacher, RA (corresponding author), Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA.							Allain JP, 1999, BRIT J HAEMATOL, V107, P186, DOI 10.1046/j.1365-2141.1999.01665.x; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Busch MP, 1998, VOX SANG, V74, P147, DOI 10.1111/j.1423-0410.1998.tb05413.x; Busch MP, 1998, TRANSFUSION, V38, p72S; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Flanagan P, 1999, TRANSFUS MED REV, V13, P164, DOI 10.1016/S0887-7963(99)80030-3; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; Matsumoto A, 1999, HEPATOLOGY, V30, P283, DOI 10.1002/hep.510300118; Rawal BD, 1998, TRANSFUSION, V38, p91S; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schuttler CG, 2000, LANCET, V355, P41, DOI 10.1016/S0140-6736(99)04719-4	13	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					331	332		10.1016/S0140-6736(99)00391-8	http://dx.doi.org/10.1016/S0140-6736(99)00391-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665547				2022-12-24	WOS:000085122100003
J	Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM				Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM			Mental disorders and use of cardiovascular procedures after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-CATHETERIZATION FACILITIES; CORONARY HEART-DISEASE; UNITED-STATES; MEDICARE PATIENTS; ELDERLY PATIENTS; RACIAL-DIFFERENCES; ANXIETY DISORDERS; OUTCOMES; ANGIOGRAPHY; CARE	Context A number of studies have found race- and sex-based differences in rates of cardiovascular procedures in the United States, Similarly, mental disorders might be expected to be associated with lower rates of such procedures on the basis of clinical, socioeconomic, patient, and provider factors, Objective To assess whether having a comorbid mental disorder is associated with a lower likelihood of cardiac catheterization and/or revascularization after acute myocardial infarction. Design Retrospective cohort study using data from medical charts and administrative files as part of the Cooperative Cardiovascular Project. Setting Acute care nongovernmental hospitals in the United States. Patients National cohort of 113 653 eligible patients 65 years or older who were hospitalized for confirmed acute myocardial infarction between February 1994 and July 1995. Main Outcome Measures Likelihood of cardiac catheterization, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft (CABG) surgery during the index hospitalization, comparing patients with and without mental disorders (classified as schizophrenia, major affective disorder, substance abuse/ dependence disorder, or other mental disorder). Results Compared with the remainder of the sample, patients with any comorbid mental disorder (n = 5365; 4.7%) were significantly less likely to undergo PTCA (11.8% vs 16.8%; P<.001) or CABG (8.2% vs 12.6%; P<.001), After adjusting for demographic, clinical, hospital, and regional factors, individuals with mental disorders were 41% (for schizophrenia) to 78% (for substance use) as likely to undergo cardiac catheterization as those without mental disorders (P<.001 for all). Among those undergoing catheterization, rates of PTCA or CABG for patients with mental disorders were not significantly different from rates for patients without mental disorders (for those with any mental disorder, P =.12 for PTCA and P =.06 for CABG), In multivariate models, the 30-day mortality did not differ between patients with and without mental disorders. Conclusions In this study, individuals with comorbid mental disorders were substantially less likely to undergo coronary revascularization procedures than those without mental disorders. Further research is needed to understand the degree to which patient and provider factors contribute to this difference and its implications for quality and long-term outcomes of care.	Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; VA Connecticut Mental Illness Res Educ & Clin Ctr, New Haven, CT USA; Yale Univ, Dept Med, Sect Cardiovasc med, New Haven, CT 06520 USA; Qualidigm, Middletown, CT USA; Med Univ S Carolina, Ctr Hlth Care Res, Charleston, SC 29425 USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Medical University of South Carolina	Druss, BG (corresponding author), 950 Campbell Ave 116A, W Haven, CT 06516 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARO S, 1995, BRIT J PSYCHIAT, V166, P759, DOI 10.1192/bjp.166.6.759; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Ayanian JZ, 1997, J GEN INTERN MED, V12, P311, DOI 10.1046/j.1525-1497.1997.012005311.x; BAUGHAN DM, 1995, AM FAM PHYSICIAN, V52, P447; BEHAR S, 1995, ARCH INTERN MED, V155, P813, DOI 10.1001/archinte.155.8.813; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; Callahan CM, 1997, ANN INTERN MED, V126, P426, DOI 10.7326/0003-4819-126-6-199703150-00002; CARNEY RM, 1995, HEALTH PSYCHOL, V14, P88, DOI 10.1037/0278-6133.14.1.88; Clark RE, 1996, HEALTH SERV RES, V31, P153; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Druss BG, 1998, AM J PSYCHIAT, V155, P1775, DOI 10.1176/ajp.155.12.1775; Druss BG, 1999, AM J PSYCHIAT, V156, P477; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FORD ES, 1995, HEALTH SERV RES, V30, P237; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUTHEIL TG, 1986, AM J PSYCHIAT, V143, P1020; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Jeste DV, 1996, SCHIZOPHRENIA BULL, V22, P413, DOI 10.1093/schbul/22.3.413; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Krumholz HM, 1997, NEW ENGL J MED, V336, P1522, DOI 10.1056/NEJM199705223362111; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Olfson M, 1999, HEALTH AFFAIR, V18, P79, DOI 10.1377/hlthaff.18.2.79; Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1007/s11606-006-5062-0; Wirshing DA, 1998, AM J PSYCHIAT, V155, P1508, DOI 10.1176/ajp.155.11.1508; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zubenko GS, 1997, AM J PSYCHIAT, V154, P1360	46	388	393	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					506	511		10.1001/jama.283.4.506	http://dx.doi.org/10.1001/jama.283.4.506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LT	10659877	Bronze			2022-12-24	WOS:000084879800030
J	Huard, B; Karlsson, L				Huard, B; Karlsson, L			KIR expression on self-reactive CD8(+) T cells is controlled by T-cell receptor engagement	NATURE			English	Article							NATURAL-KILLER-CELLS; CLASS-I MOLECULES; INHIBITORY RECEPTORS; HLA-E; LYMPHOCYTES; CD94/NKG2A; CYTOTOXICITY	Natural killer cell tolerance is maintained by the interaction of killer inhibitory receptors (KIRs) with self-major histocompatibility complex class I gene products. A subset of T cells also expresses inhibitory receptors, but the functional significance of these receptors on T cells is unclear(1-3). Here we show that, in the absence of T-cell receptor (TCR) engagement, KIRs expressed on CD8(+) T cells are slowly downregulated by KIR ligands expressed on antigen-presenting cells. The resulting expression levels of KIR are no longer able to inhibit T-cell function. In contrast, TCR engagement sustains KIR expression, and re-induces functional levels of KIR expression after ligand-induced downregulation of KIR. Our data indicate that KIR expression on CD8(+) T cells in vivo maybe maintained through continuous encounters with antigen. As KIR-mediated inhibition of T-cell activation can be bypassed at high antigen concentrations, dynamic KIR expression may mediate T-cell tolerance to self-antigens by sparing self-reactive T cells, thus enabling them to mediate potentially useful immune functions to quantitatively or qualitatively different antigens.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Fac Pharm Chatenay Malabry, Lab Immunol Tumeurs, F-92296 Chatenay Malabry, France	Johnson & Johnson; Johnson & Johnson USA; UDICE-French Research Universities; Universite Paris Saclay	Huard, B (corresponding author), Ctr Med Univ Geneva, Dermatol Lab 5 222, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		huard, bertrand/L-8011-2013	huard, bertrand/0000-0003-1358-6576				Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Boullier S, 1998, EUR J IMMUNOL, V28, P3399, DOI 10.1002/(SICI)1521-4141(199811)28:11<3399::AID-IMMU3399>3.0.CO;2-W; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Carena I, 1997, J EXP MED, V186, P1769, DOI 10.1084/jem.186.10.1769; FALK CS, 1995, J EXP MED, V182, P1005, DOI 10.1084/jem.182.4.1005; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Gumperz JE, 1996, J EXP MED, V183, P1817, DOI 10.1084/jem.183.4.1817; Hoglund P, 1997, IMMUNOL REV, V155, P11, DOI 10.1111/j.1600-065X.1997.tb00936.x; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Mingari MC, 1998, IMMUNOL TODAY, V19, P153, DOI 10.1016/S0167-5699(97)01236-X; Mingari MC, 1997, INT IMMUNOL, V9, P485, DOI 10.1093/intimm/9.4.485; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Muller U, 1997, NEUROGENETICS, V1, P1; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Ponte M, 1999, P NATL ACAD SCI USA, V96, P5674, DOI 10.1073/pnas.96.10.5674; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; Speiser DE, 1999, EUR J IMMUNOL, V29, P1990, DOI 10.1002/(SICI)1521-4141(199906)29:06<1990::AID-IMMU1990>3.3.CO;2-0; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343	26	120	124	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					325	328		10.1038/35002105	http://dx.doi.org/10.1038/35002105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659853				2022-12-24	WOS:000084899700056
J	Martina, M; Vida, I; Jonas, P				Martina, M; Vida, I; Jonas, P			Distal initiation and active propagation of action potentials in interneuron dendrites	SCIENCE			English	Article							CA1 PYRAMIDAL NEURONS; HIPPOCAMPUS IN-VITRO; RAT HIPPOCAMPUS; INHIBITORY NEURONS; CELL DENDRITES; MITRAL CELLS; SODIUM; ACTIVATION; SYNAPSES; CHANNELS	Fast and reliable activation of inhibitory interneurons is critical for the stability of cortical neuronal networks. Active conductances in dendrites may facilitate interneuron activation, but direct experimental evidence was unavailable. Patch-clamp recordings from dendrites of hippocampal oriens-alveus interneurons revealed high densities of voltage-gated sodium and potassium ion channels. Simultaneous recordings from dendrites and somata suggested that action potential initiation occurs preferentially in the axon with long threshold stimuli, but can be shifted to somatodendritic sites when brief stimuli are applied. After initiation, action potentials propagate over the somatodendritic domain with constant amplitude, high velocity, and reliability, even during high-frequency trains.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Jonas, P (corresponding author), Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany.		Vida, Imre/F-8275-2012	Vida, Imre/0000-0003-3214-2233; martina, marco/0000-0002-9648-2918; Jonas, Peter/0000-0001-5001-4804				Ali AB, 1998, J PHYSIOL-LONDON, V507, P185, DOI 10.1111/j.1469-7793.1998.185bu.x; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; Bischofberger J, 1997, J PHYSIOL-LONDON, V504, P359, DOI 10.1111/j.1469-7793.1997.359be.x; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; Cash S, 1999, NEURON, V22, P383, DOI 10.1016/S0896-6273(00)81098-3; Chen WR, 1997, SCIENCE, V278, P463, DOI 10.1126/science.278.5337.463; COLQUHOUN D, 1995, SINGLE CHANNEL RECOR, pCH19; COOMBS JS, 1957, J PHYSIOL-LONDON, V139, P232, DOI 10.1113/jphysiol.1957.sp005888; Csicsvari J, 1998, NEURON, V21, P179, DOI 10.1016/S0896-6273(00)80525-5; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1999, HDB EXPT PHARM, V141, pCH11; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; KOSAKA T, 1983, BRAIN RES, V271, P157, DOI 10.1016/0006-8993(83)91377-X; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; Martina M, 1997, J PHYSIOL-LONDON, V505, P593, DOI 10.1111/j.1469-7793.1997.593ba.x; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P810, DOI 10.1152/jn.1995.73.2.810; PEREZ Y, 1999, 29 M SOC NEUR MIAM B; SAKMANN B, 1995, SINGLE CHANNEL RECOR, pCH21; SIK A, 1995, J NEUROSCI, V15, P6651; SOFTKY W, 1994, NEUROSCIENCE, V58, P13, DOI 10.1016/0306-4522(94)90154-6; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P249, DOI 10.1177/33.3.2579124; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Traub RD, 1995, J COMPUT NEUROSCI, V2, P291, DOI 10.1007/BF00961441; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998; ZILBERTER Y, 1999, 29 M SOC NEUR MIAM B	46	250	253	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					295	300		10.1126/science.287.5451.295	http://dx.doi.org/10.1126/science.287.5451.295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634782				2022-12-24	WOS:000084769600037
J	Pawlowski, B; Dunbar, RIM; Lipowicz, A				Pawlowski, B; Dunbar, RIM; Lipowicz, A			Evolutionary fitness - Tall men have more reproductive success	NATURE			English	Article							SHORT STATURE; ATTRACTIVENESS		Univ Wroclaw, Dept Anthropol, PL-50138 Wroclaw, Poland; Univ Liverpool, Sch Biol Sci, ESRC Res Ctr Econ Learning & Social Evolut, Liverpool L69 3BX, Merseyside, England; Polish Acad Sci, Inst Anthropol, PL-50951 Wroclaw, Poland	University of Wroclaw; UK Research & Innovation (UKRI); Economic & Social Research Council (ESRC); University of Liverpool; Polish Academy of Sciences	Pawlowski, B (corresponding author), Univ Wroclaw, Dept Anthropol, Ul Kuznicza 35, PL-50138 Wroclaw, Poland.	rimd@liv.ac.uk	Lipowicz, Anna M/A-1730-2017; Pawlowski, Boguslaw/C-1088-2013	Lipowicz, Anna M/0000-0002-9182-6953; Pawlowski, Boguslaw/0000-0002-7418-475X				BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; Bielicki T, 1999, J BIOSOC SCI, V31, P525, DOI 10.1017/S0021932099005258; Bogin Barry, 1988, PATTERNS HUMAN GROWT; HEBERT PR, 1993, CIRCULATION, V88, P1437, DOI 10.1161/01.CIR.88.4.1437; HOLL RW, 1991, DEUT MED WOCHENSCHR, V116, P928, DOI 10.1055/s-2008-1063699; Kee F, 1997, INT J EPIDEMIOL, V26, P748, DOI 10.1093/ije/26.4.748; Komlos J, 1994, STATURE LIVING STAND; MACINTYRE S, 1991, SOCIOL HEALTH ILL, V13, P149, DOI 10.1111/1467-9566.ep11340769; *MIEJSK URS STAT W, 1971, ROCZNIK STAT MIAST W; Perrett DI, 1998, NATURE, V394, P884, DOI 10.1038/29772; SCHUMACHER A, 1982, J HUM EVOL, V11, P697, DOI 10.1016/S0047-2484(82)80058-4; TEASDALE TW, 1991, HUM BIOL, V63, P19	12	233	236	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					156	156		10.1038/35003107	http://dx.doi.org/10.1038/35003107			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	275TB	10646589	Bronze			2022-12-24	WOS:000084835300040
J	Bae, S; Kurtz, RC				Bae, S; Kurtz, RC			Strategy after diagnosis of pancreatic dysplasia	LANCET			English	Editorial Material							HEREDITARY PANCREATITIS; CANCER		Mem Sloan Kettering Canc Ctr, Serv Gastroenterol & Nutr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kurtz, RC (corresponding author), Mem Sloan Kettering Canc Ctr, Serv Gastroenterol & Nutr, 1275 York Ave, New York, NY 10021 USA.							Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Finch MD, 1997, DIGESTION, V58, P564, DOI 10.1159/000201502; Flanders TY, 1996, J MED GENET, V33, P889, DOI 10.1136/jmg.33.11.889; GRUBAN RH, 1993, AM J PATHOL, V143, P545; LEE JG, 1995, GASTROINTEST ENDOSC, V42, P317, DOI 10.1016/S0016-5107(95)70129-X; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; Lynch HT, 1996, SEMIN ONCOL, V23, P251; Markowitz A, 1999, GASTROENTEROLOGY, V116, pA458; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861	10	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					85	86		10.1016/S0140-6736(99)00354-2	http://dx.doi.org/10.1016/S0140-6736(99)00354-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675163				2022-12-24	WOS:000085557200007
J	Herrmann, BG; Koschorz, B; Wertz, K; McLaughlin, KJ; Kispert, A				Herrmann, BG; Koschorz, B; Wertz, K; McLaughlin, KJ; Kispert, A			A protein kinase encoded by the t complex responder gene causes non-mendelian inheritance	NATURE			English	Article							TRANSMISSION RATIO DISTORTION; DYNEIN LIGHT-CHAIN; TERT-HAPLOTYPES; TRANSGENIC MICE; SPERM MOTILITY; MEIOTIC DRIVE; MOUSE; LOCUS; IDENTIFICATION; FAMILY	Males heterozygous for the t-haplotype form of mouse chromosome 17 preferentially transmit the t-chromosome to their progeny. Several distorter/sterility loci carried on the t-haplotype together impair flagellar function in all spermatozoa whereas the responder, Tcr, rescues t-sperm but not wild-type sperm. Thus, t-sperm have an advantage over wild-type sperm in fertilizing egg cells. We have isolated Tcr by positional cloning and show that it is a member of a novel protein kinase gene family, designated Smok, which is expressed late during spermiogenesis, Smok kinases are components of a signal cascade which may control sperm motility, Tcr has a reduced kinase activity, which may allow it to counterbalance a signalling impairment caused by the distorter/sterility loci, Tcr transgene constructs cause non-mendelian transmission of chromosomes on which they are carried, which leads to sex-ratio distortion when Tcr cosegregates with the Y chromosome.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	Max Planck Society	Herrmann, BG (corresponding author), Max Planck Inst Immunbiol, Stubeweg 51, D-79108 Freiburg, Germany.		McLaughlin, Kenneth/E-3648-2011					Albanesi C, 1996, DEVELOPMENT, V122, P1291; BENNETT D, 1983, GENET RES, V41, P29, DOI 10.1017/S0016672300021042; Bracho GE, 1998, BIOCHEM BIOPH RES CO, V242, P231, DOI 10.1006/bbrc.1997.7937; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; BULLARD DC, 1992, MAMM GENOME, V3, P579, DOI 10.1007/BF00350625; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; Cosson J, 1996, CELL BIOL INT, V20, P83, DOI 10.1006/cbir.1996.0012; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ewulonu UK, 1996, GENETICS, V144, P785; FOX HS, 1985, CELL, V40, P63, DOI 10.1016/0092-8674(85)90309-5; Fraser LR, 1999, BIOESSAYS, V21, P304, DOI 10.1002/(SICI)1521-1878(199904)21:4<304::AID-BIES6>3.0.CO;2-H; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; Kispert A, 1999, MAMM GENOME, V10, P794, DOI 10.1007/s003359901094; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LYON MF, 1990, GENET RES, V55, P13, DOI 10.1017/S0016672300025143; LYON MF, 1987, GENET RES, V50, P29, DOI 10.1017/S0016672300023302; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; LYON MF, 1984, CELL, V37, P621, DOI 10.1016/0092-8674(84)90393-3; MAZARAKIS N, 1909, DEVELOPMENT, V111, P561; OLDSCLARKE P, 1993, DEV BIOL, V155, P14, DOI 10.1006/dbio.1993.1002; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROSEN LL, 1990, GENOMICS, V8, P134, DOI 10.1016/0888-7543(90)90235-M; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Rugh R, 1990, MOUSE ITS REPROD DEV; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SCHIMENTI J, 1988, CELL, V55, P71, DOI 10.1016/0092-8674(88)90010-4; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SILVER LM, 1987, GENET RES, V49, P51, DOI 10.1017/S0016672300026720; TASH JS, 1988, J CELL BIOL, V106, P1625, DOI 10.1083/jcb.106.5.1625; TASH JS, 1984, CELL, V38, P551, DOI 10.1016/0092-8674(84)90509-9; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	38	128	139	4	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					141	146		10.1038/45970	http://dx.doi.org/10.1038/45970			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647005				2022-12-24	WOS:000083716400038
J	Yasui, M; Hazama, A; Kwon, TH; Nielsen, S; Guggino, WB; Agre, P				Yasui, M; Hazama, A; Kwon, TH; Nielsen, S; Guggino, WB; Agre, P			Rapid gating and anion permeability of an intracellular aquaporin	NATURE			English	Article							MAJOR INTRINSIC PROTEIN; CD WATER CHANNELS; KIDNEY; MEMBRANE; CLONING; CONDUCTANCE; CHIP28; PUMP; LENS	Aquaporin (AQP) water-channel proteins are freely permeated by water but not bg ions or charged solutes(1), Although mammalian aquaporins were believed to be located in plasma membranes, rat AQP6 is restricted to intracellular vesicles in renal epithelia(2). Here we show that AQP6 is functionally distinct from other known aquaporins. When expressed in Xenopus laevis oocytes, AQP6 exhibits low basal water permeability; however, when treated with the known water channel inhibitor, Hg2+, the water permeability of AQP6 oocytes rapidly rises up to tenfold and is accompanied by ion conductance. AQP6 colocalizes with H+-ATPase in intracellular vesicles of acid-secreting alpha-intercalated cells in renal collecting duct. At pH less than 5.5, anion conductance is rapidly and reversibly activated in AQP6 oocytes. Site-directed mutation of lysine to glutamate at position 72 in the cytoplasmic mouth of the pore changes the cation/anion selectivity: but leaves low pH activation intact, Our results demonstrate unusual biophysical properties of an aquaporin, and indicate that anion-channel function may now be explored in a protein with known structure.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Aarhus University	Agre, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.		Kwon, Tae-Hwan/ABA-1981-2020; Yasui, Masato/L-3312-2013					Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1993, BIOCHEM BIOPH RES CO, V197, P654, DOI 10.1006/bbrc.1993.2529; MITSUOKA K, IN PRESS J STRUCT BI; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216	23	371	378	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					184	187		10.1038/46045	http://dx.doi.org/10.1038/46045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647010				2022-12-24	WOS:000083716400051
J	During, MJ; Symes, CW; Lawlor, PA; Lin, J; Dunning, J; Fitzsimons, HL; Poulsen, D; Leone, P; Xu, RA; Dicker, BL; Lipski, J; Young, D				During, MJ; Symes, CW; Lawlor, PA; Lin, J; Dunning, J; Fitzsimons, HL; Poulsen, D; Leone, P; Xu, RA; Dicker, BL; Lipski, J; Young, D			An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; GLUTAMIC-ACID DECARBOXYLASE; GLYCINE-BINDING-SITE; D-ASPARTATE RECEPTOR; STIFF-MAN SYNDROME; STATUS EPILEPTICUS; RAT; AUTOANTIBODIES; SUBUNIT; MK-801	The brain is generally considered immunoprivileged, although increasing examples of immunological responses to brain antigens, neuronal expression of major histocompatibility class I genes, and neurological autoimmunity have been recognized. An adeno-associated virus (AAV) vaccine generated autoantibodies that targeted a specific brain protein, the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor. After peroral administration of the AAV vaccine, transgene expression persisted for at least 5 months and was associated with a robust humoral response in the absence of a significant cell-mediated response. This single-dose vaccine was associated with strong anti-epileptic and neuroprotective activity in rats for both a kainate-induced seizure model and also a middle cerebral artery occlusion stroke model at 1 to 5 months following vaccination. Thus, a vaccination strategy targeting brain proteins is feasible and may have therapeutic potential for neurological disorders.	Univ Auckland, Sch Med, Dept Mol Med, Auckland, New Zealand; Univ Auckland, Sch Med, Dept Physiol, Auckland, New Zealand; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Jefferson Med Coll, Dept Neurosurg, Philadelphia, PA 19107 USA	University of Auckland; University of Auckland; Jefferson University; Jefferson University	During, MJ (corresponding author), Univ Auckland, Sch Med, Dept Mol Med, Auckland, New Zealand.	matthew.during@mail.tju.edu	During, Matthew/AAC-1388-2020; Dicker, Bridget/F-8770-2019	Dicker, Bridget/0000-0002-8151-7356; Lipski, Janusz/0000-0001-6109-8724; Fitzsimons, Helen/0000-0001-7825-3911; Young, Deborah/0000-0003-1085-2824; Lin, John/0000-0002-1723-4597				AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; Albayrak S, 1997, ACTA NEUROPATHOL, V94, P158, DOI 10.1007/s004010050688; BARAN H, 1994, BRAIN RES, V652, P195, DOI 10.1016/0006-8993(94)90227-5; Beal M F, 1992, Curr Opin Neurobiol, V2, P657, DOI 10.1016/0959-4388(92)90035-J; BEAR MF, 1990, J NEUROSCI, V10, P909; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Butcher SP, 1997, J NEUROSCI, V17, P6939; CARLSSON M, 1990, LIFE SCI, V47, P1729, DOI 10.1016/0024-3205(90)90346-S; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Dinkel K, 1998, ANN NEUROL, V44, P194, DOI 10.1002/ana.410440209; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; DURING MJ, UNPUB; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Gusev EI, 1996, ZH NEVROPATOL PSIKH, V96, P68; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; POSNER JB, 1990, RES P ARNMD, V68, P187; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; Schehr RS, 1996, NAT BIOTECHNOL, V14, P1549, DOI 10.1038/nbt1196-1549; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SHALABY WSW, 1995, CLIN IMMUNOL IMMUNOP, V74, P127, DOI 10.1006/clin.1995.1019; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; STEINBERG GK, 1995, NEUROSCIENCE, V64, P99, DOI 10.1016/0306-4522(94)00374-E; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; Wood MW, 1997, J BIOL CHEM, V272, P3532, DOI 10.1074/jbc.272.6.3532; WOZNIAK DF, 1990, PSYCHOPHARMACOLOGY, V101, P47, DOI 10.1007/BF02253717; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; ZUCKER DK, 1983, EXP NEUROL, V79, P422, DOI 10.1016/0014-4886(83)90223-6	38	183	218	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	2000	287	5457					1453	1460		10.1126/science.287.5457.1453	http://dx.doi.org/10.1126/science.287.5457.1453			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688787				2022-12-24	WOS:000085531600041
J	Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA				Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA			Physicians' experiences with the Oregon Death with Dignity Act.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSISTED SUICIDE; TERMINALLY ILL; EUTHANASIA; DESIRE; CARE	Background: Physician-assisted suicide was legalized in Oregon in October 1997. There are data on patients who have received prescriptions for lethal medications and died after taking the medications. There is little information, however, on physicians' experiences with requests for assistance with suicide. Methods: Between February and August 1999, we mailed a questionnaire to physicians who were eligible to prescribe lethal medications under the Oregon Death with Dignity Act. Results: Of 4053 eligible physicians, 2649 (65 percent) returned the survey. Of the respondents, 144 (5 percent) had received a total of 221 requests for prescriptions for lethal medications since October 1997. We received information on the outcome in 165 patients (complete information for 143 patients and partial for an additional 22). The mean age of the patients was 68 years; 76 percent had an estimated life expectancy of less than six months. Thirty-five percent requested a prescription from another physician. Twenty-nine patients (18 percent) received prescriptions, and 17 (10 percent) died from taking the prescribed medication. Twenty percent of the patients had symptoms of depression; none of these patients received a prescription for a lethal medication. In the case of 68 patients, including 11 who received prescriptions and 8 who died by taking the prescribed medication, the physician implemented at least one substantive palliative intervention, such as control of pain or other symptoms, referral to a hospice program, a consultation, or a trial of antidepressant medication. Forty-six percent of the patients for whom substantive interventions were made changed their minds about assisted suicide, as compared with 15 percent of those for whom no substantive interventions were made (P<0.001). Conclusions: Our data indicate that in Oregon, physicians grant about 1 in 6 requests for a prescription for a lethal medication and that 1 in 10 requests actually results in suicide. Substantive palliative interventions lead some -- but not all -- patients to change their minds about assisted suicide. (N Engl J Med 2000;342:557-63.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Portland, OR USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence Hlth Syst, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Div Mental Hlth, P-7-1DMH,POB 1034, Portland, OR 97207 USA.							Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1995, ACAD MED, V70, P583; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; EMANUEL EJ, 1998, 1997 98 ASCO SURVEY; Faber-Langendoen K, 1998, CANCER-AM CANCER SOC, V82, P35, DOI 10.1002/(SICI)1097-0142(19980101)82:1<35::AID-CNCR4>3.3.CO;2-#; Fisher L, 1993, BIOSTATISTICS METHOD; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Henriksson MM, 1995, J AFFECT DISORDERS, V36, P11, DOI 10.1016/0165-0327(95)00047-X; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; *OR HLTH DIV, 1997, OR VIT STAT ANN REP, V12; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L	19	275	275	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					557	563		10.1056/NEJM200002243420806	http://dx.doi.org/10.1056/NEJM200002243420806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684915				2022-12-24	WOS:000085422400006
J	Christakis, NA; Lamont, EB				Christakis, NA; Lamont, EB			Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX HELP; PREFERENCES; SURVIVAL; CANCER; UNCERTAINTY; PREDICTIONS; ACCURACY; CARE	Objective To describe doctors' prognostic accuracy in terminally ill patients and to evaluate the determinants of that accuracy. Design Prospective cohort study. Setting Five outpatient hospice programmes in Chicago. Participants 343 doctors provided survival estimates for 468 terminally ill patients at the time of hospice referral. Main outcome measures Patients' estimated and actual survival. Results Median survival was 24 days. Only 20% (92/468) of predictions were accurate (within 33% of actual survival); 63% (295/468) were overoptimistic and 17% (81/468) were over-pessimistic. Overall, doctors overestimated survival by a factor of 5.3. Few patient or doctor characteristics were associated with prognostic accuracy. Male patients were 58% less likely to have over-pessimistic predictions. Non-oncology medical specialists were 326% more likely than general internists to make overpessimistic predictions. Doctors in the upper quartile of practice experience were the most accurate. As duration of doctor-patient relationship increased and time since last contact decreased, prognostic accuracy decreased. Conclusion Doctors are inaccurate in their prognoses for terminally ill patients and the error is systematically optimistic The inaccuracy is, in general, not restricted to certain kinds of doctors or patients. These phenomena may be adversely affecting the quality of care given to patients near the end of life.	Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Med Ctr, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	Christakis, NA (corresponding author), Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA.		Christakis, Nicholas A/C-3205-2009; Ram, Prem/K-4511-2012; Christakis, Nicholas A/B-6690-2008	Lamont, Elizabeth/0000-0001-6604-678X				ADDINGTONHALL JM, 1990, BRIT J CANCER, V62, P695, DOI 10.1038/bjc.1990.360; [Anonymous], 1999, DEATH FORETOLD PROPH; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 1997, SOC SCI MED, V44, P301, DOI 10.1016/S0277-9536(96)00100-1; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EVANS C, 1985, LANCET, V1, P1204; FLETCHER SW, 1981, BIOMEDICAL INNOVATIO; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; HEVSEMOORE LH, 1987, PALLIATIVE MED, V1, P165; IWASHYNA TJ, 1998, PALLIATIVE MED, V1, P241; LYNN J, 1995, WESTERN J MED, V163, P250; Mackillop WJ, 1997, J CLIN EPIDEMIOL, V50, P21, DOI 10.1016/S0895-4356(96)00316-2; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; PEARLMAN RA, 1988, ARCH INTERN MED, V148, P2537, DOI 10.1001/archinte.148.12.2537; POSES RM, 1991, CRIT CARE MED, V19, P1533, DOI 10.1097/00003246-199112000-00016; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Zubrod C.G., 1960, J CHRON DIS, V11, P7	21	907	914	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					469	472		10.1136/bmj.320.7233.469	http://dx.doi.org/10.1136/bmj.320.7233.469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678857	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000085562200018
J	Wang, BL; Fallon, JF; Beachy, PA				Wang, BL; Fallon, JF; Beachy, PA			Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb	CELL			English	Article							PROTEIN-KINASE-A; GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; TERMINAL CLEAVAGE PRODUCT; VENTRAL NEURAL-TUBE; SONIC-HEDGEHOG; FLOOR PLATE; CUBITUS-INTERRUPTUS; SIGNALING PATHWAY; TRANSCRIPTION FACTOR; PATTERNING ACTIVITY	Ci/Gli zinc finger proteins mediate the transcriptional effects of Hedgehog protein signals. In Drosophila, Ci action as transcriptional repressor or activator is contingent upon Hedgehog-regulated, PKA-dependent proteolytic processing. We demonstrate that PKA-dependent processing of vertebrate Gli3 in developing limb similarly generates a potent repressor in a manner antagonized by apparent long-range signaling from posteriorly localized Sonic hedgehog protein. The resulting anterior/posterior Gli3 repressor gradient can be perturbed by mutations of Gli3 in human genetic syndromes or by misregulation of Gli3 processing in the chicken mutant talpid(2), producing a range of limb patterning malformations. The high relative abundance and potency of Gli3 repressor suggest specialization of Gli3 and its products for negative Hedgehog pathway regulation.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA	Howard Hughes Medical Institute; Johns Hopkins University; University of Wisconsin System; University of Wisconsin Madison	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.				NICHD NIH HHS [HD32551] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032551] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Biesecker LG, 1997, NAT GENET, V17, P259, DOI 10.1038/ng1197-259; Borycki AG, 1998, DEVELOPMENT, V125, P777; Buscher D, 1998, MAMM GENOME, V9, P676, DOI 10.1007/s003359900845; Caruccio NC, 1999, DEV BIOL, V212, P137, DOI 10.1006/dbio.1999.9321; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; DANIELS K, 1998, METHOD CELL BIOL, P237; Ding Q, 1998, DEVELOPMENT, V125, P2533; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hughes DC, 1997, GENOMICS, V39, P205, DOI 10.1006/geno.1996.4468; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Lee J, 1997, DEVELOPMENT, V124, P2537; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MARTI E, 1995, DEVELOPMENT, V121, P2537; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x; Tatusova TA, 1999, FEMS MICROBIOL LETT, V177, P187, DOI 10.1111/j.1574-6968.1999.tb13730.x; Ungar AR, 1996, DEV BIOL, V178, P186, DOI 10.1006/dbio.1996.0209; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang BL, 1996, ONCOGENE, V12, P1921; Wild A, 1997, HUM MOL GENET, V6, P1979, DOI 10.1093/hmg/6.11.1979; Yang Y, 1997, DEVELOPMENT, V124, P4393; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zou H, 1997, COLD SPRING HARB SYM, V62, P269	57	787	815	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 18	2000	100	4					423	434		10.1016/S0092-8674(00)80678-9	http://dx.doi.org/10.1016/S0092-8674(00)80678-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693759	Bronze			2022-12-24	WOS:000085446900005
J	Lichtenstein, GR; Yang, YX; Nunes, FA; Lewis, JD; Tuchman, M; Tino, G; Kaiser, LR; Palevsky, HI; Kotloff, RM; Furth, EE; Bavaria, JE; Stecker, MM; Kaplan, P; Berry, GT				Lichtenstein, GR; Yang, YX; Nunes, FA; Lewis, JD; Tuchman, M; Tino, G; Kaiser, LR; Palevsky, HI; Kotloff, RM; Furth, EE; Bavaria, JE; Stecker, MM; Kaplan, P; Berry, GT			Fatal hyperammonemia after orthotopic lung transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPERAMMONEMIA; ENCEPHALOPATHY; AMMONIA	Background: A case of fatal hyperammonemia complicating orthotopic lung transplantation was previously reported. Objective: To describe the incidence, clinical features, and treatment of hyperammonemia associated with orthotopic lung transplantation. Design: Retrospective cohort analysis. Setting: Academic medical center and lung transplantation center in Philadelphia, Pennsylvania. Patients: 145 sequential adult patients who underwent orthotopic lung transplantation. Measurements: Plasma ammonium levels. Results: Six of the 145 patients who had had orthotopic lung transplantation developed hyperammonemia, all within the first 26 days after transplantation. The 30-day post-transplantation mortality rate was 67% for patients with hyperammonemia compared with 17% for those without hyperammonemia (P = 0.01). Development of major gastrointestinal complications (P = 0.03), use of total parenteral nutrition (P < 0.001), and lung transplantation for primary pulmonary hypertension (P = 0.045) were associated with hyperammonemia. Conclusions: Hyperammonemia is a potentially fatal event occurring after orthotopic lung transplantation. It is associated with high nitrogen load, concurrent medical stressors, primary pulmonary hypertension, and hepatic glutamine synthetase deficiency.	Hosp Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Washington Childrens Hosp, Washington, DC USA	University of Pennsylvania; Pennsylvania Medicine; Children's National Health System	Lichtenstein, GR (corresponding author), Hosp Univ Penn, Sch Med, Dept Med, Div Gastroenterol, 3 Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.		Kaiser, Larry/L-7940-2019; Kotloff, Robert/R-2579-2019	Berry, Gerard/0000-0001-5299-3313; Stecker, Mark/0000-0002-9632-168X				Armitage P., 1987, STAT METHODS MED RES; Berry GT, 1999, ARCH NEUROL-CHICAGO, V56, P481, DOI 10.1001/archneur.56.4.481; Breningstall G N, 1986, Pediatr Neurol, V2, P253, DOI 10.1016/0887-8994(86)90016-0; BRESSLER R, 1969, PHARMACOL REV, V21, P105; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; COULTER DL, 1981, J PEDIATR-US, V99, P317, DOI 10.1016/S0022-3476(81)80489-1; Davies SM, 1996, BONE MARROW TRANSPL, V17, P1119; EGGERMONT E, 1980, ACTA PAEDIATR BELG, V33, P163; GLASGOW AM, 1972, AM J DIS CHILD, V124, P827, DOI 10.1001/archpedi.1972.02110180029003; HOYUMPA AM, 1979, GASTROENTEROLOGY, V76, P184; Lichtenstein GR, 1997, GASTROENTEROLOGY, V112, P236, DOI 10.1016/S0016-5085(97)70240-3; MOURE JMB, 1970, ARCH NEUROL-CHICAGO, V23, P365, DOI 10.1001/archneur.1970.00480280079009; Rueda JF, 1998, ANN INTERN MED, V128, P956, DOI 10.7326/0003-4819-128-11-199806010-00022; SAMTOY B, 1980, PEDIATRICS, V65, P294, DOI 10.1542/peds.65.2.294; TRULOCK EP, 1993, CHEST, V103, P1566, DOI 10.1378/chest.103.5.1566; Tuchman M, 1997, ANN INTERN MED, V127, P446, DOI 10.7326/0003-4819-127-6-199709150-00005; WATSON AJ, 1985, LANCET, V2, P1271	17	65	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					283	287		10.7326/0003-4819-132-4-200002150-00006	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681283				2022-12-24	WOS:000085372900005
J	Hemminki, E; McPherson, K				Hemminki, E; McPherson, K			Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease	LANCET			English	Article							REPLACEMENT THERAPY; CLINICAL-TRIALS; INFORMATION	Background In a previous study of pooled data from published trials, we found no evidence to support the claim that postmenopausal hormone therapy (PHT) is associated with a decrease in cardiovascular disease. The purpose of this study was to see whether reports of clinical trials attached to drug-licensing applications in Finland could be obtained for scientific purposes, whether they are useful for studying cardiovascular events resulting from PHT, and if so, whether these unpublished reports corroborate the results of published reports. Methods Since clinical trials in drug-licensing documents are confidential, we had to obtain special permission from the Ministry of Social Affairs and Health to use the data for research purposes. After permission was granted, we studied the clinical sections of licensing documents for PHT drugs sent by drug companies to the Finnish Drug Agency. We aimed to identify trials that compared PHT and a placebo (or no therapy, or vitamin-mineral drugs), and that reported on cardiovascular and thromboembolic events or superficial phlebitis. New trials were identified and their data were pooled with those of published trials. Findings 17 licensing applications for drugs used as PHT were found. The number, type, and quality of reporting of clinical trials varied widely between applications. The trials and their reporting of unanticipated adverse events were mostly inadequate. Six new trials tie, those fulfilling the inclusion criteria and not included in our earlier report) were found. The new trials added little to the conclusions of previously published studies: the calculated odds ratios of cardiovascular and thromboembolic events for women taking PHT versus those not taking it was 1.97 (95% CI 0.84-4.63), compared with 1.65 (0.65-4.21) in our previous study. Interpretation In this case, unpublished trials added only a little to the data available from published trials, mainly due to the type of clinical data used in the licensing applications. The new data did not change the previous conclusion that clinical trials do not support a beneficial effect of PHT on cardiovascular diseases.	Natl Res & Dev Ctr Welf & Hlth, Hlth Serv Res Unit, FIN-00531 Helsinki, Finland; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Hemminki, E (corresponding author), Natl Res & Dev Ctr Welf & Hlth, Hlth Serv Res Unit, POB 220, FIN-00531 Helsinki, Finland.							Bardy AH, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60576-4; Bardy AH, 1998, BRIT J CLIN PHARMACO, V46, P147, DOI 10.1046/j.1365-2125.1998.00759.x; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Josefson D, 1999, BRIT MED J, V318, P753, DOI 10.1136/bmj.318.7186.753; Meschia M, 1998, MENOPAUSE, V5, P157; Ollila E, 1996, Int J Risk Saf Med, V9, P161, DOI 10.3233/JRS-1996-9306; 1996, INT J RISK SAFETY ME, V9, P131	10	30	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					566	569		10.1016/S0140-6736(99)03432-7	http://dx.doi.org/10.1016/S0140-6736(99)03432-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683020				2022-12-24	WOS:000085487400039
J	Nuorti, JP; Butler, JC; Gelling, L; Kool, JL; Reingold, AL; Vugia, DJ				Nuorti, JP; Butler, JC; Gelling, L; Kool, JL; Reingold, AL; Vugia, DJ			Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; BACTERIAL PNEUMONIA; ANTIBODY-RESPONSES; UNITED-STATES; BACTEREMIA; INFECTION; VACCINE; POPULATION; INFLUENZA	Background: Patients with AIDS have a high incidence of invasive pneumococcal disease, but no population-based data are available on secular trends or rates of this disease in specific demographic groups. Objective: To compare clinical characteristics, rates, and trends of pneumococcal disease in HIV-infected and non-HIV-infected persons. Design: Population-based laboratory surveillance and chart review. Setting: All of the 13 microbiology laboratories in San Francisco County, California. Patients: Persons who had a sterile site culture that was positive for Streptococcus pneumoniae between October 1994 and June 1997. Measurements: Stratified incidence rates and adjusted rate ratios, serotyping of isolates, and comparison of secular trends and rates according to census tract by Poisson regression. Results: Persons infected with HIV accounted for 54.2% of 399 patients 18 to 64 years of age who had pneumococcal disease. The incidence of pneumococcal disease per 100 000 person-years was 35.0 cases overall and 802.9 cases in patients with AIDS. Compared with persons who were not known to be HIV-infected, the rate ratio for patients with AIDS was 46.0 (95% CI, 36.0 to 58.9); 55.2% of cases were attributable to HIV. In HIV-infected patients, 82.5% of isolates were serotypes that are included in the pneumococcal polysaccharide vaccine. The incidence of pneumococcal disease in black patients with AIDS (2384.6 cases per 100 000 person-years) was 5.4 times that in nonblack patients with AIDS. Rates by census tract were inversely associated with income (P < 0.001). During the study period, the incidence of pneumococcal disease decreased from 10.6 cases per 1000 person-years to 4.2 cases per 1000 person-years in patients with AIDS (P = 0.004, Poisson regression). Conclusions: In a community with a high prevalence of HIV infection, much of the burden of pneumococcal disease was attributable to AIDS. High incidence rates were seen in young adults and especially in black persons. Efforts to increase pneumococcal vaccination rates should target HIV-infected adults, particularly those living in poor urban areas.	Calif Dept Hlth Serv, Calif Emerging Infect Program, Berkeley, CA USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	California Department of Health Care Services; California Emerging Infections Program; University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA	Nuorti, JP (corresponding author), Natl Publ Hlth Inst, Dept Infect Dis Epidemiol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	pekka.nuorti@ktl.fi		Kool, Jacob/0000-0002-9605-2918				[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; Bloch KC, 1998, ANN INTERN MED, V129, P698, DOI 10.7326/0003-4819-129-9-199811010-00004; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; Chan CY, 1996, J INFECT DIS, V173, P256, DOI 10.1093/infdis/173.1.256; Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; Frankel RE, 1996, CLIN INFECT DIS, V23, P577, DOI 10.1093/clinids/23.3.577; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; Gebo KA, 1996, J INFECT DIS, V173, P857, DOI 10.1093/infdis/173.4.857; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JANOFF EN, 1993, J INFECT DIS, V167, P49, DOI 10.1093/infdis/167.1.49; KELLER DW, 1995, CLIN INFECT DIS, V21, pS77, DOI 10.1093/clinids/21.Supplement_1.S77; KLEINBAUM DG, 1998, APPL REGRESSION ANAL, P687; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RODRIGUEZBARRADAS MC, 1992, J INFECT DIS, V165, P553, DOI 10.1093/infdis/165.3.553; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P267; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; Schwarcz SK, 1999, AIDS, V13, P1109, DOI 10.1097/00002030-199906180-00015; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; WORTLEY PM, 1994, AIDS, V8, P941, DOI 10.1097/00002030-199407000-00010; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, MMWR MORB WKLY REP, V46, P1; 1997, DIVISION HIV AIDS, V9, P6	34	156	158	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					182	190		10.7326/0003-4819-132-3-200002010-00003	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	276XE	10651598				2022-12-24	WOS:000084903000002
J	Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME				Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME			Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-TRACT INFECTION; AFRICAN CHILDREN; INDUCED SPUTUM; HIV; DIAGNOSIS; ZIMBABWE; THERAPY; DISEASE; VIRUS	Background Necropsy studies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infants with HIV infection. We aimed to describe the rate, clinical presentation, and outcome of PCP in young Malawian children with acute severe pneumonia. Methods Children aged between 2 months and 5 years who were in hospital with a diagnosis of severe pneumonia were admitted to a study ward for clinical monitoring. We carried out blood culture, immunofluorescence on nasopharyngeal aspirate samples to test for PCP, polymerase chain reaction to detect HIV, and chest radiography. Findings 16 cases of PCP were identified among 150 children With radiologically confirmed severe pneumonia. All were HIV-positive and younger than 6 months. 21 children had bacterial pneumonia (including one who was also PCP positive) and 114 were not confirmed. The most common bacterial pathogens among children without PCP were Streptococcus pneumoniae (eight) and non-typhoidal salmonellae (seven). On admission, children with confirmed PCP had a lower mean age, body temperature, and oxygen saturation than children with bacterial pneumonia and were less likely to have a focal abnormality on auscultation. Oxygen requirements were much greater in children with PCP than those with bacterial pneumonias (96 of 105 hospital days vs 15 of 94, p<0.0001). Ten of 16 children with PCP and six of 21 with bacterial pneumonia died (relative risk 2.19 [95%. CI 1.0-4.7]). The overall case-fatality rate of severe pneumonia was 22%, In addition to a strong association with PCP, a fatal outcome was significantly and independently associated with HIV infection (2.98 [1.1-7.9]) and with age under 6 months (2.76 [1.0-5.2]). Interpretation PCP is common and contributes to the high mortality from pneumonia in Malawian infants, Clinical features are helpful in diagnosis. The study highlights the impact of HIV infection and difficult issues of management in countries with few resources.	Univ Liverpool, Dept Med Microbiol, Liverpool L69 3GA, Merseyside, England; Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi; Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi; Sch Trop Med, Liverpool, Merseyside, England	University of Liverpool; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine	Graham, SM (corresponding author), Univ Liverpool, Dept Med Microbiol, 8th Floor,Duncan Bldg, Liverpool L69 3GA, Merseyside, England.	smgraham@liverpool.ac.uk		Graham, Stephen/0000-0003-3525-2294				AMUNDSON DE, 1989, SOUTHERN MED J, V82, P711, DOI 10.1097/00007611-198906000-00009; BLASER J, 1993, INFECTION, V21, P206, DOI 10.1007/BF01728888; BYE MR, 1987, PEDIATR PULM, V3, P425, DOI 10.1002/ppul.1950030609; *CDC, 1993, HIV AIDS SURV REP, P16; CHAUDHARY S, 1977, AM J DIS CHILD, V131, P902, DOI 10.1001/archpedi.1977.02120210080017; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; HAGUE RA, 1990, ARCH DIS CHILD, V65, P1364, DOI 10.1136/adc.65.12.1364; Harries AD, 1997, INT J TUBERC LUNG D, V1, P346; Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124, DOI 10.1136/adc.76.2.124; Jeena PM, 1997, ANN TROP PAEDIATR, V76, P124; Kamiya Y, 1997, ANN TROP PAEDIATR, V17, P121, DOI 10.1080/02724936.1997.11747874; Lepage P, 1998, PEDIATR INFECT DIS J, V17, P581, DOI 10.1097/00006454-199807000-00002; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MCLAUGHLIN GE, 1995, J PEDIATR-US, V126, P821, DOI 10.1016/S0022-3476(95)70421-3; MIMICA I, 1971, AM J DIS CHILD, V122, P278, DOI 10.1001/archpedi.1971.02110040062002; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; *NAT COMM CLIN LAB, 1993, PERF STAND ANT SUSC; NATHOO KJ, 1993, ANN TROP PAEDIATR, V13, P253, DOI 10.1080/02724936.1993.11747655; OGNIBENE FP, 1989, J PEDIATR-US, V115, P430, DOI 10.1016/S0022-3476(89)80848-0; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROGERS MF, 1987, PEDIATRICS, V79, P1008; SHANN F, 1988, LANCET, V2, P1238; Shann F, 1995, CLIN INFECT DIS, V21, pS218, DOI 10.1093/clind/21.Supplement_3.S218; Shata AMA, 1996, ARCH DIS CHILD, V74, P535, DOI 10.1136/adc.74.6.535; SLEASMAN JW, 1993, AM J DIS CHILD, V147, P29, DOI 10.1001/archpedi.1993.02160250032012; Smyth A, 1997, ARCH DIS CHILD, V77, P227, DOI 10.1136/adc.77.3.227; STAGNO S, 1981, PEDIATRICS, V68, P322; VanDyke R.B., 1995, SEMIN PEDIAT INFECT, V6, P10, DOI 10.1016/S1045-1870(05)80018-4; Vetter KM, 1996, PEDIATR INFECT DIS J, V15, P438, DOI 10.1097/00006454-199605000-00011; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; *WHO, 1993, WHOARI9328; *WHO PROGR CONTR A, 1994, WHOARI905 PROGR CONT	37	116	117	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					369	373		10.1016/S0140-6736(98)11074-7	http://dx.doi.org/10.1016/S0140-6736(98)11074-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665557				2022-12-24	WOS:000085122100013
J	Banfield, JF; Marshall, CR				Banfield, JF; Marshall, CR			Earth science and evolution - Genomics and the geosciences	SCIENCE			English	Editorial Material									Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard University	Banfield, JF (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.	jill@geology.wisc.edu; marshall@eps.harvard.edu		Banfield, Jill/0000-0001-8203-8771				Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; DAVIDSON EH, 1995, SCIENCE, V270, P1319, DOI 10.1126/science.270.5240.1319; Edwards KJ, 1999, APPL ENVIRON MICROB, V65, P3627; Fitz-Gibbon ST, 1999, NUCLEIC ACIDS RES, V27, P4218, DOI 10.1093/nar/27.21.4218; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; Nealson KH, 1997, REV MINERAL, V35, P5; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; Valentine JW, 1999, DEVELOPMENT, V126, P851; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	12	13	16	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					605	606		10.1126/science.287.5453.605	http://dx.doi.org/10.1126/science.287.5453.605			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10691543				2022-12-24	WOS:000084989400034
J	Thisse, B; Wright, CVE; Thisse, C				Thisse, B; Wright, CVE; Thisse, C			Activin- and Nodal-related factors control antero-posterior patterning of the zebrafish embryo	NATURE			English	Article							NERVOUS-SYSTEM; FATE MAP; XENOPUS; EXPRESSION; SIGNALS; GENE; INDUCTION; SPECIFICATION; NOTOCHORD; MESODERM	Definition of cell fates along the dorso-ventral axis depends on an antagonistic relationship between ventralizing transforming growth factor-beta superfamily members, the bone morphogenetic proteins' and factors secreted from the dorsal organizer, such as Noggin and Chordin. The extracellular binding of the last group to the bone morphogenetic proteins prevents them from activating their receptors(2-4), and the relative ventralizer:antagonist ratio is thought to specify different dorso-ventral cell fates. Here, by taking advantage of a non-genetic interference method using a specific competitive inhibitor, the Lefty-related gene product Antivin(5), we provide evidence that cell fate along the anteroposterior axis of the zebrafish embryo is controlled by the morphogenetic activity of another transforming growth factor-beta superfamily subgroup-the Activin and Nodal-related faaors(6-9). Increasing antivin doses progressively deleted posterior fates within the ectoderm, eventually resulting in the removal of all fates except forebrain and eyes. In contrast, overexpression of activin or nodal-related factors converted ectoderm that was fated to be forebrain into more posterior ectodermal or mesendodermal fates, We propose that modulation of intercellular signalling by Antivin/Activin and Nodal-related factors provides a mechanism for the graded establishment of cell fates along the antero-posterior axis of the zebrafish embryo.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University	Thisse, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.			THISSE, Christine/0000-0002-8684-1681				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHENG A, IN PRESS DEVELOPMENT; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRISTMAN K, 1999, CELL, V97, P121; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Melby AE, 1996, DEVELOPMENT, V122, P2225; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Prince VE, 1998, DEV GENES EVOL, V208, P517, DOI 10.1007/s004270050210; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Reifers F, 1998, DEVELOPMENT, V125, P2381; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SPERMANN H, 1938, EMBRYONIC DEV INDUCT; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thisse C, 1999, DEVELOPMENT, V126, P229; THISSE C, 1993, DEVELOPMENT, V119, P1203; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WOO K, 1995, DEVELOPMENT, V121, P2595; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	26	168	170	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					425	428		10.1038/35000200	http://dx.doi.org/10.1038/35000200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667793				2022-12-24	WOS:000085121100049
J	Galy, V; Olivo-Marin, JC; Scherthan, H; Doye, V; Rascalou, N; Nehrbass, U				Galy, V; Olivo-Marin, JC; Scherthan, H; Doye, V; Rascalou, N; Nehrbass, U			Nuclear pore complexes in the organization of silent telomeric chromatin	NATURE			English	Article							DOUBLE-STRAND BREAKS; END-JOINING REPAIR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST KU; PROTEINS; LENGTH; GENE; MAINTENANCE; REPRESSION	The functional regulation of chromatin is closely related to its spatial organization within the nucleus. In yeast, perinuclear chromatin domains constitute areas of transcriptional repression(1-3). These 'silent' domains are defined by the presence of perinuclear telomere clusters(4). The only protein found to be involved in the peripheral localization of telomeres is Yku70/Yku80 (ref. 5). This conserved heterodimer(6) can bind telomeres(7) and functions in both repair of DNA double-strand breaks(8-11) and telomere maintenance(7,12-15) These findings, however, do not address the underlying structural basis of perinuclear silent domains. Here we show that nuclear-pore-complex extensions formed by the conserved TpR(16,17) homologues Mlp1 and Mlp2(18,19) are responsible for the structural and functional organization of perinuclear chromatin. Loss of MLP2 results in a severe deficiency in the repair of double-strand breaks. Furthermore, double deletion of MLP1 and MLP2 disrupts the clustering of perinuclear telomeres and releases telomeric gene repression. These effects are probably mediated through the interaction with Yku70. Mlp2 physically tethers Yku70 to the nuclear periphery, thus forming a link between chramatin and the nuclear envelope. We show, moreover, that this structural link is docked to nuclear-pore complexes through a cleavable nucleoporin, Nup145(20). We propose that, through these interactions, nuclear-pore complexes organize a nuclear subdomain that is intimately involved in the regulation of chromatin metabolism.	Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA 1773, F-75724 Paris 15, France; Inst Pasteur, Lab Anal & Images Quantitat, CNRS, URA 1947, F-75724 Paris 15, France; Univ Kaiserslautern, Abt Humanbiol, D-67653 Kaiserslautern, Germany; Univ Kaiserslautern, Abt Zellbiol, D-67653 Kaiserslautern, Germany; Inst Curie, CNRS, UMR144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Kaiserslautern; University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Nehrbass, U (corresponding author), Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA 1773, 25 Rue Docteur Roux, F-75724 Paris 15, France.		Olivo-Marin, Jean-Christophe/K-4428-2015	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Nehrbass, Ulf/0000-0002-7028-8076				Andrulis ED, 1998, NATURE, V395, P525, DOI 10.1038/26795; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; Bangs P, 1998, J CELL BIOL, V143, P1801, DOI 10.1083/jcb.143.7.1801; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOLLING R, 1993, MOL GEN GENET, V237, P359; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Olivo JC, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL I, P311, DOI 10.1109/ICIP.1996.559495; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Shore D, 1997, BIOL CHEM, V378, P591; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Trelles-Sticken E, 1999, J CELL SCI, V112, P651	30	252	259	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					108	112		10.1038/47528	http://dx.doi.org/10.1038/47528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638763				2022-12-24	WOS:000084687400053
J	Muller-Navarra, DC; Brett, MT; Liston, AM; Goldman, CR				Muller-Navarra, DC; Brett, MT; Liston, AM; Goldman, CR			A highly unsaturated fatty acid predicts carbon transfer between primary producers and consumers	NATURE			English	Article							DAPHNIA GROWTH; LIMITATION; ZOOPLANKTON; MICROALGAE; QUALITY	The factors that regulate energy transfer between primary producers and consumers in aquatic ecosystems have been investigated for more than 50 years (refs 1-3). Among all levels of the food web (plants, herbivores, carnivores), the plant-animal interface is the most variable and least predictable link(4-6). In hypereutrophic lakes, for example, biomass and energy transfer is often inhibited at the phytoplankton-zooplankton link(4), resulting in an accumulation of phytoplankton biomass instead of sustaining production at higher trophic levels, such as fish. Accumulation of phytoplankton (especially cyanobacteria) results in severe deterioration of water quality, with detrimental effects on the health of humans and domestic animals, and diminished recreational value of water bodies(7,8). We show here that low transfer efficiencies between primary producers and consumers during cyanobacteria bloom conditions are related to low relative eicosapentaenoic acid (20:5 omega 3) content of the primary producer community. Zooplankton growth and egg production were strongly related to the primary producer 20:5 omega 3 to carbon ratio. This indicates that limitation of zooplankton production by this essential fatty acid is of central importance at the pelagic producer-consumer interface.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	University of California System; University of California Davis; University of Washington; University of Washington Seattle	Muller-Navarra, DC (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.		Brett, Michael T/A-2066-2010					AHLGREN G, 1992, J PHYCOL, V28, P37, DOI 10.1111/j.0022-3646.1992.00037.x; ARNOLD DE, 1971, LIMNOL OCEANOGR, V16, P906, DOI 10.4319/lo.1971.16.6.0906; Brett MT, 1996, P NATL ACAD SCI USA, V93, P7723, DOI 10.1073/pnas.93.15.7723; Brett MT, 1997, FRESHWATER BIOL, V38, P483, DOI 10.1046/j.1365-2427.1997.00220.x; Brett MT, 1997, SCIENCE, V275, P384, DOI 10.1126/science.275.5298.384; COBELAS MA, 1989, GRASAS ACEITES, V40, P118; Greenberg AE, 1995, STANDARD METHODS EXA; GULATI RD, 1990, BIOMANIPULATION TOOL, V200, P29; GULATI RD, 1997, FRESHWAT BIOL, V38; KATTNER G, 1986, J CHROMATOGR, V361, P263, DOI 10.1016/S0021-9673(01)86914-4; LAMPERT W, 1977, Archiv fuer Hydrobiologie Supplement, V48, P310; LAMPERT W, 1988, B MAR SCI, V43, P620; Lampert W., 1987, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V45, P143; LAMPERT W, 1985, ARCH HYDROBIOL BEIH, V21, pR5; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; Marker A. F. H., 1980, ARCH HYDROBIOL S, V14, P52; MCQUEEN DJ, 1989, ECOL MONOGR, V59, P289, DOI 10.2307/1942603; MULLERNAVARRA D, 1995, ARCH HYDROBIOL, V132, P297; MullerNavarra D, 1996, J PLANKTON RES, V18, P1137, DOI 10.1093/plankt/18.7.1137; PORTER KG, 1987, EVOLUTION ECOLOGY ZO, P268; STERNER RW, 1993, ECOLOGY, V74, P2351, DOI 10.2307/1939587; URABE J, 1992, LIMNOL OCEANOGR, V37, P244, DOI 10.4319/lo.1992.37.2.0244; VINCENT WF, 1987, NZ J MAR FRESHWAT RE, V221; Wood B.J.B., 1974, ALGAL PHYSL BIOCH, P236; [No title captured]	25	568	586	15	249	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					74	77		10.1038/47469	http://dx.doi.org/10.1038/47469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638754				2022-12-24	WOS:000084687400044
J	Lenoir, N				Lenoir, N			Europe confronts the embryonic stem cell research challenge	SCIENCE			English	Editorial Material								Europe's historic plurality and the Lack of a commonly accepted definition of the moral status of the embryo have led to varying regulation in European countries. Council of Europe and European Union Legislation, based on fundamental ethical principles, does exist for specific issues, such as prohibition against producing embryos solely for research. Such principles have recently been elucidated by the European Group on Ethics in Science and New Technologies. Newly emerging research techniques are beginning to cause reconsideration of the regulation of embryo research in Europe.	Conseil Constitut, F-75001 Paris, France		Lenoir, N (corresponding author), Conseil Constitut, 2 Rue Montpensier, F-75001 Paris, France.							Deutsch E, 1993, Med Law, V12, P535; KNOPPERS M, HUMAN DIGNITY GENETI; Marshall E, 1998, SCIENCE, V282, P1014, DOI 10.1126/science.282.5391.1014; McLaren Angus, 1990, HIST CONTRACEPTION; Noonan John T., 1965, CONTRACEPTION HIST I; RABELAIS F, 1991, GARGANTUA PANTAGRUEL	6	56	63	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1425	1427		10.1126/science.287.5457.1425	http://dx.doi.org/10.1126/science.287.5457.1425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688780				2022-12-24	WOS:000085531600034
J	Braun, S; Pantel, K; Muller, P; Janni, W; Hepp, F; Kentenich, CRM; Gastroph, S; Wischnik, A; Dimpfl, T; Kindermann, G; Riethmuller, G; Schlimok, G				Braun, S; Pantel, K; Muller, P; Janni, W; Hepp, F; Kentenich, CRM; Gastroph, S; Wischnik, A; Dimpfl, T; Kindermann, G; Riethmuller, G; Schlimok, G			Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDIAN FOLLOW-UP; MONOCLONAL-ANTIBODIES; PROGNOSTIC-SIGNIFICANCE; PREMENOPAUSAL WOMEN; ANTI-CYTOKERATIN; PRIMARY SURGERY; NODAL STATUS; TUMOR-CELLS; MICROMETASTASES; CARCINOMA	Background: Cytokeratins are specific markers of epithelial cancer cells in bone marrow. We assessed the influence of cytokeratin-positive micrometastases in the bone marrow on the prognosis of women with breast cancer. Methods: We obtained bone marrow aspirates from both upper iliac crests of 552 patients with stage I, II, or III breast cancer who underwent complete resection of the tumor and 191 patients with nonmalignant disease. The specimens were stained with the monoclonal antibody A45-B/B3, which binds to an antigen on cytokeratins. The median follow-up was 38 months (range, 10 to 70). The primary end point was survival. Results: Cytokeratin-positive cells were detected in the bone marrow specimens of 2 of the 191 control patients with nonmalignant conditions (1 percent) and 199 of the 552 patients with breast cancer (36 percent). The presence of occult metastatic cells in bone marrow was unrelated to the presence or absence of lymph-node metastasis (P = 0.13). After four years of follow-up, the presence of micrometastases in bone marrow was associated with the occurrence of clinically overt distant metastasis and death from cancer-related causes (P<0.001), but not with locoregional relapse (P = 0.77). Of 199 patients with occult metastatic cells, 49 died of cancer, whereas of 353 patients without such cells, 22 died of cancer-related causes (P<0.001). Among the 301 women without lymph-node metastases, 14 of the 100 with bone marrow micrometastases died of cancer-related causes, as did 2 of the 201 without bone marrow micrometastases (P<0.001). The presence of occult metastatic cells in bone marrow, as compared with their absence, was an independent prognostic indicator of the risk of death from cancer (relative risk, 4.17; 95 percent confidence interval, 2.51 to 6.94; P<0.001), after adjustment for the use of systemic adjuvant chemotherapy. Conclusions: The presence of occult cytokeratin-positive metastatic cells in bone marrow increases the risk of relapse in patients with stage I, II, or III breast cancer. (N Engl J Med 2000;342:525-33.) (C)2000, Massachusetts Medical Society.	Univ Munich, Klinikum Innenstadt, Frauenklin 1, D-80337 Munich, Germany; Univ Munich, Klinikum Innenstadt, Inst Immunol, D-80337 Munich, Germany; Univ Hamburg, Krankenhaus Eppendorf, Frauenklin, D-2000 Hamburg, Germany; Zent Klinikum, Med Klin 2, Augsburg, Germany; Zent Klinikum, Frauenklin, Augsburg, Germany	University of Munich; University of Munich; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Braun, S (corresponding author), Univ Munich, Klinikum Innenstadt, Frauenklin 1, Maistr 11, D-80337 Munich, Germany.	sbraun@fk-i.med.uni-muenchen.de						[Anonymous], 1997, J CLIN PATHOL; Black, 1997, EUR J CANCER, V33, P2440; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; Braun S, 1998, J NATL CANCER I, V90, P1099, DOI 10.1093/jnci/90.14.1099; Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80; Brugger W, 1999, J CLIN ONCOL, V17, P1535, DOI 10.1200/JCO.1999.17.5.1535; Cevatli BS, 1999, EUR J CANCER, V35, pS86, DOI 10.1016/S0959-8049(99)80716-3; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COURTEMANCHE DJ, 1991, CAN J SURG, V34, P21; COX DR, 1972, J R STAT SOC B, V34, P187; DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152; DELSOL G, 1984, LANCET, V2, P1124; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; DOGLIONI C, 1990, VIRCHOWS ARCH A, V416, P479, DOI 10.1007/BF01600298; FISHER B, 1981, CANCER-AM CANCER SOC, V48, P1863, DOI 10.1002/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-U; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HARBECK N, 1994, BRIT J CANCER, V69, P566, DOI 10.1038/bjc.1994.103; Hellman S, 1997, NEW ENGL J MED, V337, P996, DOI 10.1056/NEJM199710023371408; Jauch KW, 1996, J CLIN ONCOL, V14, P1810, DOI 10.1200/JCO.1996.14.6.1810; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASPER M, 1987, EUR J CANCER CLIN ON, V23, P137, DOI 10.1016/0277-5379(87)90007-1; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Landys K, 1998, BREAST CANCER RES TR, V49, P27, DOI 10.1023/A:1005980919916; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Liu D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P268; Mansi JL, 1999, LANCET, V354, P197, DOI 10.1016/S0140-6736(98)10175-7; MENARD S, 1994, BRIT J CANCER, V70, P709, DOI 10.1038/bjc.1994.379; Molino A, 1997, BREAST CANCER RES TR, V42, P23, DOI 10.1023/A:1005747711084; Mueller P, 1998, CANCER-AM CANCER SOC, V83, P538, DOI 10.1002/(SICI)1097-0142(19980801)83:3<538::AID-CNCR23>3.0.CO;2-W; Muller P, 1996, CANCER GENET CYTOGEN, V88, P8, DOI 10.1016/0165-4608(95)00189-1; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RIETHMULLER G, 1992, CURR OPIN IMMUNOL, V4, P647, DOI 10.1016/0952-7915(92)90041-C; SALVADORI B, 1990, EUR J CANCER, V26, P865, DOI 10.1016/0277-5379(90)90185-V; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Stigbrand T, 1998, TUMOR BIOL, V19, P132, DOI 10.1159/000029984; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; THOR A, 1988, BREAST CANCER RES TR, V11, P133, DOI 10.1007/BF01805837	45	766	805	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					525	533		10.1056/NEJM200002243420801	http://dx.doi.org/10.1056/NEJM200002243420801			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684910				2022-12-24	WOS:000085422400001
J	Eeva, T; Lehikoinen, E				Eeva, T; Lehikoinen, E			Pollution - Recovery of breeding success in wild birds	NATURE			English	Article							FICEDULA-HYPOLEUCA; PIED FLYCATCHERS; METAL POLLUTION; PARUS-MAJOR; PASSERINES; GRADIENT; FINLAND		Univ Turku, Dept Biol, Sect Ecol, FIN-20014 Turku, Finland	University of Turku	Eeva, T (corresponding author), Univ Turku, Dept Biol, Sect Ecol, FIN-20014 Turku, Finland.		Eeva, Tapio/V-8922-2018; Lehikoinen, Esa/I-6128-2013	Eeva, Tapio/0000-0002-0395-1536; Lehikoinen, Esa/0000-0002-6932-3604				Eeva T, 1997, ECOLOGY, V78, P1120, DOI 10.1890/0012-9658(1997)078[1120:PRVIFS]2.0.CO;2; Eeva T, 1996, OECOLOGIA, V108, P631, DOI 10.1007/BF00329036; EEVA T, 1995, OECOLOGIA, V102, P312, DOI 10.1007/BF00329798; FRITZE H, 1989, BIOL FERT SOILS, V8, P87, DOI 10.1007/BF00260522; GRAVELAND J, 1994, NATURE, V368, P446, DOI 10.1038/368446a0; Heliovaara K, 1990, ACIDIFICATION FINLAN, P447; HYNNINEN V, 1986, ANN BOT FENN, V23, P83; Jussila I, 1997, SYKESARJA B, V12, P1; Nyholm NEI, 1998, ARCH ENVIRON CON TOX, V35, P632, DOI 10.1007/s002449900425	9	59	59	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					851	852		10.1038/35002672	http://dx.doi.org/10.1038/35002672			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706274				2022-12-24	WOS:000085559200045
J	Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G				Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G			Clinical problems with the performance of euthanasia and physician-assisted suicide in the netherlands.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; ATTITUDES; LIFE; END; ONCOLOGISTS; DECISIONS; OREGON; DEATH	Background and Methods: The characteristics and frequency of clinical problems with the performance of euthanasia and physician-assisted suicide are uncertain. We analyzed data from two studies of euthanasia and physician-assisted suicide in the Netherlands (one conducted in 1990 and 1991 and the other in 1995 and 1996), with a total of 649 cases. We categorized clinical problems as technical problems, such as difficulty inserting an intravenous line; complications, such as myoclonus or vomiting; or problems with completion, such as a longer-than-expected interval between the administration of medications and death. Results: In 114 cases, the physician's intention was to provide assistance with suicide, and in 535, the intention was to perform euthanasia. Problems of any type were more frequent in cases of assisted suicide than in cases of euthanasia. Complications occurred in 7 percent of cases of assisted suicide, and problems with completion (a longer-than-expected time to death, failure to induce coma, or induction of coma followed by awakening of the patient) occurred in 16 percent of the cases; complications and problems with completion occurred in 3 percent and 6 percent of cases of euthanasia, respectively. The physician decided to administer a lethal medication in 21 of the cases of assisted suicide (18 percent), which thus became cases of euthanasia. The reasons for this decision included problems with completion (in 12 cases) and the inability of the patient to take all the medications (in 5). Conclusions: There may be clinical problems with the performance of euthanasia and physician-assisted suicide. In the Netherlands, physicians who intend to provide assistance with suicide sometimes end up administering a lethal medication themselves because of the patient's inability to take the medication or because of problems with the completion of physician-assisted suicide. (N Engl J Med 2000;342:551-6.) (C)2000, Massachusetts Medical Society.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Social Med, Amsterdam, Netherlands	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Groenewoud, JH (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; *GEN BOARD RDMA, 1996, EUTH NETH; Gevers S, 1996, BRIT MED BULL, V52, P326; *KON NED MAATSCH B, 1994, TOEP BER EUTH SGRAV; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LEGEMAATE J, 1995, CAMB Q HEALTHC ETHIC, V4, P112; Matzo M L, 1997, Oncol Nurs Forum, V24, P1725; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MULLER MT, 1992, VOX HOSP, V16, P3; Onwuteaka-Philipsen B D, 1995, Arch Fam Med, V4, P951, DOI 10.1001/archfami.4.11.951; OnwuteakaPhilipsen BD, 1997, J AM GERIATR SOC, V45, P1208, DOI 10.1111/j.1532-5415.1997.tb03771.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Wal G, 1992, Ned Tijdschr Geneeskd, V136, P1299; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; *WET I NED AP, 1998, MED CONTACT, V53, P1366; Woolfrey J, 1998, HASTINGS CENT REP, V28, P9, DOI 10.2307/3528645	28	123	123	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					551	556		10.1056/NEJM200002243420805	http://dx.doi.org/10.1056/NEJM200002243420805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684914	Green Published, Bronze			2022-12-24	WOS:000085422400005
J	Dawkins, MS; Woodington, A				Dawkins, MS; Woodington, A			Pattern recognition and active vision in chickens	NATURE			English	Article							ORIENTATION FLIGHTS; WASPS	Recognition of objects or environmental landmarks is problematic because appearance can vary widely depending on illumination, viewing distance, angle of view and so on(1). Storing a separate image or 'template' for every possible view requires vast numbers to be stored and scanned, has a high probability of recognition error and appears not to be the solution adopted by primates(2-3). However, some invertebrate template matching systems can achieve recognition by 'active vision' in which the animal's own behaviour is used to achieve a fit between template and object(4), for example by repeatedly following a set path(5-7). Recognition is thus limited to views from the set path but achieved with a minimal number of templates. Here we report the first evidence of similar active vision in a bird, in the form of locomotion and individually distinct head movements that give the eyes a similar series of views on different occasions. The hens' ability to recognize objects is also found to decrease when their normal paths are altered.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Dawkins, MS (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	marian.dawkins@zoo.ox.ac.uk						Andrew R.J., 1993, VISION BRAIN BEHAV B, P319; Baker R. R., 1978, EVOLUTIONARY ECOLOGY; COLLETT TS, 1992, PHILOS T R SOC B, V337, P295, DOI 10.1098/rstb.1992.0107; COLLETT TS, 1995, J COMP PHYSIOL A, V177, P737, DOI 10.1007/BF00187632; Dawkins MS, 1996, BEHAVIOUR, V133, P663, DOI 10.1163/156853996X00413; Edelman S, 1997, TRENDS COGN SCI, V1, P296, DOI 10.1016/S1364-6613(97)01090-5; Land MF, 1997, FROM LIVING EYES TO SEEING MACHINES, P16; PRATT DW, 1982, J EXP BIOL, V97, P217; ROLLS ET, 1994, BEHAV PROCESS, V33, P113, DOI 10.1016/0376-6357(94)90062-0; TURKEL J, 1977, NEUR ABSTR, V3, P158; Ullman S., 1996, HIGH LEVEL VISION OB; Wallman Josh, 1993, P245; ZEIL J, 1993, J COMP PHYSIOL A, V172, P189, DOI 10.1007/BF00189396	13	47	47	0	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					652	655		10.1038/35001064	http://dx.doi.org/10.1038/35001064			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688200				2022-12-24	WOS:000085288200052
J	Kyne, L; Warny, M; Qamar, A; Kelly, CP				Kyne, L; Warny, M; Qamar, A; Kelly, CP			Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED-PATIENTS; RISK-FACTORS; DIARRHEA; INFECTION; COLITIS; COLONIZATION; ACQUISITION; COHORT; EPIDEMIOLOGY; PURIFICATION	Background: Clostridium difficile infection can result in asymptomatic carriage, mild diarrhea, or fulminant pseudomembranous colitis. We studied whether antibody responses to C. difficile toxins affect the risks of colonization, diarrhea, and asymptomatic carriage. Methods: We prospectively studied C. difficile infections in hospitalized patients who were receiving antibiotics. Serial stool samples were tested for C. difficile colonization by cytotoxin assay and culture. Serum antibody (IgA, IgG, and IgM) levels and fecal antibody (IgA and IgG) levels against C. difficile toxin A, toxin B, and nontoxin antigens were measured by an enzyme-linked immunosorbent assay (ELISA). Results: Of 271 patients, 37 (14 percent) were colonized with C. difficile at the time of admission, 18 of whom were asymptomatic carriers. An additional 47 patients (17 percent) became infected in the hospital, 19 of whom remained asymptomatic. The base-line antibody levels were similar in the patients who later became colonized and those who did not. After colonization, those who became asymptomatic carriers had significantly greater increases in serum levels of IgG antibody against toxin A than did the patients in whom C. difficile diarrhea developed (P<0.001). The adjusted odds ratio for diarrhea was 48.0 (95 percent confidence interval, 3.4 to 678) among patients with colonization who had a serum level of IgG antibody against toxin A of 3.00 ELISA units or less, as compared with patients with colonization who had a level of more than 3.00 ELISA units. Conclusions: We find no evidence of immune protection against colonization by C. difficile. However, after colonization there is an association between a systemic anamnestic response to toxin A, as evidenced by increased serum levels of IgG antibody against toxin A, and asymptomatic carriage of C. difficile. (N Engl J Med 2000;342:390-7.) (C)2000, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kelly, CP (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.				NCRR NIH HHS [RR-01032] Funding Source: Medline; NIA NIH HHS [AG16956, AG08812] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, R03AG016956, P30AG008812] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON AE, 1994, DIAGN MICR INFEC DIS, V18, P205, DOI 10.1016/0732-8893(94)90021-3; Bliss DZ, 1998, ANN INTERN MED, V129, P1012, DOI 10.7326/0003-4819-129-12-199812150-00004; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng SH, 1997, CLIN INFECT DIS, V25, P157, DOI 10.1086/516891; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; Guerrant R. L., 1990, REV INFECT DIS, V12, P41; HANFF PA, 1993, CLIN INFECT DIS, V16, pS245, DOI 10.1093/clinids/16.Supplement_4.S245; HOHMANN A, 1983, J IMMUNOL METHODS, V64, P199, DOI 10.1016/0022-1759(83)90398-8; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1992, J INFECT DIS, V166, P1287, DOI 10.1093/infdis/166.6.1287; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kelly CP, 1996, ANTIMICROB AGENTS CH, V40, P373, DOI 10.1128/AAC.40.2.373; Kelly CP, 1996, EUR J GASTROEN HEPAT, V8, P1048, DOI 10.1097/00042737-199611000-00004; KELLY CP, 1992, GASTROENTEROLOGY, V102, P35, DOI 10.1016/0016-5085(92)91781-X; Kent KC, 1998, ANN SURG, V227, P296, DOI 10.1097/00000658-199802000-00021; Kyne L, 1999, AGE AGEING, V28, P107, DOI 10.1093/ageing/28.2.107; Kyne L, 1998, BIODRUGS, V10, P173, DOI 10.2165/00063030-199810030-00001; Kyne L, 1998, AGE AGEING, V27, P339, DOI 10.1093/ageing/27.3.339; LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1; MCFARLAND LV, 1991, INFECT IMMUN, V59, P2456, DOI 10.1128/IAI.59.7.2456-2462.1991; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1987, J CLIN MICROBIOL, V25, P2241, DOI 10.1128/JCM.25.11.2241-2242.1987; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MCFARLAND LV, 1995, AM J INFECT CONTROL, V23, P295, DOI 10.1016/0196-6553(95)90060-8; MULLIGAN ME, 1993, CLIN INFECT DIS, V16, pS239, DOI 10.1093/clinids/16.Supplement_4.S239; Pothoulakis C, 1996, EUR J GASTROEN HEPAT, V8, P1041, DOI 10.1097/00042737-199611000-00003; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; RUBIN MS, 1995, DIS COLON RECTUM, V38, P350, DOI 10.1007/BF02054220; Salcedo J, 1997, GUT, V41, P366, DOI 10.1136/gut.41.3.366; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8; Starr JM, 1997, LANCET, V349, P426, DOI 10.1016/S0140-6736(97)80053-0; SULLIVAN NM, 1982, INFECT IMMUN, V35, P1032, DOI 10.1128/IAI.35.3.1032-1040.1982; VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994	40	694	747	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					390	397		10.1056/NEJM200002103420604	http://dx.doi.org/10.1056/NEJM200002103420604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666429				2022-12-24	WOS:000085205200004
J	Bello, YM; Phillips, TJ				Bello, YM; Phillips, TJ			Recent advances in wound healing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GROWTH FACTOR-BB; PRESSURE ULCERS; SKIN		Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Phillips, TJ (corresponding author), 609 Albany St, Boston, MA 02118 USA.	skin@bu.edu		Phillips, Tania/0000-0003-2744-4931				Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; Association A.D., 1999, DIABETES CARE, V22, P1354, DOI DOI 10.2337/DIACARE.22.8.1354; Bello YM, 1999, WOUNDS, V11, P2; BERGSTROM N, 1994, AHCPR PUBLICATION; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CULLUM N, 1999, COMPRESSION BANDAGES; DARKE SG, 1992, EUR J VASCULAR SURG, V6, P4, DOI 10.1016/S0950-821X(05)80086-6; Eaglstein WH, 1997, SURG CLIN N AM, V77, P689, DOI 10.1016/S0039-6109(05)70575-2; Falanga V, 1999, WOUND REPAIR REGEN, V7, P208, DOI 10.1046/j.1524-475X.1999.00208.x; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Kanj LF, 1998, J AM ACAD DERMATOL, V38, P517, DOI 10.1016/S0190-9622(98)70113-6; LAZARUS GS, 1994, ARCH DERMATOL, V130, P489, DOI 10.1001/archderm.130.4.489; MASUDA EM, 1994, J VASC SURG, V19, P391, DOI 10.1016/S0741-5214(94)70066-4; MUSTOE TA, 1994, ARCH SURG-CHICAGO, V129, P213; OUAHES N, 1995, CURR PROBL DERMATOL, V7, P109; OVINGTON LG, 1999, OSTOMY WOUND MAN S1A, V45, P94; Pham HT, 1999, WOUNDS, V11, P79; Phillips TJ, 1998, ARCH DERMATOL, V134, P344, DOI 10.1001/archderm.134.3.344; Rees RS, 1999, WOUND REPAIR REGEN, V7, P141, DOI 10.1046/j.1524-475X.1999.00141.x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Whiteley MS, 1998, ANN ROY COLL SURG, V80, P104; Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822	23	84	90	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					716	718		10.1001/jama.283.6.716	http://dx.doi.org/10.1001/jama.283.6.716			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683040	Green Submitted			2022-12-24	WOS:000085129000001
J	Fransz, PF; Armstrong, S; de Jong, JH; Parnell, LD; van Drunen, C; Dean, C; Zabel, P; Bisseling, T; Jones, GH				Fransz, PF; Armstrong, S; de Jong, JH; Parnell, LD; van Drunen, C; Dean, C; Zabel, P; Bisseling, T; Jones, GH			Integrated cytogenetic map of chromosome arm 4S of A-thaliana: Structural organization of heterochromatic knob and centromere region	CELL			English	Article							RECOMBINANT INBRED LINES; ARABIDOPSIS-THALIANA; REPETITIVE DNA; SEQUENCES; GENOME; RETROELEMENT; LIBRARY; MEIOSIS; MARKERS; ATHILA	We have constructed an integrated cytogenetic map of chromosome arm 4S of Arabidopsis thaliana. The map shows the detailed positions of various multicopy and unique sequences relative to euchromatin and heterochromatin segments. A quantitative analysis of the map positions at subsequent meiotic stages revealed a striking pattern of spatial and temporal variation in chromatin condensation for euchromatin and heterochromatin. For example, the centromere region consists of three domains with distinguishable structural, molecular, and functional properties. We also characterized a conspicuous heterochromatic knob of approximately 700 kb that accommodates a tandem repeat and several dispersed pericentromere-specific repeats. Moreover, our data provide evidence for an inversion event that relocated pericentromeric sequences to an interstitial position, resulting in the heterochromatic knob.	Univ Birmingham, Sch Biol Sci, Birmingham B15 2TT, W Midlands, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Amsterdam, EC Slater Inst Biochem Res, NL-1018 TV Amsterdam, Netherlands; John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UH, Norfolk, England	University of Birmingham; Cold Spring Harbor Laboratory; University of Amsterdam; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Fransz, PF (corresponding author), Inst Plant Genet & Crop Plant Res IPK, Corrensstr 3, D-06466 Gatersleben, Germany.	fransz@ipk-gatersleben.de	Bisseling, Ton/A-2421-2013	van Drunen, Cornelis M/0000-0001-5503-066X				Ananiev EV, 1998, GENETICS, V149, P2025; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Fransz PF, 1996, PLANT J, V9, P421, DOI 10.1046/j.1365-313X.1996.09030421.x; Fuchs J, 1996, CHROMOSOMA, V104, P315, DOI 10.1007/s004120050121; Gasser SM, 1998, CELL MOL LIFE SCI, V54, P1, DOI 10.1007/s000180050120; GOLDSTEIN P, 1986, J CELL SCI, V82, P119; Hardtke CS, 1996, PLANT MOL BIOL, V32, P915, DOI 10.1007/BF00020488; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; Heslop-Harrison JS, 1999, PLANT CELL, V11, P31, DOI 10.1105/tpc.11.1.31; HESLOPHARRISON JS, 1990, HEREDITY, V65, P385, DOI 10.1038/hdy.1990.108; Jackson SA, 1998, GENOME, V41, P566, DOI 10.1139/gen-41-4-566; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kubo H, 1999, PLANT CELL, V11, P1217, DOI 10.1105/tpc.11.7.1217; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LIMADEFARIA A, 1983, MOL EVOLUTION ORG CH; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; McClintock B, 1929, SCIENCE, V69, P629, DOI 10.1126/science.69.1798.629; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; NEUFFER MG, 1997, MUTANTS MAIZE, P32; Pelissier T, 1995, PLANT MOL BIOL, V29, P441, DOI 10.1007/BF00020976; Pelissier T, 1996, GENETICA, V97, P141, DOI 10.1007/BF00054621; Ross KJ, 1996, CHROMOSOME RES, V4, P507, DOI 10.1007/BF02261778; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Thompson HL, 1996, NUCLEIC ACIDS RES, V24, P3017, DOI 10.1093/nar/24.15.3017; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4	46	250	276	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					367	376		10.1016/S0092-8674(00)80672-8	http://dx.doi.org/10.1016/S0092-8674(00)80672-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676818	Bronze			2022-12-24	WOS:000085204400010
J	Smith, MA; Brandt, J; Shadmehr, R				Smith, MA; Brandt, J; Shadmehr, R			Motor disorder in Huntington's disease begins as a dysfunction in error feedback control	NATURE			English	Article							SOMATOSENSORY EVOKED-POTENTIALS; STRIATAL GLUCOSE CONSUMPTION; BASAL GANGLIA VOLUME; GENE; CARRIERS; MEMORY; DYNAMICS; MODEL; RISK	A steady progression of motor dysfunction takes place in Huntington's disease(1) (HD), The origin of this disturbance with relation to the motor control process is not understood. Here we studied reaching movements in asymptomatic HD gene-carriers (AGCs) and subjects with manifest HD. We found that movement jerkiness, which characterizes the smoothness and efficiency of motion, was a sensitive indicator of presymptomatic HD progression. A large fraction of AGCs displayed elevated jerk even when more than seven years remained until predicted disease onset. Movement termination was disturbed much more than initiation and was highly variable from trial to trial. Analysis of this variability revealed that the sensitivity of end-movement jerk to subtle, self-generated early-movement errors was greater in HD subjects than in controls. Additionally, we found that HD corrective responses to externally-generated force pulses were greatly disturbed, indicating that HD subjects display aberrant responses to both external and self-generated errors. Because feedback corrections are driven by error and are delayed such that they predominantly affect movement termination, these findings suggest that a dysfunction in error correction characterizes the motor control deficit in early HD. This dysfunction may be observed years before clinical disease onset and grows worse as the disease progresses.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Smith, MA (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.			Brandt, Jason/0000-0001-7381-6244; smith, maurice/0000-0003-4214-1277	NIGMS NIH HHS [T32 GM007057] Funding Source: Medline; NINDS NIH HHS [R01 NS037422, R01 NS037422-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKESON CG, 1985, J NEUROSCI, V5, P2318; Aylward EH, 1997, NEUROLOGY, V48, P394, DOI 10.1212/WNL.48.2.394; Aylward EH, 1996, ARCH NEUROL-CHICAGO, V53, P1293, DOI 10.1001/archneur.1996.00550120105023; Bhushan N, 1999, BIOL CYBERN, V81, P39, DOI 10.1007/s004220050543; BLACKMORE L, 1995, J MED GENET, V32, P358, DOI 10.1136/jmg.32.5.358; BRANDT J, 1984, J CLIN NEUROPSYCHOL, V6, P401, DOI 10.1080/01688638408401231; CORDO PJ, 1990, J NEUROPHYSIOL, V63, P161, DOI 10.1152/jn.1990.63.1.161; deBoo GM, 1997, ARCH NEUROL-CHICAGO, V54, P1353, DOI 10.1001/archneur.1997.00550230030012; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; FOLSTEIN SE, 1989, HUNTIGNTONS DIS DISO; FOROUD T, 1995, ANN NEUROL, V37, P657, DOI 10.1002/ana.410370516; Gabrieli JDE, 1997, NEUROPSYCHOLOGY, V11, P272, DOI 10.1037/0894-4105.11.2.272; Hogan N., 1990, MULTIPLE MUSCLE SYST, P149, DOI [10.1007/978-1-4613-9030-5_9, DOI 10.1007/978-1-4613-9030-5_9]; KUWERT T, 1993, MOVEMENT DISORD, V8, P98, DOI 10.1002/mds.870080118; KUWERT T, 1993, J NEUROL, V241, P31, DOI 10.1007/BF00870669; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAZZIOTTA JC, 1987, NEW ENGL J MED, V316, P357, DOI 10.1056/NEJM198702123160701; MEYER BU, 1992, ELECTROEN CLIN NEURO, V85, P197, DOI 10.1016/0168-5597(92)90133-V; MIALL RC, 1986, BEHAV BRAIN RES, V20, P185, DOI 10.1016/0166-4328(86)90003-3; Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4; NOTH J, 1985, BRAIN, V108, P65, DOI 10.1093/brain/108.1.65; ROTHLIND JC, 1993, ARCH NEUROL-CHICAGO, V50, P799, DOI 10.1001/archneur.1993.00540080010005; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, J NEUROSCI, V17, P409, DOI 10.1523/JNEUROSCI.17-01-00409.1997; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; Siemers E, 1996, ARCH NEUROL-CHICAGO, V53, P487, DOI 10.1001/archneur.1996.00550060029011; TOPPER R, 1993, BRAIN, V116, P87, DOI 10.1093/brain/116.1.87; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	29	262	262	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					544	549		10.1038/35000576	http://dx.doi.org/10.1038/35000576			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676962	Green Published, Green Accepted			2022-12-24	WOS:000085227300050
J	Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC				Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC			Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Conference of the Society-for-Medical-Decision-Making	OCT 24-28, 1998	BOSTON, MASSACHUSETTS	Soc Med Decis Making			CORONARY HEART-DISEASE; 20-YEAR FOLLOW-UP; OVARIAN-CANCER; DECISION-ANALYSIS; PROPHYLACTIC MASTECTOMY; COST-EFFECTIVENESS; RISK FACTOR; MORTALITY; SURVIVAL; CARCINOMA	Context Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy. It is not proven to what extent these strategies reduce risk of second cancers in such patients. Objective To examine the effect of tamoxifen therapy, bilateral prophylactic oophorectomy (PO), prophylactic contralateral mastectomy (PCM), and combinations of these strategies on life expectancy for women with unilateral breast cancer and a BRCA1 or BRCA2 gene mutation. Design and Setting Decision analysis using a Markov model. Probabilities for developing contralateral breast cancer and ovarian cancer, dying from these cancers, dying from primary breast cancer, and the reduction in cancer incidence and mortality due to prophylactic surgeries and/or tamoxifen were estimated from published studies. Participants Hypothetical breast cancer patients with BRCA1 or BRCA2 mutations facing decisions about secondary cancer prevention strategies. Interventions Seven strategies, including 5 years of tamoxifen use, PO, PCM, and combinations of these strategies, compared with careful surveillance. Main Outcome Measures Total and incremental life expectancy (LE) with each intervention strategy. Results Depending on the assumed penetrance of the BRCA mutation, compared with surveillance alone, 30-year-old early-stage breast cancer patients with BRCA mutations gain in LE 0.4 to 1.3 years from tamoxifen therapy, 0.2 to 1.8 years from PO, and 0.6 to 2.1 years from PCM, The magnitude of these gains is least for women with low-penetrance mutations (assumed contralateral breast cancer risk of 24% and ovarian cancer risk of 6%) and greatest for those with high-penetrance mutations (assumed contralateral breast cancer risk of 65% and ovarian cancer risk of 40%.) Older age and poorer prognosis from primary breast cancer further attenuate these gains. Conclusions Interventions to prevent second cancers, particularly PCM, may offer substantial LE gain for young women with BRCA-associated early-stage breast cancer. Estimates of LE gain may help women and their physicians consider the uncertainties, risks, and advantages of these interventions and lead to more informed choices about cancer prevention strategies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave, New York, NY 10021 USA.		Kleibl, Zdenek/A-2009-2008	Kleibl, Zdenek/0000-0003-2050-9667				Abe O, 1998, LANCET, V352, P930; Bandera CA, 1998, OBSTET GYNECOL, V92, P596, DOI 10.1016/S0029-7844(98)00223-3; BARTLETT K, 1993, LANCET, V341, P1293; BROET P, 1995, J CLIN ONCOL, V13, P1578, DOI 10.1200/JCO.1995.13.7.1578; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Clarke M, 1996, LANCET, V348, P1189; Clarke M, 1998, LANCET, V351, P1451; Colditz G A, 1997, Oncology (Williston Park), V11, P1491; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Cooper GS, 1998, ANN EPIDEMIOL, V8, P229, DOI 10.1016/S1047-2797(97)00207-X; DePriest PD, 1997, GYNECOL ONCOL, V65, P408, DOI 10.1006/gyno.1997.4705; DISAIA PJ, 1995, CANCER, V76, P2075, DOI 10.1002/1097-0142(19951115)76:10+<2075::AID-CNCR2820761328>3.0.CO;2-2; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Grann VR, 1998, J CLIN ONCOL, V16, P979, DOI 10.1200/JCO.1998.16.3.979; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; HEALEY EA, 1993, J CLIN ONCOL, V11, P1545, DOI 10.1200/JCO.1993.11.8.1545; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Khovidhunkit W, 1999, ANN INTERN MED, V130, P431, DOI 10.7326/0003-4819-130-5-199903020-00015; Lakhani SR, 1997, LANCET, V349, P1505; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; Lee JS, 1999, JNCI-J NATL CANCER I, V91, P259, DOI 10.1093/jnci/91.3.259; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; RIES LAG, 1993, CANCER-AM CANCER SOC, V71, P524; Rivkin SE, 1996, J CLIN ONCOL, V14, P46, DOI 10.1200/JCO.1996.14.1.46; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; ROSEN PP, 1989, SURGERY, V106, P904; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schairer C, 1997, INT J CANCER, V70, P150, DOI 10.1002/(SICI)1097-0215(19970117)70:2<150::AID-IJC2>3.0.CO;2-W; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Struewing J P, 1995, J Natl Cancer Inst Monogr, P33; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tengs TO, 1998, MED DECIS MAKING, V18, P365, DOI 10.1177/0272989X9801800402; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; *US SURV EP END RE, 1996, SEER PUBL US DAT 197; vanderSchouw YT, 1996, LANCET, V347, P714, DOI 10.1016/S0140-6736(96)90075-6; VENTURA SJ, 1998, NATL VITAL STAT REPO, V47, P1; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	57	157	159	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					617	624		10.1001/jama.283.5.617	http://dx.doi.org/10.1001/jama.283.5.617			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665701	Bronze			2022-12-24	WOS:000084956500027
J	Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK				Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK			A pigment-binding protein essential for regulation of photosynthetic light harvesting	NATURE			English	Article							PHOTOSYSTEM-II; ENERGY-DISSIPATION; XANTHOPHYLL CYCLE; CHLOROPHYLL FLUORESCENCE; VIOLAXANTHIN DEEPOXIDATION; CHLORINA MUTANTS; ANTENNA PROTEINS; HIGHER-PLANTS; GREEN PLANTS; S PROTEIN	Photosynthetic light harvesting in plants is regulated in response to changes in incident light intensity. Absorption of light that exceeds a plant's capacity for fixation of CO2 results in thermal dissipation of excitation energy in the pigment antenna of photosystem II by a poorly understood mechanism. This regulatory process, termed nonphotochemical quenching, maintains the balance between dissipation and utilization of light energy to minimize generation of oxidizing molecules, thereby protecting the plant against photo-oxidative damage. To identify specific proteins that are involved in nonphotochemical quenching, we have isolated mutants of Arabidopsis thaliana that cannot dissipate excess absorbed light energy. Here we show that the gene encoding PsbS, an intrinsic chlorophyll-binding protein of photosystem II, is necessary for nonphotochemical quenching but not for efficient light harvesting and photosynthesis, These results indicate that PsbS may be the site for nonphotochemical quenching, a finding that has implications for the functional evolution of pigment-binding proteins.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden	University of California System; University of California Berkeley; Carnegie Institution for Science; Umea University	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891; Rosenquist, Magnus/0000-0001-7795-9728				BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BELL WR, 1994, SEMIN HEMATOL, V31, P19; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAU H, 1994, J PHOTOCH PHOTOBIO B, V26, P3, DOI 10.1016/1011-1344(94)85032-1; Demmig-Adams B, 1998, PLANT CELL PHYSIOL, V39, P474, DOI 10.1093/oxfordjournals.pcp.a029394; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; FUNK C, 1995, J BIOL CHEM, V270, P30141; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GHANOTAKIS DF, 1987, PHOTOSYNTH RES, V14, P191, DOI 10.1007/BF00032704; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 1992, PHOTOSYNTH RES, V34, P375, DOI 10.1007/BF00029812; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; JAHNS P, 1994, PLANTA, V192, P176, DOI 10.1007/BF01089032; Jansson S, 1997, BBA-BIOENERGETICS, V1320, P297, DOI 10.1016/S0005-2728(97)00033-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P673, DOI 10.1111/j.1365-3040.1993.tb00485.x; KIM KH, 1992, MED CHEM RES, V2, P22; KIM S, 1994, BBA-BIOENERGETICS, V1188, P339, DOI 10.1016/0005-2728(94)90054-X; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OTTANDER C, 1995, PLANTA, V197, P176, DOI 10.1007/BF00239954; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	47	1128	1186	13	312	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					391	395		10.1038/35000131	http://dx.doi.org/10.1038/35000131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667783				2022-12-24	WOS:000085121100039
J	Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR				Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR			The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCYTIAL VIRUS-INFECTION; RESPIRATORY-DISEASE; YOUNG-CHILDREN; OTITIS-MEDIA; A-VIRUS; IMPACT; VACCINE; EPIDEMIOLOGY; MORTALITY; AGE	Background: Despite high annual rates of influenza in children, influenza vaccines are given to children infrequently. We measured the disease burden of influenza in a large cohort of healthy children in the Tennessee Medicaid program who were younger than 15 years of age. Methods: We determined the rates of hospitalization for acute cardiopulmonary conditions, outpatient visits, and courses of antibiotics over a period of 19 consecutive years. Using the differences in the rates of these events when influenzavirus was circulating and the rates from November through April when there was no influenza in the community, we calculated morbidity attributable to influenza. There was a total of 2,035,143 person-years of observation. Results: During periods when influenzavirus was circulating, the average number of hospitalizations for cardiopulmonary conditions in excess of the expected number was 104 per 10,000 children per year for children younger than 6 months of age, 50 per 10,000 per year for those 6 months to less than 12 months, 19 per 10,000 per year for those 1 year to less than 3 years, 9 per 10,000 per year for those 3 years to less than 5 years, and 4 per 10,000 per year for those 5 years to less than 15 years. For every 100 children, an annual average of 6 to 15 outpatient visits and 3 to 9 courses of antibiotics were attributable to influenza. In winter, 10 to 30 percent of the excess number of courses of antibiotics occurred during periods when influenzavirus was circulating. Conclusions: Healthy children younger than one year of age are hospitalized for illness attributable to influenza at rates similar to those for adults at high risk for influenza. The rate of hospitalization decreases markedly with age. Influenza accounts for a substantial number of outpatient visits and courses of antibiotics in children of all ages. (N Engl J Med 2000; 342:225-31.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	University of Washington; University of Washington Seattle; Vanderbilt University; Vanderbilt University; Vanderbilt University	Neuzil, KM (corresponding author), Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, 1660 S Columbian Way, Seattle, WA 98108 USA.	kneuzil@u.washington.edu			PHS HHS [U50/CCU41398-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Clements ML, 1996, J INFECT DIS, V173, P44, DOI 10.1093/infdis/173.1.44; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Fisher RG, 1997, PEDIATRICS, V99, pE71, DOI 10.1542/peds.99.2.e7; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; FOY HM, 1973, AM J EPIDEMIOL, V97, P93, DOI 10.1093/oxfordjournals.aje.a121493; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; GLEZEN WP, 1982, J INFECT DIS, V146, P313, DOI 10.1093/infdis/146.3.313; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; KARRON RA, 1995, PEDIATR INFECT DIS J, V14, P10, DOI 10.1097/00006454-199501000-00002; KIM HW, 1979, AM J EPIDEMIOL, V109, P464, DOI 10.1093/oxfordjournals.aje.a112704; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; LONGINI IM, 1982, AM J EPIDEMIOL, V115, P736, DOI 10.1093/oxfordjournals.aje.a113356; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT 10, V193; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Piper J M, 1991, Paediatr Perinat Epidemiol, V5, P402, DOI 10.1111/j.1365-3016.1991.tb00726.x; PUCK JM, 1980, J INFECT DIS, V142, P844, DOI 10.1093/infdis/142.6.844; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Rothman K., 1998, MODERN EPIDEMIOLOGY; Simonsen L, 1997, EPIDEMIOLOGY, V8, P390, DOI 10.1097/00001648-199707000-00007; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; WRIGHT PF, 1980, AM J EPIDEMIOL, V112, P814, DOI 10.1093/oxfordjournals.aje.a113053; WRIGHT PF, 1977, NEW ENGL J MED, V296, P829, DOI 10.1056/NEJM197704142961501	36	830	868	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					225	231		10.1056/NEJM200001273420401	http://dx.doi.org/10.1056/NEJM200001273420401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648763				2022-12-24	WOS:000084941000001
J	Ye, XD; Al-Babili, S; Kloti, A; Zhang, J; Lucca, P; Beyer, P; Potrykus, I				Ye, XD; Al-Babili, S; Kloti, A; Zhang, J; Lucca, P; Beyer, P; Potrykus, I			Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm	SCIENCE			English	Article							VITAMIN-A-DEFICIENCY; NARCISSUS-PSEUDONARCISSUS; FUNCTIONAL EXPRESSION; PLANT TRANSFORMATION; PHYTOENE SYNTHASE; VECTORS	Rice (Oryza sativa), a major staple food, is usually milled to remove the oil-rich aleurone layer that turns rancid upon storage, especially in tropical areas. The remaining edible part of rice grains, the endosperm, Lacks several essential nutrients, such as provitamin A. Thus, predominant rice consumption promotes vitamin A deficiency, a serious public health problem in at least 26 countries, including highly populated areas of Asia, Africa, and Latin America. Recombinant DNA technology was used to improve its nutritional value in this respect. A combination of transgenes enabled biosynthesis of provitamin A in the endosperm.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Univ Freiburg, Ctr Appl Biosci, D-79104 Freiburg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Freiburg	Beyer, P (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland.			Al-Babili, Salim/0000-0003-4823-2882				Al-Babili S., 1996, PLANT PHYSIOL, V112, P1398; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; Burkhardt PK, 1997, PLANT J, V11, P1071, DOI 10.1046/j.1365-313X.1997.11051071.x; GRANT JP, 1991, STATE WORLDS CHILDRE; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HOEKEMA A, 1983, NATURE, V303, P179, DOI 10.1038/303179a0; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309; MISAWA N, 1993, PLANT J, V4, P833, DOI 10.1046/j.1365-313X.1993.04050833.x; PIRIE A, 1983, P NUTR SOC, V42, P53, DOI 10.1079/PNS19830007; Schledz M, 1996, PLANT J, V10, P781, DOI 10.1046/j.1365-313X.1996.10050781.x; SOMMER A, 1989, J NUTR, V119, P96, DOI 10.1093/jn/119.1.96; SOMMER A, 1989, ELEVATED DOSAGES VIT, P37; Uze M, 1997, PLANT SCI, V130, P87, DOI 10.1016/S0168-9452(97)00211-2; WEST KP, 1989, ANNU REV NUTR, V9, P63, DOI 10.1146/annurev.nu.09.070189.000431; WUENN J, 1996, BIOTECHNOLOGY, V14, P171; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	18	1458	1703	19	628	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					303	305		10.1126/science.287.5451.303	http://dx.doi.org/10.1126/science.287.5451.303			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634784				2022-12-24	WOS:000084769600039
J	Teeling, EC; Scally, M; Kao, DJ; Romagnoli, ML; Springer, MS; Stanhope, MJ				Teeling, EC; Scally, M; Kao, DJ; Romagnoli, ML; Springer, MS; Stanhope, MJ			Molecular evidence regarding the origin of echolocation and flight in bats	NATURE			English	Article							MAMMALS; COST	Bats (order Chiroptera) are one of the few orders of mammals that echolocate and the only group with the capacity for powered flight. The order is subdivided into Microchiroptera and Megachiroptera, with an array of characteristics defining each group(1), including complex laryngeal echolocation systems in microbats and enhanced visual acuity in megabats. The respective monophylies of the two suborders have been tacitly assumed, although microbat monophyly is uncorroborated by molecular data, Here we present a phylogenetic analysis of bat relationships using DNA sequence data from four nuclear genes and three mitochondrial genes (total of 8,230 base pairs), indicating that microbat families in the superfamily Rhinolophoidea are more closely related to megabats than they are to other microbats, This implies that echolocation systems either evolved independently in rhinolophoids and other microbats or were lost in the evolution of megabats, Our data also reject flying lemur (order Dermoptera) as the bat sister group, indicating that presumed shared derived characters for flying lemurs and bats(2) are convergent features that evolved in association with gliding and flight, respectively.	Queens Univ Belfast, Belfast BT9 7BL, Antrim, North Ireland; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	Queens University Belfast; University of California System; University of California Riverside	Springer, MS (corresponding author), Queens Univ Belfast, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	mark.springer@ucr.edu; Michael_J_Stanhope@sbphrd.com		Teeling, Emma/0000-0002-3309-1346				Altringham J.D., 1996, BATS BIOL BEHAV; Beard K. C., 1993, PRIMATES THEIR RELAT, P63, DOI DOI 10.1007/978-1-4899-2388-2; CUMMINGS MP, 1995, MOL BIOL EVOL, V12, P814; FORSMAN KA, 1988, J ZOOL, V216, P655, DOI 10.1111/j.1469-7998.1988.tb02463.x; GOULD EDWIN, 1965, PROC AMER PHIL SOC, V109, P352; Hill J., 1984, BATS NATURAL HIST; Hutcheon JM, 1998, PHILOS T R SOC B, V353, P607, DOI 10.1098/rstb.1998.0229; KALKO EKV, 1994, FOLIA ZOOL, V43, P363; KISHINO H, J MOL EVOL, V29, P170; LyonsWeiler J, 1996, MOL BIOL EVOL, V13, P749, DOI 10.1093/oxfordjournals.molbev.a025635; Miller Jr G.S., 1907, B US NAT MUS, V57, P1; NOVACEK M J, 1986, Cladistics, V2, P257, DOI 10.1111/j.1096-0031.1986.tb00463.x; NOVACEK MJ, 1980, P 5 INT BAT RES C, P317; Pumo DE, 1998, J MOL EVOL, V47, P709, DOI 10.1007/PL00006430; RAYNER JMV, 1991, NATURE, V350, P383, DOI 10.1038/350383a0; Simmons NB, 1998, B AM MUS NAT HIST, P1; Simmons NB, 1995, SYM ZOOL S, P27; SPEAKMAN JR, 1991, NATURE, V350, P421, DOI 10.1038/350421a0; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Springer MS, 1999, SYST BIOL, V48, P65, DOI 10.1080/106351599260445; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Swofford David L., 1996, P407; SWOFFORD DL, 1998, PAUP PHYLOGENEITC AN; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; TOMASI TE, 1979, J MAMMAL, V60, P751, DOI 10.2307/1380190; Woodburne M.O., 1995, GEOCHRONOLGY TIME SC, V54, P335, DOI DOI 10.2110/PEC.95.04.0335)	26	210	213	1	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					188	192		10.1038/35003188	http://dx.doi.org/10.1038/35003188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646602				2022-12-24	WOS:000084835300053
J	Bennett, MJ; Lebron, JA; Bjorkman, PJ				Bennett, MJ; Lebron, JA; Bjorkman, PJ			Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor	NATURE			English	Article							HEMOCHROMATOSIS GENE-PRODUCT; CELL-SURFACE EXPRESSION; INSULIN-RECEPTOR; LIGAND-BINDING; IRON RELEASE; HLA-H; ASSOCIATION; PROGRAM; BETA(2)-MICROGLOBULIN; REFINEMENT	HFE is related to major histocompatibility complex (MHC) class I proteins and is mutated in the iron-overload disease hereditary haemochromatosis. HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin. The 2.8 Angstrom crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer. On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain. The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains. The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Bjorkman, PJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; Barton JC, 1999, BLOOD CELL MOL DIS, V25, P146; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; Creighton T. E., 1993, PROTEINS STRUCTURES; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; ENNS CA, 1981, J BIOL CHEM, V256, P9820; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Henry J.B, 1996, CLIN DIAGNOSIS MANAG, V9th; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; Lebron JA, 1999, J MOL BIOL, V289, P1109, DOI 10.1006/jmbi.1999.2842; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; VERLAND S, 1989, J IMMUNOL, V143, P945; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Wilson IA, 1998, CURR OPIN IMMUNOL, V10, P67, DOI 10.1016/S0952-7915(98)80034-4; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	47	275	283	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					46	53		10.1038/47417	http://dx.doi.org/10.1038/47417			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638746				2022-12-24	WOS:000084687400036
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cell biology - Sorting on silicon	SCIENCE			English	Article																		Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2293	2294						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636792				2022-12-24	WOS:000084318500044
J	Keen, RW				Keen, RW			Effects of lifestyle interventions on bone health	LANCET			English	Editorial Material							OSTEOPOROTIC FRACTURES; RISK-FACTORS; WOMEN; MASS; EXERCISE; DENSITY		UCL, Bone & Mineral Ctr, London WC1E 6JJ, England	University of London; University College London	Keen, RW (corresponding author), UCL, Bone & Mineral Ctr, London WC1E 6JJ, England.							COMPSTON JE, 1992, CLIN SCI, V82, P429, DOI 10.1042/cs0820429; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Heinonen A, 1996, LANCET, V348, P1343, DOI 10.1016/S0140-6736(96)04214-6; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; Ralston SH, 1997, BMJ-BRIT MED J, V315, P469, DOI 10.1136/bmj.315.7106.469; REID IR, 1995, J CLIN ENDOCR METAB, V80, P1764, DOI 10.1210/jc.80.6.1764; Royal College of Physicians, 1999, OST CLIN GUID PREV T; Salamone LM, 1999, AM J CLIN NUTR, V70, P97; TORGERSON DJ, 1995, BRIT J RHEUMATOL, V34, P620	12	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1923	1924		10.1016/S0140-6736(99)00406-7	http://dx.doi.org/10.1016/S0140-6736(99)00406-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622292				2022-12-24	WOS:000084034700006
J	Onishi, A; Koike, S; Ida, M; Imai, H; Shichida, Y; Takenaka, O; Hanazawa, A; Konatsu, H; Mikami, A; Goto, S; Suryobroto, B; Kitahara, K; Yamamori, T				Onishi, A; Koike, S; Ida, M; Imai, H; Shichida, Y; Takenaka, O; Hanazawa, A; Konatsu, H; Mikami, A; Goto, S; Suryobroto, B; Kitahara, K; Yamamori, T			Vision - Dichromatism in macaque monkeys	NATURE			English	Article							VISUAL PIGMENT GENES; LINKED COLOR-VISION; MOLECULAR-GENETICS; OLD; EVOLUTION; ANCESTRY; PRIMATE; DEFECTS; GREEN; BLUE		Natl Inst Basic Biol, Lab Speciat Mechanisms J, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Tokyo Metropolitan Inst Neurosci, Dept Microbiol & Immunol, Tokyo 1838526, Japan; Primate Res Inst, Dept Cellular & Mol Biol, Aichi 4848506, Japan; Primate Res Inst, Dept Behav & Brain Sci, Aichi 4848506, Japan; Primate Res Inst, Ctr Appl Primatol & Human Evolutionary Modelling, Aichi 4848506, Japan; Natl Inst Physiol Sci, Neural Control Lab, Okazaki, Aichi 4448585, Japan; Bogor Agr Univ, Dept Biol, Bogor 16143, Indonesia; Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, Tokyo 1050003, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Bogor Agricultural University; Jikei University	Onishi, A (corresponding author), Natl Inst Basic Biol, Lab Speciat Mechanisms J, 38 Myodaijicho, Okazaki, Aichi 4448585, Japan.		Yamamori, Tetsuo/N-6536-2015	Yamamori, Tetsuo/0000-0001-5016-0078; Suryobroto, Bambang/0000-0002-9393-4085; Imai, Hiroo/0000-0003-0729-0322				BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071; DEEB SS, 1992, AM J HUM GENET, V51, P687; DRUMMONDBORG M, 1989, P NATL ACAD SCI USA, V86, P983, DOI 10.1073/pnas.86.3.983; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; Fletcher R., 1985, DEFECTIVE COLOUR VIS; Jacobs GH, 1997, VISUAL NEUROSCI, V14, P921, DOI 10.1017/S0952523800011639; JACOBS GH, 1989, AM J PRIMATOL, V18, P35, DOI 10.1002/ajp.1350180104; JORGENSEN AL, 1990, P NATL ACAD SCI USA, V87, P6512, DOI 10.1073/pnas.87.17.6512; Kojima D, 1996, BIOCHEMISTRY-US, V35, P2625, DOI 10.1021/bi9511548; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Neitz J, 1996, SCIENCE, V274, P801, DOI 10.1126/science.274.5288.801; TOVEE MJ, 1994, TRENDS NEUROSCI, V17, P30, DOI 10.1016/0166-2236(94)90032-9; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827	14	55	56	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					139	140		10.1038/45966	http://dx.doi.org/10.1038/45966			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647004				2022-12-24	WOS:000083716400037
J	Schauser, L; Roussis, A; Stiller, J; Stougaard, J				Schauser, L; Roussis, A; Stiller, J; Stougaard, J			A plant regulator controlling development of symbiotic root nodules	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; LOTUS-JAPONICUS; LEUCINE ZIPPER; RHIZOBIUM-LOTI; DNA; IDENTIFICATION; CHLAMYDOMONAS; GENES; TRANSCRIPTION; NODULATION	Symbiotic nitrogen-fixing root nodules on legumes are founded by root cortical cells that de-differentiate and restart cell division to establish nodule primordia. Bacterial microsymbionts invade these primordia through infection threads laid down by the plant and, after endocytosis, membrane-enclosed bacteroids occupy cells in the nitrogen-fixing tissue of functional nodules, The bacteria excrete lipochitin oligosaccharides(1,2), triggering a developmental process that is controlled by the plant and can be suppressed, Nodule inception initially relies on cell competence in a narrow infection zone located just behind the growing root tip. Older nodules then regulate the number of nodules on a root system by suppressing the development of nodule primordia(3), To identify the regulatory components that act early in nodule induction, ive characterized a transposon-tagged Lotus japonicus mutant, nin (for nodule inception), arrested at the stage of bacterial recognition. We show that rlin is required for the formation of infection threads and the initiation of primordia, NlN protein has regional similarity to transcription factors, and the predicted DNA-binding/dimerization domain identifies and typifies a consensus motif conserved in plant proteins with a function in nitrogen-controlled development.	Aarhus Univ, Dept Mol & Struct Biol, Lab Gene Express, DK-8000 Aarhus C, Denmark	Aarhus University	Stougaard, J (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Lab Gene Express, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Stiller, Jiri/E-1564-2012; Roussis, Andreas/AAZ-2468-2021	Stougaard, Jens/0000-0002-9312-2685; Roussis, Andreas/0000-0003-2346-7132				Beck CF, 1996, INT REV CYTOL, V168, P259, DOI 10.1016/S0074-7696(08)60886-4; BOIVIN C, 1990, PLANT CELL, V2, P1157, DOI 10.1105/tpc.2.12.1157; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; EARP DJ, 1990, NUCLEIC ACIDS RES, V18, P3271, DOI 10.1093/nar/18.11.3271; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Ferris PJ, 1997, GENETICS, V146, P859; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHMBECK J, 1986, PLANT MOL BIOL, V7, P3, DOI 10.1007/BF00020126; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Papadopoulou K, 1996, PLANT MOL BIOL, V30, P403, DOI 10.1007/BF00049320; PLANO GV, 1991, J BACTERIOL, V173, P3389, DOI 10.1128/jb.173.11.3389-3396.1991; PUYET A, 1993, J BIOL CHEM, V268, P25402; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1996, PLANT CELL, V8, P1885; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; THYKJAER T, 1995, PLANT MOL BIOL, V27, P981, DOI 10.1007/BF00037025; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	25	601	643	5	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					191	195		10.1038/46058	http://dx.doi.org/10.1038/46058			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647012				2022-12-24	WOS:000083716400053
J	Yan, H; Papadopoulos, N; Marra, G; Perrera, C; Jiricny, J; Boland, CR; Lynch, HT; Chadwick, RB; de la Chapelle, A; Berg, K; Eshleman, JR; Yuan, WS; Markowitz, S; Laken, SJ; Lengauer, C; Kinzler, KW; Vogelstein, B				Yan, H; Papadopoulos, N; Marra, G; Perrera, C; Jiricny, J; Boland, CR; Lynch, HT; Chadwick, RB; de la Chapelle, A; Berg, K; Eshleman, JR; Yuan, WS; Markowitz, S; Laken, SJ; Lengauer, C; Kinzler, KW; Vogelstein, B			Conversion of diploidy to haploidy - Individuals susceptible to multigene disorders may now be spotted more easily.	NATURE			English	Article							MONOALLELIC MUTATION ANALYSIS; HYBRIDS; GENES; MICE		Johns Hopkins Univ, Howard Hughes Med Inst, Ctr Oncol, Dept Math Sci, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Univ Calif San Diego, La Jolla, CA 92093 USA; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE 68178 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Columbia University; University of California System; University of California San Diego; Creighton University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Yan, H (corresponding author), Johns Hopkins Univ, Howard Hughes Med Inst, Ctr Oncol, Dept Math Sci, Baltimore, MD 21231 USA.		Papadopoulos, Nickolas/K-7272-2012					ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARRIS H, 1985, J CELL SCI, V79, P83; IMREH S, 1994, GENE CHROMOSOME CANC, V11, P237, DOI 10.1002/gcc.2870110406; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Lynch HT, 1999, J MED GENET, V36, P801; McDaniel LD, 1997, HUM MUTAT, V10, P317, DOI 10.1002/(SICI)1098-1004(1997)10:4<317::AID-HUMU8>3.3.CO;2-J; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; PATERSON D, 1982, ANN NY ACAD SCI, V396, P69; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SCHULTZ RA, 1987, P NATL ACAD SCI USA, V84, P4176, DOI 10.1073/pnas.84.12.4176; Warthin AS, 1913, ARCH INTERN MED, V12, P546; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Yuan ZQ, 1999, J MED GENET, V36, P790	15	209	222	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					723	724		10.1038/35001659	http://dx.doi.org/10.1038/35001659			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693791				2022-12-24	WOS:000085423100038
J	Bilder, D; Perrimon, N				Bilder, D; Perrimon, N			Localization of apical epithelial determinants by the basolateral PDZ protein Scribble	NATURE			English	Article							LEUCINE-RICH REPEATS; TIGHT JUNCTIONS; PLASMA-MEMBRANE; DROSOPHILA; CRUMBS; DOMAINS; CELLS; EXPRESSION; ENCODES; FAMILY	The generation of membrane domains with distinct protein constituents is a hallmark of cell polarization. In epithelia, segregation of membrane proteins into epical and basolateral compartments is critical for cell morphology, tissue physiology and cell signalling. Drosophila proteins that confer apical membrane identity have been found(1,2), but the mechanisms that restrict these determinants to the apical cell surface are unknown. Here we show that a laterally localized protein is required for the apical confinement of polarity determinants. Mutations in Drosophila scribble (scrib), which encodes a multi-PDZ (PSD-95, Discs-large and ZO-1) and leucine-rich-repeat protein, cause aberrant cell shapes and loss of the monolayer organization of embryonic epithelia. Scrib is localized to the epithelial septate junction, the analogue of the vertebrate tight junction(3), at the boundary of the apical and basolateral cell surfaces. Loss of scrib function results in the misdistribution of apical proteins and adherens junctions to the basolateral cell surface, but basolateral protein localization remains intact. These phenotypes can be accounted for by mislocalization of the apical determinant Crumbs. Ow results show that the lateral domain of epithelia, particularly the septate junction, functions in restricting apical membrane identity and correctly placing adherens junctions.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Bilder, D (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X; Bilder, David/0000-0002-1842-4966				Apperson ML, 1996, J NEUROSCI, V16, P6839; Balda MS, 1998, J CELL SCI, V111, P541; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 1998, DEVELOPMENT, V125, P1781; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; CAMPOSORGEGA JA, 1997, EMBRYONIC DEV DROSOP; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Grawe F, 1996, DEVELOPMENT, V122, P951; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Salzberg A, 1997, GENETICS, V147, P1723; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spradling AC, 1999, GENETICS, V153, P135; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	29	548	557	2	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					676	680		10.1038/35001108	http://dx.doi.org/10.1038/35001108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688207				2022-12-24	WOS:000085288200059
J	Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ				Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ			End-of-life care content in 50 textbooks from multiple specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Conference on Improving End-of-Life Care - A Conference of Nursing and Medical Textbook Publishers	MAR 12, 1999	OPEN SOC INST, NEW YORK, NY	Robert Wood Johnson Fdn, Last Acts Program	OPEN SOC INST		MEDICAL-EDUCATION; PALLIATIVE CARE; DYING PATIENTS; CHALLENGE; MODEL	Context Prior reviews of small numbers of medical textbooks suggest that end-of-life care is not well covered in textbooks. No broad study of end-of-life care content analysis has been performed on textbooks across a wide range of medical, pediatric, psychiatric, and surgical specialties. Objective To determine the quantity and rate the adequacy of information on end-of-life care in textbooks from multiple medical disciplines. Design and Sources A 1998 review of 50 top-selling textbooks from multiple specialties (cardiology, emergency medicine, family and primary care medicine, geriatrics, infectious disease and acquired immunodeficiency syndrome [AIDS], internal medicine, neurology, oncology and hematology, pediatrics, psychiatry, pulmonary medicine, and surgery) for the presence and adequacy of content in 13 end-of-life care domains. Main Outcome Measures Chapters on diseases commonly causing death and those devoted to end-of-life care were identified, read, rated, and compared by textbook specialty, chapter, and domain for the presence of helpful information in the 13 domains. Content for each domain was rated as absent, minimally present, or helpful. Textbook indexes were analyzed for the number of pages relevant to end-of-life care. Results Overall, helpful information was provided in 24.1% (range, 8.7%-44.2%) of the expected end-of-life content domains; in 19.1% (range, 6.2%-38.5%), expected content received minimal attention; and in 56.9% (range, 23.1%-77.9%), expected content was absent. As a group, the textbooks with the highest percentages of absent content were in surgery (71.8%), infectious diseases and AIDS (70%), and oncology and hematology (61.9%). Textbooks with the highest percentage of helpful end-of-life care content were in family medicine (34.4%), geriatrics (34.4%), and psychiatry (29.6%), In internal medicine textbooks, the content domains with the greatest amount of helpful information were epidemiology and natural history. Content domains covered least well were social, spiritual, ethical, and family issues, as well as physician after-death responsibilities. On average, textbook indexes cited 2% of their total pages as pertinent to end-of-life care. Conclusion Top-selling textbooks generally offered little helpful information on caring for patients at the end of life. Most disease-oriented chapters had no or minimal end-of-life care content. Specialty textbooks with information about particular diseases often did not contain helpful information on caring for patients dying from those diseases.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rabow, MW (corresponding author), Univ Calif San Francisco, Mt Zion, 1701 Divisadero St,5th Floor, San Francisco, CA 94115 USA.	mrabow@medicine.ucsf.edu						American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLANCHARD CG, 1981, CANCER, V47, P2756, DOI 10.1002/1097-0142(19810601)47:11<2756::AID-CNCR2820471135>3.0.CO;2-G; Block S D, 1998, J Palliat Med, V1, P347, DOI 10.1089/jpm.1998.1.347; Carron A T, 1999, Ann Intern Med, V130, P82; *CDCP, 1998, 10 LEAD CAUS DEATH U; Emanuel EJ, 1997, LANCET, V349, P1714, DOI 10.1016/S0140-6736(05)62952-2; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Ferrell B R, 1999, J Palliat Med, V2, P161, DOI 10.1089/jpm.1999.2.161; GIBSON R, 1998, J PALLIAT MED, V1, P415; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; Hill Wendy C., 1998, Pediatric Research, V43, p111A; HOLLEMAN WL, 1994, TEACH LEARN MED, V6, P260; *I MED COMM CAR EN, 1997, APPR DEATH IMPR CAR; Kaye J M, 1991, J Cancer Educ, V6, P21; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; *LOG BROTH CO INC, 1997, ORD FORM MOST POP TI; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MACDONALD N, 1991, CANADIAN PALLIATIVE; MCWHINNEY IR, 1994, CAN FAM PHYSICIAN, V40, P240; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Quill TE, 1998, ANN INTERN MED, V129, P590, DOI 10.7326/0003-4819-129-7-199810010-00026; Rabow M W, 1999, J Palliat Med, V2, P153, DOI 10.1089/jpm.1999.2.153; RAPPAPORT W, 1993, SURGERY, V113, P163; *RW JOHNS FDN LAST, 1999, C NURS MED TXB PUBL; SCHEIDERMAMN LJ, 1997, J FAM PRACTICE, V45, P259; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinmetz D, 1993, Arch Fam Med, V2, P753, DOI 10.1001/archfami.2.7.753; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; von Gunten C F, 1995, Am J Hosp Palliat Care, V12, P38, DOI 10.1177/104990919501200413; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Woods NF., 1988, NURSING RES THEORY P	34	125	126	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					771	778		10.1001/jama.283.6.771	http://dx.doi.org/10.1001/jama.283.6.771			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	280XL	10683056				2022-12-24	WOS:000085129000029
J	Kwan, P; Brodie, MJ				Kwan, P; Brodie, MJ			Early identification of refractory epilepsy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACTABLE EPILEPSY; ANTIEPILEPTIC DRUGS; UNTREATED EPILEPSY; SEIZURES; REMISSION; PROGNOSIS; PREDICTORS; CHILDHOOD; COMMUNITY; SURGERY	Background: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures. Methods: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year. Results: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent). Conclusions: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy. (N Engl J Med 2000;342:314-9.) (C) 2000, Massachusetts Medical Society.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.	martin.j.brodie@clinmed.gla.ac.uk		Kwan, Patrick/0000-0001-7310-276X				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BEGHI E, 1992, EPILEPSIA, V33, P45; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Brodie MJ, 1999, EPILEPSIA, V40, pS17, DOI 10.1111/j.1528-1157.1999.tb00928.x; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 1999, EPILEPSY RES, V34, P199, DOI 10.1016/S0920-1211(98)00110-7; Brodie MJ, 1996, LANCET, V347, P777, DOI 10.1016/S0140-6736(96)90863-6; Brodie MJ, 1997, EPILEPSY RES, V26, P423, DOI 10.1016/S0920-1211(96)01007-8; Brodie MJ, 1996, NEW ENGL J MED, V334, P479; BRODIE MJ, 1995, LANCET, V345, P662; Camfield C, 1996, NEUROLOGY, V46, P41, DOI 10.1212/WNL.46.1.41; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Cockerell OC, 1996, J NEUROL NEUROSUR PS, V60, P247; Devinsky O, 1999, NEW ENGL J MED, V340, P1565, DOI 10.1056/NEJM199905203402008; DREIFUSS FE, 1998, EPILEPSY COMPREHENSI, V1, P517; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; *ILEA COMM, 1997, EPILEPSIA, V38, P614; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; MCKEE PJW, 1993, THER DRUG MONIT, V15, P83, DOI 10.1097/00007691-199304000-00003; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; Perucca E, 1998, CNS DRUGS, V10, P171, DOI 10.2165/00023210-199810030-00002; REYNOLDS EH, 1995, BRIT MED J, V310, P176, DOI 10.1136/bmj.310.6973.176; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SCHMIDT D, 1995, CNS DRUGS, V3, P194, DOI 10.2165/00023210-199503030-00005; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; Shorvon SD, 1996, EPILEPSIA, V37, pS1, DOI 10.1111/j.1528-1157.1996.tb06027.x; SILLANPAA M, 1993, EPILEPSIA, V34, P930, DOI 10.1111/j.1528-1157.1993.tb02114.x; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Tobias E S, 1994, Seizure, V3, P37, DOI 10.1016/S1059-1311(05)80161-X; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x; Wieser HG, 1998, SEIZURE-EUR J EPILEP, V7, P173, DOI 10.1016/S1059-1311(98)80032-0; WOLF P, 1998, EPILEPSY COMPREHENSI, V1, P773	42	3291	3419	9	229	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					314	319		10.1056/NEJM200002033420503	http://dx.doi.org/10.1056/NEJM200002033420503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10660394				2022-12-24	WOS:000085070300003
J	Scanlon, JD; Lee, MSY				Scanlon, JD; Lee, MSY			The Pleistocene serpent Wonambi and the early evolution of snakes	NATURE			English	Article							ANATOMY	The Madtsoiidae were medium sized to gigantic snakes with a fossil record extending from the mid-Cretaceous to the Pleistocene, and spanning Europe, Africa, Madagascar, South America and Australia(1-3), This widely distributed group survived for about 90 million years (70% of known ophidian history), and potentially provides important insights into the origin and early evolution of snakes. However, madtsoiids are known mostly from their vertebrae, and their skull morphology and phylogenetic affinities have been enigmatic. Here we report new Australian material of Wonambi, one of the last-surviving madtsoiids(4-6), that allows the first detailed assessment of madtsoiid cranial anatomy and relationships, Despite its recent age, which could have overlapped with human history in Australia, Wonambi is one of the most primitive snakes known-as basal as the Cretaceous forms Pachyrhachis(7) and Dinilysia(8). None of these three primitive snake lineages shows features associated with burrowing, nor do any of the nearest lizard relatives of snakes (varanoids), These phylogenetic conclusions contradict the widely held 'subterranean' theory of snake origins(9-12), and instead imply that burrowing snakes (scolecophidians and anilioids) acquired their fossorial adaptations after the evolution of the snake body form and jaw apparatus in a large aquatic or (surface-active) terrestrial ancestor.	Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia; Univ New S Wales, Dept Biol Sci, Sydney, NSW 2052, Australia	University of Queensland; University of New South Wales Sydney	Scanlon, JD (corresponding author), Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia.	jscanlon@ultra.net.au						ARCHER M, 1997, C BIOCH 97, P131; BARRIE DJ, 1990, MEMOIRS QUEENSLAND M, V28, P139; BELLAIRS AD, 1951, BIOL REV, V26, P193, DOI 10.1111/j.1469-185X.1951.tb00646.x; CoPE E. D., 1869, P BOSTON SOC NATURAL, V12, P250; CUNDALL D, 1993, ZOOL J LINN SOC-LOND, V109, P275, DOI 10.1006/zjls.1993.1039; CUNDALL D, 1995, J ZOOL, V237, P353, DOI 10.1111/j.1469-7998.1995.tb02767.x; ESTES R, 1970, Bulletin of the Museum of Comparative Zoology, V140, P25; FRAZZETTA T H, 1970, Forma et Functio, V3, P205; Hecht MK., 1982, NEUES JB GEOLOGIE PA, P523; HEISE PJ, 1995, MOL BIOL EVOL, V12, P259; IANENSCH W, 1906, BEITR PALAEONT GEOL, V19, P1; Kluge A.G., 1991, MISCELLANEOUS PUBLIC, V178, P1; LaDuke T.C., 1991, CONTRIBUTIONS SCI NA, V424, P1, DOI [10.5962/p.226807, DOI 10.5962/P.226807]; Lee MSY, 1998, BIOL J LINN SOC, V65, P369, DOI 10.1111/j.1095-8312.1998.tb01148.x; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; McDowell SB, 1987, SNAKES ECOLOGY EVOLU, P1; NOPESA F, 1923, PALAEONTOGRAPHICA, V65, P99; Rage Jean-Claude, 1998, Palaeovertebrata (Montpellier), V27, P109; RAGE JG, 1984, HDB PALAEHERPETOL 11; RIEPPEL O, 1988, EVOL BIOL, V22, P37; Scanlon John D., 1997, Memoirs of the Queensland Museum, V41, P393; Scanlon John D., 1995, Proceedings of the Linnean Society of New South Wales, V115, P233; SMITH M J, 1976, Transactions of the Royal Society of South Australia, V100, P39; SWOFFORD DL, 1999, PAUP VERSION 4 PHYLO; Underwood G., 1976, Linnean Soc Symp Ser, V3, P151; Underwood G., 1967, CONTRIBUTION CLASSIF; Wallach V, 1998, AMPHIBIA-REPTILIA, V19, P385, DOI 10.1163/156853898X00052; WALLS G.L., 1940, COPEIA, V1940, P1; Woodward AS, 1901, P ZOOL SOC LOND, V1, P169; Zaher H, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011029	30	100	102	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					416	420		10.1038/35000188	http://dx.doi.org/10.1038/35000188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667791				2022-12-24	WOS:000085121100047
J	Silverberg, R				Silverberg, R			Pluto story - The discovery of extraterrestrial life was the key event of the third millennium.	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					367	367		10.1038/35000306	http://dx.doi.org/10.1038/35000306			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667769	Bronze			2022-12-24	WOS:000085121100024
J	Murphy, AM; Kogler, H; Georgakopoulos, D; McDonough, JL; Kass, DA; Van Eyk, JE; Marban, E				Murphy, AM; Kogler, H; Georgakopoulos, D; McDonough, JL; Kass, DA; Van Eyk, JE; Marban, E			Transgenic mouse model of stunned myocardium	SCIENCE			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC TROPONIN-I; CELLULAR MECHANISMS; THIN FILAMENT; MUSCLE; CA2+; MUTATIONS; PROTEINS; CALCIUM; HEART	Stunned myocardium is a syndrome of reversible contractile failure that frequently complicates coronary artery disease. Cardiac excitation is uncoupled from contraction at the level of the myofilaments, Selective proteolysis of the thin filament protein troponin I has been correlated with stunned myocardium. Here, transgenic mice expressing the major degradation product of troponin I (TnI(1-193)) in the heart were found to develop ventricular dilatation, diminished contractility, and reduced myofilament calcium responsiveness, recapitulating the phenotype of stunned myocardium. Proteolysis of troponin I also occurs in ischemic human cardiac muscle. Thus, troponin I proteolysis underlies the pathogenesis of a common acquired form of heart failure.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3W6, Canada; Queens Univ, Dept Physiol, Kingston, ON K7L 3W6, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Queens University - Canada; Queens University - Canada	Murphy, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Ross Bldg 1144,720 Rutland Ave, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [HL 63038, HL 44065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044065, R56HL063038, R01HL063038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BECKER LC, 1986, J AM COLL CARDIOL, V7, P580, DOI 10.1016/S0735-1097(86)80468-5; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BOLLI R, 1985, AM J CARDIOL, V56, P964, DOI 10.1016/0002-9149(85)90413-8; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Foster DB, 1999, CIRC RES, V85, P470, DOI 10.1161/01.RES.85.5.470; Gao WD, 1996, CIRC RES, V78, P455; Gao WD, 1998, J PHYSIOL-LONDON, V507, P175, DOI 10.1111/j.1469-7793.1998.175bu.x; Gao WD, 1999, J CLIN INVEST, V103, P661, DOI 10.1172/JCI5220; GAO WD, 1995, CIRC RES, V76, P1036, DOI 10.1161/01.RES.76.6.1036; GAO WD, 1997, CIRC RES, V80, P383; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; GEORGAKOPOULOS D, 1998, AM J PHYSIOL-HEART C, V274, P1416; HUNKELER NM, 1991, CIRC RES, V69, P1409, DOI 10.1161/01.RES.69.5.1409; James J, 1999, CIRCULATION, V100, P276; James J., UNPUB; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KUSUOKA H, 1992, ANNU REV PHYSIOL, V54, P243, DOI 10.1146/annurev.ph.54.030192.001331; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; McDonald KS, 1998, J MOL CELL CARDIOL, V30, P285, DOI 10.1006/jmcc.1997.0603; McDonough JL, 1999, CIRCULATION, V100, P767; McDonough JL, 1999, CIRC RES, V84, P9; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Shen YT, 1996, AM J PHYSIOL-HEART C, V270, pH1312, DOI 10.1152/ajpheart.1996.270.4.H1312; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; Thomas SA, 1999, CIRC RES, V85, P446, DOI 10.1161/01.RES.85.5.446; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Van Eyk JE, 1998, CIRC RES, V82, P261	37	203	214	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					488	491		10.1126/science.287.5452.488	http://dx.doi.org/10.1126/science.287.5452.488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642551				2022-12-24	WOS:000084929900049
J	Orentlicher, D; Caplan, A				Orentlicher, D; Caplan, A			The Pain Relief Promotion Act of 1999 - A serious threat to palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTED SUICIDE; SUPREME-COURT	Recent educational efforts in the US medical community have begun to address the critical issue bf palliative care for terminally ill patients. However, a newly introduced bill in; Congress, the Pain Relief Promotion Act of 1999 (PRPA), could dramatically hinder these efforts if enacted. The act criminally punishes the use of controlled substances to cause-or assist in causing-a patient's death. The primary purposes of PRPA are to override the physician-assisted suicide law currently in effect in Oregon and prohibit other states from enacting similar laws, The act also includes valuable provisions for better research and education in palliative care, but the benefits of those provisions are outweighed by the punitive sections of the act. Under PRPA, the quality of palliative care in the United States could be compromised when physicians, fearing criminal prosecution, err on the side of caution rather than risk their patients' deaths by using highly aggressive pain treatments. Furthermore,PRPA would put Drug Enforcement Administration officials, who have no medical expertise, in the position of regulating medical decisions. The act also would interfere with individual states' long-standing authority over medical practice. Finally, PRPA would discourage physicians from engaging in experimentation and innovation in palliative care, again out of concern for crossing the line between relief of suffering and physician-assisted suicide. Other bills have been introduced that go much further than PRPA to encourage palliative care, without its problematic provisions. Regardless of the controversy surrounding physician-assisted suicide in the United States, the need for quality end-of-life care will be far better sewed if Congress enacts one of these bills rather than PRPA.	Indiana Univ, Sch Law, Ctr Law & Hlth, Indianapolis, IN 46202 USA; Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Pennsylvania; Pennsylvania Medicine	Orentlicher, D (corresponding author), Indiana Univ, Sch Law, Ctr Law & Hlth, 735 W New York St, Indianapolis, IN 46202 USA.							Alpers A, 1998, J LAW MED ETHICS, V26, P308, DOI 10.1111/j.1748-720X.1998.tb01678.x; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; *BNA, 1999, BNA HLTH LAW RE 0624, V8, P1027; Brody H, 1998, J Palliat Med, V1, P329, DOI 10.1089/jpm.1998.1.329; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; JORANSON DE, 1994, PSYCHIAT PRACTICE FI, P173; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Meisel A, 1999, ARCH INTERN MED, V159, P1089, DOI 10.1001/archinte.159.10.1089; Noble Holcomb B, 1999, N Y Times Web, pA13; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Quill T E, 1998, J Palliat Med, V1, P333, DOI 10.1089/jpm.1998.1.333	14	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					255	258		10.1001/jama.283.2.255	http://dx.doi.org/10.1001/jama.283.2.255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634344				2022-12-24	WOS:000084661400034
J	Bernhard, JM; Buck, KR; Farmer, MA; Bowser, SS				Bernhard, JM; Buck, KR; Farmer, MA; Bowser, SS			The Santa Barbara Basin is a symbiosis oasis	NATURE			English	Article							SEDIMENTS; SEA; HYPOTHESIS; DIVERSITY; BACTERIA; PATTERNS; PROTOZOA; WATER	It is generally agreed that the origin and initial diversification of Eucarya occurred in the late Archaean or Proterozoic Eons when atmospheric oxygen levels were low(1) and the risk of DNA damage due to ultraviolet radiation was high(2). Because deep water provides refuge against ultraviolet radiation(3) and early eukaryotes may have been aerotolerant anaerobes(1,4,5), deep-water dysoxic environments are likely settings for primeval eukaryotic diversification. Fossil evidence shows that deep-sea microbial mats, possibly of sulphur bacteria similar to Beggiatoa, existed during that time(6). Here we report on the eukaryotic community of a modern analogue, the Santa Barbara Basin (California, USA). The Beggiatoa mats of these severely dysoxic and sulphidic sediments support a surprisingly abundant protistan and metazoan meiofaunal community, most members of which harbour prokaryotic symbionts, Many of these taxa are new to science, and both microaerophilic and anaerobic taxa appear to be represented. Compared with nearby aerated sites, the Santa Barbara Basin is a 'symbiosis oasis' offering a new source of organisms for testing symbiosis hypotheses of eukaryogenesis.	Univ S Carolina, Sch Publ Hlth, Dept Environm Hlth Sci, Columbia, SC 29208 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Monterey Bay Aquarium Research Institute; University System of Georgia; University of Georgia; State University of New York (SUNY) System; Wadsworth Center	Bernhard, JM (corresponding author), Univ S Carolina, Sch Publ Hlth, Dept Environm Hlth Sci, Columbia, SC 29208 USA.		Bernhard, Joan/M-3260-2013	Bernhard, Joan/0000-0003-2121-625X				ALONGI DM, 1987, DEEP-SEA RES, V34, P1245, DOI 10.1016/0198-0149(87)90074-4; ANDERSON OR, 1992, SYMBIOSIS, V12, P237; Baldauf J. G., 1995, P OC DRILL PROGR S 2, V146; Bernard C, 1995, MAR ECOL PROG SER, V128, P171, DOI 10.3354/meps128171; Bernhard JM, 1999, EARTH-SCI REV, V46, P149, DOI 10.1016/S0012-8252(99)00017-3; Bernhard Joan M., 1996, Revue de Paleobiologie, V15, P261; BROENKOW WW, 1969, LIMNOL OCEANOGR, V14, P450, DOI 10.4319/lo.1969.14.3.0450; Buck KR, 1998, CAH BIOL MAR, V39, P333; Cockell CS, 1998, J THEOR BIOL, V193, P717, DOI 10.1006/jtbi.1998.0738; Desbruyeres D, 1998, DEEP-SEA RES PT II, V45, P383, DOI 10.1016/S0967-0645(97)00083-0; Diaz RJ, 1995, OCEANOGR MAR BIOL, V33, P245; Epstein SS, 1995, AQUAT MICROB ECOL, V9, P219, DOI 10.3354/ame009219; Esteban G, 1995, ARCH PROTISTENKD, V146, P137; FENCHEL T, 1995, OPHELIA, V43, P45, DOI 10.1080/00785326.1995.10430576; FENCHEL T, 1995, ECOLOGY EVOLUTION AN; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KNOLL AH, 1995, EFFECTS PAST GLOBAL, P21; Kuwabara JS, 1999, GEOCHIM COSMOCHIM AC, V63, P2199, DOI 10.1016/S0016-7037(99)00084-8; Lee J.J., 1991, BIOL FORAMINIFERA; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; OTT JA, 1991, PSZNI MAR ECOL, V12, P261; Reimers CE, 1996, GEOCHIM COSMOCHIM AC, V60, P4037, DOI 10.1016/S0016-7037(96)00231-1; Richardson SL, 1999, SYMBIOSIS, V26, P299; Saphonov MV, 1997, OPHELIA, V47, P215, DOI 10.1080/00785236.1997.10428672; Simonson BM, 1999, PALAIOS, V14, P13, DOI 10.2307/3515358; Simpson AGB, 1997, ARCH PROTISTENKD, V147, P213, DOI 10.1016/S0003-9365(97)80049-8; SOUTAR A, 1977, GEOL SOC AM BULL, V88, P1161, DOI 10.1130/0016-7606(1977)88<1161:SACPIT>2.0.CO;2; STARINK M, 1994, APPL ENVIRON MICROB, V60, P167, DOI 10.1128/AEM.60.1.167-173.1994; STOLZ JF, 1986, NATURE, V321, P849, DOI 10.1038/321849a0	30	182	195	1	35	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					77	80		10.1038/47476	http://dx.doi.org/10.1038/47476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638755				2022-12-24	WOS:000084687400045
J	di Bernardo, D; Murray, A				di Bernardo, D; Murray, A			Medical physics - Explaining the T-wave shape in the ECG	NATURE			English	Article							REPOLARIZATION; MODEL		Newcastle Univ, Freeman Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK	di Bernardo, D (corresponding author), Newcastle Univ, Freeman Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.		di Bernardo, Diego/AAF-5881-2021; di Bernardo, Diego/I-9440-2012	di Bernardo, Diego/0000-0002-1911-7407; di Bernardo, Diego/0000-0002-1911-7407; Murray, Alan/0000-0003-2621-4632				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; CONOVER MB, 1992, UNDERSTANDING ELECTR; COWAN JC, 1988, BRIT HEART J, V60, P424; FRANZ MR, 1987, CIRCULATION, V75, P379, DOI 10.1161/01.CIR.75.2.379; GELERNTER HL, 1964, BIOPHYS J, V4, P285, DOI 10.1016/S0006-3495(64)86783-7; HIGUCHI T, 1984, AM HEART J, V108, P290, DOI 10.1016/0002-8703(84)90614-8; MERRI M, 1989, CIRCULATION, V80, P1301, DOI 10.1161/01.CIR.80.5.1301; MURRAY A, 1994, BRIT HEART J, V71, P386; NOBLE D, 1978, CARDIOVASC RES, V12, P13, DOI 10.1093/cvr/12.1.13; SIMMS HD, 1995, J CARDIOVASC ELECTR, V6, P522, DOI 10.1111/j.1540-8167.1995.tb00425.x; WOHLFART B, 1987, EUR HEART J, V8, P409, DOI 10.1093/oxfordjournals.eurheartj.a062295; Yan GX, 1998, CIRCULATION, V98, P1928, DOI 10.1161/01.CIR.98.18.1928	12	38	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					40	40		10.1038/47409	http://dx.doi.org/10.1038/47409			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638744	Bronze			2022-12-24	WOS:000084687400034
J	Shahar, Y				Shahar, Y			Dimension of time in illness: An objective view	ANNALS OF INTERNAL MEDICINE			English	Article							TEMPORAL ABSTRACTION; FRAMEWORK	It is almost impossible to try to represent acid analyze clinical data in the absence of a temporal dimension. The temporal aspect is especially important when automated decision support is used for patient care over substantial periods. This paper emphasizes the crucial role that tasks of temporal reasoning and temporal maintenance play in modern medical information and decision support systems; it also discusses the implications of providing automated support to clinicians who must perform such tasks as part of broader clinical tasks (for example, monitoring and therapy). Temporal reasoning tasks mainly involve intelligent analysis of time-oriented clinical data, and temporal maintenance tasks focus on effective storage and retrieval of these data. Both types of tasks, however, are highly relevant for such applications as patient monitoring, proper use of therapeutic guidelines, assessment of the quality of guideline use, and visualization and exploration of time-oriented biomedical data. Scientists in medical informatics should view the integration of these two areas as a major research and development goal. This paper demonstrates one approach to integration by presenting the concept of a temporal mediator, which combines temporal reasoning and temporal maintenance. Use of the temporal mediator in several clinical tasks is also presented and discussed.	Stanford Univ, Stanford Med Informat, Stanford, CA 94305 USA	Stanford University	Shahar, Y (corresponding author), Stanford Univ, Stanford Med Informat, Med Sch Off Bldg X215,251 Campus Dr, Stanford, CA 94305 USA.	shahar@smi.stanford.edu	Shahar, Yuval/P-5185-2019	Shahar, Yuval/0000-0003-0328-2333	NLM NIH HHS [LM06245] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R29LM006245] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Cousins S. B., 1991, Artificial Intelligence in Medicine, V3, P341, DOI 10.1016/0933-3657(91)90005-V; DAS AK, 1994, METHOD INFORM MED, V33, P358; Keravnou E. T., 1990, Artificial Intelligence in Medicine, V2, P239, DOI 10.1016/0933-3657(90)90001-8; Musen MA, 1996, J AM MED INFORM ASSN, V3, P367, DOI 10.1136/jamia.1996.97084511; Nguyen JH, 1999, J INTELL INF SYST, V13, P121, DOI 10.1023/A:1008711006591; Russ T. A., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P38; Shahar Y, 1999, J AM MED INFORM ASSN, V6, P494, DOI 10.1136/jamia.1999.0060494; Shahar Y, 1996, ARTIF INTELL MED, V8, P267, DOI 10.1016/0933-3657(95)00036-4; Shahar Y, 1998, ANN MATH ARTIF INTEL, V22, P159, DOI 10.1023/A:1018998326167; Shahar Y, 1997, ARTIF INTELL, V90, P79, DOI 10.1016/S0004-3702(96)00025-2; Shahar Y, 1998, ARTIF INTELL MED, V14, P29, DOI 10.1016/S0933-3657(98)00015-3; SHAHAR Y, TOPICS HLTH INFORMAT, V20, P15; Snodgrass R., 1986, IEEE COMPUT, V19, P3542; [No title captured]; [No title captured]	15	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					45	53		10.7326/0003-4819-132-1-200001040-00008	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627251				2022-12-24	WOS:000084518600007
J	Lutter, R				Lutter, R			Policy forum: Food safety - Food irradiation - The neglected solution to food-borne illness	SCIENCE			English	Article									Amer Enterprise Inst Publ Policy Res, Brookings Joint Ctr Regulatory Studies, Washington, DC 20036 USA	American Enterprise Institute for Public Policy Research	Lutter, R (corresponding author), Amer Enterprise Inst Publ Policy Res, Brookings Joint Ctr Regulatory Studies, 1150 17th St NW, Washington, DC 20036 USA.	rlutter@aei.org						ALTEKURSE S, 1997, EMERG INFECT DIS, V3, P3; BUZBY JC, 1996, 741 USDA; CARLTON J, 1999, WALL STREET J   0715, pA1; *CONS UN, 1998, TMD94002 NAT ORG PRO; Fox JA, 1998, RADIAT PHYS CHEM, V52, P63, DOI 10.1016/S0969-806X(98)00075-9; LUTTER R, 1999, AEI BROOKINGS JOINT, V992; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; OSTERHOLM M, 1997, US TODAY        1104, pD4; *PUBL VOIC FOOD HL, 1998, ID ADDR OV CONS CON; *US CDC, 1999, MMWR-MORBID MORTAL W, V48, P189; *US GEN ACC OFF, 1996, GAORCED9696; *USDA, 1999, IRR MEAT MEAT PROD R; *WHO, 1997, WHO68; WHO, 1981, WHO TECH REP SER, V659; WILKINSON VM, 1996, FOOD IRRADIATION; 1994, FED REG, V164, P43838; 1997, FED REG, V232, P64107; 1999, FED REG, V36, P9089; 1996, MENDOCINO ENV C 0922; 1990, FED REG, V85, P18539	20	27	32	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2275	2276		10.1126/science.286.5448.2275	http://dx.doi.org/10.1126/science.286.5448.2275			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636787				2022-12-24	WOS:000084318500031
J	Shirayama, M; Toth, A; Galova, M; Nasmyth, K				Shirayama, M; Toth, A; Galova, M; Nasmyth, K			APC(Cdc20) promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; S-PHASE; COMPLEX; PROTEOLYSIS; TRANSITION; PROTEIN; KINASE; APC; UBIQUITINATION	Ubiquitin-mediated proteolysis due to the anaphase-promoting complex/cyclosome (APC/C) is essential for separation of sister chromatids, requiring degradation of the anaphase inhibitor Pds1, and for exit from mitosis, requiring inactivation of cyclin B Cdk1 kinases(1). Exit from mitosis in yeast involves accumulation of the cyclin kinase inhibitor Sic1 as well as cyclin proteolysis mediated by APC/C bound by the activating subunit Cdh1/Hct1 (ApC(Cdh1))(2,3). Both processes require the Cdc(14) phosphatase, whose release from the nucleolus during anaphase causes dephosphorylation and thereby activation of Cdh1 and accumulation of another protein, Sic1 (refs 4-7). We do not know what determines the release of Cdc14 and enables it to promote Cdk1 inactivation, but it is known to be dependent on APC/C bound by Cdc20 (ApC(Cdc20)) (ref. 4). Here we show that ApC(Cdc20) allows activation of Cdc 14 and promotes exit from mitosis by mediating proteolysis of Pds1 and the S phase cyclin Clb5 in the yeast Saccharomyces cerevisiae. Degradation of Pds1 is necessary for release of Cdc14 from the nucleolus, whereas degradation of Clb5 is crucial if Cdc14 is to overwhelm Cdk1 and activate its foes (Cdh1 and Sic1). Remarkably, cells lacking both Pds1 and Clb5 can proliferate in the complete absence of Cdc20.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Toth, Attila/C-9624-2013	Toth, Attila/0000-0001-5744-3847; Nasmyth, Kim/0000-0001-7030-4403				BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Novak B, 1999, J THEOR BIOL, V199, P223, DOI 10.1006/jtbi.1999.0956; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	288	292	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					203	207		10.1038/46080	http://dx.doi.org/10.1038/46080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647015				2022-12-24	WOS:000083716400056
J	Horvath, A; Berry, EA; Maslov, DA				Horvath, A; Berry, EA; Maslov, DA			Translation of the edited mRNA for cytochrome b in trypanosome mitochondria	SCIENCE			English	Article							CRITHIDIA-FASCICULATA; C-OXIDASE; MESSENGER-RNA; KINETOPLASTID MITOCHONDRIA; SUBUNIT-II; BRUCEI; OXIDOREDUCTASE; NUCLEOTIDES; TRANSCRIPT; MECHANISM	The type of RNA editing found in the kinetoplast-mitochondria of trypanosomes and related protozoa, involving uridylate insertions and deletions, creates translatable messenger RNAs (mRNAs) out of nonsense pre-edited RNAs by correcting encoded defects that vary from simple frameshifts to Large "cryptic" regions. However, any evidence for translation of these mRNAs in the kinetoplast has been missing for decades. We identified a kinetoplast-encoded protein, apocytochrome b, whose mRNA is edited in the 5' region. The determined amino-terminal sequence of the protein coincides with the predicted sequence derived from the edited region, demonstrating that the cognate apocytochrome b mRNA is translated into a functional protein. This finding represents the first direct evidence for a functional translation system in the kinetoplasts.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Berkeley, Div Struct Biol, Berkeley, CA 94720 USA	University of California System; University of California Riverside; University of California System; University of California Berkeley	Maslov, DA (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.		Horvath, Anton/I-3626-2014; Horvath, Anton/V-1097-2018	Horvath, Anton/0000-0003-0785-4204	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044842] Funding Source: NIH RePORTER; NIAID NIH HHS [R29AI40634] Funding Source: Medline; NIDDK NIH HHS [R01DK44842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; AVILA HA, COMMUNICATION; Beattie DS, 1996, EUR J BIOCHEM, V241, P888, DOI 10.1111/j.1432-1033.1996.00888.x; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; Breek CKD, 1997, BIOL CHEM, V378, P837, DOI 10.1515/bchm.1997.378.8.837; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; Simpson L, 1998, NUCLEIC ACIDS RES, V26, P170, DOI 10.1093/nar/26.1.170; Speijer D, 1997, MOL BIOCHEM PARASIT, V85, P171, DOI 10.1016/S0166-6851(96)02823-X; Speijer D, 1996, MOL BIOCHEM PARASIT, V79, P47, DOI 10.1016/0166-6851(96)02648-5; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613	18	58	62	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1639	1640		10.1126/science.287.5458.1639	http://dx.doi.org/10.1126/science.287.5458.1639			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698736				2022-12-24	WOS:000085628200034
J	Gavrilova, O; Marcus-Samuels, B; Leon, LR; Vinson, C; Reitman, ML				Gavrilova, O; Marcus-Samuels, B; Leon, LR; Vinson, C; Reitman, ML			Hormones - Leptin and diabetes in lipoatrophic mice	NATURE			English	Article							ADIPOSE-TISSUE; OBESITY		NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gavrilova, O (corresponding author), NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA.	mlr@helix.nih.gov	Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK047031] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; FOSTER DW, 1994, HARRISONS PRINCIPLES, P2131; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213	9	63	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					850	850		10.1038/35002663	http://dx.doi.org/10.1038/35002663			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706272				2022-12-24	WOS:000085559200042
J	Reinhart, BJ; Slack, FJ; Basson, M; Pasquinelli, AE; Bettinger, JC; Rougvie, AE; Horvitz, HR; Ruvkun, G				Reinhart, BJ; Slack, FJ; Basson, M; Pasquinelli, AE; Bettinger, JC; Rougvie, AE; Horvitz, HR; Ruvkun, G			The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; HETEROCHRONIC MUTANTS; GENE; NEMATODE; PROTEIN; LIN-14; ENCODES; SWITCH; REGION	The C. elegans heterochronic gene pathway consists of a cascade of regulatory genes that are temporally controlled to specify the timing of developmental events(1). Mutations in heterochronic genes cause temporal transformations in cell fates in which stage-specific events are omitted or reiterated(2). Here we show that let-7 is a heterochronic switch gene. Loss of let-7 gene activity causes reiteration of larval cell fates during the adult stage, whereas increased let-7 gene dosage causes precocious expression of adult fates during larval stages. let-7 encodes a temporally regulated 21-nucleotide RNA that is complementary to elements in the 3' untranslated regions of the heterochronic genes lin-14, lin-28, lin-41, lin-42 and daf-12, indicating that expression of these genes may be directly controlled by let-7. A reporter gene bearing the lin-41 3' untranslated region is temporally regulated in a let-7-dependent manner. A second regulatory RNA, lin-4, negatively regulates lin-14 and lin-28 through RNA-RNA interactions with their 3' untranslated regions(3,4). We propose that the sequential stage-specific expression of the lin-4 and let-7 regulatory RNAs triggers transitions in the complement of heterochronic regulatory proteins to coordinate developmental timing.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Minnesota System; University of Minnesota Twin Cities	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.			Slack, Frank/0000-0001-8263-0409	NIAMS NIH HHS [P30 AR046032] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046032] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrahante JE, 1998, GENETICS, V149, P1335; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; Bettinger JC, 1996, DEVELOPMENT, V122, P2517; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Feinbaum R, 1999, DEV BIOL, V210, P87, DOI 10.1006/dbio.1999.9272; Jeon M, 1999, SCIENCE, V286, P1141, DOI 10.1126/science.286.5442.1141; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIU Z, 1990, THESIS HARVARD U; MENEELY PM, 1979, GENETICS, V92, P99; Moore DD, 1995, GLOB MOB SURV; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; ROUGVIE AE, 1995, DEVELOPMENT, V121, P2491; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1983, GENETICS, V104, P619; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; YEH WY, 1991, THESIS U MISSOURI CO; ZUCKERAPRISON E, 1989, J MOL EVOL, V28, P487, DOI 10.1007/BF02602929	21	3223	3764	17	447	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					901	906		10.1038/35002607	http://dx.doi.org/10.1038/35002607			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706289				2022-12-24	WOS:000085559200060
J	Bui, JD; Calbo, S; Hayden-Martinez, K; Kane, LP; Gardner, P; Hedrick, SM				Bui, JD; Calbo, S; Hayden-Martinez, K; Kane, LP; Gardner, P; Hedrick, SM			A role for CaMKII in T cell memory	CELL			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; STAPHYLOCOCCAL ENTEROTOXIN-B; II MUTANT MICE; TRANSGENIC MICE; MOLECULAR MECHANISM; POSITIVE SELECTION; ANTIGEN RECEPTOR; EXPRESSION; CALCIUM	In order to study the role of calcium/calmodulin kinase II (CaMKII) in T cells, we generated transgenic mice expressing CaMKII gamma B* (T287D), a partially calcium-independent mutant of CaMKII gamma B. In these mice, the size of the thymus was increased 1.5- to 2-fold, at least in part due to an increase in the lifespan of double-positive (DP) thymocytes. More importantly, there was an increase in the number of T cells in the secondary lymphoid organs that had acquired an antigen-dependent memory phenotype. These T cells were bonafide memory cells as assessed by a variety of criteria. In addition, T cells from wild-type mice acquired calcium-independent CaMKII activity after several rounds of antigen-stimulated division. We propose that CaMKII controls a distinct process of activation-induced cellular differentiation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Stanford Univ, Dept Mol Pharmacol & Med, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University	Hedrick, SM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	shedrick@ucsd.edu	Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751; Kane, Lawrence/0000-0001-5198-516X	NIAID NIH HHS [R01AI21372-15] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021372] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; ERNST DN, 1993, J IMMUNOL, V151, P575; Fukunaga K, 1996, NEUROCHEM INT, V28, P343, DOI 10.1016/0197-0186(95)00097-6; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Heist EK, 1998, CELL CALCIUM, V23, P103; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; LEE WT, 1990, J IMMUNOL, V144, P3288; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MACDONALD HR, 1991, EUR J IMMUNOL, V21, P1963, DOI 10.1002/eji.1830210827; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; Opferman JT, 1999, SCIENCE, V283, P1745, DOI 10.1126/science.283.5408.1745; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Petschner F, 1998, EUR J IMMUNOL, V28, P560, DOI 10.1002/(SICI)1521-4141(199802)28:02<560::AID-IMMU560>3.0.CO;2-Q; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1993, MOL CELL BIOCHEM, V128, P93, DOI 10.1007/BF01076760; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Vasseur F, 1999, J IMMUNOL, V162, P5164; WEBB SR, 1994, J IMMUNOL, V152, P586; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	69	54	54	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 18	2000	100	4					457	467		10.1016/S0092-8674(00)80681-9	http://dx.doi.org/10.1016/S0092-8674(00)80681-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693762	Bronze			2022-12-24	WOS:000085446900008
J	Prober, DA; Edgar, BA				Prober, DA; Edgar, BA			Ras1 promotes cellular growth in the Drosophila wing	CELL			English	Article							EGF RECEPTOR GENE; SACCHAROMYCES-CEREVISIAE; TYROSINE KINASE; CYCLE MACHINERY; PROTO-ONCOGENE; LOCUS ENCODES; EXPRESSION; DIVISION; PATHWAY; PROLIFERATION	The Ras GTPase links extracellular mitogens to intracellular mechanisms that control cell proliferation. To understand how Ras regulates proliferation in vivo, we activated or inactivated Ras in cell clones in the developing Drosophila wing. Cells lacking Ras were smaller, had reduced growth rates, accumulated in G1, and underwent apoptosis due to cell competition. Conversely, activation of Ras increased cell size and growth rates and promoted G1/S transitions. Ras upregulated the growth driver dMyc, and both Pas and dMyc increased levels of cyclin E posttranscriptionally. We propose that Pas primarily promotes growth and that growth is coupled to G1/S progression via cyclin E. Interestingly, upregulation of growth by Pas did not deregulate G2/M progression or a developmentally regulated cell cycle exit.	Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ Washington, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA15704-26] Funding Source: Medline; NIGMS NIH HHS [GM51186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1994, GENETICS, V137, P513; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CLIFFORD RJ, 1989, GENETICS, V123, P771; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Downward J, 1997, CURR BIOL, V7, P258; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Guichard A, 1999, DEVELOPMENT, V126, P2663; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HAY BA, 1994, DEVELOPMENT, V120, P2121; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Karim FD, 1998, DEVELOPMENT, V125, P1; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee T, 1996, DEVELOPMENT, V122, P409; Lehman DA, 1999, DEVELOPMENT, V126, P1793; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Schnorr JD, 1996, GENETICS, V144, P1545; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Simcox A, 1997, MECH DEVELOP, V62, P41, DOI 10.1016/S0925-4773(96)00643-0; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Winston JT, 1996, ONCOGENE, V12, P127; XU T, 1993, DEVELOPMENT, V117, P1223	64	233	238	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 18	2000	100	4					435	446		10.1016/S0092-8674(00)80679-0	http://dx.doi.org/10.1016/S0092-8674(00)80679-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693760	Green Accepted, Bronze			2022-12-24	WOS:000085446900006
J	Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB				Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB			Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; ORAL-CONTRACEPTIVES; GENE; THROMBOEMBOLISM; LEIDEN	Background: Venous thromboembolism is a leading cause of morbidity and mortality during pregnancy and the puerperium. However, the role of mutations in the prothrombin and factor V genes and other thrombophilic abnormalities as risk factors for thromboembolism in women during pregnancy and the puerperium is not known. Methods: In a study of 119 women with a history of venous thromboembolism during pregnancy and the puerperium and 233 age-matched normal women, we measured the activity of antithrombin, protein C, protein S, and lupus anticoagulant. We also performed genetic analyses to detect the G1691A mutation in the factor V gene (factor V Leiden), the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase gene. Blood samples were obtained at least three months post partum or after the cessation of lactation. Results: Among the women with a history of venous thromboembolism, the prevalence of factor V Leiden was 43.7 percent, as compared with 7.7 percent among the normal women (relative risk of venous thromboembolism, 9.3; 95 percent confidence interval, 5.1 to 16.9); that of the G20210A prothrombin-gene mutation, 16.9 percent as compared with 1.3 percent (relative risk, 15.2; 95 percent confidence interval, 4.2 to 52.6); and that of both factor V Leiden and the G20210A prothrombin-gene mutation, 9.3 percent as compared with 0 (estimated odds ratio, 107). Assuming an overall risk of 1 in 1500 pregnancies, the risk of thrombosis among carriers of factor V Leiden was 0.2 percent, among carriers of the G20210A prothrombin-gene mutation, 0.5 percent, and among carriers of both defects, 4.6 percent, as calculated in a multivariate analysis. Conclusions: The G20210A prothrombin-gene mutation and factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation. (N Engl J Med 2000;342:374-80.) (C)2000, Massachusetts Medical Society.	Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Vasc Surg & Kidney Transplantat, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Zotz, RB (corresponding author), Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, Moorenstr 5, D-40225 Dusseldorf, Germany.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; Cumming AM, 1997, BRIT J HAEMATOL, V98, P353, DOI 10.1046/j.1365-2141.1997.2353052.x; DAHLBACK E, 1994, HAEMOSTASIS THROMBOS, V1, P671; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GREEK D, 1994, PROF ENG, V7, P4; Hallak M, 1997, AM J OBSTET GYNECOL, V176, P889, DOI 10.1016/S0002-9378(97)70617-3; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; Kluijtmans LAJ, 1998, THROMB HAEMOSTASIS, V79, P254, DOI 10.1055/s-0037-1614974; KNIEMEYER HW, 1993, CLIN INVESTIGATOR, V72, P40; KNIEMEYER HW, 1990, GYNAKOLOGE, V23, P91; KNIEMEYER HW, 1990, KLIN WOCHENSCHR, V68, P1208, DOI 10.1007/BF01796511; KOLVENBACH R, 1991, GYNAKOLOGE, V24, P305; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Margaglione M, 1998, THROMB HAEMOSTASIS, V79, P907; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RUTHERFORD S, 1991, American Journal of Obstetrics and Gynecology, V164, P286; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; Zotz RB, 1996, THROMB HAEMOSTASIS, V76, P53	26	360	373	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					374	380		10.1056/NEJM200002103420602	http://dx.doi.org/10.1056/NEJM200002103420602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666427				2022-12-24	WOS:000085205200002
J	Parkhill, J; Wren, BW; Mungall, K; Ketley, JM; Churcher, C; Basham, D; Chillingworth, T; Davies, RM; Feltwell, T; Holroyd, S; Jagels, K; Karlyshev, AV; Moule, S; Pallen, MJ; Penn, CW; Quail, MA; Rajandream, MA; Rutherford, KM; van Vliet, AHM; Whitehead, S; Barrell, BG				Parkhill, J; Wren, BW; Mungall, K; Ketley, JM; Churcher, C; Basham, D; Chillingworth, T; Davies, RM; Feltwell, T; Holroyd, S; Jagels, K; Karlyshev, AV; Moule, S; Pallen, MJ; Penn, CW; Quail, MA; Rajandream, MA; Rutherford, KM; van Vliet, AHM; Whitehead, S; Barrell, BG			The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences	NATURE			English	Article							HELICOBACTER-PYLORI; GENES; VIRULENCE; IDENTIFICATION; BACTERIA; PROGRAM; CELLS	Campylobacter jejuni, from the delta-epsilon group of proteobacteria, is a microaerophilic, Gram-negative, flagellate, spiral bacterium-properties it shares with the related gastric pathogen Helicobacter pylori. It is the leading cause of bacterial food-borne diarrhoeal disease throughout the world(1). In addition, infection with C. jejuni is the most frequent antecedent to a form of neuromuscular paralysis known as Guillain-Barre syndrome(2). Here we report the genome sequence of C. jejuni NCTC11168. C. jejuni has a circular chromosome of 1,641,481 base pairs (30.6% G+C) which is predicted to encode 1,654 proteins and 54 stable RNA species. The genome is unusual in that there are virtually no insertion sequences or phage-associated sequences and very few repeat sequences. One of the most striking findings in the genome was the presence of hypervariable sequences. These short homopolymeric runs of nucleotides were commonly found in genes encoding the biosynthesis or modification of surface structures, or in closely linked genes of unknown function. The apparently high rate of variation of these homopolymeric tracts may be important in the survival strategy of C. jejuni.	Sanger Ctr, Cambridge CB10 1SA, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Queens Univ Belfast, Dept Microbiol & Immunobiol, Belfast BT12 6BN, Antrim, North Ireland; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Free Univ Amsterdam, Fac Med, Dept Med Microbiol, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Fac Med, Dept Gastroenterol, NL-1081 BT Amsterdam, Netherlands	Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine; University of Leicester; Queens University Belfast; University of Birmingham; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Parkhill, J (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.		Parkhill, Julian/G-4703-2011; Karlyshev, Andrey/D-2797-2011; Quail, michael/ABE-6131-2020; Rutherford, Kim/Y-7995-2018; van Vliet, Arnoud HM/B-5155-2013; Pallen, Mark J./E-7619-2011	Parkhill, Julian/0000-0002-7069-5958; Karlyshev, Andrey/0000-0003-3124-019X; Rutherford, Kim/0000-0001-6277-726X; van Vliet, Arnoud/0000-0003-0203-1305; Davies, Robert/0000-0002-9983-1378; Pallen, Mark/0000-0003-1807-3657				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baillon MLA, 1999, J BACTERIOL, V181, P4798, DOI 10.1128/JB.181.16.4798-4804.1999; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Blaser MJ, 1997, J INFECT DIS, V176, pS103, DOI 10.1086/513780; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; *CPHLS, 1999, COMMUNICAB DIS REP, V9, P11; Doig P, 1996, MOL MICROBIOL, V20, P885, DOI 10.1111/j.1365-2958.1996.tb02526.x; Domingo E, 1997, REV MED VIROL, V7, P87, DOI 10.1002/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0; Frishman D, 1998, NUCLEIC ACIDS RES, V26, P2941, DOI 10.1093/nar/26.12.2941; FRY B, IN PRESS CAMPYLOBACT; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Hood DW, 1996, P NATL ACAD SCI USA, V93, P11121, DOI 10.1073/pnas.93.20.11121; Hughes NJ, 1998, J BACTERIOL, V180, P1119, DOI 10.1128/JB.180.5.1119-1128.1998; Jones AC, 1997, J BACTERIOL, V179, P5643, DOI 10.1128/jb.179.17.5643-5647.1997; Konkel ME, 1999, MOL MICROBIOL, V32, P691, DOI 10.1046/j.1365-2958.1999.01376.x; Lavitola A, 1999, MOL MICROBIOL, V33, P119, DOI 10.1046/j.1365-2958.1999.01454.x; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nachamkin I, 1998, CLIN MICROBIOL REV, V11, P555, DOI 10.1128/CMR.11.3.555; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; van Vliet AHM, 1998, J BACTERIOL, V180, P5291, DOI 10.1128/JB.180.20.5291-5298.1998; Wassenaar TM, 1997, CLIN MICROBIOL REV, V10, P466, DOI 10.1128/CMR.10.3.466; Wood AC, 1999, MICROBIOL-UK, V145, P379, DOI 10.1099/13500872-145-2-379; Wren BW, 1998, MICROBIOL-SGM, V144, P1205, DOI 10.1099/00221287-144-5-1205; Yao RJ, 1997, MOL MICROBIOL, V23, P1021, DOI 10.1046/j.1365-2958.1997.2861650.x; YAO RJ, 1994, MOL MICROBIOL, V14, P883, DOI 10.1111/j.1365-2958.1994.tb01324.x; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456	30	1536	2086	5	148	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					665	668		10.1038/35001088	http://dx.doi.org/10.1038/35001088			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688204	Bronze			2022-12-24	WOS:000085288200056
J	Caramazza, A; Chialant, D; Capasso, R; Miceli, G				Caramazza, A; Chialant, D; Capasso, R; Miceli, G			Separable processing of consonants and vowels	NATURE			English	Article							PHONEMIC PARAPHASIA; SPEECH; ERRORS	There are two views about the nature of consonants and vowels. One view holds that they are categorically distinct objects that play a fundamental role in the construction of syllables in speech production(1-3). The other view is that they are convenient labels for distinguishing between peak (vowel) and non-peak (consonant) parts of a continuous stream of sound that varies in sonority (roughly the degree of openness of the vocal apparatus during speech)(4-6), or that they are summary labels for bundles of feature segments(7,8). Taking the latter view, consonants and vowels do not have an independent status in language processing. Here we provide evidence for the possible categorical distinction between consonants and vowels in the brain. We report the performance of two Italian-speaking aphasics who show contrasting, selective difficulties in producing vowels and consonants. Their performance in producing individual consonants is independent of the sonority value and feature properties of the consonants. This pattern of results suggests that consonants and vowels are processed by distinct neural mechanisms, thereby providing evidence for their independent status in language production.	Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, Cambridge, MA 02138 USA; Ist Ricovero & Cura Carattere Sci S Lucia, I-00179 Rome, Italy; Univ Cattolica, Dept Neurol, I-00168 Rome, Italy	Harvard University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Caramazza, A (corresponding author), Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, 33 Kirkland St, Cambridge, MA 02138 USA.		Miceli, Gabriele/J-8908-2014	Capasso, Rita/0000-0003-1523-7302				Beland R., 1990, J NEUROLINGUIST, V5, P125, DOI [10.1016/0911-6044(90)90009-N, DOI 10.1016/0911-6044(90)90009-N]; BLUMSTEIN SE, 1978, SYLLABLES SEGMENTS, P189; Boatman D, 1997, CORTEX, V33, P83, DOI 10.1016/S0010-9452(97)80006-8; BUCKINGHAM HW, 1986, COGNITIVE SCI, V10, P195, DOI 10.1207/s15516709cog1002_4; CANTER GJ, 1985, BRAIN LANG, V24, P204, DOI 10.1016/0093-934X(85)90131-2; CHRISTMAN SS, 1992, CLIN LINGUIST PHONET, V6, P219, DOI 10.3109/02699209208985532; CLEMENTS GN, 1983, MONOGRAPH SERIES MIT, V9; Goldsmith J., 1990, AUTOSEGMENTAL METRIC; Kenstowicz Michael, 1994, PHONOLOGY GENERATIVE; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; MacNeilage PF, 1998, BEHAV BRAIN SCI, V21, P499, DOI 10.1017/S0140525X98001265; MCCARTHY JJ, 1981, LINGUIST INQ, V12, P373; Miceli G., 2006, BATTERIA ANALISI DEF; NESPOT M, 1986, PRASODIC PHONOLOGY; Ramus F, 1999, J ACOUST SOC AM, V105, P512, DOI 10.1121/1.424522; Roelofs A, 1999, LANG COGNITIVE PROC, V14, P173, DOI 10.1080/016909699386338; Romani C, 1996, BRAIN LANG, V55, P144; Romani C, 1998, BRAIN LANG, V64, P83, DOI 10.1006/brln.1998.1958; Selkirk E. O., 1982, STRUCTURE PHONOLOG 2; Stevens K.N., 1998, ACOUSTIC PHONETICS; YIP M, 1982, LINGUIST INQ, V13, P637	21	129	130	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					428	430		10.1038/35000206	http://dx.doi.org/10.1038/35000206			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	280UA	10667794				2022-12-24	WOS:000085121100050
J	Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D				Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D			Fluoride in drinking water and risk of hip fracture in the UK: a case-control study	LANCET			English	Article							PROXIMAL FEMUR; BONE; OSTEOPOROSIS; STRENGTH; WOMEN	Background Although the benefits of water fluoridation for dental health are widely accepted, concerns remain about possible adverse effects, particularly effects on bone. Several investigators have suggested increased rates of hip fracture in places with high concentrations of fluoride in drinking water, but this finding has not been consistent, possibly because of unrecognised confounding effects. Methods We did a case-control study of men and women aged 50 years and older from the English county of Cleveland, and compared patients with hip fracture with community controls. Current addresses were ascertained for all participants; for those who agreed to an interview and who passed a mental test, more detailed information was obtained about lifetime residential history and exposure to other known and suspected risk factors for hip fracture. Exposures to fluoride in water were estimated from the residential histories and from information provided by water suppliers. Analysis was by logistic regression. Findings 914 cases and 1196 controls were identified, of whom 514 and 527, respectively, were interviewed. Among those interviewed, hip fracture was strongly associated with low body-mass index (p for trend <0.001) and physical inactivity (p for trend <0.001). Estimated average lifetime exposure to fluoride in drinking water ranged from 0.15 to 1.79 ppm. Current residence in Hartlepool was a good indicator for high lifetime exposure to fluoride, After adjustment for potential confounders, the odds ratio associated with an average lifetime exposure to fluoride greater than or equal to 0.9 ppm was 1.0 [95% CI 0.7-1.5]. Interpretation There is a low risk of hip fracture for people ingesting fluoride in drinking water at concentrations of about 1 ppm. This low risk should not be a reason for withholding fluoridation of water supplies.	Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England; Univ Sheffield, Sch Med, Dept Human Metab & Clin Biochem, Sheffield S10 2RX, S Yorkshire, England	University of Southampton; University of Sheffield	Coggon, D (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.		Leary, Sam/B-4456-2016	Cooper, Cyrus/0000-0003-3510-0709; Russell, Robert Graham G/0000-0002-4136-1828; Leary, Sam/0000-0002-1706-0689				ALFFRAM PA, 1969, ACTA ORTHOP SCAND, V40, P137, DOI 10.3109/17453676908989494; ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P344, DOI 10.3109/17453678608994408; CAULEY JA, 1995, J BONE MINER RES, V10, P1076; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; DANIELSON C, 1992, JAMA-J AM MED ASSOC, V268, P746; Department of Health and Social Security Scottish Office Welsh Office, 1969, REP PUBL HLTH MED SU; GOGGIN JE, 1965, PUBLIC HEALTH REP, V80, P1005, DOI 10.2307/4592594; GORDON SL, 1992, OSTEOPOROSIS INT, V2, P109, DOI 10.1007/BF01623816; ISHIGURO K, 1993, CALCIFIED TISSUE INT, V52, P278, DOI 10.1007/BF00296652; Jacobsen S J, 1992, Ann Epidemiol, V2, P617, DOI 10.1016/1047-2797(92)90006-C; JACOBSEN SJ, 1993, AM J PUBLIC HEALTH, V83, P743, DOI 10.2105/AJPH.83.5.743; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; JACQMINGADDA H, 1995, JAMA-J AM MED ASSOC, V273, P775, DOI 10.1001/jama.1995.03520340029026; KORNS RF, 1969, PUBLIC HEALTH REP, V84, P815, DOI 10.2307/4593687; LI Y, 1999, J DENT RES S1, V78, P263; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; Martyn CN, 1999, LANCET, V353, P769, DOI 10.1016/S0140-6736(98)00390-0; Meunier PJ, 1996, INT CONGR SER, V1118, P305; QUERESHI KN, 1974, AGE AGEING, V3, P152; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SHERLOCK JC, 1984, J R SOC HLTH, V1, P34; SIMONEN O, 1985, LANCET, V2, P432; SUAREZALMAZOR ME, 1993, AM J PUBLIC HEALTH, V83, P689, DOI 10.2105/AJPH.83.5.689; WHITFORD GM, 1996, METABOLISM TOXICITY, P1	27	47	51	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					265	269		10.1016/S0140-6736(99)07161-5	http://dx.doi.org/10.1016/S0140-6736(99)07161-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675073				2022-12-24	WOS:000085045600009
J	Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E				Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E			Directed actin polymerization is the driving force for epithelial cell-cell adhesion	CELL			English	Article							ALPHA-CATENIN; VINCULIN; PROTEIN; COMPLEX; FIBROBLASTS; CADHERINS; CONTACTS; MOTILITY; GTPASES; CDC42	We have found that epithelial cells engage in a process of cadherin-mediated intercellular adhesion that utilizes calcium and actin polymerization in unexpected ways. Calcium stimulates filopodia, which penetrate and embed into neighboring cells. E-cadherin complexes cluster at filopodia tips, generating a two-rowed zipper of embedded puncta. Opposing cell surfaces are clamped by desmosomes, while vinculin, zyxin, VASP, and Mena are recruited to adhesion zippers by a mechanism that requires alpha-catenin. Actin reorganizes and polymerizes to merge puncta into a single row and seal cell borders. In keratinocytes either null for alpha-catenin or blocked in VASP/Mena function, filopodia embed, but actin reorganization/polymerization is prevented, and membranes cannot seal. Taken together, a dynamic mechanism for intercellular adhesion is unveiled involving calcium-activated filopodia penetration and VASP/Mena-dependent actin reorganization/polymerization.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016	Vasioukhin, Valeri/0000-0002-6730-0281	NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NIDCR NIH HHS [5P50DE11921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BERSHADSKY A, 1998, GUIDEBOOK EXTRACELLU, P3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; GELGER B, 1992, COLD SPRING HARB SYM, V57, P631; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Stoffler HE, 1998, J CELL SCI, V111, P2779; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; YONEMURA S, 1995, J CELL SCI, V108, P127	39	909	928	1	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					209	219		10.1016/S0092-8674(00)81559-7	http://dx.doi.org/10.1016/S0092-8674(00)81559-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660044	Bronze			2022-12-24	WOS:000084932200005
J	del Camino, D; Holmgren, M; Liu, Y; Yellen, G				del Camino, D; Holmgren, M; Liu, Y; Yellen, G			Blocker protection in the pore of a voltage-gated K+ channel and its structural implications	NATURE			English	Article							SHAKER POTASSIUM CHANNELS; TETRAETHYLAMMONIUM ION; INACTIVATION; BINDING; SITE; MECHANISMS; REGION; CELLS	The structure of the bacterial potassium channel KcsA(1) has provided a framework for understanding the related voltage-gated potassium channels (Kv channels) that are used for signalling in neurons. Opening and closing of these Kv channels (gating) occurs at the intracellular entrance to the pore, and this is also the site at which many open channel blockers affect Kv channels(2-4). To learn more about the sites of blocker binding and about the structure of the open Ky channel, we investigated here. the ability of blockers to protect against chemical modification of cysteines introduced at sites in transmembrane segment S6, which contributes to the intracellular entrance. Within the intracellular half of S6 we found an abrupt cessation of protection for both large and small blockers that is inconsistent with the narrow 'inner pore' seen in the KcsA structure. These and other results are most readily explained by supposing that the structure of Ky channels differs from that of the non-voltage-gated bacterial channel by the introduction of a sharp bend in the inner (S6) helices. This bend would occur at a Pro-X-Pro sequence that is highly conserved in Ky channels, near the site of activation gating.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yellen, G (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.			Yellen, Gary/0000-0003-4228-7866	NINDS NIH HHS [R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Gardner S, 1998, ACTA CRYSTALLOGR D, V54, P1071, DOI 10.1107/S0907444998007112; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SWENSON RP, 1981, J GEN PHYSIOL, V77, P255, DOI 10.1085/jgp.77.3.255; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	27	279	281	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					321	325		10.1038/35002099	http://dx.doi.org/10.1038/35002099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659852				2022-12-24	WOS:000084899700055
J	Ramer, MS; Priestley, JV; McMahon, SB				Ramer, MS; Priestley, JV; McMahon, SB			Functional regeneration of sensory axone into the adult spinal cord	NATURE			English	Article							DORSAL-ROOT AXONS; NERVE GROWTH-FACTOR; TRANSPLANTS; NEURONS; RAT; LESION; EXPRESSION; RECEPTORS; TARGETS; BRAIN	The arrest of dorsal root axonal regeneration at the transitional zone between the peripheral and central nervous system has been repeatedly described since the early twentieth century(1). Here we show that, with trophic support to damaged sensory axons, this regenerative barrier is surmountable. In adult rats with injured dorsal roots, treatment with nerve growth factor (NGF), neurotrophin-3 (NT3) and glial-cell-line-derived neurotrophic factor (GDNF), but not brain-derived neurotrophic factor (BDNF), resulted in selective regrowth of damaged axons across the dorsal root entry zone and into the spinal cord. Dorsal horn neurons were found to be synaptically driven by peripheral nerve stimulation in rats treated with NGF, NT3 and GDNF, demonstrating functional reconnection. In behavioural studies, rats treated with NGF and GDNF recovered sensitivity to noxious heat and pressure. The observed effects of neurotrophic factors corresponded to their known actions on distinct subpopulations of sensory neurons. Neurotrophic factor treatment may thus serve as a viable treatment in promoting recovery from root avulsion injuries.	Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, London SE1 7EH, England; Univ London Queen Mary & Westfield Coll, Div Biomed Sci, Neurosci Sect, London E1 4NS, England	University of London; King's College London; University of London; Queen Mary University London	Ramer, MS (corresponding author), Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, St Thomas Campus,Lambeth Palace Rd, London SE1 7EH, England.			McMahon, Stephen/0000-0003-4656-5536				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Bradbury EJ, 1999, EUR J NEUROSCI, V11, P3873, DOI 10.1046/j.1460-9568.1999.00809.x; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal RS., 1928, DEGENERATION REGENER; Chong MS, 1999, J COMP NEUROL, V410, P42; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Dyer JK, 1998, EXP NEUROL, V154, P12, DOI 10.1006/exnr.1998.6905; Fraher JP, 1999, J ANAT, V194, P161, DOI 10.1046/j.1469-7580.1999.19420161.x; Houle JD, 1996, EXP NEUROL, V139, P278, DOI 10.1006/exnr.1996.0101; ITOH Y, 1990, J COMP NEUROL, V302, P272, DOI 10.1002/cne.903020207; Iwaya K, 1999, NEUROSURGERY, V44, P589, DOI 10.1097/00006123-199903000-00085; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; KOZLOVA EN, 1995, NEUROREPORT, V6, P269, DOI 10.1097/00001756-199501000-00011; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; ROSARIO CM, 1992, EXP NEUROL, V115, P158, DOI 10.1016/0014-4886(92)90241-H; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SIMS TJ, 1994, EXP BRAIN RES, V99, P25; TESSLER A, 1988, J COMP NEUROL, V270, P537, DOI 10.1002/cne.902700407; THOMPSON SWN, 1995, PAIN, V62, P219, DOI 10.1016/0304-3959(94)00271-F; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Zhang Y, 1998, J NEUROSCI RES, V54, P554; Zhou XF, 1999, EUR J NEUROSCI, V11, P1711, DOI 10.1046/j.1460-9568.1999.00589.x	27	405	441	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					312	316		10.1038/35002084	http://dx.doi.org/10.1038/35002084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659850				2022-12-24	WOS:000084899700053
J	Folks, TM				Folks, TM			Chimpanzees as original source for HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IDENTIFICATION	The human AIDS viruses human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) represent cross-species (zoonotic) infections. Although the primate reservoir of HIV-2 has been clearly identified as the sooty mangabey (Cercocebus atys), the origin of HIV-1 remains uncertain. Viruses related to HIV-1 have been isolated from the common chimpanzee (Pan troglodytes), but only three such SIVcpz infections have been documented, one of which involved a virus so divergent that it might represent a different primate lentiviral lineage. In a search for the HIV-1 reservoir, we have now sequenced the genome of a new SIVcpz strain (SIVcpzUS) and have determined, by mitochondrial DNA analysis, the subspecies identity of all known SIVcpz-infected chimpanzees. We find that two chimpanzee subspecies in Africa, the central P, t, troglodytes and the eastern P, t, schweinfurthii, harbour SIVcpz and that their respective viruses form two highly divergent (but subspecies-specific) phylogenetic lineages. All HIV-1 strains known to infect man, including HIV-1 groups M, N and O, are closely related to just one of these SIVcpz lineages, that found in P, t, troglodytes. Moreover, we find that HIV-1 group N is a mosaic of SIVcpzUS- and HIV-1-related sequences, indicating an ancestral recombination event in a chimpanzee host. These results, together with the observation that the natural range of P, t. troglodytes coincides uniquely with areas of HIV-1 group M, N and O endemicity, indicate that P, t. troglodytes is the primary reservoir for HIV-1 and has been the source of at least three independent introductions of SIVcpz into the human population.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div HIV AIDS, HIV & Retrovirol Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Folks, TM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div HIV AIDS, HIV & Retrovirol Branch, Atlanta, GA 30333 USA.							Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Heneine W, 1998, NAT MED, V4, P403, DOI 10.1038/nm0498-403; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; SHARP PM, 1994, AIDS, V8, P527; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					310	310		10.1001/jama.283.3.310	http://dx.doi.org/10.1001/jama.283.3.310			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647783				2022-12-24	WOS:000084732400002
J	Young, RK				Young, RK			How to have your first mammogram	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					171	171		10.1001/jama.283.2.171	http://dx.doi.org/10.1001/jama.283.2.171			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634321				2022-12-24	WOS:000084661400001
J	Dudman, NPB				Dudman, NPB			An alternative view of homocysteine	LANCET			English	Editorial Material							PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; RISK; STROKE		Univ New S Wales, Prince Wales Hosp, Fac Med, Ctr Thrombosis & Vasc Res, Randwick, NSW, Australia	University of New South Wales Sydney	Dudman, NPB (corresponding author), Care of Chesterman C, Univ New S Wales, Prince Wales Hosp, Ctr Thrombosis & Vasc Res, Barker St, Randwick, NSW 2031, Australia.							ANDERSSON A, 1992, CLIN CHEM, V38, P1311; BLOM HJ, 1992, J INHERIT METAB DIS, V15, P419, DOI 10.1007/BF02435993; Dudman N. P. B., 1998, Netherlands Journal of Medicine, V52, pS22; Dudman NPB, 1999, CIRC RES, V84, P409, DOI 10.1161/01.RES.84.4.409; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P512, DOI 10.1161/01.ATV.13.4.512; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Dudman NPB, 1997, DEV CARDIOVASC MED, P267; DURAND P, 1997, FASEB J, V11, P1; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Gudnason V, 1998, ATHEROSCLEROSIS, V136, P347, DOI 10.1016/S0021-9150(97)00237-2; Guo X. W., 1998, Netherlands Journal of Medicine, V52, pS58; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Jacobsen D. W., 1998, Netherlands Journal of Medicine, V52, pS1; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; Lai KN, 1996, CLIN IMMUNOL IMMUNOP, V80, P47, DOI 10.1006/clin.1996.0093; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Mann N. J., 1998, Netherlands Journal of Medicine, V52, pS10; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; REICHENBACH D, 1991, CARDIOVASC PATHOL, P61; Tosetto A, 1997, BRIT J HAEMATOL, V97, P804, DOI 10.1046/j.1365-2141.1997.1422957.x; UELAND PM, 1993, CLIN CHEM, V39, P1764; Wang Hong, 1998, Netherlands Journal of Medicine, V52, pS8; WANG PY, 1993, STROKE, V24, P236, DOI 10.1161/01.STR.24.2.236; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878; Wilcken DEL, 1992, MOL GENETICS CORONAR, P311	27	129	131	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2072	2074		10.1016/S0140-6736(99)03383-8	http://dx.doi.org/10.1016/S0140-6736(99)03383-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636386				2022-12-24	WOS:000084183300046
J	Onyango, AW; Esrey, SA; Kramer, MS				Onyango, AW; Esrey, SA; Kramer, MS			Continued breastfeeding and child growth in the second year of life: a prospective cohort study in western Kenya	LANCET			English	Article							NUTRITIONAL-STATUS; PERUVIAN TODDLERS; BREAST-MILK; WATER; MALNUTRITION; INFANTS; ASSOCIATION; HEALTH; FOODS; AGE	Background The value of postinfancy breastfeeding for growth and nutritional status is debated. We have investigated this issue in a longitudinal study. Methods We prospectively followed up a cohort of 264 children in western Kenya for 6 months (mean age 14 months [range 9-18] at baseline) to investigate the nature of the association between breastfeeding and growth. Only 14 (5.3%) children had been weaned at baseline, and 173 (65.5%) were still breastfed at follow-up. For analysis, children were classified into three groups of breastfeeding duration as a proportion Of the total follow-up period (0-49%, n=42; 50-99%, n=49; and 100%, n=173). Findings In general linear models multivariate analysis, children in the longest-duration breastfeeding group gained 3.4 cm (p=0.0001) and 370 g (p=0.005) more than those in the shortest duration group, and 0.6 cm (p=0.0015) and 230 g (p=0.038) more than children in the intermediate group. The strongest association between breastfeeding and linear growth was observed in households that had no latrine and daily water use of less than 10 L per person. Interpretation Our findings support WHO's recommendation to continue breastfeeding for at least 2 years, especially in settings with poor sanitation and inadequate water supply.	WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland; UNICEF, New York, NY USA; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	World Health Organization; UNICEF; McGill University; McGill University	Onyango, AW (corresponding author), WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland.							ADAIR L, 1993, EUR J CLIN NUTR, V47, P42; BUTZ WP, 1984, AM J EPIDEMIOL, V119, P516, DOI 10.1093/oxfordjournals.aje.a113769; CAIRNCROSS S, 1987, T ROY SOC TROP MED H, V81, P51, DOI 10.1016/0035-9203(87)90280-X; Caulfield LE, 1996, INT J EPIDEMIOL, V25, P693, DOI 10.1093/ije/25.4.693; COHEN RJ, 1994, LANCET, V344, P288, DOI 10.1016/S0140-6736(94)91337-4; ESREY SA, 1992, AM J EPIDEMIOL, V135, P659, DOI 10.1093/oxfordjournals.aje.a116345; Esrey SA, 1996, AM J EPIDEMIOL, V143, P608, DOI 10.1093/oxfordjournals.aje.a008791; *FAO WHO, 1992, INT C NUTR WORLD DEC; Fawzi WW, 1998, INT J EPIDEMIOL, V27, P255, DOI 10.1093/ije/27.2.255; GRUMMERSTRAWN LM, 1993, PEDIATRICS, V91, P766; LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M; Marquis GS, 1997, INT J EPIDEMIOL, V26, P349, DOI 10.1093/ije/26.2.349; Marquis GS, 1997, AM J CLIN NUTR, V66, P1102, DOI 10.1093/ajcn/66.5.1102; MARTINES JC, 1994, J NUTR, V124, P1189, DOI 10.1093/jn/124.8.1189; MARTORELL R, 1988, NESTLE NUTRITION WOR, V14, P57; Molbak K, 1997, INT J EPIDEMIOL, V26, P458, DOI 10.1093/ije/26.2.458; NGANDU NH, 1990, J EPIDEMIOL COMMUN H, V44, P281, DOI 10.1136/jech.44.4.281; Nube M, 1996, EUR J CLIN NUTR, V50, P171; SAULS HS, 1979, PEDIATRICS, V64, P523; Simondon KB, 1998, INT J EPIDEMIOL, V27, P490, DOI 10.1093/ije/27.3.490; TAREN D, 1993, AM J CLIN NUTR, V58, P862, DOI 10.1093/ajcn/58.6.862; Victora C G, 1991, Epidemiology, V2, P175, DOI 10.1097/00001648-199105000-00003; VICTORA CG, 1984, AM J CLIN NUTR, V39, P307, DOI 10.1093/ajcn/39.2.307; WHO, 1995, WEEKLY EPIDEMIOLOGIC, V70, P119; *WHO UNICEF, 1990, WHO UNICEF POL MAK M	25	51	54	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2041	2045		10.1016/S0140-6736(99)02168-6	http://dx.doi.org/10.1016/S0140-6736(99)02168-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636370				2022-12-24	WOS:000084183300013
J	Schlichting, I; Berendzen, J; Chu, K; Stock, AM; Maves, SA; Benson, DE; Sweet, BM; Ringe, D; Petsko, GA; Sligar, SG				Schlichting, I; Berendzen, J; Chu, K; Stock, AM; Maves, SA; Benson, DE; Sweet, BM; Ringe, D; Petsko, GA; Sligar, SG			The catalytic pathway of cytochrome P450cam at atomic resolution	SCIENCE			English	Article							PEROXIDASE COMPOUND-I; PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; CRYSTAL-STRUCTURE; OXYGEN ACTIVATION; C PEROXIDASE; CRYSTALLOGRAPHY; HYDROXYLATION; P-450CAM; INTERMEDIATE; SPECTROSCOPY	Members of the cytochrome P450 superfamily catalyze the addition of molecular oxygen to nonactivated hydrocarbons at physiological temperature-a reaction that requires high temperature to proceed in the absence of a catalyst. Structures were obtained for three intermediates in the hydroxylation reaction of camphor by P450cam with trapping techniques and cryocrystallography. The structure of the ferrous dioxygen adduct of P450cam was determined with 0.91 angstrom wavelength x-rays; irradiation with 1.5 angstrom x-rays results in breakdown of the dioxygen molecule to an intermediate that would be consistent with an oxyferryl species. The structures show conformational changes in several important residues and reveal a network of bound water molecules that may provide the protons needed for the reaction.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Los Alamos Natl Lab, Biophys Grp, Los Alamos, NM 87545 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Max Planck Society; United States Department of Energy (DOE); Los Alamos National Laboratory; Rutgers State University New Brunswick; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Brookhaven National Laboratory; Brandeis University	Schlichting, I (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.	ilme.schlichting@mpi-dortmund.mpg.de	Petsko, Gregory/AAO-7962-2020; Schlichting, Ilme/I-1339-2013	Stock, Ann/0000-0002-0446-8079; Berendzen, Joel/0000-0002-9454-9074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM033775, R01GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33775, GM31756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKENS J, 1994, J AM CHEM SOC, V116, P1143, DOI 10.1021/ja00082a051; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Borman S, 1999, CHEM ENG NEWS, V77, P31, DOI 10.1021/cen-v077n049.p031; BREWER CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P515, DOI 10.1016/0003-9861(86)90029-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CHANCE B, 1980, FEBS LETT, V112, P178, DOI 10.1016/0014-5793(80)80174-8; Contzen J, 1999, BIOCHEMISTRY-US, V38, P16253, DOI 10.1021/bi991759u; DAVYDOV R, 1991, FEBS LETT, V295, P113, DOI 10.1016/0014-5793(91)81398-R; DAWSON JH, 1986, J AM CHEM SOC, V108, P8114, DOI 10.1021/ja00285a052; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; EDWARDS SL, 1987, BIOCHEMISTRY-US, V26, P1503, DOI 10.1021/bi00380a002; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; Gouet P, 1996, NAT STRUCT BIOL, V3, P951, DOI 10.1038/nsb1196-951; Groves John T., 1995, P3; GROVES JT, 1984, J AM CHEM SOC, V106, P2177, DOI 10.1021/ja00319a044; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; Harris D, 1998, J AM CHEM SOC, V120, P4308, DOI 10.1021/ja974110q; Harris DL, 1996, J AM CHEM SOC, V118, P6377, DOI 10.1021/ja954101m; HEDEGAARD J, 1965, J BIOL CHEM, V240, P4038; Honeychurch MJ, 1999, FEBS LETT, V451, P351, DOI 10.1016/S0014-5793(99)00610-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; KOBAYASHI K, 1990, BIOCHIM BIOPHYS ACTA, V1037, P297, DOI 10.1016/0167-4838(90)90028-E; KUBOTA M, 1991, J BIOCHEM-TOKYO, V110, P232, DOI 10.1093/oxfordjournals.jbchem.a123562; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER VP, 1992, J BIOL CHEM, V267, P8936; Mueller Ernest J., 1995, P83; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWCOMB M, IN PRESS J AM CHEM S; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; PETSKO GA, 1992, PHILOS T ROY SOC A, V340, P323, DOI 10.1098/rsta.1992.0070; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1982, J BIOL CHEM, V257, P427; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RINGE D, 1992, PHILOS T R SOC A, V340, P273, DOI 10.1098/rsta.1992.0066; Schlichting I, 1997, METHOD ENZYMOL, V277, P467, DOI 10.1016/S0076-6879(97)77026-5; SCHLICHTING I, UNPUB; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; SHIMADA H, 1994, CYTOCHROME P450, P299; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stoddard BL, 1996, PHARMACOL THERAPEUT, V70, P215, DOI 10.1016/0163-7258(96)00058-7; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WATANABE R, 1995, INT J RADIAT BIOL, V68, P113, DOI 10.1080/09553009514551011; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531	66	1123	1137	7	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2000	287	5458					1615	1622		10.1126/science.287.5458.1615	http://dx.doi.org/10.1126/science.287.5458.1615			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698731				2022-12-24	WOS:000085628200028
J	Hariharan, S; Johnson, CP; Bresnahan, BA; Taranto, SE; McIntosh, MJ; Stablein, D				Hariharan, S; Johnson, CP; Bresnahan, BA; Taranto, SE; McIntosh, MJ; Stablein, D			Improved graft survival after renal transplantation in the United States, 1988 to 1996.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Transplantation	MAY 15-19, 1999	CHICAGO, ILLINOIS	Amer Soc Transplantat			ALLOGRAFT SURVIVAL; ACUTE REJECTION; CYCLOSPORINE ERA; RISK-FACTORS; RECIPIENTS; PREDICTORS; IMPACT; RACE	Background: The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods: We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results: From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased from 75.7 to 87.7 percent. The half-life for grafts from living donors increased steadily from 12.7 to 21.6 years, and that for cadaveric grafts increased from 7.9 to 13.8 years. After censoring of data for patients who died with functioning grafts, the half-life for grafts from living donors increased from 16.9 years to 35.9 years, and that for cadaveric grafts increased from 11.0 years to 19.5 years. The average yearly reduction in the relative hazard of graft failure after one year was 4.2 percent for all recipients (P<0.001), 0.4 percent for those who had acute rejection (P=0.57), and 6.3 percent for those who did not have acute rejection (P<0.001). Conclusions: Since 1988, there has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors. (N Engl J Med 2000;342:605-12.) (C)2000, Massachusetts Medical Society.	Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Transplant Surg, Milwaukee, WI 53226 USA; United Network Organ Sharing, Richmond, VA USA; EMMES Corp, Potomac, MD USA	Medical College of Wisconsin; Medical College of Wisconsin; United Network for Organ Sharing; Emmes Corporation	Hariharan, S (corresponding author), Med Coll Wisconsin, Div Nephrol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.				NIAID NIH HHS [N01-AI-25132] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025132] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER JW, 1994, TRANSPLANTATION, V57, P871, DOI 10.1097/00007890-199403270-00018; ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; Cho S, 1999, AM J KIDNEY DIS, V34, P296; COLE E, 1995, CLIN TRANSPLANT, V9, P282; Cosio FG, 1997, TRANSPLANTATION, V63, P1611, DOI 10.1097/00007890-199706150-00013; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; Hariharan S, 1996, CLIN TRANSPLANT, V10, P186; Hariharan S, 1997, TRANSPLANTATION, V64, P1748, DOI 10.1097/00007890-199712270-00022; HARIHARAN S, 1993, CLIN TRANSPLANT, V7, P235; Hariharan S, 1996, CLIN TRANSPLANT, V10, P538; HUME DM, 1955, J CLIN INVEST, V34, P327, DOI 10.1172/JCI103085; Jindal RM, 1999, NEPHRON, V83, P13, DOI 10.1159/000045468; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KERMAN RH, 1991, TRANSPLANTATION, V51, P338, DOI 10.1097/00007890-199102000-00013; MERION RM, 1984, NEW ENGL J MED, V310, P148, DOI 10.1056/NEJM198401193100303; MORRIS PJ, 1994, BRIT J SURG, V81, P635, DOI 10.1002/bjs.1800810503; PAUL LC, 1995, KIDNEY INT, V47, P1491, DOI 10.1038/ki.1995.211; Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013; Rush D, 1998, J AM SOC NEPHROL, V9, P2129; RUSH DN, 1995, TRANSPLANTATION, V59, P511; SCHROEDER TJ, 1995, TRANSPLANT P, V27, P837; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SUMRANI N, 1993, TRANSPLANT P, V25, P2259; Tejani A, 1996, J AM SOC NEPHROL, V7, P550; Tejani A, 1996, TRANSPLANTATION, V61, P1054, DOI 10.1097/00007890-199604150-00011; TESI RJ, 1993, CLIN TRANSPLANT, V7, P345; THIEL G, 1994, TRANSPLANT P, V26, P2493; *USRDS, 1998, NIH PUBL, P39; Valente JF, 1997, CLIN TRANSPLANT, V11, P231	31	1496	1579	0	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2000	342	9					605	612		10.1056/NEJM200003023420901	http://dx.doi.org/10.1056/NEJM200003023420901			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288QV	10699159	Bronze			2022-12-24	WOS:000085575500001
J	Tunstall-Pedoe, H; Vanuzzo, D; Hobbs, M; Mahonen, M; Cepaitis, Z; Kuulasmaa, K; Keil, U				Tunstall-Pedoe, H; Vanuzzo, D; Hobbs, M; Mahonen, M; Cepaitis, Z; Kuulasmaa, K; Keil, U		WHO MONICA Project	Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIALS; UNSTABLE ANGINA; CASE-FATALITY; REINFARCTION; MANAGEMENT; GUIDELINES; PREVENTION; DECLINE; FAILURE	Background The revolution in coronary care in the mid-1980s to mid-1990s corresponded with monitoring of coronary heart disease (CHD) in 31 populations of the WHO MONICA Project. We studied the impact of this revolution on coronary endpoints. Methods Case fatality, coronary-event rates, and CHD mortality were monitored in men and women aged 35-64 years in two separate 3-4-year periods. In each period, we recorded percentage use of eight treatments: coronary-artery reperfusion before, thrombolytics during, and beta-blockers, antiplatelet drugs, and angiotensin-converting-enzyme (ACE) inhibitors before and during non-fatal myocardial infarction. Values were averaged to produce treatment scores. We correlated changes across populations, and regressed changes in coronary endpoints on changes in treatment scores. Findings Treatment changes correlated positively with each other but inversely with change in coronary endpoints. By regression, for the common average treatment change of 20, case fatality fell by 19% (95% CI 12-26) in men and 16% (5-27) in women; coronary-event rates fell by 25% (16-35) and 23% (7-39); and CHD mortality rates fell by 42% (31-53) and 34% (17-50). The regression model explained an estimated 61% and 41% of variance for men and women in trends for case fatality, 52% and 30% for coronary-event rates, and 72% and 56% for CHD mortality. Interpretation Changes in coronary care and secondary prevention were strongly linked with declining coronary endpoints. Scores and benefits followed a geographical east-to-west gradient. The apparent effects of the treatment might be exaggerated by other changes in economically successful populations, so their specificity needs further assessment.	Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, MONICA Qual Control Ctr Event Registrat, Dundee DD1 9SY, Scotland; Ctr Malattie Cardiovasc, ASS4 Medio Friuli, Udine, Italy; Univ Western Australia, Dept Publ Hlth, Perth, WA 6009, Australia; Natl Publ Hlth Inst, KTL, MONICA Data Ctr, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Univ Munster, Dept Epidemiol & Social Med, D-4400 Munster, Germany	University of Dundee; University of Western Australia; Finland National Institute for Health & Welfare; University of Munster	Tunstall-Pedoe, H (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, MONICA Qual Control Ctr Event Registrat, Dundee DD1 9SY, Scotland.	h.tunstallpedoe@dundee.ac.uk	Zikic, Milorad/Q-6630-2019	Paluzie, Guillermo/0000-0002-5808-6041; Kuulasmaa, Kari/0000-0003-2165-1411				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; *ANT TRIAL COLL, 1988, BMJ-BRIT MED J, V196, P320; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; Bots M L, 1996, J Cardiovasc Risk, V3, P271, DOI 10.1097/00043798-199606000-00002; Chambless L, 1997, CIRCULATION, V96, P3849; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FRYE RL, 1982, CIRCULATION, V65, P111; Fuller W. A., 1987, MEASUREMENT ERROR MO; FURBERG CD, 1985, AM J CARDIOL, V55, P1110, DOI 10.1016/0002-9149(85)90756-8; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HJALMARSON A, 1981, LANCET, V2, P823; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; KUULASMAA K, 1997, B INT STAT I, P295; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; NORRIS RM, 1969, LANCET, V1, P274; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PEDERSEN TR, 1994, LANCET, V344, P1383; PEEL AAF, 1962, BRIT HEART J, V24, P745; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259	39	346	360	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	2000	355	9205					688	700		10.1016/S0140-6736(99)11181-4	http://dx.doi.org/10.1016/S0140-6736(99)11181-4			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703800				2022-12-24	WOS:000085615600010
J	Antson, AA; Burns, JE; Moroz, OV; Scott, DJ; Sanders, CM; Bronstein, IB; Dodson, GG; Wilson, KS; Maitland, NJ				Antson, AA; Burns, JE; Moroz, OV; Scott, DJ; Sanders, CM; Bronstein, IB; Dodson, GG; Wilson, KS; Maitland, NJ			Structure of the intact transactivation domain of the human papillomavirus E2 protein	NATURE			English	Article							DNA-BINDING DOMAIN; FUNCTIONAL INTERACTION; AMINO-ACIDS; REPLICATION; ACTIVATION; DIMERS	Papillomaviruses cause warts and proliferative lesions in skin and other epithelia. In a minority of papillomavirus types ('high risk'. including human papillomaviruses 16, 18, 31, 33, 45 and 56), further transformation of the wart lesions can produce tumours'. The papillomavirus E2 protein controls primary transcription and replication of the viral genome(2). Both activities are governed by a similar to 200 amino-acid amino-terminal module (E2NT) which is connected to a DNA-binding carboxy-terminal module by a flexible linker. Here we describe the crystal structure of the complete E2NT module from human papillomavirus 16. The E2NT module forms a dimer both in the crystal and in solution. Amino acids that are necessary for transactivation are located at the dimer interface, indicating that the dimer structure may be important in the interactions of E2NT with viral and cellular transcription factors. We propose that dimer formation may contribute to the stabilization of DNA loops(3) which may serve to relocate distal DNA-binding transcription factors to the site of human papillomavirus transcription initiation.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Univ York, Dept Biol, YCR Canc Res Unit, York YO10 5DD, N Yorkshire, England; Natl Inst Med Res, London NW7 1AA, England	University of York - UK; University of York - UK; MRC National Institute for Medical Research	Wilson, KS (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England.		Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816; Burns, Julie/0000-0003-1238-8826; Maitland, Norman/0000-0003-1607-9035; Wilson, Keith/0000-0002-3581-2194; Scott, David/0000-0002-6726-2078; Moroz, Olga/0000-0002-0354-6119				Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Brokaw JL, 1996, J VIROL, V70, P23, DOI 10.1128/JVI.70.1.23-29.1996; Burns JE, 1998, ACTA CRYSTALLOGR D, V54, P1471, DOI 10.1107/S0907444998010889; Chao SF, 1999, BIOCHEMISTRY-US, V38, P4586, DOI 10.1021/bi982616v; COLLETTI V, 1994, SKULL BASE SURG, V4, P1, DOI 10.1055/s-2008-1058981; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Foguel D, 1998, J BIOL CHEM, V273, P9050, DOI 10.1074/jbc.273.15.9050; GAUTHIER JM, 1991, NEW BIOL, V3, P498; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laue MT, 1992, ANAL ULTRACENTRIFUGA, P90; MCBRIDE AA, 1997, HUMAN PAPILLOMAVIRUS, P54; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Mok YK, 1996, PROTEIN SCI, V5, P310; OLDFIELD TJ, 1994, P CCP4 STUD WEEK 1 M, P15; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131	29	88	93	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					805	809		10.1038/35001638	http://dx.doi.org/10.1038/35001638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693813				2022-12-24	WOS:000085423100060
J	Brazma, A; Robinson, A; Cameron, G; Ashburner, M				Brazma, A; Robinson, A; Cameron, G; Ashburner, M			One-stop shop for microarray data - Is a universal, public DNA-microarray database a realistic goal?	NATURE			English	Editorial Material									European Bioinformat Inst, Wellcome Trust Genome, Cambridge CB10 1SD, England	European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute	Brazma, A (corresponding author), European Bioinformat Inst, Wellcome Trust Genome, Campus, Cambridge CB10 1SD, England.	brazma@ebi.ac.uk		Brazma, Alvis/0000-0001-5988-7409				*CHIPP FOR, 1999, NATURE GENET S, V21; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Kaiser J, 1999, SCIENCE, V284, P410; Pennisi E, 1999, SCIENCE, V286, P449, DOI 10.1126/science.286.5439.449; 1999, NATURE GENET, V22, P211	5	101	106	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					699	700		10.1038/35001676	http://dx.doi.org/10.1038/35001676			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693778				2022-12-24	WOS:000085423100020
J	Kitov, PI; Sadowska, JM; Mulvey, G; Armstrong, GD; Ling, H; Pannu, NS; Read, RJ; Bundle, DR				Kitov, PI; Sadowska, JM; Mulvey, G; Armstrong, GD; Ling, H; Pannu, NS; Read, RJ; Bundle, DR			Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands	NATURE			English	Article							HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI; RECEPTOR; BINDING; IDENTIFICATION; PATHOGENESIS; GLYCOSIDES; TYPE-1; MICE	The diseases caused by Shiga and cholera toxins account for the loss of millions of lives each year(1). Both belong to the clinically significant subset of bacterial AB(5) toxins consisting of an enzymatically active A subunit that gains entry to susceptible mammalian cells after oligosaccharide recognition by the B-5 homopentamer(2,3), Therapies might target the obligatory oligosaccharide-toxin recognition event(4), but the low intrinsic affinity of carbohydrate-protein interactions hampers the development of low-molecular-weight inhibitors(5). The toxins circumvent low affinity by binding simultaneously to five or more cell-surface carbohydrates(6), Here we demonstrate the use of the crystal structure of the B-5 subunit Of Escherichia coli O157:H7 Shiga-like toxin I (SLT-I) in complex with an analogue of its carbohydrate receptor(6) to design an oligovalent, water-soluble carbohydrate ligand (named STARFISH), with subnanomolar inhibitory activity. The in vitro inhibitory activity is 1-10-million-fold higher than that of univalent ligands and is by far the highest molar activity of any inhibitor yet reported for Shiga-like toxins I and II. Crystallography of the STARFISH/Shiga-like toxin I complex explains this activity. Two trisaccharide receptors at the tips of each of five spacer arms simultaneously engage all five B subunits of two toxin molecules.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Alberta; University of Alberta; University of Alberta; University of Cambridge	Bundle, DR (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.		Kitov, Pavel/J-3714-2014; Ling, Hong/E-3729-2010; Read, Randy J/L-1418-2013	Read, Randy J/0000-0001-8273-0047				ARMSTRONG GD, 1991, J INFECT DIS, V164, P1160, DOI 10.1093/infdis/164.6.1160; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Bast DJ, 1999, MOL MICROBIOL, V32, P953, DOI 10.1046/j.1365-2958.1999.01405.x; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; DEGRANDIS S, 1987, J BACTERIOL, V169, P4313, DOI 10.1128/jb.169.9.4313-4319.1987; Dubber M, 1998, CARBOHYD RES, V310, P35, DOI 10.1016/S0008-6215(98)00155-4; FUCHS G, 1986, INFECT IMMUN, V53, P372, DOI 10.1128/IAI.53.2.372-377.1986; HOLMGREN J, 1992, GASTROENTEROL CLIN N, V21, P283; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Kitov PI, 1998, CARBOHYD RES, V307, P361, DOI 10.1016/S0008-6215(98)00053-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; Mulvey G, 1998, J MICROBIOL METH, V32, P247, DOI 10.1016/S0167-7012(98)00028-1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nyholm PG, 1996, CHEM BIOL, V3, P263, DOI 10.1016/S1074-5521(96)90106-4; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; Shimizu H, 1998, BIOCHEMISTRY-US, V37, P11078, DOI 10.1021/bi980946+; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STHILAIRE PM, 1994, BIOCHEMISTRY-US, V33, P14452, DOI 10.1021/bi00252a011; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993	30	730	757	1	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					669	672		10.1038/35001095	http://dx.doi.org/10.1038/35001095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688205				2022-12-24	WOS:000085288200057
J	Mayer, W; Niveleau, A; Walter, J; Fundele, R; Haaf, T				Mayer, W; Niveleau, A; Walter, J; Fundele, R; Haaf, T			Embryogenesis - Demethylation of the zygotic paternal genome	NATURE			English	Article							DNA-REPLICATION; PREIMPLANTATION DEVELOPMENT; MOUSE EMBRYOS; METHYLATION		Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Grenoble 1, Mol & Struct Virol Unit, F-38706 La Tronche, France	Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)								Adenot PG, 1997, DEVELOPMENT, V124, P4615; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BouniolBaly C, 1997, EXP CELL RES, V236, P201, DOI 10.1006/excr.1997.3708; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; HOWLETT SK, 1986, ROUX ARCH DEV BIOL, V195, P499, DOI 10.1007/BF00375890; MONK M, 1987, DEVELOPMENT, V99, P371; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; SCHEER U, 1987, EUR J CELL BIOL, V43, P358; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	10	1011	1066	0	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					501	502		10.1038/35000656	http://dx.doi.org/10.1038/35000656			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676950				2022-12-24	WOS:000085227300037
J	Mange, KC; Cizman, B; Joffe, M; Feldman, HI				Mange, KC; Cizman, B; Joffe, M; Feldman, HI			Arterial hypertension and renal allograft survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; DISEASE; PROGRESSION; RECIPIENTS; FAILURE	Context Several observational studies have investigated the significance of hypertension in renal allograft failure; however, these studies have been complicated by the lack of adjustment for baseline renal function, leaving the role of elevated blood pressure in allograft failure unclear. Objective To examine the relationship between blood pressure adjusted for renal function and survival after cadaveric allograft transplantation. Design Nonconcurrent historical cohort study conducted from 1985 through 1997. Setting University teaching hospital. Participants A total of 277 patients aged 18 years or older who underwent cadaveric renal transplantation without another simultaneous organ transplantation and whose allograft was functioning for a minimum of 1 year. Follow-up continued through 1997 (mean follow-up, 5.7 years). Main Outcome Measure Time to allograft failure (defined as death, return to dialysis, or retransplantation) by systolic, diastolic, and mean arterial blood pressure measurements at 1 year after transplantation. Results Multivariate Cox proportional hazards modeling demonstrated that nonwhite ethnicity, history of acute rejection, and nondiabetic kidney disease were significant predictors of failure (P = .01 for all), In addition, the calculated creatinine clearance at 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95% confidence interval [CI], 0.62-0.88). The RR per 10-mm Hg in crease in blood pressure measured at 1 year after transplantation, after adjustment for creatinine clearance, was 1.15 (95% CI, 1.02-1.30) for systolic pressure, 1.27 (95% CI, 1.01-1.60) for diastolic pressure, and 1.30 (95% CI, 1.05-1.61) for mean arterial pressure. Supplemental analyser that did not include death as a failure event or reduce the minimum allograft survival time for study subjects to 6 months yielded results consistent with the primary analysis. There was no evidence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes mellitus. Conclusions Systolic, diastolic, and mean arterial blood pressures at 1 year posttransplantation strongly predict allograft survival adjusted for baseline renal function. More aggressive control of blood pressure may prolong cadaveric allograft survival.	Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Feldman, HI (corresponding author), Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, 423 Guardian Dr,720 Blockley Hall, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006, P50DK045191] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07006, DK-45191] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAGNAC A, 1992, TRANSPLANTATION, V53, P766, DOI 10.1097/00007890-199204000-00012; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COSIO FG, 1995, KIDNEY INT, V47, P1136, DOI 10.1038/ki.1995.162; COX DR, 1972, J R STAT SOC B, V34, P187; Feldman HI, 1996, J AM SOC NEPHROL, V7, P151; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; LEE E, 1994, BIOMETRIKA, V81, P515; Opelz G, 1998, KIDNEY INT, V53, P217, DOI 10.1046/j.1523-1755.1998.00744.x; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RUGGENENTI P, 1993, KIDNEY INT, V43, P706, DOI 10.1038/ki.1993.101; VIANELLO A, 1993, AM J KIDNEY DIS, V21, P79, DOI 10.1016/0272-6386(93)70099-K; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085	15	229	241	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					633	638		10.1001/jama.283.5.633	http://dx.doi.org/10.1001/jama.283.5.633			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665703				2022-12-24	WOS:000084956500029
J	Shakespeare, J; Neve, E; Hodder, K				Shakespeare, J; Neve, E; Hodder, K			Is norethisterone a lifestyle drug? Results of database analysis	BRITISH MEDICAL JOURNAL			English	Article									Summertown Hlth Ctr, Oxford OX2 7BS, England; Oxfordshire Hlth Author, Oxford OX3 9LG, England		Shakespeare, J (corresponding author), Summertown Hlth Ctr, 160 Banbury Rd, Oxford OX2 7BS, England.							[Anonymous], 1999, CONCISE OXFORD DICT; COULTER A, 1995, INT J TECHNOL ASSESS, V11, P456, DOI 10.1017/S0266462300008679; *NHS CTR REV DISS, 1995, EFF HLTH CAR, V9; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL, V1; *STAT OFF, 1999, DRUG TAR	5	24	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	2000	320	7230					291	291		10.1136/bmj.320.7230.291	http://dx.doi.org/10.1136/bmj.320.7230.291			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650028	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000085132700025
J	Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC				Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC			Maturation dynamics of a viral capsid: Visualization of transitional intermediate states	CELL			English	Article							CRYOELECTRON MICROSCOPY; STRUCTURAL TRANSITIONS; BIOLOGICAL MACROMOLECULES; ELECTRON CRYOMICROSCOPY; CONFORMATIONAL-CHANGES; BACTERIAL-VIRUS; IN-VITRO; PROTEIN; DNA; BACTERIOPHAGE-T4	Typical of DNA bacteriophages and herpesviruses, HK97 assembles in two stages: polymerization and maturation. First, capsid protein polymerizes into closed shells; then, these precursors mature into larger, stabler particles. Maturation is initiated by proteolysis, producing a metastable particle primed for expansion-the major structural transition. We induced expansion in vitro by acidic pH and monitored the resulting changes by time-resolved X-ray diffraction and cryo-electron microscopy. The transition, which is not synchronized over the population, proceeds in a series of stochastically triggered subtransitions. Three distinct intermediates were identified, which are comparable to transitional states in protein folding. The intermediates' structures reveal the molecular events occurring during expansion. Integrated into a movie (see Dynamic Visualization below), they show capsid maturation as a dynamic process.	NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Stanford Univ, Stanford Linear Accelerator Ctr, SSRL, Palo Alto, CA 94309 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Steven, AC (corresponding author), NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA.		Conway, James F/A-2296-2010	Conway, James F/0000-0002-6581-4748; Duda, Robert/0000-0002-9517-2731	NCRR NIH HHS [P41 RR01209] Funding Source: Medline; NIAID NIH HHS [R01 AI040101, R01 AI40101] Funding Source: Medline; NIGMS NIH HHS [R01 GM47795, R01 GM047795] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAYER ME, 1973, VIROLOGY, V54, P465, DOI 10.1016/0042-6822(73)90157-8; Belnap DM, 1997, J STRUCT BIOL, V120, P44, DOI 10.1006/jsbi.1997.3896; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; COOKE R, 1995, FASEB J, V9, P636, DOI 10.1096/fasebj.9.8.7768355; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; Duda RL, 1998, CELL, V94, P55, DOI 10.1016/S0092-8674(00)81221-0; Flynn DL, 1997, CURR OPIN CHEM BIOL, V1, P190, DOI 10.1016/S1367-5931(97)80009-9; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Hendrix RW, 1998, ADV VIRUS RES, V50, P235, DOI 10.1016/S0065-3527(08)60810-6; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; Jardine PJ, 1998, J MOL BIOL, V284, P661, DOI 10.1006/jmbi.1998.2179; KING J, 1997, STRUCTURAL BIOL VIRU, P288; MULLER M, 1994, J STRUCT BIOL, V112, P199, DOI 10.1006/jsbi.1994.1021; Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024; Newcomb WW, 1996, J MOL BIOL, V263, P432, DOI 10.1006/jmbi.1996.0587; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SERWER P, 1978, J VIROL, V28, P917, DOI 10.1128/JVI.28.3.917-928.1978; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; STEVEN AC, 1990, BIOCHEMISTRY-US, V29, P5556, DOI 10.1021/bi00475a020; STEVEN AC, 1979, J SUPRAMOL STR CELL, V10, P1, DOI 10.1002/jss.400100102; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; Tuma R, 1998, P NATL ACAD SCI USA, V95, P9885, DOI 10.1073/pnas.95.17.9885; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; WALKER M, 1995, BIOPHYS J, V68, pS87; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; Wikoff WR, 1999, ACTA CRYSTALLOGR D, V55, P763, DOI 10.1107/S0907444998017661; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	46	120	127	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					253	263		10.1016/S0092-8674(00)81563-9	http://dx.doi.org/10.1016/S0092-8674(00)81563-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660048	Bronze			2022-12-24	WOS:000084932200009
J	Murakami, Y; Tsuyama, M; Kobayashi, Y; Kodama, H; Iba, K				Murakami, Y; Tsuyama, M; Kobayashi, Y; Kodama, H; Iba, K			Trienoic fatty acids and plant tolerance of high temperature	SCIENCE			English	Article							CHLOROPLAST OMEGA-3-FATTY-ACID DESATURASE; ENHANCED THERMAL TOLERANCE; ARABIDOPSIS DEFICIENT; GROWTH TEMPERATURE; MUTANT; LIPIDS; PHOTOSYNTHESIS; ACCLIMATION; STABILITY; MEMBRANES	The chloroplast membrane of higher plants contains an unusually high concentration of trienoic fatty acids. Plants grown in colder temperatures have a higher content of trienoic fatty acids. Transgenic tobacco plants in which the gene encoding chloroplast omega-3 fatty acid desaturase, which synthesizes trienoic fatty acids, was silenced contained a lower level of trienoic fatty acids than wild-type plants and were better able to acclimate to higher temperatures.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Dept Forestry, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Iba, K (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	koibascb@mbox.nc.kyushu-u.ac.jp						BERRY J, 1980, ANNU REV PLANT PHYS, V31, P491, DOI 10.1146/annurev.pp.31.060180.002423; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUGLY S, 1992, PLANT PHYSIOL, V99, P197, DOI 10.1104/pp.99.1.197; HUGLY S, 1989, PLANT PHYSIOL, V90, P1134, DOI 10.1104/pp.90.3.1134; IBA K, 1993, J BIOL CHEM, V268, P24099; KOBAYASHI Y, 1994, PHOTOSYNTH RES, V41, P419, DOI 10.1007/BF02183044; KODAMA H, 1994, PLANT PHYSIOL, V105, P601, DOI 10.1104/pp.105.2.601; KODAMA H, 1995, PLANT PHYSIOL, V107, P1177, DOI 10.1104/pp.107.4.1177; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; LEE JH, 1995, PLANT J, V8, P603, DOI 10.1046/j.1365-313X.1995.8040603.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; MCCONN M, 1994, PLANT PHYSIOL, V106, P1609, DOI 10.1104/pp.106.4.1609; MURAKAMI Y, UNPUB; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PEARCY RW, 1978, PLANT PHYSIOL, V61, P484, DOI 10.1104/pp.61.4.484; RAISON JK, 1982, BIOCHIM BIOPHYS ACTA, V688, P218, DOI 10.1016/0005-2736(82)90597-1; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; THOMAS PG, 1986, BIOCHIM BIOPHYS ACTA, V849, P131, DOI 10.1016/0005-2728(86)90104-0; WEIS E, 1988, SYM SOC EXP BIOL, V42, P329	21	295	352	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					476	479		10.1126/science.287.5452.476	http://dx.doi.org/10.1126/science.287.5452.476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642547				2022-12-24	WOS:000084929900045
J	Bellentani, S; Saccoccio, G; Masutti, F; Croce, LS; Brandi, G; Sasso, F; Cristanini, G; Tiribelli, C				Bellentani, S; Saccoccio, G; Masutti, F; Croce, LS; Brandi, G; Sasso, F; Cristanini, G; Tiribelli, C			Prevalence of and risk factors for hepatic steatosis in northern Italy	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	33rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver	APR 15-18, 1998	LISBON, PORTUGAL	European Assoc Study Liver			ALCOHOLIC LIVER-DISEASE; JEJUNOILEAL BYPASS; OBESE SUBJECTS; FATTY LIVER; WEIGHT-LOSS; ABNORMALITIES; FIBROSIS	Background: Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown. Objective: To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity. Design: Cross-sectional, observational study. Setting: Participants in the Dionysos Study. Patients: 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers). Measurements: Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done. Results: The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1-fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (CI, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P < 0.001), but heavy drinking was associated with only a 1.3-fold (CI, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis. Conclusions: Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.	Univ Trieste, Ctr Studi Fegato, Dept Biochem Biophys & Chem Macromol, I-34100 Trieste, Italy; Fondo Studio Malattie Fegato, Trieste, Italy	University of Trieste	Tiribelli, C (corresponding author), Univ Trieste, Ctr Studi Fegato, Dept Biochem Biophys & Chem Macromol, Via Giorgieri 1, I-34100 Trieste, Italy.	liver@fmc.univ.trieste.it	croce', lory saveria l/E-2565-2011; Brandi, Giovanni/AAD-6327-2021; Bellentani, Stefano/L-3600-2019; Tiribelli, Claudio/A-4716-2014	croce', lory saveria l/0000-0001-9890-7011; Brandi, Giovanni/0000-0003-0013-2858; Tiribelli, Claudio/0000-0001-6596-7595; Bellentani, Stefano/0000-0003-2836-8870				ADLER M, 1979, AM J MED, V67, P811, DOI 10.1016/0002-9343(79)90740-X; ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; Bellentani S, 1997, GUT, V41, P845, DOI 10.1136/gut.41.6.845; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BOULTON R, 1995, GASTROENTEROLOGY, V109, P1324, DOI 10.1016/0016-5085(95)90595-2; BRAILLON A, 1985, GUT, V26, P133, DOI 10.1136/gut.26.2.133; CONTE D, 1995, ITAL J GASTROENTEROL, V27, P363; CUBEAU J, 1980, REV EPIDEMIOL SANTE, V28, P367; DAY CP, 1994, BBA-LIPID LIPID MET, V1215, P33, DOI 10.1016/0005-2760(94)90089-2; FLEISS JL, 1981, STAT METHODS RATES P, P83; GODDARD CJR, 1992, DIGEST DIS, V10, P218, DOI 10.1159/000171360; HAINES NW, 1981, HEPATOLOGY, V1, P161, DOI 10.1002/hep.1840010212; HOSMER DW, 1989, APPL LOGISTIC; IKAI E, 1995, J HUM HYPERTENS, V9, P101; JOSEPH AEA, 1991, CLIN RADIOL, V43, P26, DOI 10.1016/S0009-9260(05)80350-2; LELBACH WK, 1976, PROGR LIVER DIS, P434; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; MARUBBIO AT, 1976, AM J CLIN PATHOL, V66, P684; Matsuura K, 1995, Nihon Shokakibyo Gakkai Zasshi, V92, P1743; MEIER P, 1988, ANAL CLIN MED, P7; Mezey E, 1998, HEPATOLOGY, V28, P901, DOI 10.1002/hep.510280401; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; PATON A, 1981, BRIT MED J, V283, P1248, DOI 10.1136/bmj.283.6301.1248; Perry IJ, 1998, DIABETES CARE, V21, P732, DOI 10.2337/diacare.21.5.732; PETERS RL, 1977, AM J CLIN NUTR, V30, P53, DOI 10.1093/ajcn/30.1.53; Ricci C, 1997, J HEPATOL, V27, P108, DOI 10.1016/S0168-8278(97)80288-7; SAVERYMUTTU SH, 1986, BRIT MED J, V292, P13, DOI 10.1136/bmj.292.6512.13; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; TIETZ NW, 1987, DUNDAMENTALS CLIN CH; VANTHIEL DH, 1985, CURR CONCEPTS GASTRO, V10, P3	33	949	995	2	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2000	132	2					112	117		10.7326/0003-4819-132-2-200001180-00004	http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	275ZZ	10644271				2022-12-24	WOS:000084852300003
J	Gupta, A; Wang, Y; Markram, H				Gupta, A; Wang, Y; Markram, H			Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex	SCIENCE			English	Article							RAT FRONTAL-CORTEX; CAT VISUAL-CORTEX; SYNAPTIC CONNECTIONS; NONPYRAMIDAL CELLS; PYRAMIDAL NEURONS; BASKET CELL; FACILITATION; CIRCUITS	A puzzling feature of the neocortex is the rich array of inhibitory interneurons. Multiple neuron recordings revealed numerous electrophysiological-anatomical subclasses of neocortical gamma-aminobutyric acid-ergic (GABAergic) interneurons and three types of GABAergic synapses. The type of synapse used by each interneuron to influence its neighbors follows three functional organizing principles. These principles suggest that inhibitory synapses could shape the impact of different interneurons according to their specific spatiotemporal patterns of activity and that GABAergic interneuron and synapse diversity may enable: combinatorial inhibitory effects in the neocortex.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Markram, H (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, 828-HSE, San Francisco, CA 94143 USA.							CAJAL SRY, 1911, HISTOLOGY DUE SYSTEM, V2; Cauli B, 1997, J NEUROSCI, V17, P3894; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; DEFELIPE J, 1982, BRAIN RES, V244, P9, DOI 10.1016/0006-8993(82)90898-8; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; FELDMAN ML, 1978, J COMP NEUROL, V179, P761, DOI 10.1002/cne.901790406; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591, DOI 10.1152/jn.1995.73.6.2591; GUPTA A, UNPUB; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; KAWAGUCHI Y, 1997, CEREB CORTEX, V7, P47; KISVARDAY ZF, 1985, J COMP NEUROL, V241, P111, DOI 10.1002/cne.902410202; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Martinotti C, 1889, ANN FRENIATR SCI AFF, V1, P314; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; SHOLL DA, 1953, J ANAT, V87, P387; Siegel M.R., 1988, NONPARAMETRIC STAT B; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; Steriade M, 1998, J NEUROPHYSIOL, V79, P483, DOI 10.1152/jn.1998.79.1.483; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Thomson AM, 1997, CEREB CORTEX, V7, P510, DOI 10.1093/cercor/7.6.510; White E.L., 1989, CORTICAL CIRCUITS SY; White EL, 1997, SOMATOSENS MOT RES, V14, P34, DOI 10.1080/08990229771204	27	774	780	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					273	278		10.1126/science.287.5451.273	http://dx.doi.org/10.1126/science.287.5451.273			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634775				2022-12-24	WOS:000084769600030
J	Foley, K				Foley, K			Dismantling the barriers: Providing palliative and pain care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; CANCER PAIN; ATTITUDES		Cornell Univ, Coll Med, New York, NY 10021 USA	Cornell University	Foley, K (corresponding author), Cornell Univ, Coll Med, New York, NY 10021 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Carron A T, 1999, Ann Intern Med, V130, P82; Foley Kathleen M., 1997, P2807; FOLEY KM, 1995, PAIN FORUM, V4, P163; *GALL I, 1997, SPIR BEL DYING PROC; *I MED DIV HLTH CA, 1997, APPROACHING DEATH IM; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEVIN DN, 1985, CANCER, V56, P2337, DOI 10.1002/1097-0142(19851101)56:9<2337::AID-CNCR2820560935>3.0.CO;2-W; MEIER DE, 1997, ANN INTERN MED, V127, P3; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; World Health Organization, 1990, CANC PAIN REL PALL C	12	19	19	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					115	115		10.1001/jama.283.1.115	http://dx.doi.org/10.1001/jama.283.1.115			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632292	hybrid			2022-12-24	WOS:000084514400037
J	Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD				Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD			Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV PROTEASE INHIBITORS; CD4 CELL COUNTS; COMBINATION THERAPY; CUBIC MILLIMETER; CONTROLLED TRIAL; ADVERSE EVENTS; DRUG-THERAPY; RITONAVIR; DISEASE; INDINAVIR	Context Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus. Objectives To ascertain if incidence of severe hepatotoxicity during antiretroviral therapy is similar for ail antiretroviral drug combinations, and to define the role of chronic viral hepatitis in its development. Design Prospective cohort study. Setting University-based urban HIV clinic. Patients A total of 298 patients who were prescribed new antiretroviral therapies between January 1996 and January 1998, 211 (71%) of whom received protease inhibitors as part of combination therapy (median follow-up, 182 days) and 87 (29%) of whom received dual nucleoside analog regimens (median follow-up, 167 days). Chronic hepatitis C and B virus infection was present in 154 (52%) and 8 (2.7%) patients, respectively. Main Outcome Measure Severe hepatotoxicity, defined as a grade 3 or 4 change in levels of serum alanine aminotransferase and aspartate aminotransferase, evaluated before and during therapy. Results Severe hepatotoxicity was observed in 31 (10.4%) of 298 patients (95% confidence interval [CI], 7.2%-14.4%). Ritonavir use was associated with a higher incidence of toxicity (30%; 95% CI, 17.9%-44.6%). However, no significant difference was detected in hepatotoxicity incidence in other treatment groups, ie, nucleoside analogs (5.7%; 95% CI, 1.2%-12.9%), nelfinavir (5.9%; 95% CI, 1.2%-16.2%), saquinavir (5.9%; 95% Cl, 0.15%-28.7%), and indinavir (6.8%; 95% CI, 3.0%-13.1%). Although chronic viral hepatitis was associated with an increased risk of severe hepatotoxicity among patients prescribed nonritonavir regimens (relative risk, 3.7; 95% CI, 1.0-11.8), most patients with chronic hepatitis C or B virus infection (88%) did not experience significant toxic effects. Rate of severe toxicity with use of any protease inhibitor in patients with hepatitis C infection was 12.2% (13/107; 95% CI, 6.6%-19.9%). In multivariate logistic regression, only ritonavir (adjusted odds ratio [AOR], 8.6; 95% CI, 3.0-24.6) and a CD4 cell count increase of more than 0.05 x 10(9)/L (AOR, 3.6; 95% CI, 1.0-12.9) were associated with severe hepatotoxicity. No irreversible outcomes were seen in patients with severe hepatotoxicity. Conclusions Our data indicate that use of ritonavir may increase risk of severe hepatotoxicity. Although hepatotoxicity may be more common in persons with chronic viral hepatitis, these data do not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Epidemiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sulkowski, MS (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Suite 450 C, Baltimore, MD 21287 USA.	msulkows@jhmi.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602] Funding Source: NIH RePORTER; AHRQ HHS [HS-07809] Funding Source: Medline; NIDA NIH HHS [DA-11602] Funding Source: Medline; FDA HHS [FD-U-000977] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FDA HHS		*AIDS CLIN TRIALS, 1996, TABL GRAD SEV AD ADV; [Anonymous], 1996, Lancet, V348, P283; Arribas JR, 1998, AIDS, V12, P1722; Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; BODSWORTH NJ, 1991, J INFECT DIS, V163, P1138, DOI 10.1093/infdis/163.5.1138; Brau N, 1997, LANCET, V349, P924, DOI 10.1016/S0140-6736(05)62700-6; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CAMERON DW, 1998, 5 C RETR OPP INF FEB; Carroll DS, 1998, PALLIATIVE MED, V12, P51, DOI 10.1191/026921698666041220; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DELMAS C, 1998, 12 WORLD AIDS C JUN; Gill MJ, 1998, AIDS, V12, P1400; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; John M, 1998, AIDS, V12, P2289, DOI 10.1097/00002030-199817000-00010; Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423; LEE BL, 1992, CLIN INFECT DIS, V14, P773, DOI 10.1093/clinids/14.3.773-a; LEE C, IN PRESS J ACQUIR IM; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Markowitz M, 1998, J INFECT DIS, V177, P1533, DOI 10.1086/515312; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Matsuda J, 1997, LANCET, V350, P364, DOI 10.1016/S0140-6736(05)63416-2; Miwa LJ, 1997, ARCH INTERN MED, V157, P2129, DOI 10.1001/archinte.157.18.2129; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; Rodriguez-Rosado R, 1998, AIDS, V12, P1256, DOI 10.1097/00002030-199810000-00025; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Thomas DL, 1998, HEPATOLOGY, V28, p568A; Ungo JR, 1998, AM J RESP CRIT CARE, V157, P1871, DOI 10.1164/ajrccm.157.6.9711039; Vento S, 1998, AIDS, V12, P116; VERDON R, 1998, 38 INT C ANT AG CHEM; Zylberberg H, 1996, CLIN INFECT DIS, V23, P1117, DOI 10.1093/clinids/23.5.1117; Zylberberg H, 1998, CLIN INFECT DIS, V26, P1104, DOI 10.1086/520281; 1998, MMWR MORB MORTAL WKL, V47, P38	39	690	710	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					74	80		10.1001/jama.283.1.74	http://dx.doi.org/10.1001/jama.283.1.74			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632283				2022-12-24	WOS:000084514400028
J	Chua, K; Reed, R				Chua, K; Reed, R			The RNA splicing factor hSlu7 is required for correct 3 ' splice-site choice	NATURE			English	Article							2ND CATALYTIC STEP; U5 SNRNA LOOP-1; CROSS-LINKING; YEAST; PROTEIN; 3'-SPLICE-SITE; MUTATIONS; SELECTION; SUGGEST; SLU7	The production of correctly spliced messenger RNA requires two catalytic splicing steps(1-3). During step II, exon 1 attacks an adenine-guanine (AG) dinucleotide at the 3' splice site. This AG is usually located between 18 and 40 nucleotides downstream from the branch site, and closer AGs are skipped in favour of AGs located more optimally downstream(4-6). At present, little is understood about how the correct AG is distinguished from other AGs. Here we describe a metazoan splicing factor (hSlu7) that is required for selection of the correct AG. In the absence of hSlu7, use of the correct AG is suppressed and incorrect AGs are activated. We investigated this loss of fidelity by analysing spliceosomes assembled in the absence of hSlu7. These studies reveal that exon 1 is loosely associated with these spliceosomes. Thus, the improperly held exon cannot access the correct AG, but can attack other AGs indiscriminately. We conclude that hSlu7 is required to hold exon 1 tightly within the spliceosome for attack on a prespecified AG.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reed, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Brys A, 1996, RNA, V2, P707; Burge CB, 1999, RNA WORLD, P525; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Chua K, 1999, GENE DEV, V13, P841, DOI 10.1101/gad.13.7.841; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; DAS R, IN PRESS RNA; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Horowitz DS, 1997, GENE DEV, V11, P139, DOI 10.1101/gad.11.1.139; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; MOORE MJ, 1993, RNA WORLD, P306; Newman AJ, 1995, RNA, V1, P968; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; O'Keefe RT, 1998, EMBO J, V17, P565, DOI 10.1093/emboj/17.2.565; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Segault V, 1999, MOL CELL BIOL, V19, P2782; SMITH CW, 1993, MOL CELL BIOL, V13, P4949; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Umen JG, 1995, RNA, V1, P869; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	27	76	78	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					207	210		10.1038/46086	http://dx.doi.org/10.1038/46086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647016				2022-12-24	WOS:000083716400057
J	Annane, D; Sebille, V; Troche, G; Raphael, JC; Gajdos, P; Bellissant, E				Annane, D; Sebille, V; Troche, G; Raphael, JC; Gajdos, P; Bellissant, E			A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPSIS SYNDROME; ADRENOCORTICAL RESPONSIVENESS; HEMODYNAMIC IMPROVEMENT; ADRENAL INSUFFICIENCY; REPLACEMENT; SURVIVAL; ILLNESS; SERUM; MULTICENTER; MORTALITY	Context The hypothalamic-pituitary-adrenal axis is a major determinant of the host response to stress. The relationship between its activation and patient outcome is not known. Objective To evaluate the prognostic Value of cortisol levels and a short corticotropin stimulation test in patients with septic shock. Design and Setting Prospective inception cohort study conducted between October 1991 and September 1995 in 2 teaching hospital adult intensive care units in France. Participants A total of 189 consecutive patients who met clinical criteria for septic shock. Intervention A short corticotropin stimulation test was performed in all patients by intravenously injecting 0.25 mg of tetracosactrin; blood samples were taken immediately before the test (T0) and 30 (T30) and 60 (T60) minutes afterward, Main Outcome Measures Twenty-eight-day mortality as a function of variables collected at the onset of septic shock, including cortisol levels before the corticotropin test and the cortisol response to corticotropin (Delta max, defined as the difference between T0 and the highest value between T30 and T60). Results The 28-day mortality was 58% (95% confidence interval [CI], 51%-65%)and median time to death was 17 days (95% CI, 14-27 days). In multivariate analysis, independent predictors of death (P less than or equal to.001 for all) were McCabe score greater than 0, organ system failure score greater than 2, arterial lactate level greater than 2.8 mmol/L, ratio of PaO2 to fraction of inspired oxygen no more than 160 mm Hg, cortisol level at T0 greater than 34 mu g/dL and Delta max no more than 9 mu g/dL. Three groups of patient prognoses were identified: good (cortisol level at T0 less than or equal to 34 mu g/dL and Delta max >9 mu g/dL; 28-day mortality rate, 26%), intermediate (cortisol level at T0 34 mu g/dL and Delta max less than or equal to 9 mu g/dL or cortisol level at T0 >34 mu g/dL and Delta max >9 Delta g/dL; 28-day mortality rate, 67%), and poor (cortisol level at T0 >34 mu g/dL and Delta max less than or equal to 9 mu g/dL; 28-day mortality rate, 82%). Conclusion Our data suggest that a short corticotropin test has a good prognostic value and could be helpful in identifying patients with septic shock at high risk for death.	Hop Raymond Poincare, Serv Reanimat Med, Dept Intens Care Unit, Sch Med Paris Ouest, F-92380 Garches, France; Hosp Antoine Beclerc, Dept Intens Care Unit, Clamart, France; Univ Rennes 1, Hosp Pontchaillou, Dept Pharmacol, Rennes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU Rennes; Universite de Rennes	Annane, D (corresponding author), Hop Raymond Poincare, Serv Reanimat Med, Dept Intens Care Unit, Sch Med Paris Ouest, 104 Blvd Raymond Poincare, F-92380 Garches, France.	djillali.annane@rpc.ap-hop-paris.fr	Sebille, Veronique/I-3309-2015; Annane, Djillali/R-7947-2019	Sebille, Veronique/0000-0002-0780-7742; Troche, Gilles/0000-0002-8150-6630				Annane D, 1998, BRIT J CLIN PHARMACO, V46, P589; Annane D, 1996, CRIT CARE MED, V24, P899, DOI 10.1097/00003246-199605000-00035; ANNANE D, 1996, BR J INTENS CARE, V6, P260; Aygen B, 1997, EXP CLIN ENDOCR DIAB, V105, P182, DOI 10.1055/s-0029-1211749; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUACHOUR G, 1995, INTENS CARE MED, V21, P57, DOI 10.1007/BF02425155; BRIEGEL J, 1992, INTENS CARE MED, V18, P318, DOI 10.1007/BF01706486; BRIEGEL J, 1991, LANCET, V338, P507, DOI 10.1016/0140-6736(91)90575-A; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; FINLAY WEI, 1982, LANCET, V1, P1414; FIRSCHEIN HE, 1957, ENDOCRINOLOGY, V60, P347, DOI 10.1210/endo-60-3-347; FRIDERICHSEN C, 1918, JB KINDERHEILKUNDE, P87; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; JURNEY TH, 1987, CHEST, V92, P292, DOI 10.1378/chest.92.2.292; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Matot I, 1998, CRIT CARE MED, V26, P627, DOI 10.1097/00003246-199804000-00002; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MCKEE JI, 1983, LANCET, V1, P484; MELBY JC, 1958, J CLIN INVEST, V37, P1791, DOI 10.1172/JCI103772; MORAN JL, 1994, INTENS CARE MED, V20, P489, DOI 10.1007/BF01711901; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; PUGEAT M, 1989, CLIN CHEM, V35, P1675; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; ROTHWELL PM, 1995, CRIT CARE MED, V23, P78, DOI 10.1097/00003246-199501000-00015; SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002; SCHNEIDER AJ, 1991, INTENS CARE MED, V17, P436, DOI 10.1007/BF01720688; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SIBBALD WJ, 1977, ANN SURG, V186, P29, DOI 10.1097/00000658-197707000-00005; SONI A, 1995, AM J MED, V98, P266, DOI 10.1016/S0002-9343(99)80373-8; SPAN LFR, 1992, INTENS CARE MED, V18, P93, DOI 10.1007/BF01705039; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; WADE CE, 1988, J CLIN ENDOCR METAB, V67, P223, DOI 10.1210/jcem-67-2-223; Waterhouse R, 1911, LANCET, V1, P577; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001	46	680	743	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1038	1045		10.1001/jama.283.8.1038	http://dx.doi.org/10.1001/jama.283.8.1038			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697064	Bronze			2022-12-24	WOS:000085308600033
J	Zeng, WL; Wharton, KA; Mack, JA; Wang, K; Gadbaw, M; Suyama, K; Klein, PS; Scott, MP				Zeng, WL; Wharton, KA; Mack, JA; Wang, K; Gadbaw, M; Suyama, K; Klein, PS; Scott, MP			Naked cuticle encodes an inducible antagonist of Wnt signalling	NATURE			English	Article							DROSOPHILA EMBRYOS; IMAGINAL DISKS; CELL FATES; WINGLESS; POLARITY; GENE; EXPRESSION; XENOPUS; EPIDERMIS; INDUCTION	During animal development, cells have to respond appropriately to localized secreted signals. Proper responses to Hedgehog, transforming growth factor-beta, epidermal growth factor and fibroblast growth factor/Ras signals require cognate inducible antagonists such as Patched, Dad, Argos and Sprouty(1). Wnt signals are crucial in development and neoplasia(2). Here we show that naked cuticle (nkd), a Drosophila segment-polarity gene, encodes an inducible antagonist for the Wnt signal Wingless (Wg). In fly embryos and imaginal discs nkd transcription is induced by Wg. In embryos, decreased nkd function has an effect similar to excess Wg; at later stages such a decrease appears to have no effect. Conversely, overproduction of Nkd in Drosophila and misexpression of Nkd in the vertebrate Xenopus laevis result in phenotypes resembling those of loss of Wg/Wnt function. nkd encodes a protein with a single EF hand (a calcium-binding motif) that is most similar to the recoverin family of myristoyl switch proteins. Nkd may therefore Link ion fluxes to the regulation of the potency, duration or distribution of Wnt signals. Signal-inducible feedback antagonists such as nkd may limit the effects of Wnt proteins in development and disease.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B300,Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B300,Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B300,Dept Pathol, Stanford, CA 94305 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; University of Pennsylvania	Scott, MP (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B300,Dept Dev Biol, 279 Campus Dr, Stanford, CA 94305 USA.			Wang, Kevin/0000-0002-5305-6791	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BAKER NE, 1988, DEVELOPMENT, V102, P489; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DINARDO S, 1994, CURR OPIN GENET DEV, V4, P529, DOI 10.1016/0959-437X(94)90068-E; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Itoh K, 1999, GENE DEV, V13, P2328, DOI 10.1101/gad.13.17.2328; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; MA CY, 1995, DEVELOPMENT, V121, P2279; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; Moline MM, 1999, DEVELOPMENT, V126, P4375; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; Pai LM, 1997, DEVELOPMENT, V124, P2255; Pazdera TM, 1998, DEVELOPMENT, V125, P3427; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Sanson B, 1999, CELL, V98, P207, DOI 10.1016/S0092-8674(00)81015-6; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Steitz MC, 1998, DEV BIOL, V197, P218, DOI 10.1006/dbio.1998.8884	30	176	186	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					789	795		10.1038/35001615	http://dx.doi.org/10.1038/35001615			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693810				2022-12-24	WOS:000085423100057
J	Porath, D; Bezryadin, A; de Vries, S; Dekker, C				Porath, D; Bezryadin, A; de Vries, S; Dekker, C			Direct measurement of electrical transport through DNA molecules	NATURE			English	Article							DISTANCE	Attempts to infer DNA electron transfer from fluorescence quenching measurements(1-9) on DNA strands doped with donor and acceptor molecules have spurred intense debate(10,11) over the question of whether or not this important biomolecule is able to conduct electrical charges. More recently, first electrical transport measurements on micrometre-long DNA 'ropes'(12), and also on large numbers of DNA molecules in films(13), have indicated that DNA behaves as a good linear conductor. Here we present measurements of electrical transport through individual 10.4-nm-long, double-stranded poly(G)-poly(C) DNA molecules connected to two metal nanoelectrodes, that indicate, by contrast, large-bandgap semiconducting behaviour. We obtain nonlinear current-voltage curves that exhibit a voltage gap at low applied bias. This is observed in air as well as in vacuum down to cryogenic temperatures. The voltage dependence of the differential conductance exhibits a peak structure, which is suggestive of the charge carrier transport being mediated by the molecular energy bands of DNA.	Delft Univ Technol, Dept Appl Sci, NL-2628 CJ Delft, Netherlands	Delft University of Technology	Dekker, C (corresponding author), Delft Univ Technol, Dept Appl Sci, POB 5046, NL-2628 CJ Delft, Netherlands.	dekker@qt.tn.tudelft.nl	Bezryadin, Alexey/H-1815-2016	Bezryadin, Alexey/0000-0002-4822-6960; Dekker, Cees/0000-0001-6273-071X				Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; BAKHSHI AK, 1994, PROG BIOPHYS MOL BIO, V61, P187, DOI 10.1016/0079-6107(94)90001-9; BARBARA PF, 1999, ADV CHEM PHYS, V107, pCH13; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; Bezryadin A, 1997, J VAC SCI TECHNOL B, V15, P793, DOI 10.1116/1.589411; Bezryadin A, 1997, APPL PHYS LETT, V71, P1273, DOI 10.1063/1.119871; Datta S, 1997, PHYS REV LETT, V79, P2530, DOI 10.1103/PhysRevLett.79.2530; ELEY DD, 1962, T FARADAY SOC, V58, P411, DOI 10.1039/tf9625800411; Fink HW, 1999, NATURE, V398, P407, DOI 10.1038/18855; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Grozema FC, 1999, INT J QUANTUM CHEM, V75, P1009, DOI 10.1002/(SICI)1097-461X(1999)75:6<1009::AID-QUA5>3.0.CO;2-A; Henderson PT, 1999, P NATL ACAD SCI USA, V96, P8353, DOI 10.1073/pnas.96.15.8353; Hutter M, 1996, J AM CHEM SOC, V118, P7574, DOI 10.1021/ja953370+; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; LADIK J, 1971, INT J QUANTUM CHEM, V4, P307; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; Meggers E, 1998, J AM CHEM SOC, V120, P12950, DOI 10.1021/ja983092p; Okahata Y, 1998, J AM CHEM SOC, V120, P6165, DOI 10.1021/ja980165w; Taubes G, 1997, SCIENCE, V275, P1420, DOI 10.1126/science.275.5305.1420; VANLITH D, 1986, J CHEM SOC FARAD T 1, V82, P2933, DOI 10.1039/f19868202933; Wan CZ, 1999, P NATL ACAD SCI USA, V96, P6014, DOI 10.1073/pnas.96.11.6014; WILSON EK, 1998, CHEM ENG NEWS, P2751	22	1532	1596	7	306	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					635	638		10.1038/35001029	http://dx.doi.org/10.1038/35001029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688194				2022-12-24	WOS:000085288200046
J	Meigs, JB; Mittleman, MA; Nathan, DM; Tofler, GH; Singer, DE; Murphy-Sheehy, PM; Lipinsky, I; D'Angostino, R; Wilson, PWF				Meigs, JB; Mittleman, MA; Nathan, DM; Tofler, GH; Singer, DE; Murphy-Sheehy, PM; Lipinsky, I; D'Angostino, R; Wilson, PWF			Hyperinsulinemia, hyperglucemia, and impaired hemostasis - The Framingham offspring study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; INSULIN-RESISTANCE SYNDROME; CORONARY-HEART-DISEASE; LINKED IMMUNOSORBENT-ASSAY; VON-WILLEBRAND-FACTOR; RISK FACTOR; VASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE; OBESE SUBJECTS; MYOCARDIAL-INFARCTION	Context Increased risk for cardiovascular disease in persons with glucose intolerance (impaired glucose tolerance and type 2 diabetes mellitus) is not fully explained by concomitant elevations in traditional atherosclerosis risk factors. Hyperinsulinemia associated with glucose intolerance may increase risk directly, or its effect could be mediated through impaired hemostatic function. Objective To evaluate associations between fasting insulin levels and hemostatic factors in subjects with normal and impaired glucose homeostasis. Design Cross-sectional analysis conducted between January 1991 and June 1995. Setting The population-based Framingham Offspring Study. Subjects A total of 1331 men and 1631 women aged 26 to 82 years, without diagnosed diabetes or cardiovascular disease and classified as having normal glucose tolerance (80.2%) or glucose intolerance (impaired glucose tolerance and impaired fasting glucose combined, 15.2%; previously undiagnosed diabetes, 4.7%) using an oral glucose tolerance test. Main Outcome Measures Trends across quintiles of fasting insulin in levels of plasminogen activator inhibitor 1 (PAI-1) antigen, tissue-type plasminogen activator (tPA) antigen, von Willebrand factor (VWF) antigen, factor VII antigen, fibrinogen, and plasma viscosity. We stratified analyses by sex and glucose tolerance status and adjusted hemostatic factor levels for obesity, lipid levels, and traditional cardiovascular disease risk factors. Results Mean levels of all hemostatic factors (except for fibrinogen in men) increased across fasting insulin quintiles among subjects with normal glucose tolerance (P<.001 for trend). Levels of PAI-1 and tPA antigens, but not other hemostatic factors, were higher comparing subjects with glucose intolerance with those with normal glucose tolerance (P<.001). Among subjects with glucose intolerance, levels of PAI-1 and tPA antigen in men and women (P<.01 for trend) and VWF antigen in men (P<.05 for trend) increased significantly across insulin quintiles, but levels of factor VII antigen, fibrinogen, and plasma viscosity did not increase. Conclusions Elevated levels of fasting insulin are associated with impaired fibrinolysis and hypercoagulability in subjects with normal glucose tolerance. Hyperinsulinemia is associated primarily with impaired fibrinolysis in subjects with glucose intolerance. Excess risk for cardiovascular disease associated with hyperinsulinemia and glucose intolerance may be mediated in part by enhanced potential for acute thrombosis.	Massachusetts Gen Hosp, Gen Internal Med Unit S50 9, Div Gen Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Inst Prevent & Cardiovasc Dis, Cardiovasc Div,Beth Israel Deaconess Med Ctr, Boston, MA USA; Boston Univ, Dept Math, Stat & Consulting Unit, Boston, MA 02215 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Framingham Heart Dis Epidemiol Study, Framingham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Boston University; Framingham Heart Study	Meigs, JB (corresponding author), Massachusetts Gen Hosp, Gen Internal Med Unit S50 9, Div Gen Med, Boston, MA 02114 USA.	jmeigs@partners.org	Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657; Mittleman, Murray/0000-0001-9788-7274	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048157] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38083, R01 HL48157] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491; Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; ANDERSON RL, 1995, AM J EPIDEMIOL, V142, P724, DOI 10.1093/aje/142.7.724; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; ASPLUNDCARLSON A, 1993, DIABETOLOGIA, V36, P817, DOI 10.1007/BF00400356; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Calles-Escandon J, 1998, DIABETES, V47, P290, DOI 10.2337/diabetes.47.2.290; CIGOLINI M, 1994, ATHEROSCLEROSIS, V106, P139, DOI 10.1016/0021-9150(94)90119-8; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CUPPLES LA, 1988, FRAMINGHAM STUDY EPI; DECLERCK PJ, 1988, BLOOD, V71, P220; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Eliasson M, 1997, DIABETES CARE, V20, P1252, DOI 10.2337/diacare.20.8.1252; ELIASSON M, 1994, METABOLISM, V43, P1579, DOI 10.1016/0026-0495(94)90020-5; Emanuele N, 1998, ARCH INTERN MED, V158, P2485, DOI 10.1001/archinte.158.22.2485; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; Gavin JR, 1997, DIABETES CARE, V20, P1183; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; GRANT PJ, 1990, CLIN SCI, V79, P513, DOI 10.1042/cs0790513; Haffner SM, 1998, STROKE, V29, P1498, DOI 10.1161/01.STR.29.8.1498; HAFFNER SM, 1994, J CLIN ENDOCR METAB, V79, P1806, DOI 10.1210/jc.79.6.1806; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; LATRON Y, 1991, ARTERIOSCLER THROMB, V11, P1821, DOI 10.1161/01.ATV.11.6.1821; Lindahl B, 1996, INT J EPIDEMIOL, V25, P291, DOI 10.1093/ije/25.2.291; Mansfield MW, 1996, CIRCULATION, V94, P2171, DOI 10.1161/01.CIR.94.9.2171; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEDVESCEK M, 1990, FIBRINOLYSIS, V4, P89, DOI 10.1016/0268-9499(90)90371-P; Meigs JB, 1997, DIABETES, V46, P1594, DOI 10.2337/diabetes.46.10.1594; Missov RM, 1996, DIABETES CARE, V19, P157, DOI 10.2337/diacare.19.2.157; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MYKKANEN L, 1994, ARTERIOSCLER THROMB, V14, P1264, DOI 10.1161/01.ATV.14.8.1264; MYKKANEN L, 1997, DIABETES S1, V46, pA72; Nagi DK, 1996, DIABETIC MED, V13, P59, DOI 10.1002/(SICI)1096-9136(199601)13:1<59::AID-DIA2>3.0.CO;2-Z; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATHAN DM, 1981, CLIN CHEM, V27, P1261; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; Pandolfi A, 1996, DIABETOLOGIA, V39, P1425, DOI 10.1007/s001250050594; PENNY WF, 1991, CIRCULATION, V83, P1630, DOI 10.1161/01.CIR.83.5.1630; Pyorala M, 1998, CIRCULATION, V98, P398, DOI 10.1161/01.CIR.98.5.398; RANBY M, 1986, CLIN CHEM, V32, P2160; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1996, DIABETES S2, V45, pA52; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothman K., 1998, MODERN EPIDEMIOLOGY; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SAS Institute Inc, 1989, SAS STAT US GUID, V2; Savage PJ, 1996, ANN INTERN MED, V124, P123, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00008; SCHNEIDER DJ, 1993, DIABETES, V42, P1, DOI 10.2337/diabetes.42.1.1; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; Sobel BE, 1999, CIRCULATION, V99, P2496, DOI 10.1161/01.CIR.99.19.2496; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study Group, 1996, ANN INTERN MED, V124, P136; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VERHEUGT FWA, 1987, AM J CARDIOL, V59, P1075, DOI 10.1016/0002-9149(87)90851-4; VUORINENMARKKOLA H, 1992, THROMB HAEMOSTASIS, V67, P117; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	77	422	450	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					221	228		10.1001/jama.283.2.221	http://dx.doi.org/10.1001/jama.283.2.221			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634338	Bronze			2022-12-24	WOS:000084661400028
J	Burns, A				Burns, A			Might olfactory dysfunction be a marker of early Alzheimer's disease?	LANCET			English	Editorial Material							DEFICITS		Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England	University of Manchester	Burns, A (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.			Burns, Alistair/0000-0002-9837-0645				BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662; COOPER AF, 1976, BRIT J PSYCHIAT, V129, P216, DOI 10.1192/bjp.129.3.216; EICHENBAUM H, 1983, BRAIN RES B, V18, P597; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; Graves AB, 1999, NEUROLOGY, V53, P1480, DOI 10.1212/WNL.53.7.1480; KOSS E, 1988, NEUROLOGY, V38, P1228, DOI 10.1212/WNL.38.8.1228; Pearson RCA, 1996, NEURODEGENERATION, V5, P429, DOI 10.1006/neur.1996.0058; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Serby M, 1996, BIOL PSYCHIAT, V39, P375, DOI 10.1016/0006-3223(95)00472-6; SERBY M, 1991, AM J PSYCHIAT, V148, P357	10	18	19	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					84	85		10.1016/S0140-6736(99)90402-6	http://dx.doi.org/10.1016/S0140-6736(99)90402-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288HT	10675162				2022-12-24	WOS:000085557200006
J	Hein, L; Altman, JD; Kobilka, BK				Hein, L; Altman, JD; Kobilka, BK			Two functionally distinct alpha(2)-adrenergic receptors regulate sympathetic neurotransmission	NATURE			English	Article							PRESYNAPTIC ALPHA(2)-AUTORECEPTORS; HEART-FAILURE; ALPHA(2A)-ADRENERGIC RECEPTOR; SUBTYPE; RAT; BRAIN; MICE; GENE; INHIBITION; ALPHA(2D)	The sympathetic nervous system regulates cardiovascular function by activating adrenergic receptors in the heart, blood vessels and kidney(1), alpha(2)-Adrenergic receptors are known to have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system(2-5); however, the individual roles of the three highly homologous alpha(2)-adrenergic-receptor subtypes (alpha(2A), alpha(2B), alpha(2C)) in this process are not known. We have now studied neurotransmitter release in mice in which the genes encoding the three alpha(z)-adrenergic-receptor subtypes were disrupted. Here we show that both the alpha(2A)- and alpha(2C)-subtypes are required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. alpha(2A)-Adrenergic receptors inhibit transmitter release at high stimulation frequencies, whereas the a,c-subtype modulates neurotransmission at lower levels of nerve activity. Both low- and high-frequency regulation seem to be physiologically important, as mice lacking both alpha(2A)- and alpha(2C)-receptor subtypes have elevated plasma noradrenaline concentrations and develop cardiac hypertrophy with decreased left ventricular contractility by four months of age.	Stanford Univ, Beckman Ctr B157, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; University of Wurzburg	Kobilka, BK (corresponding author), Stanford Univ, Beckman Ctr B157, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990				Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; BYLUND DB, 1994, PHARMACOL REV, V46, P121; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Graefe KH, 1997, N-S ARCH PHARMACOL, V356, P115, DOI 10.1007/PL00005018; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Langer SZ, 1997, TRENDS PHARMACOL SCI, V18, P95, DOI 10.1016/S0165-6147(96)01034-6; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; LIMBERGER N, 1995, N-S ARCH PHARMACOL, V352, P43; LINK R, 1992, MOL PHARMACOL, V42, P16; LINK RE, 1995, MOL PHARMACOL, V48, P48; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; McLachlan EM, 1997, J PHYSIOL-LONDON, V501, P165, DOI 10.1111/j.1469-7793.1997.165bo.x; Miller RJ, 1998, ANNU REV PHARMACOL, V38, P201, DOI 10.1146/annurev.pharmtox.38.1.201; MOLDERINGS GJ, 1995, N-S ARCH PHARMACOL, V352, P483; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sallinen J, 1998, J NEUROSCI, V18, P3035; SINGER EA, 1988, TRENDS PHARMACOL SCI, V9, P274, DOI 10.1016/0165-6147(88)90004-1; SMITH K, 1995, BRIT J PHARMACOL, V115, P316, DOI 10.1111/j.1476-5381.1995.tb15879.x; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; STJARNE L, 1989, REV PHYSL BIOCH PHAR, V112, P4; TAUBE HD, 1977, N-S ARCH PHARMACOL, V299, P123, DOI 10.1007/BF00498554; TAYLOR AA, 1994, J CLIN PHARMACOL, V34, P363, DOI 10.1002/j.1552-4604.1994.tb04976.x; Trendelenburg AU, 1997, N-S ARCH PHARMACOL, V356, P721, DOI 10.1007/PL00005111; TRENDELENBURG AU, 1993, N-S ARCH PHARMACOL, V348, P35, DOI 10.1007/BF00168534; Wahl CA, 1996, N-S ARCH PHARMACOL, V354, P253	30	396	412	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					181	184		10.1038/46040	http://dx.doi.org/10.1038/46040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647009				2022-12-24	WOS:000083716400050
J	Odenbreit, S; Puls, J; Sedlmaier, B; Gerland, E; Fischer, W; Haas, R				Odenbreit, S; Puls, J; Sedlmaier, B; Gerland, E; Fischer, W; Haas, R			Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion	SCIENCE			English	Article							VACUOLATING CYTOTOXIN; SHUTTLE MUTAGENESIS; VIRULENCE FACTORS; SYSTEM; PROTEIN; STRAINS; TRANSFORMATION; EXPRESSION	The Gram-negative bacterium Helicobacter pylori is a causative agent of gastritis and peptic ulcer disease in humans. Strains producing the CagA antigen (cagA(+)) induce strong gastric inflammation and are strongly associated with gastric adenocarcinoma and MALT Lymphoma. We show here that such strains translocate the bacterial protein CagA into gastric epithelial cells by a type IV secretion system, encoded by the cag pathogenicity island. CagA is tyrosine-phosphorylated and induces changes in the tyrosine phosphorylation state of distinct cellular proteins. Modulation of host cells by bacterial protein translocation adds a new dimension to the chronic Helicobacter infection with yet unknown consequences.	Univ Munich, Max von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany	University of Munich	Haas, R (corresponding author), Univ Munich, Max von Pettenkofer Inst Hyg & Med Microbiol, Pettenkoferstr 9A, D-80336 Munich, Germany.							Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; HAAS R, 1993, MOL MICROBIOL, V8, P753, DOI 10.1111/j.1365-2958.1993.tb01618.x; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Kahrs AF, 1995, GENE, V167, P53, DOI 10.1016/0378-1119(95)00671-0; POHLNER J, 1993, GENE, V130, P121, DOI 10.1016/0378-1119(93)90354-6; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	18	983	1040	4	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1497	1500		10.1126/science.287.5457.1497	http://dx.doi.org/10.1126/science.287.5457.1497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688800				2022-12-24	WOS:000085531600054
J	Neda, Z; Ravasz, E; Brechet, Y; Vicsek, T; Barabasi, AL				Neda, Z; Ravasz, E; Brechet, Y; Vicsek, T; Barabasi, AL			The sound of many hands clapping - Tumultuous applause can transform itself into waves of synchronized clapping	NATURE			English	Article									Univ Babes Bolyai, Dept Theoret Phys, RO-3400 Cluj Napoca, Romania; INP Grenoble, ENSEEG, LTPCM, St Martin Dheres, France; Eotvos Lorand Univ, Dept Biol Phys, H-1117 Budapest, Hungary; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA	Babes Bolyai University from Cluj; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Eotvos Lorand University; University of Notre Dame	Neda, Z (corresponding author), Univ Babes Bolyai, Dept Theoret Phys, Str Kogalniceanu 1, RO-3400 Cluj Napoca, Romania.		Vicsek, Tamas/A-3305-2009; Regan, Erzsébet Ravasz/AAG-8989-2019; Néda, Zoltán/C-3754-2011; Barabasi, Albert-Laszlo/S-6474-2017	Regan, Erzsébet Ravasz/0000-0002-8663-3153; Barabasi, Albert/0000-0002-4028-3522				Bottani S, 1996, PHYS REV E, V54, P2334, DOI 10.1103/PhysRevE.54.2334; Glass L., 1988, CLOCKS CHAOS RHYTHMS; KURAMOTO Y, 1987, J STAT PHYS, V49, P569, DOI 10.1007/BF01009349; MIROLLO RE, 1990, SIAM J APPL MATH, V50, P1645, DOI 10.1137/0150098; STROGATZ SH, 1997, SCI AM, V54, P2334; WINFREE AT, 1967, J THEOR BIOL, V16, P15, DOI 10.1016/0022-5193(67)90051-3	6	438	457	3	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					849	850		10.1038/35002660	http://dx.doi.org/10.1038/35002660			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706271	Green Submitted			2022-12-24	WOS:000085559200041
J	de Costa, CM				de Costa, CM			A matter of choice	LANCET			English	Article									Univ Queensland, Cairns Base Hosp, N Queensland Clin Sch, Dept Obstet & Gynaecol, Cairns, Qld 4870, Australia	University of Queensland	de Costa, CM (corresponding author), Univ Queensland, Cairns Base Hosp, N Queensland Clin Sch, Dept Obstet & Gynaecol, POB 902, Cairns, Qld 4870, Australia.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					649	650		10.1016/S0140-6736(99)11158-9	http://dx.doi.org/10.1016/S0140-6736(99)11158-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696998				2022-12-24	WOS:000085615400043
J	Hofmann, HA; Stevenson, PA				Hofmann, HA; Stevenson, PA			Flight restores fight in crickets	NATURE			English	Article									Univ Leipzig, Inst Zool, D-04103 Leipzig, Germany	Leipzig University	Hofmann, HA (corresponding author), Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.		Hofmann, Hans A/E-4538-2016; Hofmann, Hans A/A-1437-2008; Stevenson, Paul A/A-2048-2010	Hofmann, Hans A/0000-0002-3335-330X; 				Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CAREW TJ, 1998, MECH RELATIONSHIPS D; CHENG MF, 1992, ANIM BEHAV, V43, P1035, DOI 10.1016/0003-3472(92)90016-3; FRANCIS RC, 1993, P NATL ACAD SCI USA, V90, P7794, DOI 10.1073/pnas.90.16.7794; Hofmann H, 1996, BIOL ZBL, V115, P206; Huber F., 1955, Zeitschrift fuer Tierpsychologie Berlin, V12, P12; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; Lorenz Konrad, 1981, FDN ETHOLOGY; STEVENSON PA, 1987, J COMP PHYSIOL A, V161, P115, DOI 10.1007/BF00609460; WU JC, 1990, AM J PSYCHIAT, V147, P14; Yeh SR, 1996, SCIENCE, V271, P366, DOI 10.1126/science.271.5247.366	11	84	88	8	117	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					613	613		10.1038/35001137	http://dx.doi.org/10.1038/35001137			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688185	Bronze			2022-12-24	WOS:000085288200037
J	Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S				Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S			A subclass of Ras proteins that regulate the degradation of I kappa B	SCIENCE			English	Article							GTP-GAMMA-S; ACTIVATION; BETA; ALPHA; PHOSPHORYLATION; TRANSFORMATION; GTPASES; COMPLEX; FAMILY; GENE	Small guanosine triphosphatases, typified by the mammalian Ras proteins, play major roles in the regulation of numerous cellular pathways. A subclass of evolutionarily conserved Ras-Like proteins was identified, members of which differ from other Ras proteins in containing amino acids at positions 12 and 61 that are similar to those present in the oncogenic forms of Ras. These proteins, kappa B-Ras1 and kappa B-Ras2, interact with the PEST domains of I kappa B alpha and I kappa B beta [inhibitors of the transcription factor nuclear factor kappa B (NF-kappa B)] and decrease their rate of degradation. In cells, kappa B-Ras proteins are associated only with NF-kappa B:I kappa B beta complexes and therefore may provide an explanation for the slower rate of degradation of I kappa B beta compared with I kappa B alpha.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Chonnam National University; Chonnam National University; Chonnam National University	Ghosh, S (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.			Fenwick, Craig/0000-0002-9435-0110				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FENWICK CW, UNPUB; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Weil R, 1997, J BIOL CHEM, V272, P9942; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	27	84	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					869	873		10.1126/science.287.5454.869	http://dx.doi.org/10.1126/science.287.5454.869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657303				2022-12-24	WOS:000085136400050
J	Goodman, KJ; Correa, P				Goodman, KJ; Correa, P			Transmission of Helicobacter pylori among siblings	LANCET			English	Article							UREA BREATH TEST; DUODENAL-ULCER; BIRTH-ORDER; INFECTION; RISK; CHILDREN; POPULATION; PREVALENCE; INFANCY; AGE	Background Helicobacter pylori infection causes chronic digestive diseases with a major public-health impact, yet the design of prevention measures is hampered by limited knowledge of transmission pathways. We studied the effect of family composition on H pylori prevalence among rural Colombian children aged 2-9 years. Methods 684 children were screened for H pylori with the UC-urea breath test, For each child, birth order, birth spacing, number of 2-9-year-old siblings, and number of H-pylori-positive 2-9-year-old siblings was recorded. Odds ratios were estimated by logistic regression, controlling for hygiene-related exposures, socioeconomic indicators, and the number of children in the household. Findings The odds of infection increased with the number of 2-9-year-old siblings in the household (odds ratios 1.4, 2.3, 2.6, and 4.3 for one, two, three, and four to five siblings, respectively). Compared with first-born children, odds ratios for children born second and third to ninth were 1.8 (95% CI 1.0-3.3) and 2.2(1.0-4.3), respectively. Compared with children born 10 or more years after the next older household member, those born within 4 years were 4.1 times (CI 2.0-8.6) more likely to be infected; the age gap to the next younger household member displayed a weaker effect. The number of H-pylori-positive 2-9-year-old siblings had particularly strong effect gradient (1.5, 3.2, 5.6, and 7.1, for one, two, three, and four positive siblings, respectively). Interpretation Among rural Andean children younger than 10 years, H pylori infection seems to be transmitted most readily among siblings who are close in age, and most frequently from older siblings to younger ones.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77225 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Louisiana State University System	Goodman, KJ (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.	kgoodman@utsph.sph.uth.tmc.edu	Goodman, Karen/D-6823-2013	Goodman, Karen/0000-0002-3790-3217	NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA28842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashorn M, 1996, ARCH DIS CHILD-FETAL, V74, pF141, DOI 10.1136/fn.74.2.F141; Blaser MJ, 1998, GUT, V43, P721, DOI 10.1136/gut.43.5.721; BLASER MJ, 1995, CANCER RES, V55, P562; BLECKER U, 1994, J PEDIATR GASTR NUTR, V19, P87, DOI 10.1097/00005176-199407000-00014; Cadranel S, 1998, J PEDIATR GASTR NUTR, V27, P275, DOI 10.1097/00005176-199809000-00001; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1995, GASTROINTESTINAL OES, P485; CORREA P, 1989, PROGR SURGICAL PATHO, V10, P191; Delvin EE, 1999, J PEDIATR GASTR NUTR, V28, P59, DOI 10.1097/00005176-199901000-00014; Fall CHD, 1997, ARCH DIS CHILD, V77, P310, DOI 10.1136/adc.77.4.310; FOX JP, 1970, EPIDEMIOLOGY MAN DIS, P199; Gold BD, 1997, PEDIATR RES, V41, P641, DOI 10.1203/00006450-199705000-00007; Goodman, 1997, Cad Saude Publica, V13 Suppl 1, P15; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; GRAHAM DY, 1991, AM J GASTROENTEROL, V86, P1118; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; *INT AG RES CANC, 1994, IARC MON EV CANC RIS, V61; ISAGER H, 1980, ACTA NEUROL SCAND, V61, P393; Kalach N, 1998, J PEDIATR GASTR NUTR, V26, P291, DOI 10.1097/00005176-199803000-00010; MACMAHON B, 1992, AM J EPIDEMIOL, V136, P916, DOI 10.1093/oxfordjournals.aje.a116564; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; POUNDER RE, 1995, ALIMENT PHARM THERAP, V9, P33; REVES R, 1985, AM J EPIDEMIOL, V122, P112, DOI 10.1093/oxfordjournals.aje.a114070; Rothenbacher D, 1997, EPIDEMIOL INFECT, V119, P151, DOI 10.1017/S0950268897007905; Rothenbacher D, 1998, INT J EPIDEMIOL, V27, P135, DOI 10.1093/ije/27.1.135; Rowland M, 1997, J PEDIATR-US, V131, P815, DOI 10.1016/S0022-3476(97)70026-X; TAYLOR I, 1964, PRINCIPLES EPIDEMIOL, P304; TEH BH, 1994, ANTICANCER RES, V14, P1389; TSUGANE S, 1994, JPN J CANCER RES, V85, P474, DOI 10.1111/j.1349-7006.1994.tb02382.x; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608; WANG JT, 1993, J INFECT DIS, V168, P1544, DOI 10.1093/infdis/168.6.1544; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	34	206	211	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					358	362		10.1016/S0140-6736(99)05273-3	http://dx.doi.org/10.1016/S0140-6736(99)05273-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665555				2022-12-24	WOS:000085122100011
J	Earn, DJD; Rohani, P; Bolker, BM; Grenfell, BT				Earn, DJD; Rohani, P; Bolker, BM; Grenfell, BT			A simple model for complex dynamical transitions in epidemics	SCIENCE			English	Article							MEASLES DYNAMICS; METAPOPULATION DYNAMICS; CHAOS; VACCINATION; PERSISTENCE; PREDICTABILITY; PERIODICITY; DISEASES; ENGLAND; IMPACT	Dramatic changes in patterns of epidemics have been observed throughout this century. For childhood infectious diseases such as measles, the major transitions are between regular cycles and irregular, possibly chaotic epidemics, and from regionally synchronized oscillations to complex, spatially incoherent epidemics. A simple model can explain both kinds of transitions as the consequences of changes in birth and vaccination rates. Measles is a natural ecological system that exhibits different dynamical transitions at different times and places, yet all of these transitions can be predicted as bifurcations of a single nonlinear model.	McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Florida, Dept Zool, Gainesville, FL 32611 USA	McMaster University; University of Cambridge; State University System of Florida; University of Florida	Earn, DJD (corresponding author), McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada.	earn@math.mcmaster.ca		Bolker, Benjamin/0000-0002-2127-0443; rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341				ANDERSON R M, 1991; Anderson R.M., 1982, POPULATION DYNAMICS; ARON JL, 1990, THEOR POPUL BIOL, V38, P58, DOI 10.1016/0040-5809(90)90003-E; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; Ellner SP, 1998, AM NAT, V151, P425, DOI 10.1086/286130; ENGBERT R, 1994, PREDICTABILITY AND NONLINEAR MODELLING IN NATURAL SCIENCES AND ECONOMICS, P204; FERGUSON NM, 1997, MONOGRAPHS POPULATIO, V30, P137; FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5; Finkenstadt B, 1998, P ROY SOC B-BIOL SCI, V265, P211, DOI 10.1098/rspb.1998.0284; Glendinning P, 1997, J MATH BIOL, V35, P359, DOI 10.1007/s002850050056; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; HASTINGS A, 1994, SCIENCE, V263, P1133, DOI 10.1126/science.263.5150.1133; Holyoak M, 1996, J ANIM ECOL, V65, P640, DOI 10.2307/5743; Hudson PJ, 1998, SCIENCE, V282, P2256, DOI 10.1126/science.282.5397.2256; Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334; LONDON WP, 1973, AM J EPIDEMIOL, V98, P453, DOI 10.1093/oxfordjournals.aje.a121575; May R.M., 1986, Biomathematics (Berlin), V17, P405; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; MOLLISON D, 1993, MATH BIOSCI, V117, P155, DOI 10.1016/0025-5564(93)90021-2; OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; RAND DA, 1991, P ROY SOC B-BIOL SCI, V246, P179, DOI 10.1098/rspb.1991.0142; Rohani P, 1999, SCIENCE, V286, P968, DOI 10.1126/science.286.5441.968; Schaffer W M, 1985, IMA J Math Appl Med Biol, V2, P221; SCHAFFER WM, 1985, J THEOR BIOL, V112, P403, DOI 10.1016/S0022-5193(85)80294-0; SCHAFFER WM, 1993, IMA J MATH APPL MED, V10, P227; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SCHWARTZ IB, 1985, J MATH BIOL, V21, P347, DOI 10.1007/BF00276232; SCHWARTZ IB, 1983, J MATH BIOL, V18, P233, DOI 10.1007/BF00276090; Turchin P, 1999, SCIENCE, V285, P1068, DOI 10.1126/science.285.5430.1068; Zimmer C, 1999, SCIENCE, V284, P83, DOI 10.1126/science.284.5411.83	39	483	500	2	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					667	670		10.1126/science.287.5453.667	http://dx.doi.org/10.1126/science.287.5453.667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650003				2022-12-24	WOS:000084989400052
J	Gartner, S				Gartner, S			AIDS - HIV infection and dementia	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; COLONY-STIMULATING FACTOR; EARLY SIV ENCEPHALOPATHY; BONE-MARROW MACROPHAGES; MYELODYSPLASTIC SYNDROMES; CEREBROSPINAL-FLUID; NONHUMAN-PRIMATES; POSITIVE PATIENTS; MONOCYTE SUBSET; BRAIN		Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Gartner, S (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Meyer Bldg 6-181,600 N Wolfe St, Baltimore, MD 21287 USA.	sgartner@jhmi.edu						BELL JE, 1993, J INFECT DIS, V168, P818, DOI 10.1093/infdis/168.4.818; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CHAKRABARTI L, 1991, AM J PATHOL, V139, P1273; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; DONALDSON YK, 1994, LANCET, V343, P382, DOI 10.1016/S0140-6736(94)91222-X; Dore GJ, 1999, AIDS, V13, P1249, DOI 10.1097/00002030-199907090-00015; Dunne J, 1996, BRIT J BIOMED SCI, V53, P263; GALLO P, 1990, J NEUROIMMUNOL, V29, P105, DOI 10.1016/0165-5728(90)90152-D; GARTNER S, 1999, 6 C RETR OPP INF CHI; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; GOSZTONYI G, 1994, J NEUROPATH EXP NEUR, V53, P521, DOI 10.1097/00005072-199409000-00012; HIRSCH VM, 1991, J INFECT DIS, V163, P976, DOI 10.1093/infdis/163.5.976; HURTREL B, 1991, J MED PRIMATOL, V20, P159; HURTREL B, 1993, RES VIROLOGY, V144, P41, DOI 10.1016/S0923-2516(06)80010-5; KALOUTSI V, 1994, AM J CLIN PATHOL, V101, P123, DOI 10.1093/ajcp/101.2.123; Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521; KITAGAWA M, 1991, AM J PATHOL, V138, P921; Lane JH, 1996, J NEUROVIROL, V2, P423, DOI 10.3109/13550289609146909; LIU Y, IN PRESS J NEUROVIRO; MANDELL CP, 1995, LAB INVEST, V72, P323; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; Munn DH, 1996, BLOOD, V88, P1215, DOI 10.1182/blood.V88.4.1215.bloodjournal8841215; MUNN DH, 1990, BLOOD, V75, P2042; Nottet HSLM, 1996, J IMMUNOL, V156, P1284; Otani I, 1998, AIDS RES HUM RETROV, V14, P1181, DOI 10.1089/aid.1998.14.1181; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; Persidsky Y, 1997, J IMMUNOL, V158, P3499; Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1; SALEH MN, 1995, BLOOD, V85, P2910, DOI 10.1182/blood.V85.10.2910.bloodjournal85102910; Sasseville VG, 1996, AM J PATHOL, V149, P1459; SASSEVILLE VG, 1992, AM J PATHOL, V141, P1021; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SCHNEIDER DR, 1985, AM J CLIN PATHOL, V84, P144, DOI 10.1093/ajcp/84.2.144; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SINCLAIR E, 1994, J NEUROPATH EXP NEUR, V53, P43, DOI 10.1097/00005072-199401000-00006; Teo I, 1997, J VIROL, V71, P2928, DOI 10.1128/JVI.71.4.2928-2933.1997; TITIUS BR, 1994, ACTA HAEMATOL-BASEL, V91, P144; VAZEUX R, 1991, PATHOBIOLOGY, V59, P214, DOI 10.1159/000163648; Weiser B, 1996, AIDS RES HUM RETROV, V12, P1551, DOI 10.1089/aid.1996.12.1551; WILLIAMS K, 1999, 6 C RETR OPP INF CHI; Zink MC, 1999, J VIROL, V73, P10480, DOI 10.1128/JVI.73.12.10480-10488.1999	43	272	284	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					602	604		10.1126/science.287.5453.602	http://dx.doi.org/10.1126/science.287.5453.602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10691542				2022-12-24	WOS:000084989400032
J	Oghalai, JS; Zhao, HB; Kutz, JW; Brownell, WE				Oghalai, JS; Zhao, HB; Kutz, JW; Brownell, WE			Voltage- and tension-dependent lipid mobility in the outer hair cell plasma membrane	SCIENCE			English	Article							ERYTHROCYTE-MEMBRANE; BIOLOGICAL-MEMBRANES; LATERAL MOBILITY; BILAYER COUPLES; SHAPE CHANGES; MOTILITY; ELECTROMOTILITY; CHOLESTEROL; CAPACITANCE; COCHLEA	The mechanism responsible for electromotility of outer hair cells in the ear is unknown but is thought to reside within the plasma membrane. Lipid Lateral diffusion in the outer hair fell plasma membrane is a sigmoidal function of transmembrane potential and bathing media osmolality. Cell depolarization or hyposmotic challenge shorten the cell and reduce membrane fluidity by half. Changing the membrane tension with amphipathic drugs results in similar reductions. These dynamic changes in membrane fluidity represent the modulation of membrane tension by lipid-protein interactions. The voltage dependence may be associated with the force-generating motors that contribute to the exquisite sensitivity of mammalian hearing.	Baylor Coll Med, Dept Otolaryngol & Commun Sci, Houston, TX 77030 USA	Baylor College of Medicine	Brownell, WE (corresponding author), Baylor Coll Med, Dept Otolaryngol & Commun Sci, 1 Baylor Plaza, Houston, TX 77030 USA.		Kutz, Joe/ABF-4855-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000354] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000354] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adachi M, 1999, P NATL ACAD SCI USA, V96, P7244, DOI 10.1073/pnas.96.13.7244; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BLOOM JA, 1983, BIOPHYS J, V42, P295, DOI 10.1016/S0006-3495(83)84397-5; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1992, J NEUROSCI, V12, P4575; DERZKO Z, 1980, BIOCHEMISTRY-US, V19, P6050, DOI 10.1021/bi00567a016; DEUTICKE B, 1968, BIOCHIM BIOPHYS ACTA, V163, P494, DOI 10.1016/0005-2736(68)90078-3; Gale JE, 1997, NATURE, V389, P63, DOI 10.1038/37968; GALE JE, 1994, P ROY SOC B-BIOL SCI, V255, P243, DOI 10.1098/rspb.1994.0035; GOLAN DE, 1984, BIOCHEMISTRY-US, V23, P332, DOI 10.1021/bi00297a024; He DZZ, 1999, P NATL ACAD SCI USA, V96, P8223, DOI 10.1073/pnas.96.14.8223; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; IWASA KH, 1992, J ACOUST SOC AM, V92, P3169, DOI 10.1121/1.404194; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; IWASA KH, 1993, BIOPHYS J, V65, P492, DOI 10.1016/S0006-3495(93)81053-1; KAKEHATA S, 1995, BIOPHYS J, V68, P2190, DOI 10.1016/S0006-3495(95)80401-7; KAPITZA HG, 1980, BIOCHIM BIOPHYS ACTA, V595, P56, DOI 10.1016/0005-2736(80)90247-3; MONTANA V, 1989, BIOCHEMISTRY-US, V28, P4536, DOI 10.1021/bi00437a003; Oghalai JS, 1999, HEARING RES, V135, P19, DOI 10.1016/S0378-5955(99)00077-5; Oghalai JS, 1998, J NEUROSCI, V18, P48; Oghalai JS, 1998, J NEUROPHYSIOL, V79, P2235, DOI 10.1152/jn.1998.79.4.2235; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SERVUSS RM, 1976, BIOCHIM BIOPHYS ACTA, V436, P900, DOI 10.1016/0005-2736(76)90422-3; SHEETZ MP, 1976, J CELL BIOL, V70, P193, DOI 10.1083/jcb.70.1.193; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; Sit PS, 1997, BIOPHYS J, V72, P2812, DOI 10.1016/S0006-3495(97)78923-9; SMITH CA, 1968, ANN OTO RHINOL LARYN, V77, P629, DOI 10.1177/000348946807700404; THOMPSON NL, 1980, BIOCHIM BIOPHYS ACTA, V597, P155, DOI 10.1016/0005-2736(80)90159-5; VAZ WLC, 1982, MEMBRANE RECONSTITUT, P83; Zhao HB, 1999, NATURE, V399, P359, DOI 10.1038/20686	35	90	95	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					658	661		10.1126/science.287.5453.658	http://dx.doi.org/10.1126/science.287.5453.658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650000	Green Accepted			2022-12-24	WOS:000084989400049
J	Mol, CD; Izumi, T; Mitra, S; Tainer, JA				Mol, CD; Izumi, T; Mitra, S; Tainer, JA			DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination	NATURE			English	Article							HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; POLYMERASE-BETA; SITES; DEOXYRIBOSE; RECOGNITION; DYNAMICS; PROTEIN; XRCC1; CELLS	Non-coding apurinic/apyrimidinic (AP) sites in DNA are continually created in cells both spontaneously and by damage-specific DNA glycosylases'. The biologically critical human base excision repair enzyme APE1 cleaves the DNA sugar-phosphate backbone at a position 5' of AP sites to prime DNA repair synthesis(2-4). Here we report three co-crystal structures of human APE1 bound to abasic DNA which show that APE1 uses a rigid, pre-formed, positively charged surface to kink the DNA helix and engulf the AP-DNA strand. APE1 inserts loops into both the DNA major and minor grooves and binds a flipped-out AP site in a pocket that excludes DNA bases and racemized beta-anomer AP sites. Both the APE1 active-site geometry and a complex with cleaved AP-DNA and Mn2+ support a testable structure-based catalytic mechanism. Alanine substitutions of the residues that penetrate the DNA helix unexpectedly show that human APE1 is structurally optimized to retain the cleaved DNA product. These structural and mutational results show how APE1 probably displaces bound glycosylases and retains the nicked DNA product, suggesting that APE1 acts in vivo to coordinate the orderly transfer of unstable DNA damage intermediates between the excision and synthesis steps of DNA repair.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	Scripps Research Institute; Scripps Research Institute; University of Texas System; University of Texas Medical Branch Galveston	Tainer, JA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; Izumi T, 1999, J MOL BIOL, V287, P47, DOI 10.1006/jmbi.1999.2573; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017	30	583	603	12	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					451	456		10.1038/35000249	http://dx.doi.org/10.1038/35000249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667800				2022-12-24	WOS:000085121100056
J	O'Donnell, HC; Rosand, J; Knudsen, KA; Furie, KL; Segal, AZ; Chiu, RI; Ikeda, D; Greenberg, SM				O'Donnell, HC; Rosand, J; Knudsen, KA; Furie, KL; Segal, AZ; Chiu, RI; Ikeda, D; Greenberg, SM			Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL AMYLOID ANGIOPATHY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; HIGH-FREQUENCY; STROKE; HEMATOMAS; ONSET	Background: Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the epsilon 2 and the epsilon 4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy. Methods: We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans. Results: Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean (+/-SD) follow-up period of 23.9+/-14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the epsilon 2 or epsilon 4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E epsilon 3/epsilon 3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon epsilon 2/epsilon 4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001). Conclusions: The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention. (N Engl J Med 2000;342:240-5.) (C)2000, Massachusetts Medical Society.	Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Greenberg, SM (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Wang ACC 836, Boston, MA 02114 USA.		Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789	NIA NIH HHS [AG00725] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; Arakawa S, 1998, STROKE, V29, P1806, DOI 10.1161/01.STR.29.9.1806; BRODERICK J, 1993, STROKE, V24, P49, DOI 10.1161/01.STR.24.1.49; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; COUNSELL C, 1995, CEREBROVASC DIS, V5, P26, DOI 10.1159/000107814; GILLES C, 1984, NEUROLOGY, V34, P730, DOI 10.1212/WNL.34.6.730; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; GRAY F, 1985, ANN NEUROL, V18, P54, DOI 10.1002/ana.410180110; Greenberg SM, 1998, NEUROLOGY, V51, P690, DOI 10.1212/WNL.51.3.690; GREENBERG SM, 1993, NEUROLOGY, V43, P2073, DOI 10.1212/WNL.43.10.2073; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; KASE CS, 1982, NEUROLOGY, V32, P1146, DOI 10.1212/WNL.32.10.1146; Kurz A, 1996, NEUROLOGY, V47, P440, DOI 10.1212/WNL.47.2.440; MASSARO AR, 1991, NEUROLOGY, V41, P1881, DOI 10.1212/WNL.41.12.1881; Mayeux R, 1998, NEW ENGL J MED, V338, P1325; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; Neau JP, 1997, NEUROLOGY, V49, P106, DOI 10.1212/WNL.49.1.106; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; PASSERO S, 1995, STROKE, V26, P1189, DOI 10.1161/01.STR.26.7.1189; Premkumar DRD, 1996, AM J PATHOL, V148, P2083; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666	33	348	359	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					240	245		10.1056/NEJM200001273420403	http://dx.doi.org/10.1056/NEJM200001273420403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648765				2022-12-24	WOS:000084941000003
J	McMurry, MT; Krangel, MS				McMurry, MT; Krangel, MS			A role for histone acetylation in the developmental regulation of V(D)J recombination	SCIENCE			English	Article							DELTA-GENE REARRANGEMENT; IN-VITRO; ALPHA/DELTA LOCUS; NUCLEOSOMAL DNA; ALPHA-ENHANCER; RECEPTOR; TRANSCRIPTION; ACCESSIBILITY; CHROMATIN; BETA	V(D)J recombination is developmentally regulated in vivo by enhancer-dependent changes in the accessibility of chromosomal recombination signal sequences to the recombinase, but the molecular nature of these changes is unknown. Here histone H3 acetylation was measured along versions of a transgenic V(D)J recombination reporter and the endogenous T cell receptor alpha/delta Locus. Enhancer activity was shown to impart Long-range, developmentally regulated changes in H3 acetylation, and H3 acetylation status was tightly Linked to V(D)J recombination. H3 hyperacetylation is proposed as a molecular mechanism coupling enhancer activity to accessibility for V(D)J recombination.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Krangel, MS (corresponding author), Duke Univ, Med Ctr, Dept Immunol, POB 3010, Durham, NC 27710 USA.		McMurry-Heath, Michelle/AAB-5420-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041052, R01GM041052] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41052] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hempel WM, 1998, ADV IMMUNOL, V69, P309, DOI 10.1016/S0065-2776(08)60610-0; Hernandez-Munain C, 1999, IMMUNITY, V10, P723, DOI 10.1016/S1074-7613(00)80071-0; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Krangel MS, 1998, IMMUNOL REV, V165, P131, DOI 10.1111/j.1600-065X.1998.tb01236.x; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; LAUZURICA P, 1994, J EXP MED, V179, P43, DOI 10.1084/jem.179.1.43; LAUZURICA P, 1994, J EXP MED, V179, P1913, DOI 10.1084/jem.179.6.1913; Lauzurica P, 1997, J EXP MED, V185, P1193, DOI 10.1084/jem.185.7.1193; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; McMurry M. T, UNPUB; McMurry MT, 1997, MOL CELL BIOL, V17, P4553, DOI 10.1128/MCB.17.8.4553; Monroe RJ, 1999, IMMUNITY, V10, P503, DOI 10.1016/S1074-7613(00)80050-3; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Schatz D G, 1997, Semin Immunol, V9, P149, DOI 10.1006/smim.1997.0068; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219	33	239	241	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					495	498		10.1126/science.287.5452.495	http://dx.doi.org/10.1126/science.287.5452.495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642553				2022-12-24	WOS:000084929900051
J	Gaist, D; Vaeth, M; Tsiropoulos, I; Christensen, K; Corder, E; Olsen, J; Sorensen, HT				Gaist, D; Vaeth, M; Tsiropoulos, I; Christensen, K; Corder, E; Olsen, J; Sorensen, HT			Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL INTRACRANIAL ANEURYSMS; CASE-FATALITY; HEMORRHAGE; REGION; CANADA	Objective To estimate the risk of occurrence of subarachnoid haemorrhage in first degree relatives (parents, siblings, children) of patients with subarachnoid haemorrhage. Design Population based cohort study using data from the Danish National Discharge Registry and the Central Person Registry. Subjects Incident cases of subarachnoid haemorrhage admitted to hospital from 1977 to 1995 (9367 patients) and their first degree relatives (14781). Main outcome measures The incidence rate of subarachnoid haemorrhage was determined for the relatives and compared with that of the entire population, standardised for age, sex, and calendar period. This process was repeated for patients discharged from neurosurgery units, as diagnoses from these wards had high validity (93%). Results 18 patients had a total of 19 first degree relatives with subarachnoid haemorrhage during the study period, corresponding to a standardised incidence ratio of 2.9 (95% confidence interval 1.9 to 4.6). Patients discharged from neurosurgery wards had a higher standardised incidence ratio (4.5, 2.7 to 7.3). Conclusions First degree relatives of patients with subarachnoid haemorrhage have a threefold to fivefold increased risk of subarachnoid haemorrhage compared with the general population.	Odense Univ, Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark; Aarhus Univ, Dept Biostat, DK-8000 Aarhus, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Univ Aarhus, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark; Univ Aarhus, Inst Epidemiol & Social Med, Aalborg Univ Hosp, DK-8000 Aarhus C, Denmark	University of Southern Denmark; Aarhus University; University of Southern Denmark; Odense University Hospital; Aarhus University; Aarhus University; Aalborg University; Aarhus University	Gaist, D (corresponding author), Odense Univ, Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark.		Gaist, David/I-4397-2014; Sorensen, Henrik Toft/Z-6181-2019; Christensen, Kaare/C-2360-2009; Vaeth, Michael/T-6882-2017	Gaist, David/0000-0001-5205-7007; Sorensen, Henrik Toft/0000-0003-4299-7040; Christensen, Kaare/0000-0002-5429-5292; Vaeth, Michael/0000-0002-0134-5006				Breslow NE, 1987, STAT METHODS CANC RE; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; BROMBERG JEC, 1995, STROKE, V26, P961, DOI 10.1161/01.STR.26.6.961; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; DeBraekeleer M, 1996, ANN HUM GENET, V60, P99, DOI 10.1111/j.1469-1809.1996.tb01181.x; LEBLANC R, 1995, NEUROSURGERY, V37, P633, DOI 10.1227/00006123-199510000-00005; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Menghini VV, 1998, NEUROLOGY, V51, P405, DOI 10.1212/WNL.51.2.405; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; Ostbye T, 1997, STROKE, V28, P793, DOI 10.1161/01.STR.28.4.793; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; Schievink WI, 1996, STROKE, V27, P340; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; Schievink WI, 1996, NEUROSURGERY, V39, P685, DOI 10.1097/00006123-199610000-00006; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schievink WI, 1997, NEUROSURGERY, V40, P651, DOI 10.1097/00006123-199704000-00001; *STAT DENM, 1998, STAT YB 1998; *SUNDH, 1981, AKT SYG 1979; Teunissen LL, 1996, STROKE, V27, P544, DOI 10.1161/01.STR.27.3.544; Truelsen T, 1998, STROKE, V29, P2298, DOI 10.1161/01.STR.29.11.2298; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026	23	62	63	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					141	145		10.1136/bmj.320.7228.141	http://dx.doi.org/10.1136/bmj.320.7228.141			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634731	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000084860300021
J	Bachmaier, K; Krawczyk, C; Kozieradzki, I; Kong, YY; Sasaki, T; Oliveira-dos-Santos, A; Mariathasan, S; Bouchard, D; Wakeham, A; Itie, A; Le, J; Ohashi, PS; Sarosi, I; Nishina, H; Lipkowitz, S; Penninger, JM				Bachmaier, K; Krawczyk, C; Kozieradzki, I; Kong, YY; Sasaki, T; Oliveira-dos-Santos, A; Mariathasan, S; Bouchard, D; Wakeham, A; Itie, A; Le, J; Ohashi, PS; Sarosi, I; Nishina, H; Lipkowitz, S; Penninger, JM			Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b	NATURE			English	Article							T-CELL RECEPTOR; PROTEIN; MICE; PROTOONCOGENE; TOLERANCE; ANTIGENS; KINASE; TISSUE; BINDS; VAV	The signalling thresholds of antigen receptors and co-stimulatory receptors determine immunity or tolerance to self molecules(1). Changes in co-stimulatory pathways can lead to enhanced activation of lymphocytes and autoimmunity, or the induction of clonal anergy(2). The molecular mechanisms that maintain immunotolerance in vivo and integrate co-stimulatory signals with antigen receptor signals in T and B lymphocytes are poorly understood. Members of the Cbl/Sli family of molecular adaptors function downstream from growth factor and antigen receptors(3-5). Here we show that gene-targeted mice lacking the adaptor Cbl-b develop spontaneous autoimmunity characterized by auto-antibody production, infiltration of activated T and B lymphocytes into multiple organs, and parenchymal damage. Resting cbl-b(-/-) lymphocytes hyperproliferate upon antigen receptor stimulation, and cbl-b(-/-) T cells display specific: hyperproduction of the T-celI growth factor interleukin-2, hut not interferon-gamma or tumour necrosis factor-alpha. Mutation of Cbl-b uncouples T-cell proliferation, interleukin-2 production and phosphorylation of the GDP/GTP exchange factor Vav1 from the requirement for CD28 costimulation. Cbl-b is thus a key regulator of activation thresholds in mature lymphocytes and immunological tolerance and autoimmunity.	Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2M9, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; NCI, Med Branch, Dept Genet, Naval Hosp, Bethesda, MD 20889 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy	Penninger, JM (corresponding author), Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/B-6331-2014; Bachmaier, Kurt/AHC-5491-2022	Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Sasaki, Takehiko/0000-0003-1837-3748; Ohashi, Pamela S./0000-0003-2915-9317	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach JF, 1997, TRENDS ENDOCRIN MET, V8, P71, DOI 10.1016/S1043-2760(96)00271-8; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CELLS E, 1992, EUR J IMMUNOL, V22, P3127; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; KEANE MM, 1995, ONCOGENE, V10, P2367; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RADVANYI LG, 1993, J IMMUNOL, V150, P5704; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6	23	526	566	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					211	216		10.1038/35003228	http://dx.doi.org/10.1038/35003228			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646608				2022-12-24	WOS:000084835300059
J	Tellides, G; Tereb, DA; Kirkiles-Smith, NC; Kim, RW; Wilson, JH; Schechner, JS; Lorber, MI; Pober, JS				Tellides, G; Tereb, DA; Kirkiles-Smith, NC; Kim, RW; Wilson, JH; Schechner, JS; Lorber, MI; Pober, JS			Interferon-gamma elicits arteriosclerosis in the absence of leukocytes	NATURE			English	Article							SMOOTH-MUSCLE CELLS; TRANSPLANTED MOUSE HEARTS; CORONARY ARTERIOSCLEROSIS; IMMUNE INTERFERON; INHIBITS PROLIFERATION; GENE-EXPRESSION; GROWTH-FACTORS; ATHEROSCLEROSIS; INVIVO; INJURY	Atherosclerosis and post-transplant graft arteriosclerosis are both characterized by expansion of the arterial intima as a result of the infiltration of mononuclear leukocytes, the proliferation of vascular smooth muscle cells (VSMCs) and the accumulation of extracellular matrix(1-3). They are also associated with the presence of the immunomodulatory cytokine interferon-gamma (IFN-gamma)(2,3). Moreover, in mouse models of atheroma formation or allogeneic transplantation, the serological neutralization(4) or genetic absence(5-8) of IFN-gamma markedly reduces the extent of intimal expansion. However, other studies have found that exogenous IFN-gamma inhibits Cultured VSMC proliferation(9-14) and matrix synthesis(15), and reduces intimal expansion in response to mechanical injury(16-18). This discrepancy is generally explained by the idea that IFN-gamma either directly activates macrophages, or, by increasing antigen presentation, indirectly activates T cells within the lesions of atherosclerosis and graft arteriosclerosis. These activated leukocytes are thought to express the VSMC-activating cytokines(1-3) and cell-surface molecules(19) that cause the observed arteriosclerotic responses. Here we have inserted pig and human arteries into the aorta of immunodeficient immunodeficient mice, and we show that IFN-gamma can induce arteriosclerotic changes in the absence of detectable immunocytes by acting on VSMCs to potentiate growth-factor-induced mitogenesis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Tellides, G (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, 333 Cedar St, New Haven, CT 06510 USA.							AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BRINCKERHOFF CE, 1985, J IMMUNOL, V134, P3142; Castronuovo J J Jr, 1995, Cardiovasc Surg, V3, P463, DOI 10.1016/0967-2109(95)94442-Y; Goes N, 1996, TRANSPLANTATION, V62, P1889, DOI 10.1097/00007890-199612270-00036; GROENEWEGEN G, 1985, NATURE, V316, P361, DOI 10.1038/316361a0; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1991, P NATL ACAD SCI USA, V88, P10530, DOI 10.1073/pnas.88.23.10530; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; HUNNINGHAKE GW, 1986, AM REV RESPIR DIS, V134, P1025, DOI 10.1164/arrd.1986.134.5.1025; LIBBY P, 1989, TRANSPLANT P, V21, P3677; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Mensink A, 1996, EUR J PHARMACOL, V310, P73, DOI 10.1016/0014-2999(96)00368-8; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Nagano H, 1998, AM J PATHOL, V152, P1187; NUNOKAWA Y, 1992, BIOCHEM BIOPH RES CO, V188, P409, DOI 10.1016/0006-291X(92)92400-R; Raisanen-Sokolowski A, 1998, AM J PATHOL, V152, P359; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL PS, 1994, TRANSPLANTATION, V57, P1367, DOI 10.1097/00007890-199405150-00014; SHIMOKADO K, 1990, ANN NY ACAD SCI, V598, P544, DOI 10.1111/j.1749-6632.1990.tb42340.x; Sultan P, 1997, P NATL ACAD SCI USA, V94, P8767, DOI 10.1073/pnas.94.16.8767; SUZUKI H, 1989, AM J PATHOL, V134, P35; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; YOKOTA T, 1992, ARTERIOSCLER THROMB, V12, P1393, DOI 10.1161/01.ATV.12.12.1393; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	30	324	331	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					207	211		10.1038/35003221	http://dx.doi.org/10.1038/35003221			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646607				2022-12-24	WOS:000084835300058
J	Schlag, J; Cai, RH; Dorfman, A; Mohempour, A; Schlag-Rey, M				Schlag, J; Cai, RH; Dorfman, A; Mohempour, A; Schlag-Rey, M			Neuroscience - Extrapolating movement without retinal motion	NATURE			English	Article							LATENCY		Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schlag, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.							Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; Gegenfurtner K, 1999, NATURE, V398, P291, DOI 10.1038/18563; Nijhawan R, 1997, NATURE, V386, P66, DOI 10.1038/386066a0; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; Purushothaman G, 1998, NATURE, V396, P424, DOI 10.1038/24766; Whitney D, 1998, NAT NEUROSCI, V1, P656, DOI 10.1038/3659	6	36	36	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					38	39		10.1038/47402	http://dx.doi.org/10.1038/47402			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638742				2022-12-24	WOS:000084687400032
J	Gundestrup, M; Storm, HH				Gundestrup, M; Storm, HH			Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study	LANCET			English	Article							MORTALITY; PILOTS; RISK; EXPOSURE	Background Cockpit crews receive cosmic radiation during flight operations. The increasing total accumulated dose over the years might be expected to cause increased frequency of radiation-induced cancer. The rate should increase with number of flight hours per year, number of years of flying, and higher flight altitude. If the cumulative radiation exposure during flights is of concern, we would expect an increased cancer risk to be present among those crew members flying jets. Methods Cockpit-crew medical records (pilots and flight engineers) from 1946 onwards, holding information on the individual, flight hours, aircraft type, and date of commercial certification and decertification, were linked to the population-based Danish Cancer Registry, the central population registry, and the National Death Index. Findings Altogether 3877 cockpit crew members could be traced for follow-up, accruing 61 095 person-years at risk in 3790 men and 661 in 87 women. The total number of cancers observed was 169 whereas 153.1 were expected (standardised incidence ratio 1.1 [95% CI 0.94-1.28]). Significantly increased risks of acute myeloid leukaemia (5.1 [1.03-14.91]), skin cancer, excluding melanoma (3.0 [2.12-4.23]), and total cancer (1.2 [1.00-1.53]) were observed among Danish male jet cockpit crew members flying more than 5000 h. Increased risk of malignant melanoma irrespective of aircraft type was also found among those flying more than 5000 h. Interpretation Both malignant melanoma and skin cancer were found in excess in cockpit crew members with a long flying history, probably attributable to sun exposure during leisure time at holiday destinations. We cannot confirm previously reported increased risk of brain and rectal cancers in pilots. The study shows that male cockpit crew members in jets flying more than 5000 h have significantly increased frequency of acute myeloid leukaemia.	Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Natl Clin Aviat Med, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Storm, HH (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, Strandblvd 49, DK-2100 Copenhagen, Denmark.			Storm, Hans/0000-0001-7223-8198				BAND PR, 1990, AVIAT SPACE ENVIR MD, V61, P299; Band PR, 1996, AM J EPIDEMIOL, V143, P137; Blettner M, 1998, RADIAT ENVIRON BIOPH, V37, P75, DOI 10.1007/s004110050097; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; FRIEDBERG W, 1989, AVIAT SPACE ENVIR MD, V60, P1104; Grayson JK, 1996, AVIAT SPACE ENVIR MD, V67, P101; IRVINE D, 1992, AVIAT SPACE ENVIR MD, V63, P276; KAJI M, 1993, AVIAT SPACE ENVIR MD, V64, P748; OBRIEN K, 1972, HEALTH PHYS, V22, P225, DOI 10.1097/00004032-197203000-00002; PARETZKE HG, 1993, RADIAT PROT DOSIM, V48, P33; PUKKALA E, 1995, BRIT MED J, V311, P349; PUKKALA E, 1995, CONTR EPIDE, V7, P1; SALISBURY DA, 1991, AVIAT SPACE ENVIR MD, V62, P351	13	114	119	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2029	2031		10.1016/S0140-6736(99)05093-X	http://dx.doi.org/10.1016/S0140-6736(99)05093-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636367				2022-12-24	WOS:000084183300010
J	Sterling, B				Sterling, B			Homo sapiens declared extinct	NATURE			English	Editorial Material																			0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					125	125		10.1038/45932	http://dx.doi.org/10.1038/45932			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10646998	Bronze			2022-12-24	WOS:000083716400024
J	Dillon, RJ; Vennard, CT; Charnley, AK				Dillon, RJ; Vennard, CT; Charnley, AK			Pheromones - Exploitation of gut bacteria in the locust	NATURE			English	Article							DESERT LOCUST; SCHISTOCERCA-GREGARIA; METARHIZIUM-ANISOPLIAE; INHIBITION; FLORA		Univ Bath, Dept Biol & Biochem, Microbial Pathogen Grp, Bath BA2 7AY, Avon, England	University of Bath	Dillon, RJ (corresponding author), Univ Bath, Dept Biol & Biochem, Microbial Pathogen Grp, Bath BA2 7AY, Avon, England.			Dillon, Rod/0000-0002-3551-0030				BYERS JA, 1991, BIOL REV, V66, P347, DOI 10.1111/j.1469-185X.1991.tb01146.x; CHARNLEY AK, 1985, J INSECT PHYSIOL, V31, P477, DOI 10.1016/0022-1910(85)90096-4; CRAWFORD RL, 1978, APPL ENVIRON MICROB, V36, P539, DOI 10.1128/AEM.36.4.539-543.1978; Dillon R.J., 1991, P129; DILLON RJ, 1988, CAN J MICROBIOL, V34, P1075, DOI 10.1139/m88-189; DILLON RJ, 1986, J INVERTEBR PATHOL, V47, P350, DOI 10.1016/0022-2011(86)90106-0; DILLON RJ, 1995, J INVERTEBR PATHOL, V66, P72, DOI 10.1006/jipa.1995.1063; FUZEAUBRAESCH S, 1988, J CHEM ECOL, V14, P1023, DOI 10.1007/BF01018790; HUNT J, 1981, J INVERTEBR PATHOL, V38, P378, DOI 10.1016/0022-2011(81)90105-1; LYSENKO O, 1985, ANNU REV MICROBIOL, V39, P673; OBENGOFORI D, 1994, J CHEM ECOL, V20, P2077, DOI 10.1007/BF02066244; STEEDMAN A, 1988, LOCUST HDB, P2	12	155	168	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					851	851		10.1038/35002669	http://dx.doi.org/10.1038/35002669			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706273				2022-12-24	WOS:000085559200044
J	Lappe, M; Awater, H; Krekelberg, B				Lappe, M; Awater, H; Krekelberg, B			Postsaccadic visual references generate presaccadic compression of space	NATURE			English	Article							EYE-MOVEMENTS; DISPLACEMENT; LOCALIZATION; SACCADES	With every rapid gaze shift (saccade), our eyes experience a different view of the world. Stable perception of visual space requires that points in the new image are associated with corresponding points in the previous image. The brain may use an extraretinal eye position signal to compensate for gaze changes(1,2), or, alternatively, exploit the image contents to determine associated locations(3,4). Support for a uniform extraretinal signal comes from findings that the apparent position of objects briefly flashed around the time of a saccade is often shifted in the direction of the saccade(5-9). This view is challenged, however, by observations that the magnitude(4,10) and direction(11) of the displacement varies across the visual field. Led by the observation that non-uniform displacements typically occurred in studies conducted in slightly illuminated rooms(4,7,10-13), here we determine the dependence of perisaccadic mislocalization on the availability of visual spatial references at various times around a saccade. We find that presaccadic compression(11) occurs only if visual references are available immediately after, rather than before or during, the saccade. Our findings indicate that the visual processes of transsaccadic spatial localization use mainly postsaccadic visual information.	Ruhr Univ Bochum, Dept Zool & Neurobiol, D-44780 Bochum, Germany	Ruhr University Bochum	Lappe, M (corresponding author), Ruhr Univ Bochum, Dept Zool & Neurobiol, D-44780 Bochum, Germany.		Krekelberg, Bart/N-7938-2019	Krekelberg, Bart/0000-0003-1083-6103				BISCHOF N, 1968, PSYCHOL FORSCH, V32, P185, DOI 10.1007/BF00418660; Bockisch CJ, 1999, VISION RES, V39, P1025, DOI 10.1016/S0042-6989(98)00205-3; Cai RH, 1997, NATURE, V386, P601, DOI 10.1038/386601a0; DASSONVILLE P, 1995, VISION RES, V35, P2191, DOI 10.1016/0042-6989(94)00317-3; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; Deubel H, 1998, VISION RES, V38, P3147, DOI 10.1016/S0042-6989(98)00048-0; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; HONDA H, 1989, PERCEPT PSYCHOPHYS, V45, P162, DOI 10.3758/BF03208051; HONDA H, 1993, VISION RES, V33, P709, DOI 10.1016/0042-6989(93)90190-8; Krekelberg B, 2000, VISION RES, V40, P201, DOI 10.1016/S0042-6989(99)00168-6; MACKAY DM, 1970, NATURE, V227, P731, DOI 10.1038/227731a0; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; Miller JM, 1997, NATURE, V386, P550, DOI 10.1038/386550a0; OREGAN JK, 1984, PERCEPT PSYCHOPHYS, V36, P1, DOI 10.3758/BF03206348; Ross J, 1997, NATURE, V386, P598, DOI 10.1038/386598a0; von Helmholtz H, 1896, HDB PHYSL OPTIK; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	17	205	205	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					892	895		10.1038/35002588	http://dx.doi.org/10.1038/35002588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706286				2022-12-24	WOS:000085559200057
J	Dahmann, C; Basler, K				Dahmann, C; Basler, K			Opposing transcriptional outputs of hedgehog signaling and engrailed control compartmental cell sorting at the Drosophila A/P boundary	CELL			English	Article							CUBITUS-INTERRUPTUS PROTEIN; KINESIN-RELATED PROTEIN; GENE; EXPRESSION; ADHESION; RECEPTOR; ENCODES; COMPLEX; PATTERN; COSTAL2	The wing imaginal disc is subdivided into two nonintermingling sets of cells, the anterior (A)I and posterior (P) compartments. Anterior cells require reception of the Hedgehog (Hh) signal to segregate from P cells. We provide evidence that Hh signaling controls A/P cell segregation not by directly modifying structural components but by a Cubitus interruptus (Ci)-mediated transcriptional response. A shift in the balance between repressor and activator forms of Ci toward the activator form is necessary and sufficient to define "A-type" cell sorting behavior. Moreover, we show that Engrailed (En), in the absence of Ci, is sufficient to specify "P-type" sorting. We propose that the opposing transcriptional activities of Ci and En control cell segregation at the A/P boundary by regulating a single cell adhesion molecule.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Wintherthurerstr 190, CH-8057 Zurich, Switzerland.	basler@molbio.unizh.ch	Dahmann, Christian/B-5841-2017	Basler, Konrad/0000-0003-3534-1529				Alcedo J, 1997, BIOL CHEM, V378, P583; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Blair SS, 1997, DEVELOPMENT, V124, P4053; BRAND AH, 1993, DEVELOPMENT, V118, P401; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; Dahmann C, 1999, TRENDS GENET, V15, P320, DOI 10.1016/S0168-9525(99)01774-6; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Gustavson E, 1996, GENETICS, V142, P893; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; Lawrence PA, 1997, NATURE, V389, P546, DOI 10.1038/39188; Lawrence PA, 1999, DEVELOPMENT, V126, P2441; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Sokal RR., 1995, BIOMETRY, V3; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Vincent JP, 1998, INT J DEV BIOL, V42, P311; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	50	127	130	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 18	2000	100	4					411	422		10.1016/S0092-8674(00)80677-7	http://dx.doi.org/10.1016/S0092-8674(00)80677-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693758	Green Accepted, Bronze			2022-12-24	WOS:000085446900004
J	Ivessa, AS; Zhou, JQ; Zakian, VA				Ivessa, AS; Zhou, JQ; Zakian, VA			The Saccharomyces Pif1p DNA helicase and the highly related Rrm3p have opposite effects on replication fork progression in ribosomal DNA	CELL			English	Article							TELOMERIC HETEROCHROMATIN; S-CEREVISIAE; GENE-PRODUCT; CELL-CYCLE; YEAST RDNA; RNA GENES; RECOMBINATION; TRANSCRIPTION; ORIGINS; PROTEIN	Replication of Saccharomyces ribosomal DNA (rDNA) proceeds bidirectionally from origins in a subset of the similar to 150 tandem repeats, but the leftward-moving fork stops when it encounters the replication fork barrier (RFB). The Pif1p helicase and the highly related Rrm3p were rDNA associated in vivo. Both proteins affected rDNA replication but had opposing effects on fork progression. Pif1p helped maintain the RFB. Rrm8p appears to be the replicative helicase for rDNA as it acted catalytically to promote fork progression throughout the rDNA. Loss of Rrm3p increased rDNA breakage and accumulation of rDNA circles, whereas breakage and circles were less common in pif1 cells. These data support a model in which replication fork pausing causes breakage and recombination in the rDNA.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Ivessa, Andreas/0000-0002-7578-1337	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BORST P, 1978, CELL, V15, P705, DOI 10.1016/0092-8674(78)90257-X; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; CHRISTMAN MF, 1993, P NATL ACAD SCI USA, V90, P7637, DOI 10.1073/pnas.90.16.7637; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; CRAMER JH, 1980, MOL GEN GENET, V177, P199; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; HARTWELL LH, 1985, GENETICS, V110, P381; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KEIL RL, 1993, GENETICS, V135, P711; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LIN YH, 1991, GENETICS, V127, P31; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; Lopez-Estrano C, 1998, J MOL BIOL, V277, P249, DOI 10.1006/jmbi.1997.1607; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Rose MD., 1990, METHODS YEAST GENETI; Sanchez JA, 1998, EXP CELL RES, V238, P220, DOI 10.1006/excr.1997.3835; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.0.CO;2-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; ZAKIAN VA, 1982, PLASMID, V8, P15, DOI 10.1016/0147-619X(82)90037-3	43	217	220	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 18	2000	100	4					479	489		10.1016/S0092-8674(00)80683-2	http://dx.doi.org/10.1016/S0092-8674(00)80683-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693764	Bronze			2022-12-24	WOS:000085446900010
J	Millonig, JH; Millen, KJ; Hatten, ME				Millonig, JH; Millen, KJ; Hatten, ME			The mouse Dreher gene Lmx1a controls formation of the roof plate in the vertebrate CNS	NATURE			English	Article							MUTANT MOUSE; LIM DOMAIN; PROTEIN; CELLS; EXPRESSION	In the vertebrate central nervous system (CNS), a cascade of signals that originates in the ectoderm adjacent to the neural tube is propagated by the roof plate to dorsalize the neural tube(1). Here we report that the phenotype of the spontaneous neurological mutant mouse dreher (dr)(2-5) results from a failure of the roof plate to develop. Dorsalization of the neural tube is consequently affected: dorsal interneurons in the spinal cord and granule neurons in the cerebellar cortex are lost, and the dorsal vertebral neural arches fail to form. Positional cloning of dreher indicates that the LIM homeodomain protein, Lmx1a, is affected in three different alleles of dreher. Lmx1a is expressed in the roof plate dong the neuraxis during development of the CNS. Thus, Lmx1a is required for development of the roof plate and, in turn, for specification of dorsal cell fates in the CNS and developing vertebrae.	Rockefeller Univ, Dev Neurobiol Lab, New York, NY 10021 USA	Rockefeller University	Hatten, ME (corresponding author), Rockefeller Univ, Dev Neurobiol Lab, 1230 York Ave, New York, NY 10021 USA.			Millen, Kathleen/0000-0001-9978-675X				Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; ALMASAN A, 1994, GENOMICS, V20, P397, DOI 10.1006/geno.1994.1193; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Bergstrom DE, 1999, GENOMICS, V59, P291, DOI 10.1006/geno.1999.5873; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Konrat R, 1997, J BIOL CHEM, V272, P12001, DOI 10.1074/jbc.272.18.12001; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LYONS M, 1996, GENETIC VARIANTS LAB, P195; Millen Kathleen J., 1996, P339; Millonig JH, 1996, MAMM GENOME, V7, P616, DOI 10.1007/s003359900183; PARR BA, 1993, DEVELOPMENT, V119, P247; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SEKIGUCHI M, 1992, DEV BRAIN RES, V67, P105, DOI 10.1016/0165-3806(92)90030-Z; SEKIGUCHI M, 1994, DEV BRAIN RES, V77, P37, DOI 10.1016/0165-3806(94)90211-9; SIDMAN RL, 1983, GENETICS NEUROLOGICA, P19; WALSTEN D, 1983, J HERED, V74, P421	25	215	222	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					764	769		10.1038/35001573	http://dx.doi.org/10.1038/35001573			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693804				2022-12-24	WOS:000085423100051
J	Hak, AE; Pols, HAP; Visser, TJ; Drexhage, HA; Hofman, A; Witteman, JCM				Hak, AE; Pols, HAP; Visser, TJ; Drexhage, HA; Hofman, A; Witteman, JCM			Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study	ANNALS OF INTERNAL MEDICINE			English	Article						hypothyroidism; autoimmune diseases; coronary arteriosclerosis; menopause; myocardial infarction	CORONARY HEART-DISEASE; THYROID-HORMONES; FOLLOW-UP; AUTOIMMUNE-THYROIDITIS; AORTIC ATHEROSCLEROSIS; NONTHYROIDAL ILLNESS; THYROTROPIN; CHOLESTEROL; PROGRESSION; LIPIDS	Background: Overt hypothyroidism has been found to be associated with cardiovascular disease. Whether subclinical hypothyroidism and thyroid autoimmunity are also risk factors for cardiovascular disease is controversial. Objective: To investigate whether subclinical hypothyroidism and thyroid autoimmunity are associated with aortic atherosclerosis and myocardial infarction in postmenopausal women. Design: Population-based cross-sectional study. Setting: A district of Rotterdam, the Netherlands. Participants: Random sample of 1149 women (mean age +/- SD, 69.0 +/- 7.5 years) participating in the Rotterdam Study. Measurements: Data on thyroid status, aortic atherosclerosis, and history of myocardial infarction were obtained at baseline. Subclinical hypothyroidism was defined as an elevated thyroid-stimulating hormone level (>4.0 mU/L) and a normal serum free thyroxine level (11 to 25 pmol/L [0.9 to 1.9 ng/d L]). In tests for antibodies to thyroid peroxidase, a serum level greater than 10 IU/mL was considered a positive result. Results: Subclinical hypothyroidism was present in 10.8% of participants and was associated with a greater age-adjusted prevalence of aortic atherosclerosis (odds ratio, 1.7 [95% CI, 1.1 to 2.6]) and myocardial infarction (odds ratio, 2.3 [CI, 1.3 to 4.0]). Additional adjustment for body mass index, total and high-density lipoprotein cholesterol level, blood pressure, and smoking status, as well as exclusion of women who took p-blockers, did not affect these estimates. Associations were slightly stronger in women who had subclinical hypothyroidism and antibodies to thyroid peroxidase (odds ratio for aortic atherosclerosis, 1.9 [CI, 1.1 to 3.6]; odds ratio for myocardial infarction, 3.1 [CI, 1.5 to 6.3]). No association was found between thyroid autoimmunity itself and cardiovascular disease. The population attributable risk percentage for subclinical hypothyroidism associated with myocardial infarction was within the range of that for known major risk factors for cardiovascular disease. Conclusion: Subclinical hypothyroidism is a strong indicator of risk for atherosclerosis and myocardial infarction in elderly women.	Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Witteman, JCM (corresponding author), Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	witteman@epib.fgg.eur.nl	Visser, Theo J/C-8059-2013	Visser, Theo J/0000-0002-6997-284X				ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; BASTENIE PA, 1977, LANCET, V2, P155; BASTENIE PA, 1967, LANCET, V2, P1221; BASTENIE PA, 1971, LANCET, V1, P203; BOTS ML, 1993, ATHEROSCLEROSIS, V102, P99, DOI 10.1016/0021-9150(93)90088-C; BRASS EP, 1984, DRUGS, V27, P447, DOI 10.2165/00003495-198427050-00004; BRENT GA, 1986, AM J MED, V81, P463, DOI 10.1016/0002-9343(86)90300-1; CARON P, 1990, CLIN ENDOCRINOL, V33, P519, DOI 10.1111/j.1365-2265.1990.tb03889.x; Chadarevian R, 1998, THROMB HAEMOSTASIS, V79, P99; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; FOWLER PBS, 1970, LANCET, V2, P488; GASPAR IA, 1968, J AM GERIATR SOC, V16, P686, DOI 10.1111/j.1532-5415.1968.tb01278.x; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; Harjai KJ, 1997, ANN INTERN MED, V126, P63, DOI 10.7326/0003-4819-126-1-199701010-00009; HEINONEN OP, 1972, LANCET, V1, P785; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, V1; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HYMAN JB, 1954, AM HEART J, V48, P540, DOI 10.1016/0002-8703(54)90119-2; ISHIKAWA T, 1989, MOL PHARMACOL, V35, P760; Klein Irwin, 1996, P799; KOLTRINGER P, 1988, J ENDOCRINOL INVEST, V11, P267; KUNG AWC, 1995, CLIN ENDOCRINOL, V43, P445, DOI 10.1111/j.1365-2265.1995.tb02616.x; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; MASAKI H, 1992, J CLIN ENDOCR METAB, V75, P721, DOI 10.1210/jc.75.3.721; MATHEWS JD, 1974, LANCET, V2, P1423; Miura S, 1996, ENDOCR J, V43, P657, DOI 10.1507/endocrj.43.657; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; NILSSON G, 1976, ACTA MED SCAND, V200, P63; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1992, CLIN ENDOCRINOL, V37, P411, DOI 10.1111/j.1365-2265.1992.tb02351.x; POWELL J, 1987, BRIT J SURG, V74, P1139, DOI 10.1002/bjs.1800741220; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; Sundaram V, 1997, J CLIN ENDOCR METAB, V82, P3421, DOI 10.1210/jcem.82.10.4315; TIECHE M, 1981, BRIT HEART J, V46, P202, DOI 10.1136/hrt.46.2.202; TRANTOW T, 1994, METHOD FIND EXP CLIN, V16, P133; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P495, DOI 10.1111/j.1365-2265.1977.tb01341.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; Vanderpump MPJ, 1996, THYROID, V6, P155; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; WITTEMAN JCM, 1986, LANCET, V2, P1120; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156; WONG ET, 1981, ARCH INTERN MED, V141, P873, DOI 10.1001/archinte.141.7.873	52	884	982	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					270	+		10.7326/0003-4819-132-4-200002150-00004	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681281	Green Published			2022-12-24	WOS:000085372900003
J	Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S				Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S			Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; SERUM IGE; ASSOCIATION; INFECTIONS; PREVALENCE; CHILDHOOD; DISEASES; HYGIENE; CELLS; FLORA	Objective To investigate if markers of exposure to foodborne and orofecal microbes versus airborne viruses are associated with atopy and respiratory allergies. Design Retrospective case-control study. Participants 240 atopic cases and 240 non-atopic controls from a population sample of 1659 participants, all Italian male cadets aged 17-24. Setting Air force school in Caserta, Italy. Main outcome measures Serology for Toxoplasma gondii, Helicobacter pylori, hepatitis A virus, measles, mumps, rubella, chickenpox, cytomegalovirus, and herpes simplex virus type 1; skin sensitisation and IgE antibodies to relevant airborne allergens; total IgE concentration; and diagnosis of allergic asthma or rhinitis, Results Compared with controls there tvas a lower prevalence of T gondii (26% v 18%, P = 0.027), hepatitis A virus (30% v 16%, P = 0.004), and H pylori (18% v 15%, P = 0.325) in atopic participants. Adjusted odds ratios of atopy decreased with a gradient of exposure to H pylori, T gondii, and hepatitis A virus (none, odds ratio 1; one, 0.70; two or three, 0.37; P for trend = 0.000045) but not with cumulative exposure to the other viruses. Conversely, total IgE concentration was not independently associated with any infection. Allergic asthma was rare (1/245, 0.4%) and allergic rhinitis infrequent (16/245, 7%) among the participants (245/1659) exposed to at least two orofecal and foodborne infections (H pylori, T gondii, hepatitis A virus). Conclusion Respiratory allergy is less frequent in people heavily exposed to orofecal and foodborne microbes. Hygiene and a westernised, semisterile diet may facilitate atopy by influencing the overall pattern of commensals and pathogens that stimulate the gut associated lymphoid tissue thus contributing to the epidemic of allergic asthma and rhinitis in developed countries.	Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR)	Matricardi, PM (corresponding author), Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy.	matricardi.pm@mclink.it	Bonini, Sergio/T-6594-2019; Riondino, Silvia/AAV-7126-2020	Bonini, Sergio/0000-0003-0079-3031; Riondino, Silvia/0000-0002-2965-402X				AIM JS, 1997, LANCET, V350, P400; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; DIXON WJ, 1990, BMDP STAT SOFTWARE, V2; Dominici P, 1999, BRIT MED J, V319, P537, DOI 10.1136/bmj.319.7209.537; Dore MP, 1999, LANCET, V354, P132, DOI 10.1016/S0140-6736(99)01724-9; DURKIN HG, 1989, J IMMUNOL, V143, P1777; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; Grubel P, 1998, LANCET, V352, P788, DOI 10.1016/S0140-6736(05)60683-6; *GRUPP STUD INT SO, 1996, VACC IT; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sudo N, 1997, J IMMUNOL, V159, P1739; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	36	501	520	0	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					412	417		10.1136/bmj.320.7232.412	http://dx.doi.org/10.1136/bmj.320.7232.412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669445	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000085377400022
J	Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW				Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW			Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome	SCIENCE			English	Article							BRAIN GROWTH SPURT; PURKINJE-CELL LOSS; STEREOLOGICAL METHODS; EXPOSURE; NEURONS; DEATH; RATS	The deleterious effects of ethanol an the developing human brain are poorly understood. Here it is reported that ethanol, acting by a dual mechanism [blockade of N-methyl-D-aspartate (NMDA) glutamate receptors and excessive activation of GABA, receptors], triggers widespread apoptotic neurodegeneration in the developing rat forebrain. Vulnerability coincides with the period of synaptogenesis, which in humans extends from the sixth month of gestation to several years after birth. During this period, transient ethanol exposure can delete millions of neurons from the developing brain. This can explain the reduced brain mass and neurobehavioral disturbances associated with human fetal alcohol syndrome.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Humboldt Univ, Virchow Clin, Dept Pediat Neurol, D-13353 Berlin, Germany; Tokyo Med & Dent Univ, Med Res Inst, Chiyod Ku, Tokyo, Japan	Washington University (WUSTL); Humboldt University of Berlin; Tokyo Medical & Dental University (TMDU)	Olney, JW (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 4940 Childrens Pl, St Louis, MO 63110 USA.				NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; Faingold CL, 1998, PROG NEUROBIOL, V55, P509, DOI 10.1016/S0301-0082(98)00027-6; Famy C, 1998, AM J PSYCHIAT, V155, P552, DOI 10.1176/ajp.155.4.552; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodlett C. R., 1992, MATERNAL SUBSTANCE A, P45; GOODLETT CR, 1990, ALCOHOL, V7, P107, DOI 10.1016/0741-8329(90)90070-S; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; Kerns KA, 1997, J LEARN DISABIL-US, V30, P685, DOI 10.1177/002221949703000612; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Paxinos G., 1991, ATLAS DEV RAT BRAIN; RYABININ AE, 1995, ALCOHOL CLIN EXP RES, V19, P784, DOI 10.1111/j.1530-0277.1995.tb01583.x; Sapp DW, 1998, J PHARMACOL EXP THER, V284, P768; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; Swayze VW, 1997, PEDIATRICS, V99, P232, DOI 10.1542/peds.99.2.232; WEST JR, 1986, ALCOHOL CLIN EXP RES, V10, P190, DOI 10.1111/j.1530-0277.1986.tb05070.x; WEST JR, 1987, ALCOHOL DRUG RES, V7, P423; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Wyllie A H, 1980, Int Rev Cytol, V68, P251	28	1081	1125	1	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1056	1060		10.1126/science.287.5455.1056	http://dx.doi.org/10.1126/science.287.5455.1056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669420				2022-12-24	WOS:000085245400052
J	Radajewski, S; Ineson, P; Parekh, NR; Murrell, JC				Radajewski, S; Ineson, P; Parekh, NR; Murrell, JC			Stable-isotope probing as a tool in microbial ecology	NATURE			English	Article							BACTERIA; POPULATIONS; SOIL	Microorganisms are responsible for driving the biogeochemical cycling of elements on Earth. Despite their importance and vast diversity(1), the taxonomic identity of the microorganisms involved in any specific process has usually been confined to that small fraction of the microbiota that has been isolated and cultivated. The recent coupling of molecular biological methods with stable-isotope abundance in biomarkers has provided a cultivation-independent means of linking the identity of bacteria with their function in the environment(2,3). Here we show that C-13-DNA, produced during the growth of metabolically distinct microbial groups on a C-13-enriched carbon source, can be resolved from C-12- DNA by density-gradient centrifugation. DNA isolated from the target group of microorganisms can be characterized taxonomically and functionally by gene probing and sequence analysis. Application of this technique to investigate methanol-utilizing microorganisms in soil demonstrated the involvement of members of two phylogenetically distinct groups of eubacteria; the alpha-proteobacterial and Acidobacterium lineages. Stable-isotope probing thus offers a powerful new technique for identifying microorganisms that are actively involved in specific metabolic processes under conditions which approach those occurring in situ.	Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England; Inst Terr Ecol, Merlewood Res Stn, Grange Sands LA11 6JU, Cumbria, England	University of Warwick; UK Centre for Ecology & Hydrology (UKCEH)	Murrell, JC (corresponding author), Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England.		Murrell, John C/B-1443-2012					AMANN RI, 1992, APPL ENVIRON MICROB, V58, P614, DOI 10.1128/AEM.58.2.614-623.1992; Barns SM, 1999, APPL ENVIRON MICROB, V65, P1731; Boschker HTS, 1998, NATURE, V392, P801, DOI 10.1038/33900; Dedysh SN, 1998, SCIENCE, V282, P281, DOI 10.1126/science.282.5387.281; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; KISHIMOTO N, 1991, CURR MICROBIOL, V22, P1, DOI 10.1007/BF02106205; Lee N, 1999, APPL ENVIRON MICROB, V65, P1289; Lidstrom M. E., 1992, The prokaryotes: a handbook on the biology of bacteria: ecophysiology, isolation, identification, applications, vol.I., P431; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; McDonald IR, 1997, APPL ENVIRON MICROB, V63, P3218, DOI 10.1128/AEM.63.8.3218-3224.1997; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; MOFFAT AJ, 1990, SOIL USE MANAGE, V6, P46, DOI 10.1111/j.1475-2743.1990.tb00797.x; MURRELL JC, 1992, METHANE METHANOL UTI; Nogales B, 1999, ENVIRON MICROBIOL, V1, P199, DOI 10.1046/j.1462-2920.1999.00024.x; Nold SC, 1999, FEMS MICROBIOL ECOL, V29, P81, DOI 10.1111/j.1574-6941.1999.tb00600.x; Ouverney CC, 1999, APPL ENVIRON MICROB, V65, P1746; Roslev P, 1999, APPL ENVIRON MICROB, V65, P4064; Rotthauwe JH, 1997, APPL ENVIRON MICROB, V63, P4704, DOI 10.1128/AEM.63.12.4704-4712.1997; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Starr M. P., 1981, PROKARYOTES; Stein JL, 1996, J BACTERIOL, V178, P591, DOI 10.1128/jb.178.3.591-599.1996; WHITTENB.R, 1970, J GEN MICROBIOL, V61, P205, DOI 10.1099/00221287-61-2-205; Yeates C, 1998, LETT APPL MICROBIOL, V27, P49, DOI 10.1046/j.1472-765X.1998.00383.x	26	835	910	14	647	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					646	649		10.1038/35001054	http://dx.doi.org/10.1038/35001054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688198				2022-12-24	WOS:000085288200050
J	Shulz, DE; Sosnik, R; Ego, V; Haidarliu, S; Ahissar, E				Shulz, DE; Sosnik, R; Ego, V; Haidarliu, S; Ahissar, E			A neuronal analogue of state-dependent learning	NATURE			English	Article							LONG-TERM ENHANCEMENT; BASAL FOREBRAIN; AUDITORY-CORTEX; NUCLEUS BASALIS; BARREL CORTEX; CUTANEOUS RECEPTORS; EVOKED-POTENTIALS; GUINEA-PIG; RAT; PLASTICITY	State-dependent learning is a phenomenon in which the retrieval of newly acquired information is possible only if the subject is in the same sensory context and physiological state as during the encoding phase(1). In spite of extensive behavioural and pharmacological characterization(2), no cellular counterpart of this phenomenon has been reported, Here we describe a neuronal analogue of state-dependent learning in which cortical neurons show an acetylcholine-dependent expression of an acetylcholine-induced functional plasticity. This was demonstrated on neurons of rat somatosensory 'barrel' cortex, whose tunings to the temporal frequency of whisker deflections were modified by cellular conditioning. Pairing whisker stimulation with acetylcholine applied iontophoretically yielded selective lasting modification of responses, the expression of which depended on the presence of exogenous acetylcholine. Administration of acetylcholine during testing revealed frequency-specific changes in response that were not expressed when tested without acetylcholine or when the muscarinic antagonist, atropine, was applied concomitantly, Our results suggest that both acquisition and recall can be controlled by the cortical release of acetylcholine.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; CNRS, Inst Alfred Fessard, UNIC, Equipe Cognisci, F-91198 Gif Sur Yvette, France	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Shulz, DE (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.			Ego-Stengel, Valerie/0000-0002-9099-9051				Ahissar E, 1996, J PHYSIOL-PARIS, V90, P353, DOI 10.1016/S0928-4257(97)87919-3; Ahissar E, 1997, P NATL ACAD SCI USA, V94, P11633, DOI 10.1073/pnas.94.21.11633; Ahissar Ehud, 1994, Current Opinion in Neurobiology, V4, P580, DOI 10.1016/0959-4388(94)90060-4; Baskerville KA, 1997, NEUROSCIENCE, V80, P1159, DOI 10.1016/S0306-4522(97)00064-X; CARVELL GE, 1990, J NEUROSCI, V10, P2638; DELACOUR J, 1990, NEUROSCIENCE, V34, P1, DOI 10.1016/0306-4522(90)90299-J; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; EDELINE JM, 1994, EXP BRAIN RES, V97, P373; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; GORDON WC, 1994, ANIMAL LEARNING COGN, P255; Haidarliu S, 1997, J COMP NEUROL, V385, P515, DOI 10.1002/(SICI)1096-9861(19970908)385:4<515::AID-CNE3>3.0.CO;2-6; Haidarliu S, 1996, PHYSIOL BEHAV, V60, P111, DOI 10.1016/0031-9384(95)02257-0; HAIDARLIU S, 1995, J NEUROSCI METH, V56, P125, DOI 10.1016/0165-0270(94)00114-V; HOWARD MA, 1994, EXP BRAIN RES, V102, P21; IZQUIERDO I, 1984, NEUROBIOLOGY LEARNIN, P333; JACOBS SE, 1995, J NEUROSCI, V15, P1099; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kilgard MP, 1998, NAT NEUROSCI, V1, P727, DOI 10.1038/3729; Maalouf M, 1998, J NEUROPHYSIOL, V80, P529, DOI 10.1152/jn.1998.80.2.529; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; METHERATE R, 1989, BRAIN RES, V480, P372, DOI 10.1016/0006-8993(89)90210-2; RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276; RICHTER LM, 1988, CHILD CARE WORKER, V6, P11; Sachdev RNS, 1998, J NEUROPHYSIOL, V79, P3216, DOI 10.1152/jn.1998.79.6.3216; Shulz DE, 1997, EUR J NEUROSCI, V9, P396, DOI 10.1111/j.1460-9568.1997.tb01409.x; SINGER W, 1990, BRAIN ORG MEMORY CEL, P211; WEBSTER HH, 1991, BRAIN RES, V545, P292, DOI 10.1016/0006-8993(91)91300-P; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	29	122	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					549	553		10.1038/35000586	http://dx.doi.org/10.1038/35000586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676963				2022-12-24	WOS:000085227300051
J	Sze, JY; Victor, M; Loer, C; Shi, Y; Ruvkun, G				Sze, JY; Victor, M; Loer, C; Shi, Y; Ruvkun, G			Food and metabolic signaling defects in a Caenorhabditis elegans serotonin-synthesis mutant	NATURE			English	Article							C-ELEGANS; PROTEINS; EXPRESSION; LONGEVITY; GENETICS; NEURONS; LONG; PHEROMONE; BEHAVIOR; DAF-2	The functions of serotonin have been assigned through serotonin-receptor-specific drugs and mutants(1,2); however because a constellation of receptors remains when a single receptor subtype is inhibited, the coordinate responses to modulation of serotonin levels may be missed. Here we report the analysis of behavioural and neuroendocrine defects caused by a complete lack of serotonin signalling. Analysis of the C. elegans genome sequence showed that there is a single tryptophan hydroxylase gene (tph-1)-the key enzyme for serotonin biosynthesis. Animals bearing a tph-1 deletion mutation do not synthesize serotonin but are fully viable. The tph-1 mutant shows abnormalities in behaviour and metabolism that are normally coupled with the sensation and ingestion of food: rates of feeding and egg laying are decreased; large amounts of fat are stored; reproductive lifespan is increased; and some animals arrest at the metabolically inactive dauer stage. This metabolic dysregulation is, in part, due to downregulation of tranforming growth factor-beta and insulin-like neuroendocrine signals. The action of the C. elegans serotonergic system in metabolic control is similar to mammalian serotonergic input to metabolism and obesity.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ San Diego, Dept Biol, San Diego, CA 92110 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of San Diego	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@frodo.mgh.harvard.edu						[Anonymous], [No title captured]; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; Breum L, 1995, METABOLISM, V44, P1570, DOI 10.1016/0026-0495(95)90077-2; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; DSa CM, 1996, J NEUROCHEM, V67, P917; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; Gems D, 1998, GENETICS, V150, P129; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Leibowitz SF, 1998, BIOL PSYCHIAT, V44, P851, DOI 10.1016/S0006-3223(98)00186-3; Loer CM, 1999, J NEUROGENET, V13, P157, DOI 10.3109/01677069909083472; Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Peschke E, 1997, J PINEAL RES, V23, P156, DOI 10.1111/j.1600-079X.1997.tb00349.x; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D.L., 1997, GENETIC ENV REGULATI, VII, P739; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; Waggoner LE, 1998, NEURON, V21, P203, DOI 10.1016/S0896-6273(00)80527-9; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Zwaal RR, 1997, GENETICS, V145, P715	30	460	482	0	80	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					560	564		10.1038/35000609	http://dx.doi.org/10.1038/35000609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676966				2022-12-24	WOS:000085227300054
J	Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS				Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS			Neurobiology - Inhibitor of neurite outgrowth in humans	NATURE			English	Article							SPINAL-CORD; GROWTH; MYELIN; IDENTIFICATION; ANTIBODY; PROTEINS; GENE		SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Bioinformat, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Prinjha, R (corresponding author), SmithKline Beecham Pharmaceut, Dept Neurosci Res, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.			Michalovich, David/0000-0003-4452-5776				BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Ramon y, 1928, DEGENERATION REGENER; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403	11	480	553	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					383	384		10.1038/35000287	http://dx.doi.org/10.1038/35000287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667780				2022-12-24	WOS:000085121100036
J	Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G				Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G			Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass	CELL			English	Article							OSTEOCLAST DIFFERENTIATION; INVOLUTIONAL OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; RECEPTOR GENE; DIABETIC MICE; FEMALE MICE; DB/DB MICE; OB/OB MICE; OBESITY; MOUSE	Gonadal failure induces bone loss while obesity prevents it. This raises the possibility that bone mass, body weight, and gonadal function are regulated by common pathways. To test this hypothesis, we studied leptin-deficient and leptin receptor-deficient mice that are obese and hypogonadic. Both mutant mice have an increased bone formation leading to high bone mass despite hypogonadism and hypercortisolism. This phenotype is dominant, independent of the presence of fat, and specific for the absence of leptin signaling. There is no leptin signaling in osteoblasts but intracerebroventricular infusion of leptin causes bone loss in leptin-deficient and wild-type mice. This study identifies leptin as a potent inhibitor of bone formation acting through the central nervous system and therefore describes the central nature of bone mass control and its disorders.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Hamburg, Dept Trauma Surg, D-20246 Hamburg, Germany; NCI, Biochem Lab, Bethesda, MD 20892 USA	Baylor College of Medicine; University of Hamburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu	takeda, shu/B-5195-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45548] Funding Source: Medline; NIDCR NIH HHS [DE11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; Aschner B, 1912, PFLUG ARCH GES PHYS, V146, P1, DOI 10.1007/BF01681114; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cooper Cyrus, 1996, P419; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Namae M, 1998, LAB ANIM SCI, V48, P103; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PECK WA, 1993, AM J MED, V94, P646; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622; Reid IR, 1997, NEW ENGL J MED, V337, P420, DOI 10.1056/NEJM199708073370609; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	1588	1699	2	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					197	207		10.1016/S0092-8674(00)81558-5	http://dx.doi.org/10.1016/S0092-8674(00)81558-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660043	Bronze			2022-12-24	WOS:000084932200004
J	Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ				Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ			E-coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy	CELL			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; RTX TOXIN; PROTEIN; MODEL; WATER; SLYA	Hemolysin E (HlyE) is a novel pore-forming toxin of Escherichia coli, Salmonella typhi, and Shigella flexneri. Here we report the X-ray crystal structure of the water-soluble form of E. coli HlyE at 2.0 Angstrom resolution and the visualization of the lipid-associated form of the toxin in projection at low resolution by electron microscopy. The crystal structure reveals HlyE to be the first member of a new family of toxin structures, consisting of an elaborated helical bundle some 100 Angstrom long. The electron micrographs show how HlyE oligomerizes in the presence of lipid to form transmembrane pores. Taken together, the data from these two structural techniques allow us to propose a simple model for the structure of the pore and for membrane interaction.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Artymiuk, PJ (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Bullough, Per/0000-0001-8147-1127				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GL, 1993, PROTEIN ENG, V6, P13; Bauer ME, 1996, INFECT IMMUN, V64, P167, DOI 10.1128/IAI.64.1.167-175.1996; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; Harbury PAB, 1998, STRUCT FOLD DES, V6, P1487, DOI 10.1016/S0969-2126(98)00147-6; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESLIE AGW, 1994, PROTEIN CRYSTALLOGR, V26; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'brien A., 1996, E COLI SALMONELLA CE, V2, P2788; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; Reingold J, 1999, VET MICROBIOL, V66, P125, DOI 10.1016/S0378-1135(98)00310-1; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; SALYERS AA, 1994, BACTERIAL PATHOGENES; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; [No title captured]	45	175	195	2	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					265	276		10.1016/S0092-8674(00)81564-0	http://dx.doi.org/10.1016/S0092-8674(00)81564-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660049	Bronze			2022-12-24	WOS:000084932200010
J	Weeks, DL; Eskandari, S; Scott, DR; Sachs, G				Weeks, DL; Eskandari, S; Scott, DR; Sachs, G			A H+-gated urea channel: The link between Helicobacter pylori urease and gastric colonization	SCIENCE			English	Article							PROTEIN; PH; TRANSPORTER; METABOLISM; MEMBRANES; ACID	Acidic media trigger cytoplasmic urease activity of the unique human gastric pathogen Helicobacter pylori. Deletion of urel prevents this activation of cytoplasmic urease that is essential for bacterial acid resistance. Urel is an inner membrane protein with six transmembrane segments as shown by in vitro transcription/translation and membrane separation. Expression of Urel in Xenopus oocytes results in acid-stimulated urea uptake, with a pH profile similar to activation of cytoplasmic urease, Mutation of periplasmic histidine 123 abolishes stimulation. Urel-mediated transport is urea specific, passive, nonsaturable, nonelectrogenic, and temperature independent. Urel functions as a H+-gated urea channel regulating cytoplasmic urease that is essential for gastric survival and colonization.	VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sachs, G (corresponding author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046917, P30DK041301, S15DK043462] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46917, DK43462, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BODE G, 1993, MED MICROBIOL IMMUN, V182, P223; Chebrou H, 1996, GENE, V182, P215, DOI 10.1016/S0378-1119(96)00478-7; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; HU LT, 1992, INFECT IMMUN, V60, P2657, DOI 10.1128/IAI.60.7.2657-2666.1992; KATAYAMA Y, 1991, J PHYSIOL-LONDON, V443, P587, DOI 10.1113/jphysiol.1991.sp018853; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; MeyerRosberg K, 1996, GASTROENTEROLOGY, V111, P886, DOI 10.1016/S0016-5085(96)70056-2; ORBACH E, 1980, J GEN PHYSIOL, V75, P427, DOI 10.1085/jgp.75.4.427; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; Rektorschek M, 1998, GASTROENTEROLOGY, V115, P628, DOI 10.1016/S0016-5085(98)70142-8; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; TAYLOR MB, 1988, FEMS MICROBIOL LETT, V55, P259, DOI 10.1016/0378-1097(88)90034-1; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TUDOR JJ, 1994, J BACTERIOL, V176, P948, DOI 10.1128/JB.176.4.948-952.1994; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	22	335	359	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					482	485		10.1126/science.287.5452.482	http://dx.doi.org/10.1126/science.287.5452.482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642549				2022-12-24	WOS:000084929900047
J	Wyckoff, GJ; Wang, W; Wu, CI				Wyckoff, GJ; Wang, W; Wu, CI			Rapid evolution of male reproductive genes in the descent of man	NATURE			English	Article							POSITIVE SELECTION; PROTEIN EVOLUTION; DROSOPHILA; PRIMATES; SUBSTITUTION; POLYMORPHISM; NUCLEOTIDE; SEQUENCES; SPERM; RATES	A diverse body of morphological and genetic evidence has suggested that traits pertaining to male reproduction may have evolved much more rapidly than other types of character(1-3). Recently, DNA sequence comparisons have also shown a very high level of divergence in male reproductive proteins between closely related Drosophila species(4-6), among marine invertebrates(7,8) and between mouse and rat(9). Here we show that rapid evolution of male reproductive genes is observable in primates and is quite notable in the lineages to human and chimpanzee. Nevertheless, rapid evolution by itself is not necessarily an indication of positive darwinian selection; relaxation of negative selection is often equally compatible with the DNA sequence data. By taking three statistical approaches, we show that positive darwinian selection is often the driving force behind this rapid evolution. These results open up opportunities to test the hypothesis that sexual selection plays some role in the molecular evolution of higher primates.	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Wu, CI (corresponding author), Univ Chicago, Comm Genet, 1101 E 57th St, Chicago, IL 60637 USA.			Wyckoff, Gerald/0000-0003-2604-2666				COULTHART MB, 1988, MOL BIOL EVOL, V5, P167; Darwin C., 1871, P423; Dixson AF, 1998, PRIMATE SEXUALITY; Eberhard W. G., 1985, SEXUAL SELECTION ANI; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; Gould K.G., 1980, International Review of Cytology, V63, P323, DOI 10.1016/S0074-7696(08)61761-1; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Kimura M, 1985, NEUTRAL THEORY MOL E; LEE Y, 1995, MOL BIOL EVOL, V6, P424; Li W-H, 1997, MOL EVOLUTION; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MAEDA N, 1988, MOL BIOL EVOL, V5, P1; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; NELSON JE, 1993, J BIOL CHEM, V268, P2932; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; QUERALT R, 1993, J FORENSIC SCI, V38, P1491; RETIEF JD, 1993, J MOL EVOL, V37, P426; RETIEF JD, 1993, EUR J BIOCHEM, V214, P609, DOI 10.1111/j.1432-1033.1993.tb17960.x; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; SCHLICKER M, 1994, HUM REPROD, V9, P2313, DOI 10.1093/oxfordjournals.humrep.a138444; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SILLENTULLBERG B, 1993, AM NAT, V141, P1, DOI 10.1086/285458; Sutton KA, 1997, J MOL EVOL, V45, P579, DOI 10.1007/PL00006262; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Tsaur SC, 1998, MOL BIOL EVOL, V15, P1040, DOI 10.1093/oxfordjournals.molbev.a026002; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; Yang ZH, 1998, MOL BIOL EVOL, V15, P1600, DOI 10.1093/oxfordjournals.molbev.a025888	30	429	454	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					304	309		10.1038/35002070	http://dx.doi.org/10.1038/35002070			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659848				2022-12-24	WOS:000084899700051
J	Imamizu, H; Miyauchi, S; Tamada, T; Sasaki, Y; Takino, R; Putz, B; Yoshioka, T; Kawato, M				Imamizu, H; Miyauchi, S; Tamada, T; Sasaki, Y; Takino, R; Putz, B; Yoshioka, T; Kawato, M			Human cerebellar activity reflecting an acquired internal model of a new tool	NATURE			English	Article							OCULAR FOLLOWING RESPONSES; TEMPORAL FIRING PATTERNS; PURKINJE-CELLS; VENTRAL PARAFLOCCULUS; COMPLEX SPIKES; HUMAN BRAIN; ACTIVATION; MOVEMENT; MONKEYS; ADAPTATION	Theories of motor control postulate that the brain uses internal models of the body to control movements accurately. Internal models are neural representations of how, for instance, the arm would respond to a neural command, given its current position and velocity(1-6), Previous studies have shown that the cerebellar cortex can acquire internal models through motor learning(7-11). Because the human cerebellum is involved in higher cognitive function(12-15) as well as in motor control, we propose a coherent computational theory in which the phylogenetically newer part of the cerebellum similarly acquires internal models of objects in the external world. While human subjects learned to use a new tool (a computer mouse with a novel rotational transformation), cerebellar activity was measured by functional magnetic resonance imaging, As predicted by our theory, two types of activity were observed. One was spread over wide areas of the cerebellum and was precisely proportional to the error signal that guides the acquisition of internal models during learning. The other was confined to the area near the posterior superior fissure and remained even after learning, when the error levels had been equalized, thus probably reflecting an acquired internal model of the new tool.	JST ERATO Kawato Dynam brain Project, Seika, Kyoto 6190288, Japan; Commun Res Lab, Nishi Ku, Kobe, Hyogo 6512401, Japan; Shiraume Gakuen Coll, Kodaira, Tokyo 1878570, Japan; ATR Human Informat Proc Res Labs, Seika, Kyoto 6190288, Japan	Japan Science & Technology Agency (JST); National Institute of Information & Communications Technology (NICT) - Japan	Imamizu, H (corresponding author), JST ERATO Kawato Dynam brain Project, 2-2 Hikaridai, Seika, Kyoto 6190288, Japan.		Pütz, Benno/P-2630-2016; Imamizu, Hiroshi/AAK-6059-2020	Pütz, Benno/0000-0002-2208-209X; Imamizu, Hiroshi/0000-0003-1024-0051; Sasaki, Yuka/0000-0002-0061-0250				ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Flament D, 1996, HUM BRAIN MAPP, V4, P210, DOI 10.1002/hbm.460040302; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Gomi H, 1998, J NEUROPHYSIOL, V80, P818, DOI 10.1152/jn.1998.80.2.818; Gomi H, 1996, SCIENCE, V272, P117, DOI 10.1126/science.272.5258.117; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; IMAMIZU H, 1995, J EXP PSYCHOL HUMAN, V21, P1174, DOI 10.1037/0096-1523.21.5.1174; ITO M, 1982, ANNU REV NEUROSCI, V5, P275, DOI 10.1146/annurev.ne.05.030182.001423; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Kobayashi Y, 1998, J NEUROPHYSIOL, V80, P832, DOI 10.1152/jn.1998.80.2.832; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; ROLAND PE, 1988, EUR J NEUROSCI, V1, P3; SASAKI K, 1977, EXP BRAIN RES, V29, P419; SEITZ RJ, 1994, NEUROREPORT, V5, P2541, DOI 10.1097/00001756-199412000-00034; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; Tamada T, 1999, NEUROREPORT, V10, P325, DOI 10.1097/00001756-199902050-00022; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023	30	676	680	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					192	195		10.1038/35003194	http://dx.doi.org/10.1038/35003194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	275TB	10646603				2022-12-24	WOS:000084835300054
J	Miller, ST; Sleeper, LA; Pegelow, CH; Enos, LE; Wang, WC; Weiner, SJ; Wethers, DL; Smith, J; Kinney, TR				Miller, ST; Sleeper, LA; Pegelow, CH; Enos, LE; Wang, WC; Weiner, SJ; Wethers, DL; Smith, J; Kinney, TR			Prediction of adverse outcomes in children with sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE-CLUSTER HAPLOTYPES; RISK-FACTORS; FETAL HEMOGLOBIN; ANEMIA; MORTALITY; DISORDERS; MORBIDITY; FAILURE; COHORT; RATES	Background: The ability to identify infants with sickle cell anemia who are likely to have severe complications later in life would permit accurate prognostication and tailoring of therapy to match disease-related risks and facilitate planning of clinical trials. We attempted to define the features of such babies by following the clinical course of 392 children with sickle cell disease from infancy to about the age of 10 years. Methods: We analyzed the records of 392 infants who received the diagnosis of homozygous sickle cell anemia or sickle cell-beta(0)-thalassemia before the age of six months and for whom comprehensive clinical and laboratory data were recorded prospectively; data were available for a mean (+/-SD) of 10.0+/-4.8 years. Results obtained before the age of two years were evaluated to determine whether they predicted the outcome later in life. Results: Of the 392 infants in the cohort, 70 (18 percent) subsequently had an adverse outcome, defined as death (18 patients [26 percent]), stroke (25 [36 percent]), frequent pain (17 [24 percent]), or recurrent acute chest syndrome (10 [14 percent]). Using multivariate analysis, we found three statistically significant predictors of an adverse outcome: an episode of dactylitis (defined as pain and tenderness in the hands or feet) before the age of one year (relative risk of an adverse outcome, 2.55; 95 percent confidence interval, 1.39 to 4.67), a hemoglobin level of less than 7 g per deciliter (relative risk, 2.47; 95 percent confidence interval, 1.14 to 5.33), and leukocytosis in the absence of infection (relative risk, 1.80; 95 percent confidence interval, 1.05 to 3.09). Conclusions: Three easily identifiable manifestations of sickle cell disease that may appear in the first two years of life (dactylitis, severe anemia, and leukocytosis) can help to predict the possibility of severe sickle cell disease later in life. (N Engl J Med 2000;342:83-9.) (C) 2000, Massachusetts Medical Society.	Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; New England Res Inst, Watertown, MA 02172 USA; Univ Miami, Miami, FL 33152 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; St Lukes Roosevelt Hosp, New York, NY USA; Harlem Hosp Med Ctr, New York, NY USA; Duke Univ, Med Ctr, Durham, NC USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; HealthCore, Inc; University of Miami; St Jude Children's Research Hospital; Mount Sinai St. Luke's; Mount Sinai West; Duke University	Miller, ST (corresponding author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 49, Brooklyn, NY 11203 USA.	stmseelig@aol.com			NHLBI NIH HHS [N01-HB-47110] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047110] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams Junius G. Iii, 1994, P457; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; Bratt J, 1997, J IMMUNOL, V159, P912; BRAY GL, 1994, AM J PEDIAT HEMATOL, V16, P50; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; COX DR, 1972, J R STAT SOC B, V34, P187; Efron B., 1993, INTRO BOOTSTRAP, P141; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; Fadlon E, 1998, BLOOD, V91, P266, DOI 10.1182/blood.V91.1.266.266_266_274; GASTON M, 1987, CONTROL CLIN TRIALS, V8, pS131; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; KOSHY M, 1989, BLOOD, V74, P1403; Koshy M, 1990, J Assoc Acad Minor Phys, V1, P71; LANE PA, 1995, BLOOD, V85, P2238, DOI 10.1182/blood.V85.8.2238.bloodjournal8582238; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MILNER PF, 1991, NEW ENGL J MED, V325, P1476, DOI 10.1056/NEJM199111213252104; Moser FG, 1996, AM J NEURORADIOL, V17, P965; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; Ohene-Frempong K, 1998, BLOOD, V91, P288; Pass KA, 1994, NEWBORN SCREENING SI, P29; PEARSON HA, 1985, PEDIATRICS, V76, P392; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1991, HEMATOL ONCOL CLIN N, V5, P475, DOI 10.1016/S0889-8588(18)30426-X; POWARS DR, 1991, SEMIN HEMATOL, V28, P202; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; REID CD, 1995, NIH PUBLICATION; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEST MS, 1992, J CLIN EPIDEMIOL, V45, P893; WRIGHTSTONE RN, 1974, AM J CLIN PATHOL, V61, P375; ZARKOWSKY HS, 1986, J PEDIATR-US, V109, P579, DOI 10.1016/S0022-3476(86)80216-5	37	320	329	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2000	342	2					83	89		10.1056/NEJM200001133420203	http://dx.doi.org/10.1056/NEJM200001133420203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273TQ	10631276				2022-12-24	WOS:000084723900003
J	Cox, PA				Cox, PA			Will tribal knowledge survive the millennium?	SCIENCE			English	Editorial Material									Natl Trop Bot Garden, Kauai, HI 96765 USA		Cox, PA (corresponding author), Natl Trop Bot Garden, POB 340, Kauai, HI 96765 USA.								0	153	168	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					44	45		10.1126/science.287.5450.44	http://dx.doi.org/10.1126/science.287.5450.44			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644221				2022-12-24	WOS:000084578400023
J	Channell, R; Lomolino, MV				Channell, R; Lomolino, MV			Dynamic biogeography and conservation of endangered species	NATURE			English	Article							EXTINCTION; PATTERNS; TRANSLOCATION; ABUNDANCE; AUSTRALIA; BIRDS	As one moves from the core to the periphery of a species' geographical range, populations occupy less favourable habitats and exhibit lower and more variable densities(1-4). Populations along the periphery of the range tend to be more fragmented and, as a result, are less likely to receive immigrants from other populations. A population's probability of extinction is directly correlated with its variability and inversely correlated with density and immigration rate(5-9). This has led to the prediction that, when a species becomes endangered, its geographical range should contract inwards, with the core populations persisting until the final stages of decline(2,10). Convinced by these logical but untested deductions, conservation biologists and wildlife managers have been instructed to avoid the range periphery when planning conservation strategies or allocating resources for endangered species(11-13). We have analysed range contraction in 245 species from a broad range of taxonomic groups and geographical regions, Here we report that observed patterns of range contraction do not support the above predictions and that most species examined persist in the periphery of their historical geographical ranges.	Ft Hays State Univ, Dept Biol Sci, Hays, KS 67601 USA; Univ Oklahoma, Dept Zool, Norman, OK 73019 USA; Oklahoma Nat Heritage Inventory, Oklahoma Biol Survey, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Channell, R (corresponding author), Ft Hays State Univ, Dept Biol Sci, Hays, KS 67601 USA.	Rchannel@FHSU.edu						BIBBY CJ, 1994, PHILOS T R SOC B, V344, P35, DOI 10.1098/rstb.1994.0048; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; BROWN JH, 1995, ECOLOGY, V76, P2028, DOI 10.2307/1941678; Brown JH, 1995, MACROECOLOGY; BURBIDGE AA, 1989, BIOL CONSERV, V50, P143, DOI 10.1016/0006-3207(89)90009-8; CHANNELL R, 1998, THESIS U OKLAHOMA; Diamond J.M., 1984, P824; Eastman J. R., 1995, IDRISI WINDOWS VERSI; FRANKLIN J, 1991, CONSERV BIOL, V5, P506, DOI 10.1111/j.1523-1739.1991.tb00358.x; GASTON KJ, 1990, BIOL REV, V65, P105, DOI 10.1111/j.1469-185X.1990.tb01185.x; Goel N., 1974, STOCHASTIC MODELS BI; GRIFFITH B, 1989, SCIENCE, V245, P477, DOI 10.1126/science.245.4917.477; Lawton John H., 1995, P147; MAC ARTHUR ROBERT H., 1967; Martin P.S., 1984, P354; Pearl Mary, 1992, P297; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; SHORT J, 1992, BIOL CONSERV, V62, P189, DOI 10.1016/0006-3207(92)91047-V; STEVENS G, 1992, SYSTEMATICS, ECOLOGY, AND THE BIODIVERSITY CRISIS, P40; TOWNS DR, 1994, NEW ZEAL J ZOOL, V21, P325, DOI 10.1080/03014223.1994.9518003; TRACY CR, 1992, AM NAT, V139, P102, DOI 10.1086/285315; Wolf CM, 1996, CONSERV BIOL, V10, P1142, DOI 10.1046/j.1523-1739.1996.10041142.x	23	438	461	4	222	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					84	86		10.1038/47487	http://dx.doi.org/10.1038/47487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638757				2022-12-24	WOS:000084687400047
J	Wikelski, M; Thom, C				Wikelski, M; Thom, C			Marine iguanas shrink to survive El Nino - Changes in bone metabolism enable these adult lizards to reversibly alter their length.	NATURE			English	Article							AMBLYRHYNCHUS-CRISTATUS; BODY-SIZE; GALAPAGOS	Changes in bone metabolism enable these adult lizards to reversibly alter their length.	Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA; Max Planck Inst Behav Physiol, D-82319 Seewiesen, Germany; Univ Bielefeld, D-33501 Bielefeld, Germany; Univ Wurzburg, Dept Biol, D-97072 Wurzburg, Germany	University of Illinois System; University of Illinois Urbana-Champaign; Max Planck Society; University of Bielefeld; University of Wurzburg	Wikelski, M (corresponding author), Univ Illinois, Dept Ecol Ethol & Evolut, 515 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.							Andrews R.M., 1982, Biology of Reptilia, V13, P273; COOPER JE, 1987, J COMP PATHOL, V97, P129, DOI 10.1016/0021-9975(87)90032-6; Enlow D. H., 1969, pUnpaginated; Grant PR, 1986, ECOLOGY EVOLUTION DA; Grigoriev A I, 1998, Aviakosm Ekolog Med, V32, P21; Jarman P.J., 1979, SERENGETI DYNAMICS E, P130, DOI DOI 10.1086/284321; LAURIE WA, 1990, J ANIM ECOL, V59, P545, DOI 10.2307/4880; LAURIE WA, 1989, GLOBAL ECOLOGICAL CO, P121; MUNDY GR, 1994, NATURE, V367, P216, DOI 10.1038/367216a0; Strollo F, 1998, AVIAT SPACE ENVIR MD, V69, P777; Wikelski M, 1997, ECOLOGY, V78, P2204, DOI 10.2307/2265956; Wikelski M, 1997, EVOLUTION, V51, P922, DOI 10.1111/j.1558-5646.1997.tb03673.x; WIKELSKI M, 1994, BEHAVIOUR, V128, P255, DOI 10.1163/156853994X00280; Wolter K., 1998, WEATHER, V53, P315, DOI DOI 10.1002/J.1477-8696.1998.TB06408.X; WRONSKI TJ, 1982, METAB BONE DIS RELAT, V4, P69, DOI 10.1016/0221-8747(82)90011-X	15	157	162	1	129	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					37	38		10.1038/47396	http://dx.doi.org/10.1038/47396			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638740				2022-12-24	WOS:000084687400030
J	Jadad, AR; Moher, M; Browman, GP; Booker, L; Sigouin, C; Fuentes, M; Stevens, R				Jadad, AR; Moher, M; Browman, GP; Booker, L; Sigouin, C; Fuentes, M; Stevens, R			Systematic reviews and meta-analyses on treatment of asthma: critical evaluation	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; CONTROLLED TRIALS; CLINICAL-TRIALS; METAANALYSIS; EFFICACY; QUALITY; SALMETEROL; ARTICLES; THERAPY	Objective To evaluate the clinical, methodological, and reporting aspects of systematic reviews and meta-analyses on the treatment of asthma and to compare those published by the Cochrane Collaboration with those published in paper based journals. Design. Analysis of studies identified from Medline, CINAHL. HealthSTAR, EMBASE, Cochrane Library, personal collections, and reference lists. Studies Articles describing a systematic review or a meta-analysis of the treatment of asthma that were published as a full report, in any language or format, in a peer reviewed journal or the Cochrane Library. Main outcome measures General characteristics of studies reviewed and methodological characteristics (sources of articles; language restrictions; format, design and publication status of studies included; type of data synthesis; and methodological quality). Results 50 systematic reviews and meta-analyses were included. More than half were published in the past two years. Twelve reviews were published in the Cochrane Library and 38 were published in 2 peer reviewed journals. Forced expiratory volume in one second was the most frequently used outcome, but few reviews evaluated the effect of treatment on costs or patient preferences. Forty reviews were judged to have serious or extensive nd rvs. All six reviews associated with industry were in this group. Seven of the 10 most rigorous reviews were published in the Cochrane Library. Conclusions Most reviews published in peer reviewed journals or funded by industry have serious methodological flaws that limit their value to guide decisions. Cochrane reviews are more rigorous and better reported than those published in peer reviewed journals.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Univ Oxford, Inst Hlth Sci, Oxford OX3 7LF, England; Foresight Consultants, Dundas, ON L9H 2R5, Canada	McMaster University; University of Oxford	Jadad, AR (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.							ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; ABRAMSON MJ, ALLERGEN SPECIFIC IM; ABRAMSON MJ, 1998, COCHRANE LIB; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Amirav I, 1997, ARCH PEDIAT ADOL MED, V151, P876, DOI 10.1001/archpedi.1997.02170460014003; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BARNES CL, 1993, ANN PHARMACOTHER, V27, P464; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Barnes N, 1998, J ALLERGY CLIN IMMUN, V101, pS460, DOI 10.1016/S0091-6749(98)70160-5; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BERNARDBONNIN AC, 1995, J ALLERGY CLIN IMMUN, V95, P34, DOI 10.1016/S0091-6749(95)70150-8; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; BIELORY L, 1994, ANN ALLERGY, V73, P89; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; CATES CJ, COMP HOLDING CHAMBER; Davies B, 1998, RESP MED, V92, P256, DOI 10.1016/S0954-6111(98)90105-6; DAVIES H, 1998, COCHRANE LIB; DAVIES H, METHOTREXATE STEROID; Devine EC, 1996, RES NURS HEALTH, V19, P367, DOI 10.1002/(SICI)1098-240X(199610)19:5<367::AID-NUR1>3.0.CO;2-O; Droogan J, 1997, Nurs Times, V93, P45; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GIBSON PG, 1998, COCHRANE LIB; GIBSON PG, EFFECTS SELF MANAGEM; GIBSON PG, EFFECTS LTD INFORMAT; Goodman DC, 1996, PEDIATR PULM, V21, P211, DOI 10.1002/(SICI)1099-0496(199604)21:4<211::AID-PPUL2>3.0.CO;2-R; Gosselink HA, 1993, J REHABILITATION SCI, V6, P66; Grunfeld A.F, 1996, CAN RESPIR J, V3, P322, DOI [10.1155/1996/254627, DOI 10.1155/1996/254627]; HAMMARQUIST C, HOUSE DUST MITE CONT; HAMMERQUIST C, 1998, COCHRANE LIB; HATOUM HT, 1994, ANN PHARMACOTHER, V28, P1285; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Jadad AR, 1998, MED DECIS MAKING, V18, P2, DOI 10.1177/0272989X9801800102; Kelloway JS, 1997, ANN PHARMACOTHER, V31, P1012, DOI 10.1177/106002809703100912; Kelly HW, 1998, ANN PHARMACOTHER, V32, P220, DOI 10.1345/aph.17014; LARSEN JS, 1993, ANN PHARMACOTHER, V27, P898, DOI 10.1177/106002809302700718; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LINDE K, ACUPUNCTURE TREATMEN; LINDE K, HOMEOPATHY CHRONIC A; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; Marin MG, 1997, CHEST, V112, P29, DOI 10.1378/chest.112.1.29; MEYER JM, 1993, ANN PHARMACOTHER, V27, P1478, DOI 10.1177/106002809302701214; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOHER D, 1999, QUOROM GROUP IMPROVI; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; MULROW CD, 1995, SYSTEMATIC REV, P1; Negro J M, 1997, Allergol Immunopathol (Madr), V25, P209; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; OBYRNE PM, 1995, J AEROSOL MED, V8, pS39; OSMOND MH, 1995, ACAD EMERG MED, V2, P651, DOI 10.1111/j.1553-2712.1995.tb03607.x; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1988, CAN MED ASSOC J, V138, P687; PANTON J, FAMILY THERAPY TREAT; PARISH RC, 1993, ANN PHARMACOTHER, V27, P599, DOI 10.1177/106002809302700515; Petticrew M, 1997, Nurs Times, V93, P53; PLOTNICK LH, 1998, COCHRANE LIB; PLOTNICK LH, EFFICACY SAFETY COMB; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; ROWE BH, 1998, COCHRANE LIB; ROWE BH, EFFECTIVENESS CORTIC; Sacks HS, 1996, MT SINAI J MED, V63, P216; SACKS HS, 1992, MED USES STATISTICS, P427; Self T H, 1992, J Am Board Fam Pract, V5, P281; SHEA B, 1999, 7 COCHR C; Smith LJ, 1996, ARCH INTERN MED, V156, P2181, DOI 10.1001/archinte.156.19.2181; SPOONER CH, 1998, COCHRANE LIB; SPOONER CH, NEDOCROMIL SODIUM SI; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; Van der Palen J, 1998, RESP MED, V92, P668, DOI 10.1016/S0954-6111(98)90516-9; VANDERKUY PHM, 1993, PHARM WEEKBLAD, V128, P1293; VanGanse E, 1997, EUR RESPIR J, V10, P2216, DOI 10.1183/09031936.97.10102216; Verberne AAPH, 1998, RESP MED, V92, P777, DOI 10.1016/S0954-6111(98)90012-9; Vickers A. J., 1997, COMPLEMENTARY THERAP, V5, P202	75	161	171	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	2000	320	7234					537	540D		10.1136/bmj.320.7234.537	http://dx.doi.org/10.1136/bmj.320.7234.537			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289LV	10688558	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000085624000020
J	Chu, K; Vojtchovsky, J; McMahon, BH; Sweet, RM; Berendzen, J; Schlichting, I				Chu, K; Vojtchovsky, J; McMahon, BH; Sweet, RM; Berendzen, J; Schlichting, I			Structure of a ligand-binding intermediate in wild-type carbonmonoxy myoglobin	NATURE			English	Article							MOLECULAR-DYNAMICS; PROTEINS; RELAXATION; MUTANTS; STATES; XENON; SITE	Small molecules such as NO, O-2, CO or H-2 are important biological ligands that bind to metalloproteins to function crucially in processes such as signal transduction, respiration and catalysis. A key issue for understanding the regulation of reaction mechanisms in these systems is whether ligands gain access to the binding sites through specific channels and docking sites, or by random diffusion through the protein matrix. A model system for studying this issue is myoglobin, a simple haem protein. Myoglobin has been studied extensively by spectroscopy, crystallography, computation and theory(1-11). It serves as an aid to oxygen diffusion but also binds carbon mono nide, a byproduct of endogenous haem catabolism. Molecular dynamics simulations(3-5), random mutagenesis(6) and flash photolysis studies(7-10) indicate that ligand migration occurs through a limited number of pathways involving docking sites. Here we report the 1.4 Angstrom resolution crystal structure of a ligand-binding intermediate in carbonmonoxy myoglobin that may have far-reaching implications for understanding the dynamics of ligand binding and catalysis.	Univ Calif Los Alamos Natl Lab, Biophys Grp P21, Los Alamos, NM 87545 USA; Univ Vermont, Dept Phys, Burlington, VT 05405 USA; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Calif Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM 87545 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Vermont; Max Planck Society; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory	Chu, K (corresponding author), Univ Calif Los Alamos Natl Lab, Biophys Grp P21, MS-D454, Los Alamos, NM 87545 USA.		Schlichting, Ilme/I-1339-2013	Berendzen, Joel/0000-0002-9454-9074				ABADAN Y, 1995, BIOPHYS J, V68, P2497, DOI 10.1016/S0006-3495(95)80432-7; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; Anfinrud P, 1999, P NATL ACAD SCI USA, V96, P8328, DOI 10.1073/pnas.96.15.8328; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; Brunori M, 1999, TRENDS BIOCHEM SCI, V24, P253, DOI 10.1016/S0968-0004(99)01421-8; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CHU K, 1995, PHYS REV LETT, V74, P2607, DOI 10.1103/PhysRevLett.74.2607; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; MCMAHON BH, 1997, THESIS U ILLINOIS UR; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6	30	230	234	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					921	923		10.1038/35002641	http://dx.doi.org/10.1038/35002641			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706294				2022-12-24	WOS:000085559200065
J	Willoughby, DA; Moore, AR; Colville-Nash, PR				Willoughby, DA; Moore, AR; Colville-Nash, PR			COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease	LANCET			English	Article							NITRIC-OXIDE SYNTHASE; RECEPTOR-GAMMA; CYCLOOXYGENASE; DRUGS	A new generation of non-steroidal anti-inflammatory drugs has been described that selectively targets the inducible isoform of cyclo-oxygenase, cyclo-oxygenase 2 (COX-5). This isoform is expressed at sites of inflammation, which has fed to the speculation that its inhibition could provide all the benefits of current nonsteroidal anti-inflammatory drugs, but without their major side-effects on the gastrointestinal system (which are due to inhibition of COX-1). We have shown that COX-2 (identified by use of specific antibodies) is induced during the resolution of an inflammatory response, inhibition of COX-2 resulting in persistence of the inflammation due to the prevention of the synthesis of a range of anti-inflammatory prostanoids. We propose that there is a third isoform of this enzyme family, COX-3, a proposal that will have implication for the prescription of both existing and new generation anti-inflammatory drugs, and might represent a new therapeutic target.	St Bartholomews & Royal London Hosp Sch Med, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England; St Bartholomews & Royal London Hosp Sch Dent, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Willoughby, DA (corresponding author), St Bartholomews & Royal London Hosp Sch Med, William Harvey Res Inst, Dept Expt Pathol, Charterhouse Sq, London EC1M 6BQ, England.							Colville-Nash PR, 1998, J IMMUNOL, V161, P978; DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103; Gilroy DW, 1998, EUR J PHARMACOL, V355, P211, DOI 10.1016/S0014-2999(98)00508-1; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; RASHAD S, 1989, LANCET, V2, P519; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P547; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	18	216	243	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					646	648		10.1016/S0140-6736(99)12031-2	http://dx.doi.org/10.1016/S0140-6736(99)12031-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696997				2022-12-24	WOS:000085615400042
J	Masliah, E; Rockenstein, E; Veinbergs, I; Mallory, M; Hashimoto, M; Takeda, A; Sagara, Y; Sisk, A; Mucke, L				Masliah, E; Rockenstein, E; Veinbergs, I; Mallory, M; Hashimoto, M; Takeda, A; Sagara, Y; Sisk, A; Mucke, L			Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; LEWY BODIES; NACP/ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BETA; AGGREGATION; MUTATION; GENE	To elucidate the role of the synaptic protein alpha-synuclein in neurodegenerative disorders, transgenic mice expressing wild-type human alpha-synuclein were generated. Neuronal expression of human alpha-synuclein resulted in progressive accumulation of alpha-synuclein-and ubiquitin-immunoreactive inclusions in neurons in the neocortex, hippocampus, and substantia nigra. Ultrastructural analysis revealed both electron-dense intranuclear deposits and cytoplasmic inclusions. These alterations were associated with Loss of dopaminergic terminals in the basal ganglia and with motor impairments. These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Yokohama City Univ, Sch Med, Dept Psychiat, Yokohama, Kanagawa 236, Japan; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yokohama City University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.				NIA NIH HHS [AG11385, AG10689, AG5131] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385, R01AG010689] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN XH, 1995, GENOMICS, V26, P425, DOI 10.1016/0888-7543(95)80237-G; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DICKSON DW, 1989, ACTA NEUROPATHOL, V78, P572, DOI 10.1007/BF00691284; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAUTHIER S, 1982, PROG NEURO-PSYCHOPH, V6, P595, DOI 10.1016/S0278-5846(82)80154-1; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOSAKA K, 1978, ACTA NEUROPATHOL, V42, P127, DOI 10.1007/BF00690978; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1998, NEUROSCI NEWS, V1, P14; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	24	1456	1563	2	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1265	1269		10.1126/science.287.5456.1265	http://dx.doi.org/10.1126/science.287.5456.1265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678833				2022-12-24	WOS:000085444700050
J	Lee, KJ; Dietrich, P; Jessell, TM				Lee, KJ; Dietrich, P; Jessell, TM			Genetic ablation reveals that the roof plate is essential for dorsal interneuron specification	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; AVIAN NEURAL CREST; SPINAL-CORD; TRANSGENIC MICE; FLOOR PLATE; COMMISSURAL INTERNEURONS; MOUSE DEVELOPMENT; TOXIN GENE; EXPRESSION; CELL	During neural development in vertebrates, a spatially ordered array of neurons is generated in response to inductive signals derived from localized organizing centres, One organizing centre that has been proposed to have a role in the control of neural patterning is the roof plate, To define the contribution of signals derived from the roof plate to the specification of neuronal cell types in the dorsal neural tube, we devised a genetic strategy to ablate the roof plate selectively in mouse embryos, Embryos without a roof plate lack all the interneuron subtypes that are normally generated in the dorsal third of the neural tube. Using a genetically based lineage analysis and in vitro assays, we show that the loss of these neurons results from the elimination of nonautonomous signals provided by the roof plate, These results reveal that the roof plate is essential for specifying multiple classes of neurons in the mammalian central nervous system.	Columbia Univ, Ctr Neurobiol & Behav, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Jessell, TM (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA.	tmj1@columbia.edu		Lee, Kevin/0000-0001-9823-0952				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Arkell R, 1997, DEVELOPMENT, V124, P1; Beattie CE, 1997, DEV BIOL, V187, P171, DOI 10.1006/dbio.1997.8604; Bei M, 1998, DEVELOPMENT, V125, P4325; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CHRISTIANS E, 1995, DEVELOPMENT, V121, P113; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; DIETRICH P, IN PRESS MAMM GENOME; Ding Q, 1998, DEVELOPMENT, V125, P2533; Dodd J, 1998, SCIENCE, V282, P1654, DOI 10.1126/science.282.5394.1654; Dudley AT, 1997, DEV DYNAM, V208, P349; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Grieshammer U, 1998, DEV BIOL, V197, P234, DOI 10.1006/dbio.1997.8859; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Helms AW, 1998, DEVELOPMENT, V125, P919; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; JONES CM, 1991, DEVELOPMENT, V111, P531; Labosky PA, 1998, MECH DEVELOP, V76, P185, DOI 10.1016/S0925-4773(98)00105-1; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Lee KJ, 1998, GENE DEV, V12, P3394, DOI 10.1101/gad.12.21.3394; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Matise MP, 1998, DEVELOPMENT, V125, P2759; MAXWELL IH, 1986, CANCER RES, V46, P4660; Millonig JH, 2000, NATURE, V403, P764, DOI 10.1038/35001573; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARR BA, 1993, DEVELOPMENT, V119, P247; Pearse RV, 1998, J EXP ZOOL, V282, P677, DOI 10.1002/(SICI)1097-010X(19981215)282:6<677::AID-JEZ4>3.0.CO;2-F; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; Shamim H, 1999, DEVELOPMENT, V126, P945; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	50	218	221	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					734	740		10.1038/35001507	http://dx.doi.org/10.1038/35001507			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693795				2022-12-24	WOS:000085423100042
J	Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG				Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG			Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I HOMOLOG; SEQUENCE-DERIVED PEPTIDES; E BINDS; REPLICATION; RECEPTOR; LYSIS; TAP; TRANSLOCATION; TRANSPORTER	The nonclassical major histocompatibility complex (MHC) class I molecule HLA-E inhibits natural killer (NK) cell-mediated lysis by interacting with CD94/ NKG2A receptors. Surface expression of HLA-E depends on binding of conserved peptides derived from MHC class I molecules. The same peptide is present in the leader sequence of the human cytomegalovirus (HCMV) glycoprotein UL40 (gpUL40). It is shown that, independently of the transporter associated with antigen processing, gpUL40 can up-regulate expression of HLA-E, which protects targets from NK cell Lysis. While classical MHC class I molecules are down-regulated, HLA-E is up-regulated by HCMV. induction of HLA-E surface expression by gpUL40 may represent an escape route for HCMV.	John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XN, S Glam, Wales	University of Oxford; Cardiff University	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.		Wilkinson, Gavin WG/J-6388-2015; braud, veronique M/I-4597-2013; McSharry, Brian/AAE-3351-2019	Wilkinson, Gavin WG/0000-0002-5623-0126; braud, veronique M/0000-0001-8213-3947; McSharry, Brian/0000-0003-0473-2789; Cerundolo, Vincenzo/0000-0003-0040-3793				Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Biron CA, 1997, CURR OPIN IMMUNOL, V9, P24, DOI 10.1016/S0952-7915(97)80155-0; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; BORYSIEWICZ LK, 1985, J IMMUNOL, V134, P2695; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MG, 1999, J IMMUNOL, V163, P1991; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Cretney E, 1999, J EXP MED, V190, P435, DOI 10.1084/jem.190.3.435; Farrell HE, 1997, NATURE, V386, P510, DOI 10.1038/386510a0; Fletcher JM, 1998, J IMMUNOL, V161, P2365; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Kubota A, 1999, CELL IMMUNOL, V191, P145, DOI 10.1006/cimm.1998.1424; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Leong CC, 1998, J EXP MED, V187, P1681, DOI 10.1084/jem.187.10.1681; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Moins-Teisserenc HT, 1999, LANCET, V354, P1598, DOI 10.1016/S0140-6736(99)04206-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Plachter B, 1996, ADV VIRUS RES, V46, P195, DOI 10.1016/S0065-3527(08)60073-1; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polic B, 1998, J EXP MED, V188, P1047, DOI 10.1084/jem.188.6.1047; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; TOMASEC P, UNPUB; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; [No title captured]	34	478	496	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1031	1033		10.1126/science.287.5455.1031	http://dx.doi.org/10.1126/science.287.5455.1031			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669413				2022-12-24	WOS:000085245400045
J	Lemieux, C; Otis, C; Turmel, M				Lemieux, C; Otis, C; Turmel, M			Ancestral chloroplast genome in Mesostigma viride reveals an early branch of green plant evolution	NATURE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; CHLOROPHYLL; PHYLOGENY; ALGA	Sequence comparisons suggest that all living green plants belong to one of two major phyla(1-3): Streptophyta(4) (land plants and their closest green algal relatives, the charophytes); and Chlorophyta(5) (the rest of green algae). Because no green algae are known that pre-date the Streptophyta/Chlorophyta split, and also because the earliest diverging green algae show considerable morphological variation, the nature of the unicellular flagellate ancestor of the two green plant phyla is unknown(1,6,7). Here we report that the flagellate Mesostigma viride belongs to the earliest diverging green plant lineage discovered to date. We have sequenced the entire chloroplast DNA (118,360 base pairs) of this green alga and have conducted phylogenetic analyses of sequences derived from this genome. Mesostigma represents a lineage that emerged before the divergence of the Streptophyta and Chlorophyta, a position that is supported by several features of its chloroplast DNA. The structure and gene organization of this genome indicate that chloroplast DNA architecture has been extremely well conserved in the line leading to land plants.	Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada	Laval University	Lemieux, C (corresponding author), Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada.	clemieux@bcm.ulaval.ca	Lemieux, Claude/L-8831-2015; Turmel, Monique/AAC-9752-2020	Lemieux, Claude/0000-0001-9580-8042; Turmel, Monique/0000-0001-7060-035X				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Bhattacharya D, 1998, J MOL EVOL, V47, P544, DOI 10.1007/PL00006410; BREMER K, 1985, Cladistics, V1, P369, DOI 10.1111/j.1096-0031.1985.tb00434.x; Chapman R.L., 1998, MOL SYSTEMATICS PLAN, VII, P508; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; FELSENSTEIN J, 1995, PHYLIP VERSION 3 5; Friedl T, 1997, PLANT SYST EVOL, P87; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; Lockhart PJ, 1996, P NATL ACAD SCI USA, V93, P1930, DOI 10.1073/pnas.93.5.1930; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Lockhart PJ, 1999, MOL BIOL EVOL, V16, P573, DOI 10.1093/oxfordjournals.molbev.a026139; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; MELKONIAN M, 1989, PLANT SYST EVOL, V164, P93, DOI 10.1007/BF00940432; MELKONIAN M, 1995, B SOC ZOOL FR, V120, P191; Melkonian M., 1990, P600; Melkonian M., 1995, BIODIVERSITY EVOLUTI, P153; Nakayama T, 1998, PROTIST, V149, P367, DOI 10.1016/S1434-4610(98)70043-4; O'Kelly C.J., 1992, P315; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Palmer J.D., 1998, MOL SYSTEMATICS PLAN, P375, DOI [10.1007/978-1-4615-5419-6_13, DOI 10.1007/978-1-4615-5419-6_13]; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SLUIMAN HJ, 1985, PLANT SYST EVOL, V149, P217, DOI 10.1007/BF00983308; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turmel M, 1999, P NATL ACAD SCI USA, V96, P10248, DOI 10.1073/pnas.96.18.10248; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967	30	198	320	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					649	652		10.1038/35001059	http://dx.doi.org/10.1038/35001059			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688199	hybrid			2022-12-24	WOS:000085288200051
J	Uetz, P; Giot, L; Cagney, G; Mansfield, TA; Judson, RS; Knight, JR; Lockshon, D; Narayan, V; Srinivasan, M; Pochart, P; Qureshi-Emili, A; Li, Y; Godwin, B; Conover, D; Kalbfleisch, T; Vijayadamodar, G; Yang, MJ; Johnston, M; Fields, S; Rothberg, JM				Uetz, P; Giot, L; Cagney, G; Mansfield, TA; Judson, RS; Knight, JR; Lockshon, D; Narayan, V; Srinivasan, M; Pochart, P; Qureshi-Emili, A; Li, Y; Godwin, B; Conover, D; Kalbfleisch, T; Vijayadamodar, G; Yang, MJ; Johnston, M; Fields, S; Rothberg, JM			A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae	NATURE			English	Article							SPINDLE CHECKPOINT; COMPLEX-FORMATION; 3-HYBRID SYSTEM; BUDDING YEAST; RECOMBINATION; GENES; CYTOPLASM; VACUOLE; ASSOCIATION; AUTOPHAGY	Two large-scale yeast two-hybrid screens were undertaken to identify protein-protein interactions between full-length open reading frames predicted from the Saccharomyces cerevisiae genome sequence. In one approach, we constructed a protein array of about 6,000 yeast transformants, with each transformant expressing one of the open reading frames as a fusion to an activation domain. This array was screened by a simple and automated procedure for 192 yeast proteins, with positive responses identified by their positions in the array, In a second approach, we pooled cells expressing one of about 6,000 activation domain fusions to generate a library. We used a high-throughput screening procedure to screen nearly all of the 6,000 predicted yeast proteins, expressed as Gal4 DNA-binding domain fusion proteins, against the library, and characterized positives by sequence analysis. These approaches resulted in the detection of 957 putative interactions involving 1,004 S. cerevisiae proteins, These data reveal interactions that place functionally unclassified proteins in a biological context, interactions between proteins involved in the same biological function, and interactions that link biological functions together into larger cellular processes. The results of these screens are shown here.	CuraGen Corp, New Haven, CT 06511 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Washington University (WUSTL)	Rothberg, JM (corresponding author), CuraGen Corp, 555 Long Wharf Dr,11th Floor, New Haven, CT 06511 USA.		Johnston, Mark/R-6156-2019; Cagney, Gerard/A-4648-2009; Uetz, Peter/A-7119-2012; Kalbfleisch, Theodore/AAN-5407-2021; Johnston, Mark/K-3543-2019	Uetz, Peter/0000-0001-6194-4927; Johnston, Mark/0000-0002-4932-7229; Judson, Richard/0000-0002-2348-9633; Kalbfleisch, Theodore/0000-0002-2370-8189; Cagney, Gerard/0000-0001-7189-9496				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GUENETTE S, 1995, J CELL SCI, V108, P1195; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KADOWAKI T, 1994, J CELL BIOL, V126, P1627; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; RAMESH V, 1991, MOL BIOL MED, V8, P81; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Seeley TW, 1999, BIOCHEM BIOPH RES CO, V257, P589, DOI 10.1006/bbrc.1999.0514; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Sherman F., 1986, METHODS YEAST GENETI; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0	42	3619	3818	8	523	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					623	627		10.1038/35001009	http://dx.doi.org/10.1038/35001009			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688190				2022-12-24	WOS:000085288200042
J	Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D				Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D			Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland; N Glasgow Hosp Univ NHS Trust, Univ Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Stallard, S (corresponding author), N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GAMBRELL RD, 1992, AM FAM PHYSICIAN S5, V46, P87; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X	5	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					348	349		10.1136/bmj.320.7231.348	http://dx.doi.org/10.1136/bmj.320.7231.348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657329	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-24	WOS:000085211400025
J	Baxter, S				Baxter, S			From Caribbean to Clementine - The road to the stars begins in the ocean depths.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					485	485		10.1038/35000671	http://dx.doi.org/10.1038/35000671			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676939	Bronze			2022-12-24	WOS:000085227300024
J	Dai, SD; Schwendtmayer, C; Schurmann, P; Ramaswamy, S; Eklund, H				Dai, SD; Schwendtmayer, C; Schurmann, P; Ramaswamy, S; Eklund, H			Redox signaling in chloroplasts: Cleavage of disulfides by an iron-sulfur cluster	SCIENCE			English	Article							FERREDOXIN-THIOREDOXIN REDUCTASE; SPINACH FERREDOXIN; PROTEIN MODELS; PHOTOSYSTEM-I; CRYSTALLOGRAPHY; POTENTIALS; RESOLUTION; REFINEMENT; DOMAINS; PEPTIDE	Light generates reducing equivalents in chloroplasts that are used not only for carbon reduction, but also for the regulation of the activity of chloroplast enzymes by reduction of regulatory disulfides via the ferredoxin:thioredoxin reductase (FTR) system, FTR, the key electron/thiol transducer enzyme in this pathway, is unique in that it can reduce disulfides by an iron-sulfur cluster, a property that is explained by the tight contact of its active-site disulfide and the iron-sulfur center. The thin, flat FTR molecule makes the two-electron reduction possible by forming on one side a mixed disulfide with thioredoxin and by providing on the opposite side access to ferredoxin for delivering electrons.	Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, S-75124 Uppsala, Sweden; Univ Neuchatel, Lab Biochim Vegetale, CH-2007 Neuchatel, Switzerland	Swedish University of Agricultural Sciences; University of Neuchatel	Eklund, H (corresponding author), Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, Box 590, S-75124 Uppsala, Sweden.	hasse@xray.bmc.uu.se	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Capitani G, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1939; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; CIURLI S, 1990, J AM CHEM SOC, V112, P2654, DOI 10.1021/ja00163a028; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HIRASAWA M, 1998, BIOCHIM BIOPHYS ACTA, V935, P1; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANGEN R, 1992, J BIOL CHEM, V267, P25625; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; LEVINGS CS, 1995, SCIENCE, V268, P695, DOI 10.1126/science.268.5211.695; Mayer KL, 1999, BIOCHEMISTRY-US, V38, P13736, DOI 10.1021/bi9910373; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; SALAMON Z, 1995, BBA-BIOENERGETICS, V1230, P114, DOI 10.1016/0005-2728(95)00042-H; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Schwendtmayer C, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1927; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; van Thor JJ, 1999, BIOCHEMISTRY-US, V38, P12735, DOI 10.1021/bi9903502; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	45	161	169	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					655	658		10.1126/science.287.5453.655	http://dx.doi.org/10.1126/science.287.5453.655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649999	Green Submitted			2022-12-24	WOS:000084989400048
J	Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA				Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA			Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma	LANCET			English	Article							POSTOBSTETRIC FECAL INCONTINENCE; ENDOSONOGRAPHY; DEFECTS; INJURY; ULTRASOUND; NEUROPATHY; SURGERY	Background Anterior structural damage to the anal sphincter occurs in up to a third of women at first vaginal delivery, and of these a third have new bowel symptoms. The standard treatment for such structural damage is anterior overlapping anal-sphincter repair. We aimed to assess the long-term results of this operation. Methods We assessed the long-term results in 55 consecutive patients who had had repair a minimum of 5 years (median 77 months [range 60-96]) previously. Questionnaire and telephone interview assessed current bowel function and continence, restriction in activities related to bowel control, and overall satisfaction with the results of surgery, 42 of these patients had been continent of solid and liquid stool at a median of 15 months after the repair. Findings We were able to contact 47 (86%) of the 55 patients. One of these patients had required a proctectomy and end ileostomy for Crohn's disease. Of the remaining 46 patients, 27 reported improved bowel control without the need for further surgery, and 23 rated their symptom improvement as 50% or greater. Seven patients had undergone further surgery for incontinence and one patient had not had a covering stoma closed. Thus, the rang-term functional outcome of the sphincter repair alone could be assessed in 38 patients. Of these patients, none was fully continent to both stool and flatus; only four were totally continent to solid and liquid stool; six had no faecal urgency; and eight had no passive soiling. Of the 38 patients, 20 still wore a pad for incontinence and 25 reported lifestyle restriction. 14 reported the onset of a new evacuation disorder after sphincter repair. 23 of the 46 patients contacted had a successful long-term outcome (defined as no further surgery and urge faecal incontinence monthly or less). Interpretation The results of overlapping sphincter repair for obstetric anal-sphincter damage seem to deteriorate with time. Preoperative counselling should emphasise that although most patients will improve after the procedure, continence is rarely perfect, many have residual symptoms, and some may develop new evacuation disorders.	St Marks Hosp, Harrow HA1 3UJ, Middx, England	Imperial College London	Kamm, MA (corresponding author), St Marks Hosp, Harrow HA1 3UJ, Middx, England.							Briel JW, 1998, DIS COLON RECTUM, V41, P209, DOI 10.1007/BF02238250; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; Cook TA, 1998, BRIT J SURG, V85, P293; CTERCTEKO G C, 1988, Australian and New Zealand Journal of Surgery, V58, P703, DOI 10.1111/j.1445-2197.1988.tb01100.x; DEEN KI, 1993, ANN SURG, V218, P201, DOI 10.1097/00000658-199308000-00013; ENGEL AF, 1994, BRIT J SURG, V81, P1231, DOI 10.1002/bjs.1800810853; FLESHMAN JW, 1991, DIS COLON RECTUM, V34, P1061, DOI 10.1007/BF02050062; GEE AS, 1995, BRIT J SURG, V82, P1179, DOI 10.1002/bjs.1800820910; Gilliland R, 1998, DIS COLON RECTUM, V41, P1516, DOI 10.1007/BF02237299; Jensen LL, 1997, DIS COLON RECTUM, V40, P197, DOI 10.1007/BF02054988; Korsgen S, 1997, DIS COLON RECTUM, V40, P835, DOI 10.1007/BF02055443; LONDONOSCHIMMER EE, 1994, INT J COLORECTAL DIS, V9, P110, DOI 10.1007/BF00699424; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; Meyenberger C, 1996, ENDOSCOPY, V28, P217, DOI 10.1055/s-2007-1005431; Norton C, 1999, BRIT J SURG, V86, P1159, DOI 10.1046/j.1365-2168.1999.01215.x; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; Peterli R, 1997, Swiss Surg, V3, P112; Romano G, 1996, BRIT J RADIOL, V69, P6, DOI 10.1259/0007-1285-69-817-6; SANGALLI MR, 1994, J AM COLL SURGEONS, V179, P583; Sentovich SM, 1997, DIS COLON RECTUM, V40, P1430, DOI 10.1007/BF02070707; Sitzler PJ, 1996, DIS COLON RECTUM, V39, P1356, DOI 10.1007/BF02054524; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT J SURG, V81, P463, DOI 10.1002/bjs.1800810349; Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77; Young CJ, 1998, DIS COLON RECTUM, V41, P344, DOI 10.1007/BF02237489	25	298	302	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					260	265		10.1016/S0140-6736(99)05218-6	http://dx.doi.org/10.1016/S0140-6736(99)05218-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675072				2022-12-24	WOS:000085045600008
J	Basden, AM; Young, GC; Coates, MI; Ritchie, A				Basden, AM; Young, GC; Coates, MI; Ritchie, A			The most primitive osteichthyan braincase?	NATURE			English	Article							FISHES	Most living vertebrates, from teleosts to tetrapods, are osteichthyans (bony fishes)(1), but the origin of this major group is poorly understood(2). The actinopterygians (ray-finned bony fishes) are the most successful living vertebrates in terms of diversity. They appear in the fossil record in the Late Silurian but are poorly known before the Late Devonian. Here we report the discovery of the oldest and most primitive actinopterygian-like osteichthyan braincase known, from 400-million-year-old limestone in southeastern Australia. This specimen displays previously unknown primitive conditions, in particular, an opening for a cartilaginous eyestalk. It provides an important and unique counterpart to the similarly aged and recently described Psarolepis from China and Vietnam(3,4). The contrasting features of these specimens, and the unusual anatomy of the new specimen in particular, provide new insights into anatomical conditions close to the evolutionary radiation of all modern osteichthyan groups.	Macquarie Univ, Dept Earth & Planetary Sci, Ctr Ecostratig & Palaeobiol, N Ryde, NSW 2109, Australia; Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia; UCL, Dept Biol Sci, London WC1E 6BT, England; Australian Museum, Sydney S, NSW 2000, Australia	Macquarie University; Australian National University; University of London; University College London; Australian Museum	Basden, AM (corresponding author), Macquarie Univ, Dept Earth & Planetary Sci, Ctr Ecostratig & Palaeobiol, N Ryde, NSW 2109, Australia.	abasden@laurel.ocs.mq.edu.au	Coates, Michael/AAO-3810-2020	Coates, Michael/0000-0003-2843-1075				Ahlberg PE, 1999, NATURE, V397, P564, DOI 10.1038/17484; [Anonymous], THESIS U STOCKHOLM; BASDEN AM, IN PRESS COUR FORSCH; Coates MI, 1998, T ROY SOC EDIN-EARTH, V89, P63, DOI 10.1017/S026359330000701X; de Beer G., 1937, DEV VERTEBRATE SKULL; Gardiner B.G., 1984, Bulletin of the British Museum (Natural History) Geology, V37, P173; Gardiner B.G., 1984, Journal of Vertebrate Paleontology, V4, P379; Gardiner B.G., 1977, PROBLEMS EARLY VERTE, P227; Goujet D, 1982, GEOBIOS MEMOIRE SPEC, V15, P27; Goujet D.F., 1984, Proceedings of the Linnean Society of New South Wales, V107, P211; Gross W., 1937, Senckenbergiana Frankfurt a M, V19, P80; Janvier P, 1996, OXFORD MONOGRAPHS GE, V33; Miles R.S., 1973, Zoological J Linn Soc, V53, P63; PATTERSON C, 1975, PHILOS T R SOC B, V269, P275, DOI 10.1098/rstb.1975.0001; SCHAEFFER B, 1937, AM MUS NOVIT, P1; SCHULTZE H-P, 1968, Bulletin of the British Museum (Natural History) Geology, V16, P343; Swofford D., 1998, PAUP PHYLOGENETIC AN; YOUNG G C, 1980, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V167, P10; YOUNG GC, 1986, ZOOL J LINN SOC-LOND, V88, P1, DOI 10.1111/j.1096-3642.1986.tb00876.x; YOUNG GC, 1979, Z J LINN SOC, V66, P307; Yu XB, 1998, J VERTEBR PALEONTOL, V18, P261, DOI 10.1080/02724634.1998.10011055; Zhu M, 1999, NATURE, V397, P607, DOI 10.1038/17594	22	59	63	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					185	188		10.1038/35003183	http://dx.doi.org/10.1038/35003183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646601				2022-12-24	WOS:000084835300052
J	Rabinowitz, D; Helin, E; Lawrence, K; Pravdo, S				Rabinowitz, D; Helin, E; Lawrence, K; Pravdo, S			A reduced estimate of the number of kilometre-sized near-Earth asteroids	NATURE			English	Article								Near-Earth asteroids are small (diameters < 10 km), rocky bodies with orbits that approach that of the Earth (they come within 1.3 AU Of the Sun). Most have a chance of approximately 0.5% of colliding with the Earth in the next million years. The total number of such bodies with diameters > 1 km has been estimated to be in the range 1,000-2,000, which translates to an approximately 1% chance of a catastrophic collision with the Earth in the next millennium(1,2). These numbers are, however, poorly constrained because of the limitations of previous searches using photographic plates. (One kilometre is below the size of a body whose impact on the Earth would produce global effects(3).) Here we report an analysis of our survey for near-Earth asteroids that uses improved detection technologies. We find that the total number of asteroids with diameters > 1 km is about half the earlier estimates. At the current rate of discovery of near-Earth asteroids, 90% will probably have been detected within the next 20 years.	Yale Univ, Dept Phys, New Haven, CT 06511 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Yale University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Rabinowitz, D (corresponding author), Yale Univ, Dept Phys, 266 Whitney Ave,JWG 552, New Haven, CT 06511 USA.	david.rabinowitz@yale.edu						Bowell E., 1994, HAZARDS DUE COMETS A, P149; Bowell E., 1989, ASTEROIDS, VII, P524; GEHRELS T, 1991, SPACE SCI REV, V58, P347, DOI 10.1007/BF01206004; HARRIS AW, IN PRESS COLLISIONAL; Helin E. F., 1990, Vistas in Astronomy, V33, P21, DOI 10.1016/0083-6656(90)90030-C; HELIN EF, 1979, ICARUS, V40, P321, DOI 10.1016/0019-1035(79)90021-6; MARSDEN BG, ELECT LISTING MINOR; MCFADDEN LA, 1989, ASTEROIDS, V2, P442; Pravdo SH, 1999, ASTRON J, V117, P1616, DOI 10.1086/300769; RABINOWITZ DL, 1994, ICARUS, V111, P364, DOI 10.1006/icar.1994.1150; RABINOWITZ DL, 1993, ASTROPHYS J, V407, P412, DOI 10.1086/172524; SHOEMAKER EM, 1990, GEOL S AM S, V247, P155; [No title captured]	13	103	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					165	166		10.1038/35003128	http://dx.doi.org/10.1038/35003128			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646594				2022-12-24	WOS:000084835300045
J	Taylor, RS; Belli, AM; Jacob, S				Taylor, RS; Belli, AM; Jacob, S			Distal venous arterialisation for salvage of critically ischaemic inoperable limbs	LANCET			English	Article								Background Amputation remains the only option in patients with extensive arterial disease in whom conventional bypass operations are not feasible. Up to 10 000 amputations for vascular disease are estimated to be done annually. We investigated the use of venous perfusion as an alternative method of limb salvage. Methods Over 28 months, 18 patients with critical-limb ischaemia underwent bypass procedures to the venous bed of the foot with vein, synthetic graft, or a combination of these as the conduit. Various methods were used to destroy the valves of the venous system. We followed up patients for a mean of 17 months. Findings Three grafts failed immediately after surgery and necessitated major amputation, with orie death. One late failure did not necessitate amputation. 15 patients had relief of symptoms and retained a useful pain-free limb with healing of ulcers and gangrene. Two patients with functioning grafts died at 5 months and 13 months, respectively. Three patients had successful further radiological intervention. The overall limb-salvage rate was 83% and 1-year limb-salvage rate was 75%. Interpretation Distal venous arterialisation is a unique procedure that has exciting possibilities for limb salvage and merits further investigation. Increased use of this procedure may help to lower the number of limbs amputated for vascular disease.	Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England	St Georges University London	Taylor, RS (corresponding author), Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England.							BAFFOUR R, 1988, SURG GYNECOL OBSTET, V166, P28; Bernheim BM, 1912, ANN SURG, V55, P195, DOI 10.1097/00000658-191202000-00002; BLAISDELL FW, 1966, AM J SURG, V112, P166, DOI 10.1016/0002-9610(66)90005-5; CARREL A, 1902, LYON MED, V99, P153; CUTTINO JT, 1975, BASIC RES CARDIOL, V70, P568, DOI 10.1007/BF01906387; DORMANDY JA, 1995, VASC MED REV, V5, P331; Francois-Franck M, 1896, COMPT REND HEBD SOC, V48, P150; GERARD DF, 1981, SURGERY, V89, P485; GOLDSMITH HS, 1984, JAMA-J AM MED ASSOC, V252, P2034, DOI 10.1001/jama.252.15.2034; Halstead AE, 1912, SURG GYNECOL OBSTET, V14, P1; KUMAR S, 1983, LANCET, V2, P364; LENGUA F, 1993, J CHIR-PARIS, V130, P12; Lengua F, 1975, NOUV PRESSE MED, V4, P1039; MATOLO NM, 1976, ANN SURG, V184, P622, DOI 10.1097/00000658-197611000-00016; Pokrovsky AV, 1996, ANN VASC SURG, V4, P73; ROBERTSON RL, 1950, SURGERY, V27, P1; ROOT HD, 1965, J AMER MED ASSOC, V191, P645, DOI 10.1001/jama.1965.03080080035008; SANMARTIN Y, 1902, JURADO MED FARMACOL, V12, P1641; SHEIL AGR, 1977, BRIT J SURG, V64, P197, DOI 10.1002/bjs.1800640314; SZILAGYI DE, 1951, AMA ARCH SURG, V63, P435, DOI 10.1001/archsurg.1951.01250040445003; WOLFE JHN, 1986, BRIT J SURG, V73, P321	21	34	43	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1962	1965		10.1016/S0140-6736(99)03164-5	http://dx.doi.org/10.1016/S0140-6736(99)03164-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622299				2022-12-24	WOS:000084034700013
J	Boudaiffa, B; Cloutier, P; Hunting, D; Huels, MA; Sanche, L				Boudaiffa, B; Cloutier, P; Hunting, D; Huels, MA; Sanche, L			Resonant formation of DNA strand breaks by low-energy (3 to 20 eV) electrons	SCIENCE			English	Article							ATTACHMENT; DAMAGE; BASES; RADIATION; YIELDS; FILMS; WATER; O-2	Most of the energy deposited in cells by ionizing radiation is channeled into the production of abundant free secondary electrons with ballistic energies between 1 and 20 electron volts. Here it is shown that reactions of such electrons, even at energies well below ionization thresholds, induce substantial yields of single- and double-strand breaks in DNA, which are caused by rapid decays of transient molecular resonances Localized on the DNA's basic components. This finding presents a fundamental challenge to the traditional notion that genotoxic damage by secondary electrons can only occur at energies above the onset of ionization, or upon solvation when they become a slowly reacting chemical species.	Univ Sherbrooke, Fac Med, Dept Med Nucl & Radiobiol, Canadian Med Res Council,Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Huels, MA (corresponding author), Univ Sherbrooke, Fac Med, Dept Med Nucl & Radiobiol, Canadian Med Res Council,Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada.							Aflatooni K, 1998, J PHYS CHEM A, V102, P6205, DOI 10.1021/jp980865n; Antic D, 1999, J PHYS CHEM B, V103, P6611, DOI 10.1021/jp990686l; Bass AD, 1998, J CHEM PHYS, V109, P8635, DOI 10.1063/1.477530; Bass AD, 1998, RADIAT ENVIRON BIOPH, V37, P243, DOI 10.1007/s004110050125; Christophorou L. G., 1994, LINKING GASEOUS COND; Cobut V, 1998, RADIAT PHYS CHEM, V51, P229, DOI 10.1016/S0969-806X(97)00096-0; COLSON AO, 1992, J PHYS CHEM-US, V96, P9787, DOI 10.1021/j100203a039; FOLKARD M, 1993, INT J RADIAT BIOL, V64, P651, DOI 10.1080/09553009314551891; FUCIARELLI AF, 1995, RAD DAMAGE DNA STRUC; Hendricks JH, 1998, J CHEM PHYS, V108, P8, DOI 10.1063/1.475360; HIEDA K, 1994, INT J RADIAT BIOL, V66, P561, DOI 10.1080/09553009414551631; HUELS MA, 1994, J CHEM PHYS, V100, P3940, DOI 10.1063/1.466329; Huels MA, 1998, J CHEM PHYS, V108, P1309, DOI 10.1063/1.475503; Huels MA, 1997, CHEM PHYS LETT, V279, P223, DOI 10.1016/S0009-2614(97)01026-9; International Commission on Radiation Units and Measurements, 1979, 31 ICRU; MICHAEL BD, 1995, RADIATION DAMAGE IN DNA: STRUCTURE/FUNCTION RELATIONSHIPS AT EARLY TIMES, P251; PIMBLOTT SM, 1976, AGING CARCINOGENESIS, P3; ROWNTREE P, 1991, J PHYS CHEM-US, V95, P4902, DOI 10.1021/j100165a054; ROWNTREE P, 1991, J CHEM PHYS, V94, P8570, DOI 10.1063/1.460090; SANCHE L, 1995, SCANNING MICROSCOPY, V9, P619; SANCHE L, UNPUB; Sieger MT, 1998, NATURE, V394, P554, DOI 10.1038/29015; SRDOC D, 1995, IAEA CRP ATOMIC MOL, pCH8; Stepanovic M, 1999, J CHEM PHYS, V110, P11376, DOI 10.1063/1.479078; SWARTS SG, 1992, RADIAT RES, V129, P333, DOI 10.2307/3578034; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Ward J.F., 1975, ADV RAD BIOL, P181; Yamamoto O., 1976, AGING CARCINOGENESIS, P165	28	1816	1833	8	242	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1658	1660		10.1126/science.287.5458.1658	http://dx.doi.org/10.1126/science.287.5458.1658			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698742				2022-12-24	WOS:000085628200040
J	Rollenhagen, JE; Olson, CR				Rollenhagen, JE; Olson, CR			Mirror-image confusion in single neurons of the macaque inferotemporal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; ORIENTATION DISCRIMINATION	Humans and animals confuse Lateral mirror images, such as the Letters "b" and "d," more often than vertical mirror images, such as the Letters "b" and "p," Experiments were performed to find a neural correlate of this phenomenon. Visually responsive pattern-selective neurons in the inferotemporal cortex of macaque monkeys responded more similarly to members of a Lateral mirror-image pair than to members of a vertical mirror-image pair. The phenomenon developed within 20 milliseconds of the onset of the visual response and persisted to its end. It occurred during presentation of stimuli both at the fovea and in the periphery.	Carnegie Mellon Univ, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Olson, CR (corresponding author), Carnegie Mellon Univ, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003631] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008098, R01EY011831] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR03631] Funding Source: Medline; NEI NIH HHS [EY08098, R01-EY11831] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIEDERMAN I, 1991, PERCEPTION, V20, P585, DOI 10.1068/p200585; BORNSTEIN MH, 1978, COGNITION, V6, P89, DOI 10.1016/0010-0277(78)90017-3; CORBALLIS MC, 1970, PSYCHOL REV, V77, P451, DOI 10.1037/h0029805; CORBALLIS MC, 1976, PSYCHOL RIGHT LEFT; DESIMONE R, 1984, J NEUROSCI, V4, P2051; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; GROSS CG, 1969, SCIENCE, V166, P1303, DOI 10.1126/science.166.3910.1303; GROSS CG, 1978, LEONARDO, V11, P29, DOI DOI 10.2307/1573500; HAMILTON CR, 1973, BRAIN RES, V64, P241, DOI 10.1016/0006-8993(73)90181-9; HUTTENLOCHER J, 1967, CHILD DEV, V38, P1169, DOI 10.1111/j.1467-8624.1967.tb04392.x; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; Olson CR, 1999, J NEUROPHYSIOL, V81, P2340, DOI 10.1152/jn.1999.81.5.2340; PERRETT DI, 1991, EXP BRAIN RES, V86, P159; RIOPELLE AJ, 1964, PERCEPT MOTOR SKILL, V19, P383, DOI 10.2466/pms.1964.19.2.383; RUDEL RG, 1963, J COMP PHYSIOL PSYCH, V56, P892, DOI 10.1037/h0046592; SEKULER RW, 1968, Q J EXP PSYCHOL, V20, P204, DOI 10.1080/14640746808400151; SERPELL R, 1971, J COMP PHYSIOL PSYCH, V75, P312, DOI 10.1037/h0030832; SUTHERLAND NS, 1960, BRIT J PSYCHOL, V51, P9, DOI 10.1111/j.2044-8295.1960.tb00719.x; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TODRIN DC, 1983, PERCEPT PSYCHOPHYS, V34, P397, DOI 10.3758/BF03203053; VOGELS R, 1994, J NEUROPHYSIOL, V71, P1428, DOI 10.1152/jn.1994.71.4.1428; VOGELS R, 1994, EUR J NEUROSCI, V6, P1680, DOI 10.1111/j.1460-9568.1994.tb00560.x	25	105	108	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1506	1508		10.1126/science.287.5457.1506	http://dx.doi.org/10.1126/science.287.5457.1506			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	287WZ	10688803				2022-12-24	WOS:000085531600057
J	Braine, J; Lisenfeld, U; Due, PA; Leon, S				Braine, J; Lisenfeld, U; Due, PA; Leon, S			Formation of molecular gas in the tidal debris of violent galaxy-galaxy interactions	NATURE			English	Article							COLD DUST; DWARF GALAXIES; SYSTEM ARP-105; LINE EMISSION; H-I; SEQUENCE	In many gravitational interactions between galaxies, gas and stars that have been torn from the precursor galaxies can collect in tidal 'tails'. Star formation begins anew in some of these regions, producing tidal dwarf galaxies(1-4). Observations of these new galaxies provides insight into processes relevant to galaxy formation more generally, because the timescale of the interaction is well defined. But tracking the star formation process has hitherto been difficult because the tidal dwarf galaxies with young stars showed no evidence of the molecular gas out of which those young stars formed(5-8). Here we report the discovery of molecular hydrogen (traced by carbon monoxide emission) in two tidal dwarf galaxies. In both cases, the concentration of molecular gas peaks at the same location as the maximum in atomic-hydrogen density, unlike the situation in most gas-rich galaxies. We infer from this that the molecular gas formed from the atomic hydrogen, rather than being torn in molecular form from the interacting galaxies. Star formation in the tidal dwarf galaxies therefore appears to mimic the process in normal spiral galaxies like our own.	Observ Bordeaux, UMR 5804, CNRS, INSU, F-33270 Floirac, France; Inst Radioastron Millimetr, Granada 18012, Spain; Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; CNRS, F-91191 Gif Sur Yvette, France; CEA, DSM, DAPNIA, Serv Astrophys, F-91191 Gif Sur Yvette, France; Acad Sinica, ASIAA, Taipei 115, Taiwan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite de Bordeaux; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Academia Sinica - Taiwan	Braine, J (corresponding author), Observ Bordeaux, UMR 5804, CNRS, INSU, BP89, F-33270 Floirac, France.	Jonathan.Braine@observ.u-bordeaux.fr	Lisenfeld, Ute/A-1637-2015; Lisenfeld, Ute/AAF-4987-2019	Lisenfeld, Ute/0000-0002-9471-5423; 				ARP H, 1966, ASTROPHYS J, VS 14, P1, DOI 10.1086/190147; BARNES JE, 1992, NATURE, V360, P715, DOI 10.1038/360715a0; BRAINE J, 1993, ASTRON ASTROPHYS, V280, P451; Braine J, 1997, ASTRON ASTROPHYS, V326, P963; BROUILLET N, 1992, ASTRON ASTROPHYS, V262, pL5; Duc PA, 1998, ASTRON ASTROPHYS, V333, P813; Duc PA, 1997, ASTRON ASTROPHYS, V326, P537; DUC PA, 1994, ASTRON ASTROPHYS, V289, P83; DUC PA, UNPUB ASTRON J; DUC PA, 1997, GALAXY INTERACTIONS, P61; Dumke M, 1997, ASTRON ASTROPHYS, V325, P124; FRITZEVALVENSLE.U, 1998, MAGELLANIC CLOUDS OT, P141; GUELIN M, 1993, ASTRON ASTROPHYS, V279, pL37; Hibbard JE, 1996, ASTRON J, V111, P655, DOI 10.1086/117815; HOLLENBACH D, 1989, ASTROPHYS J, V342, P306, DOI 10.1086/167595; Kennicutt RC, 1998, ANNU REV ASTRON ASTR, V36, P189, DOI 10.1146/annurev.astro.36.1.189; MIRABEL IF, 1992, ASTRON ASTROPHYS, V256, pL19; Neininger N, 1996, ASTRON ASTROPHYS, V310, P725; SAGE LJ, 1990, ASTRON ASTROPHYS, V239, P125; SCHWEIZER F, 1978, STRUCTURE PROPERTIES, P279; SMITH BJ, 1994, ASTRON J, V108, P837, DOI 10.1086/117115; Smith BJ, 1999, ASTRON J, V117, P1237, DOI 10.1086/300785; Taylor CL, 1998, ASTRON J, V116, P2746, DOI 10.1086/300655; Walter F, 1999, ASTROPHYS J, V519, pL69, DOI 10.1086/312097; ZWICKY F, 1956, ERG EXAKT NATURWISS, V29, P344, DOI 10.1007/BFb0118841	25	56	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					867	869		10.1038/35002521	http://dx.doi.org/10.1038/35002521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706277				2022-12-24	WOS:000085559200048
J	Yu, FW; Morin, X; Cai, Y; Yang, XH; Chia, W				Yu, FW; Morin, X; Cai, Y; Yang, XH; Chia, W			Analysis of partner of inscuteable, a novel player of Drosophila asymmetric divisions, reveals two distinct steps in inscuteable apical localization	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GANGLION MOTHER CELLS; CAENORHABDITIS-ELEGANS; ADAPTER PROTEIN; MAMMALIAN NUMB; PROSPERO GENE; DAUGHTER CELL; FATES; NOTCH; MITOSIS	Asymmetric localization is a prerequisite for inscuteable (insc) to function in coordinating and mediating asymmetric cell divisions in Drosophila. We show here that Partner of Inscuteable (Pins), a new component of asymmetric divisions, is required for Inscuteable to asymmetrically localize. In the absence of pins, Inscuteable becomes cytoplasmic and asymmetric divisions of neuroblasts and mitotic domain 9 cells show defects reminiscent of insc mutants. Pins colocalizes with Insc and interacts with the region necessary and sufficient for directing its asymmetric localization. Analyses of pins function in neuroblasts reveal two distinct steps for Insc apical cortical localization: A pins-independent, bazooka-dependent initiation step during delamination (interphase) and a later maintenance step during which Baz, Pins, and Insc localization are interdependent.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Chia, W (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbwchia@imcb.nus.edu.sg	Cai, Yu/R-7737-2019; morin, xavier/AAI-3306-2020	Cai, Yu/0000-0003-2044-3290; Yu, Fengwei/0000-0003-0268-199X; Morin, Xavier/0000-0001-9999-0355				Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Buescher M, 1998, GENE DEV, V12, P1858, DOI 10.1101/gad.12.12.1858; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Doe CQ, 1996, CURR OPIN GENET DEV, V6, P562, DOI 10.1016/S0959-437X(96)80084-0; Dye CA, 1998, DEVELOPMENT, V125, P1845; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Hung TJ, 1999, DEVELOPMENT, V126, P127; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; Skeath JB, 1998, DEVELOPMENT, V125, P1857; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Tio M, 1999, J CELL SCI, V112, P1541; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	55	297	305	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 18	2000	100	4					399	409		10.1016/S0092-8674(00)80676-5	http://dx.doi.org/10.1016/S0092-8674(00)80676-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	286LF	10693757	Bronze			2022-12-24	WOS:000085446900003
J	Corey, L; Handsfield, HH				Corey, L; Handsfield, HH			Genital herpes and public health - Addressing a global problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SIMPLEX VIRUS; RISK FACTOR; TYPE-2 INFECTION; CONTROLLED TRIAL; ULCER DISEASE; ACYCLOVIR; TRANSMISSION; ASSOCIATION; SUPPRESSION	Genital herpes can be caused by herpes simplex virus 2 (HSV-2) or, less commonly, by herpes simplex virus 1 (HSV-1). With a seroprevalence of antibodies to HSV-2 of 22% in the general population, genital herpes is 1 of the 3 most prevalent sexually transmitted diseases (STDs) in the United States, A central issue in the public health problem of genital herpes is the high proportion of genital HSV infections that are unrecognized by both patients and clinicians. Persons who are HSV-2 seropositive may be symptomatic but nevertheless fail to recognize genital herpes; they serve as reservoirs for transmission. Physicians and patients must be aware of the subclinical presentation of genital herpes and the potential these patients have for transmitting HSV, Serious consequences of HSV infection include neonatal herpes and increased risk of human immunodeficiency virus transmission. Recommendations to physicians for prevention include using type-specific tests for HSV when screening for other STDs and testing for HSV when evaluating patients with genital ulcers. Researchers must evaluate the performance of type-specific tests and strategies to prevent transmission.	Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Publ Hlth Seattle & King Cty, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis, 1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashley RL, 1999, J CLIN MICROBIOL, V37, P1632, DOI 10.1128/JCM.37.5.1632-1633.1999; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CATOTTI DN, 1993, SEX TRANSM DIS, V20, P77, DOI 10.1097/00007435-199303000-00004; Corey L, 1998, SEX TRANSM DIS, V25, P58, DOI 10.1097/00007435-199802000-00002; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1999, SEXUALLY TRANSMITTED, P285; Diamond C, 1999, SEX TRANSM DIS, V26, P221, DOI 10.1097/00007435-199904000-00007; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1990, SCAND J INFECT DIS, P37; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; Gwanzura L, 1998, J INFECT DIS, V177, P481, DOI 10.1086/517381; Handsfield HH, 1999, SEX TRANSM DIS, V26, P228, DOI 10.1097/00007435-199904000-00009; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; *INT HERP MAN FOR, 1999, HERPES, V6, P1; JOHNSON RE, 1990, NEW ENGL J MED, V321, P8; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; Langenberg AGM, 1999, NEW ENGL J MED, V341, P1432, DOI 10.1056/NEJM199911043411904; MARAZZO JM, 1997, INFECT DIS OBSTET GY, V5, P29; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; Mertz KJ, 1998, J INFECT DIS, V178, P1795, DOI 10.1086/314502; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Morse SA, 1997, J INFECT DIS, V175, P583, DOI 10.1093/infdis/175.3.583; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; ROSS JDC, 1993, GENITOURIN MED, V69, P381; Schacker T, 1998, J INFECT DIS, V178, P1616, DOI 10.1086/314486; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1980, PEDIATRICS, V66, P495; WHITLEY RJ, 1995, INFECT DIS FETUS NEW, P354	42	174	183	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					791	794		10.1001/jama.283.6.791	http://dx.doi.org/10.1001/jama.283.6.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683059				2022-12-24	WOS:000085129000032
J	Baysal, BE; Ferrell, RE; Willett-Brozick, JE; Lawrence, EC; Myssiorek, D; Bosch, A; van der Mey, A; Taschner, PEM; Rubinstein, WS; Myers, EN; Richard, CW; Cornelisse, CJ; Devilee, P; Devlin, B				Baysal, BE; Ferrell, RE; Willett-Brozick, JE; Lawrence, EC; Myssiorek, D; Bosch, A; van der Mey, A; Taschner, PEM; Rubinstein, WS; Myers, EN; Richard, CW; Cornelisse, CJ; Devilee, P; Devlin, B			Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma	SCIENCE			English	Article							SUCCINATE-UBIQUINONE OXIDOREDUCTASE; CAROTID-BODY CHEMORECEPTORS; CHROMOSOME 11Q23; ESCHERICHIA-COLI; HIGH-ALTITUDES; NECK REGION; HYPOXIA; CELLS; HEAD; HYPERPLASIA	Hereditary paraganglioma (PGL) is characterized by the development of benign, vascularized tumors in the head and neck. The most common tumor site is the carotid body (CB), a chemoreceptive organ that senses oxygen Levels in the blood. Analysis of families carrying the PGL1 gene, described here, revealed germ line mutations in the SDHD gene on chromosome 11q23. SDHD encodes a mitochondrial respiratory chain protein-the small subunit of cytochrome b in succinate-ubiquinone oxidoreductase (cybS). In contrast to expectations based on the inheritance pattern of PGL, the SDHD gene showed no evidence of imprinting. These findings indicate that mitochondria play an important role in the pathogenesis of certain tumors and that cybS plays a role in normal CB physiology.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Long Isl Jewish Med Ctr, Dept Otolaryngol & Communicat Disorders, New York, NY 11040 USA; Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otolaryngol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Wyeth Ayerst Res, Genet Inst, Cambridge, MA 02140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwell Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Pfizer	Baysal, BE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.	baysalbe@msx.upmc.edu	DEVILEE, PETER/ABR-2140-2022; Taschner, Peter/J-8853-2014; Brozick, Joan/AAA-5785-2019	Taschner, Peter/0000-0001-9621-465X; 	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057881] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57881] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARIASSTELLA J, 1976, ARCH PATHOL LAB MED, V100, P636; ARIASSTELLA J, 1976, HUM PATHOL, V7, P361, DOI 10.1016/S0046-8177(76)80052-4; Baysal BE, 1997, AM J HUM GENET, V60, P121; Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BAYSAL BE, UNPUB; BEE D, 1986, ACTA ANAT, V126, P226; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; EDWARDS C, 1971, J PATHOL, V104, P231, DOI 10.1002/path.1711040404; Farr JE, 1999, AM J HUM GENET, V65, pA271; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Heutink Peter, 1994, European Journal of Human Genetics, V2, P148; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; Koreth J, 1999, J PATHOL, V187, P28, DOI 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R; LACK EE, 1979, HUM PATHOL, V10, P191, DOI 10.1016/S0046-8177(79)80008-8; LACK EE, 1985, AM J PATHOL, V119, P301; LACK EE, 1978, AM J PATHOL, V91, P497; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Milunsky J, 1997, AM J MED GENET, V72, P66, DOI 10.1002/(SICI)1096-8628(19971003)72:1<66::AID-AJMG14>3.0.CO;2-S; MORELLI L, 1994, SCI TOTAL ENVIRON, V150, P215, DOI 10.1016/0048-9697(94)90153-8; Morison IM, 1998, HUM MOL GENET, V7, P1599, DOI 10.1093/hmg/7.10.1599; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Nurse CA, 1997, DEV BIOL, V184, P197, DOI 10.1006/dbio.1997.8539; SALDANA MJ, 1973, HUM PATHOL, V4, P251, DOI 10.1016/S0046-8177(73)80012-7; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; STILLER D, 1975, VIRCHOWS ARCH A, V365, P163, DOI 10.1007/BF00432387; van Schothorst EM, 1998, AM J HUM GENET, V63, P468, DOI 10.1086/301951; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANDERMEY AGL, 1989, LANCET, V2, P1291; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; Vu TH, 1997, NAT GENET, V17, P12, DOI 10.1038/ng0997-12; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	41	1231	1271	4	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					848	851		10.1126/science.287.5454.848	http://dx.doi.org/10.1126/science.287.5454.848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657297				2022-12-24	WOS:000085136400044
J	Tessier-Lavigne, M; Goodman, CS				Tessier-Lavigne, M; Goodman, CS			Neurobiology - Regeneration in the Nogo Zone	SCIENCE			English	Editorial Material							MYELIN-ASSOCIATED GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; NEURITE GROWTH; AXONAL REGENERATION; INHIBITOR; IDENTIFICATION		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.							CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Kandel ER, 2000, PRINCIPLES NEURAL SC; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.0.CO;2-K; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403	18	19	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					813	814		10.1126/science.287.5454.813	http://dx.doi.org/10.1126/science.287.5454.813			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10691556				2022-12-24	WOS:000085136400031
J	Henney, JE				Henney, JE			Sertraline approved for posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-24	WOS:000084956500007
J	Jamieson, DJ; Meikle, SF; Hillis, SD; Mtsuko, D; Mawji, S; Duerr, A				Jamieson, DJ; Meikle, SF; Hillis, SD; Mtsuko, D; Mawji, S; Duerr, A			An evaluation of poor pregnancy outcomes among Burundian refugees in Tanzania	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; LOW-BIRTH-WEIGHT; MALAWI; RISK; PREVENTION; MORTALITY; MALARIA; INFANT; WOMEN	Context Little is known about pregnancy outcomes among the approximately 11 million refugees worldwide, 25% of whom are women of reproductive age. Objective To estimate incidence of and determine risk factors for poor pregnancy outcomes and to calculate the contribution of mortality from neonatal and maternal deaths to overall mortality in a refugee camp. Design Cross-sectional review of records and survey, conducted in February and March 1998, Setting Mtendeli refugee camp, Tanzania, Participants For the overall assessment, 664 Burundi women who had a pregnancy outcome during a recent 5-month period (September 1, 1997-January 31, 1998) and their 679 infants; 538 women (81%) completed the survey. Main Outcome Measures Incidence of fetal death (fetus born greater than or equal to 500 g or greater than or equal to 22 weeks' gestation with no signs of life), low birth weight (<2500 g), neonatal death (death <28 days of life), and maternal death (deaths during or within 42 days of pregnancy from any cause related to or aggravated by the pregnancy or its management). Results The fetal death rate was 45.6 per 1000 births, the neonatal mortality rate was 29.3 per 1000 live births, and 22.4% of all live births were low birth weight. Compared with women without poor pregnancy outcome, those with poor pregnancy outcome were more likely to report prior high socioeconomic status (adjusted odds ratio [OR], 1.6; 95 % confidence interval [CI], 1.1-2.4), having a first or second pregnancy (OR, 2.2; 95% CI, 1.4-3.4), and having 3 or more episodes of malaria during pregnancy (OR, 2.0; 95% CI, 1.4-3.1). Neonatal and maternal deaths accounted for 16% of all deaths during the period studied. Conclusions Poor pregnancy outcomes were common in this refugee setting, and neonatal and maternal deaths, 2 important components of reproductive health-related deaths, contributed substantially to overall mortality.	Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Int Rescue Comm, New York, NY USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Jamieson, DJ (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mailstop K 34, Atlanta, GA 30341 USA.			Jamieson, Denise/0000-0003-2597-1201				Abouzahr Carla, 1996, World Health Statistics Quarterly, V49, P77; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; Basso O, 1997, BRIT MED J, V315, P1498, DOI 10.1136/bmj.315.7121.1498; *CDCP, 1991, EP APPR REPR HLTH; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P705; DALLABETTA GA, 1993, J INFECT DIS, V167, P36, DOI 10.1093/infdis/167.1.36; *M STOP INT, 1998, REPR HLTH CAR REF SE; *MAT HLTH SAF MOTH, 1992, LOW BIRTH WEIGHT TAB; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Sachs L, 1997, Afr Health, V19, P24; SCHULZ KF, 1987, GENITOURIN MED, V63, P320; SEIDMAN DS, 1988, OBSTET GYNECOL, V72, P158; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; *UN HIGH COMM REF, 1999, REG OTH CONC UNHCR 1; *UN HIGH COMM REF, 1995, REPR HLTH REF SIT IN; VANDERSTUYFT P, 1993, ANN SOC BELG MED TR, V73, P81; *WOM COMM REF WOM, 1996, FACT SHEET; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220	20	37	37	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					397	402		10.1001/jama.283.3.397	http://dx.doi.org/10.1001/jama.283.3.397			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647805				2022-12-24	WOS:000084732400034
J	Soto, C; Kascsak, RJ; Saborio, GP; Aucouturier, P; Wisniewski, T; Prelli, F; Kascsak, R; Mendez, E; Harris, DA; Ironside, J; Tagliavini, F; Carp, RI; Frangione, B				Soto, C; Kascsak, RJ; Saborio, GP; Aucouturier, P; Wisniewski, T; Prelli, F; Kascsak, R; Mendez, E; Harris, DA; Ironside, J; Tagliavini, F; Carp, RI; Frangione, B			Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides	LANCET			English	Article							SCRAPIE AGENT; AMYLOIDOSIS; INHIBITION; MICE; CJD	Background Transmissible spongiform encephalopathies are associated with a structural transition in the prion protein that results in the conversion of the physiological PrPc to pathological PrPSc. We investigated whether this conformational transition can be inhibited and reversed by peptides homologous to the PrP fragments implicated in the abnormal folding. which contain specific residues acting as beta-sheet blockers (beta-sheet breaker peptides). Methods We studied the effect of a 13-residue beta-sheet breaker peptide (iPrP13) on the reversion of the abnormal structure and properties of PrPSc; purified from the brains of mice with experimental scrapie and from human beings affected by sporadic and variant Creutzfeldt-Jakob disease. In a cellular model of familial prion disease, we studied the effect of the peptide in the production of the abnormal form of PrP in intact cells. The influence of the peptide on prion infectivity was studied in vivo by incubation time assays in mice with experimental scrapie. Findings The beta-sheet breaker peptide partly reversed in-vitro PrPSc to a biochemical and structural state similar to that of PrPc. The effect of the peptide was also detected in intact cells. Treatment of prion infectious material with iPrP13 delayed the appearance of clinical symptoms and decreased infectivity by 90-95% in mice with experimental scrapie. Interpretation beta-sheet breaker peptides reverse PrP conformational changes implicated in the pathogenesis of spongiform encephalopathies, These peptides or their derivatives provide a useful tool to study the role of PrP conformation and might represent a novel therapeutic approach for prion-related disorders.	Serono Pharmaceut Res Inst, Dept Cellular Biochem, Geneva, Switzerland; NYU, Med Ctr, New York, NY 10016 USA; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; CSIC, Ctr Nacl Biotecnol, Madrid, Spain; Washington Univ, Sch Med, St Louis, MO USA; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Ist Nazl Neurol Carlo Besta, Milan, Italy	New York University; Institute for Basic Research in Developmental Disabilities; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Washington University (WUSTL); University of Edinburgh; IRCCS Istituto Neurologico Besta	Soto, C (corresponding author), Serono Pharmaceut Res Inst, Dept Cellular Biochem, Geneva, Switzerland.		Tagliavini, Fabrizio/AAO-7891-2021; Wisniewski, Thomas/Q-6525-2019	Tagliavini, Fabrizio/0000-0003-1039-7315; Wisniewski, Thomas/0000-0002-3379-8966; Ironside, James/0000-0001-5869-2108; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER; NIAMS NIH HHS [ARD2594] Funding Source: Medline; NINDS NIH HHS [NS35496] Funding Source: Medline; PHS HHS [M56472] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adjou KT, 1998, CNS DRUGS, V10, P83, DOI 10.2165/00023210-199810020-00001; Aucouturier P, 1999, NEUROSCI LETT, V274, P33, DOI 10.1016/S0304-3940(99)00659-X; Brown P, 1990, ANTIVIR CHEM CHEMOTH, V1, P75, DOI 10.1177/095632029000100201; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CARP RI, 1994, ANN NY ACAD SCI, V724, P221, DOI 10.1111/j.1749-6632.1994.tb38912.x; CARP RI, 1984, INTERVIROLOGY, V21, P61, DOI 10.1159/000149503; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Haywood AM, 1997, NEW ENGL J MED, V337, P1821, DOI 10.1056/NEJM199712183372508; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kascsak RJ, 1997, IMMUNOL INVEST, V26, P259, DOI 10.3109/08820139709048931; KIMBERLIN RH, 1976, SCI PROGRESS-UK, V63, P461; Li SC, 1996, P NATL ACAD SCI USA, V93, P6676, DOI 10.1073/pnas.93.13.6676; MOORE GJ, 1994, TRENDS PHARMACOL SCI, V15, P124, DOI 10.1016/0165-6147(94)90049-3; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, CNS DRUGS, V12, P347, DOI 10.2165/00023210-199912050-00002; WILL RG, 1996, LANCET, V347, P925; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	30	242	267	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					192	197		10.1016/S0140-6736(99)11419-3	http://dx.doi.org/10.1016/S0140-6736(99)11419-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675119				2022-12-24	WOS:000084879700013
J	Crowley, MP; Fahrer, AM; Baumgarth, N; Hampl, J; Gutgemann, I; Teyton, L; Chien, YH				Crowley, MP; Fahrer, AM; Baumgarth, N; Hampl, J; Gutgemann, I; Teyton, L; Chien, YH			A population of murine gamma delta T cells that recognize an inducible MHC class lb molecule	SCIENCE			English	Article							LYMPHOCYTES; ACTIVATION; ANTIGEN; GAMMA/DELTA; DEFICIENT; INFECTION; INDUCTION; TOLERANCE; RESPONSES; PRODUCT	Although gamma delta T cells are implicated in regulating immune responses, gamma delta T cell-ligand pairs that could mediate such regulatory functions have not been identified. Here, the expression of the major histocompatibility complex (MHC) class Ib T22 and the closely related T10 molecules is shown to be activation-induced, and they confer specificity to about 0.4% of the gamma delta T cells in normal mice. Thus, the increased expression of T22 and/or T'10 might trigger immunoregulatory gamma delta T cells during immune responses. Furthermore, the fast on-rates and slow off-rates that characterize this receptor/ligand interaction would compensate for the low ligand stability and suggest a high threshold for gamma delta T cell activation.	Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Stanford University; Stanford University; Stanford University; Scripps Research Institute	Chien, YH (corresponding author), Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA.	chien@leland.stanford.edu	Gütgemann, Ines/ABH-6426-2020; Fahrer, Aude M/C-9318-2009; Baumgarth, Nicole/AAI-6949-2020	Fahrer, Aude/0000-0001-8556-0223	NIAID NIH HHS [AI42267, AI34762-34, AI33431] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034762, R21AI142267, R01AI042267, R01AI033431] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; BAUMGARTH N, UNPUB; Bigos A, 1999, CYTOMETRY, V36, P36; Born W, 1999, Adv Immunol, V71, P77; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; CROWLEY MP, UNPUB; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; EMOTO M, 1995, INFECT IMMUN, V63, P3736, DOI 10.1128/IAI.63.9.3736-3738.1995; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; GUTGEMANN I, UNPUB; HOULDEN BA, 1989, COLD SH Q B, V54, P45; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; Ke Y, 1997, J IMMUNOL, V158, P3610; MAVADDAT N, 1995, THESIS U W AUSTR NED; MCKEARN TJ, 1979, TRANSPLANT P, V11, P932; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; Ogg GS, 1998, CURR OPIN IMMUNOL, V10, P393, DOI 10.1016/S0952-7915(98)80110-6; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; SPANER D, 1995, J IMMUNOL, V155, P3866; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	29	150	150	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					314	316		10.1126/science.287.5451.314	http://dx.doi.org/10.1126/science.287.5451.314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634788				2022-12-24	WOS:000084769600043
J	Samet, JM				Samet, JM			Concepts of time in clinical research	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; HIV-INFECTION; LUNG-CANCER; SEROCONVERSION; MODELS; PERIOD; AGE; INTERMEDIATE; INCUBATION	The study of events in time is fundamental to biomedical research and public health surveillance. Clinicians have an intuitive appreciation for the relevance of time to health and disease, and patients invariably ask questions relating to time for which clinicians need answers. An appreciation of the picture of health and disease over time is equally fundamental to public health. Research designs that incorporate time have long been in use; the cohort study, which involves follow-up of persons over time, is the fundamental design. Analysis of longitudinal data, generated by cohort studies and related approaches, has been enhanced by new statistical methods that are appropriate to data collected over time from repeated observations. In the next millennium, new and increasingly complex questions will undoubtedly require investigation. The research designs and analytic methods used to address clinical questions in time will continue to evolve and will provide better, sharper answers.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University	Samet, JM (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Suite 6041, Baltimore, MD 21205 USA.							*ACT SOC AM, 1903, SPEC MORT INV; ANDVORD K. F., 1930, Norsk Magazin for Laegevidenskaben, V91, P642; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; BROWN L, 1904, AM MED, V8, P879; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; *COMM HLTH RISKS E, 1998, BEIR, V5; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR, 1980, FRAMINGHAM STUDY EPI, P1; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Diggle PJ, 2002, ANAL LONGITUDINAL DA; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; EYLER JM, 1978, TIMES PLACES PERSONS, P1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Frost WH, 1939, AM J HYG, V30, P91, DOI 10.1093/oxfordjournals.aje.a118570; Gange SJ, 1996, STAT MED, V15, P2323, DOI 10.1002/(SICI)1097-0258(19961115)15:21<2323::AID-SIM451>3.0.CO;2-P; GANGE SJ, 1997, J ACQ IMMUN DEF SYND, V15, pS5; Goldberg RJ, 1999, NEW ENGL J MED, V340, P1162, DOI 10.1056/NEJM199904153401504; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; Hu FB, 1999, JAMA-J AM MED ASSOC, V281, P1387, DOI 10.1001/jama.281.15.1387; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LAST JM, 1995, DICT EPIDEMIOLOGY; LUNDIN FD, 1979, P WORK GROUP 2 C SOC, P243; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller R. G., 1981, SURVIVAL ANAL; Munoz A, 1998, EPIDEMIOL REV, V20, P29, DOI 10.1093/oxfordjournals.epirev.a017970; MUNOZ A, 1992, STAT MED, V11, P939, DOI 10.1002/sim.4780110711; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; Munoz A, 1997, AIDS, V11, pS69; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; MUNOZ A, 1995, USE COHORT STUDIES E, P423; *NCI, 1998, SEER CANC STAT REV 1; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; Pearl R, 1938, SCIENCE, V87, P216, DOI 10.1126/science.87.2253.216; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Samet JM, 1998, EPIDEMIOL REV, V20, P1; SARTWELL PE, 1951, AM REV TUBERC PULM, V63, P608; SCHULL WJ, 1995, EFFECTS ATOMIC RAD H, P1; Singer R B, 1985, Natl Cancer Inst Monogr, V67, P15; Speizer F E, 1979, Epidemiol Rev, V1, P124; Strong JP, 1999, JAMA-J AM MED ASSOC, V281, P727, DOI 10.1001/jama.281.8.727; TAYLOR JMG, 1990, STAT MED, V9, P505, DOI 10.1002/sim.4780090504; Thomas D, 1998, EPIDEMIOL REV, V20, P122, DOI 10.1093/oxfordjournals.epirev.a017967; *US DHEW, 1964, DHEW PUBL, V1103; Vogelstein B., 1998, GENETIC BASIS HUMAN; WHITE C, 1990, YALE J BIOL MED, V63, P29; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; Wynder EL, 1997, AM J EPIDEMIOL, V146, P687	61	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					37	44		10.7326/0003-4819-132-1-200001040-00007	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627250				2022-12-24	WOS:000084518600006
J	Ma, HT; Patterson, RL; van Rossum, DB; Birnbaumer, L; Mikoshiba, K; Gill, DL				Ma, HT; Patterson, RL; van Rossum, DB; Birnbaumer, L; Mikoshiba, K; Gill, DL			Requirement of the inositol trisphosphate receptor for activation of store-operated Ca2+ channels	SCIENCE			English	Article							CAPACITATIVE CALCIUM-ENTRY; DEPLETION; CELLS; RELEASE; SIGNAL; INFLUX	The coupling mechanism between endoplasmic reticulum (ER) calcium ion (Ca2+) stores and plasma membrane (PM) store-operated channels (SOCs) is crucial to Ca2+ signaling but has eluded detection. SOCs may be functionally related to the TRP family of receptor-operated channels. Direct comparison of endogenous SOCs with stably expressed TRP3 channels in human embryonic kidney (HEK293) cells revealed that TRP3 channels differ in being store independent. However, condensed cortical F-actin prevented activation of both SOC and TRP3 channels, which suggests that ER-PM interactions underlie coupling of both channels. A cell-permeant inhibitor of inositol trisphosphate receptor (InsP(2)R) function, 2-aminoethoxydiphenyl berate, prevented both receptor-induced TRP3 activation and receptor-induced SOC activation. It is concluded that InsP(3)Rs mediate both SOC and TRP channel opening and that the InsP(3)R is essential for maintaining coupling between store emptying and physiological activation of SOCs.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo, Japan	University System of Maryland; University of Maryland Baltimore; University of California System; University of California Los Angeles; University of Tokyo	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	dgill@umaryland.edu	Mikoshiba, Katsuhiko/N-7943-2015	van Rossum, Damian/0000-0003-1011-2586	NHLBI NIH HHS [HL55426] Funding Source: Medline; NIAMS NIH HHS [AR07592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Favre CJ, 1998, J BIOL CHEM, V273, P30855, DOI 10.1074/jbc.273.47.30855; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; MA HT, UNPUB; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	23	508	523	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2000	287	5458					1647	1651		10.1126/science.287.5458.1647	http://dx.doi.org/10.1126/science.287.5458.1647			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698739				2022-12-24	WOS:000085628200037
J	Pearson, GD; Veille, JC; Rahimtoola, S; Hsia, J; Oakley, CM; Hosenpud, JD; Ansari, A; Baughman, KL				Pearson, GD; Veille, JC; Rahimtoola, S; Hsia, J; Oakley, CM; Hosenpud, JD; Ansari, A; Baughman, KL			Peripartum cardiomyopathy - National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR FUNCTION; ENDOMYOCARDIAL BIOPSY; MYOCARDITIS; PREGNANCY; FAILURE; CELLS; CARVEDILOL; AMLODIPINE; DIAGNOSIS; MORBIDITY	Objective Peripartum cardiomyopathy (PPCM) is a rare life-threatening cardiomyopathy of unknown cause that occurs in the peripartum period in previously healthy women. In April 1997, the National Heart, Lung, and Blood Institute (NHLBI) and the Office of Rare Diseases of the National Institutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review of information and to develop recommendations for research and education. Participants Fourteen workshop participants were selected by NHLBI staff and represented cardiovascular medicine, obstetrics, immunology, and pathology. A representative subgroup of 8 participants and NHLBI staff formed the writing group for this article and updated the literature on which the conclusions were based. The workshop was an open meeting, consistent with NIH policy. Evidence Data presented at the workshop were augmented by a MEDLINE search for English-language articles published from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy. Articles on the epidemiology, pathogenesis, pathophysiology, diagnosis, treatment, and prognosis of PPCM were included. Recommendation Process After discussion of data presented, workshop participants agreed on a standardized definition of PPCM, a general clinical approach, and the need for a registry to provide an infrastructure for future research. Conclusions Peripartum cardiomyopathy is a rare lethal disease about which little is known. Diagnosis is confined to a narrow period and requires echocardiographic evidence of left ventricular systolic dysfunction. Symptomatic patients should receive standard therapy for heart failure, managed by a multidisciplinary team. If subsequent pregnancies occur, they should be managed in collaboration with a high-risk perinatal center. Systematic data collection is required to answer important questions about incidence, treatment, and prognosis.	NHLBI, Div Heart & Vasc Dis, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27103 USA; Univ So Calif, Div Cardiol, Los Angeles, CA USA; George Washington Univ, Sch Med & Hlth Sci, Div Cardiol, Washington, DC 20052 USA; Imperial Coll Med Sch, London, England; Med Coll Wisconsin, Div Cardiovasc Med, Milwaukee, WI 53226 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; University of Southern California; George Washington University; Imperial College London; Medical College of Wisconsin; Emory University; Johns Hopkins University	Pearson, GD (corresponding author), NHLBI, Div Heart & Vasc Dis, NIH, 6701 Rockledge Dr,Room 9146,MSC 7940, Bethesda, MD 20892 USA.							ANSARI AA, 1993, CLIN IMMUNOL IMMUNOP, V68, P208, DOI 10.1006/clin.1993.1120; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Bozkurt B, 1999, J AM COLL CARDIOL, V34, P177, DOI 10.1016/S0735-1097(99)00161-8; Ceci O, 1998, EUR J OBSTET GYN R B, V76, P29, DOI 10.1016/S0301-2115(97)00148-6; CHOW LH, 1989, J AM COLL CARDIOL, V14, P915, DOI 10.1016/0735-1097(89)90465-8; COSTANZONORDIN MR, 1989, PROG CARDIOL, V2, P225; Coulson CC, 1996, OBSTET GYNECOL, V87, P610, DOI 10.1016/0029-7844(95)00493-9; CUNNINGHAM FG, 1986, OBSTET GYNECOL, V67, P157; DEMAKIS JG, 1971, CIRCULATION, V44, P964, DOI 10.1161/01.CIR.44.5.964; DEMAKIS JG, 1971, CIRCULATION, V44, P1053, DOI 10.1161/01.CIR.44.6.1053; FARBER PA, 1970, AM HEART J, V80, P96, DOI 10.1016/0002-8703(70)90042-6; Frishman WH, 1998, NEW ENGL J MED, V339, P1759, DOI 10.1056/NEJM199812103392407; Geva T, 1997, AM HEART J, V133, P53, DOI 10.1016/S0002-8703(97)70247-3; Goulet B, 1937, AM J MED SCI, V194, P185; HAUCK AJ, 1989, MAYO CLIN PROC, V64, P1235, DOI 10.1016/S0025-6196(12)61286-5; JULIAN DG, 1985, PROG CARDIOVASC DIS, V27, P223, DOI 10.1016/0033-0620(85)90007-6; KEOGH A, 1994, J HEART LUNG TRANSPL, V13, P202; KOTHARI SS, 1977, INT J CARDIOL, V60, P111; LAMPERT MB, 1995, AM HEART J, V130, P860, DOI 10.1016/0002-8703(95)90089-6; Lampert MB, 1997, AM J OBSTET GYNECOL, V176, P189, DOI 10.1016/S0002-9378(97)80034-8; LUDWIG P, 1997, AUST N Z J OBSTET GY, V37, P156; LYDEN DC, 1984, CELL IMMUNOL, V87, P462, DOI 10.1016/0008-8749(84)90015-7; Mann Douglas L., 1996, Cytokine and Growth Factor Reviews, V7, P341, DOI 10.1016/S1359-6101(96)00043-3; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MASSAD LS, 1993, OBSTET GYNECOL, V81, P886; MELVIN KR, 1982, NEW ENGL J MED, V307, P731, DOI 10.1056/NEJM198209163071207; MIDEI MG, 1990, CIRCULATION, V81, P922, DOI 10.1161/01.CIR.81.3.922; Mohler ER, 1997, J AM COLL CARDIOL, V30, P35, DOI 10.1016/S0735-1097(97)00145-9; Mone SM, 1996, CIRCULATION, V94, P667, DOI 10.1161/01.CIR.94.4.667; Nelson J L, 1998, J Am Med Womens Assoc (1972), V53, P31; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; OCONNELL JB, 1986, J AM COLL CARDIOL, V8, P52, DOI 10.1016/S0735-1097(86)80091-2; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEARL W, 1995, AM HEART J, V129, P421, DOI 10.1016/0002-8703(95)90032-2; Pierce JA, 1962, ARCH INTERN MED, V111, P163; Rahimtoola S H, 1996, Curr Probl Cardiol, V21, P781, DOI 10.1016/S0146-2806(96)80001-6; SUTTON MS, 1991, AM HEART J, V121, P1776; VEILLE JC, 1984, AM J OBSTET GYNECOL, V148, P805, DOI 10.1016/0002-9378(84)90572-6; Ventura S J, 1997, Mon Vital Stat Rep, V46, P1; Witlin AG, 1997, AM J OBSTET GYNECOL, V176, P182, DOI 10.1016/S0002-9378(97)80033-6	43	532	572	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1183	1188		10.1001/jama.283.9.1183	http://dx.doi.org/10.1001/jama.283.9.1183			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703781	Bronze			2022-12-24	WOS:000085424100028
J	Donovan, JL; Blake, DR				Donovan, JL; Blake, DR			Qualitative study of interpretation of reassurance among patients attending rheumatology clinics: "just a touch of arthritis, doctor?"	BRITISH MEDICAL JOURNAL			English	Article							DECISION-MAKING; LAY BELIEFS; CONSULTATION; EDUCATION; DISEASE	Objectives To examine commonly used methods of reassurance by clinicians and explore their effect on patients. Design Qualitative study of tape recordings of in-depth, semistructured interviews with patients before and after consultation and of their consultations with doctors. Setting NHS specialist rheumatology clinics in two large British cities. Participants 35 patients selected by consultant rheumatologists from general practitioner referral letters (28 women, 7 men; 24 with inflammatory arthropathies, ii other rheumatological complaints). Main outcome measures Patients' perceptions of reassurance. Results Reassurance was an important part of consultations, whether the diagnosis was clear or uncertain. Clinicians tried to reduce anxiety by emphasising the mildness, early stage, or non-seriousness of the disorder and the likelihood that patients would recover. Patients interpreted reassurance in the context of their own views and perceptions. Doctors' emphasis on the mildness or earliness of the condition raised the spectre of future pain and disability rather than providing reassurance. Patients who felt;hat their problems were properly acknowledged felt more reassured. Conclusions Typical patterns of reassurance were not successful because of the differences in perspective of patients and doctors. A key to successful reassurance seemed to be the doctor's ability to acknowledge patients' perspectives of their difficulties.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England	University of Bristol; Royal National Hospital for Rheumatic Diseases (RNHRD)	Donovan, JL (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							BARTLETT EE, 1984, J CHRON DIS, V37, P755, DOI 10.1016/0021-9681(84)90044-4; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; DONOVAN J, 1991, ANN RHEUM DIS, V50, P418, DOI 10.1136/ard.50.Suppl_3.418; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; DONOVAN JL, 1989, BRIT J RHEUMATOL, V28, P58; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; EYLES J, 1990, SOCIAL EFFECTS HLTH; Fitzpatrick R, 1996, BRIT MED J, V313, P311, DOI 10.1136/bmj.313.7053.311; FITZPATRICK R, 1981, J NEUROL NEUROSUR PS, V44, P1061, DOI 10.1136/jnnp.44.12.1061; FRANCIS V, 1969, NEW ENGL J MED, V280, P535, DOI 10.1056/NEJM196903062801004; Freidson E., 1970, PROFESSION MED STUDY; Glaser B. G., 1978, AWARENESS DYING; Hammersley M., 1983, ETHNOGRAPHY; HENBEST RJ, 1990, FAM PRACT, V7, P28, DOI 10.1093/fampra/7.1.28; KESSEL N, 1979, LANCET, V1, P1128; MAYOU R, 1976, BRIT J PSYCHIAT, V129, P55, DOI 10.1192/bjp.129.1.55; Mays N, 1996, QUALITATIVE RES HLTH; McDonald IG, 1996, BRIT MED J, V313, P329, DOI 10.1136/bmj.313.7053.329; Miles M., 1994, QUALITATIVE DATA ANA; Mishler EG, 1984, DISCOURSE MED DIALEC; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Silverman D., 1987, COMMUNICATION MED PR; Williams S, 1996, MODER MED LAY PERSPE; 1993, ANN PHARMACOTHERAPY, V27, pS5	24	97	98	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	2000	320	7234					541	544		10.1136/bmj.320.7234.541	http://dx.doi.org/10.1136/bmj.320.7234.541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289LV	10688559	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000085624000021
J	Greenbaum, L				Greenbaum, L			That's what it is	LANCET			English	Article									Indiana Internal Med, Beech Grove Off, Beech Grove, IN 46107 USA		Greenbaum, L (corresponding author), Indiana Internal Med, Beech Grove Off, Beech Grove, IN 46107 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 26	2000	355	9205					745	+		10.1016/S0140-6736(99)11157-7	http://dx.doi.org/10.1016/S0140-6736(99)11157-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703817				2022-12-24	WOS:000085615600044
J	Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH				Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH			Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE PATHWAY; POLARIZED CELL-GROWTH; FILAMENTOUS-GROWTH; ACTIN CYTOSKELETON; INVASIVE GROWTH; REGULATED GENES; SHUTTLE VECTORS; MATING FACTOR; PHEROMONE	Genome-wide transcript profiling was used to monitor signal transduction during yeast pheromone response. Genetic manipulations allowed analysis of changes in gene expression underlying pheromone signaling, cell cycle control, and polarized morphogenesis. A two-dimensional hierarchical clustered matrix, covering 383 of the most highly regulated genes, was constructed from 46 diverse experimental conditions. Diagnostic subsets of coexpressed genes reflected signaling activity, cross talk, and overlap of multiple mitogen-activated protein kinase (MAPK) pathways. Analysis of the profiles specified by two different MAPKs-Fus3p and Kss1p-revealed functional overlap of the filamentous growth and mating responses. Global transcript analysis reflects biological responses associated with the activation and perturbation of signal transduction pathways.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Rosetta Inpharmat, Kirkland, WA 98034 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	Queens University - Canada; Merck & Company; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Boone, C (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.		Pillay, Nischalan/F-9536-2012; Tyers, Michael/ABE-3194-2021					Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Blanco P, 1998, FEMS MICROBIOL LETT, V164, P249, DOI 10.1016/S0378-1097(98)00220-1; Brachmann CB, 1998, YEAST, V14, P115; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; ERDMAN S, COMMUNICATION; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gognies S, 1999, YEAST, V15, P11, DOI 10.1002/(SICI)1097-0061(19990115)15:1<11::AID-YEA336>3.0.CO;2-O; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hartigan J. A., 1975, CLUSTERING ALGORITHM; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Karos M, 1999, MOL GEN GENET, V260, P510, DOI 10.1007/s004380050924; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liu HP, 1996, GENETICS, V144, P967; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; NAIR PB, UNPUB; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SIKORSKI RS, 1989, GENETICS, V122, P19; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	78	701	733	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					873	880		10.1126/science.287.5454.873	http://dx.doi.org/10.1126/science.287.5454.873			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657304				2022-12-24	WOS:000085136400051
J	Alizadeh, AA; Eisen, MB; Davis, RE; Ma, C; Lossos, IS; Rosenwald, A; Boldrick, JG; Sabet, H; Tran, T; Yu, X; Powell, JI; Yang, LM; Marti, GE; Moore, T; Hudson, J; Lu, LS; Lewis, DB; Tibshirani, R; Sherlock, G; Chan, WC; Greiner, TC; Weisenburger, DD; Armitage, JO; Warnke, R; Levy, R; Wilson, W; Grever, MR; Byrd, JC; Botstein, D; Brown, PO; Staudt, LM				Alizadeh, AA; Eisen, MB; Davis, RE; Ma, C; Lossos, IS; Rosenwald, A; Boldrick, JG; Sabet, H; Tran, T; Yu, X; Powell, JI; Yang, LM; Marti, GE; Moore, T; Hudson, J; Lu, LS; Lewis, DB; Tibshirani, R; Sherlock, G; Chan, WC; Greiner, TC; Weisenburger, DD; Armitage, JO; Warnke, R; Levy, R; Wilson, W; Grever, MR; Byrd, JC; Botstein, D; Brown, PO; Staudt, LM			Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling	NATURE			English	Article							NON-HODGKINS-LYMPHOMA; GERMINAL-CENTER FORMATION; CHROMOSOMAL TRANSLOCATION; PROGNOSTIC-SIGNIFICANCE; PROTEIN EXPRESSION; MOLECULAR-CLONING; BCL-6 EXPRESSION; ANTIGEN; CLASSIFICATION; TRANSCRIPTION	Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumours, Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal centre B cells ('germinal centre B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'), Patients with germinal centre B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL, The molecular classification of tumours on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer.	NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy Stat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; NIH, Bioinformat & Mol Anal Sect, CBEL, CIT, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Res Genet Inc, Huntsville, AL 35801 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); US Food & Drug Administration (FDA); University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Staudt, LM (corresponding author), NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA.		B, shaizimah/AAS-2555-2020; Staudt, Louis/AAC-5324-2019; Sherlock, Gavin J/B-1831-2009; Alizadeh, Ash A/C-5594-2009; Sherlock, Gavin J/E-9110-2012	Alizadeh, Ash A/0000-0002-5153-5625; Levy, Ronald/0000-0003-2061-0650; Sherlock, Gavin/0000-0002-1692-4983	CENTER FOR INFORMATION TECHNOLOGY [ZIACT000260, Z01CT000260] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; ALIZADEH AA, IN PRESS COLD SPRING; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chan WC, 1997, BLOOD, V89, P3909; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DeRisi J, 1996, NAT GENET, V14, P457; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FLENGHI L, 1995, AM J PATHOL, V147, P405; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gascoyne RD, 1997, BLOOD, V90, P244; GOLAY J, 1994, J IMMUNOL, V153, P543; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GROGAN TM, 1988, BLOOD, V71, P1157; Harada S, 1999, LEUKEMIA, V13, P1441, DOI 10.1038/sj.leu.2401487; HARRIS NL, 1994, BLOOD, V84, P1361; Hodgkin, 1832, Med Chir Trans, V17, P68; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; Khan J, 1998, CANCER RES, V58, P5009; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Klein U, 1998, IMMUNOL REV, V162, P261; Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Liu J, 1996, Biomed Environ Sci, V9, P1; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pittaluga S, 1996, J PATHOL, V179, P145; Preti HA, 1997, ANN INTERN MED, V127, P186, DOI 10.7326/0003-4819-127-3-199708010-00002; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Reed D., 1902, JOHNS HOPKINS HOS RE, V10, P133; ROSENBERG SA, 1994, BLOOD, V84, P1359; SCHEINER SM, 1995, ACADEME, V81, P4; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Sternberg C. U., 1898, Z HEILK, V19, P21; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vose UM, 1998, SEMIN ONCOL, V25, P483; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	50	7082	7533	11	558	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					503	511		10.1038/35000501	http://dx.doi.org/10.1038/35000501			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676951				2022-12-24	WOS:000085227300039
J	Ludwig, MZ; Bergman, C; Patel, NH; Kreitman, M				Ludwig, MZ; Bergman, C; Patel, NH; Kreitman, M			Evidence for stabilizing selection in a eukaryotic enhancer element	NATURE			English	Article							EVEN-SKIPPED PROMOTER; DROSOPHILA EMBRYO; EXPRESSION; EVOLUTION; STRIPE; PATTERNS; REGION; SITES	Eukaryotic gene expression is mediated by compact cis-regulatory modules, or enhancers, which are bound by specific sets of transcription factors(1). The combinatorial interaction of these bound transcription factors determines time- and tissue-specific gene activation or repression. The even-skipped stripe 2 element controls the expression of the second transverse stripe of a even-skipped messenger RNA in Drosophila melanogaster embryos, and is one of the best characterized eukaryotic enhancers(2-4). Although even-skipped stripe 2 expression is strongly conserved in Drosophila, the stripe 2 element itself has undergone considerable evolutionary change in its binding-site sequences and the spacing between them. We have investigated this apparent contradiction, and here we show that two chimaeric enhancers, constructed by swapping the 5' and 3' halves of the native stripe 2 elements of two species, no longer drive expression of a reporter gene in the wildtype pattern. Sequence differences between species have functional consequences, therefore, but they are masked by other coevolved differences. On the basis of these results, we present a model for the evolution of eukaryotic regulatory sequences.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Ludwig, MZ (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.		Bergman, Casey/F-7854-2010	Bergman, Casey/0000-0002-5462-9854; Patel, Nipam/0000-0003-4328-654X				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Arnosti DN, 1996, DEVELOPMENT, V122, P205; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; Hewitt GF, 1999, DEVELOPMENT, V126, P1201; KIMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P5773, DOI 10.1073/pnas.78.9.5773; Kimura M, 1985, NEUTRAL THEORY MOL E; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Long AD, 1998, GENETICS, V149, P999; Ludwig MZ, 1998, DEVELOPMENT, V125, P949; LUDWIG MZ, 1995, MOL BIOL EVOL, V12, P1002; OHTA T, 1990, GENETICS, V126, P219; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715	19	435	448	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					564	567		10.1038/35000615	http://dx.doi.org/10.1038/35000615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676967				2022-12-24	WOS:000085227300055
J	Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE				Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE			Sex differences in evaluation and outcome of unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; GENDER-RELATED DIFFERENCES; EMERGENCY ROOM; CHEST PAIN; CARDIAC PROCEDURES; BYPASS-SURGERY; BIAS; MANAGEMENT; MORTALITY	Context The existence of sex bias in the delivery of cardiac care is controversial,and little is known about the association between sex and delivery of care and outcomes at an early point in the diagnostic sequence, such as when patients present for the evaluation of chest pain. Objective To test the hypothesis that female sex is negatively associated with care delivered to and outcomes of persons diagnosed as having unstable angina. Design Inception population-based cohort study with an average of 6 years of follow-up. Setting Emergency departments (EDs) in Olmsted County, Minnesota. Patients A total of 2271 Olmsted County residents (1306 men and 965 women) who presented to the ED for the first time with symptoms meeting criteria for unstable angina between 1985 and 1992, Main Outcome Measures Use of cardiac procedures within 90 days of ED visit, overall mortality, and cardiac events (cardiac death, nonfatal myocardial infarction, nonfatal cardiac arrest, and congestive heart failure), com pared by sex and Agency for Health Care Policy and Research cardiovascular risk category (low, intermediate, or high). Results Women were older (P<.001), more likely to have a history of hypertension (P=.001), and less likely to present with typical angina (P=.004) than men. Men were more likely than women to undergo noninvasive cardiac tests (relative risk [RR], 1.27; 95% confidence interval [CI], 1.14-1.40) as well as invasive cardiac procedures (RR, 1.72; 95% CI, 1.51-1.97). After adjustment, male sex was associated with a 24% increase in the use of cardiac procedures. Survival of both men and women in the high and intermediate risk categories was significantly lower than expected per the general population (P<.001). Women had a worse outcome than men, but after multivariate adjustment, male sex was associated with a trend toward an increase in the risk of death (RR, 1.23; 95% CI, 0.99-1.54) and significantly associated with increased risk of cardiac events (RR, 1.21;95% CI, 1.03-1.42). Conclusions Our population-based data indicate that after an ED visit for symptoms of unstable angina, the use of cardiac procedures was lower in women, but after taking into account baseline characteristics, men experienced worse outcomes.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Epidemiol Sect, Rochester, MN 55905 USA; Olmsted Med Ctr, Dept Res, Rochester, MN USA; Mt Sinai Med Ctr, Cardiovasc Inst, Div Cardiol, New York, NY 10029 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Olmsted Medical Center; Icahn School of Medicine at Mount Sinai	Roger, VL (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Roger, Veronique/AAV-5951-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59205] Funding Source: Medline; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Braunwald E, 1994, UNSTABLE ANGINA DIAG; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FUNK M, 1994, AM J CARDIOL, V74, P1170, DOI 10.1016/0002-9149(94)90475-8; HACHAMOVITCH R, 1995, J AM COLL CARDIOL, V26, P1457, DOI 10.1016/0735-1097(95)00356-8; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; Karlson BW, 1996, CORONARY ARTERY DIS, V7, P231; KARLSON BW, 1993, CORONARY ARTERY DIS, V4, P761, DOI 10.1097/00019501-199309000-00002; Karlson BW, 1997, AM J EMERG MED, V15, P1, DOI 10.1016/S0735-6757(97)90038-3; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MAIR J, 1995, CHEST, V108, P1502, DOI 10.1378/chest.108.6.1502; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Maynard C, 1996, CIRCULATION, V94, P93; MELTON LJ, 1985, MAYO CLIN PROC, V60, P880, DOI 10.1016/S0025-6196(12)64794-6; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Roger VL, 1997, CIRCULATION, V95, P405; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stussman BJ, 1997, DHHS PUBLICATION; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502	32	116	116	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					646	652		10.1001/jama.283.5.646	http://dx.doi.org/10.1001/jama.283.5.646			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665705	Bronze			2022-12-24	WOS:000084956500031
J	Lamont, D; Parker, L; White, M; Unwin, N; Bennett, SMA; Cohen, M; Richardson, D; Dickinson, HO; Adamson, A; Alberti, KGMM; Craft, AW				Lamont, D; Parker, L; White, M; Unwin, N; Bennett, SMA; Cohen, M; Richardson, D; Dickinson, HO; Adamson, A; Alberti, KGMM; Craft, AW			Risk of cardiovascular disease measured by carotid intima-media thickness at age 49-51: lifecourse study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; B-MODE ULTRASOUND; FETAL GROWTH; MYOCARDIAL-INFARCTION; PERIPHERAL ARTERIES; WALL THICKNESS; FOLLOW-UP; CHILDHOOD; WOMEN; ATHEROSCLEROSIS	Objective To quantify the direct and indirect effects of fetal life, childhood, and adult life on risk of cardiovascular disease at age 49-51 years. Design Follow up study of the "Newcastle thousand families" birth cohort established in 1947. Participants 154 men and 193 women who completed a health and lifestyle questionnaire and attended for clinical examination between October 1996 and December 1998. Main outcome measures Correlations between mean intima-media thickness of the carotid artery (carotid intima-media thickness) and family history, birth weight, and socioeconomic position around birth; socioeconomic position, growth, illness, and adverse Life events in childhood; and adult socioeconomic position, lifestyle, and biological risk markers. Proportions of variance in carotid intima-media thickness that were accounted for by each stage of the lifecourse. Results Socioeconomic position at birth and birth weight were negatively associated with carotid intima-media thickness, although only social class at birth in women was a statistically significant covariate independent of adult lifestyle. These early life variables accounted directly for 2.2% of total variance in men and 2.0% in women. More variation in carotid intima-media thickness was explained by adult socioeconomic position and lifestyle, which accounted directly and indirectly for 3.4% of variance in men (95% confidence interval 0.5% to 6.2%) and 7.6% in women (2.1% to 13.0%). Biological risk markers measured in adulthood independently accounted for a further 9.5% of variance in men (2.4% to 14.2%) and 4.9% in women (1.6% to 7.4%). Conclusions Adult lifestyle and biological risk markers were the most important determinants of the cardiovascular health of the study members of the Newcastle thousand families cohort at age 49-51 years. The limited overall effect of early life factors may reflect the postwar birth year of this cohort.	Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Hlth Care Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE1 4HH, Tyne & Wear, England; Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Royal Victoria Infirm, Dept Radiol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Lamont, D (corresponding author), Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	d.w.lamont@ncl.ac.uk	White, Martin J. R./G-2410-2010	Unwin, Nigel/0000-0002-1368-1648; Adamson, Ashley/0000-0003-3735-2846; PARKER, LOUISE/0000-0002-5188-8113	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker DJP, 1998, MOTHERS BABIES HLTH; Ben Shlomo, 1997, LIFECOURSE APPROACH; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; *DEP HLTH, 1992, 41 DEP HLTH; Dubuisson JT, 1998, DIABETES CARE, V21, P1790, DOI 10.2337/diacare.21.11.1790; EBRAHIM S, 1994, BRIT HEART J, V72, P501; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HOLLINGSWORTH D, 1991, ENGLISHMANS FOOD 5 C, P429; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; KUH DJL, 1992, J EPIDEMIOL COMMUN H, V46, P114, DOI 10.1136/jech.46.2.114; Lamont DW, 1998, PUBLIC HEALTH, V112, P85, DOI 10.1016/S0033-3506(98)00591-5; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Little R. J. A., 1987, STAT ANAL MISSING DA; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; Martyn CN, 1998, LANCET, V352, P173, DOI 10.1016/S0140-6736(97)10404-4; Njolstad I, 1996, CIRCULATION, V93, P450; PETRIE JC, 1990, RECOMMENDATIONS BLOO; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Power C, 1998, LANCET, V352, P877, DOI 10.1016/S0140-6736(98)23937-7; Prineas R.J, 1982, MINNESOTA MANUAL ELE; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Williams S, 1999, BRIT MED J, V318, P897, DOI 10.1136/bmj.318.7188.897; World Health Organisation, 1990, MONICA MAN 3	33	134	138	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2000	320	7230					273	278		10.1136/bmj.320.7230.273	http://dx.doi.org/10.1136/bmj.320.7230.273			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650022	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000085132700018
J	Hazuda, DJ; Felock, P; Witmer, M; Wolfe, A; Stillmock, K; Grobler, JA; Espeseth, A; Gabryelski, L; Schleif, W; Blau, C; Miller, MD				Hazuda, DJ; Felock, P; Witmer, M; Wolfe, A; Stillmock, K; Grobler, JA; Espeseth, A; Gabryelski, L; Schleif, W; Blau, C; Miller, MD			Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INTEGRASE; VIRAL-DNA; PREINTEGRATION COMPLEXES; STABLE COMPLEX; PROTEIN; INVITRO; IDENTIFICATION; GENE; SITE	Integrase is essential for human immunodeficiency virus-type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochemical assays has not readily translated into antiviral activity in a manner consistent with inhibition of integration. In this report, we describe diketo acid inhibitors of HIV-1 integrase that manifest antiviral activity as a consequence of their effect on integration. The antiviral activity of these compounds is due exclusively to inhibition of one of the two catalytic functions of integrase, strand transfer.	Merck Sharp & Dohme Res Labs, Dept Antiviral Res, W Point, PA 19486 USA	Merck & Company	Hazuda, DJ (corresponding author), Merck Sharp & Dohme Res Labs, Dept Antiviral Res, W Point, PA 19486 USA.							CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ESPESETH A, UNPUB; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; FARNET CM, 1991, J VIROL, V65, P6942, DOI 10.1128/JVI.65.12.6942-6952.1991; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Hazuda D, 1997, Drug Des Discov, V15, P17; Hazuda DJ, 1997, J VIROL, V71, P7005, DOI 10.1128/JVI.71.9.7005-7011.1997; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; Miller M. M., UNPUB; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Richman D.D, 1996, ANTIVIRAL DRUG RESIS; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; WITMER M, UNPUB; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996	26	967	1028	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					646	650		10.1126/science.287.5453.646	http://dx.doi.org/10.1126/science.287.5453.646			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649997				2022-12-24	WOS:000084989400046
J	Rossi, DJ; Oshima, T; Attwell, D				Rossi, DJ; Oshima, T; Attwell, D			Glutamate release in severe brain ischaemia is mainly by reversed uptake	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; METHYL-D-ASPARTATE; NEURONAL DEATH; IN-VITRO; ISCHEMIA; ACTIVATION; TRANSPORT; CALCIUM; ANOXIA; MECHANISMS	The release of glutamate during brain anoxia or ischaemia triggers the death of neurons', causing mental or physical handicap. The mechanism of glutamate release is controversial, however. Four release mechanisms have been postulated: vesicular release dependent on external calcium(2) or Ca(2+) released from intracellular stores(3); release through swelling-activated onion channels(4); an indomethacin-sensitive process in astrocytes(5-7); and reversed operation of glutamate transporters(8,9). Here we have mimicked severe ischaemia in hippocampal slices and monitored glutamate release as a receptor-gated current in the CA1 pyramidal cells that are killed preferentially in ischaemic hippocampus. Using blockers of the different release mechanisms, we demonstrate that glutamate release is largely by reversed operation of neuronal glutamate transporters, and that it plays a key role in generating the anoxic depolarization that abolishes information processing in the central nervous system a few minutes after the start of ischaemia. A mathematical model incorporating K(+) channels, reversible uptake carriers and NMDA (N-methyl-D-aspartate) receptor channels reproduces the main features of the response to ischaemia. Thus, transporter-mediated glutamate homeostasis fails dramatically in ischaemia: instead of removing extracellular glutamate to protect neurons, transporters release glutamate, triggering neuronal death.	UCL, Dept Physiol, London WC1E 6BT, England; Shionogi & Co Ltd, Toyonaka, Osaka 561, Japan	University of London; University College London; Shionogi & Company Limited	Attwell, D (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	D.Attwell@ucl.ac.uk	Attwell, David/ABE-6750-2020					ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Basarsky TA, 1999, J NEUROSCI, V19, P6439; BEDNAR M M, 1992, Neurological Research, V14, P53; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FRIEDMAN JE, 1994, BRAIN RES, V663, P329, DOI 10.1016/0006-8993(94)91281-5; GUNDERSEN V, 1993, NEUROSCIENCE, V57, P97, DOI 10.1016/0306-4522(93)90114-U; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; JAHR CE, 1990, J NEUROSCI, V10, P3178; KATCHMAN AN, 1993, J NEUROPHYSIOL, V70, P1; LERMA J, 1992, MOL PHARMACOL, V41, P217; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MADL JE, 1993, J NEUROSCI, V13, P4429; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; PARPURA V, 1909, NATURE, V28, P159; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; SAH P, 1988, J GEN PHYSIOL, V92, P263, DOI 10.1085/jgp.92.2.263; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STORMMATHISEN J, 1992, PROG BRAIN RES, V94, P225; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; WALZ W, 1993, DEV NEUROSCI-BASEL, V15, P216, DOI 10.1159/000111337; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	30	870	909	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					316	321		10.1038/35002090	http://dx.doi.org/10.1038/35002090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659851				2022-12-24	WOS:000084899700054
J	Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S				Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S			A strong source of methyl chloride to the atmosphere from tropical coastal land	NATURE			English	Article							SOUTH-ATLANTIC; BIOSYNTHESIS; HALOMETHANES; METHANETHIOL; HALIDES	Methyl chloride (CH3Cl), the most abundant halocarbon in the atmosphere, has received much attention as a natural source of chlorine :atoms in the stratosphere(1,2). The annual global flux of CH3Cl has been estimated to be around 3.5 Tg on the grounds that this must balance the loss through reaction with OH radicals (which gives a lifetime for atmospheric CH3Cl of 1.5 yr)(3-5), The most likely main source of methyl chloride has been thought to be oceanic emission(2,6-8), with biomass burning the second largest source(9). But recent seawater measurements(10) indicate that oceanic fluxes cannot account for more than 12% of the estimated global flux of CH3Cl, raising the question of where the remainder comes from. Here we report evidence of significant CH3Cl emission from warm coastal land, particularly from tropical islands. This conclusion is based on a global monitoring study and spot measurements, which show enhancement of atmospheric CH3Cl in the tropics, a close correlation between CH3Cl concentrations and those of biogenic compounds emitted by terrestrial plants, and OH-linked seasonality of CH3Cl concentrations in middle and high latitudes, A strong, equatorially located source of this nature would explain why the distribution of CH3Cl is uniform between the Northern and Southern hemispheres, despite their differences in ocean and land area.	Natl Inst Environm Studies, Tsukuba, Ibaraki 3050053, Japan; Atmospher Environm Serv, Toronto, ON M3H 5T4, Canada; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Tohoku Univ, Ctr Atmospher & Ocean Studies, Aoba Ku, Sendai, Miyagi 9800845, Japan	National Institute for Environmental Studies - Japan; Environment & Climate Change Canada; Meteorological Service of Canada; University of Tokyo; Tohoku University	Yokouchi, Y (corresponding author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3050053, Japan.		Machida, Toshinobu/H-6526-2018; 陽子, 横内/E-8041-2010; Nojiri, Yukihiro/D-1999-2010	Machida, Toshinobu/0000-0003-3312-8775; Nojiri, Yukihiro/0000-0001-9885-9195				ATLAS E, 1993, J GEOPHYS RES-ATMOS, V98, P16933, DOI 10.1029/93JD01005; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; Blake NJ, 1996, J GEOPHYS RES-ATMOS, V101, P24151, DOI 10.1029/96JD00561; CICERONE RJ, 1981, REV GEOPHYS, V19, P123, DOI 10.1029/RG019i001p00123; Fabian P., 1986, AIR POLLUTION, P23, DOI [10.1007/978-3-540-39222-4_2, DOI 10.1007/978-3-540-39222-4_2]; GRAEDEL TE, 1995, GLOBAL BIOGEOCHEM CY, V9, P47, DOI 10.1029/94GB03103; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Khalil MAK, 1999, ATMOS ENVIRON, V33, P1305, DOI 10.1016/S1352-2310(98)00234-9; KOPPMANN R, 1993, J GEOPHYS RES-ATMOS, V98, P20517, DOI 10.1029/93JD01864; Li HJ, 1999, ATMOS ENVIRON, V33, P1881, DOI 10.1016/S1352-2310(98)00303-3; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; SINGH HB, 1983, J GEOPHYS RES-OCEANS, V88, P3684, DOI 10.1029/JC088iC06p03684; Yokouchi Y, 1999, J GEOPHYS RES-ATMOS, V104, P8067, DOI 10.1029/1998JD100013; YOKOUCHI Y, 1981, J CHROMATOGR, V209, P293, DOI 10.1016/S0021-9673(00)81591-5; Zimmerman P. R., 1979, EPA450479004	18	115	120	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					295	298		10.1038/35002049	http://dx.doi.org/10.1038/35002049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659845				2022-12-24	WOS:000084899700048
J	Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H				Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H			Measles history and atopic diseases - A population-based cross-sectional study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION PROGRAM; ASTHMA; INFECTIONS; CHILDHOOD; RUBELLA; FINLAND; MUMPS; CHILDREN; SIZE	Context Many recent cross-sectional studies have suggested that lack of early exposure to communicable diseases, including measles, in affluent countries may have increased rates of atopic disease. Objective To study the association between natural measles infection and atopy, Design and Setting Cross-sectional nationwide study in Finland using data gathered between November 1, 1982, and June 30, 1986. Subjects A total of 547 910 individuals aged 14 months to 19 years who at the time of measles-mumps-rubella (MMR) vaccination had relevant information collected on the occurrence of measles and allergic rhinitis, eczema, and asthma. Main Outcome Measures Lifetime occurrence of atopic manifestations in subjects who had had measles compared with those who had not, expressed as age-specific and age-adjusted prevalence ratios. Results The age-adjusted prevalence ratio of atopic manifestations among those who had had measles (n = 20 690) compared with those who had not (n = 527 220) was 1.32 (95% confidence interval [CI], 1.27-1.36) for eczema, 1.41 (95% CI, 1.33-1.49) for rhinitis, and 1.67 (95% CI, 1.54-1.79) for asthma. The positive association between measles and atopy was evident at all ages, in both urban and rural dwellers, and among subjects with many or few contacts at home or in day care. Conclusions Based on our data, measles and atopy occur more frequently together than expected, which does not support the hypothesis that experiencing natural measles infection offers protection against atopic disease.	Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Assoc Local & Reg Author, Dept Hosp Serv, Helsinki, Finland; Natl Publ Hlth Inst, Dept Infect Dis, Helsinki, Finland; Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Paunio, M (corresponding author), Minist Social Affairs & Hlth, POB 267, Helsinki 00171, Finland.							Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Campbell DE, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65244-0; *CENTR STAT OFF FI, 1987, STAT YB FINL 1987; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hayney M S, 1998, Int J Infect Dis, V2, P143, DOI 10.1016/S1201-9712(98)90116-3; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PELTOLA H, 1986, LANCET, V1, P137; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Soothill JF, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65245-2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	22	131	136	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					343	346		10.1001/jama.283.3.343	http://dx.doi.org/10.1001/jama.283.3.343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647796	Bronze			2022-12-24	WOS:000084732400025
J	Tateno, M; Nishida, Y; Adachi-Yamada, T				Tateno, M; Nishida, Y; Adachi-Yamada, T			Regulation of JNK by Src during Drosophila development	SCIENCE			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; CELL SHEET MOVEMENT; TYROSINE KINASE; C-SRC; DORSAL CLOSURE; MORPHOGENESIS; EXPRESSION; ACTIVATION; PP60C-SRC	In Drosophila, the Jun amino-terminal kinase (JNK) homolog Basket (Bsk) is required for epidermal closure. Mutants for Src42A, a Drosophila c-src protooncogene homolog, are described. Src42A functions in epidermal closure during both embryogenesis and metamorphosis. The severity of the epidermal closure defect in the Src42A mutant depended on the amount of Bsk activity, and the amount of Bsk activity depended. on the amount of Src42A. Thus, activation of the Bsk pathway is required downstream of Src42A in epidermal closure. This work confirms mammalian studies that demonstrated a physiological link between Src and JNK.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Adachi-Yamada, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	adachi@bio.nagoya-u.ac.jp						BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Dodson GS, 1998, DEVELOPMENT, V125, P2883; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lu XY, 1999, DEV BIOL, V208, P233, DOI 10.1006/dbio.1999.9196; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TATENO M, UNPUB; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947	36	113	114	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					324	327		10.1126/science.287.5451.324	http://dx.doi.org/10.1126/science.287.5451.324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634792				2022-12-24	WOS:000084769600047
J	Nakagawa, T; Zhu, H; Morishima, N; Li, E; Xu, J; Yankner, BA; Yuan, JY				Nakagawa, T; Zhu, H; Morishima, N; Li, E; Xu, J; Yankner, BA; Yuan, JY			Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta	NATURE			English	Article							CELL-DEATH; ALZHEIMERS-DISEASE; PROTEASE; RECEPTOR; PROTEINS; COMPLEX; ICE	Apoptosis, or cellular suicide, is important for normal development and tissue homeostasis, but too much or too Little apoptosis can also cause disease(1,2). The family of cysteine proteases, the so-called caspases, are critical mediators of programmed cell death(3), and thus far 14 family members have been identified. Some of these, such as caspase-(8) (refs 4, 5), mediate signal transduction downstream of death receptors located on the plasma membrane. Others, such as caspase-9 (ref. 6), mediate apoptotic signals after mitochondrial damage. Stress in the endoplasmic reticulum (ER) can also result in apoptosis(7). Here we show that caspase-12 is localized to the ER and activated by ER stress, including disruption of ER calcium homeostasis and accumulation of excess proteins in ER, but not by membrane- or mitochondrial-targeted apoptotic signals. Mice that are deficient in caspase-12 are resistant to ER stress-induced apoptosis, but their cells undergo apoptosis in response to other death stimuli. Furthermore, we show that caspase-12-deficient cortical neurons are defective in apoptosis induced by amyloid-beta protein but not by staurosporine or trophic factor deprivation. Thus, caspase-12 mediates an ER-specific apoptosis pathway and may contribute to amyloid-beta neurotoxicity.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; RIKEN, Inst Phys & Chem Res, Biodesign Res Grp, Wako, Saitama 3510198, Japan; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02119 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; RIKEN; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Morishima, Nobuhiro/D-3946-2017	Nakagawa, Toshiyuki/0000-0001-8415-4119; Xu, Jin/0000-0001-6617-5311; Zhu, Hong/0000-0002-2575-4031				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Troy CM, 1996, J NEUROSCI, V16, P253; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yan SD, 1997, NATURE, V389, P689; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	17	2775	3011	8	364	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					98	103		10.1038/47513	http://dx.doi.org/10.1038/47513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638761				2022-12-24	WOS:000084687400051
J	Botvinick, M; Nystrom, LE; Fissell, K; Carter, CS; Cohen, JD				Botvinick, M; Nystrom, LE; Fissell, K; Carter, CS; Cohen, JD			Conflict monitoring versus selection-for-action in anterior cingulate cortex	NATURE			English	Article							HUMAN-BRAIN; ACTIVATION; SYSTEM; PET	The anterior cingulate cortex (ACC), on the medial surface of the frontal lobes of the brain, is widely believed to be involved in the regulation of attention(1,2), Beyond this, however, its specific contribution to cognition remains uncertain, One influential theory has interpreted activation within the ACC as reflecting 'selection-for-action'(3-5), a set of processes that guide the selection of environmental objects as triggers of or targets for action. We have proposed an alternative hypothesis, in which the ACC serves not to exert top-down attentional control but instead to detect and signal the occurrence of conflicts in information processing(6-8). Here, to test this theory against the selection-for-action theory, we used functional magnetic resonance imaging to measure brain activation during performance of a task where, for a particular subset of trials, the strength of selection-for action is inversely related to the degree of response conflict. Activity within the ACC was greater during trials featuring high levels of conflict (and weak selection-for-action) than during trials with low levels of conflict (and strong selection-for-action), providing evidence in favour of the conflict-monitoring account of ACC function.	Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Botvinick, M (corresponding author), Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA.		Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026				Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Botvinick M. M., 1998, 981 CTR NEUR BAS COG; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CARTER CS, UNPUB P NATL ACAD SC; Casey BJ, 1998, J COGNITIVE NEUROSCI, V10, P108; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; COHEN JD, 1992, AM J PSYCHOL, V105, P239, DOI 10.2307/1423029; COLES MGH, 1985, J EXP PSYCHOL HUMAN, V11, P529, DOI 10.1037/0096-1523.11.5.529; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Posner MI, 1998, ATTENTIVE BRAIN, P401; Sanders Andries, 1987, PERSPECTIVES PERCEPT, P395; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	20	1560	1605	1	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					179	181		10.1038/46035	http://dx.doi.org/10.1038/46035			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	256FZ	10647008				2022-12-24	WOS:000083716400049
J	Meijers, JCM; Tekelenburg, WLH; Bouma, BN; Bertina, RM; Rosendaal, FR				Meijers, JCM; Tekelenburg, WLH; Bouma, BN; Bertina, RM; Rosendaal, FR			High levels of coagulation factor XI as a risk factor for venous thrombosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT KININOGEN; DEEP-VEIN THROMBOSIS; LEIDEN THROMBOPHILIA; BLOOD-COAGULATION; FIBRINOLYSIS INHIBITOR; ASHKENAZI JEWS; HUMAN PLASMA; DEFICIENCY; CARBOXYPEPTIDASE	Background: Factor XI, a component of the intrinsic pathway of coagulation, contributes to the generation of thrombin, which is involved in both the formation of fibrin and protection against fibrinolysis. A deficiency of factor XI is associated with bleeding, but a role of high factor XI levels in thrombosis has not been investigated. Methods: We determined factor XI antigen levels in the patients enrolled in the Leiden Thrombophilia Study, a large population-based, case-control study (with a total of 474 patients and 474 controls) designed to estimate the contributions of genetic and acquired factors to the risk of deep venous thrombosis. Odds ratios were calculated as a measure of relative risk. Results: The age- and sex-adjusted odds ratio for deep venous thrombosis in subjects who had factor XI levels above the 90th percentile, as compared with those who had factor XI levels at or below that value, was 2.2 (95 percent confidence interval, 1.5 to 3.2). There was a dose-response relation between the factor XI level and the risk of venous thrombosis. Adjustment of the odds ratios for other risk factors such as oral-contraceptive use, homocysteine, fibrinogen, factor VIII, female sex, and older age did not alter the result. Also, when we excluded subjects who had known genetic risk factors for thrombosis (e.g., protein C or S deficiency, antithrombin deficiency, the factor V Leiden mutation, or the prothrombin G20210A mutation), the odds ratio remained the same, indicating that the risk of venous thrombosis associated with elevated levels of factor XI was not the result of one of the known risk factors for thrombosis. Conclusions: High levels of factor XI are a risk factor for deep venous thrombosis, with a doubling of the risk at levels that are present in 10 percent of the population. (N Engl J Med 2000;342:696-701.) (C)2000, Massachusetts Medical Society.	Univ Med Ctr, Dept Hematol, Thrombosis & Hemostasis Lab, Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, Utrecht, Netherlands; Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Meijers, JCM (corresponding author), Acad Med Ctr, Dept Vasc Med, G1-143,POB 22660, NL-1100 DD Amsterdam, Netherlands.		Bertina, Rogier/AGQ-5246-2022; Rosendaal, Frits/Q-3842-2017; Meijers, J.C.M./S-5981-2019	Rosendaal, Frits/0000-0003-2558-7496; Meijers, J.C.M./0000-0002-4198-6780				ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; BERLINER S, 1992, BLOOD COAGUL FIBRIN, V3, P465, DOI 10.1097/00001721-199203040-00014; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOUMA BN, 1983, BLOOD, V62, P1123; Bouma BN, 1998, THROMB HAEMOSTASIS, V80, P24; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EATON DL, 1991, J BIOL CHEM, V266, P21833; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Minnema MC, 1998, J CLIN INVEST, V101, P10, DOI 10.1172/JCI781; Minnema MC, 1998, J CLIN INVEST, V101, P917; NAITO K, 1991, J BIOL CHEM, V266, P7353; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Oliver JA, 1999, ARTERIOSCL THROM VAS, V19, P170, DOI 10.1161/01.ATV.19.1.170; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SELIGSOHN U, 1993, THROMB HAEMOSTASIS, V70, P68; SELIGSOHN U, 1978, BLOOD, V51, P1223; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VONDEMBORNE PAK, 1994, THROMB HAEMOSTASIS, V72, P397; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517	33	488	539	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2000	342	10					696	701		10.1056/NEJM200003093421004	http://dx.doi.org/10.1056/NEJM200003093421004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ZW	10706899				2022-12-24	WOS:000085708800004
J	Gajiwala, KS; Chen, H; Cornille, F; Roques, BP; Reith, W; Mach, B; Burley, SK				Gajiwala, KS; Chen, H; Cornille, F; Roques, BP; Reith, W; Mach, B; Burley, SK			Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding	NATURE			English	Article							LINKER HISTONE H5; GLOBULAR DOMAIN; NUCLEOSOME BINDING; CRYSTAL-STRUCTURE; SITE; IDENTIFICATION; RECOGNITION; FAMILY; MOTIF; HEAD	Regulatory factor X (RFX) proteins are transcriptional activators that recognize X-boxes (DNA of the sequence 5'-GTNRCC(0-3N) RGYAAC-3', where N is any nucleotide, R is a purine and Y is a pyrimidine) using a highly conserved 76-residue DNA-binding domain (DBD). DNA-binding defects in the protein RFX5 cause bare lymphocyte syndrome or major histocompatibility antigen class II defciency(1), RFXI, -2 and -3 regulate expression of other medically important gene products (for example, interleukin-5 receptor alpha chain, IL-5R alpha)(2). Fusions of the ligand-binding domain of the oestrogen receptor with the DBD of RFX4 occur in some human breast tumours'. Here we present a 1.5 Angstrom-resolution structure of two copies of the DBD of human RFXI (hRFX1) binding cooperatively to a symmetrical X-box(4,5), hRFX1 is an unusual member of the winged-helix subfamily of helix-turn-helix proteins(6) because it uses a beta-hairpin (or wing) to recognize DNA instead of the recognition helix typical of helix-turn-helix proteins. A new model for interactions between linker histones and DNA is proposed.	Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; UFR Sci Pharmaceut & Biol, Dept Pharmacol Mol & Struct, CNRS,URA D1500, INSERM,U266, F-75720 Paris, France; Ctr Med Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Geneva	Burley, SK (corresponding author), Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Burley, Stephen K./0000-0002-2487-9713				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cornille F, 1998, NUCLEIC ACIDS RES, V26, P2143, DOI 10.1093/nar/26.9.2143; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Emery P, 1996, MOL CELL BIOL, V16, P4486; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Iwama A, 1999, MOL CELL BIOL, V19, P3940; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	25	261	272	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					916	921		10.1038/35002634	http://dx.doi.org/10.1038/35002634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706293				2022-12-24	WOS:000085559200064
J	Bochtler, M; Hartmann, C; Song, HK; Bourenkov, GP; Bartunik, HD; Huber, R				Bochtler, M; Hartmann, C; Song, HK; Bourenkov, GP; Bartunik, HD; Huber, R			The structures of HsIU and ATP-dependent protease HsIU-HsIV	NATURE			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; UBIQUITIN SYSTEM; 20S PROTEASOME; P-LOOP; DEGRADATION; PROTEINS; BINDING; CHAPERONES; RESOLUTION	The degradation of cytoplasmic proteins is an ATP-dependent process'. Substrates are targeted to a single soluble protease, the 26S proteasome(2,3), in eukaryotes and to a number of unrelated proteases in prokaryotes(4,5). A surprising Link emerged with the discovery of the ATP-dependent protease HslVU (heat shock locus VU)(6-8) in Escherichia coli. Its protease component HsIV shares similar to 20% sequence similarity(6) and a conserved fold(9) with 20S proteasome beta-subunits. HslU is a member of the Hsp100 (Clp) family of ATPases. Here we report the crystal structures of free HslU and an 820,000 relative molecular mass complex of HslU and HslV-the first structure of a complete set of components of an ATP-dependent protease. HslV and HslU display sixfold symmetry, ruling out mechanisms of protease activation that require a symmetry mismatch between the two components. Instead, there is conformational flexibility and domain motion in HslU and a localized order-disorder transition in HslV. Individual subunits of HslU contain two globular domains in relative orientations that correlate with nucleotide bound and unbound states. They are surprisingly similar to their counterparts in N-ethylmaleimide-sensitive fusion protein(10,11), the prototype of an AAA-ATPase. A third, mostly a-helical domain in HslU mediates the contact with HslV and may be the structural equivalent of the amino-terminal domains in proteasomal AAA-ATPases.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Gesell, Arbeitsgrp Strukturelle Mol Biol, D-22603 Hamburg, Germany	Max Planck Society; Max Planck Society	Bochtler, M (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	bochtler@bio-chem.mpg.de	Bourenkov, Gleb P/C-7794-2017; Song, Hyun Kyu/D-6763-2016; Bochtler, Matthias/A-4514-2010	Bourenkov, Gleb P/0000-0002-2617-5920; Song, Hyun Kyu/0000-0001-5684-4059; Bochtler, Matthias/0000-0001-7884-4463				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; Feng HP, 1998, CURR BIOL, V8, pR464, DOI 10.1016/S0960-9822(98)70294-5; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Huang HC, 1997, J BIOL CHEM, V272, P21364, DOI 10.1074/jbc.272.34.21364; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; Neuwald AF, 1999, GENOME RES, V9, P27; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	30	362	370	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					800	805		10.1038/35001629	http://dx.doi.org/10.1038/35001629			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693812				2022-12-24	WOS:000085423100059
J	Gylfe, A; Bergstrom, S; Lunstrom, J; Olsen, B				Gylfe, A; Bergstrom, S; Lunstrom, J; Olsen, B			Epidemiology - Reactivation of Borrelia infection in birds	NATURE			English	Article							BURGDORFERI SENSU-LATO		Umea Univ, Dept Microbiol, SE-90187 Umea, Sweden; Uppsala Univ, Dept Populat Biol, Evolutionary Biol Ctr, SE-75236 Uppsala, Sweden; Umea Univ, Dept Infect Dis, SE-90187 Umea, Sweden; Kalmar Cty Hosp, Dept Infect Dis, SE-39185 Kalmar, Sweden	Umea University; Uppsala University; Umea University	Gylfe, A (corresponding author), Umea Univ, Dept Microbiol, SE-90187 Umea, Sweden.	bjornol@ltkalmar.se		Olsen, Bjorn/0000-0002-4646-691X				Alerstam T, 1990, BIRD MIGRATION; Apanius V, 1998, ADV STUD BEHAV, V27, P133; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; Holberton RL, 1996, AUK, V113, P558, DOI 10.2307/4088976; Hubalek Z, 1998, J MED MICROBIOL, V47, P929, DOI 10.1099/00222615-47-10-929; Humair PF, 1998, ZBL BAKT-INT J MED M, V287, P521, DOI 10.1016/S0934-8840(98)80194-1; Kurtenbach K, 1998, APPL ENVIRON MICROB, V64, P1169; OLSEN B, 1995, APPL ENVIRON MICROB, V61, P3082; Raberg L, 1998, P ROY SOC B-BIOL SCI, V265, P1637, DOI 10.1098/rspb.1998.0482; WELTY JC, 1988, LIFE BIRDS, P119	11	134	138	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					724	725		10.1038/35001663	http://dx.doi.org/10.1038/35001663			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693792				2022-12-24	WOS:000085423100039
J	Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE				Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE			Population dynamical consequences of climate change for a small temperate songbird	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; ENVIRONMENTAL STOCHASTICITY	Predicting the effects of an expected climatic change requires estimates and modeling of stochastic factors as well as density-dependent effects in the population dynamics. In a population of a small songbird, the dipper (Cinclus cinclus), environmental stochasticity and density dependence both influenced the population growth rate. About half of the environmental variance was explained by variation in mean winter temperature. Including these results in a stochastic model shows that an expected change In climate will strongly affect the dynamics of the population, Leading to a nonlinear increase in the carrying capacity and in the expected mean population size.	Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Math Sci, N-7491 Trondheim, Norway; Aurebekk, N-4500 Mandal, Norway; Agr Univ Norway, Dept Biol & Nat Conservat, N-1432 As, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Life Sciences	Saether, BE (corresponding author), Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway.	Bernt-Erik.Sathere@chembio.ntnu.no	Tufto, Jarle/I-4817-2013					ATHREYA KB, 1971, ANN MATH STAT, V42, P1499, DOI 10.1214/aoms/1177693150; Bartlett MS., 1960, STOCHASTIC POPULATIO; Berger J.O., 2013, STAT DECISION THEORY; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Chatfield C., 1989, ANAL TIME SERIES INT; Corti S, 1999, NATURE, V398, P799, DOI 10.1038/19745; Crick HQP, 1997, NATURE, V388, P526, DOI 10.1038/41453; DUNHAM AE, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P95; Engen S, 1998, OIKOS, V83, P345, DOI 10.2307/3546848; Forchhammer MC, 1998, NATURE, V391, P29, DOI 10.1038/34070; Gilks W. R., 1996, MARKOV CHAIN MONTE C; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; Intergovernmental Panel on Climate Change, 1996, CLIM CHANG 1995 SCI; IVES AR, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P120; LAMB PJ, 1987, B AM METEOROL SOC, V68, P1218, DOI 10.1175/1520-0477(1987)068<1218:NAOCAA>2.0.CO;2; Lande R, 1999, AM NAT, V154, P271, DOI 10.1086/303240; Lande R, 1998, OIKOS, V83, P353, DOI 10.2307/3546849; MAY RM, 1973, AM NAT, V107, P621, DOI 10.1086/282863; McCleery RH, 1998, NATURE, V391, P30, DOI 10.1038/34073; Newton I., 1998, POPULATION LIMITATIO; ORMEROD SJ, 1994, DIPPERS; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Ranta E, 1998, ENVIRONM INTELL UNIT, P47; ROGERS JC, 1984, MON WEATHER REV, V112, P1999, DOI 10.1175/1520-0493(1984)112<1999:TABTNA>2.0.CO;2; Saether BE, 1997, TRENDS ECOL EVOL, V12, P143, DOI 10.1016/S0169-5347(96)10068-9; Saether BE, 1998, AM NAT, V151, P441, DOI 10.1086/286131; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Solbreck Christer, 1995, P279, DOI 10.1016/B978-012159270-7/50015-4; SPIEGELHALTER DJ, 1996, BUGS 5 0 BAYESIAN IN; Tufto J, 2000, OIKOS, V88, P273, DOI 10.1034/j.1600-0706.2000.880205.x; Turchin Peter, 1995, P19, DOI 10.1016/B978-012159270-7/50003-8	33	252	256	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					854	856		10.1126/science.287.5454.854	http://dx.doi.org/10.1126/science.287.5454.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657299				2022-12-24	WOS:000085136400046
J	Chen, CK; Burns, ME; He, W; Wensel, TG; Baylor, DA; Simon, MI				Chen, CK; Burns, ME; He, W; Wensel, TG; Baylor, DA; Simon, MI			Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1	NATURE			English	Article							PHOTORECEPTOR G-PROTEIN; CGMP PHOSPHODIESTERASE; TARGET ENZYME; GAMMA-SUBUNIT; RETINAL RODS; TRANSDUCIN; PHOTOTRANSDUCTION; DEACTIVATION; ACTIVATION; EXPRESSION	Timely deactivation of the alpha-subunit of the rod G-protein transducin (G alpha t) is essential for the temporal resolution of rod vision(1). Regulators of G-protein signalling (RGS) proteins accelerate hydrolysis of GTP by the alpha-subunits of heterotrimeric G proteins(2-4) in vitro. Several retinal RGS proteins can act in vitro as GTPase accelerating proteins (GAP) for G alpha t(5-8). Recent reconstitution experiments indicate that one of these, RGS9-1, may account for much of the G alpha t GAP activity in rod outer segments (ROS)(8,9). Here we report that ROS membranes from mice lacking RGS9-1 hydrolyse GTP more slowly than ROS membranes from control mice. The G beta 5-L protein that forms a complex with RGS9-1 (ref. 10) was absent from RGS9(-/-) retinas, although G beta 5-L messenger RNA was still present. The flash responses of RGS9(-/-) rods rose normally, but recovered much more slowly than normal. We conclude that RGS9-1, probably in a complex with G beta 5-L, is essential for acceleration of hydrolysis of GTP by G alpha t and for normal recovery of the photoresponse.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Stanford Univ, Med Ctr, Dept Neurobiol, Stanford, CA 94305 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	California Institute of Technology; Stanford University; Baylor College of Medicine	Simon, MI (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Wensel, Theodore/0000-0003-3518-9352				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Makino CL, 1998, PHOTOSTASIS AND RELATED PHENOMENA, P129; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PAGES F, 1992, J BIOL CHEM, V267, P22018; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rieke F, 1998, REV MOD PHYS, V70, P1027, DOI 10.1103/RevModPhys.70.1027; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Wieland T, 1997, J BIOL CHEM, V272, P8853; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	30	315	320	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					557	560		10.1038/35000601	http://dx.doi.org/10.1038/35000601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676965				2022-12-24	WOS:000085227300053
J	Jiang, Y; Haxby, JV; Martin, A; Ungerleider, LG; Parasuraman, R				Jiang, Y; Haxby, JV; Martin, A; Ungerleider, LG; Parasuraman, R			Complementary neural mechanisms for tracking items in human working memory	SCIENCE			English	Article							PREFRONTAL CORTEX; RETRIEVAL; FMRI	Recognition of a specific visual target among equally familiar distracters requires neural mechanisms for tracking items in working memory. Event-related functional magnetic resonance imaging revealed evidence for two such mechanisms: (i) Enhanced neural responses, primarily in the frontal cortex, were associated with the target and were maintained across repetitions of the target. (ii) Reduced responses, primarily in the extrastriate visual cortex, were associated with stimulus repetition, regardless of whether the stimulus was a target or a distracter, These complementary neural mechanisms track the status of familiar items in working memory, allowing for the efficient recognition of a currently relevant object and rejection of irrelevant distracters.	NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA; Catholic Univ Amer, Cognit Sci Lab, Washington, DC 20064 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Catholic University of America	Jiang, Y (corresponding author), NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.		martin, alex/B-6176-2009	JIANG, Yang/0000-0003-4589-0097	NIA NIH HHS [AG07569] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002035, Z01MH002588, ZIAMH002588, ZIAMH002035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Clark VP, 1998, J NEUROPHYSIOL, V79, P3257, DOI 10.1152/jn.1998.79.6.3257; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; DEMB JB, 1995, J NEUROSCI, V15, P5870; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Haxby JV, 1999, NEURON, V22, P189, DOI 10.1016/S0896-6273(00)80690-X; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; HAXBY JV, MAPPING MODELING HUM; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; Miller EK, 1996, J NEUROSCI, V16, P5154; Parasuraman R, 1998, ATTENTIVE BRAIN, P3; Schacter DL, 1998, PHILOS T ROY SOC B, V353, P1861, DOI 10.1098/rstb.1998.0338; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Suzuki WA, 1999, NEURON, V24, P295, DOI 10.1016/S0896-6273(00)80844-2; Talairach J., 1988, COPLANAR STEREOTAXIC; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X	21	141	157	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					643	646		10.1126/science.287.5453.643	http://dx.doi.org/10.1126/science.287.5453.643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649996				2022-12-24	WOS:000084989400045
J	Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM				Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM			Design of single-layer beta-sheets without a hydrophobic core	NATURE			English	Article							ROTATIONAL DIFFUSION ANISOTROPY; HETERONUCLEAR NMR-SPECTROSCOPY; BORRELIA-BURGDORFERI OSPA; PROTEIN DESIGN; STRUCTURAL CHARACTERIZATION; BACKBONE DYNAMICS; RELAXATION; N-15; SCATTERING; DOMAIN	The hydrophobic effect is the main thermodynamic driving force in the folding of water-soluble proteins(1,2), Exclusion of nonpolar moieties from aqueous solvent results in the formation of a hydrophobic core in a protein, which has been generally considered essential for specifying and stabilizing the folded structures of proteins(1-6). Outer surface protein A (OspA) from Borrelia burgdorferi contains a three-stranded beta-sheet segment which connects two globular domains(7). Although this single-layer beta- sheet segment is exposed to solvent on both faces and thus does not contain a hydrophobic core, the segment has a high conformational stability(8), Here we report the engineering of OspA variants that contain larger single-layer beta-sheets (comprising five and seven beta-strands) by duplicating a beta-hairpin unit within the beta-sheet, Nuclear magnetic resonance and small-angle X-ray scattering analyses reveal that these extended single-layer beta-sheets are formed as designed, and amide hydrogen-deuterium exchange and chemical denaturation show that they are stable. Thus, interactions within the beta-hairpin unit and those between adjacent units, which do not involve the formation of a hydrophobic core, are sufficient to specify and stabilize the single-layer beta-sheet structure. Our results provide an expanded view of protein folding, misfolding and design.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	University of Rochester; Yale University	Koide, S (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.							Beasley JR, 1997, J BIOL CHEM, V272, P2031, DOI 10.1074/jbc.272.4.2031; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bu ZM, 1998, PROTEIN SCI, V7, P2681, DOI 10.1002/pro.5560071223; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Kataoka M, 1997, PROTEIN SCI, V6, P422; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koide S, 1999, BIOCHEMISTRY-US, V38, P4757, DOI 10.1021/bi982443+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacroix E, 1999, CURR OPIN STRUC BIOL, V9, P487, DOI 10.1016/S0959-440X(99)80069-4; LATTMAN EE, 1994, CURR OPIN STRUC BIOL, V4, P87, DOI 10.1016/S0959-440X(94)90064-7; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pham TN, 1998, NAT STRUCT BIOL, V5, P115, DOI 10.1038/nsb0298-115; Pham TN, 1998, J BIOMOL NMR, V11, P407, DOI 10.1023/A:1008246908142; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; WISCHART DS, 1994, J BIOMOL NMR, V4, P171	30	47	49	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					456	460		10.1038/35000255	http://dx.doi.org/10.1038/35000255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667801				2022-12-24	WOS:000085121100057
J	Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX				Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX			Materials - Creating the narrowest carbon nanotubes	NATURE			English	Article									Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Physics, CAS	Sun, LF (corresponding author), Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, POB 603, Beijing 100080, Peoples R China.							AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; Chang BH, 1998, SCI CHINA SER A, V41, P431, DOI 10.1007/BF02879035; Endo M., 1996, CARBON NANOTUBES; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Piskoti C, 1998, NATURE, V393, P771, DOI 10.1038/31668; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R	7	136	153	4	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					384	384		10.1038/35000290	http://dx.doi.org/10.1038/35000290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667781	Bronze			2022-12-24	WOS:000085121100037
J	Kawai, N; Matsuzawa, T				Kawai, N; Matsuzawa, T			Cognition - Numerical memory span in a chimpanzee	NATURE			English	Article							PAN-TROGLODYTES		Kyoto Univ, Primate Res Inst, Aichi 4848506, Japan	Kyoto University	Kawai, N (corresponding author), Kyoto Univ, Primate Res Inst, Aichi 4848506, Japan.		Kawai, Nobuyuki/M-4902-2014	Kawai, Nobuyuki/0000-0003-0372-1703				Biro D, 1999, J COMP PSYCHOL, V113, P178, DOI 10.1037/0735-7036.113.2.178; Boysen ST, 1999, ANIM LEARN BEHAV, V27, P229, DOI 10.3758/BF03199679; Brannon EM, 1998, SCIENCE, V282, P746, DOI 10.1126/science.282.5389.746; MATSUZAWA T, 1985, NATURE, V315, P57, DOI 10.1038/315057a0; MATSUZAWA T, 1991, PRIMATOLOGY TODAY, P317; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Murofushi K, 1997, JPN PSYCHOL RES, V39, P140, DOI 10.1111/1468-5884.00050; RUMBAUGH DM, 1987, J EXP PSYCHOL ANIM B, V13, P107, DOI 10.1037/0097-7403.13.2.107; Tomonaga M., 1993, PRIMATE RES, V9, P67; TOMONAGA M, IN PRESS ANIM COGN	10	125	129	2	46	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					39	40		10.1038/47405	http://dx.doi.org/10.1038/47405			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	273BM	10638743				2022-12-24	WOS:000084687400033
J	Williams, KA				Williams, KA			Three-dimensional structure of the ion-coupled transport protein NhaA	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; NA+/H+ ANTIPORTER; ESCHERICHIA-COLI; WATER CHANNEL; RESOLUTION; BACTERIORHODOPSIN; CRYOMICROSCOPY; CONFORMATION; AQUAPORIN-1	Ion-coupled membrane-transport proteins, or secondary transporters, comprise a diverse and abundant group of membrane proteins that are found in all organisms. These proteins facilitate solute accumulation and toxin removal against concentration gradients using energy supplied by ion gradients across membranes. NhaA is a Na+/H+ antiporter of relative molecular mass 42,000, which is found in the inner membrane of Escherichia coli, and which has been cloned and characterized(1,2). NhaA uses the H+ electrochemical gradient to expel Na+ from the cytoplasm, and functions primarily in the adaptation to high salinity at alkaline pH(1,2). Most secondary transporters, including NhaA(3), are predicted to have 12 transmembrane helices. Here we report the structure of NhaA, at 7 Angstrom resolution in the membrane plane and at 14 Angstrom vertical resolution, determined from two-dimensional crystals(4) using electron cryo-microscopy. The three-dimensional map of NhaA reveals 12 tilted, bilayer-spanning helices. A roughly linear arrangement of six helices is adjacent to a compact bundle of six helices, with the density for one helix in the bundle not continuous through the membrane. The molecular organization of NhaA represents a new membrane-protein structural motif and offers the first insights into the architecture of an ion-coupled transport protein.	Max Planck Inst Biophys, Dept Biol Struct, D-60528 Frankfurt, Germany	Max Planck Society	Williams, KA (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.							Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P899; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; Padan E, 1999, NOVART FDN SYMP, V221, P183; Padan E., 1996, HDB BIOL PHYS, V2, P501; PERUSE E, 1999, SCIENCE, V285, P73; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, P879; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	30	192	195	1	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					112	115		10.1038/47534	http://dx.doi.org/10.1038/47534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638764				2022-12-24	WOS:000084687400054
J	Henney, JE				Henney, JE			FDA's proposed strategy on reuse of single-use devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-24	WOS:000084514400007
J	Brahams, D				Brahams, D			End of compensation for unwanted healthy children	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Sq Chambers, London WC1R 5LQ, England.							JOHNSTONE H, 1999, TIMES           1126; 1999, TIMES           1126	2	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1924	1924		10.1016/S0140-6736(99)00434-1	http://dx.doi.org/10.1016/S0140-6736(99)00434-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622293				2022-12-24	WOS:000084034700007
J	Vazquez-Torres, A; Xu, YS; Jones-Carson, J; Holden, DW; Lucia, SM; Dinauer, MC; Mastroeni, P; Fang, FC				Vazquez-Torres, A; Xu, YS; Jones-Carson, J; Holden, DW; Lucia, SM; Dinauer, MC; Mastroeni, P; Fang, FC			Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase	SCIENCE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; III SECRETION SYSTEM; NITRIC-OXIDE; MYCOBACTERIUM-TUBERCULOSIS; SUPEROXIDE PRODUCTION; BACTERIAL VIRULENCE; RADICAL PRODUCTION; RESPIRATORY BURST; HOST-CELLS; TYPHIMURIUM	A type III protein secretion system encoded by Salmonella pathogenicity island 2 (SPI2) has been found to be required for virulence and survival within macrophages. Here, SPI2 was shown to allow Salmonella typhimurium to avoid NADPH oxidase-dependent killing by macrophages. The ability of SPI2-mutant bacteria to survive in macrophages and to cause Lethal infection in mice was restored by abrogation of the NADPH oxidase-dependent respiratory burst. Ultrastructural and immunofluorescence microscopy demonstrated efficient Localization of the NADPH oxidase in the proximity of vacuoles containing SPI2-mutant but not wild-type bacteria, suggesting that SPI2 interferes with trafficking of oxidase-containing vesicles to the phagosome.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, London W12 0NN, England; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2BZ, England	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Imperial College London; Indiana University System; Indiana University-Purdue University Indianapolis; Imperial College London	Fang, FC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.		Timms, Andrew/K-2380-2019	Timms, Andrew/0000-0001-7439-1073; Mastroeni, Pietro/0000-0003-3838-4962; Fang, Ferric/0000-0002-3243-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044486, R01AI039557, R21AI039557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39557, AI44486] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen LAH, 1999, BLOOD, V93, P3521, DOI 10.1182/blood.V93.10.3521.410k21_3521_3530; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; BRIGGS RT, 1975, J CELL BIOL, V67, P566, DOI 10.1083/jcb.67.3.566; BUCHMEIER NA, 1995, J CLIN INVEST, V95, P1047, DOI 10.1172/JCI117750; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Dusi S, 1996, J IMMUNOL, V157, P4615; Fang FC, 1997, INFECT IMMUN, V65, P5371, DOI 10.1128/IAI.65.12.5371-5375.1997; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; Kobayashi T, 1998, J CELL SCI, V111, P81; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MASTROENI P, UNPUB; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; OBRIEN S, 1991, MICROB PATHOGENESIS, V10, P199, DOI 10.1016/0882-4010(91)90054-E; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Taylor PD, 1998, INFECT IMMUN, V66, P3208, DOI 10.1128/IAI.66.7.3208-3217.1998; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; VanCott JL, 1998, NAT MED, V4, P1247, DOI 10.1038/3227; VAZQUEZTORRES A, UNPUB; WILES ME, 1995, LIFE SCI, V57, P1533, DOI 10.1016/0024-3205(95)02114-X; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	45	432	441	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1655	1658		10.1126/science.287.5458.1655	http://dx.doi.org/10.1126/science.287.5458.1655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698741				2022-12-24	WOS:000085628200039
J	Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW				Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW			Requirement for DARPP-32 in progesterone-facilitated sexual receptivity in female rats and mice	SCIENCE			English	Article							REGULATED NEURONAL PHOSPHOPROTEIN; CYCLIC-AMP; PROTEIN PHOSPHATASE-1; OVARIECTOMIZED RATS; DOPAMINE; BEHAVIOR; RECEPTOR; PHOSPHORYLATION; ACTIVATION; LORDOSIS	DARPP-32, a dopamine- and adenosine 3',5'-monophosphate (cAMP)-regulated phosphoprotein (32 kilodaltons in size), is an obligate intermediate in progesterone (P)-facilitated sexual receptivity in female rats and mice. The facilitative effect of P on sexual receptivity in female rats was blocked by antisense oligonucleotides to DARPP-32. Homozygous mice carrying a null mutation for the DARPP-32 gene exhibited minimal levels of P-facilitated sexual receptivity when compared to their wild-type Littermates. P significantly increased hypothalamic cAMP levels and cAMP-dependent protein kinase activity. These increases were not inhibited by a D-1 subclass dopamine receptor antagonist. P also enhanced phosphorylation of DARPP-32 on threonine 34 in the hypothalamus of mice. DARPP-32 activation is thus an obligatory step in progestin receptor regulation of sexual receptivity in rats and mice.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA	Baylor College of Medicine; Rockefeller University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of Texas System	Mani, SK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	smani@bcm.tmc.edu	O'Callaghan, James/O-2958-2013		NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH057442, R01MH057442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHS [MH49662, MH57442] Funding Source: Medline; NINDS NIH HHS [NS 35457] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN PB, UNPUB; Apostolakis EM, 1996, J NEUROSCI, V16, P4823; BEYER C, 1986, ANN NY ACAD SCI, V474, P270, DOI 10.1111/j.1749-6632.1986.tb28018.x; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; KIMURA F, 1980, ENDOCRINOLOGY, V106, P631, DOI 10.1210/endo-106-2-631; Kohlert JG, 1997, HORM BEHAV, V32, P143, DOI 10.1006/hbeh.1997.1415; Kow L, 1994, NEUROSCI BIOBEHAV R, V18, P1; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANI SK, 1994, ENDOCRINOLOGY, V135, P1409, DOI 10.1210/en.135.4.1409; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; Meredith JM, 1998, J NEUROSCI, V18, P10189; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; Nishi A, 1997, J NEUROSCI, V17, P8147; OCALLAGHAN JP, 1983, BRAIN RES BULL, V11, P31, DOI 10.1016/0361-9230(83)90054-0; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; SNYDER GL, 1994, J NEUROCHEM, V63, P1766; VATHY I, 1989, J NEUROENDOCRINOL, V1, P383, DOI 10.1111/j.1365-2826.1989.tb00133.x; WHALEN RE, 1986, NEUROSCI BIOBEHAV R, V10, P47, DOI 10.1016/0149-7634(86)90032-1; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WISE PM, 1981, ENDOCRINOLOGY, V108, P2186, DOI 10.1210/endo-108-6-2186	29	105	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1053	1056		10.1126/science.287.5455.1053	http://dx.doi.org/10.1126/science.287.5455.1053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669419				2022-12-24	WOS:000085245400051
J	Hoffman, GR; Nassar, N; Cerione, RA				Hoffman, GR; Nassar, N; Cerione, RA			Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI	CELL			English	Article							GDP-DISSOCIATION INHIBITOR; GUANINE-NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; RAS; GTPASES; PROGRAM; DOMAIN; CYTOSKELETON; ACTIVATION; ANALOG	The RhoGDI proteins serve as key multifunctional regulators of Rho family GTP-binding proteins. The 2.6 Angstrom X-ray crystallographic structure of the Cdc42/RhoGDI complex reveals two important sites of interaction between GDI and Cdc42. First, the amino-terminal regulatory arm of the GDI binds to the switch I and II domains of Cdc42 leading to the inhibition of both GDP dissociation and GTP hydrolysis. Second, the geranylgeranyl moiety of Cdc42 inserts into a hydrophobic pocket within the immunoglobulin-like domain of the GDI molecule leading to membrane release. The structural data demonstrate how GDIs serve as negative regulators of small GTP-binding proteins and how the isoprenoid moeity is utilized in this critical regulatory interaction.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NEI NIH HHS [EY-06429] Funding Source: Medline; NIGMS NIH HHS [GM-47458] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Gillilan R. E., 1995, Computer Graphics, V29, P55, DOI 10.1145/204362.204376; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HORI Y, 1991, ONCOGENE, V6, P515; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153	40	410	419	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					345	356		10.1016/S0092-8674(00)80670-4	http://dx.doi.org/10.1016/S0092-8674(00)80670-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676816	Bronze			2022-12-24	WOS:000085204400008
J	Richens, J; Imrie, J; Copas, A				Richens, J; Imrie, J; Copas, A			Condoms and seat belts: the parallels and the lessons	LANCET			English	Editorial Material							BEHAVIORAL INTERVENTIONS; HIV-INFECTION; LEGISLATION; THAILAND; MEN; PREVENTION; DECLINE; SEX; GAY		UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Richens, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, Mortimer Market, London WC1E 6AU, England.	jrichens@gum.ucl.ac.uk	Richens, John/C-1876-2008	Copas, Andrew/0000-0001-8968-5963				Adams J., 1995, RISK, V1st ed.; Adams J., 1985, RISK FREEDOM RECORD; ADAMS JGU, 1994, SAFETY SCI, V18, P135, DOI 10.1016/0925-7535(94)90022-1; Aral SO, 1998, LANCET, V351, P33; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; Brody S, 1996, NEW ENGL J MED, V335, P1998, DOI 10.1056/NEJM199612263352614; COHEN DA, 1992, SEX TRANSM DIS, V19, P245, DOI 10.1097/00007435-199209000-00002; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Evans L., 1991, TRAFFIC SAFETY DRIVE; HARVEY AC, 1986, J ROY STAT SOC A STA, V149, P187, DOI 10.2307/2981553; Hopperus Buma A. P. C. C., 1995, Genitourinary Medicine, V71, P172; Janssen W, 1991, 1991C15 IZF TNO I PE; Kalichman SC, 1998, AM J PREV MED, V15, P120, DOI 10.1016/S0749-3797(98)00037-3; Kelly JA, 1998, AIDS, V12, pF91, DOI 10.1097/00002030-199810000-00001; MCCARTHY M, 1989, J EPIDEMIOL COMMUN H, V43, P218, DOI 10.1136/jech.43.3.218; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Organization for Economic Cooperation and Development, 1990, BEH AD CHANG ROAD TR; OTTEN MW, 1993, AM J PUBLIC HEALTH, V83, P529, DOI 10.2105/AJPH.83.4.529; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; SHRADERFRESHETT.KS, 1990, RISK HLTH SAFETY ENV, V1, P34; Smeed R. J., 1970, TRAFFIC ENG CONTROL, V12, P150; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; Wilde G. J. S., 1994, TARGET RISK; 1986, LANCET, V1, P75	26	100	101	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					400	403		10.1016/S0140-6736(99)09109-6	http://dx.doi.org/10.1016/S0140-6736(99)09109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665571				2022-12-24	WOS:000085122100039
J	Hayflick, L				Hayflick, L			New approaches to old age - To truly understand ageing, we must look beyond the diseases of old age.	NATURE			English	Editorial Material									Univ Calif San Francisco, Dept Anat, Sea Ranch, CA 95497 USA	University of California System; University of California San Francisco	Hayflick, L (corresponding author), Univ Calif San Francisco, Dept Anat, POB 89, Sea Ranch, CA 95497 USA.		Hayflick, Leonard/AAW-2460-2020						0	39	44	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					365	365		10.1038/35000303	http://dx.doi.org/10.1038/35000303			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667768	Bronze			2022-12-24	WOS:000085121100023
J	Robzyk, K; Recht, L; Osley, MA				Robzyk, K; Recht, L; Osley, MA			Rad6-dependent ubiquitination of histone H2B in yeast	SCIENCE			English	Article							CONJUGATING ENZYME RAD6; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; CHROMATIN MODIFICATION; PROTEIN-DEGRADATION; CRYSTAL-STRUCTURE; GENE; MUTATIONS; TRANSCRIPTION; NUCLEOSOMES	Although ubiquitinated histones are present in substantial Levels in vertebrate cells, the roles they play in specific biological processes and the cellular factors that regulate this modification are not well characterized. Ubiquitinated H2B (uH2B) has been identified in the yeast Saccharomyces cerevisiae, and mutation of the conserved ubiquitination site is shown to confer defects in mitotic cell growth and meiosis. uH2B was not detected in rad6 mutants, which are defective for the ubiquitin-conjugating enzyme Ubc2, thus identifying Rad6 as the major cellular activity that ubiquitinates H2B in yeast.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Osley, MA (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.			Recht, Judith/0000-0003-3572-0457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40118, R01 GM040118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; Chen HY, 1998, J BIOL CHEM, V273, P13165, DOI 10.1074/jbc.273.21.13165; DAVIE JR, 1991, BIOCHEM CELL BIOL, V69, P66, DOI 10.1139/o91-009; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DAVIE JR, 1994, BIOCHEM BIOPH RES CO, V203, P344, DOI 10.1006/bbrc.1994.2188; Dor Y, 1996, MOL MICROBIOL, V21, P1197, DOI 10.1046/j.1365-2958.1996.671433.x; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1991, J BIOL CHEM, V266, P4104; HENSOLD JO, 1988, BLOOD, V71, P1153; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KANG XL, 1992, GENETICS, V130, P285; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LIEBMAN SW, 1993, GENETICS, V133, P499; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; RABOY B, 1994, EUR J BIOCHEM, V221, P247, DOI 10.1111/j.1432-1033.1994.tb18735.x; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; ROBZYK K, UNPUB; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SIEDE W, 1988, RADIAT ENVIRON BIOPH, V27, P277, DOI 10.1007/BF01209756; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Storchova Z, 1998, MOL GEN GENET, V258, P546, DOI 10.1007/s004380050766; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; VANHOLDE KE, 1988, CHROMATIN, P111; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VASSILEV AP, 1995, J CELL SCI, V108, P1205; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP., 1998, CHROMATIN STRUCTURE; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271	47	503	521	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					501	504		10.1126/science.287.5452.501	http://dx.doi.org/10.1126/science.287.5452.501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642555				2022-12-24	WOS:000084929900053
J	Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS				Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS			Molecular basis of a yeast prion species barrier	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; AMYLOID FIBRILS; RELEASE FACTOR; IN-VITRO; PROTEIN; PSI; PROPAGATION; DETERMINANT; MICROSCOPY	The yeast [PSI+] factor is inherited by a prion mechanism involving self-propagating Sup35p aggregates. We find that Sup35p prion function is conserved among distantly related yeasts. As with mammalian prions, a species barrier inhibits prion induction between Sup35p from different yeast species. This barrier is faithfully reproduced in vitro where, remarkably, ongoing polymerization of one Sup35p species does not affect conversion of another. Chimeric analysis identifies a short domain sufficient to allow foreign Sup35p to cross this barrier. These observations argue that the species barrier results from specificity in the growing aggregate, mediated by a well-defined epitope on the amyloid surface and, together with our identification of a novel yeast prion domain, show that multiple prion-based heritable states can propagate independently within one cell.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu		Weissman, Jonathan/0000-0003-2445-670X				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Bailleul PA, 1999, GENETICS, V153, P81; Bates GP, 1998, BIOCHEM SOC T, V26, P471, DOI 10.1042/bst0260471; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1996, GENETICS, V144, P1375; DOEL SM, 1994, GENETICS, V137, P659; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KURTZMAN CP, 1994, YEAST, V10, P1727, DOI 10.1002/yea.320101306; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	37	231	235	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					277	288		10.1016/S0092-8674(00)81565-2	http://dx.doi.org/10.1016/S0092-8674(00)81565-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660050	Bronze			2022-12-24	WOS:000084932200011
J	Ebrahim, SH; Floyd, RL; Merritt, RK; Decoufle, P; Holtzman, D				Ebrahim, SH; Floyd, RL; Merritt, RK; Decoufle, P; Holtzman, D			Trends in pregnancy-related smoking rates in the United States, 1987-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CESSATION; INTERVENTIONS; METAANALYSIS; PEOPLE	Context Rates of smoking are increasing among adolescents and young adults, but trends in smoking among pregnant women have not been studied, Objective To assess pregnancy-related variations in smoking behaviors and their determinants among women of childbearing age in the United States, Design Analysis of data collected between 1987-1996 from the Behavioral Risk Factor Surveillance System survey. Setting and Subjects A total of 187 302 (178 499 nonpregnant and 8803 pregnant) noninstitutionalized women aged 18 to 44 years from 33 states. Main Outcome Measures Prevalence rates of smoking initiation and current smoking, median number of cigarettes smoked, and adjusted odds ratios for smoking stratified by pregnancy status; prevalence rate ratio for current smoking comparing pregnant with nonpregnant women, Results The overall percentage of women who had ever initiated smoking decreased significantly from 44.1% in 1987 to 38.2% in 1996, During that 10-year period, the prevalence of current smoking also decreased significantly among both pregnant women (16.3% to 11.8%) and nonpregnant women (26.7% to 23.6%), Overall, pregnant women were about half (54%) as likely as nonpregnant women to be current smokers during 1987-1996. Over time, the median number of cigarettes smoked per day by pregnant smokers remained at 10, whereas among nonpregnant smokers it decreased from 19 to 15 (P<.05 for trend). in the same period, among young women (aged 18-20 years), prevalence rates of smoking initiation and current smoking increased slightly, Sociodemographic subgroups of women at increased risk for current smoking were the same for pregnant and nonpregnant women tie, those with a completed high school education or less, whites, and those who were unmarried). Conclusions In this analysis, the decline in smoking over time among pregnant women was primarily due to the overall decline in smoking initiation rates among women of childbearing age, not to an increased rate of smoking cessation related to pregnancy. To foster effective perinatal tobacco control, efforts are needed to further reduce the number of young women who begin smoking. Clinicians should query all pregnant women and women of childbearing age about smoking and provide cessation and relapse interventions to each smoker.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Ebrahim, SH (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.							Appleton PL, 1998, BRIT J HEALTH PSYCH, V3, P361, DOI 10.1111/j.2044-8287.1998.tb00580.x; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1048; Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, 1989, DHHS PUBL, V(CDC) 89-8411; Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P504; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P537; DiFranza JR, 1996, PEDIATRICS, V97, P560; DOLANMULLEN P, 1994, AM J OBSTET GYNECOL, V171, P1328, DOI 10.1016/0002-9378(94)90156-2; Evans WN, 1999, J PUBLIC ECON, V72, P135, DOI 10.1016/S0047-2727(98)00090-5; FERGUSSON DM, 1993, PEDIATRICS, V92, P815; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Fiore MC, 1996, AHCPR PUBLICATION, V96-0692; Grant TM, 1996, AM J PUBLIC HEALTH, V86, P1816; HOLLIS JF, 1993, ANN INTERN MED, V118, P521, DOI 10.7326/0003-4819-118-7-199304010-00006; Hurt RD, 1999, B WORLD HEALTH ORGAN, V77, P367; Kendrick JS, 1996, AM J OBSTET GYNECOL, V175, P528; Klerman LV, 1999, J NURSE-MIDWIFERY, V44, P118, DOI 10.1016/S0091-2182(99)00031-2; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; LECLERE FB, 1997, ADV DATA VITAL HLTH, V288; McBride CM, 1999, AM J PUBLIC HEALTH, V89, P706, DOI 10.2105/AJPH.89.5.706; *NCI, 1994, MONOGR NCI, V5, P1; OWEN L, 1999, SMOKING PREGNANCY SU; *PHS, 1991, DHHS PUBL; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; SHAH BV, 1996, SUDAAN COMP SOFTW VE; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; U.S. Bureau of the Census, 1997, STAT ABSTR US 1997; *US DEP HHS, 1998, TARG TOB US NAT LEAD; *US DEP HHS, 1994, PREV TOB US YOUNG PE; Vartiainen E, 1998, AM J PUBLIC HEALTH, V88, P81, DOI 10.2105/AJPH.88.1.81; VENTURA SJ, 1997, REPORT FINAL NATALIT, P11; Wechsler H, 1998, JAMA-J AM MED ASSOC, V280, P1673, DOI 10.1001/jama.280.19.1673; [No title captured]	32	175	181	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					361	366		10.1001/jama.283.3.361	http://dx.doi.org/10.1001/jama.283.3.361			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	273WM	10647799	Bronze			2022-12-24	WOS:000084732400028
J	Perry, D				Perry, D			Patients' voices: The powerful sound in the stem cell debate	SCIENCE			English	Editorial Material								Millions of patients may benefit from the applications of stem cell research, although there is disagreement about whether public funds should be used to develop the science. Patients have been key to winning political support. Acting as advocates, they have contended that public investment will speed the research and bring accountability to biomedical technology. A political dispute about the new research, which holds the potential for cures to devastating diseases and to foster healthy aging, shows the need to respect public sensibilities and to court public approval, as well as the importance of involving patients in debates where the methods of biomedical discoveries and ethical beliefs collide.	Alliance Aging Res, Washington, DC 20006 USA		Perry, D (corresponding author), Alliance Aging Res, 2021 K St NW,Suite 305, Washington, DC 20006 USA.							*ALL AG RES, 1999, 106 C CAN ACH HLTH I; Alliance for Aging Research, 1999, IND OLD AM INV OUR N; *AM ASS ADV SCI I, 1999, STEM CELL RES APPL M; DICKEY J, 1999, ROLL CALL       0603, P4; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; 1999, THEOLOGIANS 4 MAJOR	6	40	42	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1423	1423		10.1126/science.287.5457.1423	http://dx.doi.org/10.1126/science.287.5457.1423			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688778				2022-12-24	WOS:000085531600032
J	McNally, JG; Muller, WG; Walker, D; Wolford, R; Hager, GL				McNally, JG; Muller, WG; Walker, D; Wolford, R; Hager, GL			The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells	SCIENCE			English	Article							TRANSCRIPTION FACTORS; MMTV PROMOTER; IN-VIVO; GENES; ACTIVATION; CHROMATIN; INTERPLAY; INVIVO	Steroid receptors bind to site-specific response elements in chromatin and modulate gene expression in a hormone-dependent fashion. With the use of a tandem array of mouse mammary tumor virus reporter elements and a form of glucocorticoid receptor labeled with green fluorescent protein, targeting of the receptor to response elements in live mouse cells was observed. Photobleaching experiments provide direct evidence that the hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment. Thus, the interaction of regulatory proteins with target sites in chromatin is a more dynamic process than previously believed.	NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hager, GL (corresponding author), NCI, Lab Receptor Biol & Gene Express, Bldg 41,Room B602, Bethesda, MD 20892 USA.	hagerg@exchange.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010027, ZIABC010027] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BELMONT A, 1996, J CELL BIOL, V135, P1685; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; ELLENBERG J, UNPUB; FLETCHER TM, UNPUBHER TM; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GRONEMEYER H, 1993, STEROID HORMONE ACTI, P94; Hager GL, 1999, METHOD ENZYMOL, V302, P73, DOI 10.1016/S0076-6879(99)02011-X; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Kramer PR, 1999, J BIOL CHEM, V274, P28590, DOI 10.1074/jbc.274.40.28590; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; Walker D, 1999, METHODS, V19, P386, DOI 10.1006/meth.1999.0874; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	34	629	642	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1262	1265		10.1126/science.287.5456.1262	http://dx.doi.org/10.1126/science.287.5456.1262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678832				2022-12-24	WOS:000085444700049
J	Mi, S; Lee, X; Li, XP; Veldman, GM; Finnerty, H; Racie, L; LaVallie, E; Tang, XY; Edouard, P; Howes, S; Keith, JC; McCoy, JM				Mi, S; Lee, X; Li, XP; Veldman, GM; Finnerty, H; Racie, L; LaVallie, E; Tang, XY; Edouard, P; Howes, S; Keith, JC; McCoy, JM			Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis	NATURE			English	Article							EXPRESSION; CELLS; VIRUS; GENE; SEQUENCE; GROWTH; ERV3	Many mammalian viruses have acquired genes from their hosts during their evolution(1). The rationale for these acquisitions is usually quite clear: the captured genes are subverted to provide a selective advantage to the virus. Here we describe the opposite situation, where a viral gene has been sequestered to serve an important function in the physiology of a mammalian host. This gene, encoding a protein that we have called syncytin, is the envelope gene of a recently identified human endogenous defective retrovirus, HERV-W-2. We find that the major sites of syncytin expression are placental syncytiotrophoblasts, multinucleated cells that originate from fetal trophoblasts. We show that expression of recombinant syncytin in a wide variety of cell types induces the formation of giant syncytia, and that fusion of a human trophoblastic cell line expressing endogenous syncytin can be inhibited by an anti-syncytin antiserum. Our data indicate that syncytin may mediate placental cytotrophoblast fusion in vivo, and thus may be important in human placental morphogenesis.	Genet Inst, Cambridge, MA 02140 USA		McCoy, JM (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.							Baergen Rebecca N., 1997, General and Diagnostic Pathology, V143, P127; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; COHEN M, 1985, VIROLOGY, V147, P449, DOI 10.1016/0042-6822(85)90147-3; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; FISCHER D, 1991, CHROMOSOMA, V101, P133, DOI 10.1007/BF00355363; Fox PT, 1997, HUM BRAIN MAPP, V5, P1, DOI 10.1002/(SICI)1097-0193(1997)5:1<1::AID-HBM1>3.0.CO;2-7; GATELY MK, 1996, CURRENT PROTOCOLS IM, V6, P16; HARRIS JR, 1991, FEBS LETT, V295, P3, DOI 10.1016/0014-5793(91)81370-N; HUNT JS, 1992, CURR OPIN IMMUNOL, V4, P591, DOI 10.1016/0952-7915(92)90032-A; Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2; Kalter S S, 1975, Bibl Haematol, P391; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOVATS S, 1990, SCIENCE, V248, P20; Lala PK, 1996, PLACENTA, V17, P545, DOI 10.1016/S0143-4004(96)80071-3; LARSSON E, 1993, J CANC RES CLIN O S1, V119, P6; Larsson Erik, 1994, Upsala Journal of Medical Sciences, V99, P113; LIMJOCO TI, 1993, J VIROL, V67, P4163, DOI 10.1128/JVI.67.7.4163-4168.1993; Lin L, 1999, PLACENTA, V20, P109, DOI 10.1053/plac.1998.0337; LYDEN TW, 1993, PLACENTA, V14, P177, DOI 10.1016/S0143-4004(05)80259-0; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; PATTILLO RA, 1968, SCIENCE, V159, P1467, DOI 10.1126/science.159.3822.1467; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; VENABLES PJW, 1995, VIROLOGY, V211, P589, DOI 10.1006/viro.1995.1442; YAMADA S, 1986, BIOCHEMISTRY-US, V25, P3703, DOI 10.1021/bi00360a034	30	1098	1152	4	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					785	789		10.1038/35001608	http://dx.doi.org/10.1038/35001608			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693809				2022-12-24	WOS:000085423100056
J	Song, HW; Mugnier, P; Das, AK; Webb, HM; Evans, DR; Tuite, MF; Hemmings, BA; Barford, D				Song, HW; Mugnier, P; Das, AK; Webb, HM; Evans, DR; Tuite, MF; Hemmings, BA; Barford, D			The crystal structure of human eukaryotic release factor eRF1 - Mechanism of stop codon recognition and peptidyl-tRNA hydrolysis	CELL			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TRANSLATION TERMINATION; TRANSFER-RNA; CHAIN TERMINATION; BINDING-SITE; FACTORS RF1; IN-VITRO; YEAST	The release factor eRF1 terminates protein biosynthesis by recognizing stop codons at the A site of the ribosome and stimulating peptidyl-tRNA bond hydrolysis at the peptidyl transferase center. The crystal structure of human eRF1 to 2.8 Angstrom resolution, combined with mutagenesis analyses of the universal GGQ motif, reveals the molecular mechanism of release factor activity. The overall shape and dimensions of eRF1 resemble a tRNA molecule with domains 1, 2, and 3 of eRF1 corresponding to the anticodon loop, aminoacyl acceptor stem, and T stem of a tRNA molecule, respectively. The position of the essential GGQ motif at an exposed tip of domain 2 suggests that the Gin residue coordinates a water molecule to mediate the hydrolytic activity at the peptidyl transferase center. A conserved groove on domain 1, 80 Angstrom from the GGQ motif, is proposed to form the codon recognition site.	Inst Canc Res, Sect Struct Biol, London SW3 6JB, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford; University of Kent; Friedrich Miescher Institute for Biomedical Research	Barford, D (corresponding author), Inst Canc Res, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	dbarford@icr.ac.uk	song, haiwei/H-6082-2011; Tuite, Mick/ABC-7909-2020	Tuite, Mick/0000-0002-5214-540X				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BARTON GJ, 1990, METHOD ENZYMOL, V183, P403; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BROWN CM, 1994, J BIOL CHEM, V269, P33164; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P2079, DOI 10.1093/nar/18.8.2079; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckingham RH, 1997, MOL MICROBIOL, V24, P449, DOI 10.1046/j.1365-2958.1997.3711734.x; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EGGERTSSON G, 1988, MICROBIOL REV, V52, P354, DOI 10.1128/MMBR.52.3.354-374.1988; Eurwilaichitr L, 1999, MOL MICROBIOL, V32, P485, DOI 10.1046/j.1365-2958.1999.01346.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P99, DOI 10.1073/pnas.67.1.99; Grentzmann G, 1997, J BIOL CHEM, V272, P12300, DOI 10.1074/jbc.272.19.12300; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McCaughan KK, 1998, BIOL CHEM, V379, P857, DOI 10.1515/bchm.1998.379.7.857; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; MIRONOVA LN, 1986, GENETIKA+, V22, P200; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; Mottagui-Tabar S, 1998, EUR J BIOCHEM, V257, P249, DOI 10.1046/j.1432-1327.1998.2570249.x; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Poole ES, 1997, RNA, V3, P974; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, CURR GENET, V27, P417, DOI 10.1007/BF00311210; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Stansfield I, 1997, EUR J BIOCHEM, V245, P557, DOI 10.1111/j.1432-1033.1997.00557.x; Stansfield I, 1996, MOL MICROBIOL, V20, P1135, DOI 10.1111/j.1365-2958.1996.tb02634.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	58	367	394	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					311	321		10.1016/S0092-8674(00)80667-4	http://dx.doi.org/10.1016/S0092-8674(00)80667-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676813	Bronze			2022-12-24	WOS:000085204400005
J	Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T				Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T			Phosphatidylinositol 4,5-bisphoshate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion	CELL			English	Article							PANCREATIC ACINAR-CELLS; ACTIN POLYMERIZATION; F-ACTIN; IN-VIVO; BINDING; GROWTH; U73122; POLYPHOSPHOINOSITIDES; JASPLAKINOLIDE; TETHERS	Binding interactions between the plasma membrane and the cytoskeleton define cell functions such as cell shape, formation of cell processes, cell movement, and endocytosis. Here we use optical tweezers tether force measurements and show that plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) acts as a second messenger that regulates the adhesion energy between the cytoskeleton and the plasma membrane. Receptor stimuli that hydrolyze PIP2 lowered adhesion energy, a process that could be mimicked by expressing PH domains that sequester PIP2 or by targeting a 5'-PIP2-phosphatase to the plasma membrane to selectively lower plasma membrane PIP2 concentration. Our study suggests that plasma membrane PIP2 controls dynamic membrane functions and cell shape by locally increasing and decreasing the adhesion between the actin-based cortical cytoskeleton and the plasma membrane.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Meyer, T (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Raucher, Drazen/AAE-4540-2022	Meyer, Tobias/0000-0003-4339-3804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672] Funding Source: Medline; NIGMS NIH HHS [GM 48113, GM 362277] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERK DA, 1992, BIOPHYS J, V61, P9, DOI 10.1016/S0006-3495(92)81811-8; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DAI J, 1999, IN PRESS BIOPHYS J; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hochmuth RM, 1996, BIOPHYS J, V70, P358, DOI 10.1016/S0006-3495(96)79577-2; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.0.CO;2-2; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Kandzari D E, 1996, Subcell Biochem, V26, P97; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.3.CO;2-M; KLEINIG H, 1970, J CELL BIOL, V46, P396, DOI 10.1083/jcb.46.2.396; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Mogami H, 1997, BIOCHEM J, V324, P645, DOI 10.1042/bj3240645; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TRAN D, 1993, CELL SIGNAL, V5, P565, DOI 10.1016/0898-6568(93)90052-N; WAUGH RE, 1995, ANN BIOMED ENG, V23, P308, DOI 10.1007/BF02584431; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YULE DI, 1992, J BIOL CHEM, V267, P13830	30	560	571	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					221	228		10.1016/S0092-8674(00)81560-3	http://dx.doi.org/10.1016/S0092-8674(00)81560-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660045				2022-12-24	WOS:000084932200006
J	Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B				Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B			Voice-selective areas in human auditory cortex	NATURE			English	Article							RHESUS-MONKEY; PERCEPTION; SPEAKER	The human voice contains in its acoustic structure a wealth of information on the speaker's identity and emotional state which we perceive with remarkable ease and accuracy(1-3). Although the perception of speaker-related features of voice plays a major role in human communication, little is known about its neural basis(4-7) Here:we show, using functional magnetic resonance imaging in human volunteers, that voice-selective regions can be found bilaterally along the upper bank of the superior temporal sulcus (STS), These regions showed greater neuronal activity when subjects listened passively to vocal sounds, whether speech or non-speech, than to non-vocal environmental sounds. Central STS regions also displayed a high degree of selectivity by responding significantly more to vocal sounds than to matched control stimuli, including scrambled voices and amplitude-modulated noise. Moreover, their response to stimuli degraded by frequency filtering paralleled the subjects' behavioural performance in voice-perception tasks that used these stimuli. The voice-selective areas in the STS may represent the counterpart of the face-selective areas in human visual cortex(8,9); their existence sheds new light on the functional architecture of the human auditory cortex.	McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Psychol, Montreal, PQ H3A 2B4, Canada; McGill Univ, McConnel Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Belin, P (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	pascal@bic.mni.mcgill.ca	Pike, Bruce/K-5562-2014; Belin, Pascal/C-6247-2009	Pike, Bruce/0000-0001-8924-683X; Belin, Pascal/0000-0002-7578-6365				ASSAL G, 1981, REV NEUROL, V137, P255; Belin P, 1999, NEUROIMAGE, V10, P417, DOI 10.1006/nimg.1999.0480; BINDER JR, 1999, J COGNITIVE NEUROS S, V11, P99; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dehaene S, 1997, NEUROREPORT, V8, P3809, DOI 10.1097/00001756-199712010-00030; DOEHRING DG, 1971, NEUROPSYCHOLOGIA, V9, P425, DOI 10.1016/0028-3932(71)90006-6; Ellis A.W., 1989, HDB RES FACE PROCESS, P207; Hall DA, 1999, HUM BRAIN MAPP, V7, P213, DOI 10.1002/(SICI)1097-0193(1999)7:3<213::AID-HBM5>3.0.CO;2-N; Imaizumi S, 1997, NEUROREPORT, V8, P2809, DOI 10.1097/00001756-199708180-00031; JONES EG, 1995, J COMP NEUROL, V362, P153, DOI 10.1002/cne.903620202; Kaas JH, 1999, CURR OPIN NEUROBIOL, V9, P164, DOI 10.1016/S0959-4388(99)80022-1; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KLATT DH, 1990, J ACOUST SOC AM, V87, P820, DOI 10.1121/1.398894; McCarthy G, 1997, J COGNITIVE NEUROSCI, V9, P605, DOI 10.1162/jocn.1997.9.5.605; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; PANDYA DN, 1995, REV NEUROL, V151, P486; PAPCUN G, 1989, J ACOUST SOC AM, V85, P913, DOI 10.1121/1.397564; Rauschecker JP, 1998, AUDIOL NEURO-OTOL, V3, P86, DOI 10.1159/000013784; Rendall D, 1998, J ACOUST SOC AM, V103, P602, DOI 10.1121/1.421104; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Talairach J., 1988, COPLANAR STEREOTAXIC; TURNER R, 1994, FUNCTIONAL NEUROIMAG, P69; Van Lancker D R, 1982, Brain Cogn, V1, P185, DOI 10.1016/0278-2626(82)90016-1; VANDOMMELEN WA, 1990, LANG SPEECH, V33, P259, DOI 10.1177/002383099003300302; VANLANCKER DR, 1989, J CLIN EXP NEUROPSYC, V11, P665, DOI 10.1080/01688638908400923; WATZLAWICKI P, 1967, STUDY INTERACTIONAL; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	28	1232	1249	7	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					309	312		10.1038/35002078	http://dx.doi.org/10.1038/35002078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276VU	10659849				2022-12-24	WOS:000084899700052
J	Gardner, TS; Cantor, CR; Collins, JJ				Gardner, TS; Cantor, CR; Collins, JJ			Construction of a genetic toggle switch in Escherichia coli	NATURE			English	Article							LOGICAL ANALYSIS; NETWORKS; DYNAMICS; EXPRESSION; CIRCUITS; SYSTEMS; LAMBDA	It has been proposed(1) that gene-regulatory circuits with virtually any desired property can be constructed from networks of simple regulatory elements. These properties, which include multistability and oscillations, have been found in specialized gene circuits such as the bacteriophage lambda switch(2) and the Cyanobacteria circadian oscillator(3), However, these behaviours have not been demonstrated in networks of non-specialized regulatory components. Here we present the construction of a genetic toggle switch-a synthetic, bistable gene-regulatory network-in Escherichia coli and provide a simple theory that predicts the conditions necessary for bistability, The toggle is constructed from any two repressible promoters arranged in a mutually inhibitory network. It is flipped between stable states using transient chemical or thermal induction and exhibits a nearly ideal switching threshold. As a practical device, the toggle switch forms a synthetic, addressable cellular memory unit and has implications for biotechnology, biocomputing and gene therapy.	Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Boston Univ, Ctr BioDynam, Boston, MA 02215 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Dept Biomed Engn, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu						Arkin A, 1998, GENETICS, V149, P1633; ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Edelstein-Keshet L., 1988, MATH MODELS BIOL; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GLASS L, 1975, J THEOR BIOL, V54, P85, DOI 10.1016/S0022-5193(75)80056-7; GLASS L, 1975, J CHEM PHYS, V63, P1325, DOI 10.1063/1.431518; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; KAPLAN D, 1995, UNDERSTANDING NONLIN; KAUFFMAN S, 1974, J THEOR BIOL, V44, P167, DOI 10.1016/S0022-5193(74)80037-8; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; MODOD J, 1961, COLD SPRING HARB SYM, V26, P389; Ptashne M, 1992, GENETIC SWITCH PHAGE; Rubinow S. I., 2002, INTRO MATH BIOL, VDover; Sambrook JFE, 1989, MOL CLONING LAB MANU; Schellenberger W, 1980, Adv Enzyme Regul, V19, P257; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SMITH TF, 1977, MATH BIOSCI, V36, P61, DOI 10.1016/0025-5564(77)90016-5; TCHURAEV RN, 1991, J THEOR BIOL, V151, P71, DOI 10.1016/S0022-5193(05)80144-4; THOMAS R, 1978, J THEOR BIOL, V73, P631, DOI 10.1016/0022-5193(78)90127-3; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; YAGIL G, 1971, BIOPHYS J, V11, P11, DOI 10.1016/S0006-3495(71)86192-1	26	2839	3019	49	705	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					339	342		10.1038/35002131	http://dx.doi.org/10.1038/35002131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659857				2022-12-24	WOS:000084899700060
J	Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF				Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF			Halocarbons produced by natural oxidation processes during degradation of organic matter	NATURE			English	Article								Volatile halogenated organic compounds (VHOC) play an important role in atmospheric chemical processes-contributing, for example, to stratospheric ozone depletion(1-4), For anthropogenic VHOC whose sources are well known(5), the global atmospheric input can be estimated from industrial production data. Halogenated compounds of natural origin can also contribute significantly to the levels of VHOC in the atmosphere(6). The oceans have been implicated as one of the main natural sources(7-10), where organisms such as macroalgae and microalgae can release large quantities of VHOC to the atmosphere(11,12), Some terrestrial sources have also been identified, such as wood-rotting fungi(13), biomass burning(14) and volcanic emissions(15). Here we report the identification of a different terrestrial source of naturally occurring VHOC, We find that, in soils and sediments, halide ions can be alkylated during the oxidation of organic matter by an electron acceptor such as Fe(III): sunlight or microbial mediation are not required for these reactions. When the available halide ion is chloride, the reaction products are CH3Cl, C2H5Cl, C3H7Cl and C4H9Cl. (The corresponding alkyl bromides or alkyl iodides are produced when bromide or iodide are present.) Such abiotic processes could make a significant contribution to the budget of the important atmospheric compounds CH3Cl, CH3Br and CH3I.	Univ Heidelberg, Inst Environm Geochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Keppler, F (corresponding author), Univ Heidelberg, Inst Environm Geochem, Neuenheimer Feld 236, D-69120 Heidelberg, Germany.		Keppler, Frank/F-4401-2012	Keppler, Frank/0000-0003-2766-8812				ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; Andreae MO, 1996, J GEOPHYS RES-ATMOS, V101, P23603, DOI 10.1029/95JD01733; Butler JH, 1999, NATURE, V399, P749, DOI 10.1038/21586; CLASS TH, 1988, J ATMOS CHEM, V6, P35, DOI 10.1007/BF00048330; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Desjardins S, 1999, J SOIL CONTAM, V8, P175; GRIBBLE GW, 1992, J NAT PROD, V55, P1353, DOI 10.1021/np50088a001; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; HOEKSTRA EJ, 1993, NATURALLY PRODUCED O, P149; Laturnus F, 1998, GEOPHYS RES LETT, V25, P773, DOI 10.1029/98GL00490; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SINGH AK, 1984, THORAC CARDIOV SURG, V32, P89, DOI 10.1055/s-2007-1023355; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; STURGES WT, 1993, TELLUS B, V45, P120, DOI 10.1034/j.1600-0889.1993.t01-1-00004.x; WEVER R, 1988, SCIENCE, V355, P501	19	272	288	6	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					298	301		10.1038/35002055	http://dx.doi.org/10.1038/35002055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659846				2022-12-24	WOS:000084899700049
J	Rossi, A; Kapahi, P; Natoli, G; Takahashi, T; Chen, Y; Karin, M; Santoro, MG				Rossi, A; Kapahi, P; Natoli, G; Takahashi, T; Chen, Y; Karin, M; Santoro, MG			Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase	NATURE			English	Article							TRANSCRIPTION FACTOR; ANTIVIRAL ACTIVITY; HUMAN-CELLS; ACTIVATION; GAMMA; IKK; MECHANISMS; EXPRESSION; COMPLEX; ALPHA	NF-kappa B is a critical activator of genes involved in inflammation and immunity(1,2). Pro-inflammatory cytokines activate the I kappa B kinase (IKK) complex that phosphorylates the NF-kappa B inhibitors, triggering their conjugation with ubiquitin and subsequent degradation(3,4). Freed NF-kappa B dimers translocate to the nucleus and induce target genes, including the one for cyclo-oxygenase 2 (COX2), which catalyses the synthesis of pro-inflammatory prostaglandins, in particular pGE(5,6). At late stages of inflammatory episodes, however, COX2 directs the synthesis of anti-inflammatory cyclopentenone prostaglandins, suggesting a role for these molecules in the resolution of inflammation(7). Cyclopentenone prostaglandins have been suggested to exert anti-inflammatory activity through the activation of peroxisome proliferator-activated receptor-gamma (refs 8, 9). Here we demonstrate a novel mechanism of antiinflammatory activity which is based on the direct inhibition and modification of the IKK beta subunit of IKK, As IKK beta is responsible for the activation of NF-kappa B by pro-inflammatory stimuli(10,11), our findings explain how cyclopentenone prostaglandins function and can be used to improve the utility of COX2 inhibitors.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Roma Tor Vergata, Dept Biol, Virol Lab, I-00133 Rome, Italy; Italian Natl Council Res, Inst Expt Med, I-00133 Rome, Italy	University of California System; University of California San Diego; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018	Santoro, Maria Gabriella/0000-0003-1432-4949; Natoli, Gioacchino/0000-0003-0711-2411; ROSSI, ANTONIO/0000-0003-0383-3828				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CALDERWOOD SK, 1989, J CELL PHYSIOL, V141, P325, DOI 10.1002/jcp.1041410214; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hirose S, 1998, J AM SOC NEPHROL, V9, P408; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LEUNG DYM, 1988, J IMMUNOL, V140, P84; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; WANG CY, 1998, SCIENCE, V274, P786; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	30	1150	1231	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					103	108		10.1038/47520	http://dx.doi.org/10.1038/47520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638762				2022-12-24	WOS:000084687400052
J	Morrison, I				Morrison, I			The future of physicians' time	ANNALS OF INTERNAL MEDICINE			English	Article								Physicians' lime is under assault in the current health care system. In particular, managed care payers are reducing compensation to physicians on a discounted fee-for service basis. More demanding consumers, complex new technologies, and increased managerial and administrative burdens are placing further constraints on physicians' time. As we look ahead, it seems likely that these pressures will intensify and transform the ways in which physicians spend their time. Physicians will play eight key roles in the future: clinical data collector, shaman, health advisor and wellness coach, knowledge navigator, proceduralist, diagnostician, physician manager, and quality assurance specialist. They will need to lead the redesign of these roles and define the ways in which they should spend their time in the health care system of the new millennium.	Inst Future, Menlo Pk, CA USA		Morrison, I (corresponding author), 1635 Bay Laurel Dr, Menlo Pk, CA 94025 USA.	seccurve@aol.com						*HARR INT, 1999, HARR POLL; MORRISON I, 2000, JOS-BAS HEA, P1; Wadland WC, 1999, J FAM PRACTICE, V48, P711	3	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					80	84		10.7326/0003-4819-132-1-200001040-00013	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627256				2022-12-24	WOS:000084518600012
J	Scannell, KA				Scannell, KA			Leave of absence	ANNALS OF INTERNAL MEDICINE			English	Article									Kaiser Permanente, Oakland, CA 94611 USA	Kaiser Permanente	Scannell, KA (corresponding author), Kaiser Permanente, 280 W MacArthur Blvd, Oakland, CA 94611 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					55	57		10.7326/0003-4819-132-1-200001040-00009	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627252				2022-12-24	WOS:000084518600008
J	Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA				Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA			Selection of metastatic tumour phenotypes by host immune systems	LANCET			English	Article							E-CADHERIN; FAS COUNTERATTACK; TAP-1 EXPRESSION; T-CELLS; CANCER; INTEGRIN; CARCINOMA; LIGAND; LYMPHOCYTES; MECHANISMS	Metastasis and the processes underlying this phenomenon make epithelial cancers so malignant. Local control of cancers by surgery is sometimes possible but locoregional and distant recurrence commonly lead to the failure of treatment with ensuing morbidity and mortality. Tumour cells express a range of new antigens during growth and there are opportunities for the host immune system to interact with these antigens. This immune interaction eliminates the tumour or allows selection of phenotypic variants. Cell phenotypes selected by an incomplete immune response resemble the cell type commonly associated with metastases. Thus we propose that the host immune system may be responsible for selection of this phenotype and progression of the disease.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Gastrointestinal Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK	Seymour, K (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Kirby, John/0000-0003-2543-4131; Seymour, Keith/0000-0003-0850-2745				Aizawa K, 1999, INT J ONCOL, V14, P85; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; Dudley ME, 1996, INT J CANCER, V65, P249, DOI 10.1002/(SICI)1097-0215(19960117)65:2<249::AID-IJC20>3.0.CO;2-7; Fey MF, 1996, ANN ONCOL, V7, P121; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; Hadley GA, 1997, J IMMUNOL, V159, P3748; Hedger M P, 1997, Rev Reprod, V2, P38, DOI 10.1530/ror.0.0020038; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kuwabara K, 1998, JPN J CANCER RES, V89, P40, DOI 10.1111/j.1349-7006.1998.tb00477.x; LEHMANN F, 1995, EUR J IMMUNOL, V25, P340, DOI 10.1002/eji.1830250206; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Pang M, 1998, ARTHRITIS RHEUM, V41, P1456, DOI 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Svane IM, 1996, EUR J IMMUNOL, V26, P1844, DOI 10.1002/eji.1830260827; TaylorPapadimitriou J, 1997, IMMUNOL TODAY, V18, P105, DOI 10.1016/S0167-5699(97)01028-1; YAMAMOTO K, 1995, J IMMUNOL, V154, P1804; YOUNG D, 1989, DRUG RESISTANCE CANC; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085	31	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1989	1991		10.1016/S0140-6736(99)04435-9	http://dx.doi.org/10.1016/S0140-6736(99)04435-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622313				2022-12-24	WOS:000084034700043
J	Xu, GL; Bestor, TH; Bourc'his, D; Hsieh, CL; Tommerup, N; Bugge, M; Hulten, M; Qu, XY; Russo, JJ; Viegas-Pequignot, E				Xu, GL; Bestor, TH; Bourc'his, D; Hsieh, CL; Tommerup, N; Bugge, M; Hulten, M; Qu, XY; Russo, JJ; Viegas-Pequignot, E			Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene	NATURE			English	Article							ICF SYNDROME; METHYLATION PATTERN; HETEROCHROMATIN; HYPOMETHYLATION; FISH; SET	The recessive autosomal disorder known as ICF syndrome(1-3) (for immunodeficiency, centromere instability and facial anomalies; Mendelian Inheritance in Man number 242860) is characterized by variable reductions in serum immunoglobulin levels which cause most ICF patients to succumb to infectious diseases before adulthood. Mild facial anomalies include hypertelorism, low-set ears, epicanthal folds and macroglossia. The cytogenetic abnormalities in lymphocytes are exuberant: juxtacentromeric heterochromatin is greatly elongated and thread-like in metaphase chromosomes, which is associated with the formation of complex multiradiate chromosomes. The same juxtacentromeric regions are subject to persistent interphase self-associations and are extruded into nuclear blebs or micronuclei. Abnormalities are largely confined to tracts of classical satellites 2 and 3 at juxtacentromeric regions of chromosomes 1, 9 and 16. Classical satellite DNA is normally heavily methylated at cytosine residues, but in ICF syndrome it is almost completely unmethylated in all tissues(4) ICF syndrome is the only genetic disorder known to involve constitutive abnormalities of genomic methylation patterns. Here we show that five unrelated ICF patients have mutations in both alleles of the gene that encodes DNA methyltransferase 3B (refs 5, 6). Cytosine methylation is essential for the organization and stabilization of a specific type of heterochromatin, and this methylation appears to be carried out by an enzyme specialized for the purpose.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Copenhagen, Inst Med Biochem & Genet, Dept Med Genet, DK-2600 Glostrup, Denmark; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, New York, NY 10032 USA	Columbia University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southern California; University of Southern California; University of Copenhagen; University of Warwick; Columbia University	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.		Tommerup, Niels/T-8776-2017	Tommerup, Niels/0000-0003-2304-0112; Bourc'his, Deborah/0000-0001-9499-7291				Bestor TH, 1998, CIBA F SYMP, V214, P187; Bourc'his D, 1999, CYTOGENET CELL GENET, V84, P245, DOI 10.1159/000015269; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HSIEH CL, IN PRESS MOL CELL BI; HULTEN M, 1978, CLIN GENET, V14, P294; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LUBIT BW, 1976, CELL, V9, P503, DOI 10.1016/0092-8674(76)90032-5; MARASCHIO P, 1988, J MED GENET, V25, P173, DOI 10.1136/jmg.25.3.173; MARASCHIO P, 1992, ANN HUM GENET, V56, P273, DOI 10.1111/j.1469-1809.1992.tb01152.x; MINIOU P, 1994, HUM MOL GENET, V3, P2093, DOI 10.1093/hmg/3.12.2093; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REYNAUD C, 1992, CANCER LETT, V61, P255, DOI 10.1016/0304-3835(92)90296-8; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SCHUFFENHAUER S, 1995, HUM GENET, V96, P562, DOI 10.1007/BF00197412; Schulz WG, 1997, CHEM ENG NEWS, V75, P64, DOI 10.1021/cen-v075n018.p064; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Sumner AT, 1998, J MED GENET, V35, P833, DOI 10.1136/jmg.35.10.833; TIEPOLO L, 1978, CLIN GENET, V14, P313; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	29	880	921	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					187	191		10.1038/46052	http://dx.doi.org/10.1038/46052			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647011				2022-12-24	WOS:000083716400052
J	Henney, JE				Henney, JE			Revised labeling for cisapride	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1131	1131		10.1001/jama.283.9.1131	http://dx.doi.org/10.1001/jama.283.9.1131			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703765				2022-12-24	WOS:000085424100006
J	Cruz, A; Green, BG				Cruz, A; Green, BG			Thermal stimulation of taste	NATURE			English	Article							TEMPERATURE-DEPENDENCE; RESPONSES; HAMSTER; NERVE	The first electrophysiological recordings from animal(1) and human(2) taste nerves gave clear evidence of thermal sensitivity, and studies have shown that as many as half of the neurons in mammalian taste pathways respond to temperature(3-6). Because temperature has never been shown to induce sensations of taste, it has been assumed that thermal stimulation in the gustatory system is somehow nulled(6). Here we show that heating or cooling small areas of the tongue can in fact cause sensations of taste: warming the anterior edge of the tongue (chorda tympani nerve) from a cold temperature can evoke sweetness, whereas cooling can evoke sourness and/or saltiness. Thermal taste also occurs on the rear of the tongue (glossopharyngeal nerve), but the relationship between temperature and taste is different there than on the front of the tongue. These observations indicate the human gustatory system contains several different types of thermally sensitive neurons that normally contribute to the sensory code for taste.	John B Pierce Fdn Lab, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Surg Otolaryngol, New Haven, CT 06519 USA	Yale University; The John B Pierce Laboratory, Inc; Yale University	Green, BG (corresponding author), John B Pierce Fdn Lab, 290 Congress Ave, New Haven, CT 06519 USA.	green@jbpierce.org						BARTOSHUK LM, 1982, PHYSIOL BEHAV, V28, P905, DOI 10.1016/0031-9384(82)90212-8; GREEN BG, 1993, CHEM SENSES, V18, P683, DOI 10.1093/chemse/18.6.683; GREEN BG, 1987, CHEM SENSES, V12, P609, DOI 10.1093/chemse/12.4.609; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; MCBURNEY DH, 1973, PHYSIOL BEHAV, V11, P89, DOI 10.1016/0031-9384(73)90127-3; NAKAMURA M, 1988, BRAIN RES, V444, P159, DOI 10.1016/0006-8993(88)90923-7; OAKLEY B, 1985, CHEM SENSES, V10, P469, DOI 10.1093/chemse/10.4.469; OGAWA H, 1968, J PHYSIOL-LONDON, V199, P223, DOI 10.1113/jphysiol.1968.sp008650; SATO M, 1975, J GEN PHYSIOL, V66, P781, DOI 10.1085/jgp.66.6.781; TRAVERS SP, 1984, J GEN PHYSIOL, V84, P221, DOI 10.1085/jgp.84.2.221; VONBEKESY G, 1964, SCIENCE, V145, P834, DOI 10.1126/science.145.3634.834; WHITEHEAD MC, 1994, J COMP NEUROL, V340, P515, DOI 10.1002/cne.903400405; Whitehead MC, 1999, NEUROSCIENCE, V93, P931, DOI 10.1016/S0306-4522(99)00115-3; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; Zotterman Y, 1935, SKAND ARCH PHYSIOL, V72, P73, DOI 10.1111/j.1748-1716.1935.tb00412.x	16	170	174	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					889	892		10.1038/35002581	http://dx.doi.org/10.1038/35002581			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706285				2022-12-24	WOS:000085559200056
J	Guo, HF; Tong, JY; Hannan, F; Luo, L; Zhong, Y				Guo, HF; Tong, JY; Hannan, F; Luo, L; Zhong, Y			A neurofibromatosis-1-regulated pathway is required for learning in Drosophila	NATURE			English	Article							PROTEIN-KINASE-A; ADENYLATE-CYCLASE; MUSHROOM BODIES; TERM-MEMORY; GENE; NF1; TYPE-1; RAS; MELANOGASTER; RUTABAGA	The tumour-suppressor gene Neurofibromatosis 1 (Nf1) encodes a Ras-specific GTPase activating protein (Ras-GAP)(1-5). In addition to being involved in tumour formation(6,7), NF1 has been reported to cause learning defects in humans(8-10) and Nf1 knockout mice(11) However, it remains to be determined whether the observed learning defect is secondary to abnormal development. The Drosophila NF1 protein is highly conserved, showing 60% identity of its 2,803 amino acids with human NF1 (ref. 12), Previous studies have suggested that Drosophila NF1 acts not only as a Ras-GAP but also as a possible regulator of the cAMP pathway that involves the rutabaga (rut)-encoded adenylyl cyclase(13). Because rut was isolated as a learning and short-term memory mutant(14,15), we have pursued the hypothesis that NF1 may affect learning through its control of the Rut-adenylyl cyclase/cAMP pathway. Here we show that NF1 affects learning and short-term memory independently of its developmental effects. We show that G-protein-activated adenylyl cyclase activity consists of NF1-independent and NF1-dependent components, and that the mechanism of the NF1-dependent activation of the Rut-adenylyl cyclase pathway is essential for mediating Drosophila learning and memory.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Guo, HF (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V86, P3599; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Ferner RE, 1996, J NEUROL SCI, V138, P125, DOI 10.1016/0022-510X(96)00022-6; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; NORTH K, 1995, DEV MED CHILD NEUROL, V37, P427, DOI 10.1111/j.1469-8749.1995.tb12026.x; NORTH K, 1994, NEUROLOGY, V44, P878, DOI 10.1212/WNL.44.5.878; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	29	186	191	3	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					895	898		10.1038/35002593	http://dx.doi.org/10.1038/35002593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706287				2022-12-24	WOS:000085559200058
J	Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB				Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB			Connectivity of marine populations: Open or closed?	SCIENCE			English	Article							GREAT-BARRIER-REEF; LARVAL FISHES; CORAL-REEFS; WEST-INDIES; RECRUITMENT; DIFFUSION; DISPERSAL; PACIFIC; DISTRIBUTIONS; CIRCULATION	Most marine populations are thought to be well connected via long-distance dispersal of larval stages. Eulerian and Lagrangian flow models, coupled with Linear mortality estimates, were used to examine this assumption. The findings show that when simple advection models are used, Larval exchange rates may be overestimated; such simplistic models fail to account for a decrease of up to nine orders of magnitude in larval concentrations resulting from diffusion and mortality. The alternative process of larval retention near local populations is shown to exist and may be of great importance in the maintenance of marine population structure and management of coastal marine resources.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA	University of Miami; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cowen, RK (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.			Lwiza, Kamazima/0000-0003-2790-9284; Paris-Limouzy, Claire Beatrix/0000-0002-0637-1334; Olson, Donald/0000-0001-7180-5672				BLACK KP, 1991, MAR ECOL PROG SER, V74, P1, DOI 10.3354/meps074001; BOEHLERT GW, 1992, DEEP-SEA RES, V39, P439, DOI 10.1016/0198-0149(92)90082-5; BOEHLERT GW, 1987, ESTUAR COAST SHELF S, V25, P261, DOI 10.1016/0272-7714(87)90071-0; CARR MH, 1993, CAN J FISH AQUAT SCI, V50, P2019, DOI 10.1139/f93-226; CHOAT JH, 1988, 6 INT COR REEF S EX, P149; COWEN RK, 1985, J MAR RES, V43, P719, DOI 10.1357/002224085788440376; COWEN RK, 1994, B MAR SCI, V54, P228; DOHERTY PJ, 1995, ECOLOGY, V76, P2373, DOI 10.2307/2265814; DORSEY S, UNPUB; DUTKIEWICZ S, 1993, J GEOPHYS RES-OCEANS, V98, P16487, DOI 10.1029/93JC01364; Govoni John J., 1994, Fisheries Oceanography, V3, P120, DOI 10.1111/j.1365-2419.1994.tb00054.x; Helbig JA, 1998, CAN J FISH AQUAT SCI, V55, P2206, DOI 10.1139/cjfas-55-10-2206; HILL AE, 1991, MAR ECOL PROG SER, V70, P117, DOI 10.3354/meps070117; HOUDE ED, 1989, FISH B-NOAA, V87, P471; JOHNS WE, 1990, J GEOPHYS RES-OCEANS, V95, P22103, DOI 10.1029/JC095iC12p22103; Jones GP, 1999, NATURE, V402, P802, DOI 10.1038/45538; Lee TN, 1999, B MAR SCI, V64, P35; Leis JM, 1997, MAR ECOL PROG SER, V159, P165, DOI 10.3354/meps159165; LEIS JM, 1991, MAR BIOL, V109, P157, DOI 10.1007/BF01320243; MEEKAN MG, 1993, MAR ECOL PROG SER, V93, P217, DOI 10.3354/meps093217; MORSE WW, 1989, FISH B-NOAA, V87, P417; OKUBO A, 1971, DEEP-SEA RES, V18, P789, DOI 10.1016/0011-7471(71)90046-5; OLSON DB, 1985, J MAR RES, V43, P113, DOI 10.1357/002224085788437325; Paiva AM, 1999, J MARINE SYST, V21, P307, DOI 10.1016/S0924-7963(99)00020-2; Polovina JJ, 1999, FISH B-NOAA, V97, P132; RICHARDSON PL, 1994, J GEOPHYS RES-OCEANS, V99, P5081, DOI 10.1029/93JC03486; Roberts CM, 1997, SCIENCE, V278, P1454, DOI 10.1126/science.278.5342.1454; Robertson DR, 1996, CORAL REEFS, V15, P121, DOI 10.1007/s003380050032; ROSENBLATT RH, 1986, COPEIA, P275, DOI 10.2307/1444988; ROUGHGARDEN J, 1985, ECOLOGY, V66, P54, DOI 10.2307/1941306; SCHELTEMA RS, 1986, B MAR SCI, V39, P290; SCHULTZ ET, 1994, MAR ECOL PROG SER, V109, P15, DOI 10.3354/meps109015; SHULMAN MJ, 1995, EVOLUTION, V49, P897, DOI 10.1111/j.1558-5646.1995.tb02325.x; Sinclair M, 1988, MARINE POPULATIONS E; Sponaugle S, 1996, MAR FRESHWATER RES, V47, P433, DOI 10.1071/MF9960433; Stansfield KL, 1995, J GEOPHYS RES-OCEANS, V100, P24819, DOI 10.1029/95JC02749; Stobutzki IC, 1997, MAR ECOL PROG SER, V149, P35, DOI 10.3354/meps149035; Swearer SE, 1999, NATURE, V402, P799, DOI 10.1038/45533; Taggart C.T., 1990, P151; THORSON G, 1950, MEDD DOMM DAN FISK P, V4, P1; WARNER RR, 1988, P 6 INT COR REEF S T, V1; Werner Francisco E., 1993, Fisheries Oceanography, V2, P43, DOI 10.1111/j.1365-2419.1993.tb00120.x; Wing SR, 1998, LIMNOL OCEANOGR, V43, P1710, DOI 10.4319/lo.1998.43.7.1710; Wolanski E, 1997, NATURWISSENSCHAFTEN, V84, P262, DOI 10.1007/s001140050394	44	905	922	2	245	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					857	859		10.1126/science.287.5454.857	http://dx.doi.org/10.1126/science.287.5454.857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657300				2022-12-24	WOS:000085136400047
J	Xue, YQ; Sherman, DH				Xue, YQ; Sherman, DH			Alternative modular polyketide synthase expression controls macrolactone structure	NATURE			English	Article							STREPTOMYCES-VENEZUELAE; BIOSYNTHESIS; ACID	Modular polyketide synthases are giant multifunctional enzymes that catalyse the condensation of small carboxylic acids such as acetate and propionate into structurally diverse polyketides that possess a spectrum of biological activities(1,2). In a modular polyketide synthase, an enzymatic domain catalyses a specific reaction, and three to six enzymatic domains involved in a condensation-processing cycle are organized into a module(3). A fundamental aspect of a modular polyketide synthase is that its module arrangement linearly specifies the structure of its polyketide product(3). Here we report a natural example in which alternative expression of the pikromycin polyketide synthase results in the generation of two macrolactone structures. Expression of the full-length modular polyketide synthase PikAIV in Streptomyces venezuelae generates the 11-membered ring macrolactone narbonolide, whereas expression of the amino-terminal truncated form of PikAIV leads to 'skipping' of the final condensation cycle in polyketide biosynthesis to generate the 12-membered ring macrolactone 10-deoxymethynolide. Our findings provide insight into the structure and function of modular polyketide synthases, as well as a new set of tools to generate structural diversity in polyketide natural products.	Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Biol Proc Technol Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Sherman, DH (corresponding author), Univ Minnesota, Dept Microbiol, Box 196,1460 Mayo Mem Bldg, Minneapolis, MN 55455 USA.			Xue, Alex/0000-0002-7388-6899				Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; Butler AR, 1999, CHEM BIOL, V6, P287, DOI 10.1016/S1074-5521(99)80074-X; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Gokhale RS, 1999, CHEM BIOL, V6, P117, DOI 10.1016/S1074-5521(99)80008-8; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HORI T, 1971, J CHEM SOC CHEM COMM, P304, DOI 10.1039/c29710000304; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; LAMBALOT RH, 1992, J ANTIBIOT, V45, P1981, DOI 10.7164/antibiotics.45.1981; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; Rangaswamy V, 1998, J BACTERIOL, V180, P3330, DOI 10.1128/JB.180.13.3330-3338.1998; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; SHERMAN DH, 1988, P 8 INT BIOT S SOC F, V1, P123; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; Tang L, 1999, CHEM BIOL, V6, P553, DOI 10.1016/S1074-5521(99)80087-8; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111	21	90	95	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					571	575		10.1038/35000624	http://dx.doi.org/10.1038/35000624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676969				2022-12-24	WOS:000085227300057
J	Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P				Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P			Stimulation by ammonium-based fertilizers of methane oxidation in soil around rice roots	NATURE			English	Article							METHANOTROPHIC BACTERIA; ORYZA-SATIVA; FOREST SOILS; INHIBITION; CONSUMPTION; KINETICS; PLANTS	Methane is involved in a number of chemical and physical processes in the Earths atmosphere, including global warming(1), Atmospheric methane originates mainly from biogenic sources, such as rice paddies and natural wetlands; the former account for at least 30% of the global annual emission of methane to the atmosphere(2). As an increase of rice production by 60% is the most appropriate way to sustain the estimated increase of the human population during the next three decades(3), intensified global fertilizer application will be necessary(3): but it is known that an increase of the commonly used ammonium-based fertilizers can enhance methane emission from rice agriculture. Approximately 10-30% of the methane produced by methanogens in rice paddies is consumed by methane-oxidizing bacteria associated with the roots of rice(4,5); these bacteria are generally thought to be inhibited by ammonium-based fertilizers, as tvas demonstrated for soils(6-8) and sediments(9,10). In contrast, we show here that the activity and growth of such bacteria in the root zone of rice plants are stimulated after fertilization. Using a combination of radioactive fingerprinting(11) and molecular biology(12) techniques, we identify the bacteria responsible for this effect. We expect that our results will make necessary a re-evaluation of the link between fertilizer use and methane emissions, with effects on global warming studies.	Netherlands Inst Ecol, Ctr Limnol, NL-3631 AC Nieuwersluis, Netherlands; Max Planck Inst Terr Microbiol, Dept Biogeochem, D-35043 Marburg, Germany; Univ Aalborg, Environm Engn Lab, DK-9000 Aalborg, Denmark	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Max Planck Society; Aalborg University	Bodelier, PLE (corresponding author), Netherlands Inst Ecol, Ctr Limnol, Rijksstr Weg 6, NL-3631 AC Nieuwersluis, Netherlands.		Bodelier, Paul/AAF-8353-2020; Bodelier, Paul L/A-9591-2011	Bodelier, Paul/0000-0002-5757-5572; Bodelier, Paul L/0000-0002-5757-5572				Banik A, 1996, BIOL FERT SOILS, V21, P319, DOI 10.1007/BF00334910; Bodelier PLE, 1999, APPL ENVIRON MICROB, V65, P1826; Bodelier PLE, 1997, PLANT SOIL, V190, P91, DOI 10.1023/A:1004212814097; BODELIER PLE, UNPUB BIOGEOCHEMISTR; BOSSE U, 1993, FEMS MICROBIOL ECOL, V13, P123, DOI 10.1016/0168-6496(93)90030-B; Bosse U, 1997, APPL ENVIRON MICROB, V63, P1199, DOI 10.1128/AEM.63.4.1199-1207.1997; Cassman KG, 1998, FIELD CROP RES, V56, P7, DOI 10.1016/S0378-4290(97)00140-8; CRUTZEN PJ, RUMINANT PHYSL DIGES, P291; DUNFIELD P, 1995, APPL ENVIRON MICROB, V61, P3129, DOI 10.1128/AEM.61.8.3129-3135.1995; Gilbert B, 1998, SOIL BIOL BIOCHEM, V30, P1903, DOI 10.1016/S0038-0717(98)00061-3; Gulledge J, 1997, SOIL BIOL BIOCHEM, V29, P13, DOI 10.1016/S0038-0717(96)00265-9; Gulledge J, 1998, APPL ENVIRON MICROB, V64, P4291; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Henckel T, 1999, APPL ENVIRON MICROB, V65, P1980; King GM, 1998, APPL ENVIRON MICROB, V64, P253; KING GM, 1994, APPL ENVIRON MICROB, V60, P3220, DOI 10.1128/AEM.60.9.3220-3227.1994; KING GM, 1994, NATURE, V370, P282, DOI 10.1038/370282a0; LINDAU CW, 1991, PLANT SOIL, V136, P195, DOI 10.1007/BF02150050; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neue HU, 1997, SOIL USE MANAGE, V13, P258, DOI 10.1111/j.1475-2743.1997.tb00597.x; Roslev P, 1999, APPL ENVIRON MICROB, V65, P4064; Roslev P, 1998, J MICROBIOL METH, V31, P99, DOI 10.1016/S0167-7012(97)00094-8; STEUDLER PA, 1989, NATURE, V341, P314, DOI 10.1038/341314a0; Strunk O, 1996, ARB SOFTWARE ENV SEQ; SUNDH I, 1995, FEMS MICROBIOL ECOL, V18, P103, DOI 10.1111/j.1574-6941.1995.tb00167.x; vanderGon HACD, 1996, BIOL FERT SOILS, V22, P359, DOI 10.1007/BF00334584; vanderNat FJWA, 1997, APPL ENVIRON MICROB, V63, P4734, DOI 10.1128/AEM.63.12.4734-4740.1997	27	371	419	11	204	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					421	424		10.1038/35000193	http://dx.doi.org/10.1038/35000193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667792				2022-12-24	WOS:000085121100048
J	Morrow, M; Schnitt, SJ				Morrow, M; Schnitt, SJ			Treatment selection in ductal carcinoma in situ	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; IN-SITU; INSITU; LESIONS; AUTOPSY; THERAPY		Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Pathol, Boston, MA USA	Northwestern University; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morrow, M (corresponding author), NW Mem Hosp, Lynn Sage Comprehens Breast Ctr, 251 E Huron St,Galter 13-174, Chicago, IL 60611 USA.							BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Hiramatsu H, 1995, Cancer J Sci Am, V1, P55; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; KINNE DW, 1989, ARCH SURG-CHICAGO, V124, P33; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; MORROW M, 2000, DIS BREAST, P383; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; Pandya S, 1998, BREAST J, V4, P146; Ravdin PM, 1998, J CLIN ONCOL, V16, P515, DOI 10.1200/JCO.1998.16.2.515; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN, P443; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754	19	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					453	455		10.1001/jama.283.4.453	http://dx.doi.org/10.1001/jama.283.4.453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659859				2022-12-24	WOS:000084879800002
J	Alexander, JH; Sparapani, RA; Mahaffey, KW; Deckers, JW; Newby, LK; Ohman, EM; Corbalan, R; Chierchia, SL; Boland, JB; Simoons, ML; Califf, RM; Topol, EJ; Harrington, RA				Alexander, JH; Sparapani, RA; Mahaffey, KW; Deckers, JW; Newby, LK; Ohman, EM; Corbalan, R; Chierchia, SL; Boland, JB; Simoons, ML; Califf, RM; Topol, EJ; Harrington, RA		PURSUIT Steering Comm	Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN-T; PROGNOSTIC-SIGNIFICANCE; CK-MB; SIZE; ISOENZYME; ISCHEMIA; RELEASE; INTERVENTIONS; PHOSPHOKINASE	Context Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation. Objectives To investigate the relationship between peak creatine kinase (CK)-MB level and outcome and to determine whether a threshold CK-MB level exists below which risk is not increased. Design and Setting Retrospective observational analysis of data from the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, conducted from November 1995 to January 1997, Patients A total of 8250 patients with acute coronary sydromes without ST-segment elevation who had at least 1 CK-MB sample collected during their index hospitalization. Main Outcome Measure Mortality at 30 days and 6 months, was assessed by category of index-hospitalization peak CK-MB level (0-1, >1-2, >2-3, >3-5, >5-10, or >10 times the upper limit of normal). Multivariable logistic regression was used to determine the independent prognostic significance of peak CK-MB level after adjustment for baseline predictors of 30-day and 6-month mortality. Results Mortality at 30 days and 6 months increased from 1.8% and 4.0%, respectively, in patients with normal peak CK-MB levels, to 3.3% and 6.2% at peak CK-MB levels 1 to 2 times normal, to 5.1% and 7.5% at peak CK-MB levels 3 to 5 times normal, and to 8.3% and 11.0% at peak CK-MB levels greater than 10 times normal. Log-transformed peak CK-MB levels were predictive of adjusted 30-day and 6-month mortality (P<.001 for both). Conclusions Our data show that elevation of CK-MB level is strongly related to mortality in patients with acute coronary syndromes without ST-segment elevation, and that the increased risk begins with CK-MB levels just above normal. in the appropriate clinical context, even minor CK-MB elevations should be considered indicative of myocardial infarction.	Duke Clin Res Inst, Durham, NC 27715 USA; Catholic Univ Chile, Santiago, Chile; Univ Milan, Osped San Raffaele, I-20127 Milan, Italy; Hop Citadelle, Liege, Belgium; Cardialysis, Rotterdam, Netherlands; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Duke University; Pontificia Universidad Catolica de Chile; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Cardialysis; Cleveland Clinic Foundation	Alexander, JH (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.		Alexander, John/GVS-7271-2022	Alexander, John/0000-0002-1444-2462; Topol, Eric/0000-0002-1478-4729; Sparapani, Rodney/0000-0002-7780-6825				Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; Adgey AAJ, 1999, CLIN CARDIOL, V22, P257; AHMED SA, 1976, CIRCULATION, V54, P187, DOI 10.1161/01.CIR.54.2.187; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BITTL JA, 1985, J BIOL CHEM, V260, P208; BLEIFELD W, 1977, CIRCULATION, V55, P303, DOI 10.1161/01.CIR.55.2.303; Boersma Eric, 1999, Journal of the American College of Cardiology, V33, p359A; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; CLYNE CA, 1989, AM HEART J, V118, P901, DOI 10.1016/0002-8703(89)90221-4; COHEN L, 1984, PRINCIPLES PRACTICE, P383; COX JR, 1976, CIRCULATION, V53, P150; Cutlip D. E., 1997, Journal of the American College of Cardiology, V29, p187A; FIORETTI P, 1985, EUR HEART J, V6, P473, DOI 10.1093/oxfordjournals.eurheartj.a061892; GELTMAN EM, 1979, AM J CARDIOL, V43, P370; GEWIRTZ H, 1979, CIRCULATION, V59, P707, DOI 10.1161/01.CIR.59.4.707; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; HONG RA, 1986, AM HEART J, V111, P1041, DOI 10.1016/0002-8703(86)90004-9; Hudson Michael P., 1999, Journal of the American College of Cardiology, V33, p325A; Koch KC, 1999, J AM COLL CARDIOL, V33, P998, DOI 10.1016/S0735-1097(98)00659-7; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; KORNOWSKI R, 1993, AM J CARDIOL, V72, P883, DOI 10.1016/0002-9149(93)91100-V; MARMOR A, 1978, LANCET, V2, P812; MATHEY D, 1974, BRIT HEART J, V36, P271; MERCER DW, 1975, CLIN CHEM, V21, P1088; MUELLER HS, 1995, J AM COLL CARDIOL, V26, P900, DOI 10.1016/0735-1097(95)00270-1; NORRIS RM, 1975, CIRCULATION, V51, P614, DOI 10.1161/01.CIR.51.4.614; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; ROBERTS R, 1975, BRIT HEART J, V37, P1169; ROGERS WJ, 1977, CIRCULATION, V56, P199, DOI 10.1161/01.CIR.56.2.199; Savonitto Stefano, 1999, Journal of the American College of Cardiology, V33, p346A; SHELL WE, 1976, CIRCULATION, V53, P98; Simoons ML, 1999, EUR HEART J, V20, P1112, DOI 10.1053/euhj.1999.1521; SOBEL BE, 1972, CIRCULATION, V46, P640, DOI 10.1161/01.CIR.46.4.640; Stone Gregg W., 1999, Journal of the American College of Cardiology, V33, p80A; Tardiff BE, 1999, J AM COLL CARDIOL, V33, P88, DOI 10.1016/S0735-1097(98)00551-8; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; van Domburg R. T., 1998, European Heart Journal, V19, P166; Wagner GS, 1982, ARCH INTERN MED, V140, P33; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; YUSUF S, 1987, AM J CARDIOL, V59, P245, DOI 10.1016/0002-9149(87)90793-4	46	88	93	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					347	353		10.1001/jama.283.3.347	http://dx.doi.org/10.1001/jama.283.3.347			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647797	Green Published, Bronze			2022-12-24	WOS:000084732400026
J	Ginsburg, J; Prelevic, GM				Ginsburg, J; Prelevic, GM			Lack of significant hormonal effects and controlled trials of phyto-oestrogens	LANCET			English	Editorial Material							SOY; MENOPAUSE; ESTROGEN; WOMEN		UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2QG, England	University of London; University College London; UCL Medical School	Ginsburg, J (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2QG, England.							ALDERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; BOULET MJ, 1994, MATURITAS, V19, P157, DOI 10.1016/0378-5122(94)90068-X; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P3479, DOI 10.1210/jc.84.10.3479; HUNTER MS, 1990, PSYCHOSOM MED, V52, P357, DOI 10.1097/00006842-199005000-00009; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Martini MC, 1999, NUTR CANCER, V34, P133, DOI 10.1207/S15327914NC3402_2; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; Nestel PJ, 1999, J CLIN ENDOCR METAB, V84, P895, DOI 10.1210/jc.84.3.895; TANG DG, 1993, PROSTAG OTH LIPID M, V45, P249, DOI 10.1016/0090-6980(93)90051-8; Xu X, 1998, CANCER EPIDEM BIOMAR, V7, P1101	12	28	29	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					163	164		10.1016/S0140-6736(99)00428-6	http://dx.doi.org/10.1016/S0140-6736(99)00428-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675113				2022-12-24	WOS:000084879700007
J	Le Naour, F; Rubinstein, E; Jasmin, C; Prenant, M; Boucheix, C				Le Naour, F; Rubinstein, E; Jasmin, C; Prenant, M; Boucheix, C			Severely reduced female fertility in CD9-deficient mice	SCIENCE			English	Article							INTEGRIN COMPLEXES; ZONA-PELLUCIDA; MOUSE OOCYTES; CELL-SURFACE; CD9 ANTIGEN; HB-EGF; GENE; EXPRESSION; PROTEINS; LOCALIZATION	CD9 is a widely expressed cell surface molecule that belongs to the tetraspanin superfamily of proteins. The tetraspanins CD9, KAI-1/CD82, and CD63 are involved in metastasis suppression, an effect that may be related to their association with beta 1 integrins. Knockout mice lacking CD9 were created to evaluate the physiological importance of CD9. CD9(-/-) females displayed a severe reduction of fertility. Oocytes were ovulated but were not successfully fertilized because sperm did not fuse with the oocytes from CD9(-/-) females. Thus, CD9 appears to be essential for sperm-egg fusion, a process involving the CD9-associated integrin alpha 6 beta 1.	Hop Paul Brousse, INSERM, U 268, F-94800 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boucheix, C (corresponding author), Hop Paul Brousse, INSERM, U 268, F-94800 Villejuif, France.	boucheix@infoblogen.fr	Rubinstein, Eric/B-4650-2019	Rubinstein, Eric/0000-0001-7623-9665; Boucheix, Claude/0000-0003-4184-7008				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Capmany G, 1998, MOL HUM REPROD, V4, P951, DOI 10.1093/molehr/4.10.951; CONOVER JC, 1988, J REPROD FERTIL, V82, P681, DOI 10.1530/jrf.0.0820681; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EVANS JP, 1995, MOL REPROD DEV, V40, P211, DOI 10.1002/mrd.1080400210; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hogan B, 1994, MANIPULATING MOUSE E; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KUBIAK JZ, 1992, J CELL SCI, V102, P457; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; LANZA F, 1991, J BIOL CHEM, V266, P10638; LeNaour F, 1997, LEUKEMIA, V11, P1290, DOI 10.1038/sj.leu.2400721; LeNaour F, 1996, ONCOGENE, V13, P481; LENAOUR F, UNPUB; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Monget P, 1999, M S-MED SCI, V15, P141, DOI 10.4267/10608/1304; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rankin T, 1996, DEVELOPMENT, V122, P2903; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; TARONE G, 1993, DEVELOPMENT, V117, P1369; Zuccotti M, 1998, DEV BIOL, V200, P27, DOI 10.1006/dbio.1998.8923	30	508	523	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					319	321		10.1126/science.287.5451.319	http://dx.doi.org/10.1126/science.287.5451.319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634790				2022-12-24	WOS:000084769600045
J	Li, JX; Wang, XQ; Watson, MB; Assmann, SM				Li, JX; Wang, XQ; Watson, MB; Assmann, SM			Regulation of abscisic acid-induced stomatal closure and anion channels by guard cell AAPK kinase	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ARABIDOPSIS-THALIANA; CALCIUM; PHOSPHATASE; RESPONSES; BLOCKERS; PLANTS; GENE; ABI1	Abscisic acid (ABA) stimulates stomatal closure and thus supports water conservation by plants during drought. Mass spectrometry-generated peptide sequence information was used to clone a Vicia faba complementary DNA, AAPK, encoding a guard cell-specific ABA-activated serine-threonine protein kinase.(AAPK). Expression in transformed guard cells of AAPK altered by one amino acid (lysine 43 to alanine 43) renders stomata insensitive to ABA-induced closure by eliminating ABA activation of plasma membrane anion channels. This information should allow cell-specific, targeted biotechnological manipulation of crop water status.	Penn State Univ, Mueller Lab 208, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Assmann, SM (corresponding author), Penn State Univ, Mueller Lab 208, Dept Biol, University Pk, PA 16802 USA.			Wang, Xi-Qing/0000-0003-4477-9557				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; Assmann SM, 1998, J EXP BOT, V49, P163, DOI 10.1093/jexbot/49.319.163; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DAVIES WJ, 1991, ABSCISIC ACID PHYSIO; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Gomez-Cadenas A, 1999, P NATL ACAD SCI USA, V96, P1767, DOI 10.1073/pnas.96.4.1767; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holappa LD, 1997, PLANT MOL BIOL, V33, P935, DOI 10.1023/A:1005720203535; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P22; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li JX, 1996, PLANT CELL, V8, P2359, DOI 10.1105/tpc.8.12.2359; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; LOO JA, 1995, BIOCONJUGATE CHEM, V6, P644, DOI 10.1021/bc00036a600; LOVEYS BR, 1984, NEW PHYTOL, V98, P563, DOI 10.1111/j.1469-8137.1984.tb04149.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Mori IC, 1997, PLANT PHYSIOL, V113, P833, DOI 10.1104/pp.113.3.833; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; SCHROEDER JI, 1993, PLANT CELL, V5, P1831, DOI 10.1105/tpc.5.12.1831; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; Schwarz M, 1998, FEBS LETT, V428, P177, DOI 10.1016/S0014-5793(98)00526-2; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Wang XQ, 1998, PLANT PHYSIOL, V118, P1421, DOI 10.1104/pp.118.4.1421; WANG YH, 1993, ARCH BIOCHEM BIOPHYS, V304, P496, DOI 10.1006/abbi.1993.1381	34	340	398	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					300	303		10.1126/science.287.5451.300	http://dx.doi.org/10.1126/science.287.5451.300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634783				2022-12-24	WOS:000084769600038
J	Dalrymple, J; Appleby, J				Dalrymple, J; Appleby, J			Cross sectional study of reporting of epileptic seizures to general practitioners	BRITISH MEDICAL JOURNAL			English	Article							POPULATION; ACCIDENTS; COMMUNITY; STIGMA; RATES	Objective Comparison of reporting of recent epileptic seizures by patients to a doctor and anonymously. Design Cross sectional study of patients with epilepsy by comparison of paired questionnaires. Setting Rural and urban general practices in Norfolk. Participants 122 patients aged over 16 years and able to self complete a questionnaire who were recruited by 31 general practitioners when attending for review of their epilepsy. Main outcome measure The difference in reported occurrence of seizure to general practitioners and in a linked anonymous questionnaire. Results 18 patients failed to report a seizure in the past year to their general practitioner (uncontrolled epilepsy). 40% (24/60) of people with epilepsy who anonymously reported a seizure in the past year held a driving licence, but only six revealed this to their general practitioner. The unemployment rate was 34%, substantially higher than the 9% in the general population. Measures of anxiety, depression and stigmatisation were higher in patients with uncontrolled epilepsy. Conclusions A significant proportion of patients with epilepsy underreport their seizures. Recognition of underreporting is important if patients are to benefit from adequate and appropriate treatment. General practitioners' ability to treat epilepsy is hampered by their role in regulating the rights of epileptic patients to hold a driving licence or access certain occupations.	Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England; Kings Fund, Policy & Dev Directorate, Hlth Syst Programme, London W1M 0AN, England	University of East Anglia	Dalrymple, J (corresponding author), Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England.							Beaussart M, 1997, Med Law, V16, P295; Black A B, 1997, Med Law, V16, P253; Brown S, 1993, Seizure, V2, P91, DOI 10.1016/S1059-1311(05)80111-6; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Collings J A, 1994, Seizure, V3, P255, DOI 10.1016/S1059-1311(05)80172-4; Gilliam F, 1997, EPILEPSIA, V38, P233, DOI 10.1111/j.1528-1157.1997.tb01102.x; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HANSOTIA P, 1991, NEW ENGL J MED, V324, P1511; HOPKINS A, 1977, LANCET, V1, P183; HOPKINS AP, 1996, OXFORD TXB MED, P3924; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KRUMHOLZ A, 1994, EPILEPSIA, V35, P668, DOI 10.1111/j.1528-1157.1994.tb02490.x; Ridsdale L, 1996, BRIT J GEN PRACT, V46, P365; SALINSKY MC, 1992, EPILEPSIA, V33, P469, DOI 10.1111/j.1528-1157.1992.tb01693.x; SCAMBLER G, 1986, SOCIOL HEALTH ILL, V8, P26, DOI 10.1111/1467-9566.ep11346455; SCAMBLER G, 1989, EXPERIENCE ILLNESS, P52; Scheinder JW, 1981, SOC SCI MED A, V15A, P211; TAYLOR J, 1995, QJM-MON J ASSOC PHYS, V88, P733; Thapar AK, 1996, BRIT J GEN PRACT, V46, P37; Troster H, 1997, EPILEPSIA, V38, P1227, DOI 10.1111/j.1528-1157.1997.tb01221.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P747, DOI 10.1111/j.1528-1157.1975.tb04760.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P743; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	63	64	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					94	97		10.1136/bmj.320.7227.94	http://dx.doi.org/10.1136/bmj.320.7227.94			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625265	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000084746600020
J	Henney, JE				Henney, JE			Injunction affecting Abbott's in vitro test devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-24	WOS:000084514400005
J	Schiffman, M; Herrero, R; Hildesheim, A; Sherman, ME; Bratti, M; Wacholder, S; Alfaro, M; Hutchinson, M; Morales, J; Greenberg, MD; Lorincz, AT				Schiffman, M; Herrero, R; Hildesheim, A; Sherman, ME; Bratti, M; Wacholder, S; Alfaro, M; Hutchinson, M; Morales, J; Greenberg, MD; Lorincz, AT			HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; ATYPICAL SQUAMOUS CELLS; INTRAEPITHELIAL NEOPLASIA; UNDETERMINED SIGNIFICANCE; TYPE-16; TRIAGE	Context Human papillomaviruses (HPVs) are known to cause most cervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been determined. Objective To provide comprehensive data on the screening performance of HPV testing for the most common carcinogenic types, at different levels of analytic sensitivity. Design Laboratory analysis conducted during 1993-1995, using 3 cytologic techniques and cervicography, followed by colposcopic examination of women with any abnormal cervical finding, to detect all high-grade intraepithelial lesions and cancer (reference standard of clinically significant disease). The HPV testing was performed subsequently with masking regarding clinical findings. Setting Guanacaste Province, Costa Rica, a region with a high age-adjusted incidence of cervical cancer. Participants Of 11742 randomly selected women, 8554 nonpregnant, sexually active women without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube test; a stratified subsample of 1119 specimens was retested using the more analytically sensitive second generation assay, the Hybrid Capture II test. Main Outcome Measures Receiver operating characteristic analysis of detection of cervical high-grade intraepithelial lesions and cancer by HPV DNA testing based on different cut points of positivity. Results An analytic sensitivity of 1.0 pg/mL using the second generation assay would have permitted detection of 88.4% of 138 high-grade lesions and cancers (all 12 cancers were HPV-positive), with colposcopic referral of 12.3% of women. Papanicolaou testing using atypical squamous cells of undetermined significance as a cut point for referral resulted in 77.7% sensitivity and 94.2% specificity, with 6.9% referred. Specificity of the second generation assay for positivity for high-grade lesions and cancer was 89.0%, with 33.8% of remaining HPV DNA-positive subjects having low-grade or equivocal microscopically evident lesions. The higher detection threshold of 10 pg/mL used with the original assay had a sensitivity of 74.8% and a specificity of 93.4%, Lower levels of detection with the second generation assay (<1 pg/mL) proved clinically nonspecific without gains in diagnostic sensitivity, Conclusions In this study population, a cut point of 1.0 pg/mL using the second generation assay permitted sensitive detection of cervical high-grade lesions and cancer, yielding an apparently optimal trade-off between high sensitivity and reasonable specificity for this test. The test will perform best in settings in which sensitive detection of high-grade lesions and cancer is paramount. Because HPV prevalence varies by population, HPV testing positive predictive value for detection of high-grade lesions and cancer will vary accordingly, with implications for utility relative to other cervical cancer screening methods.	NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Int Agcy Res Canc, F-69372 Lyon, France; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Costa Rican Social Secur Adm, San Jose, Costa Rica; Brown Univ, Women & Infants Hosp, Providence, RI USA; Omnia, Blue Bell, PA USA; Digene Corp, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); World Health Organization; International Agency for Research on Cancer (IARC); Johns Hopkins University; Johns Hopkins Medicine; Brown University; Women & Infants Hospital Rhode Island	Schiffman, M (corresponding author), NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Room 7066,6120 Execut Blvd, Rockville, MD 20852 USA.	schiffmm@exchange.nih.gov	Schiffman, Mark/B-9766-2015		NATIONAL CANCER INSTITUTE [Z01CP010124, ZIACP010124] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ALTS GROUP, IN PRESS J NATL CANC; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; Carter JJ, 1996, J INFECT DIS, V174, P927, DOI 10.1093/infdis/174.5.927; Cox JT, 1998, J FAM PRACTICE, V46, P121; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Crum CP, 1998, AM J PATHOL, V153, P1667, DOI 10.1016/S0002-9440(10)65679-9; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Herrero R, 1993, Bull Pan Am Health Organ, V27, P15; HERRERO R, 1997, PAN AM J PUBLIC HLTH, V1, P362; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; Kaufman RH, 1997, AM J OBSTET GYNECOL, V177, P930, DOI 10.1016/S0002-9378(97)70296-5; KIVIAT NB, 1990, AM J CLIN PATHOL, V94, P561, DOI 10.1093/ajcp/94.5.561; LORINCZ A, 1996, PAPILLOMAVIRUS REPOR, V7, P1; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; SCHIFFMAN MH, 1992, EPIDEMIOLOGY HUMAN P, P169; SCHIFFMAN MH, 1994, EARLY DETECTION CANC, P265; SCHIFFMAN MH, 1997, VIRAL INFECT HUMANS, P983; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; Schneider DL, 1999, AM J OBSTET GYNECOL, V180, P290, DOI 10.1016/S0002-9378(99)70202-4; Sherman ME, 1998, CANCER CYTOPATHOL, V84, P273; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	405	430	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					87	93		10.1001/jama.283.1.87	http://dx.doi.org/10.1001/jama.283.1.87			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632285	Bronze			2022-12-24	WOS:000084514400030
J	Pepin, M; Schwarze, U; Superti-Furga, A; Byers, PH				Pepin, M; Schwarze, U; Superti-Furga, A; Byers, PH			Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIEXON DELETION; III COLLAGEN; COL3A1 GENE; PREGNANCY; COMPLICATIONS; PROCOLLAGEN; MUTATIONS; DNA; SUBSTITUTION; ALLELE	Background: Ehlers-Danlos syndrome type IV, the vascular type, results from mutations in the gene for type III procollagen (COL3A1). Affected patients are at risk for arterial, bowel, and uterine rupture, but the timing of these events, their frequency, and the course of the disease are not well documented. Methods: We reviewed the clinical and family histories of and medical and surgical complications in 220 index patients with biochemically confirmed Ehlers-Danlos syndrome type IV and 199 of their affected relatives. We identified the underlying COL3A1 mutation in 135 index patients. Results: Complications were rare in childhood; 25 percent of the index patients had a first complication by the age of 20 years, and more than 80 percent had had at least one complication by the age of 40. The calculated median survival of the entire cohort was 48 years. Most deaths resulted from arterial rupture. Bowel rupture, which often involved the sigmoid colon, accounted for about a quarter of complications but rarely led to death. Complications of pregnancy led to death in 12 of the 81 women who became pregnant. The types of complications were not associated with specific mutations in COL3A1. Conclusions: Although most affected patients survive the first and second major complications, Ehlers-Danlos syndrome type IV results in premature death. The diagnosis should be considered in young people who come to medical attention because of uterine rupture during pregnancy or arterial or visceral rupture. (N Engl J Med 2000;342:673-80.) (C)2000, Massachusetts Medical Society.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Zurich, Dept Pediat, Div Metab & Mol Dis, Zurich, Switzerland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Zurich	Byers, PH (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	pbyers@u.washington.edu	superti-furga, andrea/E-9162-2015	superti-furga, andrea/0000-0002-3543-7531; Byers, Peter H./0000-0001-7786-7030	NIAMS NIH HHS [AR 21557] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BEIGHTON P, 1993, MCKUSICKS HERITABLE; Bergqvist D, 1996, EUR J SURG, V162, P163; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRIGHOUSE D, 1992, BRIT J ANAESTH, V69, P517, DOI 10.1093/bja/69.5.517; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; DEPAEPE A, 1989, EUR J OBSTET GYN R B, V33, P189, DOI 10.1016/0028-2243(89)90214-1; Freeman RK, 1996, AM SURGEON, V62, P869; Gilchrist D, 1999, AM J MED GENET, V82, P305, DOI 10.1002/(SICI)1096-8628(19990212)82:4<305::AID-AJMG6>3.3.CO;2-3; JAMES LM, 1993, TERATOLOGY, V48, P707; KONTUSAARI S, 1992, AM J HUM GENET, V51, P497; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; MILEWICZ DM, 1993, AM J HUM GENET, V53, P62; NARCISI P, 1994, HUM MOL GENET, V3, P1617, DOI 10.1093/hmg/3.9.1617; *NAT CTR HLTH STAT, 1998, DHHS PUBL; North KN, 1995, ANN NEUROL, V38, P960, DOI 10.1002/ana.410380620; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEACEMAN AM, 1987, OBSTET GYNECOL, V69, P428; Pope FM, 1996, BRIT J DERMATOL, V135, P163, DOI 10.1046/j.1365-2133.1996.d01-971.x; POPE FM, 1983, LANCET, V1, P249; RUDD NL, 1983, LANCET, V1, P50; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook JFE, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwarze U, 1997, AM J HUM GENET, V61, P1276, DOI 10.1086/301641; Steinmann Beat, 1993, P351; VENTURA SJ, 1995, MON VITAL STAT REP S, V44, P75; VISSING H, 1991, J BIOL CHEM, V266, P5244; WEINBAUM PJ, 1987, AM J PERINAT, V4, P134, DOI 10.1055/s-2007-999756	30	775	814	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2000	342	10					673	680		10.1056/NEJM200003093421001	http://dx.doi.org/10.1056/NEJM200003093421001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ZW	10706896	Bronze			2022-12-24	WOS:000085708800001
J	Tosswill, JHC; Taylor, GP; Tedder, RS; Mortimer, PP				Tosswill, JHC; Taylor, GP; Tedder, RS; Mortimer, PP			HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, London W2 1PG, England; Cent Publ Hlth Lab, Virus Reference Div, London NW9 5HT, England; UCL, Royal Free & Univ Coll Med Sch, Dept Virol, London W1P 6DB, England	Imperial College London; Public Health England; University of London; University College London	Taylor, GP (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, Praed St, London W2 1PG, England.	g.p.taylor@ic.ac.uk						HASKEY J, 1997, POPULATION TRENDS, V88, P13; International Agency of Research on Cancer, 1996, IARC MON EV CARC RIS, V67; KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096; Simms I, 1994, Commun Dis Rep CDR Rev, V4, pR65; Tynell E, 1998, BRIT MED J, V316, P1417, DOI 10.1136/bmj.316.7142.1417	5	28	28	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 4	2000	320	7235					611	612		10.1136/bmj.320.7235.611	http://dx.doi.org/10.1136/bmj.320.7235.611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291NH	10698878	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000085742600024
J	Nakano, S; Chadalavada, DM; Bevilacqua, PC				Nakano, S; Chadalavada, DM; Bevilacqua, PC			General acid-base catalysis in the mechanism of a hepatitis delta virus ribozyme	SCIENCE			English	Article							METAL-ION CATALYSIS; GROUP-I RIBOZYME; ACTIVE-SITE; CRYSTAL-STRUCTURE; RNA; CLEAVAGE; HAIRPIN; HAMMERHEAD; DOMAIN; SPECIFICITY	Many protein enzymes use general acid-base catalysis as a way to increase reaction rates. The amino acid histidine is optimized for this function because it has a pK(a) (where K-a is the acid dissociation constant) near physiological pH. The RNA enzyme (ribozyme) from hepatitis delta virus catalyzes self-cleavage of a phosphodiester bond. Reactivity-pH profiles in monovalent or divalent cations, as well as distance to the Leaving-group oxygen, implicate cytosine 75 (C75) of the ribozyme as the general acid and ribozyme-bound hydrated metal hydroxide as the general base in the self-cleavage reaction. Moreover, C75 has a pK(a) perturbed to neutrality, making it "histidine-like." Anticooperative interaction is observed between protonated C75 and a metal ion, which serves to modulate the pK(a) of C75. General acid-base catalysis expands the catalytic repertoire of RNA and may provide improved rate acceleration.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bevilacqua, PC (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.		Chadalavada, Durga/A-5233-2011	Bevilacqua, Philip/0000-0001-8074-3434; Ghosh, Durga/0000-0003-1367-8198	NIGMS NIH HHS [GM58709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASOLO R, 1988, MECHANISMS INORGANIC; Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Cech TR, 1999, RNA WORLD, P321; CHADALAVADA D, UNPUB; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DASILVA FJJ, 1993, BIOL CHEM ELEMENTS; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fersht A., 1985, ENZYME STRUCTURE MEC; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hampel KJ, 1998, BIOCHEMISTRY-US, V37, P14672, DOI 10.1021/bi981083n; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Jencks W. P., 1987, CATALYSIS CHEM ENZYM, P163; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KIRBY AJ, 1970, J CHEM SOC B, P1165, DOI 10.1039/j29700001165; KIRBY AJ, 1970, J CHEM SOC B, P510, DOI 10.1039/j29700000510; Legault P, 1997, J AM CHEM SOC, V119, P6621, DOI 10.1021/ja9640051; LEGAULT P, 1994, J AM CHEM SOC, V116, P8390, DOI 10.1021/ja00097a066; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; Oivanen M, 1998, CHEM REV, V98, P961, DOI 10.1021/cr960425x; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; Pontius BW, 1997, P NATL ACAD SCI USA, V94, P2290, DOI 10.1073/pnas.94.6.2290; Saenger W., 1984, PRINCIPLES NUCL ACID; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Segel I.H, 1993, ENZYME KINETICS; Shan SO, 1999, P NATL ACAD SCI USA, V96, P12299, DOI 10.1073/pnas.96.22.12299; Shih IH, 1999, RNA, V5, P1140, DOI 10.1017/S1355838299990763; Shim JH, 1999, BIOCHEMISTRY-US, V38, P10024, DOI 10.1021/bi9904609; Suga H, 1998, BIOCHEMISTRY-US, V37, P10118, DOI 10.1021/bi980432a; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; Wadkins TS, 1999, RNA, V5, P720, DOI 10.1017/S1355838299990209; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; Yoshida A, 1999, NAT STRUCT BIOL, V6, P318; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760	48	352	368	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1493	1497		10.1126/science.287.5457.1493	http://dx.doi.org/10.1126/science.287.5457.1493			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10688799				2022-12-24	WOS:000085531600053
J	Reed, MB; Saliba, KJ; Caruana, SR; Kirk, K; Cowman, AF				Reed, MB; Saliba, KJ; Caruana, SR; Kirk, K; Cowman, AF			Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum	NATURE			English	Article							CHLOROQUINE RESISTANCE; P-GLYCOPROTEIN; PHYSICOCHEMICAL PROPERTIES; HALOFANTRINE RESISTANCE; MALARIA PARASITES; IN-VITRO; GENE; AMPLIFICATION; DRUG; TRANSFORMATION	Throughout the latter half of this century, the development and spread of resistance to most front-line antimalarial compounds used in the prevention and treatment of the most severe form of human malaria has given cause for grave clinical concern. Polymorphisms in pfmdr1, the gene encoding the P-glycoprotein homologue 1 (Pgh1) protein of Plasmodium falciparum, have been linked to chloroquine resistance(1); Pgh1 has also been implicated in resistance to mefloquine and halofantrine(2-5). However, conclusive evidence of a direct causal association between pfmdr1 and resistance to these antimalarials has remained elusive, and a single genetic cross has suggested that Pgh1 is not involved in resistance to chloroquine and mefloquine(6). Here we provide direct proof that mutations in Pgh1 can confer resistance to mefloquine, quinine and halofantrine. The same mutations influence parasite resistance towards chloroquine in a strain-specific manner and the level of sensitivity to the structurally unrelated compound, artemisinin, This has important implications for the development and efficacy of future antimalarial agents.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Australian Natl Univ, Fac Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Walter & Eliza Hall Institute; Australian National University	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	cowman@wehi.edu.au	Saliba, Kevin J/C-9166-2009; Cowman, Alan F/C-7642-2013; Kirk, Kiaran/C-8299-2009	Saliba, Kevin J/0000-0003-3345-8440; Cowman, Alan F/0000-0001-5145-9004; Kirk, Kiaran/0000-0002-5613-2622				Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Bray PG, 1996, MOL PHARMACOL, V50, P1559; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; CREMER G, 1995, EXP PARASITOL, V81, P1, DOI 10.1006/expr.1995.1086; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DOURY JC, 1992, TROP MED PARASITOL, V43, P197; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEARY TG, 1990, BIOCHEM PHARMACOL, V40, P685, DOI 10.1016/0006-2952(90)90302-2; Hawley SR, 1996, BIOCHEM PHARMACOL, V52, P723, DOI 10.1016/0006-2952(96)00354-1; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; PEEL SA, 1993, AM J TROP MED HYG, V48, P385, DOI 10.4269/ajtmh.1993.48.385; PEEL SA, 1994, AM J TROP MED HYG, V51, P648, DOI 10.4269/ajtmh.1994.51.648; Ritchie GY, 1996, MOL BIOCHEM PARASIT, V83, P35, DOI 10.1016/S0166-6851(96)02746-6; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; WARD SA, 1995, ANN TROP MED PARASIT, V89, P121, DOI 10.1080/00034983.1995.11812942; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	27	682	704	0	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					906	909		10.1038/35002615	http://dx.doi.org/10.1038/35002615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706290				2022-12-24	WOS:000085559200061
J	Averof, M; Rokas, A; Wolfe, KH; Sharp, PM				Averof, M; Rokas, A; Wolfe, KH; Sharp, PM			Evidence for a high frequency of simultaneous double-nucleotide substitutions	SCIENCE			English	Article							NONSYNONYMOUS SUBSTITUTIONS; MOLECULAR EVOLUTION; UBIQUITIN GENES; 2 SERINES; SEQUENCE; DNA; DIVERGENCE; ALIGNMENT; MUTATION; GENOME	Point mutations are generally assumed to involve changes of single nucleotides. Nevertheless, the nature and known mechanisms of mutation do not exclude the possibility that several adjacent nucleotides may change simultaneously in a single mutational event. Two independent approaches are used here to estimate the frequency of simultaneous double-nucleotide substitutions. The first examines switches between TCN and ACY (where N is any nucleotide and Y is a pyrimidine) codons encoding absolutely conserved serine residues in a number of proteins from diverse organisms. The second reveals double-nucleotide substitutions in primate noncoding sequences. These two complementary approaches provide similar high estimates for the rate of doublet substitutions, on the order of 0.1 per site per billion years.	FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England	Foundation for Research & Technology - Hellas (FORTH); University of Edinburgh; Trinity College Dublin; University of Nottingham	Averof, M (corresponding author), FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece.		Sharp, Paul M/F-5783-2010; Wolfe, Kenneth H/B-4653-2009; Rokas, Antonis/A-9775-2008; Sharp, Paul M/GPX-1497-2022; Sharp, Paul/Y-3787-2019	Sharp, Paul M/0000-0001-9771-543X; Rokas, Antonis/0000-0002-7248-6551; Sharp, Paul M/0000-0001-9771-543X; Averof, Michalis/0000-0002-6803-7251; Wolfe, Kenneth/0000-0003-4992-4979				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Bailey WJ, 1992, MOL PHYLOGENET EVOL, V1, P97, DOI 10.1016/1055-7903(92)90024-B; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Comeron JM, 1998, GENETICS, V150, P767; DIAZLAZCOZ Y, 1995, J MOL BIOL, V250, P123, DOI 10.1006/jmbi.1995.0363; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Gaut BS, 1998, EVOL BIOL, V30, P93; GOLDFARB PS, 1988, NATURE, V336, P429, DOI 10.1038/336429a0; GOLDING GB, 1985, P NATL ACAD SCI USA, V82, P8577, DOI 10.1073/pnas.82.24.8577; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; HAMPSEY DM, 1988, J MOL BIOL, V201, P471, DOI 10.1016/0022-2836(88)90629-8; IRWIN DM, 1988, NATURE, V336, P429, DOI 10.1038/336429b0; Kimura M., 1985, POPULATION GENETICS, P19; KOONIN EV, 1989, NATURE, V338, P467, DOI 10.1038/338467b0; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li W-H, 1997, MOL EVOLUTION; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MIYAMOTO MM, 1988, P NATL ACAD SCI USA, V85, P7627, DOI 10.1073/pnas.85.20.7627; MOUCHIROUD D, 1995, J MOL EVOL, V40, P107, DOI 10.1007/BF00166602; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PALMER JD, 1988, ANN MO BOT GARD, V75, P1180, DOI 10.2307/2399279; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHARP PM, 1987, J MOL EVOL, V25, P58, DOI 10.1007/BF02100041; SHARP PM, 1995, PHILOS T R SOC B, V349, P241, DOI 10.1098/rstb.1995.0108; SHARP PM, 1987, TRENDS ECOL EVOL, V2, P328, DOI 10.1016/0169-5347(87)90108-X; Smith NGC, 1999, GENETICS, V153, P1395; SWOFFORD DL, 1990, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	38	91	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1283	1286		10.1126/science.287.5456.1283	http://dx.doi.org/10.1126/science.287.5456.1283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678838				2022-12-24	WOS:000085444700055
J	Goodson, JL; Bass, AH				Goodson, JL; Bass, AH			Forebrain peptides modulate sexually polymorphic vocal circuitry	NATURE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; TELEOST FISH; VASOTOCIN; VASOPRESSIN; AGGRESSION; OXYTOCIN; NEURONS; BRAIN; RATS; VERTEBRATES	The peptide arginine-vasopressin (mammals) and its evolutionary precursor arginine-vasotocin (non-mammals) modulate reproductive physiology and numerous related social behaviours, as do oxytocin (mammals) and its homologues mesotocin and isotocin (fish)(1). The distributions in the brain and/or the behavioural functions of these peptides often differ between the sexes(2-4), and between species with divergent social structures(3,5,6). Here we present neurophysiological evidence that males with vocal characteristics typical of females share a pattern of neuropeptide function with females rather than conspecific males. The plainfin midshipman fish (Porichthys notatus) has two male morphs with different reproductive tactics and vocalizations (a key species-typical behaviour which varies in its physical attributes and contextual usage, depending on the morph's social strategy)(7,8). Forebrain-evoked, rhythmic vocal-motor activity that precisely mimics natural vocalizations was modulated by arginine-vasotocin, isotocin and their antagonists delivered to the preoptic area-anterior hypothalamus, a primary site for behavioural integration in all vertebrates. Peptides had different effects in males that acoustically court females (arginine-vasotocin-sensitive) than in females and sneak-spawning males (isotocin-sensitive), showing that the neuromodulatory mechanisms that establish reproduction-related behaviour can be dissociated from gonadal sex.	Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA; Univ Calif Bodega, Marine Lab, Bodega Bay, CA 94923 USA	Cornell University	Goodson, JL (corresponding author), Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA.	jlg14@cornell.edu						Bass AH, 1996, AM SCI, V84, P352; BASS AH, 1990, J NEUROBIOL, V21, P1155, DOI 10.1002/neu.480210802; BASS AH, 1994, J NEUROSCI, V14, P4025; Bass AH, 1997, BRAIN BEHAV EVOLUT, V50, P3, DOI 10.1159/000113351; BATTEN TFC, 1990, J COMP NEUROL, V302, P893, DOI 10.1002/cne.903020416; BLUTHE RM, 1990, BRAIN RES, V535, P301, DOI 10.1016/0006-8993(90)91613-L; BRANTLEY RK, 1994, ETHOLOGY, V96, P213, DOI 10.1111/j.1439-0310.1994.tb01011.x; Delville Y, 1998, J NEUROSCI, V18, P2667; Emerson SB, 1999, BRAIN BEHAV EVOLUT, V53, P187, DOI 10.1159/000006594; Everts HGJ, 1997, HORM BEHAV, V31, P136, DOI 10.1006/hbeh.1997.1375; FINE ML, 1994, J COMP PHYSIOL A, V174, P173; Floody OR, 1998, PEPTIDES, V19, P833, DOI 10.1016/S0196-9781(98)00029-1; Foran CM, 1998, GEN COMP ENDOCR, V111, P271, DOI 10.1006/gcen.1998.7113; Goodson JL, 1998, GEN COMP ENDOCR, V111, P233, DOI 10.1006/gcen.1998.7112; Goodson JL, 1998, HORM BEHAV, V34, P67, DOI 10.1006/hbeh.1998.1467; Grober MS, 1996, NEUROREPORT, V7, P2945, DOI 10.1097/00001756-199611250-00029; HAUSMANN H, 1995, FEBS LETT, V370, P227, DOI 10.1016/0014-5793(95)00832-T; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MANNING M, 1989, J MED CHEM, V32, P382, DOI 10.1021/jm00122a016; Marler CA, 1999, HORM BEHAV, V36, P53, DOI 10.1006/hbeh.1999.1524; MOORE FL, 1992, ANN NY ACAD SCI, V652, P156, DOI 10.1111/j.1749-6632.1992.tb34352.x; MOORE FL, 1983, PEPTIDES, V4, P97, DOI 10.1016/0196-9781(83)90173-0; Moore FL, 1998, COMP BIOCHEM PHYS C, V119, P251, DOI 10.1016/S0742-8413(98)00014-0; Northcutt RG, 1980, COMP NEUROLOGY TELEN; Ota Y, 1999, GEN COMP ENDOCR, V116, P40, DOI [10.1006/gcen.1999.7344, 10.1006/gcen.1999.7343]; ROSE JD, 1995, NEUROENDOCRINOLOGY, V62, P406, DOI 10.1159/000127030; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; WINSLOW JT, 1993, EUR J PHARMACOL, V233, P101, DOI 10.1016/0014-2999(93)90354-K; YOUNG DS, 1975, CLIN CHEM, V21, pD1; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475	30	219	222	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					769	772		10.1038/35001581	http://dx.doi.org/10.1038/35001581			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693805				2022-12-24	WOS:000085423100052
J	Hall, S; Bobrow, M; Marteau, TM				Hall, S; Bobrow, M; Marteau, TM			Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NATIONAL REGISTER; ENGLAND; CHILD; WALES	Objective To determine the psychological consequences for parents of children with Down's syndrome of having received a false negative result on prenatal screening. Design Comparison of adjustment of parents who received a false negative result with that of parents not offered a test and those who declined a test. Setting Parents were interviewed in their own homes. Participants Parents of 179 children with Down's syndrome (mean age 4 (range 2-6) years). Main outcome measures Anxiety, depression, parenting stress, attitudes towards the child, and attributions of blame for the birth of the affected child. Results Overall, regardless of screening history, parents adjusted well to having a child with Down's syndrome. Compared with mothers who declined a test, mothers in the false negative group had higher parenting stress (mean score 81.2 v 71.8, P = 0.016, 95% confidence interval for the difference 1.8 to 17.0) and more negative attitudes towards their children (124.9 v 134.2, P = 0.009, -16.2 to -2.4). Fathers in the false negative group had higher parenting stress test scores (77.8 v 70.0, P = 0.046, 1.5 to 14.2) than fathers not offered a test Mothers in the false negative group were more likely to blame others for the outcome than mothers who had not been offered the test (28% v 13%, P = 0.032, 3% to 27%). Mothers and fathers in the false negative group were more likely to blame others for this outcome than parents who had declined a test (mothers 28% v 0%, P = 0.001, 19% to 37%; fathers 27% v 0%, P = 0.004, 17% to 38%). Blaming others was associated with poorer adjustment for mothers and fathers. Conclusions A false negative result on prenatal screening seems to have a small adverse effect on parental adjustment evident two to six years after the birth of an affected child.	Guys Kings Coll, Psychol & Genet Res Grp, London SE1 9RT, England; St Thomass Sch Med, London SE1 9RT, England; Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of London; King's College London; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Marteau, TM (corresponding author), Guys Kings Coll, Psychol & Genet Res Grp, Thomas Guy House,Guys Campus, London SE1 9RT, England.	theresa.marteau@kcl.ac.uk	Sandall, Jane/D-4146-2009; Hall, Sue/C-3584-2009	Sandall, Jane/0000-0003-2000-743X; Marteau, Theresa/0000-0003-3025-1129				Abidin R.R., 1990, PARENTING STRESS IND; Allanson A, 1997, J Med Screen, V4, P21; Cockburn J, 1995, J Med Screen, V2, P224; GARDNER SB, 1989, STAT CONFIDENCE; Hall S, 1997, PSYCHOL HEALTH, V12, P579, DOI 10.1080/08870449708406733; JUDSON SL, 1980, CHILD CARE HLTH DEV, V6, P47, DOI 10.1111/j.1365-2214.1980.tb00796.x; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; MUTTON DE, 1993, BRIT MED J, V306, P431, DOI 10.1136/bmj.306.6875.431; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PETTIGREW M, IN PRESS HLTH TECHNO; QUINE L, 1991, J COMMUNITY APPL SOC, V1, P57, DOI 10.1002/casp.2450010109; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SMITH DK, 1994, BRIT MED J, V309, P776, DOI 10.1136/bmj.309.6957.776; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; TENNEN H, 1990, PSYCHOL BULL, V108, P209, DOI 10.1037/0033-2909.108.2.209; Wald N J, 1997, J Med Screen, V4, P181; Wald NJ, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03819-2	19	51	51	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					407	412		10.1136/bmj.320.7232.407	http://dx.doi.org/10.1136/bmj.320.7232.407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285EU	10669444	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000085377400021
J	Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL				Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL			Evidence for DNA loss as a determinant of genome size	SCIENCE			English	Article							DROSOPHILA; EVOLUTION; PSEUDOGENES; RETROTRANSPOSONS; GENES	Eukaryotic genome sizes range over five orders of magnitude. This variation cannot be explained by differences in organismic complexity (the C value paradox). To test the hypothesis that some variation in genome size can be attributed to differences in the patterns of insertion and deletion (indel) mutations among organisms, this study examines the indel spectrum in Laupala crickets, which have a genome size 11 times larger than that of Drosophila. Consistent with the hypothesis. DNA Loss is more than 40 times slower in Laupala than in Drosophila.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA	Harvard University; Texas A&M University System; Texas A&M University College Station	Petrov, DA (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BELDA JE, 1991, CYTOBIOS, V67, P13; CAVALIERSMITH T, 1985, EVOLUTION GENOME SIZ, P523; Charlesworth B, 1996, NATURE, V384, P315, DOI 10.1038/384315a0; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JOHN B, 1988, EUKARYOTIC GENOME DE; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451; MORIYAMA E, 1997, MOL BIOL EVOL, V15, P770; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; PETROV D, UNPUB; Petrov DA, 1998, MOL BIOL EVOL, V15, P1562, DOI 10.1093/oxfordjournals.molbev.a025883; Petrov DA, 1997, GENE, V205, P279, DOI 10.1016/S0378-1119(97)00516-7; Petrov DA, 1998, MOL BIOL EVOL, V15, P293, DOI 10.1093/oxfordjournals.molbev.a025926; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; RUDKIN GT, 1969, GENETICS, V61, P227; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; Shaw KL, 1996, EVOLUTION, V50, P237, DOI 10.1111/j.1558-5646.1996.tb04488.x; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; THINDWA HP, 1994, SOUTHWEST ENTOMOL, V19, P371; THOMAS CA, 1971, ANNU REV GENET, V5, P237, DOI 10.1146/annurev.ge.05.120171.001321; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Wright DA, 1996, GENETICS, V142, P569; [No title captured]	27	256	271	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1060	1062		10.1126/science.287.5455.1060	http://dx.doi.org/10.1126/science.287.5455.1060			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669421				2022-12-24	WOS:000085245400053
J	Groombridge, JJ; Jones, CG; Bruford, MW; Nichols, RA				Groombridge, JJ; Jones, CG; Bruford, MW; Nichols, RA			Conservation biology - 'Ghost' alleles of the Mauritius kestrel	NATURE			English	Article							POPULATIONS; BIRDS		Zool Soc London, Inst Zool, London NW1 4RY, England; Mauritius Wildlife Fdn, Black River, Mauritius; Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England	Zoological Society of London; University of London; Queen Mary University London	Groombridge, JJ (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Bruford, Michael/Y-7463-2019; Nichols, Richard/B-7732-2008; Bruford, Michael W/D-3750-2009; Groombridge, Jim/G-8060-2011	Bruford, Michael/0000-0001-6357-6080; Nichols, Richard/0000-0002-4801-9312; Bruford, Michael W/0000-0001-6357-6080; 				Bataillon T, 2000, GENET RES, V75, P75, DOI 10.1017/S0016672399004048; Frankham R, 1997, HEREDITY, V78, P311, DOI 10.1038/hdy.1997.46; Gelman A, 2013, BAYESIAN DATA ANAL, P16; Gilpin M.E., 1986, P19; JOHNSON TH, 1990, IBIS, V132, P167, DOI 10.1111/j.1474-919X.1990.tb01036.x; Jones C. G., 1987, STUDIES MASCARENE IS, P5; JONES CG, 1995, IBIS, V137, pS173, DOI 10.1111/j.1474-919X.1995.tb08439.x; Madsen T, 1999, NATURE, V402, P34, DOI 10.1038/46941; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; Saccheri IJ, 1996, EVOLUTION, V50, P2000, DOI 10.1111/j.1558-5646.1996.tb03587.x; Safford RJ, 1997, BIODIVERS CONSERV, V6, P1445, DOI 10.1023/A:1018350016327	11	131	135	1	71	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					616	616		10.1038/35001148	http://dx.doi.org/10.1038/35001148			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688188	Bronze			2022-12-24	WOS:000085288200040
J	Hou, SB; Larsen, RW; Boudko, D; Riley, CW; Karatan, E; Zimmer, M; Ordal, GW; Alam, M				Hou, SB; Larsen, RW; Boudko, D; Riley, CW; Karatan, E; Zimmer, M; Ordal, GW; Alam, M			Myoglobin-like aerotaxis transducers in Archaea and Bacteria	NATURE			English	Article							AMINO-ACID-SEQUENCES; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; HALOBACTERIUM-SALINARIUM; SERINE CHEMORECEPTOR; RHIZOBIUM-MELILOTI; GENE-EXPRESSION; PROTEINS; OXYGEN; METHYLATION	Haem-containing proteins such as haemoglobin and myoglobin play an essential role in oxygen transport and storage. Comparison of the amino-acid sequences of globins from Bacteria and Eukarya suggests that they share an early common ancestor, even though the proteins perform different functions in these two kingdoms(1-6). Until now, no members of the globin family have been found in the third kingdom, Archaea. Recent studies of biological signalling in the Bacteria and Eukarya have revealed a new class of haem-containing proteins that serve as sensors(7). Until now, no haem-based sensor has been described in the Archaea. Here we report the first myoglobin-like, haem-containing protein in the Archaea, and the first haem-based aerotactic transducer in the Bacteria (termed HemAT-Hs for the archaeon Halobacterium salinarum, and HemAT-Bs for Bacillus subtilis). These proteins exhibit spectral properties similar to those of myoglobin and trigger aerotactic responses.	Univ Hawaii, Dept Microbiol, Honolulu, HI 96822 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Hawaii, Dept Chem, Honolulu, HI 96822 USA	University of Hawaii System; University of Illinois System; University of Illinois Urbana-Champaign; University of Hawaii System	Alam, M (corresponding author), Univ Hawaii, Dept Microbiol, Snyder Hall 207,2538 Mall, Honolulu, HI 96822 USA.			Hou, Shaobin/0000-0003-3467-8242; Boudko, Dmitri/0000-0002-1899-044X				ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; Brooun A, 1998, J BACTERIOL, V180, P1642, DOI 10.1128/JB.180.7.1642-1646.1998; BROOUN A, 1997, PRIMARY STRUCTURES F; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hardison R, 1999, AM SCI, V87, P126, DOI 10.1511/1999.20.809; Hardison R, 1998, J EXP BIOL, V201, P1099; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LINDBECK JC, 1995, MICROBIOL-SGM, V141, P2945, DOI 10.1099/13500872-141-11-2945; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Suzuki T, 1998, CELL MOL LIFE SCI, V54, P979, DOI 10.1007/s000180050227; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WONG LS, 1995, J BACTERIOL, V177, P3985, DOI 10.1128/jb.177.14.3985-3991.1995; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P4649, DOI 10.1073/pnas.93.10.4649; Zhulin IB, 1998, MOL MICROBIOL, V29, P1522; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	28	229	238	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					540	544		10.1038/35000570	http://dx.doi.org/10.1038/35000570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676961				2022-12-24	WOS:000085227300049
J	Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J				Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J			OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; TGF-BETA; CRYSTAL-STRUCTURE; GENE-EXPRESSION; HOMEOBOX GENE; FUNCTIONAL-CHARACTERIZATION; TUMOR-SUPPRESSOR; XENOPUS MESODERM; TRANSCRIPTION; REGULATORS	We have identified the 30-zinc finger protein OAZ as a DNA-binding factor that associates with Smads in response to BMP2, forming a complex that transcriptionally activates the homeobox regulator of Xenopus mesoderm and neural development, Xvent-2. OAZ contains a BMP signaling module formed by two clusters of fingers that bind Smads and the Xvent-2 BMP response element, respectively. Previously implicated as a transcriptional partner of Olf-1/EBF in olfactory epithelium and lymphocyte development in the rat, OAZ fulfills this role through clusters of fingers that are separate from the BMP signaling module. The mutually exclusive use of OAZ by the BMP-smad and Olf pathways illustrates the dual role of a multi-zinc finger protein in signal transduction during development.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HemmatiBrivanlou A, 1997, ANNU REV NEUROSCI, V20, P43, DOI 10.1146/annurev.neuro.20.1.43; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shou J, 1999, NAT NEUROSCI, V2, P339, DOI 10.1038/7251; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang ZJ, 1998, RNA, V4, P394; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	46	353	379	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					229	240		10.1016/S0092-8674(00)81561-5	http://dx.doi.org/10.1016/S0092-8674(00)81561-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660046	Bronze			2022-12-24	WOS:000084932200007
J	Barnes, DM; Miles, DW				Barnes, DM; Miles, DW			Response of metastatic breast cancer to trastuzumab?	LANCET			English	Editorial Material							MONOCLONAL-ANTIBODY; NEU ONCOGENE; PHASE-II		Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England; Guys Hosp, Imperial Canc Res Fund, Breast Biol Grp, London SE1 9RT, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Barnes, DM (corresponding author), Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England.							Allred DC, 1998, MODERN PATHOL, V11, P155; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; Jacobs TW, 1999, J CLIN ONCOL, V17, P1974, DOI 10.1200/JCO.1999.17.7.1974; Jacobs TW, 1999, J CLIN ONCOL, V17, P1983, DOI 10.1200/JCO.1999.17.7.1983; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; McNeil C, 1999, J NATL CANCER I, V91, P110, DOI 10.1093/jnci/91.2.110; NAINGGOLAN L, 1999, SCRIP, V2493, P21; NORTON L, 1999, P AM SOC CLIN ONCOL, V18; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wisecarver JL, 1999, AM J CLIN PATHOL, V111, P299	16	15	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					160	161		10.1016/S0140-6736(99)00430-4	http://dx.doi.org/10.1016/S0140-6736(99)00430-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675110				2022-12-24	WOS:000084879700004
J	Bader, B; Kuhn, K; Owen, DJ; Waldmann, H; Wittinghofer, A; Kuhlmann, J				Bader, B; Kuhn, K; Owen, DJ; Waldmann, H; Wittinghofer, A; Kuhlmann, J			Bioorganic synthesis of lipid-modified proteins for the study of signal transduction	NATURE			English	Article							RAS LIPOPEPTIDES; BINDING-SITE; PRENYLATION; VESICLES; EXPRESSION; MEMBRANES; P21(RAS); DOMAIN; ESTER	Biological membranes define the boundaries of the cellular compartments in higher eukaryotes and are active in many processes such as signal transduction and vesicular transport. Although post-translational lipid modification of numerous proteins in signal transduction is crucial for biological function(1), analysis of protein-protein interactions has mainly focused on recombinant proteins in solution under defined in vitro conditions. Here we present a new strategy for the synthesis of such lipid-modified proteins. It involves the bacterial expression of a carboxy-terminally truncated non-lipidated protein, the chemical synthesis of differently lipidated peptides representing the C terminus of the proteins, and their covalent coupling. Our technique is demonstrated using Ras constructs, which exhibit properties very similar to fully processed Ras, but can be produced in high yields and are open for selective modifications. These constructs are operative in biophysical and cellular assay systems, showing specific recognition of effecters by Ras lipoproteins inserted into the membrane surface of biosensors and transforming activity of oncogenic variants aft er microinjection into cultured cells.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Dortmund, D-44227 Dortmund, Germany	Max Planck Society; Dortmund University of Technology	Waldmann, H (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Waldmann, Herbert/B-7406-2017	Waldmann, Herbert/0000-0002-9606-7247; Owen, David/0000-0002-9165-1540; Bader, Benjamin/0000-0002-5299-396X				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Nagele E, 1998, J AM CHEM SOC, V120, P6889, DOI 10.1021/ja9805627; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Schelhaas M, 1999, CHEM-EUR J, V5, P1239, DOI 10.1002/(SICI)1521-3765(19990401)5:4<1239::AID-CHEM1239>3.0.CO;2-N; Schelhaas M, 1996, ANGEW CHEM INT EDIT, V35, P106, DOI 10.1002/anie.199601061; Schmidt G, 1996, ONCOGENE, V12, P87; Schmittberger T, 1998, CHEM COMMUN, P937, DOI 10.1039/a708749g; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Waddick KG, 1998, BIOCHEM PHARMACOL, V56, P1411, DOI 10.1016/S0006-2952(98)00211-1; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1998, BIOL CHEM, V379, P933	21	134	145	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					223	226		10.1038/35003249	http://dx.doi.org/10.1038/35003249			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646611				2022-12-24	WOS:000084835300062
J	Chiang, YPJ; Kole, HK; Brown, K; Naramura, M; Fukuhara, S; Hu, RJ; Jang, IK; Gutkind, JS; Shevach, E; Gu, H				Chiang, YPJ; Kole, HK; Brown, K; Naramura, M; Fukuhara, S; Hu, RJ; Jang, IK; Gutkind, JS; Shevach, E; Gu, H			Cbl-b regulates the CD28 dependence of T-cell activation	NATURE			English	Article							RECEPTOR TRANSGENIC MICE; SIGNAL-TRANSDUCTION; C-CBL; ANTIGEN RECEPTORS; DEFICIENT MICE; VAV; PROTOONCOGENE; THYMOCYTES; RESPONSES; PRODUCT	Whereas co-stimulation of the T-cell antigen receptor (TCR) and CD28 triggers T-cell activation, stimulation of the TCR alone may result in an anergic state or T-cell deletion, both possible mechanisms of tolerance induction(1,2), Here we show that T cells that are deficient in the adaptor molecule Cbl-b, (ref. 3) do not require CD28 engagement for interleukin-2 production, and that the Cbl-b-null mutation (Cbl-b(-/-)) fully res;tores T-cell-dependent antibody responses in CD28(-/-) mice. The main TCR signalling pathways, such as tyrosine kinases Zap-70 and Lck, Ras/mitogen-activated kinases, phospholipase C gamma-1 and Ca2+ mobilization, were not affected in Cbl-b(-/-) T cells. In contrast, the activation of Vav, a guanine nucleotide exchange factor for Rac1/Rho/CDC42, was significantly enhanced. Our findings indicate that Cbl-b may influence the CD28 dependence of T-cell activation by selectively suppressing TCR-mediated Vav activation, Mice deficient in Cbl-b are highly susceptible to experimental autoimmune encephalomyelitis, suggesting that the dysregulation of signalling pathways modulated by Cbl-b may also contribute to human autoimmune diseases such as multiple sclerosis.	NIAID, Immunol Lab, NIH, Rockville, MD 20852 USA; NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gu, H (corresponding author), NIAID, Immunol Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Naramura, Mayumi/0000-0003-3658-0767; Jang, Ihn Kyung/0000-0001-8899-7930	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6	26	465	488	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					216	220		10.1038/35003235	http://dx.doi.org/10.1038/35003235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646609				2022-12-24	WOS:000084835300060
J	Fricke, H; Hissmann, K; Schauer, J; Erdmann, M; Moosa, MK; Plante, R				Fricke, H; Hissmann, K; Schauer, J; Erdmann, M; Moosa, MK; Plante, R			Conservation - Biogeography of the Indonesian coelacanths	NATURE			English	Article							HOME		Max Planck Inst Verhaltensphysiol, D-82319 Seewiesen, Germany; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Indonesian Inst Sci, Jakarta 11048, Indonesia; Ctr Oceanol Marseille, Marine Endoume Stn, F-13007 Marseille, France	Max Planck Society; University of California System; University of California Berkeley; Indonesian Institute of Sciences	Fricke, H (corresponding author), Max Planck Inst Verhaltensphysiol, D-82319 Seewiesen, Germany.							Erdmann MV, 1998, NATURE, V395, P335, DOI 10.1038/26376; Forey P, 1998, NATURE, V395, P319, DOI 10.1038/26328; FRICKE H, 1994, MAR BIOL, V120, P171, DOI 10.1007/BF00349676; FRICKE HW, IN PRESS MAR BIOL; Gordon AL, 1996, NATURE, V379, P146, DOI 10.1038/379146a0; Holder MT, 1999, P NATL ACAD SCI USA, V96, P12616, DOI 10.1073/pnas.96.22.12616; Pouyaud L, 1999, CR ACAD SCI III-VIE, V322, P261, DOI 10.1016/S0764-4469(99)80061-4	7	21	24	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					38	38		10.1038/47400	http://dx.doi.org/10.1038/47400			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638741	Bronze			2022-12-24	WOS:000084687400031
J	Loitman, JE				Loitman, JE			Pain management: Beyond pharmacology to acupuncture and hypnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Brown Univ, Sch Med, Providence, RI 02912 USA	Brown University	Loitman, JE (corresponding author), Brown Univ, Sch Med, Providence, RI 02912 USA.							Blumberg D L, 1995, Altern Ther Health Med, V1, P31; BROSE W, 1992, AM PSYCHIAT PRESS TX; Crock RD, 1999, ALTERN THER HEALTH M, V5, P61; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Freeman J W, 1997, S D J Med, V50, P65; KELLERMAN J, 1983, J ADOLESC HLTH CARE, V4, P35; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X; Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005; MORGAN AH, 1973, INT J CLIN EXP HYP, V21, P78, DOI 10.1080/00207147308409308; National Institutes of Health, 1995, INT BEH REL APPR TRE, P1; *NIH, 1997, NIH CONS DEV C AC; Pomeranz B, 1996, J Altern Complement Med, V2, P53, DOI 10.1089/acm.1996.2.53; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; Reston, 1971, NY TIMES, P1; Reston J, 1971, NY TIMES, V1, P6; Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004	17	3	4	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					118	119		10.1001/jama.283.1.118	http://dx.doi.org/10.1001/jama.283.1.118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632295				2022-12-24	WOS:000084514400040
J	Shay, JW; Wright, WE				Shay, JW; Wright, WE			Molecular biology - Mutant dyskerin ends relationship with telomerase	SCIENCE			English	Editorial Material							DYSKERATOSIS		Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011					Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Dokal I, 1999, J PEDIAT HEMATOL ONC, V21, P344, DOI 10.1097/00043426-199909000-00002; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X	10	26	26	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2284	2285		10.1126/science.286.5448.2284	http://dx.doi.org/10.1126/science.286.5448.2284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636790				2022-12-24	WOS:000084318500037
J	Ernst, E				Ernst, E			Second thoughts about safety of St John's wort	LANCET			English	Editorial Material									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							AJOHNE A, 1999, JAHR KLIN PHARM BERL; BON S, 1999, SCHWEITZER APOTHEKER, V16, P535; Brevoort P., 1998, HerbalGram, P33; ERESHEFSKY B, 1999, P 39 ANN M NEW CLIN; GEWERTZ N, P 39 ANN M NEW CLIN; Harrison P, 1998, CAN MED ASSOC J, V158, P637; Lantz MS, 1999, J GERIATR PSYCH NEUR, V12, P7, DOI 10.1177/089198879901200103; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Martin TG, 1996, ANN EMERG MED, V28, P520, DOI 10.1016/S0196-0644(96)70116-6; MAURER A, 1999, EUR J CLIN PHARMACOL, V55, pA22; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Rey JM, 1998, MED J AUSTRALIA, V169, P583, DOI 10.5694/j.1326-5377.1998.tb123424.x; ROBY CA, 1999, P 39 ANN M NEW CLIN; Stevinson C, 1999, CNS DRUGS, V11, P125, DOI 10.2165/00023210-199911020-00004	15	221	229	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2014	2016		10.1016/S0140-6736(99)00418-3	http://dx.doi.org/10.1016/S0140-6736(99)00418-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636361				2022-12-24	WOS:000084183300004
J	Cutfield, WS; Wilton, P; Bennmarker, H; Albertsson-Wikland, K; Chatelain, P; Ranke, MB; Price, DA				Cutfield, WS; Wilton, P; Bennmarker, H; Albertsson-Wikland, K; Chatelain, P; Ranke, MB; Price, DA			Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment	LANCET			English	Article							RISING INCIDENCE; INSULIN; IDDM	Background Growth hormone (GH) contributes to insulin resistance, but whether children treated with GH are at increased risk of diabetes has not been established. We undertook a retrospective analysis of data from an international pharmacoepidemiological survey of children treated with GH to find out the incidence of impaired glucose tolerance and types 1 and 2 diabetes mellitus. Methods Reports to the survey of abnormal glucose metabolism were investigated and classified. The incidence and age-distribution of type 1 diabetes were compared with values from a model of reference data. The incidence of type 2 diabetes was compared with data from two reports of children not treated with GH. Findings 85 (0.36%) of 23 333 children were reported with abnormal glucose metabolism. After investigation, 43 had confirmed glucose disorders (11 with type 1 diabetes, 18 with type 2 diabetes, and 14 with impaired glucose tolerance). The incidence and age at diagnosis of type 1 diabetes in children treated with GH did not differ from expected values. The incidence of type 2 diabetes was 34.4 cases per 100 000 years of GH treatment which was six-fold higher than reported in children not treated with GH. Type 2 diabetes did not resolve after GH therapy was stopped. Interpretation GH treatment did not affect the incidence of type 1 diabetes mellitus in any age group. We postulate that the higher than expected incidence of type 2 diabetes mellitus with GH treatment may be an acceleration of the disorder in predisposed individuals.	Univ Auckland, Dept Paediat, Auckland, New Zealand; Pharmacia & Upjohn Inc, Stockholm, Sweden; East Hosp, Dept Paediat, Gothenburg, Sweden; Univ Lyon 1, Serv Pediat Endocrinol & Diabetol Infantiles, Hop Debrousse, F-69365 Lyon, France; Univ Tubingen, Childrens Hosp, Tubingen, Germany; St Marys Hosp, Dept Paediat, Manchester M13 0JH, Lancs, England	University of Auckland; Pfizer; Pharmacia Corporation; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Manchester	Cutfield, WS (corresponding author), Univ Auckland, Dept Paediat, Private Bag 92019, Auckland, New Zealand.	waynec@ahsl.co.nz	Albertsson-Wikland, Kerstin/D-3843-2012					AMIEL SA, 1986, NEW ENGL J MED, V315, P215, DOI 10.1056/NEJM198607243150402; Blethen SL, 1996, J CLIN ENDOCR METAB, V81, P1704, DOI 10.1210/jc.81.5.1704; BOUGNERES PF, 1990, ACTA PAEDIATR SCAND, P38; CAPRIO S, 1992, HORM RES, V38, P47, DOI 10.1159/000182594; CUTFIELD WS, 1990, J CLIN ENDOCR METAB, V70, P1644, DOI 10.1210/jcem-70-6-1644; CZERNICHOW P, 1993, HORM RES, V39, P102; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Gardner SG, 1997, BRIT MED J, V315, P713, DOI 10.1136/bmj.315.7110.713; Gavin JR, 1997, DIABETES CARE, V20, P1183; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; JADRESIC A, 1982, Q J MED, V51, P189; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; KITAGAWA T, 1994, DIABETES RES CLIN PR, V24, pS7, DOI 10.1016/0168-8227(94)90221-6; Neu A, 1997, DIABETES CARE, V20, P530, DOI 10.2337/diacare.20.4.530; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; Rangasami JJ, 1997, ARCH DIS CHILD, V77, P210, DOI 10.1136/adc.77.3.210; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SHIZUME K, 1984, ENDOCRINOL JAPON, V31, P201; Smith TR, 1997, AM J PHYSIOL-ENDOC M, V272, pE1071, DOI 10.1152/ajpendo.1997.272.6.E1071; VERGE CF, 1994, DIABETES CARE, V17, P693, DOI 10.2337/diacare.17.7.693; WASS JAH, 1980, CLIN ENDOCRINOL, V12, P53, DOI 10.1111/j.1365-2265.1980.tb03132.x	22	211	220	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2000	355	9204					610	613		10.1016/S0140-6736(99)04055-6	http://dx.doi.org/10.1016/S0140-6736(99)04055-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696981				2022-12-24	WOS:000085615400012
J	Grosman, C; Zhou, M; Auerbach, A				Grosman, C; Zhou, M; Auerbach, A			Mapping the conformational wave of acetylcholine receptor channel gating	NATURE			English	Article							FREE-ENERGY RELATIONSHIPS; ENGINEERED PROTEINS; MECHANISM; VOLTAGE; ENZYME	Allosteric transitions allow fast regulation of protein function in living systems. Even though the end points of such conformational changes are known for many proteins, the characteristics of the paths connecting these states remain largely unexplored. Rate-equilibrium linear free-energy relationships (LFERs) provide information about such pathways by relating changes in the free energy of the transition state to those of the ground states upon systematic perturbation of the system(1). Here we present an LFER analysis of the gating reaction pathway of the muscle acetylcholine receptor. We studied the closed reversible arrow open conformational change at the single-molecule level following perturbation by series of single-site mutations, agonists and membrane voltages. This method provided a snapshot of several regions of the receptor at the transition state in terms of their approximate positions along the reaction coordinate, on a scale from 0 (closed-like) to 1 (open-like). The resulting map reveals a spatial gradient of positional values, which suggests that the conformational change proceeds in a wave-like manner, with the low-to-high affinity change at the transmitter-binding sites preceding the complete opening of the pore.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Grosman, C (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.			Grosman, Claudio/0000-0001-8093-8362				Akk G, 1999, BIOPHYS J, V76, P207, DOI 10.1016/S0006-3495(99)77190-0; Akk G, 1996, J PHYSIOL-LONDON, V496, P185, DOI 10.1113/jphysiol.1996.sp021676; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P6030, DOI 10.1021/bi00393a013; FERSHT AR, 1986, NATURE, V322, P284, DOI 10.1038/322284a0; FERSHT AR, 1995, CURR OPIN STRUC BIOL, V5, P79, DOI 10.1016/0959-440X(95)80012-P; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hammett L. P., 1972, ADV LINEAR FREE ENER, pvii; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; JAFFE HH, 1953, CHEM REV, V53, P191, DOI 10.1021/cr60165a003; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kirsch JF., 1972, ADV LINEAR FREE ENER, P369, DOI [10.1007/978-1-4615-8660-9_8, DOI 10.1007/978-1-4615-8660-9_8]; KYTE J, 1995, MECHANISM PROTEIN CH, P461; Leffler J. E., 1963, RATES EQUILIBRIA ORG; LEFFLER JE, 1953, SCIENCE, V117, P340, DOI 10.1126/science.117.3039.340; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P151, DOI 10.1113/jphysiol.1972.sp009839; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Onuchic JN, 1996, FOLD DES, V1, P441, DOI 10.1016/S1359-0278(96)00060-0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Salamone FN, 1999, J PHYSIOL-LONDON, V516, P315, DOI 10.1111/j.1469-7793.1999.0315v.x; STRAUB JE, 1990, PROTEIN ENG, V3, P673, DOI 10.1093/protein/3.8.673; Sunderman ER, 1999, J GEN PHYSIOL, V113, P621, DOI 10.1085/jgp.113.5.621; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; Yifrach O, 1998, J AM CHEM SOC, V120, P13262, DOI 10.1021/ja983136u; Zhou M, 1999, P NATL ACAD SCI USA, V96, P10466, DOI 10.1073/pnas.96.18.10466	31	280	282	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					773	776		10.1038/35001586	http://dx.doi.org/10.1038/35001586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693806				2022-12-24	WOS:000085423100053
J	Jones, G				Jones, G			Total internal reflection - The secret of the accidental immortals can now be made known.	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					707	707		10.1038/35001682	http://dx.doi.org/10.1038/35001682			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693780	Bronze			2022-12-24	WOS:000085423100027
J	Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR				Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR			Polarization of chemoattractant receptor signaling during neutrophil chemotaxis	SCIENCE			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; BINDING; ACTIVATION; CDC42; CELLS; PHOSPHOINOSITIDES; LEUKOCYTES	Morphologic polarity is necessary for chemotaxis of mammalian cells. As a probe of intracellular signals responsible for this asymmetry, the pleckstrin homology domain of the AKT protein kinase (or protein kinase B), tagged with the green fluorescent protein (PHAKT-GFP), was expressed in neutrophils. Upon exposure of cells to chemoattractant, PHAKT-GFP is recruited selectively to membrane at the cell's leading edge, indicating an internal signaling gradient that is much steeper than that of the chemoattractant. Translocation of PHAKT-GFP is inhibited by toxin-B from Clostridium difficile, indicating that it requires activity of one or more Rho guanosine triphosphatases.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.		Weiner, Orion D/F-2576-2011	Weiner, Orion D/0000-0002-1778-6543; Balla, Tamas/0000-0002-9077-3335	NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-25101, R01 GM027800-27, GM-27800] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R01GM025101, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Cassimeris L, 1990, Semin Cell Biol, V1, P125; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SERVANT G, UNPUB; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	48	703	717	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1037	1040		10.1126/science.287.5455.1037	http://dx.doi.org/10.1126/science.287.5455.1037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669415	Green Accepted			2022-12-24	WOS:000085245400047
J	Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC				Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC			Symptoms and suffering at the end of life in children with cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALLIATIVE CARE; FAMILY MEMBERS; PAIN	Background: Cancer is the second leading cause of death in children, after accidents. Little is known, however, about the symptoms and suffering at the end of life in children with cancer. Methods: In 1997 and 1998, we interviewed the parents of children who had died of cancer between 1990 and 1997 and who were cared for at Children's Hospital in Boston, the Dana-Farber Cancer Institute, or both. Additional data were obtained by reviewing medical records. Results: Of 165 eligible parents, we interviewed 103 (62 percent), 98 by telephone and 5 in person. The interviews were conducted a mean (+/-SD) of 3.1+/-1.6 years after the death of the child. Almost 80 percent died of progressive disease, and the rest died of treatment-related complications. Forty-nine percent of the children died in the hospital; nearly half of these deaths occurred in the intensive care unit. According to the parents, 89 percent of the children suffered "a lot'' or "a great deal'' from at least one symptom in their last month of life, most commonly pain, fatigue, or dyspnea. Of the children who were treated for specific symptoms, treatment was successful in 27 percent of those with pain and 16 percent of those with dyspnea. On the basis of a review of the medical records, parents were significantly more likely than physicians to report that their child had fatigue, poor appetite, constipation, and diarrhea. Suffering from pain was more likely in children whose parents reported that the physician was not actively involved in providing end-of-life care (odds ratio, 2.6; 95 percent confidence interval, 1.0 to 6.7). Conclusions: Children who die of cancer receive aggressive treatment at the end of life. Many have substantial suffering in the last month of life, and attempts to control their symptoms are often unsuccessful. Greater attention must be paid to palliative care for children who are dying of cancer. (N Engl J Med 2000;342:326-33.) (C) 2000, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu	Harding, Richard/G-9729-2012		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER; AHRQ HHS [5 T32 HS00063] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fainsinger R, 1991, J Palliat Care, V7, P5; FIELD MJ, 1997, APPROACHING DEATH IM, V17, P437; Frager G, 1996, J PALLIATIVE CARE, V12, P9; Goldman A, 1998, BRIT MED J, V316, P49, DOI 10.1136/bmj.316.7124.49; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; KANE RL, 1984, LANCET, V1, P890; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MAUER AM, 1987, AM J PEDIAT HEMATOL, V9, P58; Monti M, 1996, J PAIN SYMPTOM MANAG, V12, P18, DOI 10.1016/0885-3924(96)00044-9; Power David, 1993, Palliative Medicine, V7, P213, DOI 10.1177/026921639300700308; Robinson WM, 1997, PEDIATRICS, V100, P205, DOI 10.1542/peds.100.2.205; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; Sanders J, 1997, PEDIATRICS, V99, P139; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; 1991, JAMA, V275, P1232	28	757	769	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					326	333		10.1056/NEJM200002033420506	http://dx.doi.org/10.1056/NEJM200002033420506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10655532				2022-12-24	WOS:000085070300006
J	Lee, BG; Griscom, SB; Lee, JS; Choi, HJ; Koh, CH; Luoma, SN; Fisher, NS				Lee, BG; Griscom, SB; Lee, JS; Choi, HJ; Koh, CH; Luoma, SN; Fisher, NS			Influences of dietary uptake and reactive sulfides on metal bioavailability from aquatic sediments	SCIENCE			English	Article							ACID-VOLATILE SULFIDE; POTAMOCORBULA-AMURENSIS; MARINE BIVALVES; ASSIMILATION; TOXICITY; ENVIRONMENTS; CADMIUM; MODEL	Understanding how animals are exposed to the Large repository of metal pollutants in aquatic sediments is complicated and is important in regulatory decisions. Experiments with four types of invertebrates showed that feeding behavior and dietary uptake control bioaccumulation of cadmium, silver, nickel, and zinc. Metal concentrations in animal tissue correlated with metal concentrations extracted from sediments, but not with metal in porewater, across a range of reactive sulfide concentrations, from 0.5 to 30 micromoles per gram. These results contradict the notion that metal bioavailability in sediments is controlled by geochemical equilibration of metals between porewater and reactive sulfides, a proposed basis for regulatory criteria for metals.	US Geol Survey, Div Water Resources, Menlo Pk, CA 94025 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA; Seoul Natl Univ, Dept Oceanog, Seoul 151742, South Korea	United States Department of the Interior; United States Geological Survey; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Seoul National University (SNU)	Lee, BG (corresponding author), US Geol Survey, Div Water Resources, Mail Stop 465,345 Middlefield Rd, Menlo Pk, CA 94025 USA.	bglee@usgs.gov						Ankley GT, 1996, ENVIRON TOXICOL CHEM, V15, P2056, DOI 10.1002/etc.5620151202; Berry WJ, 1999, ENVIRON TOXICOL CHEM, V18, P40, DOI 10.1897/1551-5028(1999)018<0040:PTOSSW>2.3.CO;2; Berry WJ, 1996, ENVIRON TOXICOL CHEM, V15, P2067, DOI 10.1002/etc.5620151203; BROWN CL, 1995, MAR ECOL PROG SER, V124, P129, DOI 10.3354/meps124129; DECHO AW, 1994, MAR ECOL PROG SER, V108, P133, DOI 10.3354/meps108133; Decho AW, 1996, LIMNOL OCEANOGR, V41, P568, DOI 10.4319/lo.1996.41.3.0568; DiToro DM, 1996, ENVIRON TOXICOL CHEM, V15, P2168, DOI 10.1002/etc.5620151212; DITORO DM, 1990, ENVIRON TOXICOL CHEM, V9, P1487; FISHER NS, 1991, MAR ECOL PROG SER, V70, P157, DOI 10.3354/meps070157; Griscom SB, 2000, ENVIRON SCI TECHNOL, V34, P91, DOI 10.1021/es981309+; HORNBERGER MI, 1999, 9955 US GEOL SURV; Luoma SN, 1997, SETAC SP P, P211; LUOMA SN, 1995, MAR POLLUT BULL, V31, P44, DOI 10.1016/0025-326X(95)00081-W; MARSH HW, 1987, J EDUC MEAS, V24, P1; MAYER LM, 1995, LIMNOL OCEANOGR, V40, P511, DOI 10.4319/lo.1995.40.3.0511; Mayer LM, 1997, J MAR RES, V55, P785, DOI 10.1357/0022240973224247; MEYER JS, 1994, BIOAVAILABILITY PHYS, P155; MORSE JW, 1994, MAR CHEM, V46, P1, DOI 10.1016/0304-4203(94)90040-X; MYER JS, 1994, BIOAVAILABILITY PHYS, P155; Reinfelder JR, 1998, SCI TOTAL ENVIRON, V219, P117, DOI 10.1016/S0048-9697(98)00225-3; SCHOONEN MAA, 1991, GEOCHIM COSMOCHIM AC, V55, P1505, DOI 10.1016/0016-7037(91)90123-M; Wang WX, 1996, LIMNOL OCEANOGR, V41, P197, DOI 10.4319/lo.1996.41.2.0197; Wang WX, 1999, MAR ECOL PROG SER, V178, P281, DOI 10.3354/meps178281	23	201	216	4	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					282	284		10.1126/science.287.5451.282	http://dx.doi.org/10.1126/science.287.5451.282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634777				2022-12-24	WOS:000084769600032
J	Bear, G				Bear, G			Deep ice and DNA languages	NATURE			English	Article																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					141	141		10.1038/35003068	http://dx.doi.org/10.1038/35003068			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646579	Bronze			2022-12-24	WOS:000084835300027
J	Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT				Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT			Midline episiotomy and anal incontinence: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FECAL INCONTINENCE; PELVIC FLOOR; SPHINCTER DAMAGE; VAGINAL DELIVERY; PERINEAL TRAUMA; FOLLOW-UP; CHILDBIRTH; REPAIR; RISK	Objective To evaluate the relation between midline episiotomy and postpartum anal incontinence. Design Retrospective cohort study with three study arms and six months of follow up. Setting University teaching hospital. Participants Primiparous women who vaginally delivered a live full term, singleton baby between 1 August 1996 and 8 February 1997: 209 who received an episiotomy; 206 who did not receive an episiotomy but experienced a second, third, or fourth degree spontaneous perineal laceration; and 211 who experienced either no laceration or a first degree perineal laceration. Main outcome measures Self reported faecal and natus incontinence at three and six months postpartum. Results Women who had episiotomies bad a higher risk of faecal incontinence at three (odds ratio 5.5, 95% confidence interval 1.8 to 16.2) and six (3.7, 0.9 to 15.6) months postpartum compared with women with an intact perineum. Compared with women with a spontaneous laceration, episiotomy tripled the risk of faecal incontinence at three months (95%, confidence interval 1.3 to 7.9) and six months (0.7 to 11.2) postpartum, and doubled the risk of flatus incontinence at three months (1.3 to 3.4) and six months (1.2 to 3.7) postpartum. A non-extending episiotomy (that is, second degree surgical incision) tripled the risk of faecal incontinence (1.1 to 9.0) and nearly doubled the risk of flatus incontinence (1.0 to 3.0) at three months postpartum compared with women who had a second degree spontaneous tear. The effect of episiotomy was independent of maternal age, infant birth weight, duration of second stage of labour, use of obstetric instrumentation during delivery, and complications of labour. Conclusions Midline episiotomy is not effective in protecting the perineum and sphincters during childbirth and may impair anal continence.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Signorello, LB (corresponding author), Int Epidemiol Inst, 1450 Res Blvd,Suite 550, Rockville, MD 20850 USA.			Harlow, Bernard/0000-0002-6735-8862				BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; DEEN KI, 1993, GUT, V34, P685, DOI 10.1136/gut.34.5.685; Frudinger A, 1997, BRIT J OBSTET GYNAEC, V104, P1009, DOI 10.1111/j.1471-0528.1997.tb12058.x; HELWIG JT, 1993, OBSTET GYNECOL, V82, P276; ISAGERSALLY L, 1986, BRIT J OBSTET GYNAEC, V93, P420; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; NIELSEN MB, 1992, BRIT J SURG, V79, P104, DOI 10.1002/bjs.1800790204; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; SORENSEN M, 1993, BRIT J SURG, V80, P392, DOI 10.1002/bjs.1800800343; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; Sultan AH, 1997, BRIT J OBSTET GYNAEC, V104, P979; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THORP JM, 1987, OBSTET GYNECOL, V70, P260; THORP JM, 1989, AM J OBSTET GYNECOL, V160, P1027, DOI 10.1016/0002-9378(89)90152-X; WALKER MPR, 1991, OBSTET GYNECOL, V77, P668	21	121	124	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					86	90		10.1136/bmj.320.7227.86	http://dx.doi.org/10.1136/bmj.320.7227.86			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625261	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000084746600016
J	De Cock, KM; Fowler, MG; Mercier, E; de Vincenzi, I; Saba, J; Hoff, E; Alnwick, DJ; Rogers, M; Shaffer, N				De Cock, KM; Fowler, MG; Mercier, E; de Vincenzi, I; Saba, J; Hoff, E; Alnwick, DJ; Rogers, M; Shaffer, N			Prevention of mother-to-child HIV transmission in resource-poor countries - Translating research into policy and practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; PREGNANT-WOMEN; CLINICAL-TRIAL; COTE-DIVOIRE; INFANT; TYPE-1; INFECTION; ABIDJAN; AFRICA	Each year, an estimated 590 000 infants acquire human immunodeficiency virus type 1 (HIV) infection from their mothers, mostly in developing countries that are unable to implement interventions now standard in the industrialized world. In resource-poor settings, the HIV pandemic has eroded hard-won gains in infant and child survival. Recent clinical trial results from international settings suggest that short-course antiretroviral regimens could significantly reduce perinatal HIV transmission worldwide if research findings could be translated into practice. This article reviews current knowledge of mother-to-child HIV transmission in developing countries, summarizes key findings from the trials, outlines future research requirements, and describes public health challenges of implementing perinatal HIV prevention interventions in resource-poor settings, Public health efforts must also emphasize primary prevention strategies to reduce incident HIV infections among adolescents and women of childbearing age. Successful implementation of available perinatal HIV interventions could substantially improve global child survival.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; UN Childrens Fund, Programme Div, New York, NY USA; WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland; WHO, Dept Policy Strategy & Res, Joint UN Programme HIV AIDS, CH-1211 Geneva, Switzerland	Centers for Disease Control & Prevention - USA; World Health Organization; World Health Organization	De Cock, KM (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, CDC MS D-21,1600 Clifton Rd, Atlanta, GA 30333 USA.							Ammann AJ, 1996, NAT MED, V2, P490, DOI 10.1038/nm0596-490a; [Anonymous], 1998, Wkly Epidemiol Rec, V73, P313; Beckerman KP, 1999, NEW ENGL J MED, V341, P205; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; DECOCK KM, 1997, INT AIDS SOC NEWSLET, V8, P9; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Graham WJ, 1999, LANCET, V353, P836, DOI 10.1016/S0140-6736(98)12374-7; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; *I MED, 1999, RED ODDS PREV PER TR; *JOINT UN PROGR HI, 1999, PREVENT HIV INFECT; *JOINT UN PROGR HI, 1997, HIV INF FEED POL STA; Kaplan JE, 1996, AM J TROP MED HYG, V55, P1; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Mbidde EK, 1998, NEW ENGL J MED, V338, P837; Minkoff H, 1998, JAMA-J AM MED ASSOC, V279, P1743, DOI 10.1001/jama.279.21.1743; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014; Mofenson LM, 1997, OBSTET GYN CLIN N AM, V24, P759, DOI 10.1016/S0889-8545(05)70343-0; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Msellati P, 1998, AIDS, V12, P1257, DOI 10.1097/00002030-199810000-00026; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NEWELL ML, 1992, LANCET, V339, P1007; Newell ML, 1998, AIDS, V12, P1571, DOI 10.1097/00002030-199813000-00003; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; SABA J, 1999, 2 C GLOB STRAT PREV; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, J INFECT DIS, V179, P590, DOI 10.1086/314641; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; SMITH M, 1999, 2 C GLOB STRAT PREV; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; *UNAIDS, 2000, GLOB HIV AIDS EP JUN; *UNAIDS, 2000, AIDS EP UPD DEC 1998; *US BUR CENS, 1999, REC HIV SER LEV COUN; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; *WHO, 1998, HIV INF FEED GUID DE; Wiktor S Z, 1997, AIDS, V11 Suppl B, pS79; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	56	689	704	1	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1175	1182		10.1001/jama.283.9.1175	http://dx.doi.org/10.1001/jama.283.9.1175			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703780				2022-12-24	WOS:000085424100027
J	Henney, JE				Henney, JE			New drug for refractory cutaneous T-cell lymphoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1131	1131		10.1001/jama.283.9.1131	http://dx.doi.org/10.1001/jama.283.9.1131			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703765				2022-12-24	WOS:000085424100005
J	Hatzakis, A; Touloumi, G; Karanicolas, R; Karafoulidou, A; Mandalaki, T; Anastassopoulou, C; Zhang, L; Goedert, JJ; Ho, DD; Kostrikis, LG				Hatzakis, A; Touloumi, G; Karanicolas, R; Karafoulidou, A; Mandalaki, T; Anastassopoulou, C; Zhang, L; Goedert, JJ; Ho, DD; Kostrikis, LG			Effect of recent thymic emigrants on progression of HIV-1 disease	LANCET			English	Article							HEMOPHILIA COHORT; NATURAL-HISTORY; T-CELLS; INFECTION; CCR5; ALLELE; PLASMA; AIDS; GENE; SEROCONVERSION	Background The concentration of T-cell receptor-rearrangement excision DNA circles (TREC) in peripheral-blood T cells is a marker of recent thymic emigrant ap T cells. We studied the predictive ability of measurements of TREC for clinical outcome in HIV-1-infected individuals. Methods We measured TREC in peripheral-blood mononuclear cells with a real-time PCR assay. We studied 131 Greek participants in the Multicenter Hemophilia Cohort Study who had known HIV-1 seroconversion dates. The prognostic value of baseline TREC, CD4 T-cell count, and HIV-1 RNA concentration was assessed by Kaplan-Meier and Cox's regression analysis. Findings Four participants had progressed to AIDS by first blood sampling. Among the remaining 127 individuals, the median value of TREC per 10(6) cells was 6900 (IQR 2370-15 604). Baseline TREC values were lower in the 53 who progressed to AIDS than in those who did not (geometric mean 2843 [95% CI 1468-5504] vs 6560 [4723-9113] per 10(6) cells; p=0.017). The relative hazard of AIDS, adjusted for plasma viral load, CD4 T-cell count, and age at seroconversion was 1.44 (95% CI 1.04-2.01; p=0.031) per ten-fold increase in TREC; that for death was 1.52 (1.12-2.06; p=0.007). The adjusted relative hazards of death were 2.91 (1.91-4.44; p<0.001) per ten-fold increase in plasma HIV-1 RNA load and 1.20 (1.04-1.38; p=0.014) per 100-cell decrease in CD4 T-cell count. Interpretation The concentration of TREC in the peripheral T-cell pool complements HIV-1 RNA load and CD4 T-cell count in predicting the rate of HIV-1 disease progression. Recent thymic emigrants have a role in the pathogenesis of HIV-1 disease.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Laikon Gen Hosp, Hemophilia Ctr, Athens, Greece; NCI, Viral Epidemiol Branch, Rockville, MD USA	Rockefeller University; Athens Medical School; National & Kapodistrian University of Athens; Laiko General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kostrikis, LG (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	Ikostrik@adarc.org	KOSTRIKIS, LEONDIOS G/A-5330-2016; Anastassopoulou, Cleo/AAO-8539-2020	KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Anastassopoulou, Cleo/0000-0001-7666-9198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043868, R01AI040387, P30AI042848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42848, R01 AI40387, R01 AI43868] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; Haynes BF, 1998, IMMUNOL RES, V18, P175, DOI 10.1007/BF02788778; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Livak F, 1996, MOL CELL BIOL, V16, P609; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; Riddler SA, 1997, AIDS, V11, pS141; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Touloumi G, 1998, AIDS, V12, P1691, DOI 10.1097/00002030-199813000-00018; Touloumi G, 1998, J ACQ IMMUN DEF SYND, V19, P89, DOI 10.1097/00042560-199809010-00014; Tyagi S, 1996, NAT BIOTECHNOL, V14, P947, DOI 10.1038/nbt0896-947b; Vigano' A, 1999, AIDS, V13, pF29, DOI 10.1097/00002030-199904010-00001; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	28	83	87	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2000	355	9204					599	604		10.1016/S0140-6736(99)10311-8	http://dx.doi.org/10.1016/S0140-6736(99)10311-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696979				2022-12-24	WOS:000085615400010
J	Wilkinson, RJ; Llewelyn, M; Toossi, Z; Patel, P; Pasvol, G; Lalvani, A; Wright, D; Latif, M; Davidson, RN				Wilkinson, RJ; Llewelyn, M; Toossi, Z; Patel, P; Pasvol, G; Lalvani, A; Wright, D; Latif, M; Davidson, RN			Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study	LANCET			English	Article							BONE-MINERAL DENSITY; START CODON POLYMORPHISM; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; GENE; SUSCEPTIBILITY; INTERFERON; WOMEN; SERUM; RISK	Background Susceptibility to disease after infection by Mycobacterium tuberculosis is influenced by environmental and host genetic factors. Vitamin D metabolism leads to activation of macrophages and restricts the intracellular growth of M tuberculosis. This effect may be influenced by polymorphisms at three sites in the Vitamin D receptor (VDR) gene. We investigated the interaction between serum vitamin D (25-hydroxycholecalciferol) concentrations and VDR genotype on susceptibility to tuberculosis. Methods This study was a hospital-based case-control analysis of Asians of Gujarati origin, a mainly vegetarian immigrant population with a high rate of tuberculosis. We typed three VDR polymorphisms (defined by the presence of restriction endonuclease sites for Taq1, Bsm1, and Fok1) in 91 of 126 untreated patients with tuberculosis and 116 healthy contacts who had been sensitised to tuberculosis. Serum 25-hydroxycholecalciferol was recorded in 42 contacts and 103 patients. Findings 25-hydroxycholecalciferol deficiency was associated with active tuberculosis (odds ratio 2.9 [95% CI 1.3-6.5], p=0.008), and undetectable serum 25-hydroxycholecalciferol (<7 nmol/L) carried a higher risk of tuberculosis (9.9 [1.3-76.2], p=0.009). Although there was no significant independent association between VDR genotype and tuberculosis, the combination of genotype TT/Tt and 25-hydroxycholecalciferol deficiency was associated with disease (2.8 [1.2-6.5]) and the presence of genotype ff or undetectable serum 25-hydroxycholecalciferol was strongly associated with disease (5.1[1.4-18.4]). Interpretation 25-hydroxycholecalciferol deficiency may contribute to the high occurrence of tuberculosis in this population. Polymorphisms in the VDR gene also contribute to susceptibility when considered in combination with 25 hydroxycholecalciferol deficiency.	Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, Wellcome Ctr Clin Trop Med, Harrow HA1 3UJ, Middx, England; Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Imperial College London; Case Western Reserve University; University of Oxford	Davidson, RN (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, Wellcome Ctr Clin Trop Med, Harrow HA1 3UJ, Middx, England.	r.n.davidson@ic.ac.uk	Pasvol, Geoffrey/B-7113-2009; Llewelyn, Martin/Y-1472-2019; Llewelyn, Martin/A-7194-2011	Llewelyn, Martin/0000-0002-6811-1124; Lalvani, Ajit/0000-0002-2396-246X; Wilkinson, Robert/0000-0002-2753-1800				Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Cippitelli M, 1998, EUR J IMMUNOL, V28, P3017, DOI 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.3.CO;2-Y; Compston JE, 1998, BRIT MED J, V317, P1466, DOI 10.1136/bmj.317.7171.1466; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; Cooper GS, 1996, J BONE MINER RES, V11, P1841; DAVIES PDO, 1987, TUBERCLE, V68, P261, DOI 10.1016/0041-3879(87)90066-3; DAVIES PDO, 1985, THORAX, V40, P187, DOI 10.1136/thx.40.3.187; DAVIS P, 1994, HEALTH POLICY, V29, P113, DOI 10.1016/0168-8510(94)90010-8; Douglas AS, 1996, THORAX, V51, P944, DOI 10.1136/thx.51.9.944; FINCH PJ, 1991, THORAX, V46, P1, DOI 10.1136/thx.46.1.1; GRANGE JM, 1985, TUBERCLE, V66, P187, DOI 10.1016/0041-3879(85)90035-2; Gross C, 1996, J BONE MINER RES, V11, P1850; Gross C, 1998, J BONE MINER RES, V13, P1691, DOI 10.1359/jbmr.1998.13.11.1691; Harris SS, 1997, J BONE MINER RES, V12, P1043, DOI 10.1359/jbmr.1997.12.7.1043; Hoal-van Helden EG, 1999, PEDIATR RES, V45, P459, DOI 10.1203/00006450-199904010-00002; Lawson M, 1999, BRIT MED J, V318, P28, DOI 10.1136/bmj.318.7175.28; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Ormerod LP, 1998, THORAX, V53, P176, DOI 10.1136/thx.53.3.176; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; Rockett KA, 1998, INFECT IMMUN, V66, P5314, DOI 10.1128/IAI.66.11.5314-5321.1998; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SHENDEROVA RJ, 1991, PROBL TUBERK, V3, P54; SINGH SPN, 1983, J INFECT DIS, V148, P676, DOI 10.1093/infdis/148.4.676; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; STRACHAN DP, 1995, THORAX, V50, P175, DOI 10.1136/thx.50.2.175; Verbeek W, 1997, BIOCHEM BIOPH RES CO, V238, P77, DOI 10.1006/bbrc.1997.7239; WILKINSON RJ, 1995, J ROY COLL PHYS LOND, V29, P86; Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863	32	583	622	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2000	355	9204					618	621		10.1016/S0140-6736(99)02301-6	http://dx.doi.org/10.1016/S0140-6736(99)02301-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696983				2022-12-24	WOS:000085615400014
J	Quint, DJ				Quint, DJ			Indications for emergent MRI of the central nervous system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VERTEBRAL ARTERY DISSECTIONS; DIFFUSION-WEIGHTED MR; SUBARACHNOID HEMORRHAGE; ACUTE STROKE; CT; ANGIOGRAPHY; INFARCTION; DIAGNOSIS; THROMBOSIS; ETIOLOGY		Univ Michigan, Med Ctr, Dept Neuroradiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Quint, DJ (corresponding author), Univ Michigan, Med Ctr, Dept Neuroradiol, 1500 E Med Ctr Dr,B1D520,Box 30, Ann Arbor, MI 48109 USA.	djquint@umich.edu						Adams HP, 1996, STROKE, V27, P1711; Adams HP, 1996, NEUROLOGY, V47, P835; Auer F, 1998, J NEUROL NEUROSUR PS, V64, P474, DOI 10.1136/jnnp.64.4.474; BACH F, 1990, ACTA NEUROCHIR, V107, P37, DOI 10.1007/BF01402610; BANNAN PE, 1992, CURR OPIN NEUROL NEU, V5, P540; Beauchamp NJ, 1998, RADIOGRAPHICS, V18, P1269, DOI 10.1148/radiographics.18.5.9747619; Beauchamp NJ, 1998, AM J ROENTGENOL, V171, P73, DOI 10.2214/ajr.171.1.9648768; Burdette JH, 1998, AM J ROENTGENOL, V171, P791, DOI 10.2214/ajr.171.3.9725318; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; Desfontaines P, 1995, ACTA NEUROL BELG, V95, P226; ELKHOURY GY, 1995, AM J ROENTGENOL, V164, P43, DOI 10.2214/ajr.164.1.7998567; Ginsberg MD, 1997, AM J NEURORADIOL, V18, P1435; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Haley GH, 1997, ANN EMERG MED, V30, P676, DOI 10.1016/S0196-0644(97)99996-0; HURST RW, 1994, SEMIN NEUROL, V14, P320, DOI 10.1055/s-2008-1041092; Jacobs A, 1997, J NEUROL SCI, V147, P27, DOI 10.1016/S0022-510X(96)05300-2; Kasner SE, 1997, STROKE, V28, P1993, DOI 10.1161/01.STR.28.10.1993; KLUFAS RA, 1995, AM J ROENTGENOL, V164, P673, DOI 10.2214/ajr.164.3.7863892; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; Patel M R, 1996, Top Magn Reson Imaging, V8, P345; Provenzale JM, 1997, AM J ROENTGENOL, V169, P1161, DOI 10.2214/ajr.169.4.9308483; Provenzale JM, 1998, AM J ROENTGENOL, V170, P777, DOI 10.2214/ajr.170.3.9490973; Russell EJ, 1997, RADIOLOGY, V205, P315, DOI 10.1148/radiology.205.2.9356608; Singer MB, 1998, RADIOLOGY, V208, P417, DOI 10.1148/radiology.208.2.9680570; Velthuis BK, 1998, RADIOLOGY, V208, P423, DOI 10.1148/radiology.208.2.9680571; Villringer A, 1997, New Horiz, V5, P332; VILLRINGER A, 1994, J NEURORADIOLOGY, V21, P72	29	18	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2000	283	7					853	855		10.1001/jama.283.7.853	http://dx.doi.org/10.1001/jama.283.7.853			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281WT	10685696				2022-12-24	WOS:000085185000001
J	Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN				Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN			Localization of the G protein beta gamma complex in living cells during chemotaxis	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; TEMPORAL MECHANISM; RECEPTORS; SUBUNIT; LEUKOCYTES; GRADIENTS; RESPONSES; FREQUENCY; DIMERS; AMEBAE	Gradients of chemoattractants elicit signaling events at the Leading edge of a cell even though chemoattractant receptors are uniformly distributed on the cell surface. In highly polarized Dictyostelium discoideum amoebas, membrane-associated beta gamma subunits of heterotrimeric guanine nucleotide-binding proteins (G proteins) were localized in a shallow anterior-posterior gradient. A uniformly applied chemoattractant generated binding sites for pleckstrin homology (PH) domains on the inner surface of the membrane in a pattern similar to that of the G beta gamma subunits. Loss of cell polarity resulted in uniform distribution of both the G beta gamma subunits and the sensitivity of PH domain recruitment. There observations indicate that G beta gamma subunits are not sufficiently localized to restrict signaling events to the Leading edge but that their distribution may determine the relative chemotactic sensitivity of polarized cells.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM-28007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010418, ZIABC010418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BOURNE H, COMMUNICATION; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Jin T, 1998, MOL BIOL CELL, V9, P2949, DOI 10.1091/mbc.9.10.2949; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MEDEN U, 1995, J BIOL CHEM, V270, P15892; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Meinhardt H, 1999, J CELL SCI, V112, P2867; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SWANSON JA, 1982, CELL, V28, P225, DOI 10.1016/0092-8674(82)90340-3; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; VARNUMFINNEY BJ, 1987, CELL MOTIL CYTOSKEL, V8, P18, DOI 10.1002/cm.970080104; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhang N.F., UNPUB; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	26	234	240	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1034	1036		10.1126/science.287.5455.1034	http://dx.doi.org/10.1126/science.287.5455.1034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669414				2022-12-24	WOS:000085245400046
J	Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME				Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME			Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1	NATURE			English	Article							GROWTH-INHIBITORS; GENE; RAT; EXPRESSION; PROTEIN; IDENTIFICATION; TRANSCRIPTS; RECOVERY; SEQUENCE; CLONING	The capacity of the adult brain and spinal cord to repair lesions by axonal regeneration or compensatory fibre growth is extremely Limited. A monoclonal antibody (IN-1) raised against NI-220/250, a myelin protein that is a potent inhibitor of neurite growth, promoted axonal regeneration and compensatory plasticity following lesions of the central nervous system (CNS) in adult rats(1-4). Here we report the cloning of nogo A, the rat complementary DNA encoding NI-220/250. The nogo gene encodes at least three major protein products (Nogo-A, -B and -C), Recombinant Nogo-A is recognized by monoclonal antibody IN-1, and it inhibits neurite outgrowth from dorsal root ganglia and spreading of 3T3 fibroblasts in an IN-1-sensitive manner. Antibodies against Nogo-A stain CNS myelin and oligodendrocytes and allow dorsal root ganglion neurites to grow on CNS myelin and into optic nerve explants. These data show that Nogo-A is a potent inhibitor of neurite growth and an IN-1 antigen produced by oligodendrocytes, and may allow the generation of new reagents to enhance CNS regeneration and plasticity.	Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schwab, ME (corresponding author), Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016					BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen M. S., 1999, Society for Neuroscience Abstracts, V25, P2030; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; Morris NJ, 1999, BBA-PROTEIN STRUCT M, V1431, P525, DOI 10.1016/S0167-4838(99)00068-0; NAGASE T, 1998, DNA RES, V5, P169; Ninkina NN, 1997, GENE, V184, P205, DOI 10.1016/S0378-1119(96)00596-3; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; SCHAERENWIEMERS N, 1995, J NEUROSCI, V15, P5753; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WIECZOREK DF, 1991, MOL BRAIN RES, V10, P33, DOI 10.1016/0169-328X(91)90053-Z	19	1168	1347	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					434	439		10.1038/35000219	http://dx.doi.org/10.1038/35000219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667796				2022-12-24	WOS:000085121100052
J	Johanson, R				Johanson, R			Perineal massage for prevention of perineal trauma in childbirth	LANCET			English	Editorial Material							EPISIOTOMY; LACERATION		N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Johanson, R (corresponding author), N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.							AVERY MD, 1987, J NURSE-MIDWIFERY, V32, P181, DOI 10.1016/0091-2182(87)90095-4; AVERY MD, 1986, J NURSE-MIDWIFERY, V31, P128, DOI 10.1016/0091-2182(86)90148-5; CARROLI G, 1999, COCHRANE LIB; Graham I. D., 1997, EPISIOTOMY CHALLENGI; KETTLE C, 1999, PERINEAL TEARS; KETTLE C, 1999, CLIN EVID, V2, P522; Klein MC, 1997, AM J OBSTET GYNECOL, V176, P403, DOI 10.1016/S0002-9378(97)70506-4; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; LABRECQUE M, 1994, BIRTH-ISS PERINAT C, V21, P20, DOI 10.1111/j.1523-536X.1994.tb00911.x; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x	13	25	27	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					250	251		10.1016/S0140-6736(00)00020-9	http://dx.doi.org/10.1016/S0140-6736(00)00020-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675069				2022-12-24	WOS:000085045600005
J	Daily, GC; Walker, BH				Daily, GC; Walker, BH			Seeking the great transition	NATURE			English	Editorial Material									Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA; CSIRO, Canberra, ACT 2601, Australia	Stanford University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Daily, GC (corresponding author), Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA.		Walker, Brian H/F-2386-2011					[Anonymous], 2013, THE FUTURE OF NATURE, DOI DOI 10.12987/9780300188479-039; Daily GC, 1996, ECOL APPL, V6, P991, DOI 10.2307/2269582; DAILY GC, UNPUB SCI; Dunphy D. C., 1998, SUSTAINABLE CORPORAT; ELKINGTON J, 1999, PEOPLE PLANET, V8, P10; Hackel JD, 1999, CONSERV BIOL, V13, P726, DOI 10.1046/j.1523-1739.1999.98210.x; Hawken Paul, 2010, NATURAL CAPITALISM C; Hawken Paul, 2011, ECOLOGY COMMERCE DEC; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; Levin S., 1999, FRAGILE DOMINION; MCNEELY JA, 1999, MOBILIZING BROADER S; Myers Norman, 1998, PERVERSE SUBSIDIES T; National Research Council, 1999, OUR COMM JOURN TRANS; RAVEN PH, IN PRESS FRONTIERS M; Rees W., 1996, OUR ECOLOGICAL FOOTP, P3; Richards D. J, 1997, IND GREEN GAME IMPLI; Romm Joseph J., 1999, COOL COMPANIES BEST; ROSENBLATT R, 1999, CONSUMING DESIRES CO; SASSEVILLE DR, 1997, ISO 14000 ANSWER BOO; Schmidheiny S., 1992, CHANGING COURSE GLOB; Schulze PC, 1999, MEASURES ENV PERFORM, P1; *SIERR BUS COUNC, 1996, SIERR NEV WEALTH IND; Socolow R, 1994, IND ECOLOGY GLOBAL C; Wilkinson P, 1998, NATURE, V396, P511, DOI 10.1038/24979	24	23	26	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					243	245		10.1038/35002194	http://dx.doi.org/10.1038/35002194			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659827				2022-12-24	WOS:000084899700022
J	Rhew, RC; Miller, BR; Weiss, RF				Rhew, RC; Miller, BR; Weiss, RF			Natural methyl bromide and methyl chloride emissions from coastal salt marshes	NATURE			English	Article							HIGHER-PLANTS; BIOSYNTHESIS; METHANE; HALOMETHANES; FLUX	Atmospheric methyl bromide (CH3Br) and methyl chloride (CH3Cl), compounds that are involved in stratospheric ozone depletion, originate from both natural and anthropogenic sources. Current estimates of CH3Br and CH3Cl emissions from oceanic sources, terrestrial plants and fungi, biomass burning and anthropogenic inputs do not balance their losses owing to oxidation by hydroxyl radicals, oceanic degradation, and consumption in soils, suggesting that additional natural terrestrial sources may be important(1). Here we show that CH3Br and CH3Cl are released to the atmosphere from all vegetation zones of two coastal salt marshes. We see very large fluxes of CH3Br and CH3Cl per unit area: up to 42 and 570 mu mol m(-2) d(-1), respectively. The fluxes show large diurnal, seasonal and spatial variabilities, but there is a strong correlation between the fluxes of CH3Br and those of CH3Cl, with an average molar flux ratio of roughly 1:20. If our measurements are typical of salt marshes globally, they suggest that such ecosystems, even though they constitute less than 0.1% of the global surface area(2), may produce roughly 10% of the total fluxes of atmospheric CH3Br and CH3Cl.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Rhew, RC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Rhew, Robert C/M-8110-2016	Rhew, Robert C/0000-0001-6358-2050; Miller, Benjamin/0000-0003-1647-0122				ALONGI D, 1998, COASTAL ECOSYSTEM PR; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; BARTLETT KB, 1985, J GEOPHYS RES-ATMOS, V90, P5710, DOI 10.1029/JD090iD03p05710; DELAUNE RD, 1983, TELLUS B, V35, P8, DOI 10.1111/j.1600-0889.1983.tb00002.x; Gan J, 1998, GEOPHYS RES LETT, V25, P3595, DOI 10.1029/98GL52697; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Kurylo MJ, 1999, SCI ASSESSMENT OZONE, P21; Livingston G., 1995, BIOGENIC TRACE GASES, P14; MANLEY SL, 1988, MAR BIOL, V98, P477, DOI 10.1007/BF00391538; Miller BR, 1998, J GEOPHYS RES-ATMOS, V103, P13237, DOI 10.1029/98JD00771; MILLER BR, 1998, THESIS U CALIFORNIA; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; Saxena D, 1998, APPL ENVIRON MICROB, V64, P2831; Scarratt MG, 1996, MAR CHEM, V54, P263, DOI 10.1016/0304-4203(96)00036-9; STEELE LP, 1987, J ATMOS CHEM, V5, P125, DOI 10.1007/BF00048857; Varner RK, 1999, GEOPHYS RES LETT, V26, P2433, DOI 10.1029/1999GL900587; Watling R, 1998, MYCOL RES, V102, P769, DOI 10.1017/S0953756298006157; Wingenter OW, 1998, GEOPHYS RES LETT, V25, P2797, DOI 10.1029/98GL02179; WOODWELL GM, 1973, BROOKHAVEN S BIOL SE, V24, P221; WUOSMAA AM, 1990, SCIENCE, V249, P160, DOI 10.1126/science.2371563; Zedler, 1982, FWSOBS8154 US FISH W	21	206	219	5	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					292	295		10.1038/35002043	http://dx.doi.org/10.1038/35002043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659844				2022-12-24	WOS:000084899700047
J	Yack, JE; Fullard, JH				Yack, JE; Fullard, JH			Ultrasonic hearing in nocturnal butterflies	NATURE			English	Article									Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Coll Nat Sci, Ottawa, ON K1S 5B6, Canada; Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada; Univ Toronto, Erindale Coll, Mississauga, ON L5L 1C6, Canada	Carleton University; Carleton University; University of Toronto; University Toronto Mississauga; University of Toronto; University Toronto Mississauga	Yack, JE (corresponding author), Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada.	jyack@ccs.carleton.ca						Conner WE, 1999, J EXP BIOL, V202, P1711; FULALRD JH, 1998, COMP HEARING INSECTS, P279; HOY R, 1989, J EXP BIOL, V146, P287; Jacobs K, 1999, J EXP ZOOL, V283, P270, DOI 10.1002/(SICI)1097-010X(19990215)283:3&lt;270::AID-JEZ5&gt;3.0.CO;2-C; Kristensen N.P., 1998, HDB ZOOLOGY, V4, P7, DOI 10.1515/9783110804744.7; NOVACEK MJ, 1985, NATURE, V315, P140, DOI 10.1038/315140a0; OTERO LD, 1990, B ENTOMOL VENEZ, V5, P128; Ribaric Darja, 1996, Acta Entomologica Slovenica, V4, P5; Scoble M.J., 1986, Bulletin of the British Museum (Natural History) Entomology, V53, P251; SCOBLE MJ, 1990, J NAT HIST, V24, P159, DOI 10.1080/00222939000770101; SILBERGLIED RE, 1984, BIOL BUTTERFLIES, P207; Vogel R, 1912, Z WISS ZOOL ABT A, V100, P210; YACK JE, 1993, ANN ENTOMOL SOC AM, V86, P677, DOI 10.1093/aesa/86.6.677	13	49	51	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					265	266		10.1038/35002247	http://dx.doi.org/10.1038/35002247			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659835				2022-12-24	WOS:000084899700037
J	Liu, QH; Wang, LM; Frutos, AG; Condon, AE; Corn, RM; Smith, LM				Liu, QH; Wang, LM; Frutos, AG; Condon, AE; Corn, RM; Smith, LM			DNA computing on surfaces	NATURE			English	Article							COMBINATORIAL TECHNOLOGIES; DRUG DISCOVERY; AMPLIFICATION; HYBRIDIZATION; COMPUTATION; BETAINE; ARRAYS; DESIGN; GOLD	DNA computing was proposed(1) as a means of solving a class of intractable computational problems in which the computing time can grow exponentially with problem size (the 'NP-complete' or non-deterministic polynomial time complete problems). The principle of the technique has been demonstrated experimentally for a simple example of the hamiltonian path problem(2) (in this case, finding an airline flight path between several cities, such that each city is visited only once(3)). DNA computational approaches to the solution of other problems have also been investigated(4-9). One technique(10-13) involves the immobilization and manipulation of combinatorial mixtures of DNA on a support. A set of DNA molecules encoding all candidate solutions to the computational problem of interest is synthesized and attached to the surface. Successive cycles of hybridization operations and exonuclease digestion are used to identify and eliminate those members of the set that are not solutions. Upon completion of all the multistep cycles, the solution to the computational problem is identified using a polymerase chain reaction to amplify the remaining molecules, which are then hybridized to an addressed array. The advantages of this approach are its scalability and potential to be automated (the use of solid-phase formats simplifies the complex repetitive chemical processes, as has been demonstrated in DNA and protein synthesis(14)). Here we report the use of this method to solve a NP-complete problem. We consider a small example of the satisfiability problem (SAT)(2), in which the values of a set of boolean variables satisfying certain logical constraints are determined.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Smith, LM (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.			Corn, Robert/0000-0002-4756-2161				Adleman LM, 1998, SCI AM, V279, P54, DOI 10.1038/scientificamerican0898-54; ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BONEH D, 1999, DIMACS SERIES DISCRE, V44, P163; CAI W, 1997, P 1 ANN INT C COMP M; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Farrell RE, 1997, IMMUNOL INVEST, V26, P3, DOI 10.3109/08820139709048910; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Frutos AG, 1997, NUCLEIC ACIDS RES, V25, P4748, DOI 10.1093/nar/25.23.4748; Frutos AG, 1998, J AM CHEM SOC, V120, P10277, DOI 10.1021/ja982030w; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Garey M.R., 1979, COMPUTERS INTRACTABI; GILLMOR SD, UNPUB LANGMUIR; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; Jordan CE, 1997, ANAL CHEM, V69, P4939, DOI 10.1021/ac9709763; Karp RM, 1999, RANDOM STRUCT ALGOR, V15, P450, DOI 10.1002/(SICI)1098-2418(199910/12)15:3/4<450::AID-RSA12>3.0.CO;2-2; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Lyamichev V, 1999, NAT BIOTECHNOL, V17, P292, DOI 10.1038/7044; MORIMOTO N, 1997, P DIMACS DNA BASED C, V3, P83; OGIHARA M, 1996, 629 TR U ROCH DEP CO; Ouyang Q, 1997, SCIENCE, V278, P446, DOI 10.1126/science.278.5337.446; Pippenger N., 1990, P S PURE MATH, V50, P311; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; SCHONING U, 1999, P 40 ANN IEEE S FDN, P410; Seeman NC, 1998, NANOTECHNOLOGY, V9, P257, DOI 10.1088/0957-4484/9/3/018; SMITH LM, 1988, ANAL CHEM, V60, pA381, DOI 10.1021/ac00157a001; Smith LM, 1998, J COMPUT BIOL, V5, P255, DOI 10.1089/cmb.1998.5.255; Voss KO, 1998, ANAL CHEM, V70, P3818, DOI 10.1021/ac980067t; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; YOSHIDA H, 1999, PRELIMINARY P DIMACS, V5, P9	33	404	510	4	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					175	179		10.1038/35003155	http://dx.doi.org/10.1038/35003155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646598				2022-12-24	WOS:000084835300049
J	Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M				Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M			Prevalence of antibody to human T cell leukaemia/lymphoma virus in women attending antenatal clinic in southeast London: retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England; Kings Healthcare Trust, Dept Obstet & Gynaecol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Zuckerman, M (corresponding author), Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England.	mark.zuckerman@kcl.ac.uk						Department of Health, 1998, PREV HIV ENGL WAL 19; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; *INT WORK PART ENH, 1998, RED MOTH CHILD TRANS; NIGHTINGALE S, 1993, EPIDEMIOL INFECT, V110, P370; Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60	5	10	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	2000	320	7227					92	93		10.1136/bmj.320.7227.92	http://dx.doi.org/10.1136/bmj.320.7227.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625263	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000084746600018
J	Abrahm, JL				Abrahm, JL			The role of the clinician in palliative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrahm, JL (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; Buckman R., 1992, BREAK BAD NEWS GUIDE; *WHO, 1990, WHO TECHN REP SER, V804	3	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					116	116		10.1001/jama.283.1.116	http://dx.doi.org/10.1001/jama.283.1.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632293	Bronze			2022-12-24	WOS:000084514400038
J	Dunton, CJ; Berd, D				Dunton, CJ; Berd, D			Vulvar melanoma, biologically different from other cutaneous melanomas	LANCET			English	Editorial Material							MALIGNANT-MELANOMA		Thomas Jefferson Univ Hosp, Div Gynecol Oncol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Div Med Oncol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Dunton, CJ (corresponding author), Thomas Jefferson Univ Hosp, Div Gynecol Oncol, Philadelphia, PA 19107 USA.							BACCHI CE, 1992, GYNECOL ONCOL, V46, P216, DOI 10.1016/0090-8258(92)90258-K; Berd D, 1997, J CLIN ONCOL, V15, P2359, DOI 10.1200/JCO.1997.15.6.2359; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Cagir B, 1999, DIS COLON RECTUM, V42, P1203, DOI 10.1007/BF02238576; CHUNG AF, 1975, OBSTET GYNECOL, V45, P638, DOI 10.1097/00006250-197506000-00008; CLARK WH, 1969, CANCER RES, V29, P705; DAVIDSON T, 1987, BRIT J OBSTET GYNAEC, V94, P473, DOI 10.1111/j.1471-0528.1987.tb03128.x; LOOK KY, 1993, CANCER, V72, P143, DOI 10.1002/1097-0142(19930701)72:1<143::AID-CNCR2820720127>3.0.CO;2-M; MASTRANGELO MJ, 1979, HUMAN MALIGNANT MELA; PIURA B, 1992, J SURG ONCOL, V50, P234, DOI 10.1002/jso.2930500408; Ragnarsson-Olding BK, 1999, CANCER, V86, P1285, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P; Ragnarsson-Olding BK, 1999, CANCER, V86, P1273, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z; ROGO K O, 1991, European Journal of Gynaecological Oncology, V12, P113; ROSE PG, 1988, AM J OBSTET GYNECOL, V159, P52, DOI 10.1016/0002-9378(88)90493-0; TASSERON EWK, 1992, GYNECOL ONCOL, V46, P170, DOI 10.1016/0090-8258(92)90250-M; TRIMBLE EL, 1992, GYNECOL ONCOL, V45, P254, DOI 10.1016/0090-8258(92)90300-8	16	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2013	2014		10.1016/S0140-6736(99)00390-6	http://dx.doi.org/10.1016/S0140-6736(99)00390-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636360				2022-12-24	WOS:000084183300003
J	Diaz, PT; King, MA; Pacht, ER; Wewers, MD; Gadek, JE; Nagaraja, HN; Drake, J; Clanton, TL				Diaz, PT; King, MA; Pacht, ER; Wewers, MD; Gadek, JE; Nagaraja, HN; Drake, J; Clanton, TL			Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers	ANNALS OF INTERNAL MEDICINE			English	Article							CELLS; VIRUS; LUNG; PNEUMONITIS; EXPRESSION; INFECTION; DISEASE	Background: Previous uncontrolled reports have suggested that HIV-seropositive persons develop an accelerated form of emphysema. Objective: To characterize the risk for emphysema in a stable HIV-seropositive outpatient population. Design: Controlled, cross-sectional analysis. Setting: Midwestern urban community. Participants: HIV-seropositive persons (n = 114)without AIDS-related pulmonary complications and HIV-seronegative controls (n = 44), matched for age and smoking history. Measurements: Measurement of pulmonary function, bronchoalveolar lavage, and high-resolution computed tomography of the chest. Results: The incidence of emphysema was 15 % (17 of 114) in the HIV-seropositive group compared with 2 % (1 of 44) in the HIV-seronegative group (P = 0.025). The incidence of emphysema in participants with a smoking history of 12 pack-years or greater was 37% (14 of 38 persons) in the HIV-seropositive group compared with 0% (0 of 14 persons) in the HIV-seronegative group (P = 0.011). The percentage of cytotoxic lymphocytes in lavage fluid was much higher in HIV-seropositive smokers with emphysema. Conclusions: infection with HIV accelerates the onset of smoking-induced emphysema. The results of this study support the emerging concept that cytotoxic lymphocytes may have an important role in emphysema pathogenesis.	Ohio State Univ, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Diaz, PT (corresponding author), Pulm & Crit Care Med, N 325 Means Hall,1654 Upham Dr, Columbus, OH 43210 USA.		Wewers, Mark/AAB-6202-2021; Clanton, Thomas/AAS-9422-2020	Clanton, Thomas/0000-0003-0600-7150	NCRR NIH HHS [2MO1-RR0034] Funding Source: Medline; NHLBI NIH HHS [R01-HL49730, R01-HL53229] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053229, R01HL049730] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agostini C, 1998, LUNG BIOL HEALTH DIS, V119, P127; BLOT F, 1991, REV MAL RESPIR, V8, P121; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; *CYT SOFTW CORP, 1995, STAT XACT 3; Dhawan S, 1997, BLOOD, V90, P1535; DIAZ PT, 1992, ANN INTERN MED, V116, P124, DOI 10.7326/0003-4819-116-2-124; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; Guillemi SA, 1996, EUR RESPIR J, V9, P33, DOI 10.1183/09031936.96.09010033; Hogg J C, 1995, Semin Respir Infect, V10, P244; Keicho N, 1997, AM J RESP CELL MOL, V16, P23, DOI 10.1165/ajrcmb.16.1.8998075; Keicho N, 1997, AM J PHYSIOL-LUNG C, V272, pL1046, DOI 10.1152/ajplung.1997.272.6.L1046; KUHLMAN JE, 1989, RADIOLOGY, V173, P23, DOI 10.1148/radiology.173.1.2781013; LAMB D, 1996, SPENCERS PATHOLOGY L, P597; OGNIBENE FP, 1988, ANN INTERN MED, V109, P874, DOI 10.7326/0003-4819-109-11-874; Pacht ER, 1997, AM J RESP CRIT CARE, V155, P374, DOI 10.1164/ajrccm.155.1.9001339; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711, DOI 10.1164/ajrccm.160.2.9812020; SAS, 1995, JMP VERS 3; SEMENZATO G, 1991, EUR RESPIR J, V4, P94; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1615, DOI 10.1164/ajrccm/146.6.1615	20	227	231	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2000	132	5					369	372		10.7326/0003-4819-132-5-200003070-00006	http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KY	10691587				2022-12-24	WOS:000085563000005
J	Myers, N; Mittermeier, RA; Mittermeier, CG; da Fonseca, GAB; Kent, J				Myers, N; Mittermeier, RA; Mittermeier, CG; da Fonseca, GAB; Kent, J			Biodiversity hotspots for conservation priorities	NATURE			English	Article							EXTINCTION; DIVERSITY; RICHNESS; FOREST; BIRDS; AREAS	Consenrationists are far from able to assist all species under threat, if only for lack of funding. This places a premium on priorities: how can we support the most species at the least cost? One way is to identify 'biodiversity hotspots' where exceptional concentrations of endemic species are undergoing exceptional loss of habitat. As many as 44% of all species of vascular plants and 35% of all species in four vertebrate groups are confined to 25 hotspots comprising only 1.4% of the land surface of the Earth. This opens the way for a 'silver bullet' strategy on the part of conservation planners, focusing on these hotspots in proportion to their share of the world's species at risk.	Univ Oxford Green Coll, Oxford OX3 8SZ, England; Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20037 USA	University of Oxford; Conservation International	Myers, N (corresponding author), Univ Oxford Green Coll, Upper Meadow,Old Rd, Oxford OX3 8SZ, England.	myersln@aol.com	campbell, Ian G/F-6006-2011; burke, daniel/D-3668-2009					[Anonymous], 1999, WALKERS MAMMALS WORL; [Anonymous], 1995, GLOBAL BIODIVERSITY; Balmford A, 1995, CONSERV BIOL, V9, P1539, DOI 10.1046/j.1523-1739.1995.09061539.x; Brooks T, 1996, NATURE, V380, P115, DOI 10.1038/380115a0; Brooks TM, 1999, CONSERV BIOL, V13, P1140, DOI 10.1046/j.1523-1739.1999.98341.x; Brooks TM, 1997, CONSERV BIOL, V11, P382, DOI 10.1046/j.1523-1739.1997.95493.x; Cowlishaw G, 1999, CONSERV BIOL, V13, P1183, DOI 10.1046/j.1523-1739.1999.98433.x; Davis S.D., 1994, CTR PLANT DIVERSITY; DINERSTEIN E, 1996, GLOBAL 200 KEY ECORE; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; EHRLICH PR, 1994, PHILOS T R SOC B, V344, P99, DOI 10.1098/rstb.1994.0057; Eschmeyer W.N., 1998, CATALOG FISHES; Farrell BD, 1998, SCIENCE, V281, P555, DOI 10.1126/science.281.5376.555; GASTON KJ, 1992, FUNCT ECOL, V6, P243, DOI 10.2307/2389513; GASTON KJ, 1995, P ROY SOC B-BIOL SCI, V259, P119, DOI 10.1098/rspb.1995.0018; Ginsberg J, 1999, CONSERV BIOL, V13, P5, DOI 10.1046/j.1523-1739.1999.013001005.x; Glaw Frank, 1998, Herpetological Review, V29, P11; Groombridge B., 1992, GLOBAL BIODIVERSITY; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; JANZEN DH, 1979, ANNU REV ECOL SYST, V10, P13, DOI 10.1146/annurev.es.10.110179.000305; Laurance WF, 1999, BIOL CONSERV, V91, P101, DOI 10.1016/S0006-3207(99)00087-7; MacArthur R. H., 1967, THEORY ISLAND BIOGEO; Mittermeier R. A., 1999, CHELONIAN CONSERV BI; Mittermeier RA, 1998, CONSERV BIOL, V12, P516, DOI 10.1046/j.1523-1739.1998.012003516.x; Myers N, 1998, NATURE, V392, P327, DOI 10.1038/32761; Myers N, 1988, Environmentalist, V8, P187, DOI 10.1007/BF02240252; Myers N, 1990, Environmentalist, V10, P243, DOI 10.1007/BF02239720; Myers N, 1996, BIODIVERS CONSERV, V5, P1025, DOI 10.1007/BF00052713; Newmark WD, 1996, CONSERV BIOL, V10, P1549, DOI 10.1046/j.1523-1739.1996.10061549.x; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; PRANCE GT, IN PRESS TROPICAL FL; Prendergast JR, 1999, CONSERV BIOL, V13, P484, DOI 10.1046/j.1523-1739.1999.97428.x; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; PRESSEY RL, 1993, TRENDS ECOL EVOL, V8, P124, DOI 10.1016/0169-5347(93)90023-I; Price PW., 1997, INSECT ECOLOGY, V3rd edn; Reid WV, 1998, TRENDS ECOL EVOL, V13, P275, DOI 10.1016/S0169-5347(98)01363-9; Sibley CG., 1990, DISTRIBUTION TAXONOM; Stattersfield Alison J., 1998, Birdlife Conservation Series, V7, P1; Strong DR, 1984, INSECTS PLANTS COMMU; TILMAN D, 1994, NATURE, V371, P65, DOI 10.1038/371065a0; Turner IM, 1996, J APPL ECOL, V33, P200, DOI 10.2307/2404743; Uetz P., 1996, HERPETOL REV, V27, P175; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Williams P, 1996, CONSERV BIOL, V10, P155, DOI 10.1046/j.1523-1739.1996.10010155.x; WILLIAMS P H, 1991, Australian Systematic Botany, V4, P665, DOI 10.1071/SB9910665; Williams PH, 1997, P ROY SOC B-BIOL SCI, V264, P141, DOI 10.1098/rspb.1997.0021; WILSON E O, 1992	48	17300	19147	202	590	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					853	858		10.1038/35002501	http://dx.doi.org/10.1038/35002501			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706275				2022-12-24	WOS:000085559200046
J	Takasaki, T; Hatakeyama, K; Suzuki, G; Watanabe, M; Isogai, A; Hinata, K				Takasaki, T; Hatakeyama, K; Suzuki, G; Watanabe, M; Isogai, A; Hinata, K			The S receptor kinase determines self-incompatibility in Brassica stigma	NATURE			English	Article							CAMPESTRIS L; MOLECULAR-CLONING; LOCUS GENES; RAPA L; OLERACEA; TRANSFORMATION; ALLELES; GLYCOPROTEINS; EXPRESSION; SEQUENCE	The self-incompatibility possessed by Brassica is an intraspecific reproductive barrier by which the stigma rejects self-pollen but accepts non-self-pollen for fertilization. The molecular/biochemical bases of recognition and rejection have been intensively studied. Self-incompatibility in Brassica is sporophytically controlled by the polymorphic S locus(1). Two tightly linked polymorphic genes at the S locus, S receptor kinase gene (SRK) and S locus glycoprotein gene (SLG), are specifically expressed in the papillar cells of the stigma(2-4), and analyses of self-compatible lines(5-7) of Brassica have suggested that together they control stigma function in self-incompatibility interactions. Here we show, by transforming self-incompatible plants of Brassica rapa with an SRK28 and an SLG(28) transgene separately, that expression of SRK28 alone, but not SLG(28) alone, conferred the ability to reject self (S-28)-pollen on the transgenic plants. We also show that the ability of SRK28 to reject S-28 pollen was enhanced by SLG(28). We conclude that SRK alone determines S haplotype specificity of the stigma, and that SLG acts to promote a full manifestation of the self-incompatibility response.	Seed Prod Co Ltd, Res Inst, Aoba Ku, Sendai, Miyagi 9893204, Japan; Kobe Univ, Fac Agr, Nada Ku, Kobe, Hyogo 6578501, Japan; Osaka Kyoiku Univ, Div Nat Sci, Osaka 5828582, Japan; Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan	Kobe University; Osaka University of Education; Iwate University; Nara Institute of Science & Technology	Takasaki, T (corresponding author), Seed Prod Co Ltd, Res Inst, Aoba Ku, 6-6-3 Minamiyoshinari, Sendai, Miyagi 9893204, Japan.		Isogai, Akira/O-8897-2017; Watanabe, Masao/E-6300-2011; Watanabe, Masao/N-1465-2019	Isogai, Akira/0000-0001-8095-0441; Watanabe, Masao/0000-0002-9419-5149; Watanabe, Masao/0000-0002-9419-5149				Bateman AJ, 1955, HEREDITY, V9, P52, DOI DOI 10.1038/HDY.1955.2; BRACE J, 1993, SEX PLANT REPROD, V6, P133, DOI 10.1007/BF00227658; Conner JA, 1997, PLANT J, V11, P809, DOI 10.1046/j.1365-313X.1997.11040809.x; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; Hatakeyama K, 1998, HEREDITY, V80, P241, DOI 10.1046/j.1365-2540.1998.00295.x; Hatakeyama K, 1998, GENETICS, V149, P1587; HINATA K, 1993, INT REV CYTOL, V143, P257; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KHO YO, 1968, EUPHYTICA, V17, P298; KISHINISHIZAWA N, 1990, PLANT CELL PHYSIOL, V31, P1207; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NASRALLAH JB, 1987, NATURE, V326, P617, DOI 10.1038/326617a0; NASRALLAH ME, 1992, PLANT J, V2, P497, DOI 10.1111/j.1365-313X.1992.00497.x; Nishio T, 1996, THEOR APPL GENET, V92, P388, DOI 10.1007/BF00223684; Nishio T, 1997, THEOR APPL GENET, V95, P335, DOI 10.1007/s001220050568; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SHIBA H, 1995, P JPN ACAD B-PHYS, V71, P81, DOI 10.2183/pjab.71.81; Stahl RJ, 1998, PLANT CELL, V10, P209, DOI 10.1105/tpc.10.2.209; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Suzuki G, 1996, PLANT CELL PHYSIOL, V37, P866, DOI 10.1093/oxfordjournals.pcp.a029024; SUZUKI G, 1995, PLANT CELL PHYSIOL, V36, P1273; Suzuki G, 1999, GENETICS, V153, P391; Takasaki T, 1997, BREEDING SCI, V47, P127; Takasaki T, 1999, PLANT MOL BIOL, V40, P659, DOI 10.1023/A:1006274525421; TAKAYAMA S, 1987, NATURE, V326, P102, DOI 10.1038/326102a0; WATANABE M, 1994, PLANT CELL PHYSIOL, V35, P1221, DOI 10.1093/oxfordjournals.pcp.a078716	30	372	446	6	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					913	916		10.1038/35002628	http://dx.doi.org/10.1038/35002628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706292				2022-12-24	WOS:000085559200063
J	Burrows, A				Burrows, A			Supernova explosions in the Universe	NATURE			English	Review							GAMMA-RAY BURST; 28 FEBRUARY 1997; NEUTRINO BURST; ELECTRON-CAPTURE; CORE-COLLAPSE; IA SUPERNOVAE; BLACK-HOLES; ERROR BOX; LOW-MASS; STARS	During the lifetime of our Milky Way galaxy, there have been something like 100 million supernova explosions, which have enriched the Galaxy with the oxygen we breathe, the iron in our cars, the calcium in our bones and the silicon in the rocks beneath our feet. These exploding stars also influence the birth of new stars and are the source of the energetic cosmic rays that irradiate us on the Earth. The prodigious amount of energy (similar to 10(51), Or similar to 2.5 x 10(28) megatonnes of TNT equivalent) and momentum associated with each supernova may even have helped to shape galaxies as they formed in the early Universe. Supernovae are now being used to measure the geometry of the Universe, and have recently been implicated in the decades-old mystery of the origin of the gamma-ray bursts. Together with major conceptual advances in our theoretical understanding of supernovae, these developments have made supernovae the centre of attention in astrophysics.	Univ Arizona, Dept Astron, Tucson, AZ 85721 USA	University of Arizona	Burrows, A (corresponding author), Univ Arizona, Dept Astron, Tucson, AZ 85721 USA.	aburrows@as.arizona.edu						Aguirre AN, 1999, ASTROPHYS J, V512, pL19, DOI 10.1086/311862; ARNETT WD, 1989, ANNU REV ASTRON ASTR, V27, P629, DOI 10.1146/annurev.aa.27.090189.003213; Aschenbach B, 1998, NATURE, V396, P141, DOI 10.1038/24103; Ashworth W. B.  Jr., 1980, Journal for the History of Astronomy, V11, P1; BARI C, 1988, NUCL INSTRUM METH A, V264, P5, DOI 10.1016/0168-9002(88)91094-7; BELLOTTI E, 1988, NUCL INSTRUM METH A, V264, P1, DOI 10.1016/0168-9002(88)91093-5; BETHE HA, 1979, NUCL PHYS A, V324, P487, DOI 10.1016/0375-9474(79)90596-7; BETHE HA, 1985, ASTROPHYS J, V295, P14, DOI 10.1086/163343; BIONTA RM, 1987, PHYS REV LETT, V58, P1494, DOI 10.1103/PhysRevLett.58.1494; Bloom JS, 1999, NATURE, V401, P453, DOI 10.1038/46744; BROWN GE, 1994, ASTROPHYS J, V423, P659, DOI 10.1086/173844; Brown GE, 1996, ASTROPHYS J, V463, P297, DOI 10.1086/177241; BRUENN SW, 1985, ASTROPHYS J SUPPL S, V58, P771, DOI 10.1086/191056; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; BURROWS A, 1993, ASTROPHYS J, V416, pL75, DOI 10.1086/187074; BURROWS A, 1988, ASTROPHYS J, V334, P891, DOI 10.1086/166885; BURROWS A, 1982, ASTROPHYS J, V259, P330, DOI 10.1086/160169; BURROWS A, 1995, ASTROPHYS J, V450, P830, DOI 10.1086/176188; BURROWS A, 1986, ASTROPHYS J, V307, P178, DOI 10.1086/164405; BURROWS A, 1988, PHYS REP, V163, P51, DOI 10.1016/0370-1573(88)90035-X; Chaboyer B, 1996, SCIENCE, V271, P957, DOI 10.1126/science.271.5251.957; Chaboyer B, 1998, ASTROPHYS J, V494, P96, DOI 10.1086/305201; COLGATE SA, 1966, ASTROPHYS J, V143, P626, DOI 10.1086/148549; COLGATE SA, 1960, PHYS REV LETT, V5, P235, DOI 10.1103/PhysRevLett.5.235; CORDES JM, 1993, NATURE, V362, P133, DOI 10.1038/362133a0; Costa E, 1997, NATURE, V387, P783, DOI 10.1038/42885; Cowan JJ, 1999, ASTROPHYS J, V521, P194, DOI 10.1086/307512; EWAN GT, 1987, SNO8712; Fryer C, 1998, ASTROPHYS J, V496, P333, DOI 10.1086/305348; FRYER C, 1999, CORE COLLAPSE SIMULA; FRYXELL B, 1991, ASTROPHYS J, V367, P619, DOI 10.1086/169657; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; GIBSON BK, 1999, HST KEY PROJECT EXTR; Hamuy M, 1996, ASTRON J, V112, P2408, DOI 10.1086/118192; HERANT M, 1994, ASTROPHYS J, V435, P339, DOI 10.1086/174817; HIRATA K, 1987, PHYS REV LETT, V58, P1490, DOI 10.1103/PhysRevLett.58.1490; *IC COLL, 1994, 94991 LNGS GRANS LAB; Iyudin AF, 1998, NATURE, V396, P142, DOI 10.1038/24106; Janka HT, 1996, ASTRON ASTROPHYS, V306, P167; KENNICUTT RC, 1995, ASTRON J, V110, P1476, DOI 10.1086/117621; KOSHIBA M, 1992, PHYS REP, V220, P229, DOI 10.1016/0370-1573(92)90083-C; LYNE AG, 1994, NATURE, V369, P127, DOI 10.1038/369127a0; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Madau P, 1998, MON NOT R ASTRON SOC, V297, pL17, DOI 10.1046/j.1365-8711.1998.01697.x; MAYLE R, 1988, ASTROPHYS J, V334, P909, DOI 10.1086/166886; McNamara BJ, 1998, NATURE, V396, P233, DOI 10.1038/24317; Messer OEB, 1998, ASTROPHYS J, V507, P353, DOI 10.1086/306323; METZGER MR, 1997, NATURE, V387, P879; NOMOTO K, 1984, ASTROPHYS J, V277, P791, DOI 10.1086/161749; NOMOTO K, 1988, PHYS REP, V163, P13, DOI 10.1016/0370-1573(88)90032-4; OSTRIKER JP, 1971, ASTROPHYS J, V164, pL95, DOI 10.1086/180699; PACZYNSKI B, 1999, GAMMARAY BURST SUPER; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; PHILLIPS MM, 1993, ASTROPHYS J, V413, pL105, DOI 10.1086/186970; PIRO L, 1997, JOINT EUR NAT ASTR M, P284; Reichart DE, 1999, ASTROPHYS J, V521, pL111, DOI 10.1086/312203; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; RIESS AG, 1999, INDICATION EVOLUTION; SAKAI S, 1999, HUBBLE SPACE TELESCO; Schmidt BP, 1998, ASTROPHYS J, V507, P46, DOI 10.1086/306308; Sollerman J, 1998, ASTROPHYS J, V493, P933, DOI 10.1086/305163; Suntzeff NB, 1999, ASTRON J, V117, P1175, DOI 10.1086/300771; TAYLOR JH, 1993, ASTROPHYS J, V411, P674, DOI 10.1086/172870; Totani T, 1998, ASTROPHYS J, V496, P216, DOI 10.1086/305364; TUELLER J, 1990, ASTROPHYS J, V351, pL41, DOI 10.1086/185675; Turatto M, 1998, ASTROPHYS J, V498, pL129, DOI 10.1086/311324; Turner MS, 1999, REV MOD PHYS, V71, pS145, DOI 10.1103/RevModPhys.71.S145; Umeda H, 1999, ASTROPHYS J, V522, pL43, DOI 10.1086/312213; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0; Wang LF, 1997, ASTROPHYS J, V476, pL27, DOI 10.1086/310495; WHEELER JC, 1999, ASYMMETRIC SUPERNOVA; Wilson J.R., 1985, NUMERICAL ASTROPHYSI, P422; WOODEN DH, 1993, ASTROPHYS J SUPPL S, V88, P477, DOI 10.1086/191830; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1992, ASTROPHYS J, V395, P202, DOI 10.1086/171644; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359; Woosley SE, 1999, ASTROPHYS J, V516, P788, DOI 10.1086/307131; Zlatev I, 1999, PHYS REV LETT, V82, P896, DOI 10.1103/PhysRevLett.82.896	78	149	149	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2000	403	6771					727	733		10.1038/35001501	http://dx.doi.org/10.1038/35001501			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693794				2022-12-24	WOS:000085423100041
J	Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP				Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP			Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation	SCIENCE			English	Article							INDUCED RESPIRATORY BURST; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-NEUTROPHILS; ACTIVATION; WORTMANNIN; CHEMOKINES; MIGRATION; INHIBITION; RECEPTORS	Phosphoinositide 3-kinase (PI3K) activity is crucial for Leukocyte function, but the roles of the four receptor-activated isoforms are unclear. Mice Lacking heterotrimeric guanine nucleotide-binding protein (G protein)-coupled PI3K gamma were viable and had fully differentiated neutrophils and macrophages. Chemoattractant-stimulated PI3K gamma(-/-) neutrophils did not produce phosphatidylinositol 3,4,5-trisphosphate, did not activate protein kinase B, and displayed impaired respiratory burst and motility. Peritoneal PI3K gamma-null macrophages showed a reduced migration toward a wide range of chemotactic stimuli and a severely defective accumulation in a septic peritonitis model. These results demonstrate that PI3K gamma is a crucial signaling molecule required for macrophage accumulation in inflammation.	Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Ist Ric Farmacol Mario Negri, Milan, Italy; Univ Brescia, Sect Gen Pathol, Brescia, Italy	University of Turin; University of Fribourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia	Hirsch, E (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.	hirsch@molinette.unito.it; matthiaspaul.wymann@unifr.ch	Sozzani, Silvano/C-1447-2009; Pirola, Luciano/I-5250-2018; Garlanda, Cecilia/K-4601-2016; Mantovani, Alberto/HCI-7449-2022; Wymann, Matthias P/C-3227-2008; Hirsch, Emilio/F-4848-2013; Katanaev, Vladimir/F-9480-2014	Sozzani, Silvano/0000-0002-3144-8743; Garlanda, Cecilia/0000-0002-1510-7703; Mantovani, Alberto/0000-0001-5578-236X; Wymann, Matthias P/0000-0003-3349-4281; Hirsch, Emilio/0000-0002-9073-6024; Katanaev, Vladimir/0000-0002-7909-5617; Pirola, Luciano/0000-0001-6539-5435	Telethon [E.0635] Funding Source: Medline	Telethon(Fondazione Telethon)		Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aratani Y, 1999, INFECT IMMUN, V67, P1828; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernstein HG, 1998, CELL MOL BIOL, V44, P973; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; HIRSCH E, UNPUB; KOWNATZKI E, 1988, CLIN EXP IMMUNOL, V74, P143; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OKADA T, 1994, J BIOL CHEM, V269, P3568; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Test S T, 1986, Methods Enzymol, V132, P401; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	28	1046	1130	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1049	1053		10.1126/science.287.5455.1049	http://dx.doi.org/10.1126/science.287.5455.1049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669418				2022-12-24	WOS:000085245400050
J	Prakash, B; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C				Prakash, B; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C			Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins	NATURE			English	Article							INTERFERON; GTPASES; PROGRAM; MOTIF; RAS; GMP	Interferon-gamma is an immunomodulatory substance that induces the expression of many genes to orchestrate a cellular response and establish the antiviral state of the cell. Among the most abundant antiviral proteins induced by interferon-gamma are guanylate-binding proteins such as GBP1 and GBP2 (refs 1, 2). These are large GTP-binding proteins of relative molecular mass 67,000 with a high-turnover GTPase activity(3) and an antiviral effect(4). Here we have determined the crystal structure of full-length human GBP1 to 1.8 Angstrom resolution. The amino-terminal 278 residues constitute a modified G domain with a number of insertions compared to the canonical pas structure, and the carboxy-terminal part is an extended helical domain with unique features. From the structure and biochemical experiments reported here, GBP1 appears to belong to the group of large GTP-binding proteins that includes Mx and dynamin, the common property of which is the ability to undergo oligomerization with a high concentration-dependent GTPase activity(5).	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de; christian.herrmann@mpi-dortmund.mpg.de	BS, Prakash/D-2337-2010	RENAULT, Louis/0000-0003-1722-074X; Praefcke, Gerrit/0000-0001-8818-1499				Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boehm U, 1998, J IMMUNOL, V161, P6715; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kochs G, 1999, J BIOL CHEM, V274, P4370, DOI 10.1074/jbc.274.7.4370; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899	30	251	257	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					567	571		10.1038/35000617	http://dx.doi.org/10.1038/35000617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676968				2022-12-24	WOS:000085227300056
J	Evans, C; Chalmers, J; Capewell, S; Redpath, A; Finlayson, A; Boyd, J; Pell, J; McMurray, J; Macintyre, K; Graham, L				Evans, C; Chalmers, J; Capewell, S; Redpath, A; Finlayson, A; Boyd, J; Pell, J; McMurray, J; Macintyre, K; Graham, L			"I don't like Mondays" - day of the week of coronary heart disease deaths in Scotland: study of routinely collected data	BRITISH MEDICAL JOURNAL			English	Article									Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland	NHS National Services Scotland; University of Glasgow; University of Glasgow; University of Glasgow	Chalmers, J (corresponding author), Natl Hlth Serv Scotland, Informat & Stat Div, Trin Pk House, Edinburgh EH5 3SQ, Midlothian, Scotland.		mcmurray, John/B-2467-2013; Macintyre, Kate/J-7174-2014	mcmurray, John/0000-0002-6317-3975; Macintyre, Kate/0000-0003-2741-0467; Boyd, James/0000-0002-8925-8811; Pell, Jill/0000-0002-8898-7035				Chen Z, 1998, CAN J EXP PSYCHOL, V52, P7, DOI 10.1037/h0087274; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; Peters Robert W., 1996, Cardiology Clinics, V14, P185; WILLICH SN, 1994, CIRCULATION, V90, P87, DOI 10.1161/01.CIR.90.1.87	4	57	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	2000	320	7229					218	219		10.1136/bmj.320.7229.218	http://dx.doi.org/10.1136/bmj.320.7229.218			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10642230	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000085029600024
J	Xu, CG; Mao, DL; Holers, VM; Palanca, B; Cheng, AM; Molina, H				Xu, CG; Mao, DL; Holers, VM; Palanca, B; Cheng, AM; Molina, H			A critical role for murine complement regulator Crry in fetomaternal tolerance	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PREFERENTIAL EXPRESSION; IMMUNE-RESPONSE; PREGNANCY; RECEPTOR; HOMOLOG; CELLS; ACTIVATION; DISTINCT	Complement is a component of natural immunity. Its regulation is needed to protect tissues from inflammation, but mice with a disrupted gene for the complement regulator decay accelerating factor were normal. Mice that were deficient in another murine complement regulator, Crry, were generated to investigate its role in vivo. Survival of Crry(-/-) embryos was compromised because of complement deposition and concomitant placenta inflammation. Complement activation at the fetomaternal interface caused the fetal Loss because breeding to C3(-/-) mice rescued Crry(-/-) mice from lethality. Thus, the regulation of complement is critical in fetal control of maternal processes that mediate tissue damage.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Vet Adm Med Ctr, St Louis, MO 63106 USA	Washington University (WUSTL); Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Molina, H (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	hmolina@imgate.wustl.edu	Palanca, Ben Julian/AAW-4006-2021	Palanca, Ben Julian/0000-0001-7535-5701	NIAID NIH HHS [R01 AI40576-01, R01 AI44912-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040576, R01AI044912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P294; BILLINGTON WD, 1992, BAILLIERE CLIN OB GY, V6, P417, DOI 10.1016/S0950-3552(05)80004-5; BOOM B W, 1991, Journal of Dermatological Science, V2, P308, DOI 10.1016/0923-1811(91)90055-3; BULMER JN, 1992, BAILLIERE CLIN OB GY, V6, P461, DOI 10.1016/S0950-3552(05)80006-9; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; HOGAN B, 1986, MANIPULATING MOUSE E, P152; HOLERS VM, 1992, IMMUNOL TODAY, V13, P231; HOLMES CH, 1992, BAILLIERE CLIN OB GY, V6, P439, DOI 10.1016/S0950-3552(05)80005-7; HOLMES CH, 1990, J IMMUNOL, V144, P3099; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; ITOH J, 1991, CLIN EXP IMMUNOL, V83, P364; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KURTZ CB, 1989, J IMMUNOL, V143, P2058; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI B, 1993, J IMMUNOL, V151, P4295; LUBLIN DM, 1990, CURR TOP MICROBIOL, V153, P123; MOLINA H, 1992, J EXP MED, V175, P121, DOI 10.1084/jem.175.1.121; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; ROONEY IA, 1993, IMMUNOL RES, V12, P276, DOI 10.1007/BF02918258; Sambrook JFE, 1989, MOL CLONING LAB MANU; Suny XJ, 1999, P NATL ACAD SCI USA, V96, P628, DOI 10.1073/pnas.96.2.628; Tsujimura A, 1998, BIOCHEM J, V330, P163, DOI 10.1042/bj3300163; WEIGLE WO, 1983, SPRINGER SEMIN IMMUN, V6, P173; WONG WW, 1985, J IMMUNOL, V134, P4048; Xu C., UNPUB	26	396	415	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					498	501		10.1126/science.287.5452.498	http://dx.doi.org/10.1126/science.287.5452.498			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642554				2022-12-24	WOS:000084929900052
J	Cha, JN; Stucky, GD; Morse, DE; Deming, TJ				Cha, JN; Stucky, GD; Morse, DE; Deming, TJ			Biomimetic synthesis of ordered silica structures mediated by block copolypeptides	NATURE			English	Article							MESOPOROUS SILICA; PROTEIN; DIATOM; ACID	In biological systems such as diatoms and sponges, the formation of solid silica structures with precisely controlled morphologies is directed by proteins and polysaccharides and occurs in water at neutral:pH and ambient temperature(1-4). Laboratory methods, in contrast, have to rely on extreme pH conditions and/or surfactants to induce the condensation of silica precursors into specific morphologies or patterned structures(5-10), This contrast in processing conditions and the growing demand for benign synthesis methods that minimize adverse environmental effects have spurred much interest in biomimetic approaches in materials science(4,5), The recent demonstration that silicatein-a protein found in the silica spicules of the sponge Tethya aurantia(11)-can hydrolyse and condense the precursor molecule tetraethoxysilane to form silica structures with controlled shapes at ambient conditions(12-14) seems particularly promising in this context, Here we describe synthetic cysteine-lysine block copolypeptides that mimic the properties of silicatein: the copolypeptides self-assemble into structured aggregates that hydrolyse tetraethoxysilane while simultaneously directing the formation of ordered silica morphologies. We find that oxidation of the cysteine sulphydryl groups, which is known to affect the assembly of the block copolypeptide(15), allows us to produce different structures: hard silica spheres and well-defined columns of amorphous silica are produced using the fully reduced and the oxidized forms of the copolymer, respectively.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BERGER A, 1956, J AM CHEM SOC, V78, P4483, DOI 10.1021/ja01598a080; BRZEZINSKI MA, 1986, MAR CHEM, V19, P139, DOI 10.1016/0304-4203(86)90045-9; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Deming TJ, 1997, NATURE, V390, P386, DOI 10.1038/37084; Huo QS, 1997, CHEM MATER, V9, P14, DOI 10.1021/cm960464p; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; Liff MI, 1998, POLYM INT, V47, P375, DOI 10.1002/(SICI)1097-0126(199811)47:3<375::AID-PI73>3.0.CO;2-D; Lukens WW, 1999, LANGMUIR, V15, P5403, DOI 10.1021/la990209u; MANN S, 1995, J MATER CHEM, V5, P935, DOI 10.1039/jm9950500935; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Morse DE, 1999, TRENDS BIOTECHNOL, V17, P230, DOI 10.1016/S0167-7799(99)01309-8; MORSE DE, IN PRESS ORGANOSILIC, V4; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SIMPSON TL, 1981, SILICON SILICEOUS ST; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; Vrieling EG, 1999, J BIOTECHNOL, V70, P39, DOI 10.1016/S0168-1656(99)00056-5; Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhao DY, 1998, CURR OPIN SOLID ST M, V3, P111, DOI 10.1016/S1359-0286(98)80073-9; Zhou Y, 1999, ANGEW CHEM INT EDIT, V38, P780	25	600	628	3	292	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					289	292		10.1038/35002038	http://dx.doi.org/10.1038/35002038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659843				2022-12-24	WOS:000084899700046
J	Hasle, H; Clemmensen, IH; Mikkelsen, M				Hasle, H; Clemmensen, IH; Mikkelsen, M			Risks of leukaemia and solid tumours in individuals with Down's syndrome	LANCET			English	Article							ACUTE MEGAKARYOBLASTIC LEUKEMIA; CANCER INCIDENCE; CHILDREN; GENE; MALFORMATIONS; DISORDER; WOMEN	Background Individuals with Down's syndrome have a greater risk for leukaemia than the general population, but reliable estimates of the age-specific risk are lacking and little is known about the risk of solid tumours. Methods We identified 2814 individuals with Down's syndrome from the Danish Cytogenetic Register, and linked the data to the Danish Cancer Registry. The number of person-years at risk was 48 453. Standardised incidence ratio (SIR) and 95% CI were calculated of the basis of cancer rates specific for age and sex in the general population. Findings 60 cases of cancer were found, with 49.8 expected (SIR 1.20 [95% CI 0.92-1.55]). Leukaemia constituted 60% of cases of malignant disease overall and 97% of cases in children. The SIR for leukaemia varied with age, being 56 (38-81) at age 0-4 years and 10 (4-20) at 5-29 years. No cases of leukaemia were seen after the age of 29 years. The SIR for acute myeloid leukaemia was 3.8 (1.7-8.4) times higher than that for acute lymphoblastic leukaemia in children aged 0-4 years. The cumulative risk for leukaemia by the age of 5 years was 2.1% and that by 30 years was 2.7%. Only 24 solid tumours were seen, with 47.8 expected (0.50 [0.32-0.75]). No cases of breast cancer were found, with 7.3 expected (p=0.0007). Higher than expected numbers of testicular cancers, ovarian cancers, and retinoblastomas were seen but were not significant. Intrepretation The occurrence of cancer in Down's syndrome is unique with a high risk of leukaemia in children and a decreased risk of solid tumours in all age-groups. The distinctive pattern of malignant diseases may provide clues in the search for leukaemogenic genes and tumour-suppressor genes on chromosome 21.	Aarhus Univ Hosp Skejby, Dept Paediat, DK-8200 Aarhus N, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; John F Kennedy Inst, DK-2600 Glostrup, Denmark	Aarhus University; Danish Cancer Society	Hasle, H (corresponding author), Aarhus Univ Hosp Skejby, Dept Paediat, DK-8200 Aarhus N, Denmark.			Hasle, Henrik/0000-0003-3976-9231				AVETLOISEAU H, 1995, J PEDIAT HEMATOL ONC, V17, P19, DOI 10.1097/00043426-199502000-00003; BAIN B, 1991, LEUKEMIA LYMPHOMA, V3, P309, DOI 10.3109/10428199109070274; BALARAJAN R, 1982, J EPIDEMIOL COMMUN H, V36, P127, DOI 10.1136/jech.36.2.127; BENTLEY D, 1975, PEDIATRICS, V56, P131; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Chik KW, 1999, J PEDIAT HEMATOL ONC, V21, P149, DOI 10.1097/00043426-199903000-00012; DelaTorre R, 1996, EXPERIENTIA, V52, P871; FABIA J, 1970, PEDIATRICS, V45, P60; FESTER A, 1986, CANCER GENET CYTOGEN, V20, P109; FONG C, 1987, CANCER GENET CYTOGEN, V28, P55, DOI 10.1016/0165-4608(87)90354-2; GERICKE GS, 1977, S AFR MED J, V51, P369; Hasle H, 1996, BRIT J CANCER, V73, P1156, DOI 10.1038/bjc.1996.222; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HASLE H, 1995, LEUKEMIA, V9, P1569; HAYASHI Y, 1988, BLOOD, V72, P15; Ho CY, 1996, BLOOD, V87, P5218, DOI 10.1182/blood.V87.12.5218.bloodjournal87125218; ISELIUS L, 1990, HUM GENET, V85, P477; Ives JH, 1998, GENE CHROMOSOME CANC, V23, P61, DOI 10.1002/(SICI)1098-2264(199809)23:1<61::AID-GCC9>3.3.CO;2-F; Kohno T, 1998, GENE CHROMOSOME CANC, V21, P236, DOI 10.1002/(SICI)1098-2264(199803)21:3<236::AID-GCC8>3.0.CO;2-0; KRIVIT W, 1957, AMA J DIS CHILD, V94, P289, DOI 10.1001/archpedi.1957.04030040075012; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; OLSON JM, 1995, MED PEDIATR ONCOL, V24, P305, DOI 10.1002/mpo.2950240507; OSTER J, 1975, ACTA PAEDIATR SCAND, V64, P322, DOI 10.1111/j.1651-2227.1975.tb03842.x; ROBISON LL, 1984, J PEDIATR-US, V105, P235, DOI 10.1016/S0022-3476(84)80119-5; Sakata K, 1997, GENE CHROMOSOME CANC, V18, P318, DOI 10.1002/(SICI)1098-2264(199704)18:4<318::AID-GCC12>3.3.CO;2-#; SALO MK, 1979, SCAND J CLIN LAB INV, V39, P485, DOI 10.3109/00365517909106135; SARGE D, 1996, PATHOL RES PRACT, V192, P1266; Satge D, 1998, CANCER RES, V58, P448; Satge D, 1998, AM J MED GENET, V78, P207, DOI 10.1002/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.3.CO;2-Q; Satge D, 1997, CANCER, V80, P929; SCHOLL T, 1982, DEV MED CHILD NEUROL, V24, P817; Schupf N, 1997, J INTELL DISABIL RES, V41, P264, DOI 10.1111/j.1365-2788.1997.tb00706.x; SHEN JJ, 1995, AM J HUM GENET, V56, P915; SIMON JH, 1987, CANCER-AM CANCER SOC, V60, P2515, DOI 10.1002/1097-0142(19871115)60:10<2515::AID-CNCR2820601028>3.0.CO;2-F; SLORDAHL SH, 1993, MED PEDIATR ONCOL, V21, P254, DOI 10.1002/mpo.2950210404; STORM HH, 1997, DAN MED B, V44, P549; WINDHAM GC, 1985, AM J EPIDEMIOL, V121, P49, DOI 10.1093/oxfordjournals.aje.a113982; ZIPURSKY A, 1994, LEUKEMIA RES, V18, P163, DOI 10.1016/0145-2126(94)90111-2; ZIPURSKY A, 1992, PEDIATR HEMAT ONCOL, V9, P139, DOI 10.3109/08880019209018329	41	544	560	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					165	169		10.1016/S0140-6736(99)05264-2	http://dx.doi.org/10.1016/S0140-6736(99)05264-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675114				2022-12-24	WOS:000084879700008
J	Lyons, RA; Delahunty, AM; Heaven, M; McCabe, M; Allen, H; Nash, P				Lyons, RA; Delahunty, AM; Heaven, M; McCabe, M; Allen, H; Nash, P			Incidence of childhood fractures in affluent and deprived areas: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales, Coll Med, Welsh Combined Ctr Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Iechyd Morgannwg Hlth, Dept Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Morriston Hosp, Dept Accid & Emergency, Swansea SA6 6NL, W Glam, Wales; Neath Gen Hosp, Local Accid Ctr, Neath SA11 2LQ, Wales	Morriston Hospital	Lyons, RA (corresponding author), Univ Wales, Coll Med, Welsh Combined Ctr Publ Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				[Anonymous], 1980, REPORT WORKING GROUP; Lyons R A, 1999, Inj Prev, V5, P129; Lyons R A, 1995, Inj Prev, V1, P173, DOI 10.1136/ip.1.3.173; Morrison A, 1999, BRIT MED J, V318, P567, DOI 10.1136/bmj.318.7183.567; Williams JM, 1997, SOC SCI MED, V44, P1881, DOI 10.1016/S0277-9536(96)00297-3	5	54	54	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					149	149		10.1136/bmj.320.7228.149	http://dx.doi.org/10.1136/bmj.320.7228.149			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634734	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000084860300024
J	Weinshenker, BG				Weinshenker, BG			Progressive forms of MS: classification streamlined or consensus overturned?	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS; NATURAL-HISTORY		Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55902 USA	Mayo Clinic	Weinshenker, BG (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1St St Sw, Rochester, MN 55902 USA.		Weinshenker, Brian G/ABH-6146-2020	Weinshenker, Brian G/0000-0001-5806-6203				Andersson PB, 1999, ARCH NEUROL-CHICAGO, V56, P1138, DOI 10.1001/archneur.56.9.1138; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kremenchutzky M, 1999, BRAIN, V122, P1941, DOI 10.1093/brain/122.10.1941; KURTZKE JF, 1977, J CHRON DIS, V30, P819, DOI 10.1016/0021-9681(77)90010-8; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Lucchinetti CF, 1998, SEMIN NEUROL, V18, P337, DOI 10.1055/s-2008-1040885; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; McAlpine D., 1955, MULT SCLER J; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Thompson AJ, 1997, BRAIN, V120, P1085, DOI 10.1093/brain/120.6.1085; Thompson AJ, 1999, ANN NEUROL, V46, P471; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weinshenker BG, 1998, NEUROLOGY, V51, P742, DOI 10.1212/WNL.51.3.742; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; WEINSHENKER BG, 1991, BRAIN, V114, P1045, DOI 10.1093/brain/114.2.1045	19	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					162	163		10.1016/S0140-6736(99)00356-6	http://dx.doi.org/10.1016/S0140-6736(99)00356-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675112				2022-12-24	WOS:000084879700006
J	Wingren, C; Crowley, MP; Degano, M; Chien, YH; Wilson, IA				Wingren, C; Crowley, MP; Degano, M; Chien, YH; Wilson, IA			Crystal structure of a gamma delta T cell receptor ligand T22: A truncated MHC-like fold	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; 2.4 ANGSTROM RESOLUTION; NEONATAL FC RECEPTOR; CLASS-I; 3-DIMENSIONAL STRUCTURE; ANTIGEN PRESENTATION; VIRAL PEPTIDES; BINDING-SITE; RECOGNITION; PROGRAM	Murine T10 and T22 are highly related nonclassical major histocompatibility complex (MHC) class Ib proteins that bind to certain gamma delta T cell receptors (TCRs) in the absence of other components. The crystal structure of T22(b) at 3.1 angstroms reveals similarities to MHC class I molecules, but one side of the normal peptide-binding groove is severely truncated, which allows direct access to the beta-sheet floor. Potential gamma delta TCR-binding sites can be inferred from functional mapping of T10 and T22 point mutants and allelic variants. Thus, T22 represents an unusual variant of the MHC-like fold and indicates that gamma delta and alpha beta TCRs interact differently with their respective MHC ligands.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Scripps Research Institute; Scripps Research Institute; Stanford University	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Degano, Massimo/K-4669-2018	Degano, Massimo/0000-0002-0787-1883	NCI NIH HHS [CA58896] Funding Source: Medline; NIAID NIH HHS [AI33431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; Boismenu R, 1997, CURR OPIN IMMUNOL, V9, P57, DOI 10.1016/S0952-7915(97)80159-8; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; Braud VM, 1999, CURR OPIN IMMUNOL, V11, P100, DOI 10.1016/S0952-7915(99)80018-1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Hampl J, 1999, J IMMUNOL, V163, P288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; Jones EY, 1998, IMMUNOL REV, V163, P121, DOI 10.1111/j.1600-065X.1998.tb01191.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Li HM, 1998, NATURE, V391, P502, DOI 10.1038/35172; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mazza G, 1998, IMMUNOL REV, V163, P187, DOI 10.1111/j.1600-065X.1998.tb01197.x; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parham P, 1996, TRENDS BIOCHEM SCI, V21, P427, DOI 10.1016/S0968-0004(96)10053-0; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; Shields MJ, 1998, MOL IMMUNOL, V35, P919, DOI 10.1016/S0161-5890(98)00083-2; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; TEITELL M, 1994, CRIT REV IMMUNOL, V14, P1; VELLIEUX FMD, DEMON PROGRAM SUITE; WANG CR, 1995, CELL, V82, P655, DOI 10.1016/0092-8674(95)90037-3; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	72	55	55	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					310	314		10.1126/science.287.5451.310	http://dx.doi.org/10.1126/science.287.5451.310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634787				2022-12-24	WOS:000084769600042
J	Bauer, J; Chen, KH; Hiltbunner, A; Wehrli, E; Eugster, M; Schnell, D; Kessler, F				Bauer, J; Chen, KH; Hiltbunner, A; Wehrli, E; Eugster, M; Schnell, D; Kessler, F			The major protein import receptor of plastids is essential for chloroplast biogenesis	NATURE			English	Article							INNER ENVELOPE MEMBRANE; ARABIDOPSIS; COMPONENT; APPARATUS; MACHINERY; INSERTION; IDENTIFICATION; TRANSLOCATION; EXPRESSION; NUCLEAR	Light triggers the developmental programme in plants that leads to the production of photosynthetically active chloroplasts from non-photosynthetic proplastids(1). During this chloroplast biogenesis, the photosynthetic apparatus is rapidly assembled, mostly from nuclear-encoded imported proteins(2-4), which are synthesized in the cytosol as precursors with cleavable amino-terminal targeting sequences called transit sequences. Protein translocon complexes at the outer (Toc complex)(5-7) and inner (Tic complex)(6,8,9) envelope membranes recognize these transit sequences, leading to the precursors being imported. The Toc complex in the pea consists of three major components, Toc75, Toc34 and Toc159 (formerly termed ToC86)(6,7,10,11). Toc159, Which is an integral membrane GTPase(12), functions as a transit-sequence recepto(5-7,13). Here we show that Arabidopsis thaliana Toc159 (atToc159) is essential for the biogenesis of chloroplasts. In an Arabidopsis mutant (ppi2) that lacks atToc159, photosynthetic proteins that are normally abundant are transcriptionally repressed, and are found in much smaller amounts in the plastids, although ppi2 does not affect either the expression or the import of less abundant non-photosynthetic plastid proteins. These findings indicate that atToc159 is required for the quantitative import of photosynthetic proteins. Two proteins that are related to atToc159 (atToc120 and atToc132) probably help to maintain basal protein import in ppi2, and so constitute components of alternative, atToc159-independent import pathways.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Swiss Fed Inst Technol, Inst Biochem, Lab Electronmicroscopy 1, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Rutgers State University Newark; Rutgers State University New Brunswick; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schnell, D (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, Univ Str 2, CH-8092 Zurich, Switzerland.		Kessler, Felix Henrique/AAO-1722-2020	Hiltbrunner, Andreas/0000-0003-0438-5297; Kessler, Felix/0000-0001-6409-5043				Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; CHEN K, IN PRESS PLANT PHYS; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; Eberhard J, 1996, PLANT J, V10, P815, DOI 10.1046/j.1365-313X.1996.10050815.x; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MA Y, 1996, J CELL BIOL, V134, P1; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; MICHEL M, 1991, J MICROSC-OXFORD, V163, P3, DOI 10.1111/j.1365-2818.1991.tb03155.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Surpin M, 1997, ESSAYS BIOCHEM, V32, P113; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x	27	284	313	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					203	207		10.1038/35003214	http://dx.doi.org/10.1038/35003214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646606	Green Submitted			2022-12-24	WOS:000084835300057
J	Peterson, S; Sanga, A; Eklof, H; Bunga, B; Taube, A; Gebre-Medhin, M; Rosling, H				Peterson, S; Sanga, A; Eklof, H; Bunga, B; Taube, A; Gebre-Medhin, M; Rosling, H			Classification of thyroid size by palpation and ultrasonography in field surveys	LANCET			English	Article							VOLUME; ULTRASOUND; IODINE	Background Goitre surveys are used to assess the degree of iodine deficiency in a population. The change of goitre classification made by WHO in 1994 implied that a smaller thyroid size should be regarded as goitre. Furthermore, the acceptable goitre prevalence was lowered from 10% to 5%, and ultrasonography was recommended as a more precise method for diagnosis of goitre. We studied the effects of the change of palpation system, and compared the precision of the old and new systems ultrasonographic examination. Methods We studied 225 schoolchildren (aged 7-14 years) in a highland village in Tanzania. The size of the thyroid was assessed in duplicate by ultrasonography and by WHO's 1960 and 1994 palpation systems. The latter were done by three examiners. Variations within and between examination methods and examiners were assessed. and measurement errors by ultrasonography were assessed from duplicate examinations. The sensitivity and specificity of the two palpation systems were calculated, with diagnosis by ultrasonography as the gold standard. Apparent palpation prevalences were calculated at a "true" 5% prevalence. Findings The lowered criterion for goitre resulted in an extra 20-33% of children being diagnosed as having goitre by palpation. The variation between repeat examinations was only slightly smaller by ultrasonography (kappa=0.63) than by experienced examiners (kappa=0.57-0.58). The variation between thyroid volume estimation by ultrasonography and the true volume was about 50% due to both measurement error and variation in the shape of thyroid lobes. The new goitre criterion decreased specificity from 76% to 29%, whereas sensitivity rose from 56% to 80%. In contrast, a suggested sharpening of the old criterion increased specificity to 90%. Interpretation A return to the old (1960) palpation criterion for goitre: "lobes larger than the terminal phalanxes of thumbs" and to an accepted palpation goitre prevalence of 10% can allow affordable monitoring of thyroid size through palpation in field surveys.	Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, SE-17176 Stockholm, Sweden; Tanzania Food & Nutr Ctr, Dar Es Salaam, Tanzania; Univ Uppsala, Dept Womens & Childrens Hlth, S-75105 Uppsala, Sweden; Univ Uppsala, Dept Radiol, S-75105 Uppsala, Sweden; Univ Uppsala, Dept Stat, S-75105 Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University; Uppsala University	Rosling, H (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, SE-17176 Stockholm, Sweden.			Peterson, Stefan/0000-0001-7203-3096				AGHINILOMBARDI F, 1995, THYROID S1, V5, pS36; BRUNN J, 1981, DEUT MED WOCHENSCHR, V106, P1338, DOI 10.1055/s-2008-1070506; CHANOINE JP, 1991, EUR J PEDIATR, V150, P395, DOI 10.1007/BF02093716; Delange F, 1997, EUR J ENDOCRINOL, V136, P180, DOI 10.1530/eje.0.1360180; Delange F, 1999, EUR J ENDOCRINOL, V140, P486, DOI 10.1530/eje.0.1400486; Delange F, 1997, B WORLD HEALTH ORGAN, V75, P95; Delange F, 1986, PAHO WHO SCI PUBLICA, P373; Demaeyer EM, 1979, CONTROL ENDEMIC GOIT; Foo LC, 1999, EUR J ENDOCRINOL, V140, P491, DOI 10.1530/eje.0.1400491; GUTEKUNST R, 1986, ACTA ENDOCRINOL-COP, V112, P494, DOI 10.1530/acta.0.1120494; GUTEKUNST R, 1993, IODINE DEFICIENCY EU; HETZEL BS, 1988, ACC SCN STATE ART SE; MACLENNAN R, 1974, ENDEMIC GOITER CRETI, P195; MACLENNAN R, 1969, ENDEMIC GOITER, P67; Nordmeyer JP, 1997, EXP CLIN ENDOCR DIAB, V105, P366, DOI 10.1055/s-0029-1211781; Perez C, 1960, ENDEMIC GOITRE, P369; PETERSON S, 1999, HLTH POLICY PLANN, V14, P400; QUERIDO A, 1974, Pan American Health Organization Scientific Publication, V292, P267; Taube A., 1995, Archives d'Anatomie et de Cytologie Pathologiques, V43, P227; TAUBE A, 1990, ACTA ONCOL, V29, P1; Tonglet Rene, 1994, Food and Nutrition Bulletin, V15, P64; 1993, METHODS MEASURING IO; VITTI P, 1994, J CLIN ENDOCR METAB, V79, P600, DOI 10.1210/jc.79.2.600; WHO/UNICEF/ICCIDD, 1994, IND ASS IOD DEF DIS; World Health Organization, 1997, WHO GLOB DAT CHILD G	25	55	60	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					106	110		10.1016/S0140-6736(99)07221-9	http://dx.doi.org/10.1016/S0140-6736(99)07221-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675168				2022-12-24	WOS:000085557200012
J	Baumler, AJ; Hargis, BM; Tsolis, RM				Baumler, AJ; Hargis, BM; Tsolis, RM			Epidemiology - Tracing the origins of Salmonella outbreaks	SCIENCE			English	Editorial Material							UNITED-STATES; ENTERITIDIS INFECTIONS; LAYER FLOCKS; EGGS; PREVALENCE; CHICKENS; MICE		Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Baumler, AJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Microbiol & Immunol, 407 Reynolds Med Bldg, College Stn, TX 77843 USA.		Baumler, Andreas J/H-2301-2011	Baumler, Andreas J/0000-0001-9152-7809; Tsolis, Renee/0000-0001-9131-6657				Anderson RM, 1995, PARASITOLOGY, V111, pS15, DOI 10.1017/S003118200007579X; Angulo FJ, 1998, J AM VET MED ASSOC, V213, P1729; ASERKOFF B, 1970, AM J EPIDEMIOL, V92, P13, DOI 10.1093/oxfordjournals.aje.a121175; BARROW PA, 1992, AVIAN DIS, V36, P227, DOI 10.2307/1591495; BARROW PA, 1992, EPIDEMIOL INFECT, V109, P361, DOI 10.1017/S0950268800050354; BLAXLAND J. D., 1958, Veterinary Record, V70, P374; BULLIS KL, 1977, AVIAN DIS, V21, P422, DOI 10.2307/1589326; COLLINS FM, 1966, J EXP MED, V124, P601, DOI 10.1084/jem.124.4.601; COOPER GL, 1989, VET REC, V125, P567; EBEL ED, 1992, AVIAN DIS, V36, P646, DOI 10.2307/1591760; Edwards PR, 1943, J INFECT DIS, V72, P58, DOI 10.1093/infdis/72.1.58; GALBRAITH N S, 1961, Vet Rec, V73, P1296; GuardPetter J, 1997, APPL ENVIRON MICROB, V63, P1588, DOI 10.1128/AEM.63.4.1588-1593.1997; HENZLER DJ, 1992, AVIAN DIS, V36, P625, DOI 10.2307/1591757; HENZLER DJ, 1994, AVIAN DIS, V38, P37, DOI 10.2307/1591834; HEPNER E, 1980, PUBLIC HEALTH, V94, P337, DOI 10.1016/S0033-3506(80)80136-3; Hinz KH, 1996, J VET MED B, V43, P23, DOI 10.1111/j.1439-0450.1996.tb00284.x; Hormaeche CE, 1996, VACCINE, V14, P251, DOI 10.1016/0264-410X(95)00249-Z; Jones FS, 1913, J MED RES, V27, P481; KRABISCH P, 1980, BERL MUNCH TIERARZTL, V93, P232; LEE JA, 1974, J HYG-CAMBRIDGE, V72, P185, DOI 10.1017/S0022172400023391; MCCOY JH, 1975, J HYG-CAMBRIDGE, V74, P271, DOI 10.1017/S0022172400024347; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; Pignato S, 1996, ZBL BAKT-INT J MED M, V283, P399, DOI 10.1016/S0934-8840(96)80075-2; POPPE C, 1991, EPIDEMIOL INFECT, V106, P259, DOI 10.1017/S0950268800048408; RODRIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21, DOI 10.1017/S0950268800047609; RYDER RW, 1976, J INFECT DIS, V133, P483, DOI 10.1093/infdis/133.4.483; SATO G, 1970, JPN J VET RES, V18, P47; Scuderi G, 1996, EPIDEMIOL INFECT, V116, P257, DOI 10.1017/S0950268800052559; Sojka W. J., 1970, Veterinary Bulletin, V40, P515; SOJKA WJ, 1975, VET REC, V96, P280; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; THRELFALL EJ, 1992, J CLIN PATHOL, V45, P34, DOI 10.1136/jcp.45.1.34; WILSON JE, 1967, BRIT VET J, V123, P139, DOI 10.1016/S0007-1935(17)40052-2; 1982, MORBID MORTAL WKLY R, V31, P613; 1982, NATL POULTRY IMPROVE	36	185	195	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					50	52		10.1126/science.287.5450.50	http://dx.doi.org/10.1126/science.287.5450.50			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644222				2022-12-24	WOS:000084578400028
J	Henney, JE				Henney, JE			New drug for stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-24	WOS:000084514400006
J	Henry, SH; Bosch, FX; Troxell, TC; Bolger, PM				Henry, SH; Bosch, FX; Troxell, TC; Bolger, PM			Public health - Reducing liver cancer - Global control of aflatoxin	SCIENCE			English	Article							HEPATITIS-B VACCINATION; METABOLISM; RISK; B-1		US FDA, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA; Inst Catala Oncol, Unitat Epidemiol, Barcelona, Spain	US Food & Drug Administration (FDA); Catalan Institute of Oncology	Henry, SH (corresponding author), US FDA, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA.	SHenry@bangate.fda.gov; X.Bosch@ico.scs.es	JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012	JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412				[Anonymous], 1998, WHO FOOD ADDITIVES S; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; EATON DL, 1994, TOXICOLOGY AFLATOXIN; Ferlay JIARC, 1998, GLOBOCAN 1 CANC INCI; Food and Agriculture Organization (FAO), 1997, WORLDW REG MYC 1995; GORELICK NJ, 1990, RISK ANAL, V10, P539, DOI 10.1111/j.1539-6924.1990.tb00538.x; Groopman, 1994, TOXICOLOGY AFLATOXIN, P3; Guengerich FP, 1996, ENVIRON HEALTH PERSP, V104, P557, DOI 10.2307/3432823; HALL AJ, 1994, TOXICOLOGY AFLATOXIN; Lee MS, 1998, INT J EPIDEMIOL, V27, P316, DOI 10.1093/ije/27.2.316; MASSEY TE, 1995, P SOC EXP BIOL MED, V208, P213, DOI 10.3181/00379727-208-43852A; MCLEAN M, 1995, PHARMACOL THERAPEUT, V65, P163, DOI 10.1016/0163-7258(94)00054-7; MILLER DM, 1994, TOXICOLOGY AFLATOXIN, P347, DOI DOI 10.1016/B978-0-12-228255-3.50021-0; ROEBUCK BD, 1994, TOXICOLOGY AFLATOXIN, P27; VANEGMOND HP, 1999, 3 JOINT FAO WHO UNEP; Wilson D.M., 1994, TOXICOLOGY AFLATOXIN, P309; 1999, AGR RES, V47	19	160	174	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2453	2454		10.1126/science.286.5449.2453	http://dx.doi.org/10.1126/science.286.5449.2453			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10636808				2022-12-24	WOS:000084429700026
J	Bird, A				Bird, A			Molecular biology - DNA methylation de novo	SCIENCE			English	Editorial Material							ICF SYNDROME; METHYLTRANSFERASES; DIFFERENTIATION; CLONING; PATTERN; CELLS		Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.			Bird, Adrian/0000-0002-8600-0372				BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Lei H, 1996, DEVELOPMENT, V122, P3195; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MINIOU P, 1994, HUM MOL GENET, V3, P2093, DOI 10.1093/hmg/3.12.2093; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	15	80	92	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2287	2288		10.1126/science.286.5448.2287	http://dx.doi.org/10.1126/science.286.5448.2287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636791				2022-12-24	WOS:000084318500040
J	Howe, DT; Gornall, R; Wellesley, D; Boyle, T; Barber, J				Howe, DT; Gornall, R; Wellesley, D; Boyle, T; Barber, J			Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans	BRITISH MEDICAL JOURNAL			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SERUM ALPHA-FETOPROTEIN; UNCONJUGATED ESTRIOL; HCG; EXPERIENCES; ENGLAND; PROGRAM; WALES	Objective To assess the effectiveness of antenatal screening for Down's syndrome by maternal age and routine mid-pregnancy ultrasound scanning. Design Retrospective six year survey. Setting Maternity units of a district general hospital. Subjects Pregnant women booked for delivery in hospital between 1 January 1993 and 31 December 1998. Main outcome measures All cases of Down's syndrome occurring in district identified from regional congenital anomaly register and cytogenetic laboratory records. Women's case notes were examined to identify indication for karyotyping, gestation at diagnosis, and outcome of pregnancy. Results 31 259 deliveries occurred during study period, and 57 cases of Down's syndrome were identified, foul in failed pregnancies and 53 in ongoing pregnancies or in neonates. The analysis was confined to ongoing pregnancies or liveborn children. Invasive antenatal tests were performed in 6.6% (2053/31 259), and 68% (95%, confidence interval 56% to 80%) of cases of Down's syndrome were detected antenatally, giving a positive predictive value of 1.8%. There were 17 undetected cases, and in seven of these the women had declined an offer of invasive testing. In women aged less than 35 years the detection rate was 53% (30% to 76%). Most of the cases detected in younger women followed identification of ultrasound anomalies. Conclusions The overall detection rate was considerably higher than assumed ill demonstration projects for serum screening: As a result, the benefits of serum screening are much less than supposed. Before any new methods to identify Down's syndrome are introduced, such as nuchal translucency or first trimester serum screening, the techniques should be tested in properly controlled trials.	Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England; Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Salisbury Dist Hosp, Cytogenet Lab, Salisbury SP2 8BJ, Wilts, England; Princess Anne Hosp, Wessex Maternal & Fetal Med Unit, Southampton SO16 5YA, Hants, England	Salisbury District Hospital; Salisbury District Hospital	Howe, DT (corresponding author), Princess Anne Hosp, Wessex Maternal & Fetal Med Unit, Southampton SO16 5YA, Hants, England.							ADAMS MM, 1981, JAMA-J AM MED ASSOC, V246, P758, DOI 10.1001/jama.246.7.758; BECKHUIS J, 1993, THESIS GRONINGEN U G; BURTON BK, 1993, AM J OBSTET GYNECOL, V169, P526, DOI 10.1016/0002-9378(93)90613-N; Cans C, 1998, PRENATAL DIAG, V18, P683, DOI 10.1002/(SICI)1097-0223(199807)18:7<683::AID-PD327>3.0.CO;2-G; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; Crossley J A, 1994, J Med Screen, V1, P180; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; DAVIES T, 1991, BRIT MED J, V303, P312; DAWSON AJ, 1993, BRIT J OBSTET GYNAEC, V100, P875, DOI 10.1111/j.1471-0528.1993.tb14326.x; GOODBURN SF, 1994, PRENATAL DIAG, V14, P391, DOI 10.1002/pd.1970140509; GREEN JM, 1994, BRIT MED J, V309, P769, DOI 10.1136/bmj.309.6957.769; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; KEATINGE RM, 1991, BRIT MED J, V303, P54, DOI 10.1136/bmj.303.6793.54-d; KELLNER LH, 1995, AM J OBSTET GYNECOL, V172, P831, DOI 10.1016/0002-9378(95)90007-1; Lam YH, 1998, PRENATAL DIAG, V18, P585, DOI 10.1002/(SICI)1097-0223(199806)18:6<585::AID-PD305>3.0.CO;2-R; MACRI JN, 1994, PRENATAL DIAG, V14, P97, DOI 10.1002/pd.1970140204; MANCINI G, 1994, INT J CLIN LAB RES, V24, P49, DOI 10.1007/BF02592410; McDuffie R S Jr, 1996, J Matern Fetal Med, V5, P70; MOONEY RA, 1994, OBSTET GYNECOL, V84, P298; NYBERG DA, 1990, OBSTET GYNECOL, V76, P370; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; Pescia G, 1993, Rev Med Suisse Romande, V113, P277; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; Piggott M, 1994, J Med Screen, V1, P45; Royal College of Obstetricians and Gynaecologists, 1993, REP WORK PART BIOCH, P19; Sadler M, 1997, BRIT J OBSTET GYNAEC, V104, P176, DOI 10.1111/j.1471-0528.1997.tb11040.x; Salonen R, 1997, ACTA OBSTET GYN SCAN, V76, P817, DOI 10.3109/00016349709024358; SHELDON T, 1991, BRIT MED J, V303, P55, DOI 10.1136/bmj.303.6793.55-a; SMITH DK, 1994, BRIT MED J, V309, P776, DOI 10.1136/bmj.309.6957.776; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; STATHAM H, 1993, BRIT MED J, V307, P174, DOI 10.1136/bmj.307.6897.174; Valerio D, 1996, Minerva Ginecol, V48, P169; van Rijn M, 1998, Ned Tijdschr Geneeskd, V142, P409; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WELLESLEY D, 1999, ANN REPORT WESSEX AN	36	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	2000	320	7235					606	610		10.1136/bmj.320.7235.606	http://dx.doi.org/10.1136/bmj.320.7235.606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291NH	10698877	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000085742600023
J	Henney, JE				Henney, JE			Celecoxib indicated for FAP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1131	1131		10.1001/jama.283.9.1131	http://dx.doi.org/10.1001/jama.283.9.1131			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703765				2022-12-24	WOS:000085424100007
J	Dornhorst, A; Frost, G				Dornhorst, A; Frost, G			Jelly-beans, only a colourful distraction from gestational glucose-challenge tests	LANCET			English	Editorial Material							TOLERANCE		Hammersmith Hosp, Imperial Coll Sch Med, Dept Metab Med, London W12 0NN, England; Hammersmith Hosp, Imperial Coll Sch Med, Dept Nutr & Dietet, London W12 0NN, England	Imperial College London; Imperial College London	Dornhorst, A (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Dept Metab Med, London W12 0NN, England.							*AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS74; HANSON U, 1993, AM J PERINAT, V10, P330, DOI 10.1055/s-2007-994754; Jarrett RJ, 1997, BMJ-BRIT MED J, V315, P736, DOI 10.1136/bmj.315.7110.736; JARRETT RJ, 1993, BMJ-BRIT MED J, V306, P37, DOI 10.1136/bmj.306.6869.37; Lamar ME, 1999, AM J OBSTET GYNECOL, V181, P1154, DOI 10.1016/S0002-9378(99)70099-2; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; Pettitt D.J., 1985, DIABETES, V34, P119, DOI DOI 10.2337/DIAB.34.2.S119; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; WALKINSHAW SA, 1999, COCHRANE LIB; WALKINSHAW SA, 2000, COCHRANE LIB	10	7	7	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 26	2000	355	9205					674	674		10.1016/S0140-6736(00)90025-4	http://dx.doi.org/10.1016/S0140-6736(00)90025-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703798				2022-12-24	WOS:000085615600007
J	Vinje, WE; Gallant, JL				Vinje, WE; Gallant, JL			Sparse coding and decorrelation in primary visual cortex during natural vision	SCIENCE			English	Article							RECEPTIVE-FIELD; STRIATE CORTEX; CORTICAL DYNAMICS; RESPONSES; SCENES; NORMALIZATION; INTEGRATION; MECHANISMS; PATTERNS; NEURONS	Theoretical studies suggest that primary visual cortex (area V1) uses a sparse code to efficiently represent natural scenes. This issue was investigated by recording from V1 neurons in awake behaving macaques during both free viewing of natural scenes and conditions simulating natural vision. Stimulation of the nonclassical receptive field increases the selectivity and sparseness of individual V1 neurons, increases the sparseness of the population response distribution, and strongly decorrelates the responses of neuron pairs. These effects are due to both excitatory and suppressive modulation of the classical receptive field by the nonclassical receptive field and do not depend critically on the spatiotemporal structure of the stimuli. During natural vision, the classical and nonclassical receptive fields function together to form a sparse representation of the visual world. This sparse code may be computationally efficient for both early vision and higher visual processing.	Univ Calif Berkeley, Program Neurosci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Gallant, JL (corresponding author), Univ Calif Berkeley, Program Neurosci, Berkeley, CA 94720 USA.		Gallant, Jack L/C-4426-2011					ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P153; Baddeley R, 1997, P ROY SOC B-BIOL SCI, V264, P1775, DOI 10.1098/rspb.1997.0246; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; Barlow HB, 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Bell AJ, 1997, VISION RES, V37, P3327, DOI 10.1016/S0042-6989(97)00121-1; Carandini M, 1997, J NEUROSCI, V17, P8621; Conner CE, 1997, J NEUROSCI, V17, P3201; Dan Y, 1996, J NEUROSCI, V16, P3351; DAUGMAN JG, 1989, IEEE T BIO-MED ENG, V36, P107, DOI 10.1109/10.16456; DILORENZO PM, 1989, J NEUROPHYSIOL, V62, P823, DOI 10.1152/jn.1989.62.4.823; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; FOLDIAK P, 1995, HDB BRAIN THEORY NEU, P895; Gallant JL, 1998, NEUROREPORT, V9, P2153, DOI 10.1097/00001756-199806220-00045; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; Gilbert CD, 1996, P NATL ACAD SCI USA, V93, P615, DOI 10.1073/pnas.93.2.615; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; JUDGE SJ, 1980, J NEUROPHYSIOL, V43, P1133, DOI 10.1152/jn.1980.43.4.1133; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Levy WB, 1996, NEURAL COMPUT, V8, P531, DOI 10.1162/neco.1996.8.3.531; Lewicki MS, 1998, ADV NEUR IN, V10, P815; Manly BFJ., 2017, RANDOMIZATION MONTE, DOI 10.1201/9781315273075; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Olshausen BA, 1997, VISION RES, V37, P3311, DOI 10.1016/S0042-6989(97)00169-7; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; ROLLS ET, 1995, J NEUROPHYSIOL, V73, P713, DOI 10.1152/jn.1995.73.2.713; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SIMONCELLI EP, 1998, ADV NEURAL INFORMATI, V11; SNODDERLY DM, 1995, J NEUROPHYSIOL, V74, P2100, DOI 10.1152/jn.1995.74.5.2100; Walker GA, 1999, J NEUROSCI, V19, P10536; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	34	827	851	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1273	1276		10.1126/science.287.5456.1273	http://dx.doi.org/10.1126/science.287.5456.1273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678835				2022-12-24	WOS:000085444700052
J	Pahlow, M; Riebesell, U				Pahlow, M; Riebesell, U			Temporal trends in deep ocean Redfield ratios	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; NORTH-ATLANTIC; NUTRIENT LIMITATION; IRON; NITROGEN; PHYTOPLANKTON; PRODUCTIVITY; NITRATE; OXYGEN; GROWTH	The Redfield ratio [carbon:nitrogen:phosphorus (C:N:P)] of particle flux to the deep ocean is a key factor in marine biogeochemical cycling. Changes in oceanic carbon sequestration have been Linked to variations in the Redfield ratio on geological time scales, but this ratio generally is assumed to be constant with time in the modern ocean. However, deep-water Redfield ratios in the northern hemisphere show evidence for temporal trends over the past five decades. The North Atlantic Ocean exhibits a rising N:P ratio, which may be related to increased deposition of atmospheric nitrous oxides from anthropogenic N emissions. In the North Pacific Ocean, increasing C:N and C:P ratios are accompanied by rising remineralization rates, which suggests intensified export production. Stronger export of carbon in this region may be due to enhanced bioavailability of aeolian iron. These findings imply that the biological part of the marine carbon cycle currently is not in steady state.	Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Pahlow, M (corresponding author), Alfred Wegener Inst Polar & Marine Res, POB 120161, D-27515 Bremerhaven, Germany.		Pahlow, Markus/AAC-4919-2020; Riebesell, Ulf/AAC-9717-2020					ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; ANDERSON LA, 1995, DEEP-SEA RES PT I, V42, P1675, DOI 10.1016/0967-0637(95)00072-E; Bacon S, 1998, NATURE, V394, P871, DOI 10.1038/29736; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; BROECKER WS, 1985, J GEOPHYS RES-OCEANS, V90, P6925, DOI 10.1029/JC090iC04p06925; BROECKER WS, 1980, DEEP-SEA RES, V27, P591, DOI 10.1016/0198-0149(80)90076-X; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Coale KH, 1996, NATURE, V379, P621, DOI 10.1038/379621a0; DOERING PH, 1995, MAR ECOL PROG SER, V124, P271, DOI 10.3354/meps124271; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; Duce R.A., 1986, ROLE AIR SEA EXCHANG, P497, DOI DOI 10.1007/978-94-009-4738-2_; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; FANNING KA, 1992, J GEOPHYS RES-OCEANS, V97, P5693, DOI 10.1029/92JC00007; FANNING KA, 1989, NATURE, V339, P460, DOI 10.1038/339460a0; GRASSHOFF K, 1968, REPORT INTERCALIBRAT; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; HAGER SW, 1972, LIMNOL OCEANOGR, V17, P931, DOI 10.4319/lo.1972.17.6.0931; HECKY RE, 1993, LIMNOL OCEANOGR, V38, P709, DOI 10.4319/lo.1993.38.4.0709; HECKY RE, 1988, LIMNOL OCEANOGR, V33, P796, DOI 10.4319/lo.1988.33.4_part_2.0796; KNAP A, 1986, NATURE, V320, P158, DOI 10.1038/320158a0; LOGAN JA, 1983, J GEOPHYS RES-OCEANS, V88, P785, DOI 10.1029/JC088iC15p10785; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; LONGHURST AR, 1991, LIMNOL OCEANOGR, V36, P1507, DOI 10.4319/lo.1991.36.8.1507; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1988, DEEP-SEA RES, V35, P177, DOI 10.1016/0198-0149(88)90035-0; MOREL FMM, 1991, LIMNOL OCEANOGR, V36, P1742, DOI 10.4319/lo.1991.36.8.1742; PRICE NM, 1991, DEEP-SEA RES, V38, P1361, DOI 10.1016/0198-0149(91)90011-4; Redfield A.C., 1963, SEA IDEA OBSERV, V2; RHEE GY, 1978, LIMNOL OCEANOGR, V23, P10, DOI 10.4319/lo.1978.23.1.0010; SAKSHAUG E, 1977, J EXP MAR BIOL ECOL, V29, P1, DOI 10.1016/0022-0981(77)90118-6; SARMIENTO JL, 1990, J GEOPHYS RES-OCEANS, V95, P18303, DOI 10.1029/JC095iC10p18303; WATSON AJ, 1985, DEEP-SEA RES, V32, P1023, DOI 10.1016/0198-0149(85)90060-3; WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9; YENTSCH CS, 1990, J PLANKTON RES, V12, P717, DOI 10.1093/plankt/12.4.717; Young RW, 1991, GLOBAL BIOGEOCHEM CY, V5, P119, DOI 10.1029/91GB00927; Zhu Z. D., 1993, Desertification Control Bulletin, P27; ZHUANG G, 1990, J GEOPHYS RES-OCEANS, V95, P16207, DOI 10.1029/JC095iC09p16207; ZHUANG GS, 1992, NATURE, V355, P537, DOI 10.1038/355537a0	38	87	92	5	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					831	833		10.1126/science.287.5454.831	http://dx.doi.org/10.1126/science.287.5454.831			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657291	Green Submitted			2022-12-24	WOS:000085136400038
J	Rivera, VM; Wang, XR; Wardwell, S; Courage, NL; Volchuk, A; Keenan, T; Holt, DA; Gilman, M; Orci, L; Cerasoli, F; Rothman, JE; Clackson, T				Rivera, VM; Wang, XR; Wardwell, S; Courage, NL; Volchuk, A; Keenan, T; Holt, DA; Gilman, M; Orci, L; Cerasoli, F; Rothman, JE; Clackson, T			Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum	SCIENCE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; INTRAMUSCULAR INJECTION; GENE-EXPRESSION; MAMMALIAN-CELLS; SKELETAL-MUSCLE; MICE; INSULIN; BINDING; ERYTHROPOIETIN; TRANSDUCTION	A system for direct pharmacologic control of protein secretion was developed to allow rapid and pulsatile delivery of therapeutic proteins. A protein was engineered so that it accumulated as aggregates in the endoplasmic reticulum. Secretion was then stimulated by a synthetic small-molecule drug that induces protein disaggregation. Rapid and transient secretion of growth hormone and insulin was achieved in vitro and in vivo. A regulated pulse of insulin secretion resulted in a transient correction of serum glucose concentrations in a mouse model of hyperglycemia. This approach may make gene therapy a viable method for delivery of polypeptides that require rapid and regulated delivery.	ARIAD Pharmaceut Inc, Gene Therapeut, Cambridge, MA 02139 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	Takeda Pharmaceutical Company Ltd; Takeda Oncology; Memorial Sloan Kettering Cancer Center; University of Geneva	Rivera, VM (corresponding author), ARIAD Pharmaceut Inc, Gene Therapeut, 26 Landsdowne St, Cambridge, MA 02139 USA.			Rivera, Victor/0000-0002-7258-3001				ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; Bohl D, 1998, BLOOD, V92, P1512, DOI 10.1182/blood.V92.5.1512.417k43_1512_1517; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; CLACKSON T, UNPUB; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; DREJER K, 1992, DIABETES METAB REV, V8, P259, DOI 10.1002/dmr.5610080305; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; HOLT DA, UNPUB; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Li FQ, 1996, J CELL BIOL, V135, P1043, DOI 10.1083/jcb.135.4.1043; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POLONSKY KS, 1988, J CLIN INVEST, V81, P442, DOI 10.1172/JCI113339; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Rivera VM, 1999, P NATL ACAD SCI USA, V96, P8657, DOI 10.1073/pnas.96.15.8657; RIVERA VM, UNPUB; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WARDWELL S, UNPUB; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88	37	253	283	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					826	830		10.1126/science.287.5454.826	http://dx.doi.org/10.1126/science.287.5454.826			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657290				2022-12-24	WOS:000085136400037
J	Henney, JE				Henney, JE			Alternative supply of penicillin G	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-24	WOS:000084956500005
J	Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED				Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED			Long-term outcomes of persons with Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; INCORRECT DIAGNOSIS; SEROLOGIC TESTS; ARTHRITIS; CHILDREN; FIBROMYALGIA; OVERDIAGNOSIS; MISDIAGNOSIS; CONNECTICUT; POPULATION	Context Few data exist about the long-term outcomes of patients with Lyme disease. Objective To assess the long-term outcomes of patients with Lyme disease. Design Two-part project including a community-based longitudinal cohort study and a matched cohort study, Setting and Participants Six hundred seventy-eight patients identified from a random sample of all reports of Connecticut residents with suspected Lyme disease submitted to the Connecticut Department of Public Health from 1984-1991 were evaluated in the longitudinal study; for a random subsample of 212 patients from the larger study, 212 age-matched controls without Lyme disease also were enrolled. Main Outcome Measures Self-reports or parents' reports of symptoms and ability to perform certain daily activities since diagnosis of Lyme disease; scores on the 36-item Short-Form Health Survey and the Center for Epidemiologic Studies-Depression scale, for adults, by case-definition status and between patients and controls. Results Of the 678 patients, 51.6% were female, 34.4% were children, and 64.3% met the national surveillance case definition for Lyme disease. Most patients (85.5%) were treated with antimicrobial agents, Interviews were conducted a median of 51 months after diagnosis (range, 15-135 months). An increased frequency of symptoms (eg, pain, fatigue) or of difficulty with daily activities (eg, performing housework, exercising) was reported by 69% of the patients, although few (19%) of these problems were attributed to Lyme disease. Whenever there was a statistically significant difference in the frequencies of either increased symptoms or increased difficulties with typical activities between those who did or did not meet the surveillance case definition, in all instances the greater frequency of problems was in the group that did not meet the case definition. The frequencies of reports of both increased symptoms and increased difficulties with typical activities among patients who had been diagnosed as having Lyme disease were similar to those among age-matched controls without Lyme disease. Conclusions: In this cohort, although many patients reported increases in symptoms and/or increased difficulties with typical daily activities between 1 and 11 years after diagnosis of Lyme disease, the frequencies of these reports were similar to the frequencies of such reports among age-matched controls without Lyme disease.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Childrens Clin Res Ctr, New Haven, CT 06520 USA; Univ Connecticut, Sch Med, Dept Pediat, Farmington, CT 06032 USA; Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA	Yale University; Yale University; Yale University; Yale University; University of Connecticut	Shapiro, ED (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06520 USA.							Adams WV, 1999, J RHEUMATOL, V26, P1190; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BURLINGTON DB, 1997, PUBLICATION FDA PUBL; *CDCP BACT ZOON BR, 1991, LYME DIS SURVEILL SU, V2, P1; CROFT P, 1993, J RHEUMATOL, V20, P710; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Gerber MA, 1998, PEDIATRICS, V102, P905, DOI 10.1542/peds.102.4.905; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; GERBER MA, 1992, 5 INT C LYM BORR MAY; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; GUSTAFSON TL, 1994, TRUE EPISTAT; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; ITOMAA M, 1998, SCAND J INFECT DIS, V30, P269; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUFT BJ, 1993, ANN INTERN MED, V119, P518; MacDonald KL, 1996, AM J MED, V100, P548, DOI 10.1016/S0002-9343(96)00017-4; MEHTA C, 1991, STATXACT COMPUTER PR; PETERSEN LR, 1989, YALE J BIOL MED, V62, P253; [Prevention Centers for Disease C], 1998, MMWR-MORBID MORTAL W, V46, P3; Radloff LS, 1977, APPL PSYCH MEAS, V1, P385, DOI DOI 10.1177/014662167700100306; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; SELVIN S, 1996, STAT ANAL EPIDEMIOLO, P197; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; Shadick NA, 1999, ANN INTERN MED, V131, P919, DOI 10.7326/0003-4819-131-12-199912210-00003; SIGAL LH, 1992, PEDIATRICS, V90, P523; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1994, AM J MED, V96, P365, DOI 10.1016/0002-9343(94)90068-X; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; SIGAL LH, 1998, NEW ENGL J MED, V339, P571; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; Wang TJ, 1998, J RHEUMATOL, V25, P2249; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; [No title captured]	43	113	116	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					609	616		10.1001/jama.283.5.609	http://dx.doi.org/10.1001/jama.283.5.609			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665700	Bronze			2022-12-24	WOS:000084956500026
J	Lundgren, O; Peregrin, AT; Persson, K; Kordasti, S; Uhnoo, I; Svensson, L				Lundgren, O; Peregrin, AT; Persson, K; Kordasti, S; Uhnoo, I; Svensson, L			Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea	SCIENCE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; INFECTED MOUSE INTESTINE; CHOLERA SECRETION; MURINE ROTAVIRUS; MICE; PATHOGENESIS; INVOLVEMENT; TRANSPORT; BLOCKADE; CHILDREN	The mechanism underlying the intestinal fluid loss in rotavirus diarrhea, which often afflicts children in developing countries, is not known. One hypothesis is that the rotavirus evokes intestinal fluid and electrolyte secretion by activation of the nervous system in the intestinal wall, the enteric nervous system (ENS). Four different drugs that inhibit ENS functions were used to obtain experimental evidence for this hypothesis in mice in vitro and in vivo, The involvement of the ENS in rotavirus diarrhea indicates potential sites of action for drugs in the treatment of the disease.	Univ Gothenburg, Dept Physiol, S-40530 Gothenburg, Sweden; Univ Uppsala Hosp, Dept Med Sci, Infect Dis Sect, S-75185 Uppsala, Sweden; Swedish Inst Infect Dis Control, Dept Virol, S-17182 Solna, Sweden	University of Gothenburg; Uppsala University; Uppsala University Hospital; Swedish Institute for Infectious Disease Control	Lundgren, O (corresponding author), Univ Gothenburg, Dept Physiol, Box 432, S-40530 Gothenburg, Sweden.		svensson, lennart/K-6163-2019					Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; BRUNSSON I, 1987, ACTA PHYSIOL SCAND, V131, P609, DOI 10.1111/j.1748-1716.1987.tb08282.x; BRUNSSON I, 1987, ACTA PHYSIOL SCAND, V130, P633, DOI 10.1111/j.1748-1716.1987.tb08186.x; CASSUTO J, 1981, SCAND J GASTROENTERO, V16, P377, DOI 10.3109/00365528109181984; CASSUTO J, 1982, ACTA PHYSIOL SCAND, V114, P573, DOI 10.1111/j.1748-1716.1982.tb07026.x; CASSUTO J, 1982, SCAND J GASTROENTERO, V17, P695, DOI 10.3109/00365528209181081; CASTAGLIUOLO I, 1994, GASTROENTEROLOGY, V107, P657, DOI 10.1016/0016-5085(94)90112-0; COELHO KIR, 1981, ULTRASTRUCT PATHOL, V2, P59, DOI 10.3109/01913128109031504; COOPER H, 1966, GASTROENTEROLOGY, V50, P1; DAVIDSON GP, 1979, ACTA PAEDIATR SCAND, V68, P181, DOI 10.1111/j.1651-2227.1979.tb04986.x; DAVIDSON GP, 1975, J CLIN PATHOL, V28, P263, DOI 10.1136/jcp.28.4.263; EKLUND S, 1988, ACTA PHYSIOL SCAND, V133, P551, DOI 10.1111/j.1748-1716.1988.tb08440.x; Hille B., 1992, IONIC CHANNELS EXCIT; JODAL M, 1993, GUT, V34, P1526, DOI 10.1136/gut.34.11.1526; JODAL M, 1995, REGULATORY MECH GAST, P99; KOHLER VT, 1990, KINDERARZTL PRAX, V58, P323; LITTLE LM, 1982, INFECT IMMUN, V38, P755, DOI 10.1128/IAI.38.2.755-763.1982; LUNDGREN O, UNPUB; MATHIAS JR, 1989, HDB PHYSL GASTROINTE, V1, P1153; OFFIT PA, 1984, J VIROL, V51, P233, DOI 10.1128/JVI.51.1.233-236.1984; OSBORNE MP, 1991, J PEDIATR GASTR NUTR, V12, P111, DOI 10.1097/00005176-199101000-00021; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; Peregrin AT, 1997, ACTA PHYSIOL SCAND, V160, P379, DOI 10.1046/j.1365-201X.1997.00173.x; Ruggeri FM, 1998, J VIROL, V72, P2708, DOI 10.1128/JVI.72.4.2708-2714.1998; SJOQVIST A, 1988, ACTA PHYSIOL SCAND, V133, P289, DOI 10.1111/j.1748-1716.1988.tb08410.x; SPENCER AJ, 1990, J PEDIATR GASTR NUTR, V10, P516, DOI 10.1097/00005176-199005000-00016; STARKEY WG, 1986, J GEN VIROL, V67, P2625, DOI 10.1099/0022-1317-67-12-2625; STARKEY WG, 1990, J PEDIATR GASTR NUTR, V11, P254, DOI 10.1097/00005176-199008000-00016; STEPHEN J, 1989, P 9 BSG SK F INT WOR; SVENSSON L, 1991, J VIROL, V65, P4190, DOI 10.1128/JVI.65.8.4190-4197.1991; Weclewicz K, 1998, BRAIN RES BULL, V46, P353, DOI 10.1016/S0361-9230(98)00013-6; 1999, WHO WEEKLY EPIDEMIOL, P33	32	178	191	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					491	495		10.1126/science.287.5452.491	http://dx.doi.org/10.1126/science.287.5452.491			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642552				2022-12-24	WOS:000084929900050
J	Stathopoulos, C; Li, T; Longman, R; Vothknecht, UC; Becker, HD; Ibba, M; Soll, D				Stathopoulos, C; Li, T; Longman, R; Vothknecht, UC; Becker, HD; Ibba, M; Soll, D			One polypeptide with two aminoacyl-tRNA synthetase activities	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASES; COMPLETE GENOME SEQUENCE; PARTITION; CODE	The genome sequences of certain archaea do not contain recognizable cysteinyl-transfer RNA (tRNA) synthetases, which are essential for messenger RNA-encoded protein synthesis. However, a single cysteinyl-tRNA synthetase activity was detected and purified from one such organism, Methanococcus jannaschii. The amino-terminal sequence of this protein corresponded to the predicted sequence of prolyl-tRNA synthetase. Biochemical and genetic analyses indicated that this archaeal form of prolyl-tRNA synthetase can synthesize both cysteinyl-tRNA(Cys) and prolyl-tRNA(Pro). The ability of one enzyme to provide two aminoacyl-tRNAs for protein synthesis raises questions about concepts of substrate specificity in protein synthesis and may provide insights into the evolutionary origins of this process.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Copenhagen, Panum Inst, Ctr Biomol Recognit, Dept Med Biochem & Genet,Lab B, DK-2200 Copenhagen N, Denmark	Yale University; Yale University; Yale University; University of Copenhagen	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu	Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127; Becker, Hubert/0000-0002-4102-7520; Stathopoulos, Constantinos/0000-0002-5699-4118				BOHMAN K, 1979, MOL GEN GENET, V176, P53, DOI 10.1007/BF00334295; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSIELLO V, 1979, BIOCHIM BIOPHYS ACTA, V564, P311, DOI 10.1016/0005-2787(79)90228-4; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; CURNOW AW, UNPUB; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Delarue M, 1995, J MOL EVOL, V41, P703; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; Kim HS, 1998, J BACTERIOL, V180, P6446, DOI 10.1128/JB.180.24.6446-6449.1998; LACEY JC, 1999, CHEMTRACTS, V12, P398; Li T, 1999, FEBS LETT, V462, P302, DOI 10.1016/S0014-5793(99)01550-1; NAGEL GM, 1995, J MOL EVOL, V40, P487; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; PEARSON RL, 1971, BIOCHIM BIOPHYS ACTA, V228, P770, DOI 10.1016/0005-2787(71)90748-9; Reeve JN, 1999, J BACTERIOL, V181, P3613, DOI 10.1128/JB.181.12.3613-3617.1999; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Springer M, 1998, COLD SPRING HARBOR M, P377; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; WHITFELD PR, 1953, NATURE, V171, P1151, DOI 10.1038/1711151a0; WOESE CR, 1966, COLD SPRING HARB SYM, V31, P723, DOI 10.1101/SQB.1966.031.01.093; Wolf YI, 1999, GENOME RES, V9, P689	28	65	71	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					479	482		10.1126/science.287.5452.479	http://dx.doi.org/10.1126/science.287.5452.479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642548				2022-12-24	WOS:000084929900046
J	Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR				Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR			Regulation of carbamoyl phosphate synthetase by MAP kinase	NATURE			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; PROTEIN-KINASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; PHOSPHORYLATION; ACTIVATION; CELLS; ENZYMES; CAD	The de novo synthesis of pyrimidine nucleotides is required for mammalian cells to proliferate. The rate-limiting step in this pathway is catalysed by carbamoyl phosphate synthetase (CPS II), part of the multifunctional enzyme CAD(1,2). Here we describe the regulation of CAD by the mitogen-activated protein (MAP) kinase cascade. When phosphorylated by MAP kinase in vitro or activated by epidermal growth factor in vivo, CAD lost its feedback inhibition (which is dependent on uridine triphosphate) and became more sensitive to activation (which depends upon phosphoribosyl pyrophosphate). Both these allosteric regulatory changes favour biosynthesis of pyrimidines for growth(2). They were accompanied by increased epidermal growth factor-dependent phosphorylation of CAD in vivo and were prevented by inhibition of MAP kinase. Mutation of a consensus MAP kinase phosphorylation site abolished the changes in CAD allosteric regulation that were stimulated by growth factors. Finally, consistent with an effect of MAP kinase signalling on CPS II activity, epidermal growth factor increased cellular uridine triphosphate and this increase was reversed by inhibition of MAP kinase. Hence these studies may indicate a direct link between activation of the MAP kinase cascade and de novo biosynthesis of pyrimidine nucleotides.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NIGMS NIH HHS [R01 GM060371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; AOKI T, 1981, SCIENCE, V212, P463, DOI 10.1126/science.7209543; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUY HI, 1994, J BIOL CHEM, V269, P23808; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; PATTERSON D, 1977, SOMAT CELL GENET, V3, P483, DOI 10.1007/BF01539120; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173	23	163	170	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					328	332		10.1038/35002111	http://dx.doi.org/10.1038/35002111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659854				2022-12-24	WOS:000084899700057
J	Seeff, LB; Miller, RN; Rabkin, CS; Buskell-Bales, Z; Straley-Eason, KD; Smoak, BL; Johnson, LD; Lee, SR; Kaplan, EL				Seeff, LB; Miller, RN; Rabkin, CS; Buskell-Bales, Z; Straley-Eason, KD; Smoak, BL; Johnson, LD; Lee, SR; Kaplan, EL			45-year follow-up of hepatitis C virus infection in healthy young adults	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; POST-TRANSFUSION HEPATITIS; VOLUNTEER BLOOD-DONORS; NON-A; HEPATOCELLULAR-CARCINOMA; POSTTRANSFUSION HEPATITIS; ALANINE AMINOTRANSFERASE; ANTIBODIES; PREVALENCE; EPIDEMIOLOGY	Background: The sequelae during the first two decades after acute hepatitis C virus (HCV) infection have been well studied, but the outcome thereafter is unknown. Objective: To conduct an extended study of the natural history of HCV infection by using archived serum specimens originally collected between 1948 and 1954. Design: Retrospective cohort study. Setting: A university, a Veterans Affairs medical center, and a medical follow-up agency that had access to the serum specimens and accompanying demographic and medical records. Participants: 8568 military recruits who were evaluated for group A streptococcal infection and acute rheumatic fever between 1948 and 1954. Blood samples were taken from the recruits and, after testing, were stored frozen for almost 45 years. Measurements: The presence of antibodies to HCV was determined by enzyme-linked immunoassay, supplementary recombinant immunoblot assay, and polymerase chain reaction for HCV RNA. Morbidity and mortality were also assessed. Results: Of 8568 persons, 17 (0.2%) had positive results on enzyme-linked immunosorbent assay and recombinant immunoblot assay. The rate was 1.8% among the African-American persons and 0.1% among the white persons in the total sample (relative risk, 25.9 [95% CI, 8.4 to 80.01]). During the 45-year follow-up, liver disease occurred in 205 of the 17 HCV-positive persons (11.8%) and 205 of the 8551 HCV-negative persons (2.4%) (ethnicity-adjusted relative risk, 3.56 [CI, 0.94 to 13.52]). Seven of the 17 HCV-positive persons (41 %) and 2226 of the 8551 HCV-negative persons (26%) had died by December 1996 (ethnicity-adjusted relative risk, 1.48 [CI, 0.8 to 2.61]). Of persons who were HCV-positive, 1 (5.9%) died of liver disease 42 years after the original phlebotomy, 5 (29%) died of non-liver-related disease a median of 37 years after the original phlebotomy, and 1 (5.9%) died of unknown causes. One hundred nineteen HCV-negative persons (1.4%) died of liver disease. Conclusions: The rate of HCV infection from 1948 to 1954 among a sample of military recruits parallels that among present-day military recruits and volunteer blood donors. During 45 years of follow-up, HCV-positive persons had low liver-related morbidity and mortality rates. This suggests that healthy HCV-positive persons may be at less risk for progressive liver disease than is currently thought.	Vet Affairs Med Ctr, Washington, DC 20422 USA; Georgetown Univ, Sch Med, Inst Med, Washington, DC USA; Walter Reed Army Inst Res, Washington, DC USA; NCI, NIH, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; Ortho Clin Diagnost, Raritan, NJ USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities	Seeff, LB (corresponding author), NIDDKD, NIH, Room 9A-18,31 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01CP005782, ZIACP005782] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; ALTER HJ, 1978, P 2 S VIR HEP U CALF, P359; BRUIX J, 1989, LANCET, V2, P1004; BUKH J, 1992, P NATL ACAD SCI USA, V89, P187, DOI 10.1073/pnas.89.1.187; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; CUCCHERINI B, 1983, J LAB CLIN MED, V102, P370; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DEAN AG, 1995, WORD PROCESSING DATA; DENNY FW, 1950, JAMA-J AM MED ASSOC, V143, P151, DOI 10.1001/jama.1950.02910370001001; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; ELSERAG HB, 1999, RISING INCIDENCE HEP, V340, P745; HYAMS KC, 1992, MIL MED, V157, P579, DOI 10.1093/milmed/157.11.579; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; MCQUILLAN GM, 1997, P IC TRIENN INT S VI, P267; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; RLES LA, 1998, ANN CAC REV 1973 199; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; SEEFF LB, 1978, P 2 S VIR HEP U CALF, P371; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TAKANO S, 1995, HEPATOLOGY, V21, P650; THOMAS RJ, 1988, REV INFECT DIS, V10, P125; TOBLER LH, 1994, TRANSFUSION, V34, P130, DOI 10.1046/j.1537-2995.1994.34294143940.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13	42	272	282	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2000	132	2					105	111		10.7326/0003-4819-132-2-200001180-00003	http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	275ZZ	10644270				2022-12-24	WOS:000084852300002
J	Kraft, GH				Kraft, GH			Rehabilitation still the only way to improve function in multiple sclerosis	LANCET			English	Editorial Material							COGNITIVE DYSFUNCTION; IMPACT		Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kraft, GH (corresponding author), Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA.							Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; Heide AC, 1998, AM J NEURORADIOL, V19, P1047; Kraft G H, 1998, J Spinal Cord Med, V21, P117; KRAFT GH, 1996, VETERANS AFFAIRS REH, V33, P329; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Rumrill Jr P. D., 1996, EMPLOYMENT ISSUES MU; Schwartz L, 1999, AM J PHYS MED REHAB, V78, P525, DOI 10.1097/00002060-199911000-00006; Solari A, 1999, NEUROLOGY, V52, P57, DOI 10.1212/WNL.52.1.57; Stolz W, 1994, CHRONIC DIS DISABILI, P3; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502	15	61	61	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2016	2017		10.1016/S0140-6736(99)90035-1	http://dx.doi.org/10.1016/S0140-6736(99)90035-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636362				2022-12-24	WOS:000084183300005
J	Raoult, D; Birg, ML; La Scola, B; Fournier, PE; Enea, M; Lepidi, H; Roux, V; Piette, JC; Vandenesch, F; Vital-Durand, D; Marrie, TJ				Raoult, D; Birg, ML; La Scola, B; Fournier, PE; Enea, M; Lepidi, H; Roux, V; Piette, JC; Vandenesch, F; Vital-Durand, D; Marrie, TJ			Cultivation of the bacillus of Whipple's disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSIS; PATIENT; FEVER; BLOOD	Background: Whipple's disease is a systemic bacterial infection, but to date no isolate of the bacterium has been established in subculture, and no strain of this bacterium has been available for study. Methods: Using specimens from the mitral valve of a patient with endocarditis due to Whipple's disease, we isolated and propagated a bacterium by inoculation in a human fibroblast cell line (HEL) with the use of a shell-vial assay. We tested serum samples from our patient, other patients with Whipple's disease, and control subjects for the presence of antibodies to this bacterium. Results: The bacterium of Whipple's disease was grown successfully in HEL cells, and we established subcultures of the isolate. Indirect immunofluorescence assays showed that the patient's serum reacted specifically against the bacterium. Seven of 9 serum samples from patients with Whipple's disease had IgM antibody titers of 1:50 or more, as compared with 3 of 40 samples from the control subjects (P<0.001). Polyclonal antibodies against the bacterium were generated by inoculation of the microorganism into mice and were used to detect bacteria in the excised cardiac tissue from our patient on immunohistochemical analysis. The 16S ribosomal RNA gene of the cultured bacterium was identical to the sequence for Tropheryma whippelii identified previously in tissue samples from patients with Whipple's disease. The strain we have grown is available in the French National Collection. Conclusions: We cultivated the bacterium of Whipple's disease, detected specific antibodies in tissue from the source patient, and generated specific antibodies in mice to be used in the immunodetection of the microorganism in tissues. The development of a serologic test for Whipple's disease may now be possible. (N Engl J Med 2000;342:620-5.) (C)2000, Massachusetts Medical Society.	Univ Mediterranee, Fac Med, Unite Rickettsies, CNRS UPRESA 6020, F-13385 Marseille, France; Univ Alberta, Dept Med, Edmonton, AB, Canada; Ctr Hosp Lyon Sud, Serv Med Interne, Lyon, France; Hop Louis Pradel, Bacteriol Lab, Lyon, France; Grp Hosp Pitie Salpetriere, Serv Med Interne, F-75634 Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; University of Alberta; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Raoult, D (corresponding author), Univ Mediterranee, Fac Med, Unite Rickettsies, CNRS UPRESA 6020, 27 Blvd Jean Moulin, F-13385 Marseille, France.		RAOULT, Didier/A-8434-2008; Fournier, Pierre-Edouard/AAC-6155-2021; LA SCOLA, Bernard/P-6477-2016; Vandenesch, Francois/C-7209-2014	RAOULT, Didier/0000-0002-0633-5974; Fournier, Pierre-Edouard/0000-0001-8463-8885; LA SCOLA, Bernard/0000-0001-8006-7704; Vandenesch, Francois/0000-0001-9412-7106				BLACKSCHAFFER B, 1949, P SOC EXP BIOL MED, V72, P225; BOSTWICK DG, 1981, NEW ENGL J MED, V305, P995, DOI 10.1056/NEJM198110223051708; Celard M, 1999, CLIN INFECT DIS, V29, P1348, DOI 10.1086/313477; GIMENEZ DF, 1964, STAIN TECHNOL, V39, P135, DOI 10.3109/10520296409061219; Hinrikson HP, 1999, INT J SYST BACTERIOL, V49, P1701, DOI 10.1099/00207713-49-4-1701; La Scola B, 1998, J CLIN MICROBIOL, V36, P2847, DOI 10.1128/JCM.36.10.2847-2852.1998; La Scola B, 1999, J CLIN MICROBIOL, V37, P1899, DOI 10.1128/JCM.37.6.1899-1905.1999; La Scola B, 1999, J CLIN MICROBIOL, V37, P785, DOI 10.1128/JCM.37.3.785-787.1999; LaScola B, 1997, CLIN INFECT DIS, V24, P1161, DOI 10.1086/513631; LaScola B, 1996, J CLIN MICROBIOL, V34, P2722, DOI 10.1128/JCM.34.11.2722-2727.1996; MAIZEL H, 1970, MEDICINE, V49, P175, DOI 10.1097/00005792-197005000-00001; MARSHALL B, 1983, LANCET, V1, P1273; MURRAY RGE, 1994, INT J SYST BACTERIOL, V44, P174, DOI 10.1099/00207713-44-1-174; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; RATLIFF NB, 1984, NEW ENGL J MED, V311, P902, DOI 10.1056/NEJM198410043111407; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman DA, 1997, J INFECT DIS, V176, P752, DOI 10.1086/514100; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; ROSE AG, 1978, THORAX, V33, P500, DOI 10.1136/thx.33.4.500; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; SHEPARD CC, 1960, J EXP MED, V112, P445, DOI 10.1084/jem.112.3.445; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; VITALDURAND D, 1997, MEDICINE, V76, P170; WEISS E, 1960, P SOC EXP BIOL MED, V103, P691, DOI 10.3181/00379727-103-25637; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; Woods GL, 1996, CLIN MICROBIOL REV, V9, P382, DOI 10.1128/CMR.9.3.382; YARDLEY JH, 1961, B JOHNS HOPKINS HOSP, V109, P80	29	300	316	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2000	342	9					620	625		10.1056/NEJM200003023420903	http://dx.doi.org/10.1056/NEJM200003023420903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288QV	10699161	Bronze			2022-12-24	WOS:000085575500003
J	Gavrilets, S				Gavrilets, S			Rapid evolution of reproductive barriers driven by sexual conflict	NATURE			English	Article							INTERSPECIFIC POLLEN COMPETITION; SELECTION; SPECIATION; REARRANGEMENTS; POLYMORPHISM; CHASE	A growing amount of experimental data indicates extremely rapid evolution of traits and proteins related to fertilization in many diverging taxa(1-3). These data come from studies of sperm or pollen competition between closely related species(3-6), and from molecular studies of fertilization proteins(2,7-10). The positive selection for evolutionary novelty that appears to be acting on fertilization systems seems paradoxical because successful reproduction requires the close matching of female and male traits. It has been suggested(11-13) that perpetual coevolution between the sexes can result from sexual conflict in mating. Sexual conflict occurs when characteristics that enhance the reproductive success of one sex reduce the fitness of the other sex(14). Numerous examples of sexual conflict resulting from sensory exploitation, polyspermy and the cost of mating have been discussed in detail(1-3,14,15). The potential for coevolution due to such conflict has been evaluated experimentally(15,16). Here I develop a simple mathematical model describing coevolutionary dynamics of male and female traits involved in reproduction. The model shows that continual change in such traits at a constant speed is expected whenever females (or eggs) experience fitness loss from having too many compatible males (or sperms). The plausibility of runaway coevolution increases with increasing population size. Rapid evolution of reproductive barriers driven by sexual conflict may explain increased speciation rates after colonization of new habitats ('adaptive radiation') and high species richness in resource-rich environments.	Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA; Univ Tennessee, Dept Math, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Gavrilets, S (corresponding author), Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA.	sergey@tiem.utk.edu	Langerhans, R. Brian/A-7205-2009					AGUADE M, 1992, GENETICS, V132, P755; ARNOLD ML, 1993, J HERED, V84, P13, DOI 10.1093/oxfordjournals.jhered.a111269; ARNQVIST G, UNPUB P R SOC LOND B; ARNQVIST G, UNPUB ANIM BEHAV; Arnqvist Goran, 1997, P146, DOI 10.1017/CBO9780511721946.009; BARTON NH, 1991, GENETICS, V127, P229; BURGER R, 1995, EVOLUTION, V49, P151, DOI 10.1111/j.1558-5646.1995.tb05967.x; Gavrilets S, 1997, J THEOR BIOL, V186, P527, DOI 10.1006/jtbi.1997.0426; Gavrilets S, 1999, AM NAT, V154, P1, DOI 10.1086/303217; Gavrilets S, 1997, TRENDS ECOL EVOL, V12, P307, DOI 10.1016/S0169-5347(97)01098-7; GAVRILETS S, 1995, GENET RES, V65, P63, DOI 10.1017/S0016672300033012; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; Holland B, 1999, P NATL ACAD SCI USA, V96, P5083, DOI 10.1073/pnas.96.9.5083; Howard DJ, 1998, ENDLESS FORMS, P279; IWASA Y, 1995, NATURE, V377, P420, DOI 10.1038/377420a0; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; PALUMBI SR, 1992, TRENDS ECOL EVOL, V7, P114, DOI 10.1016/0169-5347(92)90144-Z; Palumbi SR, 1998, ENDLESS FORMS, P271; Parker GA, 1998, PHILOS T R SOC B, V353, P261, DOI 10.1098/rstb.1998.0208; Rice WR, 1998, ENDLESS FORMS, P261; Rice WR, 1997, BEHAV ECOL SOCIOBIOL, V41, P1, DOI 10.1007/s002650050357; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; RIESEBERG LH, 1995, AM J BOT, V82, P515, DOI 10.2307/2445699; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Schluter D, 1998, ENDLESS FORMS, P114; Stockley P, 1997, TRENDS ECOL EVOL, V12, P154, DOI 10.1016/S0169-5347(97)01000-8; Vacquier VD, 1993, ZYGOTE, V1, P181, DOI 10.1017/S0967199400001465; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23; WALSH JB, 1982, AM NAT, V120, P510, DOI 10.1086/284008	30	414	429	0	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					886	889		10.1038/35002564	http://dx.doi.org/10.1038/35002564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706284				2022-12-24	WOS:000085559200055
J	Holmgren, M; Wagg, J; Bezanilla, F; Rakowski, RF; De Weer, P; Gadsby, DC				Holmgren, M; Wagg, J; Bezanilla, F; Rakowski, RF; De Weer, P; Gadsby, DC			Three distinct and sequential steps in the release of sodium ions by the Na+/K+-ATPase	NATURE			English	Article							VOLTAGE DEPENDENCE; NA,K PUMP; TRANSLOCATION; CHANNEL; NA,K-ATPASE; PATHWAY	The Na+/K+ pump, a P-type ion-motive ATPase, exports three sodium ions and then imports two potassium ions in each transport cycle. Ions on one side of the membrane bind to sites within the protein and become temporarily occluded (trapped within the protein) before being released to the other side(1,2), but details of these occlusion and de-occlusion transitions remain obscure for all P-type ATPases, If it is deprived of potassium ions, the Na+/K+ pump is restricted to sodium translocation steps(3), at least one involving charge movement through the membrane's electric field(4,5). Changes in membrane potential alter the rate of such electrogenic reactions and so shift the distribution of enzyme conformations. Here we use high-speed voltage jumps to initiate this redistribution and show that the resulting pre-steady-state charge movements relax in three identifiable phases, apparently reflecting de-occlusion and release of the three sodium ions. Reciprocal relationships among the sizes of these three charge components show that the three sodium ions are de-occluded and released to the extracellular solution one at a time, in a strict order.	Marine Biol Lab, Woods Hole, MA 02543 USA	Marine Biological Laboratory - Woods Hole	Gadsby, DC (corresponding author), Rockefeller Univ, Lab Cardiac Membrane Physiol, 1230 York Ave, New York, NY 10021 USA.							BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; FENDLER K, 1985, EMBO J, V4, P3079, DOI 10.1002/j.1460-2075.1985.tb04048.x; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; Friedrich T, 1997, BIOPHYS J, V73, P186, DOI 10.1016/S0006-3495(97)78059-7; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GARRAHAM PJ, 1967, J PHYSL, V192, P161; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; INESI G, 1987, J BIOL CHEM, V262, P16338; LAIGER P, 1991, ELECTROGENIC ION PUM; LAUGER P, 1988, BIOCHIM BIOPHYS ACTA, V944, P451, DOI 10.1016/0005-2736(88)90516-0; LU CC, 1995, P NATL ACAD SCI USA, V92, P11220, DOI 10.1073/pnas.92.24.11220; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; POST RL, 1972, J BIOL CHEM, V247, P6350; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; WUDDEL I, 1995, BIOPHYS J, V69, P909, DOI 10.1016/S0006-3495(95)79965-9	17	137	139	5	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					898	901		10.1038/35002599	http://dx.doi.org/10.1038/35002599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706288				2022-12-24	WOS:000085559200059
J	Mullen, PE; Burgess, P; Wallace, C; Palmer, S; Ruschena, D				Mullen, PE; Burgess, P; Wallace, C; Palmer, S; Ruschena, D			Community care and criminal offending in schizophrenia	LANCET			English	Article							MENTAL DISORDER; VIOLENCE	Background The introduction of community care in psychiatry is widely thought to have resulted in more offending among the seriously mentally ill. This view affects public policy towards and public perceptions of such people. We investigated the association between the introduction of community care and the pattern of offending in patients with schizophrenia in Victoria, Australia. Methods We established patterns of offending from criminal records in two groups of patients with schizophrenia over their lifetime to date and in the 10 years after their first hospital admission. One group was first admitted in 1975 before major deinstitutionalisation in Victoria, the second group in 1985 when community care was becoming the norm. Each patient was matched to a control, by age, sex, and place of residence to allow for changing patterns of offending over time in the wider community. Findings Compared with controls, significantly more of those with schizophrenia were convicted at least once for ail categories of criminal offending except sexual offences (relative risk of offending in 1975=3.5 [95% CI 2.0-5.5), p=0.001, in 1985=3.0 [1.9-4.9], p=0.001). Among men, more offences were committed in the 1985 group than the 1975 group, but this was matched by a similar increase in convictions among the community controls. Those with schizophrenia who had also received treatment for substance abuse accounted for a disproportionate amount of offending. Analysis of admission data for the patients and the total population of admissions with schizophrenia showed that although there had been an increase of 74 days per annum spent in the community for each of the study population as a whole, first admissions spent only 1 more day in the community in 1985 compared with 1975. Interpretation Increased rates in criminal conviction for those with schizophrenia over the last 20 years are consistent with change in the pattern of offending in the general community. Deinstitutionalisation does not adequately explain such change. Mental-health services should aim to reduce the raised rates of criminal offending associated with schizophrenia, but turning the clock back on community care is unlikely to contribute towards any positive outcome.	Victorian Inst Forens Mental Hlth, Fairfield, Vic 3084, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic, Australia; Monash Univ, Dept Psychol Med, Clayton, Vic 3168, Australia	Monash University	Mullen, PE (corresponding author), Victorian Inst Forens Mental Hlth, Locked Bag 10, Fairfield, Vic 3084, Australia.	pmullen@vicnet.net.au	Burgess, Philip/ABD-3040-2020	Burgess, Philip/0000-0001-7184-0363				BURGESS PM, 1992, SOC PSYCH PSYCH EPID, V27, P83, DOI 10.1007/BF00788511; EATON WW, 1992, SCHIZOPHRENIA BULL, V18, P217, DOI 10.1093/schbul/18.2.217; HALL C, 1998, DAILY TELEGRAPH  FEB; *HLTH COMM SERV, 1993, VICT HLTH REF PSYCH; *HLTH COMM SERV, 1996, VICT MENT HLTH SERV; Krupinski J, 1982, SPECIAL PUBLICATION, V12; LINDQVIST P, 1990, BRIT J PSYCHIAT, V157, P345, DOI 10.1192/bjp.157.3.345; Modestin J, 1996, SCHIZOPHRENIA BULL, V22, P69, DOI 10.1093/schbul/22.1.69; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TAYLOR PJ, 1984, BRIT MED J, V288, P1945, DOI 10.1136/bmj.288.6435.1945; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; TAYLOR PJ, 1993, CRIME MENTAL DISORDE, P63; Torrey EF, 1995, AM J PUBLIC HEALTH, V85, P1611, DOI 10.2105/AJPH.85.12.1611; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458	16	141	143	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2000	355	9204					614	617		10.1016/S0140-6736(99)05082-5	http://dx.doi.org/10.1016/S0140-6736(99)05082-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	289HX	10696982				2022-12-24	WOS:000085615400013
J	DeLano, WL; Ultsch, MH; de Vos, AM; Wells, JA				DeLano, WL; Ultsch, MH; de Vos, AM; Wells, JA			Convergent solutions to binding at a protein-protein interface	SCIENCE			English	Article							CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; DOMAIN; FC; RECEPTOR; COMPLEX; IGG; VARIANTS; FRAGMENT; HORMONE	The hinge region on the Fe fragment of human immunoglobulin G interacts with at least four different natural protein scaffolds that bind at a common site between the C-H2 and C-H3 domains. This "consensus" site was also dominant for binding of random peptides selected in vitro for high affinity (dissociation constant, about 25 nanomolar) by bacteriophage display, Thus, this site appears to be preferred owing to its intrinsic physiochemical properties, and not for biological function alone. A 2.7 angstrom crystal structure of a selected 13-amino acid peptide in complex with Fc demonstrated that the peptide adopts a compact structure radically different from that of the other Fc binding proteins. Nevertheless, the specific Fc binding interactions of the peptide strongly mimic those of the other proteins. Juxtaposition of the available Fc-complex crystal structures showed that the convergent binding surface is highly accessible, adaptive, and hydrophobic and contains relatively few sites for polar interactions. These are all properties that may promote cross-reactive binding, which is common to protein-protein interactions and especially hormone-receptor complexes.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Sunesis Pharmaceut, Redwood City, CA 94063 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; Roche Holding; Genentech	Wells, JA (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.	jaw@sunesis-pharma.com	Wells, Jim A/O-9854-2016					BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELANO WL, UNPUB; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, pCH11; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; JENDEBERG L, 1995, J MOL RECOGNIT, V8, P270, DOI 10.1002/jmr.300080405; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KARLSSON R, 1995, J IMMUNOL METHODS, V183, P43, DOI 10.1016/0022-1759(95)00030-E; Kay BK, 1998, DRUG DISCOV TODAY, V3, P370, DOI 10.1016/S1359-6446(98)01220-3; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Medesan C, 1997, J IMMUNOL, V158, P2211; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YOUNG L, 1994, PROTEIN SCI, V3, P717	26	566	648	6	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1279	1283		10.1126/science.287.5456.1279	http://dx.doi.org/10.1126/science.287.5456.1279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678837				2022-12-24	WOS:000085444700054
J	Rudolph, KL; Chang, S; Millard, M; Schreiber-Agus, N; DePinho, RA				Rudolph, KL; Chang, S; Millard, M; Schreiber-Agus, N; DePinho, RA			Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery	SCIENCE			English	Article							MOUSE CELLS LACKING; LIFE-SPAN; HEPATOCELLULAR-CARCINOMA; PLASMINOGEN-ACTIVATOR; HUMAN FIBROBLASTS; DEATH RATES; LENGTH; DISEASES; PATHOGENESIS; REGENERATION	Accelerated telomere loss has been proposed to be a factor Leading to end-stage organ failure in chronic diseases of high cellular turnover such as liver cirrhosis. To test this hypothesis directly, telomerase-deficient mice, null for the essential telomerase RNA (mTR) gene, were subjected to genetic, surgical, and chemical ablation of the liver. Telomere dysfunction was associated with defects in liver regeneration and accelerated the development of liver cirrhosis in response to chronic liver injury. Adenoviral delivery of mTR into the livers of mTR(-/-) mice with short dysfunctional telomeres restored telomerase activity and telomere function, alleviated cirrhotic pathology, and improved liver function. These studies indicate that telomere dysfunction contributes to chronic diseases of continual cellular loss-replacement and encourage the evaluation of "telomerase therapy" for such diseases.	Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Yeshiva University; Albert Einstein College of Medicine	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; Rudolph, Karl Lenhard/0000-0002-4839-2862	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034880, R01HD028317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG001019] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG001019] Funding Source: Medline; NICHD NIH HHS [R01HD28317, R01HD34880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ANTHONY PP, 1977, B WORLD HEALTH ORGAN, V55, P521; Ball SE, 1998, BLOOD, V91, P3582; BEDOSSA P, 1972, HEPATOLOGY, V21, P76095; Blackburn E, 1997, Ciba Found Symp, V211, P2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; FAUSTO N, 1991, CIBA F SYMP, V157, P165; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; Huang GT, 1998, EUR J CANCER, V34, P1946, DOI 10.1016/S0959-8049(98)00237-8; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOJLMA H, 1997, GASTROENTEROLOGY, V112, P493; KORULA J, 1992, LIVER BILIARY DIS, P529; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; McClintock B, 1941, GENETICS, V26, P234; MILANI S, 1991, AM J PATHOL, V139, P1221; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Mondello C, 1997, EXP CELL RES, V236, P385, DOI 10.1006/excr.1997.3756; NAKISHIO R, 1998, NIPPON RINSHO, V56, P1239; Nichols WS, 1999, SCAND J IMMUNOL, V49, P302, DOI 10.1046/j.1365-3083.1999.00505.x; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Ohyashiki JH, 1999, CLIN CANCER RES, V5, P1155; OHYASHIKI JH, 1994, CANCER RES, V54, P3557; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Park YM, 1998, EXP MOL MED, V30, P35, DOI 10.1038/emm.1998.5; PODOLSKY DK, 1998, HARRISONS PRINCIPLES, P17084; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 1999, HEPATOLOGY, V30, P1159, DOI 10.1002/hep.510300502; RUDOLPH KL, UNPUB; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smart RG, 1998, J STUD ALCOHOL, V59, P245, DOI 10.15288/jsa.1998.59.245; Smart RG, 1996, ALCOHOL ALCOHOLISM, V31, P487; SMART RG, 1991, J STUD ALCOHOL, V52, P232, DOI 10.15288/jsa.1991.52.232; SMART RG, 1993, MMWR-MORBID MORTAL W, V41, P969; Suda T, 1998, HEPATOLOGY, V27, P402, DOI 10.1002/hep.510270213; TAHARA H, 1995, CANCER RES, V55, P2734; TAMAYO RP, 1983, HEPATOLOGY, V3, P112; Urabe Y, 1996, LIVER, V16, P293; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Williams EJ, 1998, POSTGRAD MED J, V74, P193, DOI 10.1136/pgmj.74.870.193	59	305	324	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1253	1258		10.1126/science.287.5456.1253	http://dx.doi.org/10.1126/science.287.5456.1253			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678830				2022-12-24	WOS:000085444700047
J	Capaldi, EA; Smith, AD; Osborne, JL; Fahrbach, SE; Farris, SM; Reynolds, DR; Edwards, AS; Martin, A; Robinson, GE; Poppy, GM; Riley, JR				Capaldi, EA; Smith, AD; Osborne, JL; Fahrbach, SE; Farris, SM; Reynolds, DR; Edwards, AS; Martin, A; Robinson, GE; Poppy, GM; Riley, JR			Ontogeny of orientation flight in the honeybee revealed by harmonic radar	NATURE			English	Article							BEES	Cognitive ethology focuses on the study of animals under natural conditions to reveal ecologically adapted modes of learning. But biologists can more easily study what an animal learns than how it learns. For example, honeybees take repeated 'orientation' flights before becoming foragers at about three weeks of age(1). These flights are a prerequisite for successful homing.(2) Little is known(2,3) about these flights because orienting bees rapidly fly out of the range of human observation. Using harmonic radar, we show for the first time a striking ontogeny to honeybee orientation flights. With increased experience, bees hold trip duration constant but fly faster, so later trips cover a larger area than earlier trips. In addition, each flight is typically restricted to a narrow sector around the hive. Orientation flights provide honeybees with repeated opportunities to view the hive and landscape features from different viewpoints, suggesting that bees learn the local landscape in a progressive fashion. We also show that these changes in orientation flight are related to the number of previous flights taken instead of chronological age, suggesting a learning process adapted to changes in weather conditions, flower availability and the needs of bee colonies.	Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Greenwich, Nat Resources Inst, Radar Entomol Unit, Malvern WR14 1LL, Worcs, England; IACR Rothamsted, Dept Entomol & Nematol, Harpenden AL5 2JQ, Herts, England	University of Illinois System; University of Illinois Urbana-Champaign; University of Greenwich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Capaldi, EA (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	ecapaldi@life.uiuc.edu	Poppy, Guy m/D-7513-2012; Osborne, Juliet L/I-6776-2012; Reynolds, Donald R/C-7361-2013	Reynolds, Donald/0000-0001-8749-7491; Farris, Sarah/0000-0003-3307-0550	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004179] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BECKER L, 1958, Z VERGL PHYSIOL, V41, P1; Capaldi EA, 1999, J EXP BIOL, V202, P1655; COLLETT TS, 1992, PHILOS T R SOC B, V337, P295, DOI 10.1098/rstb.1992.0107; DYER FC, 1994, P NATL ACAD SCI USA, V91, P4471, DOI 10.1073/pnas.91.10.4471; LINDAUER M, 1959, Z VERGL PHYSIOL, V42, P43, DOI 10.1007/BF00297689; OBSORNE JL, 1999, J APPL ECOL, V36, P519; Ribbands C.R., 1953, BEHAV SOCIAL LIFE HO; Riley JR, 1996, NATURE, V379, P29, DOI 10.1038/379029b0; *SAS I, 1988, SAS STAT US GUID; VISSCHER PK, 1982, ECOLOGY, V63, P1790, DOI 10.2307/1940121; Vollbehr J., 1975, Zoologische Jb (Allg Zool), V79, P33; Wehner R, 1981, COMP PHYS EVOLUTION, VVII/ 6C, P287, DOI DOI 10.1007/978-3642-67868-4; White G.C., 1990, ANAL WILDLIFE RADIO; Winston M., 1987, The biology of the honey bee.; Zar JH, 1996, BIOSTATISTICAL ANAL	15	230	234	5	97	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					537	540		10.1038/35000564	http://dx.doi.org/10.1038/35000564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676960				2022-12-24	WOS:000085227300048
J	Tang, L; Shah, S; Chung, L; Carney, J; Katz, L; Khosla, C; Julien, B				Tang, L; Shah, S; Chung, L; Carney, J; Katz, L; Khosla, C; Julien, B			Cloning and heterologous expression of the epothilone gene cluster	SCIENCE			English	Article							ENGINEERED BIOSYNTHESIS; POLYKETIDES	The polyketide epothilone is a potential anticancer agent that stabilizes microtubules in a similar manner to Taxol. The gene cluster responsible for epothilone biosynthesis in the myxobacterium Sorangium cellulosum was cloned and completely sequenced. It encodes six multifunctional proteins composed of a loading module, one nonribosomal peptide synthetase module, eight polyketide synthase modules, and a P450 epoxidase that converts desoxyepothilone into epothilone. Concomitant expression of these genes in the actinomycete Streptomyces coelicolor produced epothilones A and B. Streptomyces coelicolor is more amenable to strain improvement and grows about 10-fold as rapidly as the natural producer, so this heterologous expression system portends a plentiful supply of this important agent.	KOSAN Biosci, Hayward, CA 94545 USA	Bristol-Myers Squibb; Kosan Biosciences, Inc.	Julien, B (corresponding author), KOSAN Biosci, 3832 Bay Ctr Pl, Hayward, CA 94545 USA.			Carney, John/0000-0002-0461-8890; Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R43CA079228] Funding Source: NIH RePORTER; NCI NIH HHS [1 R43 CA79228-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balog A, 1996, ANGEW CHEM INT EDIT, V35, P2801, DOI 10.1002/anie.199628011; BEDFORD DJ, 1995, J BACTERIOL, V177, P4544, DOI 10.1128/jb.177.15.4544-4548.1995; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; BOLLAG DM, 1995, CANCER RES, V55, P2325; CASPERS P, 1994, CELL MOL BIOL, V40, P635; Chou TC, 1998, P NATL ACAD SCI USA, V95, P15798, DOI 10.1073/pnas.95.26.15798; Chou TC, 1998, P NATL ACAD SCI USA, V95, P9642, DOI 10.1073/pnas.95.16.9642; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; Gerth K, 1996, J ANTIBIOT, V49, P560, DOI 10.7164/antibiotics.49.560; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; Hopwood D. A., 1985, GENETIC MANIPULATION; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Nicolaou KC, 1997, ANGEW CHEM INT EDIT, V36, P2097, DOI 10.1002/anie.199720971; Proctor RH, 1999, FUNGAL GENET BIOL, V27, P100, DOI 10.1006/fgbi.1999.1141; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Su DS, 1997, ANGEW CHEM INT EDIT, V36, P2093, DOI 10.1002/anie.199720931; Tang L., UNPUB; Xue Q, 1999, P NATL ACAD SCI USA, V96, P11740, DOI 10.1073/pnas.96.21.11740; YANG Z, 1995, ANGEW CHEM INT EDIT, V35, P2399; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658	25	339	401	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					640	642		10.1126/science.287.5453.640	http://dx.doi.org/10.1126/science.287.5453.640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649995				2022-12-24	WOS:000084989400044
J	Freire-de-Lima, CG; Nascimento, DO; Soares, MBP; Bozza, PT; Castro-Faria-Neto, HC; de Mello, FG; DosReis, GA; Lopes, MF				Freire-de-Lima, CG; Nascimento, DO; Soares, MBP; Bozza, PT; Castro-Faria-Neto, HC; de Mello, FG; DosReis, GA; Lopes, MF			Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages	NATURE			English	Article							FACTOR-BETA; TGF-BETA; VITRONECTIN RECEPTOR; CRUZI; ACTIVATION; DECARBOXYLASE; IDENTIFICATION; INVOLVEMENT; LYMPHOCYTES; INHIBITION	After apoptosis, phagocytes prevent inflammation and tissue damage by the uptake and removal of dead cells(1). In addition, apoptotic cells evoke an anti-inflammatory response through macrophages(2,3). We have previously shown that there is intense lymphocyte apoptosis in an experimental model of Chagas' disease(4), a debilitating cardiac illness caused by the protozoan Trypanosoma cruzi. Here we show that the interaction of apoptotic, but not necrotic T lymphocytes with macrophages infected with I: cruzi fuels parasite growth in a manner dependent on prostaglandins, transforming growth factor-beta (TGF-beta) and polyamine biosynthesis. We show that the vitronectin receptor is critical, in both apoptotic-cell cytoadherence and the induction of prostaglandin E-2/TGF-beta release and ornithine decarboxylase activity in macrophages. A single injection of apoptotic cells in infected mice increases parasitaemia, whereas treatment with cyclooxygenase inhibitors almost completely ablates it in vivo. These results suggest that continual lymphocyte apoptosis and phagocytosis of apoptotic cells by macrophages have a role in parasite persistence in the host, and that cyclooxygenase inhibitors have potential therapeutic application in the control of parasite replication and spread in Chagas' disease.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944970 Rio De Janeiro, Brazil; Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil; Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	DosReis, GA (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944970 Rio De Janeiro, Brazil.	gdosreis@biof.ufrj.br; mlopes@niaid.nih.gov	Soares, Milena B. P./O-3771-2018; NASCIMENTO, DANIELLE/ABE-1057-2020; Bozza, Patricia T./AAE-2933-2021; Lopes, Marcela Freitas/E-2201-2012; de Lima, Celio Geraldo Freire/A-9057-2012; Bozza, Patricia T./AAM-4537-2021	NASCIMENTO, DANIELLE/0000-0001-8946-6998; Lopes, Marcela Freitas/0000-0002-4508-0505; Bozza, Patricia T./0000-0001-8349-9529; DosReis, George/0000-0002-8924-4727; Soares, Milena/0000-0001-7549-2992				BOUTARD V, 1995, J IMMUNOL, V155, P2077; CELENTANO AM, 1995, PROSTAGLANDINS, V49, P141, DOI 10.1016/0090-6980(95)00002-R; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; Corraliza IM, 1997, BBA-GEN SUBJECTS, V1334, P123, DOI 10.1016/S0304-4165(96)00081-5; De Mello F G, 1976, J Neurochem, V27, P847; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KIERSZENBAUM F, 1987, P NATL ACAD SCI USA, V84, P4278, DOI 10.1073/pnas.84.12.4278; LOPES MF, 1995, J IMMUNOL, V154, P744; MAMONT PS, 1976, P NATL ACAD SCI USA, V73, P1626, DOI 10.1073/pnas.73.5.1626; MAXFIELD SR, 1989, J EXP MED, V169, P2173, DOI 10.1084/jem.169.6.2173; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Nunes MP, 1998, J IMMUNOL, V160, P1313; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PROSSER EH, 1998, ARCH BIOCHEM BIOPHYS, V260, P218; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; Soares MBP, 1997, INFECT IMMUN, V65, P2837, DOI 10.1128/IAI.65.7.2837-2845.1997; STURMER AM, 1992, J IMMUNOL METHODS, V146, P105, DOI 10.1016/0022-1759(92)90053-V; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	29	349	358	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					199	203		10.1038/35003208	http://dx.doi.org/10.1038/35003208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646605	Green Published			2022-12-24	WOS:000084835300056
J	Kessel, A; Watts, C; Weiss, HA				Kessel, A; Watts, C; Weiss, HA			Bad blood? Survey of public's views on unlinked anonymous testing of blood for HIV and other diseases	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Epidemiol Unit, London WC1E 7HT, England; Barking & Havering Hlth Author, Directorate Publ Hlth, Barking IG11 8EY, England; Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kessel, A (corresponding author), Univ London London Sch Hyg & Trop Med, Epidemiol Unit, Keppel St, London WC1E 7HT, England.		weiss, helen/ABC-7823-2021	weiss, helen/0000-0003-3547-7936				Berridge V., 1996, AIDS UK MAKING POLIC; *DEP HLTH HUM SERV, 1997, CHILD MALTR 1995 REP, P2; GILL ON, 1989, BRIT MED J, V299, P1297; Kessel Anthony S, 1997, Sci Eng Ethics, V3, P297, DOI 10.1007/s11948-997-0036-0; KOPELMAN LM, 1994, J MED PHILOS, V19, P525, DOI 10.1093/jmp/19.6.525	5	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					90	91		10.1136/bmj.320.7227.90	http://dx.doi.org/10.1136/bmj.320.7227.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625262	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000084746600017
J	Sheridan, RL; Hinson, MI; Liang, MH; Nackel, AF; Schoenfeld, DA; Ryan, CM; Mulligan, JL; Tompkins, RG				Sheridan, RL; Hinson, MI; Liang, MH; Nackel, AF; Schoenfeld, DA; Ryan, CM; Mulligan, JL; Tompkins, RG			Long-term outcome of children surviving massive burns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SF-36 HEALTH SURVEY; THERMAL-INJURY; FULL-THICKNESS; BODY-SURFACE; VALIDITY; QUALITY; LIFE; MORTALITY; EXCISION; DETERMINANTS	Context Major advances in treatment of burn injuries in the last 20 years have made it possible to save the lives of children with massive burns, but whether their survival comes at the cost of impaired quality of life is unknown. Objective To investigate the long-term quality of life in children who have survived massive burns. Design and Setting Retrospective, cross-sectional study conducted in a regional pediatric burn center. Patients Eighty subjects who were younger than 18 years at the time of injury, who survived massive burns involving greater than or equal to 70% of the body surface, and who were admitted to the burn center between 1969 and 1992 were evaluated an average (SD) of 14.7 (6.0) years after injury. Main Outcome Measures Short Form 36 (SF-36) scores of the 60 patients aged at least 14 years were compared with national norms and the impact of clinical variables on individual domain scores was assessed. Results The SF-36 domain scores of the study patients, who had survived massive burns at a mean (SD) age of 8.8 (5.5) years, were generally similar to the normal population). However, 15% and 20% of the burn patients had scores in the physical functioning and physical role domains, respectively, that were more than 2 SDs below the relevant norm, indicating that a few patients had continuing serious physical disability. Better functional status of the family predicted a higher score in physical role (P = .04). The child's early reintegration with preburn activities predicted higher scores in general health (P = .03), physical functioning (P = .003), and physical role (P = .01). Children followed up consistently in the multidisciplinary burn clinic for 2 years had higher physical functioning (P = .04). Conclusions In this study, while some children surviving severe burns had lingering physical disability, most had a satisfying quality of life. Comprehensive burn care that included experienced multidisciplinary aftercare played an important role in recovery.	Massachusetts Gen Hosp, Burn Serv, Boston, MA 02114 USA; Shriners Burns Hosp Children, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Tompkins, RG (corresponding author), Massachusetts Gen Hosp, Burn Serv, GRB1302,55 Fruit St, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X	NIGMS NIH HHS [GM P50-21700, GM T32-07035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007035, P50GM021700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaronson N K, 1988, Oncology (Williston Park), V2, P69; ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; Anderson C, 1996, STROKE, V27, P1812, DOI 10.1161/01.STR.27.10.1812; BLAKENEY P, 1990, Journal of Burn Care and Rehabilitation, V11, P472, DOI 10.1097/00004630-199009000-00018; BROWNE G, 1985, BURNS, V12, P28, DOI 10.1016/0305-4179(85)90180-9; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; BURKE JF, 1976, SURG CLIN N AM, V56, P477; Byrne C, 1986, J Burn Care Rehabil, V7, P247, DOI 10.1097/00004630-198605000-00011; EYLES P, 1984, BURNS, V10, P427, DOI 10.1016/0305-4179(84)90084-6; Fratianne R B, 1992, J Burn Care Rehabil, V13, P600, DOI 10.1097/00004630-199209000-00018; HERNDON DN, 1986, J TRAUMA, V26, P609, DOI 10.1097/00005373-198607000-00004; HERNDON DN, 1987, J TRAUMA, V27, P208, DOI 10.1097/00005373-198702000-00020; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PERNEGER TV, 1995, J CLIN EPIDEMIOL, V48, P1051, DOI 10.1016/0895-4356(94)00227-H; PINNEGAR MD, 1986, BURNS, V12, P508, DOI 10.1016/0305-4179(86)90079-3; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; SAWYER MG, 1983, BURNS, V9, P205, DOI 10.1016/0305-4179(83)90040-2; Sheridan R L, 1994, J Intensive Care Med, V9, P6; Sheridan R L, 1998, Curr Probl Pediatr, V28, P105, DOI 10.1016/S0045-9380(98)80021-2; Sheridan R L, 1998, Curr Probl Pediatr, V28, P139, DOI 10.1016/S0045-9380(98)80061-3; SHERIDAN RL, 1995, J TRAUMA, V38, P48, DOI 10.1097/00005373-199501000-00014; STODDARD FJ, 1989, J AM ACAD CHILD PSY, V28, P589, DOI 10.1097/00004583-198907000-00020; Stoll T, 1997, J RHEUMATOL, V24, P1608; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006; VANDAM F, 1986, B CANCER, V73, P607; Warden Glenn D., 1993, Journal of Burn Care and Rehabilitation, V14, P581, DOI 10.1097/00004630-199311000-00001; WARE JE, 1993, SF 36 HLTH SURVEY MA, V3, P4; Wolf SE, 1997, ANN SURG, V225, P554, DOI 10.1097/00000658-199705000-00012; WRIGHT L, 1974, PEDIATR RES, V8, P931, DOI 10.1203/00006450-197412000-00003; [No title captured]	32	188	193	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					69	73		10.1001/jama.283.1.69	http://dx.doi.org/10.1001/jama.283.1.69			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270AZ	10632282	Bronze			2022-12-24	WOS:000084514400027
J	Mitchell, E				Mitchell, E			Commentary: Cot death-the story so far	BRITISH MEDICAL JOURNAL			English	Editorial Material							SLEEPING POSITION		Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Auckland 1, New Zealand	University of Auckland	Mitchell, E (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Postbag 92019, Auckland 1, New Zealand.							Fleming PJ, 1999, ARCH DIS CHILD, V81, P112, DOI 10.1136/adc.81.2.112; L'Hoir MP, 1998, EUR J PEDIATR, V157, P681, DOI 10.1007/s004310050911; MITCHELL EA, 1999, INT CONSULTATION ENV, P105; NELSON EAS, 1989, LANCET, V1, P199; Scragg RKR, 1998, ANN MED, V30, P345, DOI 10.3109/07853899809029933	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1461	1462						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10644147				2022-12-24	WOS:000084129200017
J	Wilson, JA; Hevey, M; Bakken, R; Guest, S; Bray, M; Schmaljohn, AL; Hart, MK				Wilson, JA; Hevey, M; Bakken, R; Guest, S; Bray, M; Schmaljohn, AL; Hart, MK			Epitopes involved in antibody-mediated protection from Ebola virus	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; VIRION GLYCOPROTEINS; PROPHYLAXIS; INFECTION; FEVER	To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to Lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.	USA, Div Virol, Med Res Inst Infect Dis, Ft Detrick, Frederick, MD 21702 USA		Hart, MK (corresponding author), USA, Div Virol, Med Res Inst Infect Dis, Ft Detrick, 1425 Porter St, Frederick, MD 21702 USA.	marykate.hart@amedd.army.mil		Hevey, Michael/0000-0001-7481-1058				Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386; *COMM CAR US LAB A, 1996, NIH PUBL; Hevey M, 1997, VIROLOGY, V239, P206, DOI 10.1006/viro.1997.8883; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; Kudoyarova-Zubavichene NM, 1999, J INFECT DIS, V179, pS218, DOI 10.1086/514294; MIKHAILOV VV, 1994, VOP VIRUSOL+, V39, P82; MOE JB, 1981, J CLIN MICROBIOL, V13, P791, DOI 10.1128/JCM.13.4.791-793.1981; Peters CJ, 1999, J INFECT DIS, V179, pIX; Pushko P, 1997, VACCINES, P253; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; Sanchez A, 1999, J INFECT DIS, V179, pS164, DOI 10.1086/514282; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; STILES BG, 1991, TOXICON, V29, P1195, DOI 10.1016/0041-0101(91)90192-T; Volchkov VE, 1998, VIROLOGY, V245, P110, DOI 10.1006/viro.1998.9143; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WILSON J, UNPUB; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037	19	363	407	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1664	1666		10.1126/science.287.5458.1664	http://dx.doi.org/10.1126/science.287.5458.1664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10698744				2022-12-24	WOS:000085628200042
J	Keshavjee, S; Becerra, MC				Keshavjee, S; Becerra, MC			Disintegrating health services and resurgent tuberculosis in post-Soviet Tajikistan: An example of structural violence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Cultural & Social Anthropol, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Harvard Medical School	Keshavjee, S (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.			Keshavjee, Salmaan/0000-0002-6967-3305				Bourdieu P., 1993, MISERE MONDE, P159; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; FARMER P, 1995, DAEDALUS, V125, P261; Harvard Medical School and Open Society Institute, 1999, GLOB IMP DRUG RES TU; KESHAVJEE S, 1998, THESIS HARVARD U BOS; Kim J. Y., 2000, DYING GROWTH GLOBAL; NAJIBULLAH F, 1998, TAJIKISTAN HLTH CARE; SCHEPERHUGHES N, 1992, DEATH WEEPING VIOLEN, P128; *WHO, 1999, TAJ HLTH SECT REP 19; World Health Organization, 1994, WHO TUB PROGR FRAM E	10	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1201	1201		10.1001/jama.283.9.1201	http://dx.doi.org/10.1001/jama.283.9.1201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286BQ	10703788	hybrid			2022-12-24	WOS:000085424100035
J	Lincoln, NB; Husbands, S; Trescoli, C; Drummond, AER; Gladman, JRF; Berman, P				Lincoln, NB; Husbands, S; Trescoli, C; Drummond, AER; Gladman, JRF; Berman, P			Five year follow up of a randomised controlled trial of a stroke rehabilitation unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England; Univ Nottingham, Ageing & Disabil Res Unit, Nottingham NG7 2UH, England; Nottingham City Hosp NHS Trust, Dept Med, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Lincoln, NB (corresponding author), Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England.	nbl@psychology.nottingham.ac.uk	Lincoln, Nadina B/B-9149-2009; Trescolí, Carlos/GLQ-7462-2022; Gladman, John/M-7429-2015	Drummond, Avril/0000-0003-1220-8354; Gladman, John/0000-0002-8506-7786				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Collin C, 1988, Int Disabil Stud, V10, P61; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005	4	31	31	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2000	320	7234					549	549		10.1136/bmj.320.7234.549	http://dx.doi.org/10.1136/bmj.320.7234.549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289LV	10688561	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000085624000023
J	Bruner, SD; Norman, DPG; Verdine, GL				Bruner, SD; Norman, DPG; Verdine, GL			Structural basis for recognition and repair of the endogenous mutagen 8-oxoguanine in DNA	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; DAMAGED DNA; OGG1 GENE; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; ESCHERICHIA-COLI; HUMAN HOMOLOG; HOGG1 GENE; GLYCOSYLASE; CLONING	Spontaneous oxidation of guanine residues in DNA generates 8-oxoguanine (oxoG), By mispairing with adenine during replication, oxoG gives rise to a G.C --> T.A transversion, a frequent somatic mutation in human cancers. The dedicated repair pathway for oxoG centres on 8-oxoguanine DNA glycosylase (h0GG1), an enzyme that recognizes oxoG.C base pairs, catalysing expulsion of the oxoG and cleavage of the DNA backbone. Here we report the X-ray structure of the catalytic core of h0GG1 bound to oxoG.C-containing DNA at 2.1 Angstrom resolution. The structure reveals the mechanistic basis for the recognition and catalytic excision of DNA damage by h0GG1 and by other members of the enzyme superfamily to which it belongs. The structure also provides a rationale for the biochemical effects of inactivating mutations and polymorphisms in hOGG1. One known mutation, R154H, converts h0GG1 to a promutator by relaxing the specificity of the enzyme for the base opposite oxoG.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	verdine@chemistry.harvard.edu						Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blons H, 1999, MOL CARCINOGEN, V26, P254; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Choi JY, 1999, FREE RADICAL BIO MED, V27, P848, DOI 10.1016/S0891-5849(99)00141-0; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; DODSON ML, 1994, J BIOL CHEM, V269, P32709; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	45	797	821	3	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					859	866		10.1038/35002510	http://dx.doi.org/10.1038/35002510			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10706276				2022-12-24	WOS:000085559200047
J	Zito, JM; Safer, DJ; dosReis, S; Gardner, JF; Boles, M; Lynch, F				Zito, JM; Safer, DJ; dosReis, S; Gardner, JF; Boles, M; Lynch, F			Trends in the prescribing of psychotropic medications to preschoolers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Psychiatric-Association	MAY 15-19, 1999	WASHINGTON, D.C.	Amer Psychiat Assoc			DEFICIT HYPERACTIVITY DISORDER; STIMULANT MEDICATION; CLONIDINE; CHILDREN; PSYCHOPHARMACOLOGY; METHYLPHENIDATE; ADOLESCENTS; PREVALENCE; QUESTIONS; EFFICACY	Context Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates. Objectives To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span. Design Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population - based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). Setting and Participants From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146 369 to 158 060; in a mid-Atlantic state Medicaid (MAM) program, from 34 842 to 54 237; and in an HMO setting in the Northwest, from 19 107 to 19 322. Main Outcome Measures Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites. Results The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); anti depressants (3.2); clonidine (2,3); and neuroleptics (0.9), A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7), Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents. Conclusions In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.	Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Kaiser Permanente, Ctr Hlth Res, Portland, OR USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Kaiser Permanente	Zito, JM (corresponding author), Univ Maryland, Sch Pharm, 100 Greene St,Room 5-13, Baltimore, MD 21201 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055259] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH55259] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHMANN PA, 1993, PEDIATRICS, V91, P1101; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P539, DOI 10.1097/00004583-199704000-00017; DAVILLA RR, 1991, CLARIFICATION POLICY; Erickson SJ, 1998, J PAEDIATR CHILD H, V34, P280, DOI 10.1046/j.1440-1754.1998.t01-1-00217.x; Firestone P, 1998, J CHILD ADOL PSYCHOP, V8, P13, DOI 10.1089/cap.1998.8.13; FOXMAN B, 1986, PEDIATRICS, V77, P482; Geller B, 1999, J AM ACAD CHILD PSY, V38, P513, DOI 10.1097/00004583-199905000-00012; Greenhill LL, 1998, CAN J PSYCHIAT, V43, P576, DOI 10.1177/070674379804300604; GRINFELD MJ, 1998, PSYCHIAT TIMES, V15, P69; Hoagwood K, 1996, J AM ACAD CHILD PSY, V35, P1055, DOI 10.1097/00004583-199608000-00017; JENSEN PS, 1994, PSYCHOPHARMACOL BULL, V30, P3; Kappagoda C, 1998, J PAEDIATR CHILD H, V34, P508, DOI 10.1046/j.1440-1754.1998.00301.x; Minde K, 1998, CAN J PSYCHIAT, V43, P571, DOI 10.1177/070674379804300603; PATHIYAL A, 1998, AM SOC CLIN PHARM TH; Perrin JM, 1999, ARCH PEDIAT ADOL MED, V153, P80; Pincus HA, 1998, JAMA-J AM MED ASSOC, V279, P526, DOI 10.1001/jama.279.7.526; POPPER CW, 1995, J CHILD ADOL PSYCHOP, V5, P157, DOI 10.1089/cap.1995.5.157; Prince JB, 1996, J AM ACAD CHILD PSY, V35, P599, DOI 10.1097/00004583-199605000-00014; RAPPLEY MD, 1998, PED AC SOC M JOINT S; Safer D.J., 2000, RITALIN THEORY PRACT, P7; Safer DJ, 1996, PEDIATRICS, V98, P1084; Swanson JM, 1995, J CHILD ADOL PSYCHOP, V5, P301, DOI 10.1089/cap.1995.5.301; Traversa G, 1998, J CHILD ADOL PSYCHOP, V8, P175, DOI 10.1089/cap.1998.8.175; Valentine J, 1996, J PAEDIATR CHILD H, V32, P223, DOI 10.1111/j.1440-1754.1996.tb01558.x; Vitiello B, 1997, ARCH GEN PSYCHIAT, V54, P871; Vitiello B, 1998, CAN J PSYCHIAT, V43, P582, DOI 10.1177/070674379804300605; Wilens TE, 1999, J AM ACAD CHILD PSY, V38, P614, DOI 10.1097/00004583-199905000-00025; Zito JM, 1998, J CHILD ADOL PSYCHOP, V8, P99, DOI 10.1089/cap.1998.8.99; ZITO JM, 1998, TRENDS PSYCHOTROPIC	29	634	641	1	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1025	1030		10.1001/jama.283.8.1025	http://dx.doi.org/10.1001/jama.283.8.1025			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	284AM	10697062	Bronze			2022-12-24	WOS:000085308600031
J	Nishita, M; Hashimoto, MK; Ogata, S; Laurent, MN; Ueno, N; Shibuya, H; Cho, KWY				Nishita, M; Hashimoto, MK; Ogata, S; Laurent, MN; Ueno, N; Shibuya, H; Cho, KWY			Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer	NATURE			English	Article							AXIS SPECIFICATION; SIGNALING PATHWAYS; XENOPUS MESODERM; GENE-EXPRESSION; SMAD PROTEINS; WINGLESS; PATTERN; ESTABLISHMENT; ANTAGONISM; INDUCTION	Members of the Wnt and TGF-beta superfamilies regulate both cell fate and proliferation during development and tissue maintenance(1-3). In the early amphibian embryo, the Wnt and TGF-beta superfamily signalling cascades are required for the establishment of a dorsal signalling centre, Spemann's organizer(4-8). Intracellular proteins of both pathways, upon activation, translocate to the nucleus to participate in transcription. Here we show that beta-catenin and Lef1/Tcf, which are downstream components of the Wnt signalling cascade, form a complex with Smad4, an essential mediator of signals initiated by members of the TGF-beta growth factor superfamily. In Xenopus, this interaction directly and synergistically affects expression of the twin (Xtwn) gene during formation of the organizer. This is, to our knowledge, the first demonstration of a physical interaction between TGF-beta and Wnt signalling components in vivo.	Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92617 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of California System; University of California Irvine	Shibuya, H (corresponding author), Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan.			Ueno, Naoto/0000-0002-8375-2317				Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Candia AF, 1997, DEVELOPMENT, V124, P4467; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; JONES CM, 1992, DEVELOPMENT, V115, P639; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theisen H, 1996, DEVELOPMENT, V122, P3939; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WATERMAN M L, 1990, New Biologist, V2, P621; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	29	386	399	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					781	785		10.1038/35001602	http://dx.doi.org/10.1038/35001602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10693808	Green Submitted			2022-12-24	WOS:000085423100055
J	Willenheimer, R; Erhardt, LR				Willenheimer, R; Erhardt, LR			Value of 6-min-walk test for assessment of severity and prognosis of heart failure	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; 6-MINUTE WALK TEST; QUALITY-OF-LIFE; OXYGEN-UPTAKE		Univ Lund, Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Willenheimer, R (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden.							BENGE W, 1980, CIRCULATION, V61, P955, DOI 10.1161/01.CIR.61.5.955; BITTNER V, 1993, CIRCULATION, V88, P590; BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; COHN JN, 1993, CIRCULATION, V87, P1; DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273; Faggiano P, 1997, AM HEART J, V134, P203, DOI 10.1016/S0002-8703(97)70125-X; GORKIN L, 1993, AM J CARDIOL, V71, P1069, DOI 10.1016/0002-9149(93)90575-W; Lucas C, 1999, AM HEART J, V138, P618, DOI 10.1016/S0002-8703(99)70174-2; RILEY M, 1992, EUR HEART J, V13, P789, DOI 10.1093/oxfordjournals.eurheartj.a060258; Roul G, 1998, AM HEART J, V136, P449, DOI 10.1016/S0002-8703(98)70219-4; Stevenson L., 1996, EXERCISE GAS EXCHANG, P271; Zugck C, 1998, CIRCULATION, V98, P157	13	22	25	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					515	516		10.1016/S0140-6736(99)00445-6	http://dx.doi.org/10.1016/S0140-6736(99)00445-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682999				2022-12-24	WOS:000085487400007
J	Glynne, R; Akkaraju, S; Healy, JI; Rayner, J; Goodnow, CC; Mack, DH				Glynne, R; Akkaraju, S; Healy, JI; Rayner, J; Goodnow, CC; Mack, DH			How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis	NATURE			English	Article							TRANSCRIPTION FACTOR; CYCLOSPORINE-A; LYMPHOCYTES; ACTIVATION; RECEPTOR; PROTEIN; GENE; IMMUNOGLOBULIN; PROLIFERATION; EXPRESSION	Therapy for transplant rejection, autoimmune disease and allergy must target mature lymphocytes that have escaped censoring during their development. FK506 and cyclosporin are immunosuppressants which block three antigen-receptor signalling pathways (NFAT, NF kappa B and JNK), through inhibition of calcineurin(1), and inhibit mature lymphocyte proliferation to antigen(2-4) Neither drug induces long-lived tolerance in vivo, however, necessitating chronic use with adverse side effects. Physiological mechanisms of peripheral tolerance to self-antigens provide an opportunity to emulate these processes pharmacologically. Here we use gene-expression arrays to provide a molecular explanation for the loss of mitogenic response in peripheral B-cell anergy, one aspect of immunological tolerance(5). Self-antigen induces a set of genes that includes negative regulators of signalling and transcription but not genes that promote proliferation. FK506 interferes with calcium-dependent components of the tolerance response and blocks an unexpectedly small fraction of the activation response. Many genes that were not previously connected to self-tolerance are revealed, and our findings provide a molecular fingerprint for the development of improved immunosuppressants that prevent lymphocyte activation without blocking peripheral tolerance.	Stanford Univ, Beckman Ctr, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Canberra, ACT 2601, Australia; Eos Biotechnol, S San Francisco, CA 94080 USA	Stanford University; Australian National University; John Curtin School of Medical Research	Goodnow, CC (corresponding author), Stanford Univ, Beckman Ctr, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				Adachi T, 1998, J IMMUNOL, V160, P4662; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Healy JI, 1998, CIBA F SYMP, V215, P137; HONG JX, 1993, J IMMUNOL, V150, P3895; HUO L, 1995, J IMMUNOL, V154, P3300; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MONROE JG, 1988, J IMMUNOL, V140, P1454; Newton JS, 1996, EUR J IMMUNOL, V26, P811, DOI 10.1002/eji.1830260413; Pfisterer P, 1996, MOL CELL BIOL, V16, P6160; Rathmell JC, 1998, J EXP MED, V188, P651, DOI 10.1084/jem.188.4.651; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; Slemmon JR, 1996, J BIOL CHEM, V271, P15911, DOI 10.1074/jbc.271.27.15911; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Svaren J, 1996, MOL CELL BIOL, V16, P3545; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017	30	139	144	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2000	403	6770					672	676		10.1038/35001102	http://dx.doi.org/10.1038/35001102			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688206				2022-12-24	WOS:000085288200058
J	Ito, K; Uno, M; Nakamura, Y				Ito, K; Uno, M; Nakamura, Y			A tripeptide 'anticodon' deciphers stop codons in messenger RNA	NATURE			English	Article							RELEASE FACTOR-2; AMINO-ACID; ESCHERICHIA-COLI; PEPTIDE; TRANSLATION; SUPPRESSOR; MUTANT	The two translational release factors of prokaryotes, RF1 and RF2, catalyse the termination of polypeptide synthesis at UAG/UAA and UGA/UAA stop codons, respectively(1-3). However, how these polypeptide release factors read both non-identical and identical stop codons is puzzling(4), Here we describe the basis of this recognition. Swaps of each of the conserved domains between RF1 and RF2 in an RF1-RF2. hybrid led to the identification of a domain that could switch recognition specificity. A genetic selection among clones encoding random variants of this domain showed that the tripeptides Pro-Ala-Thr and Ser-Pro-Phe determine release-factor specificity in vivo in RF1 and RF2, respectively. An in vitro release study of tripeptide variants indicated that the first and third amino acids independently discriminate the second and third purine bases, respectively. Analysis with stop codons containing base analogues indicated that the C2 amino group of purine may be the primary target of discrimination of G from A. These findings show that the discriminator tripeptide of bacterial release factors is functionally equivalent to that of the anticodon of transfer RNA, irrespective of the difference between protein and RNA.	Univ Tokyo, Inst Med Sci, Dept Tumor Biol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Tumor Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	nak@ims.u-tokyo.ac.jp	Uno, Masatoshi/V-7934-2019	Ito, Koichi/0000-0002-2042-405X				AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; Buckingham RH, 1997, MOL MICROBIOL, V24, P449, DOI 10.1046/j.1365-2958.1997.3711734.x; GRICK FHC, 1966, J MOL BIOL, V19, P548; Ito K, 1998, P NATL ACAD SCI USA, V95, P8165, DOI 10.1073/pnas.95.14.8165; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; KAWAKAMI K, 1988, J BACTERIOL, V170, P5378, DOI 10.1128/jb.170.11.5378-5381.1988; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; RYDEN SM, 1984, MOL GEN GENET, V193, P38, DOI 10.1007/BF00327411; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SOLL D, 1967, J MOL BIOL, V29, P113, DOI 10.1016/0022-2836(67)90184-2; Uno M, 1996, BIOCHIMIE, V78, P935, DOI 10.1016/S0300-9084(97)86715-6; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Yoshimura K, 1999, GENES CELLS, V4, P253, DOI 10.1046/j.1365-2443.1999.00260.x	16	218	226	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2000	403	6770					680	684		10.1038/35001115	http://dx.doi.org/10.1038/35001115			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283RD	10688208				2022-12-24	WOS:000085288200060
J	Li, GY; Weis, RM				Li, GY; Weis, RM			Covalent modification regulates ligand binding to receptor complexes in the chemosensory system of Escherichia coli	CELL			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; KINASE CHEA; SERINE CHEMORECEPTOR; CYTOPLASMIC FRAGMENT; RESPONSE REGULATOR; ASPARTATE RECEPTOR; SENSORY RECEPTOR; PROTEIN; METHYLATION	In the Escherichia coli chemosensory pathway, receptor modification mediates adaptation to ligand. Evidence is presented that covalent modification influences ligand binding to receptors in complexes with CheW and the kinase CheA. Kinase inhibition was measured with serine receptor complexes in different modification levels; K-i for serine-mediated inhibition increased 10,000-fold from the lowest to the highest level. Without CheA and CheW, ligand binding is unaffected by covalent modification; thus, the influence of covalent modification is mediated only in the receptor complex, a conclusion supported by an analogy to allosteric enzymes and the observation of cooperative kinase inhibition. Also, the finding that a subsaturating serine concentration accelerates active receptor-kinase complex assembly implies that the assembly/disassembly process may also contribute to kinase regulation.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Grad Program Mol & Cellular Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Weis, RM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.	rmweis@chem.umass.edu			NIGMS NIH HHS [R01 GM53210] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; Barnakov AN, 1998, J BACTERIOL, V180, P6713, DOI 10.1128/JB.180.24.6713-6718.1998; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; CONLEY MP, 1989, J BACTERIOL, V171, P5190, DOI 10.1128/jb.171.9.5190-5193.1989; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MADDOCK JR, 1993, SCIENCE, V259, P1717; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; RICE MS, 1991, J BIOL CHEM, V266, P9746; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P16336, DOI 10.1021/bi961749i; SLOCUM MK, 1983, J BACTERIOL, V155, P565, DOI 10.1128/JB.155.2.565-577.1983; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; Wyman J, 1968, Q Rev Biophys, V1, P35; YONEKAWA H, 1986, FEBS LETT, V198, P21, DOI 10.1016/0014-5793(86)81176-0	42	163	165	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					357	365		10.1016/S0092-8674(00)80671-6	http://dx.doi.org/10.1016/S0092-8674(00)80671-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676817	Bronze			2022-12-24	WOS:000085204400009
J	Ryu, WS; Berry, RM; Berg, HC				Ryu, WS; Berry, RM; Berg, HC			Torque-generating units of the flagellar motor of Escherichia coli have a high duty ratio	NATURE			English	Article							OPTICAL TWEEZERS; ROTATION; MOVEMENT; MOTILITY; DOMAIN; MODEL	Rotation of the bacterial flagellar motor is driven by an ensemble of torque-generating units containing the proteins MotA and; MotB(1-3). Here, by inducing expression of MotA in motA(-) cells under conditions of low viscous load, we show that the limiting speed of the motor is independent of the number of units: at vanishing load, one unit turns the motor as rapidly as many. This result indicates that each unit may remain attached to the rotor for most of its mechanochemical cycle, that is, that it has a high duty ratio(4). Thus, torque generators behave more like kinesin, the protein that moves vesicles along microtubules, than myosin, the protein that powers muscle. However, their translation rates, stepping frequencies and power outputs are much higher, being greater than 30 mu m s(-1), 12 Hz and 1.5 x 10(5) pN nm s(-1) respectively.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Rowland Inst Sci Inc, Cambridge, MA 02142 USA; Kings Coll London, Randall Ctr, London SE1 1UL, England	Harvard University; University of London; King's College London	Berg, HC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.							ARMSTRONG JB, 1967, GENETICS, V56, P363; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; Berry RM, 1999, BIOPHYS J, V76, P580, DOI 10.1016/S0006-3495(99)77226-7; Berry RM, 1999, ADV MICROB PHYSIOL, V41, P291, DOI 10.1016/S0065-2911(08)60169-1; Berry RM, 1997, P NATL ACAD SCI USA, V94, P14433, DOI 10.1073/pnas.94.26.14433; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHEN X, IN PRESS BIOPHYS J; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FUNG DCY, 1994, THESIS HARVARD U; Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007; Happel J, 1991, LOW REYNOLDS NUMBER; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MACNAB RM, 1977, P NATL ACAD SCI USA, V74, P221, DOI 10.1073/pnas.74.1.221; Macnab RM, 1996, ESCHERICHIA COLI SAL, V1, P123; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MURAMOTO K, 1995, J MOL BIOL, V251, P50, DOI 10.1006/jmbi.1995.0415; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SILVERMAN M, 1976, NATURE, V264, P577, DOI 10.1038/264577a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; [No title captured]	30	183	186	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					444	447		10.1038/35000233	http://dx.doi.org/10.1038/35000233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667798				2022-12-24	WOS:000085121100054
J	Kavanagh, AM; Mitchell, H; Giles, GG				Kavanagh, AM; Mitchell, H; Giles, GG			Hormone replacement therapy and accuracy of mammographic screening	LANCET			English	Article							BREAST-CANCER; FAMILY HISTORY; DENSITY; WOMEN; AGE; SENSITIVITY; ESTROGEN; SPECIFICITY; INTERVAL; PROGRAM	Background Hormone replacement therapy (HRT) is commonly used and may affect the accuracy of mammographic screening. Methods We examined the sensitivity, specificity, and small-cancer detection rate according to HRT use in 103 770 women in Victoria, Australia, who attended first-round screening in 1994 and who did not have a personal history of breast cancer or a breast lump or a bloodstained or watery nipple discharge at the time of screening. BreastScreen Victoria provides mammography to women aged 40 years and older every 2 years. Unconditional logistic modelling was used to adjust for age, family history, and symptom status. Findings The sensitivity of screening mammography for a 2-year screening interval was lower in HRT users (64.8% [95% CI 58-72]) than nonusers (77.3% [74-81]). In the target group (50-69 years), the sensitivity was 64.3% (57-72) in HRT users and 79.8% (76-84) in non-users. Among women who were diagnosed with cancer during the 2-year screening interval, HRT users were more likely to have a false negative result than nonusers (odds ratio 1.60 [1.04-2.21]) after adjusting for potential confounding factors. Specificity was 0.6% lower in HRT users compared with nonusers. Among women who did not have cancer diagnosed in the interval, HRT users were more likely to have a false positive result (adjusted odds ratio 1.12 [1.05-1.19]). Interpretation We show that HRT use reduces the sensitivity of mammographic screening. In countries where HRT use is widespread, the reduction in sensitivity with HRT use may undermine the capacity of population-based mammographic-screening programmes to realise their potential mortality benefit.	La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic 3000, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton South, Vic, Australia; Victoria BreastScreen Registry, Carlton South, Vic, Australia	La Trobe University	Kavanagh, AM (corresponding author), La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, 215 Franklin St, Melbourne, Vic 3000, Australia.		Kavanagh, Anne/U-4826-2019	Kavanagh, Anne/0000-0002-1573-3464; Giles, Graham/0000-0003-4946-9099				Australian Bureau of Statistics, 1999, AUSTR DEM STAT; Beral V, 1997, LANCET, V349, P1103, DOI 10.1016/S0140-6736(05)62328-8; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P503, DOI 10.1093/oxfordjournals.aje.a115364; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BRISSON J, 1988, J NATL CANCER I, V80, P1534, DOI 10.1093/jnci/80.19.1534; Cohen MEL, 1997, LANCET, V349, P1624, DOI 10.1016/S0140-6736(05)61662-5; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey JA, 1997, J NATL CANCER I, V89, P1623, DOI 10.1093/jnci/89.21.1623; Holli K, 1997, LANCET, V350, P1704, DOI 10.1016/S0140-6736(05)64308-5; HURLEY SF, 1992, EPIDEMIOL REV, V14, P101, DOI 10.1093/oxfordjournals.epirev.a036082; Kavanagh AM, 1999, J MED SCREEN, V6, P139, DOI 10.1136/jms.6.3.139; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; Leung W, 1997, SURGERY, V122, P669, DOI 10.1016/S0039-6060(97)90072-6; Litherland JC, 1997, CLIN RADIOL, V52, P276, DOI 10.1016/S0009-9260(97)80053-0; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X; Lundstrom E, 1999, AM J OBSTET GYNECOL, V181, P348, DOI 10.1016/S0002-9378(99)70560-0; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; MACLENNAN AH, 1995, MED J AUSTRALIA, V162, P420, DOI 10.5694/j.1326-5377.1995.tb139971.x; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; Marugg RC, 1997, EUR RADIOL, V7, P749, DOI 10.1007/BF02742938; MCNICHOLAS MMJ, 1994, AM J ROENTGENOL, V163, P311, DOI 10.2214/ajr.163.2.8037021; Peer PGM, 1996, BREAST CANCER RES TR, V38, P153, DOI 10.1007/BF01806669; Persson I, 1997, J CLIN ONCOL, V15, P3201, DOI 10.1200/JCO.1997.15.10.3201; Rand T, 1997, ACTA RADIOL, V38, P228; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Roubidoux MA, 1998, RADIOLOGY, V208, P725, DOI 10.1148/radiology.208.3.9722852; Salmon RJ, 1995, LANCET, V346, P1702, DOI 10.1016/S0140-6736(95)92864-2; Schouten LJ, 1997, LANCET, V349, P1104, DOI 10.1016/S0140-6736(05)62329-X; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; SHELLEY JM, 1995, AUST J PUBLIC HEALTH, V19, P387; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; Threlfall AG, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61182-8; Thurfjell EL, 1997, RADIOLOGY, V203, P339, DOI 10.1148/radiology.203.2.9114085; van Gils CH, 1998, J EPIDEMIOL COMMUN H, V52, P267, DOI 10.1136/jech.52.4.267; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189	40	131	136	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					270	274		10.1016/S0140-6736(99)07319-5	http://dx.doi.org/10.1016/S0140-6736(99)07319-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675074				2022-12-24	WOS:000085045600010
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Biological rhythms - Circadian clocks limited by noise	NATURE			English	Article									Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University	Barkai, N (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.							Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edmund L.N., 1988, CELLULAR MOL BASIS B; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Goldbeter A., 1995, BIOCH OSCILLATIONS C; KO MSH, 1992, BIOESSAYS, V14, P341, DOI 10.1002/bies.950140510; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Murray J. D., 1994, MATH BIOL; Suri V, 1999, EMBO J, V18, P675, DOI 10.1093/emboj/18.3.675; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	12	394	402	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					267	268		10.1038/35002258	http://dx.doi.org/10.1038/35002258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659837				2022-12-24	WOS:000084899700040
J	Miyado, K; Yamada, G; Yamada, S; Hasuwa, H; Nakamura, Y; Ryu, F; Suzuki, K; Kosai, K; Inoue, K; Ogura, A; Okabe, M; Mekada, E				Miyado, K; Yamada, G; Yamada, S; Hasuwa, H; Nakamura, Y; Ryu, F; Suzuki, K; Kosai, K; Inoue, K; Ogura, A; Okabe, M; Mekada, E			Requirement of CD9 on the egg plasma membrane for fertilization	SCIENCE			English	Article							DIPHTHERIA-TOXIN RECEPTOR; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; CELL-SURFACE; IN-VITRO; BINDING; PROTEIN; EXPRESSION; MOTILITY; INTEGRINS	CD9 is an integral membrane protein associated with integrins and other membrane proteins, Mice lacking CD9 were produced by homologous recombination. Both male and female CD9(-/-) mice were born healthy and grew normally, However, the litter size from CD9(-/-) females was less than 2% of that of the wild type. In vitro fertilization experiments indicated that the cause of this infertility was due to;the failure of sperm-egg fusion. When sperm were injected into oocytes with assisted microfertilization techniques, however, the fertilized eggs developed to term. These results indicate that CD9 has a crucial role in sperm-egg fusion.	Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Fukuoka 8300011, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan; Program Promot Basic Res Act Innovat Biosci, Tokyo 1050001, Japan; St Marys Hosp, Fukuoka 8300047, Japan; Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka 5650861, Japan	Kurume University; Kurume University; Kumamoto University; National Institute of Infectious Diseases (NIID); Osaka University	Mekada, E (corresponding author), Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan.	emekada@lsi.kurume-u.ac.jp	Ogura, Atsuo/J-3916-2014; Hasuwa, Hidetoshi/B-1083-2009; MIYADO, KENJI/E-6568-2013; Okabe, Masaru/B-6917-2015	Ogura, Atsuo/0000-0003-0447-1988; Mekada, Eisuke/0000-0001-8858-4781; Miyado, Kenji/0000-0002-8339-6738; Okabe, Masaru/0000-0002-0803-9044; Yamada, Gen/0000-0001-6160-2660				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ANTON ES, 1995, J NEUROSCI, V15, P584; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; Loffler S, 1997, J VIROL, V71, P42; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MIYADO K, UNPUB; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakamura Y, 1996, AM J PATHOL, V149, P575; NEWMAN RA, 1982, BIOCHIM BIOPHYS ACTA, V701, P318, DOI 10.1016/0167-4838(82)90234-5; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	31	523	554	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					321	324		10.1126/science.287.5451.321	http://dx.doi.org/10.1126/science.287.5451.321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634791				2022-12-24	WOS:000084769600046
J	Ratsitorahina, M; Chanteau, S; Rahalison, L; Ratsifasoamanana, L; Boisier, P				Ratsitorahina, M; Chanteau, S; Rahalison, L; Ratsifasoamanana, L; Boisier, P			Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar	LANCET			English	Article							ASSAY	Background Plague is a re-emerging disease and pneumonic plague is the most feared clinical form. We describe a well-documented outbreak of pneumonic plague in Madagascar. Methods Field epidemiological data were collected. Biological tests (microscopy, culture of Yersinia pestis, F1 antigen ELISA and dipstick assays, IgG anti-Fl ELISA) were done on sputum, serum, or necropsy samples. The infection rate among 154 contacts was assessed by anti-Fl serological techniques. Findings The index case was a bubonic patient with a secondary lung infection, who contaminated a traditional healer and his family. Funeral ceremonies and attendance on patients contaminated other villagers. In total 18 cases were recorded, and eight died. F1 antigen could be detected in sputum by ELISA and dipstick tests as early as the second day after the onset of the symptoms and also 48 h after treatment. Among the contact population 13 of 154 (8.4%) have been exposed to the plague bacillus (symptomless or latent infections). Interpretation The F1 dipstick assay on sputum is an invaluable diagnostic tool for pneumonic plague. Treatment of patients and chemoprophylaxis of contacts were efficient in stopping the epidemic.	Inst Pasteur Madagascar, Antananarivo, Madagascar; Minist Hlth, Natl Control Plague Programme, Antananarivo, Madagascar	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	Chanteau, S (corresponding author), Inst Pasteur Madagascar, POB 1274, Antananarivo, Madagascar.	chanteau@pasteur.mg	BOISIER, PASCAL/A-2922-2009					[Anonymous], 1998, Wkly Epidemiol Rec, V73, P366; BRYGOO E. R., 1958, BULL SOC PATHOL EXOT, V51, P47; Chanteau S, 1998, EMERG INFECT DIS, V4, P101, DOI 10.3201/eid0401.980114; Chanteau S, 1998, T ROY SOC TROP MED H, V92, P572, DOI 10.1016/S0035-9203(98)90923-3; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GIRARD G., 1927, BULL SOC PATH EXOT, V20, P233; POLLITZER R, 1954, WHO MONOGR SER, V22, P533; Rasoamanana B, 1997, CLIN DIAGN LAB IMMUN, V4, P587, DOI 10.1128/CDLI.4.5.587-591.1997; Rasoamanana B, 1996, T ROY SOC TROP MED H, V90, P651, DOI 10.1016/S0035-9203(96)90420-4; THIROUX A, 1920, B SOC PATHOL EXOT, V22, P704; WINTER C C, 1960, Bull World Health Organ, V23, P408; WU LT, 1928, N MANCHURIAN PLAGUE, V6, P55	12	95	100	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					111	113		10.1016/S0140-6736(99)05163-6	http://dx.doi.org/10.1016/S0140-6736(99)05163-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675169				2022-12-24	WOS:000085557200013
J	Smith, O				Smith, O			Nota bene: Aging - Sensing old age	SCIENCE			English	Editorial Material																		Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					54	54		10.1126/science.287.5450.54	http://dx.doi.org/10.1126/science.287.5450.54			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644225				2022-12-24	WOS:000084578400031
J	Rongo, C; Kaplan, JM				Rongo, C; Kaplan, JM			CaMKII regulates the density of central glutamatergic synapses in vivo	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN-KINASE-II; RECEPTOR; PHOSPHORYLATION; LOCALIZATION; SUBUNIT; MUTANTS; NEURONS	Synaptic connections undergo a dynamic process of stabilization or elimination during development, and this process is thought to be critical in memory and learning and in establishing the specificity of synaptic connections(1). The type II calcium- and calmodulin-dependent protein kinase (CaMKII) has been proposed to be pivotal in regulating synaptic strength(2-4) and in maturation of synapses during developments. Here we describe how CaMKII regulates the formation of central glutamatergic synapses in Caenorhabditis elegans, During larval development, the density of ventral nerve cord synapses containing the GLR-1 glutamate receptor is held constant despite marked changes in neurite length. The coupling of synapse number to neurite length requires both CaMKII and voltage-gated calcium channels. CaMKII regulates GLR-1 by at least two distinct mechanisms: regulating transport of GLR-1 from cell bodies to neurites; and regulating the addition or maintenance of GLR-1 to postsynaptic elements.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Kaplan, JM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, LSA 361, Berkeley, CA 94720 USA.							Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; FONG YL, 1989, J BIOL CHEM, V264, P16759; HART A, 1993, NATURE, V378, P82; Hebb D.O., 1949, ORG BEHAV; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Nonet ML, 1998, J NEUROSCI, V18, P70; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Reiner DJ, 1999, NATURE, V402, P199, DOI 10.1038/46072; Riddle DL, 1997, C ELEGANS; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222	27	153	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					195	199		10.1038/46065	http://dx.doi.org/10.1038/46065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647013				2022-12-24	WOS:000083716400054
